screening 2014.82 
MeSHChorionicGonadotropin 2000.78 
screen 1972.31 
trimester 1814.89 
MeSHDownSyndrome 1644.08 
MeSHPregnancyTrimester 1642.74 
pregnancies 1641.99 
Chorionic 1641.16 
Trimester 1636.28 
maternal 1632.03 
MeSHChorion 1621.24 
Down 1617.30 
serum 1582.83 
hCG 1462.33 
alpha-Fetoprotein 1385.58 
nad 1381.08 
detection 1368.69 
dot 1302.54 
fetoprotein 1288.19 
MeSHSensitivityandSpecificity 1284.89 
Sensitivity 1242.69 
alpha- 1211.07 
MeSHLymphNodes 1207.35 
Nodes 1202.30 
value 1200.24 
MeSHPrenatal 1186.55 
Specificity 1185.38 
gestation 1174.70 
Prenatal 1170.16 
MeSHPregnancy 1151.72 
Pregnancy 1149.05 
MeSHbetaSubunit 1142.57 
Specific 1131.56 
MeSHLymphNode 1130.03 
Do 1108.55 
alpha-feto 1103.53 
detect 1100.44 
alpha-fetoprotein 1095.81 
specificity 1086.15 
sensitivity 1080.30 
Syndrome 1075.99 
MeSHFirst 1069.58 
Node 1068.44 
city 1053.56 
chorionic 1028.75 
chorion 1021.82 
false 996.39 
Spec 982.27 
Maternal 977.26 
First 953.53 
Value 950.42 
hCG) 937.42 
MeSHPrenatalDiagnosis 925.56 
-hCG 916.99 
Lymph 909.34 
nuchal 908.43 
estriol 886.79 
beta 878.82 
translucency 864.24 
AFP 861.91 
lucency 849.75 
a-hCG 848.41 
beta-hCG 837.24 
station 832.93 
multiples 829.28 
positive 823.45 
unconjugated 820.43 
alpha 808.73 
proteins 802.10 
beta- 795.66 
CG) 789.33 
mph 780.80 
syndrome 778.99 
MeSHEstriol 774.96 
women 774.82 
Predictive 762.42 
MeSHSecond 755.50 
FP 755.17 
gonadotrophin 753.06 
false-positive 749.76 
MeSHPredictiveValueofTests 743.92 
(AFP) 724.39 
marker 724.31 
Screen 723.77 
(AFP 719.79 
conjugated 715.97 
Screening 713.90 
values 700.67 
MoM 699.52 
FP) 696.18 
gestational 694.83 
MeSHPregnancy-AssociatedPlasmaProtein-A 692.48 
own 691.47 
singleton 688.72 
predict 687.09 
protein 684.92 
PAPP-A 671.89 
Se 661.34 
Second 654.15 
MeSHGestationalAge 649.65 
PAP 647.70 
Gestational 646.92 
predictive 639.92 
markers 636.58 
accuracy 634.53 
Down's 632.28 
Associated 610.89 
(hCG) 610.01 
median 609.65 
fetal 603.03 
(hCG 602.87 
9 598.51 
gonadotropin 590.42 
Ha 586.27 
lymph 582.76 
pregnancy 581.84 
MeSHVagina 555.64 
second-trimester 551.21 
unaffected 550.20 
Test 549.59 
Intraepithelial 543.08 
MeSHCervicalIntraepithelialNeoplasia 541.54 
ASC 538.20 
% 529.75 
MeSHFalsePositiveReactions 525.92 
specific 521.25 
Neoplasia 520.19 
-positive 516.23 
intraepithelial 514.15 
Biomarkers 513.22 
MeSHBiomarkers 511.77 
MeSHVaginalSmears 507.21 
False 506.11 
5% 504.44 
week 503.24 
MeSHMaternalAge 502.23 
weeks 500.10 
test 499.31 
No 497.69 
mark 495.49 
second- 492.50 
Smears 490.48 
MeSHMassScreening 485.84 
trisomy 483.23 
oestriol 475.79 
MOM 475.24 
HL 472.96 
US) 472.19 
PV 464.54 
Xpert 462.79 
node 457.44 
risk 451.52 
8 448.20 
testing 445.79 
Tests 444.30 
compare 443.70 
7 439.48 
first-trimester 434.06 
MTB/RIF 433.20 
performance 432.56 
undetermined 431.74 
Prospective 430.73 
Carcinoembryonic 428.42 
thickness 426.33 
MeSHCarcinoembryonicAntigen 424.50 
HPV 423.82 
MoM) 422.85 
assay 420.93 
RESULTS 420.88 
RESULTS: 418.28 
US 417.91 
0% 417.77 
human 417.26 
PV) 414.79 
sonography 413.89 
uE3 413.67 
rim 413.17 
(NT) 411.05 
Papilloma 410.88 
95 410.68 
RES 407.95 
colposcopy 407.03 
MeSHProspectiveStudies 406.67 
papillomavirus 403.59 
papilloma 402.02 
6 399.00 
MeSHShoulder 398.79 
compared 398.72 
pregnancy-associated 398.62 
PAPP-A) 398.20 
fetuses 396.08 
high-risk 395.90 
(MoM 395.11 
measurement 394.97 
(PAPP-A 393.03 
NT) 392.15 
MeSHUltrasonography 390.93 
respectively 390.77 
E3 386.34 
Assoc 385.72 
Shoulder 384.78 
(PAPP-A) 382.90 
respective 381.18 
Ultrasonography 380.72 
7% 376.01 
calculate 373.88 
Spinal 372.25 
calculated 371.07 
SI 370.76 
unit 370.69 
(NT 370.43 
(MoM) 366.06 
LUS 363.30 
5 361.35 
4 361.16 
tears 360.98 
MOM) 359.87 
detecting 359.55 
affected 359.52 
sample 358.62 
CONCLUSION 357.47 
USI 357.27 
levels 357.00 
Rotator 356.95 
CIN 355.52 
HPV) 355.04 
(uE3) 353.20 
AP 353.16 
ES 351.82 
6% 351.74 
rotator 351.13 
MeSHPapillomaviridae 350.68 
3% 350.35 
negative 350.11 
SIL 349.65 
cuff 349.19 
uE3) 347.93 
inhibin 346.89 
respect 346.47 
Positive 345.18 
OBJECTIVE 345.08 
3 343.91 
determine 343.85 
Pr 343.57 
measure 339.44 
NC 337.71 
2% 337.47 
Plasma 337.29 
1% 336.77 
IO 336.54 
(MOM) 335.70 
screened 334.89 
tests 334.56 
Pap 333.43 
second 333.06 
tear 331.95 
(CIN 330.96 
9% 330.00 
0 327.36 
MeSHPapillomavirusInfections 327.23 
high- 326.36 
00% 324.95 
hole 324.88 
fetus 324.22 
Mass 322.71 
Papillomavirus 322.65 
100% 320.71 
prospective 320.20 
norm 318.85 
MeSHRotatorCuff 318.60 
normal 318.00 
Cuff 317.89 
ASCUS 317.79 
MeSHInhibins 317.39 
CEA 316.97 
Capture 316.37 
triple 316.27 
shoulder 316.16 
samples 315.93 
Inhibin 314.85 
Studies 314.06 
8% 313.37 
determined 311.77 
embryonic 308.66 
triage 304.65 
J 304.51 
MeSHPapanicolaouTest 304.08 
were 303.45 
MeSHCholelithiasis 303.24 
= 302.04 
vertebra 301.88 
lithiasis 300.80 
thick 300.34 
first- 296.09 
MeSHRotatorCuffInjuries 295.81 
2 295.42 
93 294.94 
Diagnosis 294.75 
Fetal 293.02 
Papanicolaou 290.82 
centile 289.98 
%) 289.61 
OD 289.54 
MeSHTuberculosis 289.44 
(HPV 289.07 
abnormal 288.78 
14 287.87 
ASC- 287.74 
METHODS: 287.52 
DS: 287.08 
Tuberculosis 286.97 
off 286.45 
90 285.63 
METHODS 285.22 
ultra 284.23 
nodes 283.41 
MeSHShoulderJoint 283.17 
MeSHFetalDiseases 282.08 
(HPV) 281.54 
study 281.05 
eg 280.76 
21 280.29 
(CI 279.86 
epithelial 278.82 
OBJECTIVE: 278.51 
DS 278.13 
medians 277.20 
Colposcopy 276.86 
-hCG) 276.56 
evaluate 276.54 
RIF 276.17 
Nuchal 276.07 
biochemical 275.48 
vertebral 274.50 
(PA 274.33 
4% 274.23 
neoplasia 273.78 
beta-human 273.61 
analyte 273.00 
A) 268.43 
screen-positive 266.84 
treat 266.31 
100 265.46 
SIL) 264.23 
chromosomal 263.23 
free 263.18 
(ASCUS 263.05 
cut-off 262.12 
MeSHUterineCervicalNeoplasms 261.86 
inhibin-A 260.80 
detected 259.16 
(A 257.63 
(CEA 257.24 
MeSHColposcopy 256.71 
U 256.51 
high 256.12 
MeSHAnimal 253.59 
1 253.34 
Reaction 253.24 
MeSHAnimals 253.11 
(ASCUS) 253.03 
(ASC- 250.37 
ASCUS) 248.73 
therapy 248.07 
high-grade 247.35 
squamous 247.01 
(CEA) 246.33 
Results 246.18 
(9 242.93 
results 241.71 
CEA) 241.16 
00 240.95 
spinal 240.71 
carcinoembryonic 238.61 
MeSHVulvarNeoplasms 236.45 
CI 236.10 
first 235.16 
useful 234.24 
(CE 233.91 
protein-A 231.78 
single 231.40 
accurate 230.81 
stone 230.30 
LSIL 228.33 
Reproducibility 228.33 
ASC-US 227.93 
Vulvar 227.28 
tuberculosis 226.49 
IV 226.01 
result 225.83 
abnormalities 225.65 
resectability 225.38 
treatment 225.29 
amniocentesis 224.77 
beta-hCG) 224.12 
sound 223.96 
embryo 223.37 
MeSHReproducibilityofResults 222.11 
rectal 222.10 
cytology 221.78 
CT 221.69 
35 221.22 
MeSHTendonInjuries 220.54 
pregnant 219.97 
colorectal 219.13 
94 218.56 
ultrasound 218.49 
media 217.91 
affect 217.87 
combination 217.31 
Lymphatic 217.09 
92 217.04 
V 216.90 
nor 216.56 
rare 216.29 
atypical 215.08 
multiple 214.92 
MeSHFetal 214.02 
95th 212.90 
sec 212.73 
PA 212.47 
go 210.95 
18 210.06 
level 209.65 
gated 208.49 
population 207.23 
Tendon 207.09 
pain 207.05 
Values 206.53 
assess 204.77 
gall 204.64 
91 204.56 
vulvar 204.20 
combined 201.96 
Uterine 201.60 
MeSHBreast 201.55 
weeks' 201.38 
vulva 201.34 
S) 200.99 
receiver 199.67 
cyst 199.63 
MeSHBreastNeoplasms 199.27 
CE 198.19 
combine 197.15 
10 195.98 
HSIL 195.12 
Risk 194.78 
liquid-based 194.57 
CIN2 194.48 
95% 193.65 
program 193.60 
lumbar 192.97 
First-trimester 191.81 
Reference 191.73 
MeSHTreatmentOutcome 191.38 
was 191.11 
HP 190.79 
stones 190.54 
hoc 190.22 
MeSHReferenceValues 190.09 
84 190.08 
Serum 190.08 
88 188.80 
son 187.87 
CONCLUSION: 187.09 
(IA) 186.85 
(GM) 186.53 
High- 185.60 
3) 185.18 
(ASC-US 185.15 
term 185.12 
16 184.50 
(GM 184.31 
arthroscopy 182.76 
( 181.60 
) 181.60 
: 181.47 
MeSHUterineCervicalDysplasia 180.30 
MeSHMannans 180.19 
(beta 179.99 
beta-core 179.94 
algorithm 179.31 
prospectively 178.41 
low-grade 178.03 
biliary 177.87 
last 177.70 
(95 177.65 
Tube 177.55 
MeSHFemale 177.17 
Female 177.05 
complication 176.99 
breast 176.94 
perform 176.73 
Rectal 176.52 
GM) 176.47 
86 175.98 
Treatment 174.96 
1: 174.86 
transvaginal 174.61 
antenatal 174.45 
LSIL) 174.28 
red 174.15 
MeSHRectal 174.05 
would 173.81 
> 173.58 
(CIN) 173.42 
(beta-hCG 173.17 
EUS) 172.58 
likelihood 172.54 
81 172.50 
CIN) 172.00 
immunoassay 171.90 
cutoff 171.50 
As 171.38 
Triage 170.77 
83 170.75 
color 169.33 
89 168.05 
elevated 168.05 
CONCLUSIONS 167.87 
immune 167.81 
rump 167.43 
MeSHViral 167.15 
13 167.06 
(IA 166.93 
CONCLUSIONS: 166.83 
galactomannan 166.83 
colposcopic 165.27 
Viral 164.68 
than 164.57 
(EUS) 164.15 
(beta-hCG) 163.77 
87 163.75 
77 162.55 
96 162.42 
11 162.41 
ones 162.18 
chromosomally 161.85 
73 161.53 
MeSHChromosomeAberrations 160.39 
Second-trimester 159.44 
measured 159.20 
lymphocyte 157.62 
ROC 157.53 
ultrasonography 157.27 
response 157.25 
(ASC-US) 156.56 
bladder 156.39 
mannan 156.37 
MeSHROCCurve 156.28 
(LSIL) 156.09 
11-14 155.88 
arthrography 155.80 
crown 155.67 
-core 155.53 
79 155.43 
MeSHHigh-Risk 155.22 
IQCODE 154.72 
rate 154.41 
90% 154.25 
(1 153.87 
MeSHLumbarVertebrae 153.57 
(M 153.38 
Arthroscopy 153.29 
male 153.27 
(EUS 152.99 
impingement 152.75 
MeSHMale 152.49 
MeSHCrown-RumpLength 152.46 
evaluated 152.38 
42 151.33 
confidence 150.89 
liquid 150.19 
gallbladder 149.95 
85 149.92 
spine 149.47 
concentration 149.08 
5th 149.06 
Gaussian 148.90 
75 148.83 
97 148.37 
prenatal 148.33 
MeSHNuchalTranslucencyMeasurement 148.10 
MeSHLymphoma 148.01 
MeSHArthroscopy 147.87 
PPV 147.79 
Translucency 147.42 
virus 147.27 
full-thickness 146.86 
base 146.70 
sonographic 146.39 
67 146.37 
66 146.13 
between 145.51 
lymphoma 145.03 
SC 144.93 
MeSHLymphaticMetastasis 144.55 
correct 144.48 
22 143.58 
using 143.40 
Ten 142.58 
crown-rump 142.43 
Informant 141.82 
QC 141.03 
34 140.86 
EUS 140.56 
NS 139.55 
IA) 139.36 
alone 138.66 
dimeric 138.66 
groins 138.55 
1:270 138.55 
diagnostic 138.55 
defects 138.19 
Cells 138.06 
Tr 137.89 
measurements 137.60 
MeSHChromosomeDisorders 137.16 
for 135.92 
lesions 135.57 
(C 135.29 
71 135.15 
Cervical 134.91 
Urine 134.90 
MeSHCervixUteri 134.73 
76 134.37 
vaginal 134.36 
75% 133.01 
uses 132.73 
MeSHColonicNeoplasms 132.57 
sensitive 131.83 
HD 131.72 
(HSIL 131.70 
treated 130.89 
MeSHRisk 130.88 
MTB 130.84 
life 130.67 
placement 130.28 
ratios 130.25 
labral 130.25 
smear 130.09 
resectable 129.91 
curative 129.73 
tube 129.65 
plasma 129.13 
labra 128.93 
subunit 128.61 
adjustment 128.58 
HR 128.41 
estimate 128.36 
predicting 128.23 
MeSHAdult 128.05 
based 127.95 
Cell 127.51 
GM 126.23 
93% 125.91 
ASC-H 125.86 
(IQCODE) 125.47 
laparoscopy 125.34 
inguinofemoral 125.32 
MeSHPair18 125.20 
cutaneous 125.19 
copy 125.18 
99 124.76 
270 124.60 
Duct 124.56 
Decline 123.88 
0) 123.74 
Adult 123.59 
midtrimester 122.85 
NT 122.39 
in- 122.32 
vagina 122.06 
45 121.99 
complications 121.93 
(N 121.92 
(DS) 121.65 
tissue 121.15 
(FPR 120.97 
smears 120.96 
Arthrography 120.74 
MeSHArthrography 120.41 
genes 120.15 
protocol 120.14 
sensitivities 120.12 
biochemistry 119.98 
informant 119.92 
risks 119.86 
72 119.75 
higher 119.72 
routine 119.45 
MeSHRectalNeoplasms 118.90 
partial-thickness 118.84 
MeSHNeoplasmRecurrence 118.60 
(HC 118.49 
die 117.92 
Cognitive 117.72 
issue 117.60 
Women 117.51 
MeSHKidneyTransplantation 117.25 
70 116.86 
back 116.46 
agreement 116.43 
FPR 116.31 
HCG 116.25 
stasis 115.66 
MeSHCholecystectomy 115.63 
MeSHMice 115.61 
pre 115.53 
lung 115.51 
82 115.35 
Digene 115.19 
partial- 115.17 
(95% 114.92 
report 114.91 
neck 114.57 
(3 114.30 
lb 114.15 
bile 114.14 
HSIL) 114.12 
(DS 113.58 
78 113.47 
preoperative 113.44 
increase 113.23 
MeSHChild 112.99 
MeSHNasalBone 112.99 
matched 112.78 
collected 112.71 
Preoperative 112.70 
38 112.66 
Pain 112.58 
IN 112.37 
63 111.99 
(sensitivity 111.97 
Os 111.88 
sign 111.82 
arthroscopic 111.68 
01 111.67 
62 111.36 
cytologic 111.33 
we 111.18 
Child 111.07 
cent 110.66 
peripheral 110.66 
arthro 110.57 
assessment 110.15 
29 110.13 
High 110.02 
Chromosome 110.00 
induce 109.91 
went 109.56 
64 109.39 
probable 109.15 
staging 108.96 
25 108.77 
91% 108.16 
spin 108.13 
MeSHTriage 107.91 
MeSHNeuralTubeDefects 107.86 
< 107.72 
Diagnostic 107.64 
27 107.11 
pathogen 107.04 
programme 106.86 
17 106.83 
(CIN2 106.77 
Endosonography 106.62 
lesion 106.50 
Testing 106.44 
fracture 106.36 
Fractures 106.20 
offered 106.05 
insulin-dependent 105.78 
total 105.51 
Fracture 105.34 
correctly 105.12 
cases 105.08 
T) 105.02 
ASC-H) 104.50 
adenopathy 104.44 
proven 104.43 
HF 104.40 
Bile 104.36 
defect 104.19 
consecutive 104.15 
HPV- 103.87 
MeSHPeptideFragments 103.80 
MeSHCholangiography 103.71 
aspergillosis 103.71 
Therapy 103.59 
screening: 103.53 
tendon 103.25 
cell 103.16 
exam 103.16 
receptor 103.08 
CD 103.07 
significance 102.97 
gallstone 102.83 
Joint 102.66 
MeSHBodyWeight 102.61 
rectosigmoid 102.57 
74 102.35 
low-risk 102.06 
analytes 101.85 
(HSIL) 101.83 
MeSHMolecularDiagnosticTechniques 101.67 
31 101.62 
NPV 101.51 
ThinPrep 101.49 
MeSHColon 101.01 
significant 101.00 
increased 100.94 
MeSHEndosonography 100.73 
[ 100.73 
acromial 100.66 
HPV-positive 100.40 
MeSHPulmonary 100.38 
DESIGN 100.22 
MeSHLocal 100.16 
adjust 100.05 
cholecystectomy 99.90 
15-22 99.79 
High-risk 99.49 
station-specific 99.47 
full- 99.17 
Alpha 99.09 
11- 98.98 
30 98.72 
Aspergillosis 98.71 
cover 98.65 
bodies 98.64 
36 98.60 
37 98.36 
interval 98.19 
(PPV 98.17 
15 98.14 
CIN2+ 98.00 
MeSHShoulderImpingementSyndrome 97.79 
(alpha-fetoprotein 97.56 
bed 97.27 
Impingement 97.27 
32 97.24 
HCG) 97.24 
33 97.14 
MeSHWoundsandInjuries 97.11 
For 96.99 
storage 96.62 
80% 96.61 
concentrations 96.58 
invasive 96.53 
98 96.52 
acute 96.52 
valuation 96.46 
MeSHGeneticTesting 96.40 
refer 96.29 
axillary 96.25 
diagnosing 96.14 
use 96.01 
50 95.91 
(free 95.91 
Disorders 95.87 
Lung 95.84 
calculation 95.77 
MeSHLymphaticDiseases 95.77 
uterosacral 95.75 
69 95.63 
LS 95.54 
collect 95.01 
body 95.01 
G 94.88 
Colon 94.75 
evaluation 94.56 
gestation-specific 94.53 
MeSHColorectalNeoplasms 94.46 
001 94.37 
cent) 94.27 
lymphadenopathy 94.24 
weight 94.23 
MoMs 94.19 
port 94.15 
compression 94.01 
5%) 93.65 
61 93.61 
can 93.44 
gram 93.24 
group 93.11 
supraspinatus 93.07 
amniocenteses 92.92 
dose 92.91 
MeSHWounds 92.83 
activity 92.73 
1) 92.65 
26 92.59 
90th 92.39 
MeSHPhysicalExamination 92.28 
Fusion 92.20 
underwent 92.14 
HR- 91.94 
(ASC-H) 91.84 
Gallbladder 91.84 
MeSHType1 91.75 
agree 91.71 
if 91.52 
(P 91.28 
determinations 91.27 
(alpha 91.26 
Disc 91.16 
describe 91.01 
plastic 90.89 
MSAFP 90.86 
significantly 90.84 
(Pap) 90.72 
MeSHLung 90.61 
DESIGN: 90.60 
TB) 90.52 
MeSHPreoperativeCare 90.48 
presented 90.44 
should 90.42 
MeSHRiskFactors 90.17 
gallstones 90.10 
Elderly 90.10 
O 90.01 
(0 89.96 
Duke 89.87 
Cepheid 89.85 
examine 89.78 
CIN3 89.72 
MeSHHPV 89.61 
expression 89.47 
hot 89.41 
top 89.38 
determination 89.31 
28 89.22 
TVS 89.15 
Comparison 89.05 
MeSHStomachNeoplasms 88.90 
groin 88.89 
39 88.86 
present 88.79 
MeSHGallbladder 88.42 
non-smoker 88.37 
spinatus 88.36 
drug 88.33 
Using 88.27 
Dukes 88.16 
neurologic 88.14 
feature 88.12 
beta-subunit 88.09 
Meta 88.01 
subacromial 87.91 
MeSHCognitionDisorders 87.91 
(Pap 87.47 
non-smokers 87.39 
combinations 87.36 
termination 87.27 
Xpert(R) 87.11 
data 87.09 
euro 86.90 
shoulders 86.88 
MeSHNormalDistribution 86.85 
56 86.75 
MeSHPregnancyinDiabetics 86.67 
44 86.65 
labrum 86.45 
induced 86.21 
Likelihood 86.11 
predicted 86.03 
stored 85.94 
terminations 85.78 
MeSHTrisomy 85.71 
genesis 85.64 
extra 85.51 
rectovaginal 85.40 
(DIE) 85.39 
Metastasis 85.38 
(Xpert 84.85 
Nasal 84.69 
ng/ml 84.58 
; 84.53 
(DR) 84.41 
MeSHReceptor 84.37 
86% 84.24 
common 84.21 
B) 84.19 
Biliary 84.17 
58 84.15 
DIE) 83.99 
combining 83.92 
Turner 83.83 
dobutamine 83.71 
53 82.95 
Trisomy 82.81 
Dr 82.80 
eight 82.79 
presentation 82.68 
SurePath 82.63 
curve 82.46 
creatinine 82.24 
greater 82.21 
96% 82.17 
HR-HPV 81.99 
Compression 81.92 
fractures 81.82 
(IDDM) 80.87 
(IDDM 80.87 
thallium 80.70 
features 80.53 
Gallstone 80.52 
(HCG) 80.49 
superior 80.43 
Outcome 80.38 
MeSHCognition 80.38 
MT 80.14 
STUDY 80.08 
nerve 79.95 
(7 79.88 
Chi 79.87 
Culture 79.81 
Local 79.81 
100%) 79.76 
characterize 79.75 
Stored 79.63 
discuss 79.54 
Cognition 79.52 
Surgical 79.03 
PPV) 78.69 
apt 78.58 
68 78.48 
dipyridamole 78.44 
booked 78.44 
Thin 78.25 
01) 78.18 
19 78.09 
characterized 78.02 
Protein 78.01 
malignant 77.87 
MeSHPostoperativeComplications 77.76 
path 77.62 
controls 77.60 
MeSHColor 77.17 
when 77.06 
conceived 76.98 
cellular 76.88 
mid-trimester 76.76 
estimates 76.69 
MeSHReceptors 76.57 
usual 76.53 
Antigen 76.27 
94% 76.13 
prediction 76.13 
20 76.03 
(PPV) 76.03 
IA 75.84 
92% 75.72 
MeSHLikelihoodFunctions 75.61 
drainage 75.59 
D: 75.41 
neurological 75.28 
each 75.24 
Defect 75.12 
tract 75.08 
drugs 74.90 
Out 74.87 
bursa 74.84 
79% 74.70 
52 74.64 
alpha-hCG 74.42 
had 74.22 
Defects 74.21 
neoplastic 74.17 
safe 74.17 
radiologist 74.15 
diseases 73.83 
(MSAFP) 73.78 
MSAFP) 73.78 
To 73.69 
responses 73.68 
10-14 73.65 
(FPR) 73.43 
Different 73.34 
specificities 73.34 
80 73.25 
right 73.21 
reveal 73.08 
operator 73.03 
88% 72.98 
radiation 72.98 
MeSHTumor-Associated 72.82 
Color 72.79 
child 72.67 
Combining 72.67 
screen-negative 72.38 
trisomies 72.31 
MeSHSpinalDiseases 72.27 
sent 71.98 
0%) 71.77 
nine 71.70 
just 71.50 
usefulness 71.23 
SLAP 71.08 
weighted 71.03 
MeSHStomach 70.81 
spina 70.71 
84% 70.66 
Stomach 70.56 
capture 70.43 
001) 70.35 
MeSHTendinopathy 70.23 
median) 70.07 
Amniocentesis 70.05 
literature 69.72 
MeSHSurgical 69.61 
MeSHBackPain 69.57 
hernia 69.57 
(TB) 69.51 
89% 69.47 
43 69.47 
valid 69.45 
MeSHDiagnosis 69.45 
infection 69.35 
MeSHBileDuct 69.22 
87% 69.08 
MeSHHematologicNeoplasms 69.01 
ltrasonographic 68.99 
Detection 68.95 
Alpha-fetoprotein 68.92 
pathogenesis 68.90 
typical 68.85 
sigmoid 68.81 
MOMs 68.80 
symptoms 68.62 
tissues 68.58 
R 68.56 
manifestation 68.42 
modelling 68.24 
hundred 68.23 
Disease 68.19 
differential 68.18 
percutaneous 67.91 
triple-marker 67.90 
12 67.86 
MeSHLowBackPain 67.83 
conceive 67.68 
MeSHAlphapapillomavirus 67.64 
MeSHPregnancyOutcome 67.54 
euploid 67.42 
offer 67.27 
aspiration 66.89 
statistic 66.84 
mechanisms 66.67 
48 66.62 
mm 66.59 
unresectability 66.56 
Dobutamine 66.50 
depth 66.49 
algorithms 66.43 
T-cell 66.35 
MeSHDifferential 66.35 
MeSHBiopsy 66.33 
2%) 66.27 
utility 66.19 
form 66.17 
accurately 66.14 
duct 65.90 
revealed 65.78 
OBJECTIVES 65.76 
Bone 65.73 
OC 65.72 
60% 65.62 
MMS 65.53 
98% 65.41 
71% 65.28 
pap 65.25 
SUBJECTS 65.24 
OBJECTIVES: 65.04 
mediastinal 65.02 
antigen 65.01 
retrospect 64.86 
LAP 64.85 
manifest 64.70 
MeSHGallstones 64.65 
MeSHNeck 64.65 
interpret 64.63 
smokers 64.60 
54 64.54 
cholelithiasis 64.50 
55 64.49 
overall 64.28 
assayed 64.22 
MeSHRupture 64.20 
(TB 64.14 
MeSHAspergillosis 64.11 
active 64.11 
dyskaryosis 64.04 
Complications 63.99 
necrosis 63.97 
tears: 63.94 
MeSHRadioimmunoassay 63.81 
retrospective 63.78 
MeSHSpinalFractures 63.77 
Sp 63.76 
GeneXpert 63.67 
aneuploid 63.62 
finding 63.58 
NTD 63.58 
elevation 63.53 
(n 63.37 
function 63.33 
having 63.29 
MeSHExerciseTest 63.21 
Accuracy 63.10 
bursal 63.09 
skin 63.08 
MeSHPregnancy-Specificbeta1-Glycoproteins 63.03 
chemotherapy 62.96 
SP1) 62.96 
97% 62.91 
ultrasonographic 62.87 
MeSHCyclin-DependentKinaseInhibitorp16 62.80 
transplant 62.79 
(ROC) 62.64 
MeSHCervicalVertebrae 62.57 
MeSHAntitubercularAgents 62.47 
Of 62.42 
Platelia 62.39 
MeSHAmniocentesis 62.38 
disc 62.35 
symptom 62.24 
pregnancies; 62.21 
recover 62.10 
inhibit 62.09 
(DR 62.04 
children 61.99 
thoracic 61.93 
MeSHAlgorithms 61.92 
performed 61.92 
inflammatory 61.86 
60 61.72 
nodal 61.65 
03 61.58 
aneuploidies 61.52 
cognitive 61.46 
assays 61.45 
echo 61.42 
MeSHEndoscopic 61.38 
IDDM 61.34 
before 61.29 
ROC) 61.28 
proliferation 61.28 
(2 61.00 
MCI 60.96 
MeSHPain 60.86 
(SURUSS) 60.86 
MeSHDipyridamole 60.86 
above 60.74 
MeSHCase-ControlStudies 60.74 
T2 60.73 
MeSHDementia 60.72 
occur 60.53 
MeSHPainMeasurement 60.51 
spleen 60.45 
When 60.45 
papilla 60.35 
(5 60.31 
exclude 60.23 
Mycobacterium 60.19 
Triple 60.15 
HC2 60.09 
Acute 60.04 
57 60.03 
whether 59.89 
Douglas 59.78 
85% 59.71 
statistical 59.58 
syndrome-affected 59.51 
(TVS) 59.51 
test) 59.50 
POPULATION 59.45 
twin 59.36 
under 59.32 
Dementia 59.29 
49 59.21 
efficiency 59.17 
reference 58.97 
Dipyridamole 58.93 
effects 58.83 
trimester: 58.78 
MeSHRectalDiseases 58.61 
(6 58.58 
POPULATION: 58.55 
mid- 58.52 
cytological 58.36 
N2 58.28 
system 58.25 
alphafetoprotein 58.19 
50% 58.18 
dementia 58.15 
led 58.14 
correlated 58.13 
MeSHCholangiopancreatography 58.07 
identify 57.94 
Assessment 57.91 
1%) 57.85 
issues 57.84 
great 57.74 
prevent 57.71 
develop 57.67 
less 57.66 
development 57.55 
vs 57.54 
find 57.51 
deficiency 57.41 
removal 57.40 
MeSHDobutamine 57.38 
findings 57.32 
CI) 57.32 
macrophage 57.22 
MeSHThallium 57.09 
smoker 57.06 
10-13 57.06 
robs 56.90 
systemic 56.77 
(DSE) 56.74 
(Digene 56.72 
hyperglycosylated 56.69 
informants 56.69 
MeSHPreschool 56.46 
sphincterotomy 56.42 
observer 56.39 
78% 56.24 
41 56.22 
(4 56.14 
involve 56.01 
HC2) 56.00 
clear 55.94 
MeSHShoulderInjuries 55.85 
deep 55.73 
Thallium 55.69 
Dimeric 55.66 
(Cepheid 55.66 
needle 55.58 
strain 55.55 
24 55.51 
MS 55.51 
(LBC) 55.49 
threshold 55.38 
leak 55.35 
SP1 55.16 
Post 55.13 
comparison 55.11 
69% 54.91 
second-look 54.90 
(SP1) 54.85 
MeSHCarbohydrate 54.75 
5) 54.70 
pillar 54.68 
bacteria 54.65 
MeSHPancreaticNeoplasms 54.59 
23 54.58 
MMSE 54.46 
Linear 54.37 
test: 54.32 
gestations 54.25 
(CAD) 54.25 
SETTING 54.24 
MeSHAntibodies 54.14 
SUBJECTS: 54.14 
MeSHSkinNeoplasms 54.13 
BACKGROUND: 54.12 
free-beta 54.04 
67% 54.03 
multiple-marker 54.01 
receiver-operator 53.94 
SURUSS 53.94 
(CIN2+ 53.94 
Asian 53.89 
(CAD 53.81 
antibodies 53.73 
DSE 53.70 
MeSHEndoscopicRetrograde 53.65 
micro 53.62 
cuff: 53.49 
endometriomas 53.42 
MeSHRadiography 53.40 
HR) 53.37 
(HR 53.36 
mechanism 53.33 
examination 53.28 
CIN2+) 53.21 
MeSHShoulderPain 53.18 
CAD) 53.13 
Her 53.12 
referred 53.12 
abscess 53.11 
biceps 53.04 
59 52.95 
lymphomas 52.77 
course 52.73 
Bethesda 52.68 
Beth 52.61 
discussed 52.48 
correlation 52.41 
DIE 52.28 
SE 52.23 
method 52.23 
56% 52.23 
Kryptor 52.17 
recurrences 52.13 
hepatic 51.94 
(HC2) 51.80 
ability 51.74 
school 51.72 
used 51.62 
47 51.61 
(SIL) 51.48 
MeSHAsia 51.40 
age 51.37 
MeSHCoronaryAngiography 51.35 
82% 51.30 
formed 51.26 
contingent 51.24 
echocardiography 51.21 
do 51.19 
those 51.17 
MeSHBileDucts 51.08 
move 51.03 
who 51.03 
fact 50.99 
integrated 50.98 
quadruple 50.98 
1:30 50.94 
65 50.77 
Negative 50.72 
patient-specific 50.71 
pregnancies: 50.71 
radiotherapy 50.70 
radiologists 50.58 
MeSHAcute 50.57 
51 50.50 
Inform 50.50 
obtain 50.43 
HPV-DNA 50.41 
MeSHPair13 50.36 
same 50.30 
organ 50.30 
obtained 50.25 
correlate 50.21 
MeSHThoracic 50.12 
CAD 50.12 
serial 50.10 
cells 49.99 
identifying 49.85 
caused 49.85 
Precancerous 49.82 
p16 49.81 
oncogenic 49.72 
karyotype 49.68 
OSCAR 49.65 
Correcting 49.65 
trimesters 49.65 
tool 49.60 
identified 49.59 
centiles 49.54 
follicular 49.51 
cholecystitis 49.51 
(8 49.50 
later 49.43 
fusion 49.42 
MHz 49.42 
chronic 49.32 
anomalies 49.26 
sonographer 49.25 
pregnancy-specific 49.22 
lab 49.14 
(CIN2+) 49.00 
syndrome: 48.93 
efficient 48.79 
(ASC) 48.75 
unnecessary 48.73 
cholangitis 48.71 
(NPV 48.69 
infected 48.66 
TT 48.65 
000 48.62 
sandwich 48.58 
FMF 48.51 
classified 48.51 
yield 48.51 
(Xpert) 48.49 
estriol: 48.49 
MeSHCholecystitis 48.48 
toxicity 48.42 
lateral 48.40 
success 48.27 
phenotype 48.27 
relief 48.24 
ani 48.17 
MeSHGastroscopy 48.16 
kappa 48.15 
NPV) 48.15 
CD4 48.11 
beta-HCG 47.99 
(US 47.98 
correcting 47.97 
mental 47.90 
described 47.89 
chemical 47.87 
MeSHLungNeoplasms 47.85 
MeSHFalseNegativeReactions 47.79 
karyotyping 47.74 
standard 47.73 
Transvaginal 47.68 
oblique 47.63 
ASC) 47.61 
latent 47.58 
(LR 47.47 
colonoscopy 47.46 
(HCII 47.44 
MeSHCholangitis 47.36 
Galactomannan 47.31 
either 47.26 
Care 47.23 
place 47.23 
IVF 47.18 
(CRL) 47.12 
disease 47.07 
mul 47.02 
MeSHInfant 46.99 
factor 46.94 
MeSHPrecancerousConditions 46.94 
ploidy 46.91 
(LUS) 46.87 
E 46.84 
MEASURES: 46.84 
70% 46.72 
corrected 46.72 
smoke 46.69 
(MCI) 46.65 
MeSHRetrospectiveStudies 46.63 
P 46.44 
(same 46.43 
Retrospective 46.37 
MeSHObserverVariation 46.37 
(HR-HPV) 46.36 
%; 46.35 
accuracies 46.30 
MeSHGlycoproteinHormones 46.30 
coronal 46.28 
interpretation 46.24 
bacterial 46.22 
HIV 46.16 
heal 46.13 
sampling 46.12 
MATERIAL 46.08 
aortic 46.04 
Caucasian 46.01 
migration 46.01 
sequential 45.99 
Normal 45.99 
mg 45.98 
MeSHNon-Hodgkin 45.97 
SETTING: 45.95 
up 45.95 
typing 45.92 
RIA 45.92 
strains 45.88 
low 45.86 
Marrow 45.85 
02 45.85 
extraction 45.84 
Atypical 45.84 
tumor 45.82 
MeSHEuropeanContinentalAncestryGroup 45.70 
CRL 45.63 
rates 45.63 
Examination 45.61 
RO 45.60 
rat 45.58 
LR+ 45.53 
MoM; 45.53 
with 45.47 
MeSHMycobacterium 45.46 
(> 45.46 
primary 45.43 
triploidy 45.43 
dissection 45.41 
ie 45.41 
stain 45.37 
root 45.26 
AD) 45.24 
examined 45.16 
(HR) 45.12 
MeSHAntitubercular 45.10 
MeSHFertilizationinVitro 45.10 
disorder 44.97 
09 44.94 
MeSHMentalStatusSchedule 44.89 
neural 44.87 
host 44.77 
46 44.74 
USL 44.72 
purpose 44.69 
Small 44.66 
MeSHCombinedModalityTherapy 44.59 
TB 44.58 
Foundation 44.57 
8) 44.57 
AGC 44.52 
9%) 44.28 
unselected 44.23 
extract 44.22 
whilst 44.22 
liter 44.21 
MeSHRadiotherapy 44.14 
mother 44.10 
Roche 44.07 
MeSHKaryotyping 44.07 
difference 44.06 
iliac 44.06 
glenoid 44.00 
addition 43.97 
once 43.94 
2) 43.94 
9) 43.93 
assessed 43.92 
(IVF) 43.89 
lower 43.84 
immunity 43.82 
so 43.80 
yr 43.73 
(multiples 43.70 
FPRs 43.70 
cancerous 43.64 
Carlo 43.60 
Over 43.57 
Schwangerschafts 43.55 
secondary 43.52 
analog 43.51 
MeSHLeukemia 43.48 
63% 43.45 
(specificity 43.39 
(I 43.36 
London 43.33 
Ultrasound 43.33 
prove 43.31 
included 43.26 
pulmonary 43.21 
hyperplasia 43.20 
MeSHLaparoscopic 43.13 
manifestations 43.13 
improves 43.12 
z 43.09 
Biopsy 43.07 
ND 43.03 
et 42.99 
Postoperative 42.99 
additional 42.93 
papillary 42.79 
73% 42.78 
12-14 42.76 
ethnic 42.75 
fit 42.75 
germ 42.75 
74% 42.74 
0-1 42.71 
two 42.68 
MeSHTendons 42.64 
leukemia 42.61 
validity 42.52 
stem 42.51 
left 42.50 
female 42.48 
MeSHGeriatricAssessment 42.47 
Mosaic 42.46 
7) 42.44 
VF 42.44 
MeSHMicroscopy 42.43 
motor 42.37 
estimated 42.35 
tuberculous 42.30 
(HCII) 42.29 
Screen- 42.29 
The 42.26 
MAIN 42.24 
(98 42.23 
Exam 42.13 
programmes 42.08 
smear-negative 42.03 
singletons 42.01 
(DCBE) 42.00 
MeSHFertilization 41.95 
min 41.86 
O'Brien 41.73 
Screen-positive 41.73 
D1 41.69 
MeSHDiabetesMellitus 41.63 
four 41.55 
biparietal 41.54 
EIA 41.53 
Prep 41.46 
frequent 41.43 
1/270 41.32 
(Platelia 41.30 
"triple 41.30 
by 41.30 
severe 41.27 
failure 41.27 
81% 41.26 
MeSHPregnancyProteins 41.25 
Drug 41.20 
77% 41.18 
MeSHAcuteDisease 41.16 
dysfunction 41.13 
CIN1 41.12 
condition 41.02 
F 41.02 
MeSHPancreatitis 41.01 
doses 40.98 
Infections 40.97 
work 40.94 
organs 40.94 
HCII 40.91 
MeSHPsychometrics 40.90 
thyroid 40.89 
antigens 40.86 
(CRC) 40.84 
BCG 40.83 
cardia 40.83 
MeSHSphincterotomy 40.78 
Twin 40.77 
dating 40.76 
log10 40.75 
recovery 40.74 
transplantation 40.73 
MeSHThalliumRadioisotopes 40.70 
relation 40.69 
LR- 40.69 
Asians 40.68 
log(10) 40.67 
MeSHMosaicism 40.63 
MeSHSpinalNeoplasms 40.59 
LR-) 40.44 
1/2 40.39 
tears) 40.37 
six 40.37 
1:250 40.36 
key 40.36 
positives 40.33 
(NPV) 40.33 
(FMF) 40.33 
long-term 40.31 
proves 40.29 
borderline 40.29 
able 40.27 
0001 40.26 
MeSHDrug 40.25 
- 40.23 
functional 40.20 
tested 40.18 
8%) 40.12 
MeSHMethods 40.11 
operating 40.08 
diagnosis 40.00 
diabetic 39.99 
p16INK 39.90 
east 39.83 
early 39.83 
antigenemia 39.82 
enema 39.80 
gonadotropin) 39.77 
adding 39.69 
Chemotherapy 39.67 
duodenal 39.67 
cavity 39.66 
Among 39.62 
femoral 39.57 
Echocardiography 39.53 
(LR+ 39.50 
fail 39.49 
Monte 39.39 
4%) 39.38 
(risk 39.35 
suspected 39.35 
1:300 39.34 
cytokine 39.33 
(r 39.31 
16- 39.30 
UE3 39.26 
culinaris 39.26 
(Cr) 39.26 
Pancreatitis 39.13 
MeSHContinentalPopulationGroups 39.13 
prevention 39.12 
suspect 39.11 
05 39.07 
AND 39.06 
MeSHEchocardiography 38.96 
rectum 38.91 
immunoglobulin 38.87 
MeSHHead 38.80 
DCBE 38.79 
(beta-core 38.79 
(USL) 38.79 
MeSHPancreasTransplantation 38.70 
long 38.68 
MeSHDiabeticNephropathies 38.60 
dysplasia 38.53 
angiography 38.48 
stay 38.44 
curves 38.41 
Levels 38.37 
Six 38.33 
sera 38.31 
understand 38.30 
correction 38.29 
Level 38.26 
shoulder: 38.24 
septum 38.22 
MeSHNeuropsychologicalTests 38.14 
could 38.09 
canal 38.08 
involved 38.05 
Mini-Mental 38.05 
Acromioclavicular 37.95 
MeSHDNA 37.93 
dominant 37.93 
abnormality 37.93 
AIDS 37.91 
p16(INK4a) 37.87 
non-smoking 37.87 
DATA: 37.86 
transabdominal 37.84 
come 37.82 
triploid 37.82 
region 37.81 
MeSHGallbladderDiseases 37.78 
MeSHAntineoplasticCombinedChemotherapyProtocols 37.74 
lymphatic 37.71 
correspond 37.69 
retrospectively 37.66 
CASE 37.64 
E) 37.64 
therapeutic 37.55 
Creatinine 37.53 
385 37.42 
against 37.40 
Fluorescence 37.37 
2+ 37.37 
DSM 37.32 
mosaicism 37.31 
MeSHTwins 37.28 
predictor 37.27 
MeSHFlowCytometry 37.20 
(G 37.20 
1/250 37.19 
270) 37.19 
complex 37.18 
D2 37.16 
CRC 37.15 
Multiples 37.14 
gastric 37.14 
stroma 37.13 
(LRs) 37.12 
blinded 37.05 
interobserver 37.01 
55% 36.98 
interpreted 36.91 
New 36.89 
nasal 36.85 
imaging 36.84 
Neuropsychological 36.81 
MeSHTraumaCenters 36.77 
Correct 36.75 
endometrioma 36.59 
remove 36.55 
83% 36.52 
(FPRs) 36.52 
N3 36.51 
reliability 36.49 
origin 36.49 
Laparoscopy 36.47 
centre 36.42 
percent 36.41 
1-glycoprotein 36.40 
Recurrence 36.36 
agglutinin-reactive 36.36 
Weight 36.33 
European 36.30 
sonographers 36.30 
balloon 36.26 
MeSHTumorVirusInfections 36.26 
42% 36.22 
bronchial 36.19 
estimation 36.19 
neutropenic 36.16 
14- 36.11 
hype 36.04 
MeSHJointInstability 36.02 
percentile 35.97 
Coronary 35.95 
MeSHInvasive 35.95 
MeSHBiliaryTract 35.94 
validation 35.91 
MeSHAsianContinentalAncestryGroup 35.89 
MeSHCoronary 35.89 
cutoffs 35.87 
calculations 35.81 
Mental 35.80 
immunohistochemical 35.79 
double-contrast 35.70 
MeSHHIV 35.70 
MeSHLaparoscopy 35.62 
disability 35.60 
mediated 35.60 
older 35.57 
whereas 35.57 
ductal 35.53 
MeSHInvasivePulmonaryAspergillosis 35.50 
noninvasive 35.50 
aging 35.48 
detects 35.48 
endosonographic 35.47 
MeSHPsychiatricStatusRatingScales 35.43 
Overall 35.40 
(10 35.40 
metastasis 35.36 
(nuchal 35.35 
utero 35.35 
Afro-Caribbean 35.30 
relocation 35.30 
age-related 35.27 
MeSHInterferon-gamma 35.27 
expected 35.26 
MeSHalphaSubunit 35.24 
MeSHKidneyFailure 35.23 
Sixty 35.20 
MeSHFluorescence 35.19 
implantation 35.14 
excluded 35.12 
paraffin 35.11 
deviation 35.09 
MeSHPoint-of-CareSystems 35.08 
MeSHCostsandCostAnalysis 35.07 
Medians 35.04 
gains 35.02 
Integrated 34.97 
process 34.96 
uncommon 34.96 
Pregnancies 34.94 
SILs 34.87 
benign 34.86 
MeSHTuberculinTest 34.85 
exposure 34.83 
Mutation 34.83 
MeSHPostoperative 34.80 
medical 34.76 
twice 34.66 
2/3 34.62 
hygroma 34.62 
MeSHNeoplastic 34.59 
database 34.57 
(97 34.54 
MeSHMediastinum 34.52 
occurs 34.51 
iron 34.48 
versus 34.44 
infusion 34.42 
TVU 34.41 
(RES) 34.40 
Laboratorium 34.39 
Algemeen 34.39 
MTB/RIF) 34.39 
diagnose 34.38 
therapies 34.38 
MeSHDisabilityEvaluation 34.38 
gene 34.36 
both 34.30 
SUMMARY 34.27 
10th 34.19 
humans 34.17 
determining 34.16 
bleeding 34.13 
Jobe 34.07 
1:350 34.07 
Antwerp 34.07 
MeSHCholecystography 34.07 
valuable 34.06 
Extra 34.05 
MeSHSmoking 34.05 
pancreatitis 34.00 
cystic 33.96 
according 33.96 
76% 33.93 
childhood 33.91 
Neoplastic 33.89 
Bacterial 33.86 
228 33.85 
Placental 33.84 
cultured 33.82 
Age 33.80 
examiner 33.76 
stratification 33.69 
triple-screen 33.66 
hCG: 33.66 
Cost 33.64 
cancer 33.62 
unresectable 33.59 
Excision 33.56 
MeSHB-Cell 33.55 
cervical 33.55 
62% 33.53 
situ 33.51 
DNA 33.49 
three 33.47 
coefficient 33.46 
reliably 33.37 
got 33.32 
HSCT 33.29 
Ca 33.23 
too 33.21 
Common 33.18 
decompression 33.14 
ducts 33.11 
aim 33.10 
coronary 33.09 
venosus 33.05 
treating 33.00 
MeSHCombination 32.94 
MeSHThoracicVertebrae 32.90 
tendons 32.88 
(US) 32.88 
0001) 32.86 
Fetuses 32.84 
factors 32.81 
hygromas 32.81 
Neer 32.81 
MeSHPolymorphism 32.79 
FET 32.74 
(accuracy 32.71 
MeSHLymphNodeExcision 32.68 
insulin 32.66 
?/nMeSHAdolescent 32.66 
Forty 32.60 
(MMSE 32.59 
Fertil 32.57 
A; 32.56 
t-test 32.56 
target 32.55 
distribution 32.53 
(SLAP) 32.48 
adult 32.48 
181 32.42 
tend 32.40 
T2- 32.34 
mycobacteria 32.30 
(MR) 32.22 
interact 32.20 
uE(3) 32.20 
(100% 32.19 
resistant 32.17 
MeSHHeadandNeckNeoplasms 32.14 
segment 32.14 
MeSHBiliaryTractDiseases 32.10 
medication 31.98 
radioimmunoassay 31.96 
MeSHImmunologic 31.95 
inform 31.93 
Smoking 31.92 
equivocal 31.91 
leakage 31.86 
lucency: 31.83 
fever 31.81 
endometriosis: 31.81 
RWC-TVS 31.80 
day-specific 31.80 
IVF-conceived 31.80 
hCG/creatinine 31.80 
"quad" 31.80 
(PAPP-A)] 31.80 
hCG/Cr 31.80 
(FET) 31.80 
6548 31.80 
supinated 31.80 
(GX) 31.80 
Grampian 31.80 
(RWC-TVS) 31.80 
ethnicity-specific 31.80 
-hCG/Cr 31.80 
(970 31.80 
[uE(3)] 31.80 
low- 31.76 
standing 31.75 
Therapeutic 31.71 
W 31.71 
etiology 31.67 
define 31.66 
Our 31.66 
MeSHCommon 31.59 
corresponding 31.57 
trimester) 31.57 
ascertain 31.56 
6) 31.55 
Elevated 31.53 
dyskaryotic 31.51 
Lens 31.51 
completely 31.47 
hysterectomy 31.47 
IFN-gamma 31.46 
4) 31.46 
five 31.46 
Yergason 31.46 
villus 31.44 
L) 31.44 
(LA) 31.43 
(p 31.43 
placed 31.42 
MeSHDrugTherapy 31.40 
?/nMeSHAged 31.40 
contain 31.40 
examiners 31.33 
Flanders 31.30 
MeSHPlacentalHormones 31.30 
MeSHPlacentalLactogen 31.30 
(LR-) 31.30 
improvement 31.29 
hr 31.24 
(SLAP 31.24 
443 31.24 
infectious 31.24 
twins 31.22 
MeSHNucleicAcidAmplificationTechniques 31.22 
Scales 31.22 
probability 31.20 
marrow 31.20 
length 31.19 
tension 31.18 
entity 31.14 
21% 31.12 
cholangiography 31.11 
seven 31.11 
1:400 31.11 
protect 31.08 
stabilization 31.07 
False-positive 31.06 
men 31.06 
350 31.02 
MeSHCreatinine 30.96 
TVUS 30.86 
14-20 30.86 
edge 30.83 
MeSHImmunohistochemistry 30.82 
(100 30.82 
myocardial 30.82 
(NTD) 30.74 
operation 30.73 
cardiac 30.73 
Measurement 30.73 
added 30.72 
MeSHNeedle 30.72 
ear 30.71 
irradiation 30.68 
Radiation 30.67 
blood 30.67 
considered 30.64 
per 30.63 
confirm 30.61 
nuclear 30.60 
overstaging 30.56 
scan 30.52 
criteria 30.50 
cost-effective 30.44 
58% 30.43 
MATERIALS 30.41 
MeSHX 30.39 
MeSHDecompression 30.39 
100%; 30.37 
animals 30.35 
Mediastinal 30.35 
19-9 30.28 
false-negative 30.27 
rating 30.26 
(OD) 30.24 
Hybrid 30.24 
CEA- 30.23 
Response 30.20 
dried 30.18 
Low 30.18 
Form 30.17 
lymphadenitis 30.17 
weeks) 30.16 
static 30.14 
SCT 30.10 
LC 30.09 
converters 30.08 
MeSHDiseaseModels 30.06 
hold 30.05 
(diagnosis); 30.03 
48% 30.01 
?/nMeSHAdult 30.01 
Neurologic 29.98 
idiopathic 29.96 
bone 29.94 
well 29.93 
MeSHCellLine 29.92 
blastic 29.90 
receptors 29.89 
mass 29.87 
morbidity 29.86 
interaction 29.83 
1:100 29.81 
colposcopically 29.81 
(detection 29.81 
equal 29.76 
point-of-care 29.76 
multicentre 29.74 
00) 29.73 
activation 29.67 
?/nMeSHAnimals 29.67 
AN 29.67 
MeSHAdjuvant 29.65 
fornix 29.62 
intrahepatic 29.62 
morphological 29.59 
Physical 29.57 
King 29.55 
Median 29.49 
Costs 29.47 
materially 29.46 
reader 29.45 
2+) 29.43 
smoking 29.43 
papillomavirus- 29.39 
scapular 29.37 
protocols 29.35 
transcription 29.35 
obstruction 29.33 
topic 29.31 
99% 29.29 
17-23 29.28 
Ethnic-specific 29.28 
ThCG 29.28 
ASCUS/LSIL 29.28 
(ThCG) 29.28 
Jorm 29.28 
25/29 29.28 
Interobserver 29.24 
medullary 29.24 
be 29.21 
where 29.20 
October 29.16 
transcript 29.16 
199 29.16 
2-14 29.15 
transmission 29.13 
programs 29.11 
T2-weighted 29.08 
era 29.03 
immunological 29.03 
torn 29.00 
simulation 28.97 
11(+0) 28.89 
(DRs) 28.89 
inhibin-A) 28.89 
Aspergillus) 28.89 
gamma 28.88 
differ 28.88 
calculating 28.85 
Neck 28.84 
Dukes' 28.82 
(maternal 28.81 
6-1 28.77 
=1 28.75 
potentially 28.74 
culture-positive 28.72 
biometry 28.71 
electrocardiogram 28.70 
treatments 28.69 
adjuvant 28.65 
MeSHAneuploidy 28.60 
93%) 28.59 
vision 28.56 
LR 28.56 
lobe 28.54 
mosaic 28.53 
ultrastaging 28.53 
MeSHDimerization 28.53 
Speed 28.53 
RTC 28.45 
best 28.43 
statistically 28.43 
(CA 28.41 
Am 28.41 
MeSHDNAProbes 28.40 
successful 28.36 
estrogen 28.36 
Hepatic 28.34 
Instability 28.30 
sp 28.28 
aspect 28.24 
MeSHImmunoglobulinG 28.20 
MeSHCholestasis 28.20 
OUTCOME 28.16 
k 28.16 
accompanied 28.15 
Laparoscopic 28.08 
I) 28.05 
145 28.00 
neoplasm 28.00 
250 27.99 
MeSHAfricanContinentalAncestryGroup 27.99 
Recombinant 27.98 
cardial 27.98 
laser 27.95 
Caucasians 27.94 
pregnancies) 27.92 
immunodeficiency 27.90 
Cohen 27.89 
converter 27.89 
like 27.85 
CAS 27.83 
>or= 27.79 
aneuploidy 27.79 
processes 27.77 
vivo 27.77 
reproduction 27.72 
cytometry 27.70 
play 27.68 
interpretations 27.68 
markers: 27.64 
thousand 27.62 
undergo 27.61 
MeSHMelanoma 27.59 
sensory 27.56 
HPV-Proofer 27.54 
Medisch 27.54 
XXY 27.50 
activin 27.49 
13(+6) 27.49 
Midtrimester 27.49 
one 27.49 
oral 27.49 
TPA 27.48 
health 27.46 
7%; 27.46 
cause 27.45 
measuring 27.44 
(t 27.43 
Carcinoma 27.43 
ductus 27.38 
naturally 27.38 
Infection 27.38 
limb 27.35 
booking 27.34 
choriogonadotropin 27.33 
(TVUS) 27.33 
61% 27.29 
72% 27.28 
assessing 27.26 
Fine 27.24 
tendinitis 27.21 
BACKGROUND 27.16 
Use 27.16 
support 27.13 
HPV-negative 27.12 
end-stage 27.09 
MR 27.07 
300 27.06 
E6 27.03 
apprehension 27.00 
test" 27.00 
Hawkins 27.00 
MeSHMutation 26.97 
chi 26.95 
progress 26.94 
vessels 26.93 
PGH 26.92 
UE3) 26.92 
(RLU 26.92 
substantial 26.91 
damage 26.90 
Transplantation 26.90 
Thirty 26.89 
bloc 26.88 
16-item 26.84 
Inter-test 26.84 
combined: 26.84 
2281 26.84 
40 26.82 
250) 26.81 
MeSHHIVInfections 26.78 
images 26.78 
exposed 26.77 
follow- 26.77 
centres 26.76 
moved 26.75 
person 26.75 
MeSHMycobacteriumtuberculosis 26.74 
but 26.72 
hrHPV 26.71 
ultrasonographer 26.71 
regression 26.70 
(MMSE) 26.70 
fat-saturated 26.69 
CIN2-3 26.69 
Probe 26.69 
regulation 26.69 
(r= 26.67 
nose 26.67 
available 26.67 
endocrine 26.66 
95) 26.60 
aspects 26.59 
reported 26.57 
perforation 26.53 
MeSHCarcinoma 26.50 
acromioclavicular 26.50 
inhibitor 26.50 
consider 26.50 
39% 26.49 
node-negative 26.48 
automated 26.46 
radiograph 26.44 
distributions 26.42 
gravidity 26.39 
loss 26.37 
ng/ml) 26.35 
?/nMeSHChorionicGonadotropin 26.32 
obstetric 26.29 
selecting 26.28 
MeSHEsophagogastricJunction 26.26 
removed 26.19 
below 26.18 
ligaments 26.18 
MeSHNeoplasms 26.18 
MeSHThyroidNeoplasms 26.16 
monitoring 26.13 
promote 26.08 
pretransplant 26.08 
PreTect 26.08 
hPGH 26.08 
GX 26.08 
King's 26.08 
(hPGH) 26.08 
subscapularis 26.07 
Usefulness 26.06 
gender-related 26.05 
CIN2) 26.05 
effectiveness 26.02 
understaging 26.01 
cent; 26.01 
MeSHHematopoieticStemCellTransplantation 26.01 
conjunction 26.00 
MeSHRecurrence 25.99 
cholesterol 25.99 
reliable 25.98 
MeSHBileDuctDiseases 25.98 
arthritis 25.98 
cities 25.97 
obliteration 25.95 
achievable 25.88 
subscapular 25.88 
conservative 25.88 
regimen 25.86 
follow-up 25.85 
548 25.78 
responding 25.74 
Group 25.74 
scapula 25.72 
interleukin 25.71 
Endoscopic 25.66 
attend 25.62 
MeSHLuminescentMeasurements 25.62 
worth 25.59 
MeSHBursitis 25.59 
are 25.57 
disk 25.56 
alcohol 25.54 
retrocervical 25.51 
(E3) 25.51 
Systems 25.47 
postnatally 25.45 
(kappa 25.45 
Study 25.42 
space 25.42 
(false 25.42 
dates 25.38 
age- 25.36 
gain 25.35 
35% 25.35 
try 25.33 
investigate 25.32 
mechanical 25.32 
MeSHHysterectomy 25.31 
Labral 25.25 
(LR+) 25.25 
fetoprotein: 25.25 
parameter 25.25 
AD 25.23 
CP 25.21 
subdeltoid 25.20 
basis 25.20 
strategy 25.18 
stimulation 25.13 
mammary 25.13 
percent) 25.11 
approaches 25.07 
regress 25.07 
Kong 25.04 
arising 25.03 
Status 25.03 
logical 25.01 
diffuse 24.97 
lift-off 24.96 
RLU 24.96 
often 24.94 
?/nMeSHBiopsy 24.93 
Oct 24.93 
respectively) 24.90 
self 24.89 
Hong 24.89 
referral 24.86 
membrane 24.85 
p16(INK4A) 24.83 
antifungal 24.80 
abnormalities) 24.79 
standard) 24.79 
suffer 24.78 
MeSHGeneExpressionRegulation 24.76 
block 24.74 
MeSHCost-BenefitAnalysis 24.69 
Diffuse 24.66 
nature 24.66 
instrumentation 24.65 
reserve 24.64 
expect 24.64 
7-year 24.63 
whom 24.63 
57% 24.56 
(42 24.56 
adjusted 24.56 
blind 24.55 
Kit 24.54 
(aMCI) 24.50 
parietal 24.50 
MeSHDuctal 24.49 
morphologic 24.49 
If 24.48 
Report 24.46 
Contingent 24.44 
MeSHTurnerSyndrome 24.43 
MeSHLiverDiseases 24.41 
accept 24.39 
MeSHIsoniazid 24.38 
Tissue 24.38 
1/1 24.37 
evaluating 24.34 
site 24.34 
intervention 24.33 
scheduled 24.33 
recipients 24.32 
humeral 24.32 
MeSHVaginalDiseases 24.31 
(IPA) 24.30 
Undetermined 24.28 
reciprocal-linear 24.24 
non-IDDM 24.24 
log10MoM 24.24 
Serotec 24.24 
1:270) 24.24 
quarter) 24.24 
Birthright 24.24 
oestriol: 24.24 
[nuchal 24.24 
(dimeric) 24.24 
(hPL) 24.24 
levels? 24.24 
(ONTD) 24.24 
impaired 24.24 
hospitalization 24.22 
Geriatric 24.21 
MeSHRiskAssessment 24.18 
structure 24.15 
frequently 24.11 
calendar 24.10 
MeSHEnema 24.10 
Enema 24.10 
strictures 24.09 
Turner's 24.06 
Seventy 24.05 
image 24.04 
separately 24.03 
isolates 24.03 
(triple 24.00 
observational 24.00 
position 23.98 
MeSHReagentKits 23.97 
molecule 23.95 
Edwards' 23.93 
gestation; 23.93 
HGS 23.93 
US; 23.93 
safety 23.92 
MeSHNeoplasmStaging 23.92 
(93 23.92 
readers 23.90 
Kappa 23.90 
w 23.90 
(10) 23.87 
confirmed 23.87 
been 23.85 
submucosal/mucosal 23.85 
MTB/RIF-generated 23.85 
2123 23.85 
(1/250) 23.85 
clunk 23.85 
Xpert-positive 23.85 
caseness 23.85 
non-IA 23.85 
GeneXpert(R) 23.85 
4841 23.85 
76%-97% 23.85 
dipyridamole-thallium 23.85 
MeSHDose-ResponseRelationship 23.85 
MeSHDiffuse 23.85 
HLA 23.85 
beta-D-glucan 23.84 
consensus 23.84 
enrolled 23.84 
(T21) 23.84 
ST 23.83 
due 23.83 
99th 23.80 
Pretransplant 23.80 
indicator 23.79 
07 23.79 
MeSHCytokines 23.78 
Staging 23.76 
MeSHFatalOutcome 23.75 
Edward 23.73 
MeSHEndometrialNeoplasms 23.73 
ProEx 23.72 
crank 23.72 
HR-HPV-positive 23.72 
Cagliari 23.72 
MeSHDisintegrins 23.72 
[PAPP-A] 23.72 
?/nMeSHArthrography 23.72 
p16INK4A 23.72 
Informants 23.72 
11-13 23.70 
854 23.66 
Rh 23.65 
prior 23.65 
responsible 23.65 
(FTS) 23.62 
MeSHArmInjuries 23.62 
receiver-operating 23.58 
VU 23.58 
Histological 23.54 
vessel 23.52 
DAT 23.51 
Immunohistochemical 23.51 
steroid 23.51 
knowledge 23.50 
ago 23.49 
CT) 23.47 
overstage 23.45 
polymorphism 23.44 
recovered 23.42 
biopsy-proven 23.42 
mining 23.39 
DATA 23.36 
environment 23.35 
self- 23.34 
resection 23.31 
[95 23.30 
administration 23.29 
surveillance 23.28 
97) 23.28 
?/nMeSHBiomarkers 23.28 
intact 23.22 
understanding 23.21 
mycobacterial 23.21 
cultures 23.17 
karyotypes 23.15 
25% 23.12 
recipient 23.10 
MeSHInSituHybridization 23.07 
individuals 23.07 
causing 23.07 
MeSHADAM12Protein 23.06 
727 23.06 
together 23.00 
plain 23.00 
protein: 22.99 
(ALTS 22.99 
endometrium 22.97 
Stepwise 22.96 
hematological 22.93 
technic 22.91 
MeSHPlasma 22.90 
units 22.84 
MeSHPeritonealNeoplasms 22.83 
thought 22.80 
pedicle 22.79 
inter-observer 22.77 
and 22.75 
421 22.75 
Resectability 22.74 
tree 22.73 
staining 22.73 
190 22.72 
rotation 22.71 
Here 22.68 
MeSHBacterial 22.68 
difficult 22.67 
MeSHMonoclonal 22.67 
containing 22.67 
infiltrating 22.66 
LEVEL 22.66 
sciatica 22.65 
approach 22.63 
examinations 22.61 
25) 22.60 
transhepatic 22.60 
melanoma 22.59 
84) 22.57 
64% 22.55 
translucency: 22.54 
300) 22.54 
Pouch 22.54 
819 22.54 
train 22.54 
nodular 22.54 
EORTC 22.54 
D-glucan 22.54 
Endometriomas 22.54 
aMCI 22.53 
nonrespiratory 22.53 
lactogen 22.53 
1:190 22.53 
EQA 22.53 
Cohort 22.53 
Assay 22.50 
missed 22.48 
face 22.48 
ethnicity 22.48 
acid 22.47 
carcinomatosis 22.43 
(11 22.43 
earlier 22.42 
potential 22.38 
UGP 22.36 
beta-subunits 22.36 
shoulder--a 22.36 
significance/low-grade 22.36 
Tayside 22.36 
"triple" 22.36 
17/40 22.36 
3466 22.36 
MeSHMemoryDisorders 22.35 
social 22.34 
producing 22.30 
04 22.27 
carcinogenic 22.27 
Pathologic 22.27 
MeSHCysticDuct 22.27 
resist 22.26 
drug-resistant 22.26 
T1- 22.25 
implement 22.21 
(HSCT) 22.20 
reassure 22.20 
discharge 22.20 
worthwhile 22.19 
diabetes 22.19 
births 22.17 
MeSHQualityofLife 22.16 
odds 22.16 
agents 22.13 
inflammation 22.13 
36% 22.12 
flow 22.11 
subunits 22.11 
Fifty 22.08 
cannot 22.06 
Only 22.05 
Belgium 22.01 
Primary 22.00 
MeSHCommonBileDuct 21.99 
shock 21.98 
T1-weighted 21.96 
2100 21.95 
Immunoassay 21.95 
ADAM12 21.93 
Edwards 21.93 
preceded 21.86 
supra 21.86 
Cuckle 21.85 
serum-based 21.85 
MeSHMinichromosomeMaintenanceComplexComponent2 21.85 
PreservCyt 21.85 
(HSILs 21.85 
joints 21.83 
pathological 21.83 
conjunct 21.81 
acceptable 21.80 
280 21.80 
analgesic 21.80 
(k 21.71 
fixation 21.70 
percent; 21.69 
MeSH"DouglasPouch 21.69 
Management 21.68 
MHz) 21.66 
Adjustment 21.66 
fluorescence 21.66 
MeSHLargeB-Cell 21.66 
MeSHInjections 21.63 
MeSHMouth 21.62 
analogue 21.60 
preliminary 21.59 
draining 21.53 
predictors 21.52 
(62 21.51 
An 21.50 
challenge 21.49 
Reagent 21.48 
convert 21.47 
281 21.47 
twenty 21.47 
generation 21.46 
Serial 21.44 
CA-19-9 21.44 
9-10 21.43 
PURPOSE: 21.42 
Diabetes 21.40 
tears; 21.40 
MeSHPaper 21.40 
two-site 21.40 
DSM-III-R 21.40 
Mini-mental 21.40 
ADNI 21.40 
cost 21.40 
barium 21.40 
biologic 21.36 
MeSHIntrahepatic 21.34 
coefficients 21.32 
Rating 21.32 
E7 21.32 
85%) 21.30 
physiologic 21.29 
(MoMs) 21.29 
(AGC) 21.29 
weekly 21.25 
D 21.23 
MeSHMagneticResonanceImaging 21.18 
291 21.17 
Malignant 21.16 
66% 21.15 
rarely 21.15 
Scotland 21.15 
spread 21.13 
monoclonal 21.12 
(92 21.12 
comparing 21.12 
10- 21.11 
MeSHThree-Dimensional 21.10 
cirrhosis 21.09 
progressive 21.09 
(a 21.08 
5-9 21.05 
AMPLICOR 21.04 
Neer's 21.04 
involvement 21.03 
yielded 21.01 
151 21.01 
Diagnostics 20.99 
facet 20.96 
way 20.96 
53% 20.95 
discriminating 20.95 
antibody 20.94 
net 20.94 
FTS 20.93 
serum-free 20.90 
CIN3) 20.90 
Intrahepatic 20.88 
usually 20.88 
HGSIL 20.87 
alpha-subunit 20.87 
MeSHImmunoradiometricAssay 20.87 
outperformed 20.87 
(t-test 20.87 
hPL 20.87 
beta-core-hCG 20.87 
ONTD 20.87 
groin) 20.87 
estriol; 20.87 
(CIN2-3) 20.87 
NEQAS 20.87 
1:380) 20.87 
2/23) 20.87 
Double-contrast 20.87 
62) 20.86 
MeSHSpermInjections 20.84 
MeSHIntracytoplasmic 20.84 
Consecutive 20.84 
urine 20.84 
USS 20.83 
regulated 20.83 
monitor 20.83 
Step 20.81 
pathway 20.81 
urban 20.81 
some 20.79 
SL 20.78 
MeSHInjurySeverityScore 20.78 
2/2 20.77 
1/3 20.76 
MeSHNeoplasm 20.75 
concordance 20.75 
MeSHBacteriologicalTechniques 20.75 
MeSHIntraoperative 20.73 
Sequential 20.71 
MeSHSyndrome 20.70 
protective 20.66 
?/nMeSHCarcinoembryonicAntigen 20.64 
Correction 20.64 
logarithm 20.64 
gold 20.64 
717 20.63 
immunohistochemistry 20.62 
prostate 20.61 
splenic 20.60 
article 20.57 
inaccurate 20.57 
incorporating 20.57 
activated 20.53 
(hrHPV) 20.53 
268 20.51 
1992 20.50 
order 20.49 
45% 20.48 
isoniazid 20.46 
33% 20.45 
Control 20.44 
axis 20.42 
RCT 20.40 
ninety 20.40 
Initiative 20.40 
Tear 20.40 
oxygen 20.39 
MeSHPapillary 20.39 
papanicolaou 20.37 
(BG) 20.37 
(Roche 20.37 
p= 20.36 
border 20.36 
kinase 20.32 
raised 20.30 
(Thin 20.30 
cases) 20.24 
release 20.23 
persons 20.23 
activities 20.18 
endometriotic 20.17 
615 20.16 
373 20.15 
causes 20.15 
mutation 20.13 
N) 20.12 
Squamous 20.11 
(CI) 20.11 
142 20.11 
Blot 20.10 
adults 20.10 
more 20.09 
odd 20.05 
16-18 20.05 
laparotomy 20.04 
003 20.02 
[9 20.01 
Measurements 20.00 
MeSHLengthofStay 20.00 
UT 19.99 
MeSHRoutine 19.99 
MeSHDiagnosticTests 19.99 
discriminator 19.96 
nucleic 19.95 
Z 19.94 
giving 19.93 
AGUS 19.90 
intra-observer 19.90 
lungs 19.90 
EVIDENCE: 19.87 
(72 19.87 
wound 19.86 
taken 19.85 
exceed 19.85 
Nine 19.83 
cytologically 19.82 
MeSHCoronaryDisease 19.82 
Europe 19.81 
triaging 19.81 
MeSHX-RayComputed 19.81 
ways 19.77 
Administration 19.77 
Peripheral 19.77 
Tears 19.77 
inhibitors 19.76 
inserted 19.76 
share 19.76 
EIA) 19.75 
computer 19.75 
plane 19.74 
onset 19.74 
operators 19.71 
MeSHScotland 19.69 
Operative 19.68 
defined 19.64 
18-week 19.63 
r-TEG 19.63 
groins) 19.63 
round-shaped 19.63 
(r-TEG) 19.63 
defects] 19.63 
(CIN2) 19.63 
spondylolisthesis 19.62 
infinity 19.61 
Proven 19.61 
320 19.59 
CD4+ 19.58 
two- 19.56 
T21 19.56 
parameters 19.55 
only 19.52 
energy 19.51 
among 19.51 
regions 19.50 
fertilization 19.50 
Imaging 19.48 
adnexal 19.48 
thallium-201 19.47 
LRs 19.47 
high-resolution 19.46 
LGSIL 19.44 
80%; 19.44 
MeSHDNATopoisomerases 19.44 
(false-positive 19.44 
IPA 19.43 
here 19.43 
sclerosis 19.41 
Ex 19.40 
non-smokers: 19.39 
r(DS) 19.39 
Xpert-negative 19.39 
high-field-strength 19.39 
MCI/AD 19.39 
cytologic/histologic 19.39 
water-contrast 19.39 
Beta-core 19.39 
Requiring 19.39 
"dead 19.39 
Xpert((R)) 19.39 
time-to-positivity 19.39 
sagittal-oblique 19.39 
(Ventana 19.39 
(IQCODE): 19.39 
beta-hCG] 19.39 
r(controls) 19.39 
ASCUS: 19.39 
2/CIN 19.39 
USLs 19.39 
2001 19.39 
culture 19.39 
post 19.38 
thresholds 19.37 
cuffs 19.36 
incidence 19.33 
linear 19.30 
MeSHMemory 19.29 
survival 19.27 
Los 19.26 
reaction 19.23 
remission 19.23 
preoperatively 19.23 
schedule 19.20 
mobilization 19.20 
implementation 19.20 
minimally 19.19 
cul-de-sac 19.17 
specimens 19.14 
mid-sagittal 19.14 
behavior 19.06 
LN 19.05 
yet 19.05 
properties 19.05 
normal) 19.02 
Intraoperative 19.01 
E6/E7 19.01 
Modelling 19.01 
MeSHTissuePolypeptideAntigen 19.01 
Neuroimaging 18.98 
620 18.98 
frequency 18.98 
Administration-approved 18.98 
Nicolaides 18.98 
beta-HCG) 18.98 
retrograde 18.98 
arthrograms 18.97 
dementia: 18.97 
15-18 18.97 
Ethnic 18.96 
retest 18.96 
methods 18.93 
colon 18.92 
MeSHRecoveryofFunction 18.92 
discharged 18.90 
Kingdom 18.90 
MeSHRabbits 18.88 
(cut 18.81 
gave 18.79 
guided 18.78 
birth 18.78 
age) 18.78 
presence 18.77 
laparotomies 18.76 
MeSHLinearModels 18.75 
experimental 18.73 
differences 18.72 
screening? 18.71 
world 18.71 
from 18.71 
interventions 18.69 
better 18.67 
NF 18.67 
So 18.64 
HPVs 18.62 
nanocolloid 18.61 
44% 18.61 
(likelihood 18.59 
MeSHPlacentaGrowthFactor 18.59 
(IFI) 18.59 
highlight 18.59 
undergoing 18.58 
AFP-L3 18.57 
cotesting 18.57 
nonconverters 18.57 
beta-hCG; 18.57 
pre-morbid 18.57 
torus 18.57 
(hyperglycosylated 18.57 
(medians 18.57 
minichromosome 18.57 
RVS 18.57 
SLs 18.57 
smokers: 18.57 
MeSHHepaticDuct 18.57 
A: 18.54 
Survival 18.51 
pattern 18.51 
ALTS 18.50 
disregard 18.50 
CH 18.50 
234 18.47 
Case 18.46 
interferon-gamma 18.46 
mycologic 18.46 
brain 18.46 
positivity 18.46 
alkaline 18.45 
repeat 18.44 
shoulders) 18.43 
367 18.43 
arthrogram 18.43 
unlikely 18.39 
ultrasonographers 18.39 
Isosulfan 18.39 
twice-weekly 18.39 
ADAM 18.39 
epidemiology 18.38 
All 18.37 
80%) 18.36 
mixed 18.35 
prophylactic 18.34 
Relations 18.28 
clinicopathologic 18.27 
endothelial 18.26 
short 18.23 
overestimate 18.22 
Rectum 18.21 
Adjusting 18.21 
12) 18.20 
Newborn 18.20 
MeSHContinuityofPatientCare 18.20 
190) 18.20 
(ALTS) 18.19 
antigen: 18.19 
discontinuity 18.19 
polynomial 18.19 
endometriosis; 18.18 
euros 18.17 
lay 18.16 
lies 18.15 
MDR-TB 18.15 
herniated 18.15 
incremental 18.15 
Papillary 18.11 
express 18.11 
pouch 18.11 
MeSHImmunoassay 18.11 
Dissection 18.11 
scale 18.09 
vaccination 18.09 
389 18.08 
65% 18.07 
traction 18.05 
glands 18.05 
lymph-node 18.04 
With 18.04 
MeSHBoneNeoplasms 18.04 
233 18.02 
benefit 18.02 
calculi 17.99 
70) 17.99 
disorders 17.99 
MeSHNewborn 17.99 
enlargement 17.99 
Separate 17.97 
autopsy 17.96 
recognize 17.94 
genotyping 17.94 
surrounding 17.93 
MeSHMolecularSequenceData 17.93 
angle 17.92 
arthroscopically 17.91 
TYPE 17.91 
diagnosed 17.89 
table 17.89 
growth 17.88 
inhibition 17.88 
movement 17.88 
rheumatoid 17.87 
(100%) 17.87 
(99 17.87 
physiological 17.87 
venous 17.86 
rely 17.86 
converted 17.86 
aggressive 17.86 
hormonal 17.85 
Methods 17.85 
technical 17.85 
procedure 17.84 
MeSHSquamousCell 17.84 
tack 17.83 
Inter-observer 17.83 
(HCT) 17.83 
Easy 17.83 
Triple-marker 17.83 
subunit) 17.83 
AR 17.82 
antibiotic 17.82 
tear) 17.81 
hematologic 17.78 
%); 17.76 
345 17.76 
illness 17.76 
Lesion 17.74 
pregnancy) 17.74 
thinning 17.74 
predefined 17.73 
MeSHHumanpapillomavirus18 17.73 
MeSHAlkalinePhosphatase 17.73 
MeSHReverseTranscriptasePolymeraseChainReaction 17.72 
counter 17.70 
preventive 17.70 
now 17.69 
dependent 17.68 
MeSHPolymeraseChainReaction 17.66 
hr-HPV 17.65 
GEJ 17.65 
pro-alpha 17.65 
redress 17.65 
1:29 17.65 
(GEJ) 17.65 
Overstaging 17.65 
Cancer/Invasive 17.65 
29/33 17.65 
437) 17.65 
again 17.62 
bovis 17.62 
domain 17.62 
post-test 17.61 
performances 17.61 
session 17.60 
127 17.60 
appropriate 17.58 
intermittent 17.56 
(p= 17.53 
adjusting 17.53 
systems 17.51 
ultrasonography: 17.51 
(7% 17.50 
several 17.50 
132 17.46 
bearing 17.46 
theses 17.46 
Diseases 17.45 
Differentiation 17.45 
receive 17.44 
CIN3+ 17.44 
(NBL) 17.44 
EORTC/MSG 17.44 
propria 17.43 
94) 17.43 
MeSHVascular 17.42 
puncture 17.42 
(56% 17.42 
MeSHEstradiol 17.41 
history 17.40 
Association 17.40 
fat-suppressed 17.39 
(16 17.38 
98%) 17.38 
114 17.38 
cluster 17.37 
Ninety 17.37 
ICSI 17.36 
MeSHChromosomes 17.36 
subsequent 17.34 
MeSHCohortStudies 17.34 
8-14 17.33 
862 17.33 
race- 17.33 
136 17.33 
FISH 17.32 
reflex 17.32 
matrix 17.31 
catheter 17.31 
re-resection 17.31 
colposcopies 17.31 
HSILs 17.31 
Disintegrin 17.31 
ASCUS-L 17.31 
MeSHSacrum 17.29 
493 17.28 
833 17.28 
echoic 17.28 
06 17.26 
(3D) 17.25 
MeSHLongitudinalStudies 17.23 
effort 17.23 
MeSHIntraoperativeComplications 17.23 
MeSHLarge 17.21 
endocervical 17.21 
MeSHAnti-InflammatoryAgents 17.21 
MeSHNecrosis 17.21 
37% 17.21 
transducer 17.20 
APTIMA 17.20 
GEI 17.20 
(TPPT) 17.20 
intent; 17.20 
accurate? 17.20 
MTB/RIF: 17.20 
(GMA) 17.20 
"20 17.20 
five-layer 17.20 
(TriPath 17.20 
tenderness-guided 17.20 
(O'Brien 17.20 
SEMs 17.20 
2336 17.20 
555; 17.20 
MeSHMagneticResonance 17.19 
y) 17.18 
laboratory 17.17 
Twenty 17.17 
beginning 17.16 
resulted 17.14 
MeSHTomography 17.14 
sagittal 17.13 
run 17.13 
story 17.13 
require 17.12 
epidemic 17.10 
sites 17.08 
gestation: 17.06 
logarithmic 17.06 
Absent 17.06 
753 17.06 
Nucleic 17.06 
cannula 17.03 
effective 17.03 
glutamyl 17.02 
healing 17.00 
19% 16.97 
submitted 16.97 
highly 16.97 
53) 16.93 
patterns 16.93 
IV) 16.93 
candidates 16.92 
ultimate 16.90 
MeSHAntineoplasticAgents 16.90 
cohort 16.89 
that 16.89 
103 16.89 
overhead 16.88 
amnestic 16.88 
tracts 16.85 
implant 16.85 
microscopic 16.84 
Herpes 16.84 
triple-test 16.83 
kidney-pancreas 16.83 
(n=60) 16.83 
MeSHMultiphasicScreening 16.83 
weight: 16.83 
Overlapping 16.83 
(UE3) 16.83 
Unresectable 16.83 
genotype-specific 16.83 
(HSILs) 16.83 
MeSHSouthAustralia 16.83 
365) 16.83 
ES; 16.83 
HSILs) 16.83 
molecules 16.82 
Loss 16.82 
PURPOSE 16.82 
log-linear 16.82 
Gaithersburg 16.82 
dye 16.81 
MeSHColonoscopy 16.80 
T1 16.79 
Receiver 16.78 
MeSHRats 16.77 
analytical 16.76 
problem 16.76 
MeSHCongenitalAbnormalities 16.76 
MeSHDuodenum 16.76 
MeSHIntestinalObstruction 16.76 
cut 16.74 
miniprobe 16.74 
Low-Grade 16.74 
attending 16.73 
routinely 16.73 
fragments 16.70 
MeSHCA-19-9Antigen 16.70 
21) 16.69 
porta 16.68 
applications 16.67 
They 16.65 
occurrence 16.64 
Aspergillus 16.62 
MeSHEsophagealNeoplasms 16.61 
MeSHAnti-BacterialAgents 16.60 
MeSHGenes 16.59 
route 16.59 
MeSHPilotProjects 16.56 
MeSHGadoliniumDTPA 16.55 
lumbosacral 16.54 
Fat 16.53 
cigarettes 16.53 
MeSHAdolescent 16.52 
distinct 16.52 
MeSHNeutropenia 16.51 
ICSI) 16.51 
(MRI) 16.49 
Computed 16.48 
(R) 16.48 
comorbid 16.48 
or 16.48 
indications 16.47 
Cl 16.46 
MeSHEvaluationStudiesasTopic 16.46 
epidemiological 16.46 
Abd 16.45 
hepatitis 16.45 
MeSHInflammation 16.44 
Deep 16.44 
commercial 16.43 
parental 16.42 
MeSHParity 16.42 
Maternal-Fetal 16.42 
psychological 16.41 
complimentary 16.40 
80) 16.40 
tap 16.39 
staged 16.38 
randomized 16.38 
younger 16.37 
Type 16.36 
large-bowel 16.35 
parasagittal 16.35 
synthesised 16.35 
45-84 16.35 
AGUS) 16.35 
(86 16.35 
anti-tuberculosis 16.34 
stratified 16.34 
clinicopathological 16.33 
<0 16.30 
MeSHImaging 16.30 
(63 16.29 
Some 16.29 
substantially 16.28 
19-9) 16.28 
cytology: 16.28 
(23 16.27 
MeSHCommonBileDuctDiseases 16.22 
purified 16.22 
1996 16.20 
03) 16.19 
(controls 16.19 
gestation) 16.13 
sonography: 16.13 
steroids 16.12 
handheld 16.12 
fungal 16.10 
colposcopy-directed 16.10 
(ITA) 16.10 
14-17 16.10 
(CIN1) 16.10 
radiographs 16.10 
clearance 16.09 
transabdominally 16.08 
14-16 16.08 
cortical 16.07 
Factors 16.06 
Confidence 16.04 
Alkaline 16.04 
MeSHEurope 16.03 
encountered 16.01 
Taiwanese 16.00 
givers 16.00 
analytic 16.00 
mortality 16.00 
negatives 15.99 
MeSHReproductiveTechniques 15.97 
11% 15.95 
Exercise 15.94 
unlike 15.93 
contact 15.93 
EL 15.93 
visit 15.92 
Stenosis 15.92 
Hyperglycosylated 15.91 
(SPR) 15.91 
Spring 15.91 
ITA) 15.91 
NIx 15.90 
alpha-fetoprotein-L2 15.90 
C-hCG/Cr 15.90 
Hp2FF 15.90 
'notched' 15.90 
AFP/Cr 15.90 
MDCT-e 15.90 
(r(controls) 15.90 
performer-specific 15.90 
CRL-related 15.90 
NT=95th 15.90 
"Consecutive 15.90 
1MSS 15.90 
MS-CA 15.90 
NTD: 15.90 
AWD: 15.90 
head-to-trunk 15.90 
47XXX 15.90 
cross-identification 15.90 
(NIx) 15.90 
assisted-conception 15.90 
(inhibin-A 15.90 
iso-risk 15.90 
curved-array 15.90 
RES; 15.90 
EUS-M/SM 15.90 
EUS-SM 15.90 
HR-MRI 15.90 
introital 15.90 
nonburn 15.90 
3252 15.90 
contingent-screening 15.90 
FMF-trained 15.90 
Performer-specific 15.90 
FMF-trainees 15.90 
(Microparticle 15.90 
'uniform' 15.90 
Spiegelhalter-Knill-Jones 15.90 
S-KJ 15.90 
95-percentile 15.90 
diabetics' 15.90 
screening-derived 15.90 
MoM-related 15.90 
volume') 15.90 
(Series 15.90 
Nan-Tou 15.90 
subunit/GAPDH 15.90 
gonadotrophin-stimulated 15.90 
1:190-200 15.90 
1:250-295 15.90 
Gamal 15.90 
Nasser 15.90 
AFPsm 15.90 
(False 15.90 
(medians: 15.90 
chromosomally-normal 15.90 
IVF-frozen 15.90 
own-FET 15.90 
(1:10-1:190) 15.90 
Chinese-specific 15.90 
alpha-subunits 15.90 
race-ethnicity-specific 15.90 
intHCG 15.90 
7718 15.90 
2533 15.90 
subradiographic 15.90 
EUS-M 15.90 
(Positive 15.90 
ventilator-free 15.90 
4145 15.90 
compression-rotation 15.90 
HSIL/CIN 15.90 
"or" 15.90 
3MS/IQCODE 15.90 
pre-renal 15.90 
dipyridamole-thallium-201 15.90 
union? 15.90 
enhanced-sensitivity 15.90 
20-weeks 15.90 
(18-week 15.90 
screening--because 15.90 
[uE(3)]) 15.90 
gonadotropin(P 15.90 
alpha-fetoprotein/human 15.90 
gonadotrophin/age 15.90 
1/1/1989-31/12/1991 15.90 
4-to-1 15.90 
8779 15.90 
non-smokers) 15.90 
2-7%) 15.90 
17-23%) 15.90 
57-67%) 15.90 
(14-22) 15.90 
(MOM); 15.90 
(43/46) 15.90 
(16/46) 15.90 
(47XXX 15.90 
Uptakes 15.90 
(pro-alphaC) 15.90 
Double-positive 15.90 
IDDM-unaffected 15.90 
(Algemeen 15.90 
Antwerp) 15.90 
FMF-reference 15.90 
FMF-specific 15.90 
NT-medians 15.90 
MoMs; 15.90 
skull) 15.90 
[pg/mL 15.90 
age)2 15.90 
Syndrome; 15.90 
1:111) 15.90 
3992 15.90 
microheterogeneity: 15.90 
("triple" 15.90 
Wallac-Perkin-Elmer 15.90 
pregnancy--the 15.90 
Gaslini' 15.90 
(Spencer 15.90 
logarithms) 15.90 
(Radioimmunoassay 15.90 
(PAPP-A)) 15.90 
4835 15.90 
2727 15.90 
(maternally 15.90 
produced) 15.90 
algorithmically 15.90 
(DS)-affected 15.90 
>1:380) 15.90 
22-24%) 15.90 
(815/1320) 15.90 
(598/818) 15.90 
unbooked 15.90 
[trisomy 15.90 
'uniformly' 15.90 
(sd-ITA): 15.90 
wide-charge 15.90 
rebooked 15.90 
"undetectable" 15.90 
non-dose-related 15.90 
Backward-stepwise 15.90 
=1:380 15.90 
LR(NT) 15.90 
LR(TT)) 15.90 
correction-in 15.90 
31-79% 15.90 
-35%--7%) 15.90 
-34%--3%) 15.90 
trisomical 15.90 
nonverified 15.90 
(7909 15.90 
alpha1-->6 15.90 
microheterogeneities 15.90 
feticidal 15.90 
"Pseudo-risks" 15.90 
421/450 15.90 
83/421 15.90 
29/450 15.90 
AMERLEX-M) 15.90 
double-positives 15.90 
unchanged' 15.90 
'diminished' 15.90 
smoothened 15.90 
log(10)(gestation)2 15.90 
log10(gestation) 15.90 
291-361) 15.90 
(S-KJ) 15.90 
3842 15.90 
"trained 15.90 
("validated 15.90 
data") 15.90 
3-49% 15.90 
5422 15.90 
mankers 15.90 
(11/2886) 15.90 
placentas) 15.90 
quintuplet 15.90 
17/400 15.90 
tetrachorionic 15.90 
(trichorionic 15.90 
chroangiogonadotropin 15.90 
(f-beta-hCG) 15.90 
volume/CRL) 15.90 
placenta/CRL-quotients 15.90 
f-beta-hCG 15.90 
(PAPP-A: 15.90 
f-beta-hCG: 15.90 
placenta/CRL 15.90 
non-insulin-requiring 15.90 
6634 15.90 
13-50; 15.90 
11+0-14+6) 15.90 
6443 15.90 
(92/6443) 15.90 
(51/63 15.90 
6258 15.90 
4453 15.90 
(2053/31 15.90 
(507/1942) 15.90 
(33/44); 15.90 
(n=813) 15.90 
ALTM 15.90 
(1:5490) 15.90 
(1:6451) 15.90 
(UGP; 15.90 
(1991-95) 15.90 
3490 15.90 
13-15-week 15.90 
hCG/uE3 15.90 
1/190) 15.90 
270); 15.90 
(14/26; 15.90 
(5/1583; 15.90 
(20/26; 15.90 
microtiter-plate 15.90 
('sagittal 15.90 
('random 15.90 
Reslicing 15.90 
within-batch 15.90 
(intrabatch 15.90 
unachievable 15.90 
IVF-versus 15.90 
naturally-conceived 15.90 
(FPR; 15.90 
84-97 15.90 
ultrasonologists 15.90 
Caserta 15.90 
Septae 15.90 
fetal-neonatal 15.90 
beta-core-hCG/ 15.90 
volume/fetal 15.90 
2863 15.90 
84mm 15.90 
NBL-by-BPD 15.90 
below-serum-risk 15.90 
11q- 15.90 
(0/390 15.90 
35-87] 15.90 
8179 15.90 
(8317/9345) 15.90 
(426/179; 15.90 
(389/437) 15.90 
(4/9345) 15.90 
2000-August 15.90 
(DSL)) 15.90 
(Serotec) 15.90 
Gausian 15.90 
50-300% 15.90 
markers--alpha-fetoprotein 15.90 
(u-E3)--were 15.90 
u-E3 15.90 
(1:9999) 15.90 
beta-hCG/Cr 15.90 
(integrated) 15.90 
46193 15.90 
46105 15.90 
AFP+F 15.90 
63-65% 15.90 
AFP+ThCG 15.90 
66-68% 15.90 
beta-hCG+PAPP-A 15.90 
(SOD): 15.90 
(SOD: 15.90 
Singapore--the 15.90 
age-only 15.90 
(KKH) 15.90 
KKH 15.90 
(35/53) 15.90 
KKH's 15.90 
52%-55% 15.90 
34%-36% 15.90 
counsellers 15.90 
69-85 15.90 
71-87 15.90 
inhibin-A-based 15.90 
text]3 15.90 
6312 15.90 
Test"--using 15.90 
"Combined 15.90 
universities' 15.90 
4436 15.90 
(>/=1/250) 15.90 
dried-blood 15.90 
paper] 15.90 
(porencephaly 15.90 
[maternity 15.90 
(alpha/betaA) 15.90 
(betaA/betaA) 15.90 
median); 15.90 
1:295 15.90 
beta(1)-glycoprotein 15.90 
steroid-only- 15.90 
non-gonadotrophin-stimulation 15.90 
monozygous) 15.90 
dizygous) 15.90 
"pseudo-risk" 15.90 
1:350-380 15.90 
alpha-2FF 15.90 
(Hp1 15.90 
Hp2) 15.90 
Mr's 15.90 
variants--Hp2FF 15.90 
Abdel 15.90 
Pandya 15.90 
(1996a) 15.90 
Schuchter 15.90 
(SAMSAS) 15.90 
3431 15.90 
2737/3431 15.90 
Interrogation 15.90 
51/3431 15.90 
NTD; 15.90 
measured--alpha-fetoprotein 15.90 
(970) 15.90 
(325) 15.90 
4072 15.90 
gondaotrophin 15.90 
11-12th 15.90 
(ATL-HDI 15.90 
EUB-450) 15.90 
72/280 15.90 
20/280 15.90 
6/188 15.90 
16/280 15.90 
(Schwangerschafts 15.90 
6/7-25 15.90 
weeks]) 15.90 
Rendered 15.90 
trimester-of-ascertainment 15.90 
Noviembre" 15.90 
radioimmunoanalysis 15.90 
(11-38 15.90 
Sangtec) 15.90 
Immunosassay 15.90 
screening--free 15.90 
162774 15.90 
11549 15.90 
one-third/two-thirds 15.90 
age/ultrasound 15.90 
(Fbeta-hCG) 15.90 
14607 15.90 
153909 15.90 
log10MoMs 15.90 
Fbeta-hCG 15.90 
2-24MoM 15.90 
log10MoM; 15.90 
log10MoM); 15.90 
IVF-pregnant 15.90 
between-trimester 15.90 
population-derived 15.90 
>21000 15.90 
inhibin-A] 15.90 
4392 15.90 
Week-specific 15.90 
AFP/creatinine 15.90 
(13/268) 15.90 
(43/268) 15.90 
s100b 15.90 
Variance-covariance 15.90 
[mm])/(mean 15.90 
(402/420) 15.90 
outer-to-outer 15.90 
13/285 15.90 
("nicks") 15.90 
7717 15.90 
(1MSS) 15.90 
1:85) 15.90 
(504/2061) 15.90 
(109/615) 15.90 
2MMS 15.90 
7497 15.90 
fetal/congenital 15.90 
1%-16%) 15.90 
(DGH) 15.90 
abnormal/high-risk 15.90 
gestations; 15.90 
840(85%) 15.90 
797(80%) 15.90 
fetopsy; 15.90 
sonogram") 15.90 
16-47]; 15.90 
12(+3) 15.90 
11-14]) 15.90 
(7/16; 15.90 
25-63]) 15.90 
(6/16; 15.90 
(5/8; 15.90 
(1/8; 15.90 
34582 15.90 
Pergonal 15.90 
(Indians 15.90 
Nepalese) 15.90 
(NuT) 15.90 
(matA) 15.90 
(NuT 15.90 
(Z)/ 15.90 
(Z)] 15.90 
matA 15.90 
NuT 15.90 
(Microsoft) 15.90 
inputting 15.90 
gestational-age-corrected 15.90 
'screen-negative' 15.90 
total-hCG 15.90 
(fbetahCG); 15.90 
hCG/PAPP-A/maternal 15.90 
6581 15.90 
Well-dated 15.90 
nonanomalous 15.90 
(MS-CA 15.90 
15-50) 15.90 
9615 15.90 
3206) 15.90 
6190 15.90 
fertilisation: 15.90 
4279 15.90 
duration-of-storage 15.90 
MOMs) 15.90 
1/365) 15.90 
ICSI-frozen 15.90 
ICSI-embryo 15.90 
own-oocyte 15.90 
(own-FET) 15.90 
oocyte-donated 15.90 
OD-conceived 15.90 
own-FET-conceived 15.90 
428410 15.90 
423895 15.90 
Flanders: 15.90 
3265 15.90 
Hajdu-Bihar 15.90 
14328 15.90 
Non-high-risk 15.90 
(1:190-1:1000) 15.90 
(1:191-1:1000) 15.90 
56%-72%) 15.90 
(49-104 15.90 
marker-screening 15.90 
positive-screening 15.90 
1:420 15.90 
22816 15.90 
9/205 15.90 
(80/107; 15.90 
(18/30; 15.90 
(8/14; 15.90 
(2912/3508) 15.90 
(25/2912) 15.90 
ballotement 15.90 
foetalis 15.90 
12-week-old 15.90 
(PIGF)concentrations 15.90 
(PIGF) 15.90 
(nape 15.90 
Trivariate 15.90 
amino-propeptide 15.90 
8297 15.90 
derived; 15.90 
two-analyte 15.90 
(intHCG) 15.90 
IntHCG 15.90 
(E3)--for 15.90 
7255 15.90 
7696 15.90 
79-100%) 15.90 
provided; 15.90 
($455 15.90 
(n=1213) 15.90 
(n=678) 15.90 
(n=859) 15.90 
(n=520) 15.90 
remains) 15.90 
(Neer's 15.90 
(79-A: 15.90 
1854-1868 15.90 
lesion-location 15.90 
'one-stop 15.90 
nondislocating 15.90 
Yocum 15.90 
Labrum 15.90 
Posterior) 15.90 
(90-day) 15.90 
(n=127) 15.90 
determination/insufficient 15.90 
re-resected 15.90 
(FTRCT) 15.90 
tears? 15.90 
coil; 15.90 
'dynamic' 15.90 
Technetium-99-labeled 15.90 
positive/AMPLICOR 15.90 
ASCUS-favor 15.90 
(Linear 15.90 
Roche's 15.90 
Parenthood 15.90 
ASCUS-positive 15.90 
(TERC) 15.90 
1999-October 15.90 
Colposcopists 15.90 
(MDCT-e) 15.90 
'tenderness-guided' 15.90 
stand-off 15.90 
retro-cervical 15.90 
"tissue" 15.90 
fornix; 15.90 
cecum) 15.90 
PKT 15.90 
608+/-272 15.90 
hematology/oncology 15.90 
Platellia 15.90 
Cancer-Mycoses 15.90 
GCS: 15.90 
13%-74%) 15.90 
T1-sm 15.90 
(Superior 15.90 
(1/29) 15.90 
GROINSS-V 15.90 
89-95%) 15.90 
ASCUS-not 15.90 
(NorChip 15.90 
4439 15.90 
85-93%) 15.90 
"and 15.90 
THRIVE 15.90 
LAVA 15.90 
76%-97%) 15.90 
23-43 15.90 
T1FS 15.90 
(Glucatell 15.90 
partial 15.88 
FNA 15.88 
Pancreatic 15.88 
pleural 15.86 
enlarged 15.86 
Cr 15.84 
34% 15.83 
86%) 15.82 
submit 15.81 
(85 15.79 
K 15.79 
undersurface 15.79 
Sensitivities 15.79 
Doppler 15.78 
(atypical 15.77 
heterogeneous 15.77 
MA 15.77 
up) 15.77 
Spontaneous 15.75 
(75%) 15.74 
proved 15.72 
MeSHOrthopedicProcedures 15.72 
numerous 15.72 
Eighty 15.71 
p< 15.70 
exp 15.69 
MeSHBariumSulfate 15.68 
maternity 15.68 
nucleus 15.68 
cholangiocarcinoma 15.68 
(12 15.68 
observers 15.68 
242 15.67 
fully 15.66 
counsel 15.66 
H-hCG 15.65 
TPPT 15.65 
Ventana 15.65 
allo-HSCT 15.65 
ProMBP 15.65 
'curative' 15.65 
papillomavirus-negative 15.65 
Three-stage 15.65 
Canick 15.65 
translucency] 15.65 
(H-hCG) 15.65 
gonadotrophin: 15.65 
ultrasound-dated 15.65 
state-approved 15.65 
disregards 15.65 
[free 15.65 
diameter/nasal 15.65 
(RVS) 15.65 
(allo-HSCT) 15.65 
100x 15.65 
CEA-level 15.65 
(Microsoft 15.65 
PAPP-A: 15.65 
p-tau 15.65 
equation 15.64 
ERC 15.64 
TD 15.61 
Acid 15.61 
Resonance 15.60 
(88 15.60 
application 15.58 
HIV- 15.56 
product 15.56 
MeSHPathologic 15.56 
(31 15.56 
graphic 15.55 
testing) 15.55 
ALP 15.55 
unsuccessful 15.51 
anticipation 15.49 
HPV+ 15.49 
Brain 15.49 
X-ray 15.48 
MeSHPlantLectins 15.47 
abduction 15.46 
continue 15.45 
tenth 15.44 
MeSHNeurologicExamination 15.44 
NT-MoM 15.43 
hc2 15.43 
ulcerous 15.43 
envelopes 15.43 
weight-adjusted 15.43 
2nd-trimester 15.43 
(PAPP)-A 15.43 
45-84) 15.43 
tendon; 15.43 
MeSHDirectServiceCosts 15.43 
inguinal-femoral 15.43 
20-59 15.43 
(HGSIL) 15.43 
1992-1994 15.43 
339) 15.43 
1/45 15.43 
fertility 15.43 
immuno 15.43 
diagnoses 15.42 
throwing 15.41 
(30 15.40 
lactic 15.40 
adjacent 15.37 
MeSHOral 15.34 
(19 15.32 
trisomy-21 15.32 
modelled 15.32 
DRs 15.32 
donor 15.31 
MeSHUterineNeoplasms 15.31 
implicate 15.31 
disappeared 15.31 
slightly 15.30 
glucan 15.28 
490 15.28 
recurrence 15.28 
MeSHOncogeneProteins 15.28 
sonogram 15.27 
coagulopathy 15.23 
(26 15.23 
cut-offs 15.23 
has 15.22 
obesity 15.20 
insufficiency 15.18 
NBL 15.18 
resisted 15.18 
mid-gestation 15.18 
1:200 15.18 
CI: 15.17 
solitary 15.16 
real-time 15.14 
MeSHRheumatoid 15.13 
MeSHInduced 15.13 
secretion 15.13 
(45 15.11 
placebo 15.10 
vascular 15.07 
MeSHPhenotype 15.06 
regimens 15.06 
MeSHBiometry 15.04 
lipid 15.04 
deemed 15.04 
parts 15.04 
MeSHBlood 15.03 
organism 15.03 
1-year 15.01 
disturbance 15.00 
40% 15.00 
view 15.00 
destruction 14.99 
MDR 14.98 
301 14.98 
272 14.98 
PT 14.97 
ultrasound-guided 14.96 
conventional 14.96 
clarify 14.95 
3D 14.94 
delta 14.94 
out 14.93 
grant 14.93 
8-year 14.92 
submucosa 14.90 
carcino-embryonic 14.90 
greater) 14.90 
ahCG 14.90 
five- 14.90 
Short 14.88 
recognized 14.88 
lectin 14.87 
MeSHFine-Needle 14.86 
(44 14.86 
multidrug 14.86 
double 14.84 
difficulties 14.83 
Global 14.83 
(DT) 14.82 
Recovery 14.79 
take 14.79 
the 14.78 
phase 14.78 
glenohumeral 14.77 
MeSHRectum 14.77 
88%) 14.77 
potent 14.76 
MEASURE: 14.76 
these 14.75 
(55 14.75 
node-positive 14.73 
(Dukes 14.71 
mellitus 14.71 
dynamics 14.70 
construction 14.69 
(31% 14.68 
Biometry 14.68 
998 14.66 
DT 14.66 
371 14.65 
MeSHPrenatalCare 14.63 
family 14.62 
multiplying 14.62 
required 14.62 
Groups 14.61 
ELISA) 14.61 
approved 14.61 
mucinous 14.60 
professional 14.60 
ERCP 14.59 
MeSHBloodCoagulationDisorders 14.58 
Colonoscopy 14.54 
placenta 14.53 
68% 14.53 
(56 14.53 
54% 14.53 
Mycoses 14.51 
83) 14.50 
extension 14.48 
fibrosis 14.48 
us 14.47 
no 14.47 
resected 14.46 
specimen 14.45 
bacilli 14.45 
foreign 14.44 
ADAS-cog 14.44 
Napoleon 14.44 
Hawkins-Kennedy 14.44 
S-IQCODE 14.44 
AxSYM 14.44 
1406 14.44 
non-IPA 14.44 
(intact 14.44 
insulin-requiring 14.44 
separately) 14.44 
MeSHCotinine 14.44 
(12-14 14.44 
(t-test: 14.44 
equates 14.44 
detected) 14.44 
CEA; 14.44 
CEA-directed 14.44 
(hr-HPV) 14.44 
cells-cannot 14.44 
Burlington 14.44 
(HC2; 14.44 
dementia? 14.44 
27/29 14.44 
38/40 14.44 
tendinitis) 14.44 
Digene) 14.44 
Novi 14.44 
SIL/CIN 14.44 
thirty-seven 14.44 
(EIA) 14.44 
455 14.44 
adjustments 14.44 
MeSHBileDuctNeoplasms 14.42 
Left 14.41 
Rotation 14.41 
did 14.40 
MeSHArticular 14.40 
reduced 14.38 
reserved 14.36 
chemiluminescence 14.36 
(%) 14.36 
Uptake 14.35 
Discriminant 14.35 
ninety-two 14.35 
67%; 14.35 
(1-->3)-beta-D-glucan 14.35 
mix 14.35 
angina 14.35 
497 14.32 
Most 14.31 
swab 14.31 
retardation 14.31 
biological 14.31 
87%) 14.29 
MeSHCoronaryArteryDisease 14.29 
clone 14.28 
content 14.27 
shorter 14.27 
dollars) 14.26 
Hitachi 14.26 
reresection 14.26 
papillomavirus-positive 14.26 
gonadotrophin) 14.26 
(LGSIL) 14.26 
mm] 14.26 
FMF- 14.26 
charge 14.26 
delayed 14.26 
Compare 14.26 
evolution 14.24 
HPV18 14.23 
222 14.22 
depict 14.22 
MeSHAbdominalPain 14.22 
MeSHLumbosacralRegion 14.20 
this 14.20 
MeSHRifampin 14.19 
CI] 14.19 
(using 14.18 
concerning 14.18 
MeSHObesity 14.17 
RT-PCR 14.16 
coding 14.16 
MeSHSigmoid 14.15 
glandular 14.15 
tendinopathy 14.15 
allow 14.13 
?/nMeSHCholangiography 14.12 
mediastinum 14.12 
ligand 14.10 
9-11 14.10 
screening; 14.10 
(114 14.10 
include 14.10 
action 14.09 
206 14.09 
pseudo 14.08 
cerebral 14.06 
MeSHPostoperativePeriod 14.05 
(33 14.03 
Risks 14.03 
Ninety-eight 14.03 
AC 14.03 
METHOD: 14.02 
(positive 14.01 
Full-thickness 14.00 
soluble 14.00 
Lumbosacral 14.00 
abnormalities: 13.98 
90) 13.98 
MeSHMaternal-FetalExchange 13.96 
(69 13.96 
provided 13.93 
MI 13.92 
2003 13.91 
normative 13.91 
performs 13.91 
understood 13.88 
epithelium 13.87 
haematological 13.87 
Articular 13.87 
erythrocyte 13.86 
going 13.86 
elements 13.85 
(none 13.84 
MeSHPlacenta 13.84 
arise 13.83 
interval) 13.82 
retroperitoneal 13.80 
near 13.80 
390 13.80 
June 13.78 
genera 13.78 
discrimination 13.75 
occasional 13.75 
15% 13.75 
>or=30 13.75 
multiethnic 13.75 
Patient-specific 13.75 
probable) 13.75 
MeSHOregon 13.75 
midgestation 13.75 
(ADNI) 13.75 
X0 13.75 
Samples 13.74 
(35 13.74 
abdominal 13.74 
every 13.74 
postoperative 13.72 
immunosorbent 13.72 
Rifampin 13.72 
Rate 13.71 
MeSHSurvivalRate 13.70 
Abdominal 13.67 
15-20 13.67 
(7%) 13.67 
subacromial-subdeltoid 13.67 
translucency) 13.67 
level: 13.67 
histology) 13.67 
11+0 13.67 
occasion 13.66 
1998 13.66 
Eighty-nine 13.65 
epidemiologic 13.64 
arthrographic 13.63 
(MSS) 13.63 
batch 13.63 
electrocardiograph 13.63 
everyday 13.63 
extensively 13.61 
MeSHAdnexalDiseases 13.61 
Allergy 13.60 
prolong 13.59 
MeSHAnesthesia 13.59 
cannulation 13.59 
Cystic 13.59 
Protocols 13.59 
variant 13.58 
MeSHLiverNeoplasms 13.56 
vitro 13.55 
(75% 13.55 
control 13.54 
insertion 13.54 
impacted 13.52 
HPV16 13.52 
fitted 13.52 
75%) 13.52 
across 13.50 
Sixty-seven 13.49 
practice 13.47 
Peritoneal 13.46 
Compared 13.46 
double-sandwich 13.46 
1514 13.46 
triple-analyte 13.46 
E-wave 13.46 
technologically 13.46 
chorionic-villus 13.46 
receiver-operator-characteristics 13.46 
beta-chorionic 13.46 
performance: 13.46 
[alpha-fetoprotein 13.46 
(T3-4 13.46 
?/nMeSHAcromioclavicularJoint 13.46 
arm" 13.46 
non-converters 13.46 
MeSHFollistatin 13.46 
crown-rump-length 13.46 
127; 13.46 
45%); 13.46 
Interval 13.44 
group) 13.44 
smoked 13.44 
(ALP) 13.44 
such 13.44 
sections 13.43 
(81 13.42 
allergic 13.42 
MeSHAlzheimerDisease 13.42 
Sonography 13.41 
67) 13.41 
MeSHConfidenceIntervals 13.37 
MeSHArthritis 13.37 
thin-layer 13.36 
markers) 13.36 
(2D) 13.36 
mycological 13.36 
intent 13.35 
MeSHCellDivision 13.35 
conceiving 13.35 
premorbid 13.35 
Prince 13.35 
density- 13.35 
Project 13.34 
Routine 13.34 
state 13.32 
297 13.31 
(32 13.29 
induces 13.28 
Observed 13.28 
increment 13.28 
(61 13.28 
clinics 13.27 
Siewert 13.27 
worse) 13.27 
(placental 13.27 
hygromata 13.27 
(gold 13.27 
(FHR) 13.27 
sonologists 13.27 
IA; 13.27 
MeSHVirology 13.27 
MeSHRegressionAnalysis 13.26 
amino 13.25 
3-T 13.25 
oligosaccharide 13.25 
(< 13.24 
MeSHGroin 13.22 
(84 13.20 
MeSHUterineCervicalDiseases 13.19 
MeSHAfrica 13.19 
MeSHBrain 13.19 
Myocardial 13.19 
contribution 13.17 
manipulation 13.17 
Success 13.16 
22% 13.16 
held 13.14 
226 13.14 
(AD) 13.14 
Marker 13.14 
APOE 13.13 
2/3) 13.13 
repeating 13.13 
LA 13.13 
Individual 13.12 
suppressor 13.11 
row 13.11 
prolonged 13.10 
generalized 13.09 
figure 13.09 
papillomaviruses 13.09 
end 13.09 
antenatally 13.07 
MRI 13.06 
signals 13.04 
linear-array 13.04 
MeSHTricuspidValveInsufficiency 13.04 
(TT) 13.04 
14-22 13.04 
(area 13.03 
preventing 13.01 
MeSHSpinalInjuries 13.01 
ectopic 13.01 
January 13.01 
baby 13.00 
(75 12.99 
parenchyma 12.98 
302 12.98 
preimplantation 12.98 
I 12.95 
protection 12.95 
metastatic 12.95 
environmental 12.95 
[95% 12.95 
Phase 12.94 
(74 12.94 
(+) 12.93 
ng 12.93 
97%) 12.91 
know 12.91 
couples 12.91 
degenerative 12.91 
Software 12.90 
MeSHDrugStability 12.90 
771 12.90 
MeSHChemotherapy 12.90 
Health 12.90 
MeSHMinimallyInvasiveSurgicalProcedures 12.90 
adduction 12.89 
305 12.88 
normals 12.87 
pancreatectomy 12.87 
radiological 12.87 
must 12.85 
60) 12.85 
radiographic 12.84 
13) 12.83 
Knowledge 12.83 
p16INK4a 12.82 
pre-transplant 12.82 
superovulation 12.82 
values; 12.82 
FHR 12.82 
ASCUS-LSIL 12.82 
96%; 12.82 
Partial-thickness 12.82 
'screen 12.82 
320) 12.82 
Ultrasonographic 12.81 
highlights 12.81 
38% 12.80 
outside 12.79 
hypoechoic 12.79 
neoplasms 12.79 
highest 12.78 
MeSHAnemia 12.76 
started 12.75 
rotator-cuff 12.75 
Cohen's 12.75 
(POD) 12.75 
186 12.74 
Signal 12.74 
Platelet 12.73 
figures 12.73 
similarly 12.73 
Y 12.73 
localization 12.72 
Protocol 12.72 
duodenum 12.71 
nervous 12.71 
alone; 12.71 
ultimately 12.70 
haematologic 12.70 
density 12.70 
cm 12.69 
continuous 12.68 
vulvectomy 12.68 
surprise 12.68 
657 12.68 
815 12.68 
Full- 12.68 
independently 12.67 
6-year 12.67 
Hispanic 12.66 
MeSHGadolinium 12.66 
Laboratories 12.64 
quadrant 12.64 
fields 12.64 
belly-press 12.62 
four-marker 12.62 
(instead 12.62 
(Roche) 12.62 
Cancer/Mycoses 12.62 
1347 12.62 
MeSHEosinophilGranuleProteins 12.62 
serum] 12.62 
inguino-femoral 12.62 
(CTR) 12.62 
Refining 12.62 
(11/28 12.62 
68) 12.62 
mobility 12.60 
magnet 12.60 
Southern 12.60 
Tumors 12.60 
emboli 12.59 
212 12.59 
MeSHHIV-1 12.57 
0005 12.56 
categorize 12.56 
exceeded 12.55 
vaccine 12.54 
cytopathology 12.53 
turnaround 12.53 
electro 12.53 
31% 12.52 
polymorphisms 12.51 
blue 12.50 
likely 12.50 
cholecystography 12.50 
MeSHHeartRate 12.50 
MeSHCytologicalTechniques 12.50 
heavy 12.47 
unique 12.47 
muscularis 12.47 
-negative) 12.47 
MeSHImmunoglobulins 12.47 
ELISA 12.46 
rifampin-resistant 12.46 
852 12.46 
+ 12.45 
RNA 12.44 
MeSHConstriction 12.44 
(controls) 12.44 
growing 12.44 
accepted 12.43 
MeSHCellTransformation 12.43 
(LR) 12.43 
0005) 12.43 
nested 12.42 
particles 12.41 
WHO 12.41 
structures 12.41 
INFORM 12.40 
MS-AFP 12.40 
multifetal 12.40 
twin-to-twin 12.40 
cut-off) 12.40 
sample; 12.40 
beforehand 12.40 
term) 12.40 
(ABER) 12.40 
(AGUS) 12.40 
rated) 12.40 
(TPA 12.40 
hCG; 12.40 
2/5 12.39 
parents 12.39 
Tesla 12.36 
(77 12.36 
(FISH) 12.36 
MeSHTechnetiumTc99mAggregatedAlbumin 12.35 
84%) 12.35 
MeSHGastrointestinalNeoplasms 12.34 
95%) 12.34 
area 12.34 
Jan 12.34 
incorporated 12.33 
depletion 12.33 
iatrogenic 12.33 
MeSHAorta 12.33 
MeSHAspergillus 12.33 
mothers 12.31 
FDG-PET 12.30 
genomic 12.30 
326 12.29 
2/7 12.29 
Combination 12.28 
lesions) 12.27 
similar 12.27 
phosphatase 12.27 
leaks 12.26 
(AFS) 12.26 
776 12.26 
619 12.26 
curable 12.25 
177 12.25 
reconstruction 12.25 
blocks 12.23 
Frequency 12.23 
immunohistochemically 12.23 
clusters 12.22 
then 12.22 
Magnetic 12.21 
tolerated 12.21 
suffering 12.21 
(AUC) 12.20 
return 12.19 
Alzheimer 12.19 
ISH 12.19 
MeSHEnzyme-LinkedImmunosorbentAssay 12.19 
DSM-IV 12.18 
Log 12.18 
author 12.16 
athletes 12.16 
42%) 12.16 
002 12.16 
field 12.16 
occlusion 12.16 
scope 12.16 
central 12.15 
reactions 12.15 
(CIs) 12.15 
MeSHChronicDisease 12.13 
drive-through 12.12 
DCUS 12.12 
Yergason's 12.12 
Test" 12.12 
alpha-human 12.12 
insulinlike 12.12 
cigarettes/day 12.12 
omnivore 12.12 
(32/52) 12.12 
Patte's 12.12 
popping 12.12 
MTB/RIF-negative 12.12 
Hartford 12.12 
M1-lymph 12.12 
empty-can 12.12 
progression/regression 12.12 
trophicity 12.12 
HSIL+ 12.12 
HPV(-) 12.12 
grade-SIL 12.12 
Uterosacral 12.12 
haemotherapy 12.12 
AUVA 12.12 
highest-level 12.12 
(12-week 12.12 
(27/19 12.12 
776; 12.12 
pregnancy--results 12.12 
C-hCG) 12.12 
alpha-hCG) 12.12 
Subcontinent 12.12 
NCSS 12.12 
Homerton 12.12 
2113 12.12 
1:22) 12.12 
pseudomembrane 12.12 
non-indicated 12.12 
filter-paper 12.12 
spots: 12.12 
post-evacuation 12.12 
Summation 12.12 
Abandonment 12.12 
36/83 12.12 
(Amersham 12.12 
data" 12.12 
3419 12.12 
1516 12.12 
(43%; 12.12 
(12/25) 12.12 
Within-run 12.12 
concentration-related 12.12 
alfa-fetoprotein 12.12 
3514 12.12 
differed: 12.12 
(1989-1990) 12.12 
reslicing 12.12 
parity; 12.12 
[CV] 12.12 
70-83 12.12 
3728 12.12 
8/253 12.12 
(11/16; 12.12 
2980 12.12 
4181 12.12 
(14-16 12.12 
7063 12.12 
combination; 12.12 
MeSHFluorenes 12.12 
(23/53) 12.12 
[symbol: 12.12 
3026 12.12 
center); 12.12 
4732 12.12 
ultrasound-defined 12.12 
(525) 12.12 
(1:10) 12.12 
9530 12.12 
side? 12.12 
25/32) 12.12 
DCTN 12.12 
2923 12.12 
(1990-1995) 12.12 
Isere 12.12 
cotinine) 12.12 
4528 12.12 
6315 12.12 
9462 12.12 
(3-21 12.12 
(197) 12.12 
1994-98 12.12 
SEMs) 12.12 
(=6 12.12 
1565 12.12 
5868 12.12 
6818 12.12 
chromosomally-abnormal 12.12 
non-IVF 12.12 
Coincidentally 12.12 
'seeing 12.12 
contract) 12.12 
population); 12.12 
1/205 12.12 
nonteaching 12.12 
1:307 12.12 
(25/48) 12.12 
2272 12.12 
"possibly 12.12 
performant 12.12 
depressed-type 12.12 
EUS-determined 12.12 
february 12.12 
full-can 12.12 
effusion/hypertrophy 12.12 
pseudolaxity 12.12 
(LDT) 12.12 
sputum-based 12.12 
[CSF] 12.12 
(T1/2) 12.12 
resectable: 12.12 
(arthroscopy 12.12 
radiologist) 12.12 
ultrastaged 12.12 
colposcopic-directed 12.12 
(AGC-NOS) 12.12 
(BNA) 12.12 
(ASCUS-LSIL) 12.12 
(ASCUS); 12.12 
(HPV-DNA) 12.12 
E6H4 12.12 
noncases 12.12 
(S-IQCODE) 12.12 
(3MS) 12.12 
filmy 12.12 
rectum? 12.12 
(USLs) 12.12 
MeSHVaginalCreams 12.12 
MeSHFoams 12.12 
(IMI) 12.12 
(22/29 12.12 
(790 12.12 
negative/culture-positive 12.12 
0-26] 12.12 
entodermal 12.12 
SILs; 12.12 
Maryland) 12.12 
CIN2; 12.12 
IQCODE: 12.12 
MeSHandJellies 12.12 
69/76 12.12 
(>or=50 12.12 
(MCI/AD) 12.12 
MCI: 12.12 
(AD)) 12.12 
Liver 12.12 
Statistical 12.11 
193 12.10 
decline 12.10 
Distribution 12.10 
contacts 12.09 
MeSHMesentery 12.09 
Intensive 12.08 
cholangiopancreatography 12.08 
character 12.07 
vomiting 12.07 
karyotyped 12.06 
pass 12.06 
corrections 12.05 
deficit 12.04 
controls) 12.04 
precancer 12.04 
(78 12.03 
percentiles 12.03 
luminescence 12.03 
ranged 12.03 
malignancies 12.02 
histologic 12.02 
retained 12.02 
criterion 12.01 
graft 12.00 
formulae 12.00 
Multicentre 12.00 
(IFD) 12.00 
=CIN 12.00 
Transrectal 12.00 
251) 12.00 
(181 12.00 
Follow-up 11.99 
daily 11.99 
count 11.98 
MeSHEndoscopy 11.98 
261 11.98 
guidance 11.96 
degeneration 11.96 
information 11.96 
size 11.96 
384 11.95 
rational 11.94 
pathways 11.94 
cholangioscopy 11.92 
days 11.92 
consecutively 11.91 
Chest 11.91 
broad 11.91 
follistatin 11.90 
positives; 11.90 
Abbott) 11.90 
patients): 11.90 
OBJECTIVE(S): 11.90 
smoking: 11.90 
C(T) 11.90 
density-weighted 11.90 
(99m)Tc-labelled 11.90 
Paps 11.90 
1661 11.90 
(n=62) 11.90 
California's 11.90 
uE3] 11.90 
16-22 11.90 
pre-operative 11.90 
predicts 11.89 
intra 11.89 
Minimally 11.89 
OF 11.87 
514 11.87 
MeSHGlycosylation 11.87 
acromioplasty 11.87 
least 11.86 
deficits 11.86 
repeatability 11.85 
827 11.85 
probabilities 11.85 
woman's 11.85 
(90 11.84 
28) 11.83 
suitable 11.82 
Mann-Whitney 11.82 
safely 11.81 
leukocyte 11.80 
MeSHAttitude 11.79 
(Down 11.79 
10) 11.79 
prominent 11.78 
random 11.78 
signaling 11.76 
Successful 11.75 
lowered 11.75 
MeSHHumanpapillomavirus16 11.75 
class 11.74 
368 11.74 
Histologic 11.73 
prevalence 11.73 
MeSHSphincterofOddi 11.72 
991 11.72 
(log 11.72 
321 11.72 
successfully 11.72 
penetrating 11.71 
plays 11.71 
14th 11.71 
Cytology 11.70 
chi-square 11.69 
restore 11.69 
analysed 11.69 
necrotizing 11.69 
extensive 11.67 
Ortho 11.67 
deltoid 11.67 
blot 11.67 
STUDY: 11.67 
types 11.66 
betahCG 11.66 
recalculated 11.66 
MeSHCognitiveDysfunction 11.66 
Proposed 11.66 
complicated 11.66 
district 11.66 
tendinosis 11.66 
nonfatal 11.66 
II/III 11.66 
MeSHTypeII 11.66 
112) 11.66 
hard 11.65 
race 11.64 
hospital 11.64 
cholecystectomies 11.63 
African 11.63 
insight 11.63 
being 11.63 
Quadruple 11.62 
Endorectal 11.62 
(uE(3)) 11.62 
14-18 11.62 
significance: 11.62 
click 11.62 
inspection 11.62 
89%) 11.62 
Sixteen 11.62 
MeSHInfertility 11.62 
code 11.61 
samples) 11.60 
ribonucleic 11.60 
MeSHLymphangioma 11.60 
eligible 11.59 
chromosomes 11.58 
visits 11.57 
37) 11.57 
infrequent 11.56 
(91% 11.56 
athlete 11.55 
azole 11.55 
swabs 11.55 
MeSHMicrobial 11.55 
infraspinatus 11.54 
category 11.54 
480 11.54 
Agreement 11.54 
fine 11.53 
proper 11.52 
I: 11.51 
log 11.51 
respiratory 11.51 
MeSHStainingandLabeling 11.50 
(median 11.50 
combines 11.50 
MeSHSpontaneous 11.49 
musculoskeletal 11.48 
43) 11.48 
dollars 11.47 
Each 11.47 
MeSHGrowthHormone 11.47 
nonpregnant 11.47 
recurrence; 11.47 
5(th) 11.47 
Estimating 11.47 
fragmentation 11.45 
44%) 11.45 
magnetic 11.45 
5%; 11.45 
occupation 11.44 
ESRD 11.44 
administer 11.44 
completed 11.43 
T 11.43 
straight 11.42 
MeSHLiverTransplantation 11.42 
En 11.42 
(under 11.41 
16-20 11.41 
(abnormal 11.41 
normal' 11.41 
cancer; 11.41 
Fifty-one 11.41 
Endoscopy 11.41 
specificity) 11.40 
conditions 11.39 
144 11.39 
tuberculosis: 11.38 
(L 11.38 
serially 11.37 
(ESRD) 11.37 
allele 11.37 
56%) 11.36 
Splenectomy 11.35 
MeSHHematologicDiseases 11.34 
MeSHCongenital 11.33 
type-specific 11.33 
males 11.33 
209 11.33 
adolescent 11.32 
night 11.32 
situation 11.30 
MeSHModels 11.30 
areas 11.29 
undetected 11.29 
ml) 11.28 
Combined 11.28 
administered 11.28 
604 11.28 
585 11.28 
[CI] 11.28 
(29 11.27 
signs) 11.27 
high-field 11.27 
double-positive 11.27 
gonadotrophins 11.27 
arthroscopies 11.27 
37%; 11.27 
GCS 11.27 
10/14 11.27 
4/29 11.27 
abnormal) 11.27 
78%; 11.27 
betaHCG 11.27 
(weeks 11.27 
overestimates 11.27 
abnormality) 11.27 
strategy: 11.27 
(hc2) 11.27 
cytobrush 11.27 
(Cohen's 11.27 
MeSHDiagnosticandStatisticalManualofMentalDisorders 11.27 
[> 11.27 
1:300) 11.27 
25/25 11.27 
CUB 11.27 
1528 11.27 
(11/16 11.27 
regarding 11.26 
MeSHNeoplasmMetastasis 11.26 
posing 11.26 
DA 11.25 
Proteins 11.25 
MeSHLiver 11.25 
deoxyribonucleic 11.25 
individual's 11.25 
hematology 11.25 
479 11.25 
549 11.25 
discordant 11.24 
USA) 11.24 
efforts 11.24 
Sixty-five 11.24 
cough 11.22 
ALT 11.22 
81%) 11.22 
cine 11.21 
picture 11.21 
TNM 11.21 
52% 11.21 
statewide 11.17 
124 11.17 
(42%) 11.15 
Safety 11.15 
age-dependent 11.15 
suffered 11.14 
41% 11.13 
middle 11.12 
Placenta 11.12 
works 11.12 
secreted 11.12 
peptides 11.10 
090 11.10 
immunoradiometric 11.10 
686 11.10 
fertilisation 11.10 
pretest 11.10 
Calculation 11.10 
Subacromial 11.10 
909 11.10 
MeSHHongKong 11.09 
solid 11.08 
(80 11.08 
extremity 11.07 
Radiographic 11.07 
MeSHSexCharacteristics 11.04 
organisms 11.04 
prenatally 11.03 
select 11.03 
act 11.03 
Infectious 11.02 
2-5 11.02 
judge 11.01 
acids 11.01 
Natural 11.01 
50) 10.99 
Trauma 10.99 
cigarette 10.97 
member 10.97 
Correlation 10.97 
MeSHJointDiseases 10.96 
053 10.96 
Respiratory 10.96 
064 10.95 
(CA) 10.95 
PTC 10.95 
morphologically 10.95 
mg/kg 10.95 
well-trained 10.94 
Party 10.94 
anxious 10.94 
amniocentesis; 10.94 
ISRCTN 10.94 
TPS 10.94 
freezer 10.94 
GP5+/6+ 10.94 
Maine 10.94 
useful? 10.94 
11-14) 10.94 
significance) 10.94 
interactions 10.94 
348 10.93 
Three 10.93 
MeSHSoftware 10.92 
17% 10.92 
MeSHCellDifferentiation 10.91 
1980 10.91 
through 10.90 
hypertrophy 10.89 
stenosis 10.89 
authors 10.89 
MeSHLymphaticSystem 10.88 
maturation 10.88 
?/nMeSHCholangiopancreatography 10.88 
ranges 10.88 
controlled 10.88 
=8 10.88 
abdomen 10.86 
MeSHBaseSequence 10.85 
MeSHSplenectomy 10.85 
8-9 10.84 
gamma-glutamyl 10.84 
m-labeled 10.84 
339 10.84 
short-term 10.84 
Eight 10.83 
species 10.82 
precede 10.82 
after 10.81 
Internal 10.81 
AUC 10.80 
histology 10.80 
Student's 10.80 
born 10.79 
short- 10.79 
Movement 10.78 
Considering 10.78 
Performance 10.78 
segments 10.76 
76) 10.75 
(HIV) 10.73 
retraction 10.73 
foot 10.73 
healthy 10.72 
Seven 10.72 
knee 10.72 
public 10.72 
From 10.71 
dual-phase 10.70 
mid-pregnancy 10.70 
ultra-sonography 10.70 
(1995) 10.70 
Asian) 10.70 
(2/4) 10.70 
testing? 10.70 
(proMBP) 10.70 
(UE) 10.70 
abnormalities? 10.70 
(TBS) 10.70 
Afro-Caribbeans 10.70 
18-35 10.70 
1936 10.70 
"or 10.70 
HDI 10.70 
Amersham 10.70 
28% 10.69 
reverse 10.69 
advances 10.69 
effector 10.68 
lymphatics 10.68 
consideration 10.68 
commercially 10.67 
non-pregnant 10.66 
MeSHMyocardialIschemia 10.66 
13-15 10.66 
In 10.66 
Barium 10.66 
fractions 10.65 
consumption 10.64 
entire 10.64 
novel 10.64 
bony 10.63 
seen 10.63 
MeSHCysts 10.63 
cancer: 10.62 
prehospital 10.62 
gamma-glutamyltransferase 10.62 
retesting 10.62 
MeSHOocyteDonation 10.62 
centralised 10.62 
reassured 10.62 
peri-ampullary 10.62 
CIN2/3 10.62 
(SILs) 10.62 
11-12 10.62 
girls 10.61 
Predicting 10.61 
concurrently 10.61 
alteration 10.61 
reactive 10.60 
mode 10.60 
prevalences 10.60 
Body 10.59 
discover 10.58 
Thirty-three 10.58 
(88%) 10.58 
MeSHMycobacteriumbovis 10.58 
spiked 10.57 
tumors 10.57 
review 10.57 
295 10.57 
consequences 10.57 
zone 10.56 
amount 10.56 
distal 10.55 
Validation 10.55 
incorporate 10.53 
<35 10.53 
614 10.53 
excised 10.52 
etiologic 10.52 
CVS 10.52 
experiments 10.52 
presenting 10.51 
NSC 10.51 
sizes 10.50 
Abbott 10.50 
72-4 10.50 
withhold 10.50 
ipsilateral 10.49 
MSS 10.48 
Ontario 10.47 
fluorescent 10.47 
identification 10.47 
large-scale 10.46 
(AUC 10.46 
thrombosis 10.45 
180 10.45 
alterations 10.45 
Restriction 10.45 
consultation 10.45 
pneumonia 10.45 
'sliding 10.43 
PIGF 10.43 
Speed's 10.43 
activin-A 10.43 
Invader 10.43 
PRISCA 10.43 
inhibin/activin 10.43 
2MSS 10.43 
translucence 10.43 
coronal-oblique 10.43 
HPV(+) 10.43 
FTRCT 10.43 
"equivocal" 10.43 
p16ink4 10.43 
sonovaginography 10.43 
dipyridamole-exercise 10.43 
C-hCG 10.43 
2-4%) 10.43 
three-analyte 10.43 
intrapersonal 10.43 
4130 10.43 
pseudo-risk 10.43 
NTD's 10.43 
IVF-embryo 10.43 
20-pound 10.43 
"Atypical 10.43 
staged) 10.43 
Crank 10.43 
Papp-A 10.43 
double-echo 10.43 
midline) 10.43 
AGC-NOS 10.43 
informant-based 10.43 
(pAD) 10.43 
Scale-cognitive 10.43 
(first-trimester 10.43 
(PALP) 10.43 
PALP 10.43 
(alphafetoprotein 10.43 
2-5%) 10.43 
14-16) 10.43 
(7/46) 10.43 
precursor) 10.43 
trimester-combined 10.43 
'dates' 10.43 
Hackney 10.43 
(18/37) 10.43 
multiracial 10.43 
microheterogeneity 10.43 
Seth 10.43 
unburdened 10.43 
acid-deficient 10.43 
II-2/nMeSHAdult 10.43 
association; 10.43 
2-analyte 10.43 
Multiplication 10.43 
Expressing 10.43 
9350 10.43 
(AFP-L3) 10.43 
Microcitemico 10.43 
(9-10 10.43 
'old' 10.43 
UKNEQAS 10.43 
2886 10.43 
10+3 10.43 
placenta-associated 10.43 
euglycemic 10.43 
12+4 10.43 
(37/63 10.43 
(35%; 10.43 
13/23) 10.43 
(37/63) 10.43 
surprised 10.43 
25-90 10.43 
(NSC) 10.43 
(second-trimester 10.43 
fetuses? 10.43 
72-89) 10.43 
(measurements 10.43 
log(10)MoM 10.43 
multi-parametric 10.43 
Auditing 10.43 
1479 10.43 
T-21 10.43 
reproduction: 10.43 
NT; 10.43 
miscarriage) 10.43 
WORDS)/nMeSHDownSyndrome 10.43 
genetics] 10.43 
=1/270 10.43 
aunder 10.43 
3111 10.43 
Hispanic) 10.43 
26]; 10.43 
27]; 10.43 
5385 10.43 
hypoplasia: 10.43 
PAPP-A; 10.43 
(UGP) 10.43 
29-fold 10.43 
1/78 10.43 
10000) 10.43 
amniocentesis--an 10.43 
[serum 10.43 
(16-22 10.43 
(98) 10.43 
uE3; 10.43 
[mm]) 10.43 
(20/40) 10.43 
1:280 10.43 
Baye's 10.43 
(2MSS) 10.43 
programme) 10.43 
3059 10.43 
analyses] 10.43 
screen-negative) 10.43 
(beta-hCG)) 10.43 
>1/250 10.43 
69XXY 10.43 
8600 10.43 
(OSB) 10.43 
13/trisomy 10.43 
(FA-2) 10.43 
multi-analyte 10.43 
markers--maternal 10.43 
undelivered 10.43 
biochemistry; 10.43 
(3D-EUS) 10.43 
1997-2001) 10.43 
O'Brien's 10.43 
liquid) 10.43 
laboratory-developed 10.43 
Alere 10.43 
(NPA) 10.43 
(LOD) 10.43 
13th+6 10.43 
era? 10.43 
(CBDs) 10.43 
perilesionally 10.43 
Retesting 10.43 
(L-SIL) 10.43 
Colposcopically 10.43 
non-negative 10.43 
HPV51 10.43 
colposcopy: 10.43 
TOMBOLA 10.43 
=CIN3) 10.43 
dyskaryosis: 10.43 
anti-p16 10.43 
52+/-12 10.43 
Scale-Cognitive 10.43 
(ADAS-cog) 10.43 
aspergilosis 10.43 
'possible' 10.43 
(AGA) 10.43 
t-testing 10.43 
(402 10.43 
HIV-burden 10.43 
95-99% 10.43 
extrarotation 10.43 
Argentina) 10.43 
borderline/mild 10.43 
ASC-US; 10.43 
26-item 10.43 
97-100% 10.43 
(converters 10.43 
(hippocampus 10.43 
hemato-oncologic 10.43 
probable/proven 10.43 
certainty: 10.43 
segmental 10.43 
band 10.43 
MeSHFluorouracil 10.42 
communication 10.42 
phenomenon 10.42 
(21 10.42 
finger 10.41 
Sixty-four 10.41 
MeSHSynovialFluid 10.41 
Mai 10.40 
MeSHEducationalStatus 10.38 
negative) 10.38 
1-10 10.38 
113 10.37 
16% 10.36 
35- 10.36 
MeSHDiagnostic 10.36 
woman 10.35 
complained 10.34 
MeSHKidney 10.34 
surgeons 10.33 
noted 10.33 
developed 10.33 
normalize 10.32 
enzyme-linked 10.32 
antibiotics 10.32 
Biological 10.32 
MeSHAdministration 10.31 
ABER 10.31 
encasement 10.31 
IFD 10.31 
exomphalos 10.31 
HPV16/18 10.31 
authority 10.31 
interpretive 10.31 
negatives) 10.31 
eighty-four 10.31 
(weighted 10.31 
10-16 10.31 
QUADAS 10.31 
3/28 10.31 
MeSHRotation 10.30 
start 10.30 
humerus 10.28 
compared: 10.28 
881 10.28 
intelligence 10.28 
sonologist 10.28 
agreements 10.28 
published 10.28 
Surgery 10.28 
killer 10.28 
device 10.28 
AL 10.26 
screenings 10.25 
encoding 10.25 
biometric 10.24 
coracoacromial 10.24 
654 10.24 
OS 10.24 
recall 10.23 
endosonography 10.23 
systolic 10.23 
MeSHComorbidity 10.23 
Fungal 10.22 
(trisomy 10.21 
lesions: 10.20 
258 10.20 
Lavage 10.20 
K) 10.20 
molecular 10.19 
antigenaemia 10.19 
sterling 10.19 
supination 10.19 
low-field 10.19 
IGFBP-3 10.19 
cotinine 10.19 
beta-subunit) 10.19 
translocation) 10.19 
(beta-HCG) 10.19 
recurrences: 10.19 
10-MHz 10.19 
speculum 10.19 
(205 10.19 
-abnormal 10.19 
(ThinPrep 10.19 
(galactomannan 10.19 
223) 10.19 
AD: 10.19 
Conventional 10.18 
44) 10.18 
Abnormal 10.14 
peritonitis 10.12 
Transport 10.12 
expansion 10.11 
period 10.11 
(to 10.11 
MeSHFungal 10.11 
(56%) 10.10 
definitions 10.10 
expressing 10.09 
people 10.09 
soon 10.09 
Th1 10.09 
Measuring 10.08 
indication 10.06 
multidrug-resistant 10.06 
=3 10.06 
flat 10.06 
participating 10.06 
>3 10.04 
biology 10.04 
115 10.03 
MeSHCartilage 10.02 
hCGbeta 10.02 
significative 10.02 
(n=32) 10.02 
theorem 10.02 
Syndrome) 10.02 
(normal) 10.02 
(fetal 10.02 
(CIN3) 10.02 
SPM2 10.02 
T2*- 10.02 
deficient 10.02 
acceptability 10.02 
results: 10.02 
exercises 10.02 
284 10.01 
MeSHIntestinalDiseases 10.01 
Three-dimensional 10.01 
principles 9.99 
reactivity 9.99 
MeSHDisease-FreeSurvival 9.99 
arrangement 9.97 
difficulty 9.96 
rib 9.96 
trisomic 9.95 
targets 9.95 
categorized 9.95 
cost-effectiveness 9.94 
Tomography 9.94 
ovulation 9.93 
Mathematical 9.92 
MeSHCryopreservation 9.91 
16/18 9.91 
279 9.91 
System 9.91 
enzymes 9.90 
lesion: 9.88 
Tricuspid 9.88 
8/13 9.88 
943 9.88 
796 9.88 
1-100 9.88 
(1--> 9.88 
familial 9.87 
ampullary 9.87 
Intestinal 9.86 
radio 9.86 
operability 9.86 
358 9.86 
case 9.86 
B1 9.86 
account 9.85 
exert 9.85 
137 9.84 
CLINICAL 9.84 
mm) 9.82 
365 9.80 
343 9.80 
hope 9.80 
X 9.78 
mutations 9.77 
disclosure 9.77 
552 9.77 
raise 9.76 
215 9.76 
AT 9.75 
(cut-off 9.75 
20-22 9.75 
megacystis 9.75 
overstaged 9.75 
intestine] 9.75 
T1/2 9.75 
(TR) 9.75 
topoisomerase 9.75 
1:6 9.75 
Oregon 9.75 
policy 9.73 
proMBP 9.72 
JOY 9.72 
(MPI) 9.72 
Inhibin-A 9.72 
14-25 9.72 
(QUADAS) 9.72 
lesion" 9.72 
negative: 9.72 
Liquid-based 9.72 
Rectovaginal 9.72 
9/72 9.72 
beta-1-glycoprotein 9.72 
complete) 9.72 
(Brazil 9.72 
Psychiatry 9.72 
reanalyse 9.72 
202 9.72 
diet 9.71 
modified 9.71 
normalized 9.69 
139 9.69 
disturbances 9.69 
stones: 9.69 
suture 9.69 
rabbit 9.68 
MeSHCystic 9.68 
non-resectable 9.68 
658 9.68 
nine) 9.68 
Recall 9.68 
(14 9.68 
excluding 9.67 
problems 9.67 
mg/d 9.67 
MeSHGallbladderNeoplasms 9.67 
failed 9.66 
stent 9.66 
MeSHInfusions 9.65 
putative 9.65 
medicine 9.65 
109 9.65 
chi2 9.65 
>/=1 9.65 
05) 9.64 
injury 9.64 
corticosteroid 9.63 
targeting 9.63 
so-called 9.63 
MeSHBodyMassIndex 9.63 
scores 9.63 
370 9.62 
hybridization 9.62 
(Down's 9.62 
MeSHDiscriminantAnalysis 9.62 
481 9.62 
CD4(+) 9.62 
Strain 9.62 
current 9.61 
slight 9.61 
decades 9.60 
205 9.60 
dilation 9.59 
University 9.59 
neutropenia 9.58 
synthesis 9.58 
follow 9.58 
histologically 9.58 
Kidney 9.57 
<3 9.56 
(76 9.56 
Gold 9.54 
cancer) 9.53 
MeSHCholecystolithiasis 9.52 
prescribed 9.52 
29) 9.52 
autologous 9.52 
terminal 9.51 
replaced 9.51 
Pearson 9.50 
129 9.50 
Seoul 9.49 
(test 9.49 
nonresectable 9.49 
113) 9.49 
Ia 9.49 
establishment 9.49 
GB 9.49 
6/6 9.49 
begin 9.48 
Longitudinal 9.48 
freeze-thaw 9.48 
2-dimensional 9.48 
Series 9.48 
(p16 9.48 
separate 9.48 
carcinoma? 9.47 
581 9.47 
78) 9.45 
49% 9.45 
tubal 9.45 
villi 9.45 
fold 9.44 
(88% 9.43 
SPECT) 9.43 
254 9.43 
grafting 9.42 
couple 9.41 
subsequently 9.41 
Present 9.40 
involving 9.40 
event 9.39 
PARTICIPANTS 9.39 
91%) 9.39 
MeSHObstructive 9.39 
cells) 9.39 
sessions 9.39 
oesophageal 9.38 
bursitis 9.38 
global 9.37 
Ninety-two 9.36 
477 9.36 
451 9.36 
[P 9.35 
33) 9.35 
229 9.35 
individually 9.34 
England 9.34 
continued 9.34 
technique 9.33 
post-transplant 9.32 
538 9.32 
765 9.32 
Calculi 9.32 
favorable 9.31 
MeSHMeglumine 9.31 
genome 9.31 
variation 9.30 
nontherapeutic 9.30 
(SD: 9.30 
ultrasound-based 9.30 
1/60 9.30 
sampling; 9.30 
22-month 9.30 
(USS) 9.30 
(7/8) 9.30 
smear) 9.30 
MeSHHeartFunctionTests 9.30 
DIA) 9.30 
Rectosigmoid 9.30 
[60 9.30 
(R 9.29 
intervals 9.29 
RealTime 9.29 
EasyQ 9.29 
LapUS 9.29 
beta-protein 9.29 
FA-2 9.29 
L1-negative 9.29 
pAD 9.29 
Regressed 9.29 
Intra-observer 9.29 
weight-related 9.29 
IPA; 9.29 
upper-third 9.29 
3D-EUS 9.29 
significance" 9.29 
HART 9.29 
IQCODE-N 9.29 
uterinus 9.29 
GM-EIA 9.29 
operators' 9.29 
Norway) 9.29 
Monte-Carlo 9.29 
1538 9.29 
Caucasian) 9.29 
Barts 9.29 
'combined 9.29 
residues) 9.29 
IGFBP-3) 9.29 
rates? 9.29 
0137) 9.29 
one--a 9.29 
appended 9.29 
B-human 9.29 
10/70 9.29 
1462 9.29 
(31/40) 9.29 
(15/23) 9.29 
7470 9.29 
analysers 9.29 
1325 9.29 
immuno-fluorometric 9.29 
1609 9.29 
12-22 9.29 
'pseudo 9.29 
trials? 9.29 
Tentative 9.29 
datasets: 9.29 
10/92 9.29 
equitably 9.29 
(880 9.29 
reinterpretation 9.29 
three-tiered 9.29 
(113) 9.29 
1:55 9.29 
1852 9.29 
17-fold 9.29 
average-risk 9.29 
Pakistanis 9.29 
1:180 9.29 
556) 9.29 
Jaffe 9.29 
3186 9.29 
2799 9.29 
Flemish 9.29 
2978 9.29 
Anglia 9.29 
(36/48) 9.29 
(n=69) 9.29 
(LapUS) 9.29 
specialising 9.29 
validly 9.29 
(experienced 9.29 
pronated 9.29 
"blindly" 9.29 
(Cepheid) 9.29 
(abdomen 9.29 
(PET)-computed 9.29 
119; 9.29 
(22/23) 9.29 
arthrography; 9.29 
vulva] 9.29 
Tucson 9.29 
HPVDNA 9.29 
two-tiered 9.29 
Papanicolou 9.29 
(RLU) 9.29 
papillomavirus-based 9.29 
Mini-Mental-State 9.29 
3MS 9.29 
(IQCODE-N) 9.29 
endocavitary 9.29 
symptom-limited 9.29 
APOE4 9.29 
predated 9.29 
T1-m 9.29 
over-staged 9.29 
IIIc) 9.29 
arthroscopic) 9.29 
86); 9.29 
[ASCUS] 9.29 
LSIL); 9.29 
[Hazard 9.29 
LFC 9.29 
stereotactical 9.29 
found 9.28 
(44%) 9.28 
good 9.28 
feasibility 9.27 
adjunct 9.27 
Radiologic 9.26 
cytometric 9.25 
sporadic 9.25 
Regression 9.24 
focal 9.24 
tolerate 9.24 
reproducibility 9.23 
necessary 9.23 
spin-echo 9.23 
endovaginal 9.23 
EBC 9.23 
"atypical 9.23 
Birmingham 9.23 
20-week 9.23 
MeSHCapsidProteins 9.23 
MeSHCaregivers 9.23 
Colposcopic 9.23 
Race 9.23 
pellet 9.23 
fatty 9.23 
intraductal 9.22 
further 9.22 
operations 9.22 
(80% 9.22 
transition 9.20 
become 9.20 
MeSHPneumonia 9.19 
200 9.19 
challenges 9.19 
applies 9.18 
MeSHMonteCarloMethod 9.18 
archived 9.18 
intensive 9.18 
depend 9.17 
(T) 9.17 
(% 9.17 
coil 9.16 
identifies 9.16 
refine 9.16 
conclusions 9.14 
agent 9.14 
L1 9.14 
(ELISA) 9.13 
susceptibility 9.13 
T3-4 9.13 
multicenter 9.13 
(22 9.12 
MeSHEmbryoTransfer 9.12 
fiber 9.12 
yielding 9.12 
deposit 9.11 
58%) 9.11 
41%) 9.11 
sole 9.09 
MeSHDogs 9.09 
morphology 9.08 
saturated 9.08 
MeSHSigmoidDiseases 9.07 
77%) 9.06 
(F 9.06 
author's 9.06 
scientific 9.05 
(EGC) 9.04 
overtreatment 9.04 
AFS) 9.04 
mildly 9.03 
Finland 9.03 
(in 9.02 
scans 9.02 
occurred 9.01 
transrectal 9.01 
MeSHOvarianNeoplasms 9.00 
prefer 9.00 
MeSHBloodPlatelets 8.99 
behaviour 8.99 
surgeries 8.99 
ninety-nine 8.99 
Subscapularis 8.99 
U-test 8.99 
perilesional 8.99 
Caregivers 8.99 
itself 8.98 
vein 8.98 
judged 8.97 
clip 8.96 
(86%) 8.95 
169 8.95 
interpreting 8.94 
submucosal 8.94 
artery 8.94 
locations 8.94 
turn 8.93 
conception 8.93 
MeSHBiological 8.93 
gallbladders 8.93 
architecture 8.93 
observations 8.91 
43% 8.90 
Corporation 8.90 
dyskinesis 8.90 
ng/ml; 8.90 
fragment) 8.90 
stomach) 8.90 
papillomavirus: 8.90 
(p16) 8.90 
(EORTC/MSG) 8.90 
CFU/ml 8.90 
(CAG) 8.90 
depiction 8.90 
substantiated 8.90 
(LG 8.90 
refractory 8.90 
establish 8.90 
C-reactive 8.89 
SS 8.89 
concern 8.89 
UK 8.89 
MeSHPancreaticDiseases 8.88 
procedures 8.87 
24) 8.87 
permanent 8.86 
61) 8.84 
extend 8.82 
introducing 8.81 
pN 8.81 
incidental 8.81 
-34 8.81 
Vater 8.81 
MeSHBrainNeoplasms 8.79 
neuropathy 8.79 
referrals 8.79 
MeSHFluoroscopy 8.78 
overestimated 8.78 
explorative 8.78 
Oxford 8.78 
(LFTs) 8.78 
laparoscopy: 8.78 
Harris 8.78 
SPR 8.78 
813 8.78 
696 8.78 
deletion 8.78 
(total 8.78 
sonograms 8.78 
Cytological 8.78 
(BAL) 8.78 
MeSHTransducers 8.78 
five) 8.77 
1:5 8.77 
anesthesia 8.76 
rheumatic 8.76 
134 8.76 
MeSHTimeFactors 8.75 
Japan 8.75 
95(th) 8.75 
single-step 8.75 
estriol) 8.75 
(n=34 8.75 
4-year 8.75 
instrument 8.73 
displacement 8.72 
MeSHTranscription 8.72 
incorrect 8.72 
resonance 8.72 
adenoma 8.72 
spared 8.71 
(SPECT) 8.71 
or=1 8.71 
differentiation 8.71 
status 8.71 
se 8.71 
mature 8.70 
countries 8.70 
146 8.70 
noticed 8.70 
reserving 8.69 
respond 8.69 
100) 8.69 
MeSHAbdominal 8.69 
dissemination 8.68 
Austria 8.68 
directed 8.67 
incorrectly 8.67 
twenty-one 8.67 
reproductive 8.66 
MeSHSingleNucleotide 8.66 
1993 8.65 
basal 8.65 
993 8.64 
(SPECT 8.64 
plots 8.64 
419 8.64 
X-rays 8.63 
sometimes 8.63 
called 8.62 
08 8.62 
pre-test 8.62 
MeSHVentricularFunction 8.62 
633 8.62 
quoted 8.62 
Endosonographic 8.62 
radiologic 8.61 
feed 8.61 
MeSHIndia 8.60 
e) 8.59 
MeSHOvulationInduction 8.58 
(author's 8.58 
phosphate 8.58 
groups 8.58 
remaind 8.58 
Logistic 8.57 
MeSHPeptides 8.57 
(98% 8.57 
three-dimensional 8.57 
MeSHFluorescentAntibodyTechnique 8.57 
oesophagus 8.56 
(chi2 8.56 
341 8.56 
two-year 8.56 
stimulate 8.56 
aspirate 8.55 
tE 8.55 
PCR-ELISA 8.54 
NPA 8.54 
result) 8.54 
economies 8.54 
2020 8.54 
tear: 8.54 
Significance/Low-Grade 8.54 
(ECG) 8.54 
MeSHCardiotonicAgents 8.54 
Deeply 8.54 
(integrated 8.54 
LSILs 8.54 
sacroiliac 8.53 
there 8.53 
Test) 8.53 
biopsy-confirmed 8.53 
8-13 8.53 
Sunnyvale 8.53 
(HPVs) 8.53 
staging) 8.53 
CCS) 8.53 
contemporaneous 8.53 
MeSHPrivatePractice 8.53 
1/28 8.53 
Memory 8.53 
(44% 8.53 
oxide 8.53 
increases 8.52 
>1 8.52 
Visual 8.51 
Medicine 8.51 
660 8.51 
rapid 8.50 
30% 8.50 
(without 8.49 
Choledocholithiasis 8.48 
unaware 8.48 
(86% 8.47 
AIM 8.47 
excision 8.47 
MeSHBiliaryTractSurgicalProcedures 8.47 
copies 8.46 
advanced 8.46 
POD 8.45 
744 8.45 
124) 8.45 
885 8.45 
668 8.45 
939 8.45 
MeSHSingle-BlindMethod 8.45 
MeSHLungDiseases 8.45 
MeSHUnitedKingdom 8.45 
strict 8.44 
reduce 8.44 
hemostasis 8.43 
avoided 8.43 
transl)] 8.43 
diploid 8.43 
ascertained 8.43 
ns) 8.42 
pathogenic 8.42 
MeSHEarlyDiagnosis 8.42 
currently 8.42 
v 8.42 
NucliSENS 8.42 
Delta-NT 8.42 
B(12) 8.42 
RLU/CO 8.42 
Immulite 8.42 
discriminability 8.42 
peel-back 8.42 
TB-LAM 8.42 
10(+0) 8.42 
transmitral 8.42 
increase: 8.42 
metalloprotease) 8.42 
CINtec 8.42 
Injured 8.42 
(AWD) 8.42 
1134 8.42 
(crown-rump 8.42 
15/45 8.42 
56-100 8.42 
Amerlex-M 8.42 
gestation-matched 8.42 
WORDS)/nMeSHAlgorithms 8.42 
12/26 8.42 
(0-19 8.42 
(together 8.42 
4131 8.42 
monochorial 8.42 
(TTTS) 8.42 
1:384 8.42 
15-16 8.42 
non-Chinese 8.42 
Goldenhar 8.42 
1421 8.42 
(MoM)] 8.42 
1819 8.42 
Categories 8.42 
0092) 8.42 
dimer) 8.42 
1515 8.42 
1/100) 8.42 
transfers) 8.42 
kd) 8.42 
(1992-1994) 8.42 
(78%; 8.42 
Georgetown 8.42 
1:100) 8.42 
services) 8.42 
8773 8.42 
unwise 8.42 
both: 8.42 
preamniocentesis 8.42 
gonadotropin: 8.42 
immunoenzymometric 8.42 
DGH 8.42 
Joubert 8.42 
[uE3] 8.42 
uncorrelated 8.42 
1997-1998 8.42 
1368 8.42 
2018 8.42 
alpha-fetoprotein] 8.42 
oedema) 8.42 
2349 8.42 
denying 8.42 
1:195 8.42 
procedural-related 8.42 
uneventful; 8.42 
peritumorous 8.42 
(regarding 8.42 
SPORTDiscus 8.42 
exist: 8.42 
assay's 8.42 
RIF-susceptible 8.42 
countries? 8.42 
CEAs 8.42 
unscheduled 8.42 
(T1/2 8.42 
?/nMeSHGastrointestinalNeoplasms 8.42 
(RTC) 8.42 
Elegra 8.42 
(45%); 8.42 
histology-confirmed 8.42 
MeSHGeriatricPsychiatry 8.42 
(RTR) 8.42 
non-blinded 8.42 
immunocapture 8.42 
galactomannan-positive 8.42 
upper-GI 8.42 
MeSHSupination 8.42 
(NPA 8.42 
chemotherapy/radiotherapy 8.42 
tear- 8.42 
[LSIL] 8.42 
(335 8.42 
26-45 8.42 
females 8.42 
West 8.41 
chose 8.40 
bacillus 8.40 
subtotal 8.40 
(41 8.40 
microarray 8.40 
metachronous 8.39 
holds 8.39 
developmental 8.38 
Accurate 8.38 
value) 8.38 
secondly 8.38 
458 8.38 
12% 8.38 
optimal 8.37 
82) 8.37 
polymorphic 8.37 
MeSHClusterAnalysis 8.37 
minimal 8.36 
subjective 8.36 
heat 8.36 
day 8.35 
Unnecessary 8.35 
347 8.35 
MeSHWestern 8.34 
discusses 8.34 
insights 8.34 
initiated 8.33 
prompt 8.32 
commonly 8.32 
discovery 8.31 
frozen-thawed 8.31 
(126 8.31 
Diameter 8.31 
sliding 8.31 
-glucose- 8.31 
COMPETING 8.31 
colloid 8.31 
overlap 8.31 
gained 8.31 
look 8.30 
genotypes 8.30 
140 8.30 
Markers 8.30 
26) 8.29 
Furthermore 8.29 
compound 8.28 
forty 8.26 
dichorionic 8.25 
22) 8.25 
intradermally 8.24 
(negative 8.24 
530 8.24 
sedimentation 8.24 
plot 8.23 
acid-fast 8.23 
stenting 8.23 
MeSHEndometrium 8.23 
Effects 8.23 
component 8.22 
November 8.22 
reconstruct 8.22 
accessory 8.21 
Histocompatibility 8.21 
Tl-201 8.20 
observed/expected 8.20 
ss-hCG 8.20 
Hyperfibrinolysis 8.20 
unprocessed 8.20 
MeSHN-AcetylneuraminicAcid 8.20 
fluoroimmunoassay 8.20 
free-beta-human 8.20 
triploidy) 8.20 
93%; 8.20 
(Hybrid 8.20 
(EBCT) 8.20 
activations 8.20 
Down-syndrome 8.20 
Interrater 8.20 
arthrotomy 8.20 
/HPV 8.20 
films 8.20 
uracil 8.20 
software 8.19 
MeSHVaccination 8.17 
marked 8.17 
waiting 8.17 
coded 8.16 
Morbidity 8.16 
Physician 8.16 
Blood 8.16 
Hybridization 8.15 
aggregation 8.14 
opportunistic 8.14 
levels: 8.14 
pathology: 8.14 
807 8.14 
paper 8.14 
measures 8.14 
29; 8.13 
414 8.13 
>or=3 8.13 
esophageal 8.13 
FDG 8.13 
eosinophil 8.12 
RA 8.12 
(81% 8.11 
pancreaticobiliary 8.11 
inducing 8.11 
quotient 8.10 
0012) 8.10 
1:380 8.10 
9-14 8.10 
L3) 8.10 
839 8.10 
P16 8.10 
CD-10 8.10 
MeSHLogisticModels 8.10 
carriers 8.10 
personal 8.10 
amounts 8.10 
85) 8.10 
details 8.09 
comparable 8.09 
216 8.08 
binding 8.08 
perceived 8.08 
resembling 8.08 
deeper 8.07 
21: 8.07 
LND 8.06 
country 8.05 
lymphoblastic 8.04 
stained 8.04 
derive 8.04 
402 8.04 
falsely 8.04 
recruited 8.04 
pus 8.03 
choledochal 8.03 
(MD 8.02 
Physicians 8.02 
Twenty-nine 8.02 
We 8.02 
corticosteroids 8.01 
innate 8.01 
etiologies 8.01 
rounded 8.01 
MeSHBelgium 8.01 
462 8.01 
-18 8.01 
Cox 8.00 
hypoplasia 8.00 
(94 7.99 
twenty-eight 7.99 
QUESTION: 7.99 
testing: 7.99 
Copenhagen 7.99 
low-back 7.98 
MeSHHeparin 7.98 
Beijing 7.98 
T3 7.97 
34) 7.97 
(78% 7.97 
USA 7.96 
56) 7.96 
breaks 7.95 
abundant 7.95 
lipids 7.95 
SILNs 7.95 
RLU/Co 7.95 
s-p53Ab 7.95 
AGC-US 7.95 
938% 7.95 
SMASH 7.95 
hpVIR 7.95 
p16-INK4A 7.95 
endo-MRI 7.95 
DCEUS 7.95 
contraceptive-use 7.95 
3DPD-US 7.95 
(Finding 7.95 
SLAP-specific 7.95 
CA-242 7.95 
T2*-Rho-GEI 7.95 
p634A4 7.95 
2/3/carcinoma 7.95 
B-mode-US 7.95 
TVUS; 7.95 
[(18)F]FDDNP 7.95 
autoheparinization 7.95 
on-scene 7.95 
10U 7.95 
scanograms 7.95 
EGGCS 7.95 
echofeatures 7.95 
IS6110-TaqMan 7.95 
nonsecretors 7.95 
TAp73 7.95 
Inv2 7.95 
MyGene 7.95 
HPVIII 7.95 
IQCODE(F) 7.95 
IQCODE-T 7.95 
G/GM 7.95 
RoTEM((R)) 7.95 
nNOS 7.95 
hypocoaguable 7.95 
938%) 7.95 
CLSRs 7.95 
CTRT 7.95 
Hydro-CT 7.95 
LSST 7.95 
SLAPprehension 7.95 
CEA+; 7.95 
MR-ARTH 7.95 
T2-GEI 7.95 
non-SILNs 7.95 
LSIL/ASC-H 7.95 
E6*I/E6*II 7.95 
ASCUS-categorized 7.95 
SHARP 7.95 
Antisaccadic 7.95 
LR-MRI 7.95 
TVUS-BP 7.95 
sonohistological 7.95 
195); 7.95 
CSE/T1FS 7.95 
CSE/T1FS/Gd-T1FS 7.95 
SEAD-J 7.95 
snaMCI 7.95 
nonburned 7.95 
Thrombotest 7.95 
MT-death 7.95 
delayed/sustained 7.95 
EHPs 7.95 
preMTP 7.95 
2099 7.95 
6474 7.95 
pain/midline 7.95 
(EGGCS: 7.95 
intermediate-stage 7.95 
non-satisfied 7.95 
expanded-indication 7.95 
LAM-positive 7.95 
CEA+CT 7.95 
TPA-GICA 7.95 
CEA-) 7.95 
reresectability 7.95 
PRTC 7.95 
CIN>/=2 7.95 
VIA-positive 7.95 
EDiTH 7.95 
ESTT 7.95 
FcGR3A 7.95 
ASCUS-diagnosed 7.95 
TS-PCR 7.95 
HS3ST2 7.95 
Cervista 7.95 
MMSE-CE 7.95 
'weighted 7.95 
inter-/intra-observer 7.95 
MSCT-c 7.95 
rectovaginal-septum 7.95 
DIE-TVUS 7.95 
DCBEs 7.95 
utero-sacral-ligaments 7.95 
posterior-vaginal-fornix 7.95 
Tl-201-DPM 7.95 
tachycardic-stress 7.95 
Myoview 7.95 
PET-CCS 7.95 
AACD 7.95 
education/occupation 7.95 
Klaue 7.95 
MCI/noDecl 7.95 
visual-spatial 7.95 
non-allo-HSCT 7.95 
PT/INR 7.95 
inter-changeability 7.95 
short-incision 7.95 
immuno-coagulatory 7.95 
Delayed/sustained 7.95 
nontraumatized 7.95 
CA(15)-EXTEM 7.95 
CA(10)-FIBTEM 7.95 
pre-TEG 7.95 
Blunt-trauma 7.95 
scanogram 7.95 
GCS<15 7.95 
LAGEC 7.95 
(EGGCS/GGCS: 7.95 
nondownstaged 7.95 
hydrogastric 7.95 
video-endoscopic 7.95 
828% 7.95 
EUS-AD 7.95 
endoscopy/EUS 7.95 
accepted/extended 7.95 
(lift-off 7.95 
(springing 7.95 
HIB) 7.95 
Evaluators 7.95 
Neer-type 7.95 
Sackett's 7.95 
acromioclavicularjoint 7.95 
(thumb 7.95 
Stage-II 7.95 
Mimori 7.95 
nonliquid 7.95 
(64%-85%) 7.95 
LCTB 7.95 
MTB/RIF(R) 7.95 
RUO 7.95 
LAM-negative 7.95 
22-61) 7.95 
days-to-TB 7.95 
SS(-) 7.95 
MTB/RIF-positive 7.95 
Flotation 7.95 
Xpert(R)MTB/RIF 7.95 
re-resections 7.95 
ceCT; 7.95 
'fast' 7.95 
microgram/l 7.95 
'slow' 7.95 
(s-p53Ab 7.95 
(nonsecretors) 7.95 
recurrence(s) 7.95 
VLBW 7.95 
TPA-CA 7.95 
TPA-GICA-CA72-4 7.95 
SL-LUS 7.95 
SL-R 7.95 
SL-NR 7.95 
EL-R 7.95 
EL-NR 7.95 
EUB-340 7.95 
EUB-515 7.95 
91%/91%; 7.95 
ms/30 7.95 
MR-Arthrography 7.95 
impact); 7.95 
COT1FS 7.95 
(stage-III) 7.95 
dual-criteria 7.95 
24-cm 7.95 
18-cm 7.95 
thinner-section 7.95 
Anucleate 7.95 
Budapest) 7.95 
Favored 7.95 
prognostic-risk 7.95 
Cyto-screen 7.95 
Clinical-Arrays 7.95 
46009 7.95 
(n=299) 7.95 
IIId 7.95 
(normal/WVI/CIN 7.95 
pre-Imager 7.95 
2+/HSIL 7.95 
HPV16/18-positive 7.95 
intraepithelial/cervical 7.95 
HPV-AD 7.95 
CIN2+lesions 7.95 
non-CIN-CIN1 7.95 
disease-negative 7.95 
most-detected 7.95 
HPV+ASCUS 7.95 
AGC-categorized 7.95 
AGC-diagnosed 7.95 
HPV-59) 7.95 
HPV-31) 7.95 
high-oncogenic-risk 7.95 
copies/microL) 7.95 
Wentzensen 7.95 
(Methylight) 7.95 
HPVII 7.95 
ASCUS" 7.95 
cervical/endocervical 7.95 
(IQCODE-T) 7.95 
Mackinnon 7.95 
Examination-Revised 7.95 
'Or' 7.95 
IQCODE-Nscore 7.95 
RUDAS 7.95 
S-MMSE 7.95 
Fat-saturation 7.95 
(spatial 7.95 
region-level 7.95 
pelvic-phased-array 7.95 
(retro-cervix 7.95 
rectum/rectosigmoid 7.95 
retro-cervix/posterior 7.95 
'unsure' 7.95 
sonologists/sonographers 7.95 
Low-resolution 7.95 
(MSCT-c) 7.95 
rectosigmoid/anterior 7.95 
endocystic 7.95 
(88-98%) 7.95 
(93-99%) 7.95 
Sonovaginography 7.95 
MR-colonography 7.95 
FRFSE 7.95 
nonendometrial 7.95 
recto-vaginal-septum 7.95 
crenulation 7.95 
SPKT 7.95 
microgram/L) 7.95 
post-testing 7.95 
sixty) 7.95 
high-CV 7.95 
(S') 7.95 
(E') 7.95 
TD-derived 7.95 
E/E') 7.95 
CCTAs 7.95 
t-tau/Abeta42 7.95 
PC5 7.95 
MCI(AD) 7.95 
MCI(MCI) 7.95 
p-tau(181p)/Abeta(1-42) 7.95 
e4+: 7.95 
converters' 7.95 
(MCI/Decl) 7.95 
(MCI/noDecl) 7.95 
MCI/Decl 7.95 
nonhypometabolic 7.95 
MCI-NC 7.95 
GM/PCR 7.95 
PA-EIA 7.95 
PADSELISA 7.95 
(LSV) 7.95 
nonsydromic 7.95 
'undetermined' 7.95 
non-neutropenia 7.95 
x(-) 7.95 
7TMS 7.95 
ATLS) 7.95 
[6%]) 7.95 
(ROTEM)-based 7.95 
Expanded; 7.95 
(extrinsically-activated 7.95 
intrinsically-activated 7.95 
(PT/INR) 7.95 
(RoTEM) 7.95 
(Copenhagen 7.95 
alpha-angleTEG 7.95 
alpha-angleRoTEM 7.95 
MA/MCF 7.95 
(Copenhagen) 7.95 
(Oslo) 7.95 
Inter-changeability 7.95 
(LDN) 7.95 
(110-250) 7.95 
(90-200); 7.95 
(6-136) 7.95 
(35-312) 7.95 
(14-84) 7.95 
(14-112) 7.95 
(62-103) 7.95 
deimplementation 7.95 
(INO) 7.95 
(ALI); 7.95 
ALI; 7.95 
PRISMA-guidelines 7.95 
Index-Expanded 7.95 
Listing 7.95 
methaemoglobin 7.95 
nonburn) 7.95 
(nonburn 7.95 
admistration 7.95 
vecalcification 7.95 
(RECA) 7.95 
r-values 7.95 
"shock 7.95 
kaolin-activated/kaolin-heparinase-activated) 7.95 
thrombomodulin) 7.95 
activation/anticoagulation 7.95 
TEG-measured 7.95 
[26-37] 7.95 
[10-26]) 7.95 
[78-140 7.95 
[18-49 7.95 
109%) 7.95 
MeSHGlycocalyx 7.95 
2009-October 7.95 
(MT-death) 7.95 
alerts/activations 7.95 
([INR] 7.95 
[PTT]) 7.95 
[>/=10 7.95 
(TCDB) 7.95 
(1-5); 7.95 
piglets: 7.95 
(nNOS) 7.95 
(totalling 7.95 
100x10/l 7.95 
[TEG: 7.95 
(EHP: 7.95 
8-30min) 7.95 
6-28min) 7.95 
(ADPtest) 7.95 
(COLtest) 7.95 
(TRAPtest) 7.95 
MCEEXTEM 7.95 
MCEFIBTEM; 7.95 
Aggregometry 7.95 
revolution: 7.95 
(nontrauma 7.95 
nontraumatized) 7.95 
(77%+/-12%) 7.95 
(41%+/-10%; 7.95 
(33%+/-10%; 7.95 
(interim) 7.95 
hypocoagulopathy 7.95 
(A5) 7.95 
bespoke 7.95 
(13-35) 7.95 
On-scene 7.95 
Drops 7.95 
</=-6 7.95 
rapid-thrombelastography 7.95 
(MTPs) 7.95 
[RBC]) 7.95 
[FFP]) 7.95 
PreMTP 7.95 
FFP; 7.95 
TEG--RapidTEG 7.95 
tests---measured 7.95 
(CA(15)) 7.95 
(CA(10)) 7.95 
CFT-INTEM 7.95 
CA(15)-INTEM 7.95 
Thiry-four 7.95 
(RBCs)/6 7.95 
(Pre-TEG) 7.95 
(INR; 7.95 
(FFP):RBCs 7.95 
platelets:RBCs 7.95 
(cryo):RBC 7.95 
(MRTG; 7.95 
(TG; 7.95 
deficit); 7.95 
neuro-deficit 7.95 
(scanogram) 7.95 
(CLSRs) 7.95 
scanograms) 7.95 
ETOH/drug 7.95 
(multi-trauma) 7.95 
ETOH/ 7.95 
(RR1) 7.95 
motorcycle/motor 7.95 
RR2) 7.95 
(RR10) 7.95 
multihospital 7.95 
(LAGEC) 7.95 
(T2-3N0-1M0-1a) 7.95 
endoscopic-ultrasound 7.95 
tumorcells 7.95 
(SKM) 7.95 
(SUV-BW) 7.95 
SKM 7.95 
SUV-BW 7.95 
staging--lymph 7.95 
invasion--results 7.95 
Maribor 7.95 
IL-type 7.95 
IL1-type) 7.95 
IM-type 7.95 
Ming's 7.95 
(2004)] 7.95 
(multimodal) 7.95 
04/01/1993 7.95 
03/31/2003 7.95 
(EGGCS 7.95 
EGGCS/GGCS 7.95 
Oesophago-gastric 7.95 
uT3-uT4 7.95 
(uT1 7.95 
uT3-4) 7.95 
concerned--namely 7.95 
(oesophageal/gastric 7.95 
(unblinded 7.95 
EUS-downstaged 7.95 
(126/186) 7.95 
(28/74) 7.95 
(39/52) 7.95 
(111/135) 7.95 
(113/135) 7.95 
histophathological 7.95 
("poor") 7.95 
("fair") 7.95 
oncosurgeons 7.95 
70%-88% 7.95 
83%-94% 7.95 
(63/67) 7.95 
stomach? 7.95 
EUS-M) 7.95 
(EUS-SM) 7.95 
Patients/Methods-EMR 7.95 
(CTRT) 7.95 
(postCTRT) 7.95 
(oesophagogastric 7.95 
(miniprobes) 7.95 
echofeatures: 7.95 
hypoenhancement 7.95 
(endo-MRI) 7.95 
hydro-computer 7.95 
(Hydro-CT) 7.95 
2-3h 7.95 
T-Staging 7.95 
submucosography 7.95 
Submucosography 7.95 
linear-type 7.95 
esophageal-gastroesophageal 7.95 
heater-probe 7.95 
TN+/- 7.95 
pT2b-carcinomas 7.95 
(1992-1996 7.95 
past--mostly 7.95 
conditions--may 7.95 
(two-phase 7.95 
(S-CT) 7.95 
nontraversed 7.95 
(UMP) 7.95 
(33/46 7.95 
(12&) 7.95 
promixal 7.95 
EUST3N1 7.95 
incisura: 7.95 
under-staged: 7.95 
over-staged) 7.95 
under-staged; 7.95 
over-staged); 7.95 
Under-staging 7.95 
Contrele 7.95 
EG-3630U/Hitachi 7.95 
EUB-525 7.95 
(41/28) 7.95 
(12/10) 7.95 
(20/12) 7.95 
(4/1) 7.95 
(41/10) 7.95 
(41/3) 7.95 
(24/10) 7.95 
(41/27) 7.95 
58/65 7.95 
(pT1-m) 7.95 
(pT1-sm) 7.95 
upper-GI-tract 7.95 
FG32-UA) 7.95 
extamural 7.95 
endoscopy/endoscopic 7.95 
jack-knife 7.95 
endoscopically-suspected 7.95 
(DCEUS) 7.95 
committee-approved 7.95 
(OCEUS) 7.95 
OCEUS 7.95 
antrum; 7.95 
linitis) 7.95 
easiness-to-use 7.95 
(259/295) 7.95 
(D-type) 7.95 
(UD-type) 7.95 
UD-type 7.95 
(EGD/EUS 7.95 
examiners: 7.95 
Yocum's 7.95 
(Jobe's 7.95 
[supraspinatus] 7.95 
[infraspinatus] 7.95 
[subscapularis] 7.95 
[long 7.95 
brachii]) 7.95 
(Speed 7.95 
anteposition 7.95 
turns; 7.95 
(Gum-Turn 7.95 
Lift-off 7.95 
(Kern 7.95 
(belly-press 7.95 
Hawkins/painful 7.95 
arc/infraspinatus 7.95 
therapist/manual 7.95 
(HIN) 7.95 
(HIB) 7.95 
agreement>or=80% 7.95 
(abduction 7.95 
(mini-Revo; 7.95 
Largo 7.95 
resisted-testing 7.95 
subdeltoid-subacromial 7.95 
Simons 7.95 
63-93%) 7.95 
67-77%) 7.95 
45-90%) 7.95 
33-100%) 7.95 
69-80%) 7.95 
"inside" 7.95 
tenopathy 7.95 
"supraspinatus 7.95 
"full-thickness 7.95 
asymetry 7.95 
(LSST) 7.95 
Efficacies 7.95 
antetilting 7.95 
Hawkin's 7.95 
(surgeon) 7.95 
(radiologist) 7.95 
(O'Brien's 7.95 
relocation) 7.95 
clunking 7.95 
athletes--diagnosis 7.95 
'dropping' 7.95 
'hornblower's' 7.95 
stage-4 7.95 
(drive-through 7.95 
lesion-location-specific 7.95 
undivided 7.95 
"general" 7.95 
invalid: 7.95 
tear--relationship 7.95 
infraspinatous 7.95 
physical-therapy 7.95 
MeSHIsotonicContraction 7.95 
calvicle 7.95 
"acromioclavicular 7.95 
noncontractile 7.95 
'SLAP' 7.95 
labrum-long 7.95 
Nonapplicable 7.95 
history-specific 7.95 
biceps-superior 7.95 
Antero-Posterior 7.95 
useability 7.95 
tendinopathy/subacromial 7.95 
pathoaetiology 7.95 
anesthetic) 7.95 
26%-50% 7.95 
51%-75% 7.95 
76%-100% 7.95 
Nonexperimental 7.95 
mechanical-impingement 7.95 
standardizations 7.95 
(OSTs) 7.95 
hornblowers's 7.95 
under-studied 7.95 
OSTs 7.95 
SLAP-lesion-specific 7.95 
(diagnostic); 7.95 
(O'Brien) 7.95 
(gradual 7.95 
non-SIS 7.95 
sulure 7.95 
rule) 7.95 
Maffet 7.95 
extra-large 7.95 
mid-glenoid 7.95 
"SLAP 7.95 
"catching" 7.95 
"popping" 7.95 
laxity) 7.95 
(arthroscopic) 7.95 
AHMED 7.95 
76%-97%); 7.95 
79%-88%); 7.95 
52-95) 7.95 
(US$21 7.95 
US$24) 7.95 
(US$266 7.95 
US$260) 7.95 
Data-driven 7.95 
Mbeya 7.95 
between-site 7.95 
One-off 7.95 
(2846 7.95 
2876 7.95 
(23-43) 7.95 
(13-21) 7.95 
(10-26) 7.95 
(30-124) 7.95 
(39-81) 7.95 
(2-8) 7.95 
5321 7.95 
9690) 7.95 
mistreatment 7.95 
(085251/B/08/Z) 7.95 
game-changer 7.95 
detection-threshold 7.95 
(BACTEC-MGIT-960) 7.95 
[(3)H]-uracil 7.95 
luciferase-reporter 7.95 
PCR(Xpert 7.95 
-MTB/RIF) 7.95 
colony-forming-units(CFU) 7.95 
7H10-Middlebrook 7.95 
>/=1x10(3) 7.95 
Xpert-MTB/RIF 7.95 
Dowdy 7.95 
large-sample 7.95 
forward] 7.95 
RIF/MTB 7.95 
Xpert-negatives 7.95 
28-180) 7.95 
Xpert-positives 7.95 
non-laboratory-based 7.95 
(LCTB) 7.95 
batched 7.95 
(47%-71%) 7.95 
(76%-93%) 7.95 
(69%-93%) 7.95 
(60/64) 7.95 
(40/64 7.95 
close-to-patient 7.95 
tuberculosis/HIV-burden 7.95 
per-sample 7.95 
(150/283 7.95 
(228/283 7.95 
[89/138] 7.95 
[139/145] 7.95 
research-use-only 7.95 
(RUO) 7.95 
(17/162) 7.95 
(9/162) 7.95 
(n=325) 7.95 
cycle-threshold 7.95 
laboratory-associated 7.95 
(IGRAs; 7.95 
Chadstone 7.95 
Australia)) 7.95 
inundated 7.95 
scarce) 7.95 
(116/242) 7.95 
(20/54) 7.95 
39-78) 7.95 
[MTB/RIF 7.95 
LAM: 7.95 
48-85) 7.95 
protein-to-creatinine 7.95 
26-58) 7.95 
time-to-positivity) 7.95 
MTB/RIF-testing 7.95 
PROSPECTIVELY 7.95 
ENROLLED 7.95 
HOSPITALIZED 7.95 
UGANDAN 7.95 
SUSPECTS 7.95 
PHASES: 7.95 
(187/237 7.95 
73-84%) 7.95 
(190/199 7.95 
92-98%) 7.95 
(34/81 7.95 
31-54%) 7.95 
0-1] 7.95 
22-55] 7.95 
0-33] 7.95 
0-5] 7.95 
0-2] 7.95 
3-53] 7.95 
1-61] 7.95 
+3% 7.95 
+27% 7.95 
+46% 7.95 
HIV/low 7.95 
hope? 7.95 
102-236) 7.95 
PCR-positive) 7.95 
("Xpert") 7.95 
participant) 7.95 
comparator) 7.95 
187/6893 7.95 
144/6893 7.95 
91/6893 7.95 
microsocopy 7.95 
rifampin-sensitive 7.95 
tuberculosis/rifampin 7.95 
tuberculosis/rifampicin) 7.95 
HIV-infected] 7.95 
(84/87 7.95 
(61/87 7.95 
[(45/63) 7.95 
444)]; 7.95 
(21/63 7.95 
(16/63 7.95 
SS(-)/GX(+) 7.95 
smear-grade 7.95 
(positive-to-negative) 7.95 
[<11% 7.95 
(1/29)] 7.95 
(21/35); 7.95 
(Xpert-negative 7.95 
(13/160) 7.95 
(146/148 7.95 
(147/148 7.95 
pre-processed 7.95 
thorasynthesis 7.95 
tuberculosis-suspected 7.95 
smear-centered 7.95 
(NDoH) 7.95 
MTB/Rif 7.95 
NDoH's 7.95 
performance-related 7.95 
sample-related 7.95 
spot-sputum 7.95 
88-98%; 7.95 
(91-96%; 7.95 
(35-73%; 7.95 
(11-27%; 7.95 
(ruled-in 7.95 
26-45%; 7.95 
(97-100%; 7.95 
XpertMTB/RIF 7.95 
Sample-specific 7.95 
threshold-cycle 7.95 
semiquantiative 7.95 
quantitated; 7.95 
same-patient 7.95 
nonviscous 7.95 
(494) 7.95 
MeSHDiagnosticTestApproval 7.95 
smear-negative) 7.95 
(62/62) 7.95 
(65-136) 7.95 
sputum-processing 7.95 
biohazards 7.95 
54/55 7.95 
simple-to-use 7.95 
cross-contaminating 7.95 
(IS6110-TaqMan 7.95 
MTB/RIF? 7.95 
unsterilized 7.95 
6-log-unit 7.95 
Spiked 7.95 
benchtop 7.95 
Noted 7.95 
GX4 7.95 
16-test 7.95 
Gene-Xpert(R) 7.95 
stool) 7.95 
single-celled 7.95 
(Determine((R)) 7.95 
Determine((R)) 7.95 
(Cepheid; 7.95 
Micoroscopic 7.95 
(MTB/RIF) 7.95 
convenient; 7.95 
(44/45); 7.95 
(84/86); 7.95 
(44/46); 7.95 
(84/85) 7.95 
(44/45) 7.95 
(31/45); 7.95 
(6/6); 7.95 
(30/33); 7.95 
(6/9); 7.95 
4306 7.95 
primordial; 7.95 
years-2 7.95 
(127; 7.95 
(77; 7.95 
(88; 7.95 
Obstruction: 7.95 
Freely 7.95 
tumours): 7.95 
Abdomino-perineal 7.95 
(Consultant 7.95 
only): 7.95 
consecutively) 7.95 
(Kaplan-Meier); 7.95 
1/2-8 7.95 
'false-negative' 7.95 
pre-operatively--varying 7.95 
recurrence-associated 7.95 
computadorized 7.95 
01/2011 7.95 
specificity% 7.95 
(GITSG) 7.95 
6175) 7.95 
7175) 7.95 
"elevated" 7.95 
micrograms/1 7.95 
(HCM); 7.95 
(LVEDV) 7.95 
mass/body 7.95 
DT(r 7.95 
(IMMU4) 7.95 
Cost/effectiveness 7.95 
CEA-detected 7.95 
(301) 7.95 
metastases-rising 7.95 
resection-was 7.95 
Dukes>> 7.95 
chi-squared); 7.95 
n=1861) 7.95 
women)--after 7.95 
E/ml)--in 7.95 
marker-negative--67 7.95 
marker-positive--19 7.95 
(38-51%) 7.95 
(61-67%) 7.95 
nononcological 7.95 
left-sited 7.95 
nonradically 7.95 
forewarned 7.95 
18-85] 7.95 
(76/118) 7.95 
18-fluoro-2-deoxy-glucose-positron 7.95 
recurrences/number 7.95 
(s-p53Abs) 7.95 
s-p53Abs 7.95 
U/microL) 7.95 
ng/mL: 7.95 
(secretors) 7.95 
CRC; 7.95 
blood-donors 7.95 
Astler-Coller) 7.95 
One-thousand 7.95 
Chorioembryonic 7.95 
techniques-directed 7.95 
(142/756) 7.95 
(129/142) 7.95 
(39/72) 7.95 
(CEA)-driven 7.95 
metastasectomies) 7.95 
CEA-driven 7.95 
(JYW) 7.95 
2-[18F]fluoro-2-deoxy-D-glucose-positron 7.95 
(12/31) 7.95 
(62/128) 7.95 
(11/34) 7.95 
close-meshed 7.95 
CT-aided 7.95 
patient-samples 7.95 
(LLT 7.95 
(193/999 7.95 
(immunoassay 7.95 
ul-1 7.95 
ul-1) 7.95 
serum-carcinoembryonic 7.95 
cathelicidins 7.95 
membrane-mimetic 7.95 
peptide-lipid 7.95 
103/201 7.95 
stage-B 7.95 
resected); 7.95 
surrenalic 7.95 
superflous 7.95 
3-118 7.95 
90/413 7.95 
Comenius 7.95 
Bratislava 7.95 
bleomycin-111indium 7.95 
were--apart 7.95 
follow-up--followed 7.95 
livermetastases 7.95 
11(63%) 7.95 
23/60 7.95 
semi-logarithmic 7.95 
[metastasis 7.95 
one-factor 7.95 
CEA-concentration 7.95 
Z-gel-method)] 7.95 
progression/remission 7.95 
(23/74) 7.95 
(hCG)beta 7.95 
findings/histology 7.95 
CEA-doubling 7.95 
CEA-dt; 7.95 
</=cCEA-dt 7.95 
>/=s80 7.95 
(VLBW) 7.95 
Cryptococcus) 7.95 
(504-1474 7.95 
(23-32 7.95 
(10-76 7.95 
nothing-but-palliative 7.95 
meta-chronous 7.95 
187--220) 7.95 
time-to-response 7.95 
(synchronously) 7.95 
(metachronously) 7.95 
remainder: 7.95 
400-patient 7.95 
[13/254]; 7.95 
[34/553]; 7.95 
[22/354]) 7.95 
(7/301) 7.95 
(20/300) 7.95 
(24/299) 7.95 
(20/302) 7.95 
CEA+CT; 7.95 
[164/901]) 7.95 
[48/301]; 7.95 
Unambiguous 7.95 
colonoscopy/barium 7.95 
CEA-initiated 7.95 
titers) 7.95 
guaiac 7.95 
[diagnostic 7.95 
(DI)] 7.95 
(Sorin 7.95 
Biomedica) 7.95 
(n=47; 7.95 
(n=156; 7.95 
(n=62); 7.95 
(n=53); 7.95 
(n=103; 7.95 
(IlIa) 7.95 
(n=21); 7.95 
(IIIb) 7.95 
(n=45); 7.95 
(IIIc) 7.95 
test-specificity 7.95 
59%-94% 7.95 
meshes 7.95 
extra-levator 7.95 
(elAPE) 7.95 
MeSHBiologicalDressings 7.95 
neoplam 7.95 
(IEV) 7.95 
CEA-TPA 7.95 
CEA-TPA-GICA 7.95 
nonrelapsed 7.95 
nadir) 7.95 
3330) 7.95 
elevated: 7.95 
CEA-; 7.95 
tumor-free) 7.95 
correspondence) 7.95 
Markers' 7.95 
concentartion 7.95 
Paulo-Escola 7.95 
Paulista 7.95 
(TPA-M 7.95 
cnt) 7.95 
(CIS-Centocor) 7.95 
Cockran's 7.95 
(PET/CT)] 7.95 
(CT)(PET/CT) 7.95 
125/82; 7.95 
colon-cancer 7.95 
haemanalysis 7.95 
miniscule 7.95 
12-187 7.95 
RCT-setting 7.95 
significance); 7.95 
explanation) 7.95 
(29/310; 7.95 
Ultrasound-based 7.95 
Firsttrimester 7.95 
[DV] 7.95 
[TR]) 7.95 
pregnancyassociated 7.95 
amniocentesis-proven 7.95 
41458 7.95 
algorythm 7.95 
diagnostic-staging 7.95 
alcoholisation 7.95 
coelomatic 7.95 
A-F) 7.95 
(peritoneum 7.95 
R0/R1/R2 7.95 
CT-staged 7.95 
11/1993 7.95 
12/1995 7.95 
periampullary/pancreatic 7.95 
bipuncture 7.95 
palliatedwithout 7.95 
(15/44) 7.95 
carcinoma-what 7.95 
legitimate? 7.95 
infra-gastric 7.95 
(217/462) 7.95 
(95/462) 7.95 
(150/462) 7.95 
(77/462) 7.95 
incurable/inoperable 7.95 
tumor-vessel 7.95 
Vater/duodenum 7.95 
ampullary/duodenal 7.95 
ampulla/duodenum 7.95 
(2/37) 7.95 
palliation) 7.95 
peritoneal/hepatic 7.95 
(FN-US)-guided 7.95 
micro-diffusion 7.95 
Stentby 7.95 
Study] 7.95 
(6%): 7.95 
7/236 7.95 
6/449 7.95 
EXPLORATION] 7.95 
(LSE) 7.95 
portomesenteric 7.95 
(unfavorable 7.95 
echolaparoscopy] 7.95 
pancreoscopy 7.95 
(ultrasonography-CT 7.95 
239/305 7.95 
(15%: 7.95 
encasement) 7.95 
(prediction 7.95 
58-73%) 7.95 
RO-resection 7.95 
(modern 7.95 
nonpancreatic) 7.95 
(SL-R) 7.95 
(SL-NR) 7.95 
(EL-R) 7.95 
(EL-NR) 7.95 
incisional-site 7.95 
Trocar/incisional 7.95 
chemotherapy/radiotherapy: 7.95 
(months): 7.95 
(48/56) 7.95 
(23%)) 7.95 
resectability?] 7.95 
DATA; 7.95 
choleangiopancreatography 7.95 
extrapancreatic/peritoneal 7.95 
84%-96% 7.95 
92%-97% 7.95 
85%-97% 7.95 
77%-87% 7.95 
no-tear 7.95 
(full-thickness 7.95 
skeletal-cartilage 7.95 
(Arthro-CT) 7.95 
(Arthro-MR) 7.95 
arthro-MR) 7.95 
Peribursal 7.95 
non-FTRCT 7.95 
Tendinitis 7.95 
28-71 7.95 
EUB-415 7.95 
arthroscopy/bursoscopy 7.95 
bursae; 7.95 
nonvisualisation 7.95 
(US): 7.95 
Medium-small 7.95 
transonic 7.95 
medium-small 7.95 
dedicated-extremity 7.95 
(E-scan) 7.95 
untorn 7.95 
long-TR 7.95 
(intrasubstance 7.95 
detachment) 7.95 
55%/62% 7.95 
76%/90% 7.95 
86%/79% 7.95 
(90%-100%) 7.95 
(29%-62%); 7.95 
non-partial-thickness 7.95 
post-dislocation 7.95 
(E-scan; 7.95 
acromiocalvicular 7.95 
five-inch 7.95 
echogradient 7.95 
(T2*-Rho-GEI) 7.95 
(500-700 7.95 
(GE-CGR) 7.95 
five-grade 7.95 
MR-Arthrografie 7.95 
athroscopy 7.95 
gadolinum 7.95 
(Superiores 7.95 
(fellow 7.95 
excitation) 7.95 
Signal-to-noise 7.95 
hypo/hyperechoic 7.95 
Lamination 7.95 
permanent-magnet 7.95 
(rim-rent 7.95 
similarly-sized 7.95 
images--with 7.95 
suppression--of 7.95 
imaging--both 7.95 
65-99%) 7.95 
39-86%) 7.95 
imaging--with 7.95 
suppression--is 7.95 
(SMASH) 7.95 
(MR-ARTH) 7.95 
(COT1FS) 7.95 
(COT2) 7.95 
(COT2FS) 7.95 
(PRTC) 7.95 
(69/76) 7.95 
COT2FS 7.95 
gadopentatate 7.95 
(refuted 7.95 
retained) 7.95 
bursa-side 7.95 
bursa-sided 7.95 
Proton-density 7.95 
530D 7.95 
(Kretztechnik 7.95 
Zipf 7.95 
plane? 7.95 
arthro-computerized 7.95 
arthro-CT's 7.95 
(stage-II) 7.95 
Single-voxel 7.95 
sensitivity--50% 7.95 
elevation-abduction 7.95 
extrarotational 7.95 
21-64 7.95 
62/74 7.95 
(89%-98%) 7.95 
(13%-74%) 7.95 
(72%-93%) 7.95 
Fortsch 7.95 
Rontgenstr 7.95 
172: 7.95 
686-691] 7.95 
Tesla? 7.95 
3-Tesla 7.95 
(AU4 7.95 
hypo-anechoic 7.95 
confirmerd 7.95 
wrap-around 7.95 
echo/T2-weighted 7.95 
145% 7.95 
(650-850/30 7.95 
2000/30 7.95 
deep/superficial 7.95 
acromioclavear 7.95 
surgically--the 7.95 
(osteochondritis) 7.95 
mechanics) 7.95 
T2*-PD 7.95 
(T2-GEI) 7.95 
OCOS 7.95 
6/128 7.95 
gamma-detector 7.95 
isosuflan 7.95 
(1993-1994) 7.95 
GOG-173 7.95 
Two-hundred-thirty-four 7.95 
(N=65) 7.95 
(N=105) 7.95 
38/65 7.95 
73/105 7.95 
unilateral-only 7.95 
sentinel-nodes 7.95 
(1-negative 7.95 
technetium-99m-nanocolloid 7.95 
(FICT) 7.95 
(plSc) 7.95 
3D-SPECT 7.95 
plSc 7.95 
technetium(99)m-labeled 7.95 
GROningen 7.95 
INternational 7.95 
(GROINSS-V) 7.95 
iodine-124 7.95 
(124I-PET/CT) 7.95 
2-[18F]fluoro-2-deoxy-D: 7.95 
(FDG-) 7.95 
Tg-antibodies 7.95 
21-275 7.95 
non-iodine-avid 7.95 
cellulitis: 7.95 
erysipelas: 7.95 
legs: 7.95 
Horst 7.95 
2000-May 7.95 
(LNE); 7.95 
LNE; 7.95 
(ICG; 7.95 
(GROINSS-V: 7.95 
74-148 7.95 
SLN-identified 7.95 
cancer--methods 7.95 
Radiocoloid 7.95 
ingvinal 7.95 
Technetium-99m-labelled 7.95 
(Sentiscint 7.95 
OSSKI 7.95 
camera-computer 7.95 
9200 7.95 
Mediso 7.95 
Vulvectomy 7.95 
SNs: 7.95 
Terada 7.95 
76:40-44 7.95 
'close-to-midline' 7.95 
Technetium-antimony 7.95 
"Outcomes 7.95 
lymphadenectomy" 7.95 
(SILN) 7.95 
SILN 7.95 
1=93% 7.95 
(38/41) 7.95 
2=95% 7.95 
3=100% 7.95 
inguinae 7.95 
inguinae) 7.95 
Jan;88(1):29-34 7.95 
peri-scar/lesional 7.95 
(99m)Technetium-labelled 7.95 
(H&E/cytokeratin 7.95 
(re-excision 7.95 
institute: 7.95 
hematoxylin/eosine 7.95 
inguinalfemoral 7.95 
pathfinders 7.95 
48-79) 7.95 
(99mTechnetium-labeled 7.95 
SFP(10)-LIPA 7.95 
immunoperoxidase-based 7.95 
HeLa-spiked 7.95 
(topoisomerase 7.95 
open-vial 7.95 
(HR-positive 7.95 
"younger" 7.95 
22%% 7.95 
17-26%) 7.95 
53-65%) 7.95 
out-of-vial 7.95 
HPV68 7.95 
(131/391) 7.95 
(175/391) 7.95 
(63/391) 7.95 
(3/52) 7.95 
(13/391) 7.95 
cervico-cytologically 7.95 
ASCUS/LSIL] 7.95 
(67/84) 7.95 
(74/170) 7.95 
(MECCS) 7.95 
Michoacan 7.95 
acid-aided 7.95 
VIA-negative 7.95 
QIAGEN 7.95 
post-ASC 7.95 
ASCUS-Premalignant 7.95 
ASCUS-Undefined 7.95 
ASCUS-Reactive 7.95 
(non-Premalignant 7.95 
signal-amplification 7.95 
41-46%] 7.95 
[31-37%] 7.95 
[29-35%] 7.95 
[22-27%] 7.95 
[88-97%] 7.95 
[70-84%] 7.95 
multiple-genotype 7.95 
carcinogenic-HPV-positive 7.95 
(CIN3): 7.95 
2(TM) 7.95 
(RLU/Co) 7.95 
64-year-olds 7.95 
34-year-olds 7.95 
genotype/quantify 7.95 
INNOLiPA 7.95 
CYTO-screen 7.95 
liquidsed 7.95 
(CIN3+/cancer) 7.95 
positive/HC2 7.95 
Human-papillomavirus 7.95 
cells-except 7.95 
80-94) 7.95 
1045; 7.95 
57-64) 7.95 
35-60-year 7.95 
cells-not 7.95 
(ASCUS-NOS) 7.95 
ASCUS-suspicious 7.95 
ASCUS-NOS 7.95 
per-speculum 7.95 
(NorChip) 7.95 
(Genomica) 7.95 
(mtm 7.95 
Lowgrade 7.95 
(ASC)" 7.95 
cells-undetermined 7.95 
Diligent 7.95 
(191/221); 7.95 
(123/221) 7.95 
(28/58) 7.95 
(23/121) 7.95 
(191/192) 7.95 
(123/129) 7.95 
(98/250) 7.95 
(6/250) 7.95 
(205/299) 7.95 
(112/299) 7.95 
(CIN2: 7.95 
CIN3: 7.95 
(30/50) 7.95 
CIN2); 7.95 
HPV-FOCAL 7.95 
three-armed 7.95 
Arm: 7.95 
6150 7.95 
(Thin-prep) 7.95 
"LSIL/ASC-H" 7.95 
"LSIL" 7.95 
(24-68%) 7.95 
(1)LSIL/ASC-H 7.95 
performance? 7.95 
'reflex' 7.95 
'reflex 7.95 
(70/112) 7.95 
cytology-reporting 7.95 
Florida/Shands-UF 7.95 
negative(-) 7.95 
UK--Influence 7.95 
identification/prediction 7.95 
(ASC-H)] 7.95 
Sensitivitives 7.95 
specificitives 7.95 
(757) 7.95 
(485) 7.95 
PapIIw 7.95 
PapIII 7.95 
papillomavirus-DNA 7.95 
(ASMT) 7.95 
ASMT 7.95 
prepared: 7.95 
cytologist; 7.95 
(HPV18) 7.95 
E6I/E6II 7.95 
(SILs; 7.95 
significance' 7.95 
(ASCUS; 7.95 
(98/382) 7.95 
(57/98) 7.95 
(20/98) 7.95 
(21/98) 7.95 
co-induced 7.95 
apoptosis-regulatory 7.95 
($4809 7.95 
$4308 7.95 
$4875 7.95 
LR/HR-HPV 7.95 
(AGUS): 7.95 
[AIS]) 7.95 
cotested 7.95 
(ASC-US)) 7.95 
Leonor 7.95 
Mendes 7.95 
Barros 7.95 
Cytology-/HPV 7.95 
/HPV-; 7.95 
Cytology-/ 7.95 
Sedfix 7.95 
cyto-spinning 7.95 
Feulgen-Thionin 7.95 
(VAIN)1 7.95 
CIN3/cervical 7.95 
significance)-LSIL 7.95 
Qiagen's 7.95 
Assay; 7.95 
cytology--potential 7.95 
(ASC-US): 7.95 
29/749 7.95 
(adjunctive 7.95 
(5528 7.95 
euros; 7.95 
52%-86% 7.95 
64%-138% 7.95 
30--39 7.95 
Harrisburgh 7.95 
(246/253) 7.95 
(335/340) 7.95 
(49/757) 7.95 
(euro177 7.95 
$249) 7.95 
(euro283 7.95 
$415) 7.95 
(euro284 7.95 
$4000) 7.95 
(euro241 7.95 
$339) 7.95 
(euro440 7.95 
$563) 7.95 
(euro386 7.95 
$543) 7.95 
papillomavirus-specific 7.95 
129/160 7.95 
NCT00092521) 7.95 
(114/123) 7.95 
non-virgins 7.95 
(ThirdWave/Hologic 7.95 
(negativisation 7.95 
under-30 7.95 
over-30 7.95 
(WVI) 7.95 
[63/113 7.95 
high/medium 7.95 
[29/113 7.95 
38/66 7.95 
26/95 7.95 
P16(INK4A) 7.95 
AGUS? 7.95 
(Imager) 7.95 
(HRHPV+) 7.95 
chi-Square 7.95 
Yate's 7.95 
post-imager 7.95 
ASCUS/SIL 7.95 
/Papanicolaou 7.95 
(187/337 7.95 
papillomavirus/Papanicolaou 7.95 
140)and 7.95 
auto-nested 7.95 
(Inv2) 7.95 
A5/A6 7.95 
MIB-1-negative 7.95 
MIB-1-test 7.95 
4235 7.95 
SurePath-collected 7.95 
ThinPrep-collected 7.95 
immunochemistry: 7.95 
HPV-augmented 7.95 
east-central 7.95 
Supposedly-negative 7.95 
Pap-plus-HPV 7.95 
insubstantial 7.95 
papillomavirus-dependent 7.95 
top-heavy 7.95 
cycle-controlling 7.95 
cytology/speculum 7.95 
cytology/blind 7.95 
44%-80% 7.95 
II/III: 7.95 
Chemiluminescence 7.95 
CE-market 7.95 
Klokkarstua 7.95 
Pap-classification 7.95 
HS67 7.95 
HPV-spiked 7.95 
immunosassay 7.95 
AGC/ASC 7.95 
(histologic/cyto-logic) 7.95 
Noncervical 7.95 
RLU/cutcuff 7.95 
biopsy/high-grade 7.95 
2+/HSIL) 7.95 
81%/82% 7.95 
dysplasia/ASCUS-not 7.95 
(ASCUS/low-grade 7.95 
lesion--LSIL) 7.95 
CIN2/CIN3 7.95 
(AGC-US) 7.95 
undermanaged 7.95 
4-9] 7.95 
9-21) 7.95 
28-48) 7.95 
HrHPV-positive 7.95 
(AGC-EC) 7.95 
(AGC-EM) 7.95 
AGC-EC 7.95 
AGC-EM 7.95 
AGC-detected 7.95 
tests/procedures 7.95 
fashionable 7.95 
offshoot 7.95 
(EDiTH 7.95 
(Preservcyt) 7.95 
SCC/LSIL 7.95 
broods 7.95 
($692 7.95 
$1246 7.95 
("biomolecular 7.95 
first-glance 7.95 
(HSIL)/cervical 7.95 
(LSIL)/CIN 7.95 
colpophotographic 7.95 
4439) 7.95 
randomisations 7.95 
(291/321) 7.95 
1(19/29 7.95 
114/291 7.95 
34/291 7.95 
56/291 7.95 
LEETZ 7.95 
ASC/LSIL 7.95 
Colposcopy-directed 7.95 
Ayre's 7.95 
Accellon 7.95 
(ASC-undetermined 7.95 
older-than-average 7.95 
computer-imaged 7.95 
MyHPV 7.95 
(MyGene 7.95 
19/97 7.95 
181/242 7.95 
61/63 7.95 
103/148 7.95 
(63/66=95%) 7.95 
(96/134=71% 7.95 
tube-based 7.95 
LSIL-positive 7.95 
"2001 7.95 
2152 7.95 
(ASCUS)/low-grade 7.95 
disscuss 7.95 
ASC-UC 7.95 
cytology(LBC) 7.95 
detectible 7.95 
(HPV-AD) 7.95 
[AGC]-associated 7.95 
AGC-related 7.95 
AGC-associated 7.95 
HPV-nonassociated 7.95 
(ASC/SIL) 7.95 
HPV-proofer 7.95 
(NCCSP) 7.95 
30? 7.95 
pap-positive 7.95 
ASC-USx1 7.95 
LSILx1 7.95 
HSILx2 7.95 
AGCx1 7.95 
CIN2+(28/557 7.95 
for16(INK4a) 7.95 
(CIN2/3; 7.95 
(GP)5+/GP6+ 7.95 
(CIN-I) 7.95 
post-colposcopic 7.95 
<CIN2; 7.95 
high-grade/cancer 7.95 
(CIN1); 7.95 
31/33/35) 7.95 
Immunointensity 7.95 
(CIN-1) 7.95 
[histology 7.95 
(TriPath) 7.95 
NILM-30 7.95 
(ASC-US)-138 7.95 
HSIL-13 7.95 
(ASC-H-13) 7.95 
LSIL-9 7.95 
(HSIL)-1 7.95 
(20/191) 7.95 
(20/60) 7.95 
lesion/high-grade 7.95 
(ASCUS/LSIL/HSIL) 7.95 
(ASC-US; 7.95 
ASC-H; 7.95 
(HR-HPV)-positive 7.95 
(2-tailed) 7.95 
Koilocytelike 7.95 
(RQ) 7.95 
(1973-2003) 7.95 
HPV18-seropositive 7.95 
cancer/SCC 7.95 
64-72%) 7.95 
[ESTT]) 7.95 
resolution: 7.95 
(29/258; 7.95 
11085 7.95 
(n=211) 7.95 
Diagnostics-Tripath 7.95 
Diagnostics-Tripath) 7.95 
(TOMBOLA): 7.95 
randomised-controlled 7.95 
(92%-98%) 7.95 
(46%-54%) 7.95 
association" 7.95 
(n=2223) 7.95 
(n=2216) 7.95 
non-attendance 7.95 
Non-attendance 7.95 
=18-month 7.95 
interval)] 7.95 
2672 7.95 
9-23%) 7.95 
p16MTS1 7.95 
(LG)-SIL 7.95 
(HG)-SIL 7.95 
TOPO2A 7.95 
CDCA1 7.95 
negative/AMPLICOR 7.95 
HCII+/AMPLICOR- 7.95 
HCII-/AMPLICOR+ 7.95 
56-phylogenetically 7.95 
LBC+HPV 7.95 
HPV+LBC 7.95 
co-screening+HPV 7.95 
only+HPV 7.95 
50-78) 7.95 
(34/45) 7.95 
(39/74) 7.95 
10-16%) 7.95 
(FcR) 7.95 
V158F 7.95 
cell-categorized 7.95 
(AGC)-categorized 7.95 
LSILs/CIN1s 7.95 
HSIL/CIN2 7.95 
Genotype-specific 7.95 
woman-friendly 7.95 
30-100%) 7.95 
co-collection 7.95 
(603 7.95 
(n=296) 7.95 
n=140) 7.95 
(n=216) 7.95 
LSIL-diagnosed 7.95 
(CMYC) 7.95 
[HR]) 7.95 
91-97%) 7.95 
17-28%) 7.95 
29-42%) 7.95 
47-61%) 7.95 
minor-abnormality 7.95 
unit/positive 7.95 
289/466 7.95 
significance-categorized 7.95 
(ASCUS)-categorized 7.95 
irregularity/grooves 7.95 
borderline/equivocal/indeterminate 7.95 
CPI/IIg 7.95 
grey-zone 7.95 
cervicographs 7.95 
cervicaltissue 7.95 
deoxyribose 7.95 
(40/42) 7.95 
(60/94) 7.95 
(21/40) 7.95 
non-eight 7.95 
(HC-1) 7.95 
Maryland); 7.95 
(HC-2); 7.95 
commonness 7.95 
high-grade-SIL 7.95 
denaturation; 7.95 
Non-denatured 7.95 
wait-and-watch 7.95 
Springs 7.95 
(Cl); 7.95 
(Innogenetics) 7.95 
Totals 7.95 
160/271 7.95 
156/271 7.95 
one-year-period 7.95 
(7/1/06 7.95 
6/30/07) 7.95 
11/30/07 7.95 
thin-prep 7.95 
(HGCIN) 7.95 
HGCIN 7.95 
Virus) 7.95 
(TS-PCR) 7.95 
10/148 7.95 
38%</= 7.95 
(conisation) 7.95 
Deaconess 7.95 
(BIDMC) 7.95 
BIDMC 7.95 
38/71 7.95 
15/73 7.95 
(LGSIL); 7.95 
(HGSIL); 7.95 
(23/229; 7.95 
8%-17%) 7.95 
[LSILs] 7.95 
nonmorphologic 7.95 
PubMed/MEDLINE/Ovid 7.95 
HealthStar 7.95 
Mirza 7.95 
Koochak 7.95 
(identifying 7.95 
(Solution 7.95 
ESwab 7.95 
(Copan) 7.95 
10(13)) 7.95 
(HSIL's) 7.95 
excession 7.95 
autocyte 7.95 
(37/47) 7.95 
CINII/III 7.95 
Guayas 7.95 
(AFR)" 7.95 
(ASC-US)" 7.95 
(DIGENE) 7.95 
2((R))) 7.95 
[CIN1+] 7.95 
Arbyn 7.95 
((3)55 7.95 
(perimenopausal 7.95 
[HSIL]); 7.95 
L1-positivity 7.95 
(n=278) 7.95 
GP5+/6+-EIA 7.95 
CIN1; 7.95 
HSIL/SCC 7.95 
normal/LSIL 7.95 
GenPoint) 7.95 
withVentana 7.95 
2198 7.95 
45-74) 7.95 
67-91) 7.95 
80-97) 7.95 
(dysplasia-free) 7.95 
I-II--78% 7.95 
II-III--89% 7.95 
carcinoma--100% 7.95 
dysplasia-free 7.95 
was--(16%) 7.95 
(100%)--in 7.95 
interpretations: 7.95 
irreproducibility 7.95 
Cervical/endocervical 7.95 
60/103 7.95 
43/103 7.95 
(433/491; 7.95 
tissue/Pap 7.95 
inpatients? 7.95 
DESIGN/PARTICIPANTS: 7.95 
Non-demented 7.95 
26-items 7.95 
dementia/delirium 7.95 
S-IQCODE: 7.95 
spanish-IQCODE 7.95 
(MMSE); 7.95 
(3-MS) 7.95 
3-MS) 7.95 
culture's 7.95 
"non-demented" 7.95 
age/education 7.95 
"and" 7.95 
(SBr) 7.95 
SBr) 7.95 
(SS-IQCODE) 7.95 
Translated 7.95 
Receiver-Operating 7.95 
155: 7.95 
1529-35] 7.95 
Edition-Revised 7.95 
CASI-estimated 7.95 
(MMSE-CE) 7.95 
dementia--is 7.95 
state? 7.95 
complaints? 7.95 
MeSHAustralianCapitalTerritory 7.95 
(Draft) 7.95 
MeSHAptitude 7.95 
'And' 7.95 
Jacomb 7.95 
(1989; 7.95 
19(4) 7.95 
mood/psychotic 7.95 
'hold' 7.95 
(MCI)] 7.95 
MCI-group 7.95 
neurovisual 7.95 
MeSHSaccades 7.95 
29/106 7.95 
MeSHStroopTest 7.95 
informant-assessment 7.95 
carers) 7.95 
(CIDS) 7.95 
Rowland 7.95 
(geriatrician 7.95 
neurologist) 7.95 
MeSHEthnopsychology 7.95 
(NC-patient 7.95 
(NC-MCI) 7.95 
(NC-AD) 7.95 
CCRs: 7.95 
NC-patient 7.95 
NC-MCI: 7.95 
NC-AD: 7.95 
specificites 7.95 
(DQ)] 7.95 
epsilon4/epsilon4 7.95 
primary-education 7.95 
Informants' 7.95 
DSMIV 7.95 
(S-MMSE) 7.95 
"weighted 7.95 
nonaphasic 7.95 
MeSHFriends 7.95 
(IQCODE; 7.95 
Korten 7.95 
multilingual 7.95 
(SENAS; 7.95 
Mungas 7.95 
2000): 7.95 
language-ethnic 7.95 
fidings 7.95 
teratoma/dermoid 7.95 
100/116) 7.95 
153/199) 7.95 
paraovarian/parasalpingeal 7.95 
fibromas/fibrothecomas 7.95 
ovaries": 7.95 
[32-148] 7.95 
[16-146]) 7.95 
[65-245 7.95 
[15-180 7.95 
minutes]) 7.95 
five-slice 7.95 
pain--can 7.95 
ultrasound-scan-based 7.95 
(MRI-e) 7.95 
250-300 7.95 
periuterine 7.95 
Deep-infiltrating 7.95 
Diaconesses 7.95 
26-46) 7.95 
lesion-level 7.95 
cul-the-sac 7.95 
cul-the-sac) 7.95 
evocated 7.95 
(LR+/-) 7.95 
81-93%) 7.95 
64-80%) 7.95 
(Kappa's 7.95 
speculum-type 7.95 
stenosis-type 7.95 
endocoil 7.95 
(TRUS): 7.95 
coils) 7.95 
100-63% 7.95 
96-92% 7.95 
90-70% 7.95 
100-85% 7.95 
97-83% 7.95 
(phased-array 7.95 
(Vercellini 7.95 
2005;84:1375-87) 7.95 
(Darai 7.95 
2005;192:394-400) 7.95 
(Abrao 7.95 
2004;11:50-4) 7.95 
Fagan's 7.95 
normogram 7.95 
Resonance: 7.95 
Rectum\Sigma\Douglas 7.95 
dataset; 7.95 
(r/l) 7.95 
96/100% 7.95 
100/99% 7.95 
100/93% 7.95 
93/100% 7.95 
67/84% 7.95 
97/86% 7.95 
73/62% 7.95 
96/95% 7.95 
POD; 7.95 
RVS; 7.95 
enterography--initial 7.95 
(TVS)? 7.95 
(3DPD-US) 7.95 
72-83% 7.95 
pre-recorded 7.95 
quality/quantity; 7.95 
2012-April 7.95 
glided 7.95 
(Fleiss' 7.95 
19-45 7.95 
rectum/sigma/pouch 7.95 
double-acquisition 7.95 
(HR)-MRI 7.95 
(LR)-MRI 7.95 
(CCDSO) 7.95 
(jelly 7.95 
(anteflexion 7.95 
retroflexion); 7.95 
uteri); 7.95 
"Haustra"; 7.95 
CCDSO 7.95 
UE; 7.95 
but-considering 7.95 
patients-delivers 7.95 
(n=666) 7.95 
BIAS 7.95 
GENERALISABILITY: 7.95 
(TVUS-BP) 7.95 
sensitivity--90% 7.95 
specificity--68% 7.95 
value--75% 7.95 
value--86% 7.95 
(LR(+) 7.95 
LR(-)) 7.95 
surgery/histology 7.95 
LR(+) 7.95 
LR(-) 7.95 
126/198 7.95 
98/126 7.95 
DIE; 7.95 
assessment--initial 7.95 
(1143 7.95 
5-2620 7.95 
5-601 7.95 
reproducible? 7.95 
(groundglass 7.95 
(anechoic 7.95 
vegetations) 7.95 
(MR)diffusion-weighted 7.95 
identified--mainly 7.95 
wall--were 7.95 
restosigmoid 7.95 
2D; 7.95 
(89-95%) 7.95 
(83-92%) 7.95 
(91-96%) 7.95 
(82-93%) 7.95 
(64-77%) 7.95 
(75-90%) 7.95 
(89-97%) 7.95 
(81-91%) 7.95 
(86-96%) 7.95 
(85-93%) 7.95 
Regione 7.95 
Autonoma 7.95 
Sardegna 7.95 
"tail" 7.95 
(uterosacral 7.95 
hypointense/hypoechoic 7.95 
rectal-layer 7.95 
rectal-resection 7.95 
(HR-MRI) 7.95 
(THRIVE) 7.95 
(BTFE) 7.95 
radiologist; 7.95 
(48/48) 7.95 
(46/46) 7.95 
(94/96) 7.95 
(45/46) 7.95 
(92/96) 7.95 
near-field 7.95 
probe's 7.95 
50/65 7.95 
"Fan 7.95 
shaped" 7.95 
(sub)mucosa 7.95 
(sub)mucosal 7.95 
endometriosis--own 7.95 
Endometriosis--due 7.95 
infertility--constitutes 7.95 
15-52 7.95 
wall--11 7.95 
body--9 7.95 
fornix--7 7.95 
colon--5 7.95 
space--5 7.95 
cervix--4 7.95 
pouch--3 7.95 
tube--2 7.95 
intestine--1 7.95 
bladder--1 7.95 
"statistics" 7.95 
18FDG-demonstrated 7.95 
MSCTe; 7.95 
sonohistology 7.95 
'sonohistological 7.95 
diagnosis') 7.95 
Douglas; 7.95 
76/119 7.95 
43/119 7.95 
32/119 7.95 
62/201 7.95 
31/201 7.95 
27/201 7.95 
48/201 7.95 
cul-de-sac: 7.95 
undepicted 7.95 
[single-shot 7.95 
(FSE)] 7.95 
broaching 7.95 
torus: 7.95 
EER; 7.95 
CUBE 7.95 
LAVA-flex 7.95 
VPN 7.95 
recto-uterine 7.95 
serosal/smooth 7.95 
(S/M) 7.95 
(histology) 7.95 
Susceptibility-weighted 7.95 
velocity-compensated 7.95 
(RVSE) 7.95 
RVSE 7.95 
perivisceral 7.95 
Bourguiba 7.95 
Sfax 7.95 
Ultrasound-CA125 7.95 
rectosigmoid) 7.95 
(rectosigmoid 7.95 
MeSHLaxatives 7.95 
laparoscopic/histologic 7.95 
Sub-stenosis 7.95 
Sveti 7.95 
(190/209) 7.95 
(55/424) 7.95 
(190/559) 7.95 
(55/74) 7.95 
nonendometriomas 7.95 
intra-vaginal 7.95 
Douglas-pouch 7.95 
MRI-sensitivity 7.95 
gel; 7.95 
Introital 7.95 
Torus 7.95 
rectoscope 7.95 
Desio 7.95 
(T1FS) 7.95 
(Gd-T1FS) 7.95 
Water-Contrast 7.95 
"pericystic 7.95 
59/75% 7.95 
52/71% 7.95 
76/86 7.95 
76/82% 7.95 
82/87 7.95 
74/81% 7.95 
89/93 7.95 
73/81% 7.95 
61/72 7.95 
76/79% 7.95 
bowel? 7.95 
TVS; 7.95 
candidates--is 7.95 
39-60 7.95 
nonlisting 7.95 
54+/-11 7.95 
<45% 7.95 
(36+/-12 7.95 
(22+/-12 7.95 
(+45%) 7.95 
hemodialysis--a 7.95 
Cardiogical 7.95 
hemnodyalisis 7.95 
scintigraphy/normal 7.95 
(>or=50%) 7.95 
(2209) 7.95 
(991) 7.95 
>or=500 7.95 
>or=2000 7.95 
>or=3000 7.95 
population--the 7.95 
exercise-thallium 7.95 
pancreato-renal 7.95 
peri-operatively 7.95 
thallium-201-dipyridamole 7.95 
thallium(Tl)-201-dipyridamole 7.95 
stress/redistribution 7.95 
37+/-9 7.95 
nonexercise 7.95 
practicably 7.95 
(SPKT) 7.95 
SPKT-eligible 7.95 
(AoC) 7.95 
anti-vitamin-K 7.95 
waiting-listed 7.95 
dipyridamole-stress 7.95 
302/558 7.95 
percutaneous/surgical 7.95 
(high-cardiological 7.95 
(>or=70% 7.95 
dipyridamole-MIBI 7.95 
dipyridamole-99m 7.95 
Tc-methoxy-isobutyl 7.95 
(99mTC-MIBI) 7.95 
(PKT) 7.95 
diabetes(78% 7.95 
CIMT< 7.95 
38/52 7.95 
IMT< 7.95 
electrocardiogram) 7.95 
[echocardiography 7.95 
(CAG)] 7.95 
CAGs 7.95 
[CVA] 7.95 
[MI]) 7.95 
post-kidney-pancreas 7.95 
$4000 7.95 
?/nMeSHAdrenergicbeta-Agonists 7.95 
renal-hypertensive 7.95 
asynergia 7.95 
Dipyridamole-Tl-201 7.95 
non-ESRF 7.95 
Dipyridamole-exercise 7.95 
revascularizations) 7.95 
iodine-123-methyl 7.95 
77/53; 7.95 
(93/130) 7.95 
positive-stress 7.95 
(n=363) 7.95 
(exercise/pacing) 7.95 
technetium-99m-tetrofosmin 7.95 
(Myoview; 7.95 
Plc) 7.95 
pancreas)] 7.95 
synchronus 7.95 
eighteen) 7.95 
T-wave 7.95 
anteroseptal 7.95 
high-cardiovascular 7.95 
Five-yr 7.95 
five-yr 7.95 
low-ejection 7.95 
dyslipidemic) 7.95 
(WMA) 7.95 
(fixed) 7.95 
(inducible) 7.95 
DSE; 7.95 
Non-survivors 7.95 
(TD)-derived 7.95 
(IVRT)) 7.95 
(A') 7.95 
Tl201 7.95 
myocadial 7.95 
cadiac 7.95 
event: 7.95 
(CCTA) 7.95 
proximal-mid 7.95 
Disease-Japan 7.95 
(SEAD-J) 7.95 
p-tau/Abeta42 7.95 
[ADAS-cog] 7.95 
PC7 7.95 
(LFC: 7.95 
(WMHs) 7.95 
beta(4)(2)-amyloid 7.95 
[E4+] 7.95 
[E4-] 7.95 
E4+/converters 7.95 
Fluoro-2-deoxy-d-glucose-PET 7.95 
(Wellcome 7.95 
MCI(AD)) 7.95 
MCI(MCI)) 7.95 
aging-associated 7.95 
(AACD) 7.95 
(AACD-converters) 7.95 
[p-tau(181p)]) 7.95 
Subscale) 7.95 
Awaiting 7.95 
Trajectories 7.95 
multi-region 7.95 
APOEepsilon4-positive 7.95 
(PET+); 7.95 
(e4+) 7.95 
not-declining 7.95 
non-decliners 7.95 
(MCI/AD); 7.95 
(hippocampus) 7.95 
'decliners' 7.95 
(P-MCI) 7.95 
(S-MCI) 7.95 
(nonconverters) 7.95 
(FDG-ROIs) 7.95 
FDG-ROI 7.95 
regularization' 7.95 
multi-kernel 7.95 
43-81) 7.95 
Buschke-Fuld 7.95 
(EADC) 7.95 
(autocorrelation 7.95 
(DLFC) 7.95 
[18F]FDDNP 7.95 
(SUVr) 7.95 
Herholz's 7.95 
(MCI-nAD) 7.95 
(MCI-NC) 7.95 
MCI-nAD 7.95 
Alzhiemer's 7.95 
[EMCI] 7.95 
[LMCI] 7.95 
[AD] 7.95 
florbetapir-positive 7.95 
(LMCI/AD) 7.95 
Test-Long 7.95 
single-non-amnestic 7.95 
(snaMCI) 7.95 
pulmomary 7.95 
reaction-ELISA 7.95 
mycological/histological 7.95 
1936-1949 7.95 
awarding 7.95 
"inductive 7.95 
"ecological 7.95 
perspective" 7.95 
theories--the 7.95 
unison 7.95 
(GeniQ-Asper) 7.95 
Wako) 7.95 
sensitivity/specificity/positive 7.95 
value/negative 7.95 
(>80-90%) 7.95 
antigalactomannan 7.95 
non-BMT 7.95 
(IA; 7.95 
1-3-beta-D-glucan 7.95 
non-aspergillosis 7.95 
Cancer-Invasive 7.95 
GM-false-positive 7.95 
261; 7.95 
antimould 7.95 
(Glucatell) 7.95 
(KCMH) 7.95 
KCMH 7.95 
toolfor 7.95 
oflA 7.95 
(PA-EIA; 7.95 
Per-episode 7.95 
per-episode 7.95 
States--improves 7.95 
sandwich-ELISA 7.95 
"valid" 7.95 
(Fusarium 7.95 
scedosporium 7.95 
GM-based 7.95 
('dynamic' 7.95 
(12/70) 7.95 
possible/proven 7.95 
glucan)/GM 7.95 
no-responded 7.95 
(PADSELISA) 7.95 
Aspergillus-precipitating 7.95 
CHROMagar 7.95 
Cancer)/MSG 7.95 
(Mycoses 7.95 
Group)-documented 7.95 
LSV; 7.95 
pneumocystosis] 7.95 
November14 7.95 
4-233) 7.95 
(PTZ) 7.95 
PTZ 7.95 
(connexin 7.95 
Hunan] 7.95 
amplifing 7.95 
DNAStar 7.95 
56/140) 7.95 
deaf-causing 7.95 
27/140) 7.95 
25/140) 7.95 
common-spot 7.95 
(Platelia) 7.95 
60%/50% 7.95 
Pneumocysitis 7.95 
(PJP) 7.95 
PJP) 7.95 
CT-outcome 7.95 
(IAARI) 7.95 
'proven' 7.95 
ustus) 7.95 
EORTC-MSG-2002 7.95 
auto-SCT 7.95 
PREMISES 7.95 
(probable/proven) 7.95 
Plasma-Lyte 7.95 
non-EIA 7.95 
pediatric-dedicated 7.95 
non-immunosuppressive 7.95 
(30/94) 7.95 
s>1/3 7.95 
[minimum 7.95 
maximum] 7.95 
LightCycler-mediated 7.95 
counterindicated 7.95 
6209 7.95 
(7TMS) 7.95 
protein's 7.95 
[(35)S]-cysteine 7.95 
[(35)S]-Na(2)SO(3) 7.95 
phenylalanines 7.95 
tyrosyl 7.95 
(TPSTs) 7.95 
TPSTs 7.95 
shRNAs 7.95 
=30 7.95 
HC 7.95 
surveys 7.95 
hormone 7.94 
lot 7.94 
equipped 7.94 
LFT 7.94 
diagnosis) 7.94 
58) 7.92 
favor 7.92 
immunocytochemistry 7.92 
ascertainment 7.91 
MeSHDiseasesinTwins 7.90 
(61% 7.90 
fluctuated 7.90 
>70% 7.90 
13+6 7.90 
kinesis 7.90 
(65 7.90 
square 7.90 
(study 7.89 
(second 7.89 
modality 7.89 
colonography 7.89 
E/A 7.89 
Incidences 7.89 
recommendable 7.89 
(carcinoembryonic 7.89 
Delfia 7.89 
recto-vaginal 7.89 
locations: 7.89 
pathologic 7.89 
MeSHJointDislocations 7.88 
products 7.88 
uterus 7.87 
71%) 7.87 
calculous 7.86 
preclude 7.86 
375 7.86 
logistic 7.85 
LFTs 7.84 
MeSHVentricularDysfunction 7.84 
(approximately 7.84 
(34 7.84 
of 7.84 
toward 7.83 
all 7.82 
46% 7.81 
9; 7.81 
examples 7.79 
planes 7.78 
was: 7.78 
reasonably 7.78 
materials 7.78 
EGC 7.77 
GGT 7.77 
positive; 7.77 
542 7.77 
19; 7.77 
mostly 7.77 
1994 7.76 
spaces 7.75 
Vaccination 7.75 
MeSHHealthKnowledge 7.75 
MeSHAttitudes 7.75 
Review 7.74 
Cost-effectiveness 7.74 
collagen 7.74 
deciding 7.72 
months 7.72 
MTP 7.72 
nested-PCR 7.72 
supraspinatus-infraspinatus 7.72 
ThinPreps 7.72 
tests' 7.72 
between-day 7.72 
(y) 7.72 
purchasing 7.72 
CEA+ 7.72 
amplification-based 7.72 
micrograms/l) 7.72 
cm/sec 7.72 
(Alzheimer's 7.72 
Cutoff 7.72 
(SBP) 7.72 
(MOI) 7.72 
non-detection 7.72 
KCl 7.72 
6-10% 7.72 
Ospedale 7.72 
1807 7.72 
24/40 7.72 
17-22 7.72 
Khon 7.72 
Kaen 7.72 
cent] 7.72 
(Double 7.72 
ultrasound-detected 7.72 
16-19 7.72 
(coronal 7.72 
views: 7.72 
settings; 7.72 
1/121 7.72 
more: 7.72 
(false-positive) 7.72 
1:34 7.72 
(UCD) 7.72 
17/26 7.72 
20-21 7.72 
endorsing 7.72 
1632 7.72 
liquid-phase 7.72 
620) 7.72 
Corrections 7.72 
two-years 7.72 
MeSHThreatened 7.72 
pleased 7.72 
length; 7.72 
sulphatase 7.72 
traversable 7.72 
carcinoma?] 7.72 
clinic' 7.72 
cuff) 7.72 
softwares 7.72 
Judged 7.72 
adenocarcinoma? 7.72 
LUS-guided 7.72 
hyperextended 7.72 
Fat-suppressed 7.72 
clearest 7.72 
Bursal 7.72 
(validation 7.72 
Motol 7.72 
(HC-II) 7.72 
L-SIL 7.72 
(rectum 7.72 
MeSHRadionuclideVentriculography 7.72 
Cancer/Mycosis 7.72 
ELISA; 7.72 
under-staged 7.72 
"full 7.72 
subdistrict 7.72 
biohazard 7.72 
test") 7.72 
(low-risk 7.72 
CIN-3 7.72 
(DQ) 7.72 
U/mL; 7.72 
(87% 7.71 
completion 7.71 
Coagulopathy 7.71 
MeSHMentalRecall 7.71 
Taiwan 7.71 
Ovulation 7.70 
MeSHFetalDevelopment 7.70 
MeSHProteinPrecursors 7.70 
Time 7.70 
ups 7.69 
Seventy-five 7.69 
influences 7.69 
nodes) 7.69 
Index 7.69 
sonographically 7.68 
(55%) 7.67 
curved 7.66 
515 7.66 
neuronal 7.66 
domains 7.66 
IE 7.65 
rapidly 7.65 
[n 7.64 
Division 7.63 
hypertension 7.63 
MeSHSocioeconomicFactors 7.63 
incident 7.63 
sixty 7.62 
MeSHBronchoalveolarLavageFluid 7.62 
at-risk 7.62 
2-6 7.61 
independent 7.60 
(58 7.60 
important 7.60 
2- 7.59 
posteroinferior 7.59 
GMA 7.59 
Austrian 7.59 
Abeta42 7.59 
cytologies 7.59 
Crown-rump 7.59 
financially 7.59 
ninety-five 7.59 
(high-grade 7.59 
serum) 7.59 
Tenderness 7.59 
(high-risk 7.59 
trained 7.59 
(15 7.58 
scanning 7.57 
160 7.57 
35-year-old 7.57 
her 7.57 
875 7.56 
age-based 7.56 
persist 7.55 
MeSHEquipmentDesign 7.55 
(ELISA 7.55 
serosa 7.54 
over 7.54 
(29% 7.53 
033 7.53 
herniations 7.53 
consequence 7.53 
099 7.52 
semi-automated 7.52 
time-resolved 7.52 
abducted 7.52 
MeSHDiabeticAngiopathies 7.52 
arterial 7.51 
Chinese 7.51 
MeSHOvarianDiseases 7.50 
item 7.50 
17) 7.47 
secrete 7.46 
IgA 7.46 
carries 7.46 
multicentric 7.46 
MeSHAlleles 7.46 
012) 7.46 
Main 7.46 
will 7.46 
confirmation 7.46 
40) 7.45 
susceptible 7.45 
falling 7.44 
Those 7.44 
(82 7.44 
reason 7.44 
cardiovascular 7.44 
punch 7.43 
366 7.43 
439 7.43 
anti-inflammatory 7.43 
injections 7.42 
non-diabetic 7.42 
organizational 7.42 
709 7.42 
871 7.42 
6)) 7.42 
1000 7.41 
Surgeons 7.40 
duplication 7.40 
focus 7.39 
serious 7.39 
mathematical 7.39 
(LN) 7.38 
slow 7.38 
bound 7.38 
Mortality 7.38 
composed 7.38 
not 7.38 
Digestive 7.37 
complexes 7.37 
second-line 7.37 
cholecystectomy] 7.37 
augmentation 7.37 
420 7.36 
insensitive 7.36 
county 7.36 
cholangiogram 7.35 
awareness 7.35 
(84%) 7.35 
replacement 7.35 
histological 7.34 
ODI 7.34 
hematoma 7.34 
hemorrhage 7.34 
value: 7.34 
proportionally 7.34 
sensitivity: 7.34 
consistencies 7.34 
2/11 7.34 
categories 7.33 
papillotomy 7.33 
analyzing 7.33 
endometrial 7.33 
Diagnosing 7.32 
608 7.32 
MeSHAdenocarcinoma 7.32 
category) 7.31 
race-specific 7.31 
bimanual 7.31 
99%; 7.31 
offline 7.31 
MeSHTertiaryCareCenters 7.31 
Remaining 7.31 
dye) 7.31 
216) 7.31 
operator-dependent 7.31 
Techniques 7.31 
autosomal 7.31 
252 7.31 
MeSHHistocytochemistry 7.30 
develops 7.30 
Jaundice 7.30 
availability 7.29 
925 7.29 
low-level 7.28 
6/7 7.28 
MeSHPedigree 7.28 
MeSHRosanilineDyes 7.28 
surgical 7.28 
Microscopic 7.27 
Seventy-eight 7.27 
internal 7.26 
170 7.24 
previously 7.24 
calcium 7.23 
peak 7.23 
On 7.23 
(CT) 7.23 
LA) 7.22 
rural 7.22 
36%) 7.22 
considering 7.22 
linearly 7.22 
20; 7.22 
(>or= 7.22 
Based 7.21 
transient 7.21 
(MA 7.21 
MeSHCholangiocarcinoma 7.21 
acromion 7.20 
(CVS) 7.20 
DF 7.20 
adenomyosis 7.19 
harvested 7.19 
MeSHOperative 7.19 
MeSHScapula 7.18 
layer 7.18 
(no 7.18 
Lesions 7.18 
performed; 7.18 
since 7.18 
interventional 7.18 
always 7.18 
midline 7.17 
Implants 7.16 
end-diastolic 7.16 
equity 7.16 
(113 7.16 
sigmoidoscopy 7.16 
MeSHEar 7.16 
MeSHStemCellTransplantation 7.15 
CCS 7.15 
10-12 7.15 
605 7.15 
(62% 7.15 
41) 7.15 
antiretroviral 7.15 
MeSHCystadenocarcinoma 7.14 
surgeon 7.14 
MeSHCytoplasm 7.14 
UCD 7.13 
DPE 7.13 
AWD 7.13 
under-represented 7.13 
(SP-1) 7.13 
Filipinos 7.13 
Jobe's 7.13 
1323 7.13 
LDT 7.13 
nonresected 7.13 
FaSTER 7.13 
(they 7.13 
1156 7.13 
marker? 7.13 
second-degree 7.13 
[MoM]) 7.13 
shipment 7.13 
1/150 7.13 
1233 7.13 
fucose 7.13 
profile: 7.13 
within-run 7.13 
10th-90th 7.13 
6/26) 7.13 
(11-14 7.13 
NBLs 7.13 
b-hCG 7.13 
anencephalus 7.13 
MeSHHealthMaintenanceOrganizations 7.13 
non-stimulated 7.13 
13-16 7.13 
(84) 7.13 
90-95% 7.13 
1781 7.13 
nondisclosure 7.13 
4215 7.13 
(abnormal) 7.13 
(plus 7.13 
(unconjugated 7.13 
MSuE3 7.13 
"genetic 7.13 
1054 7.13 
population-wide 7.13 
category: 7.13 
Log-linear 7.13 
non-specifically 7.13 
(T18) 7.13 
oedema: 7.13 
(virtual 7.13 
shoulder's 7.13 
Azerbaijan 7.13 
trimester; 7.13 
(CUB 7.13 
serum; 7.13 
Statistics) 7.13 
1045 7.13 
arthrography] 7.13 
CBD; 7.13 
gamma-detection 7.13 
35-60 7.13 
(endocervical 7.13 
(hr) 7.13 
detection; 7.13 
MeSHMyocardialReperfusion 7.13 
AD-typical 7.13 
esophageal) 7.13 
873) 7.13 
three-arm 7.13 
090) 7.13 
(JOY 7.13 
bursoscopy 7.13 
9/69 7.13 
arthro-CT 7.13 
diagnostic) 7.13 
1137 7.13 
(124) 7.13 
Competency 7.13 
37); 7.13 
(probable 7.13 
remainder 7.13 
(AP) 7.12 
(84% 7.11 
finally 7.11 
date 7.11 
(usually 7.11 
precuneus 7.11 
363 7.11 
466 7.11 
metaphase 7.11 
MeSHNeovascularization 7.11 
cava 7.11 
MeSHAthleticInjuries 7.11 
provide 7.11 
Radiological 7.11 
Histologically 7.11 
remaining 7.10 
film 7.10 
kDa 7.08 
(MDR) 7.08 
MeSHPatientSatisfaction 7.07 
(41%) 7.06 
he 7.06 
Long-term 7.05 
Prediction 7.05 
illustrates 7.05 
EBCT 7.05 
234) 7.05 
zygomycosis 7.05 
data; 7.05 
MeSHAsianAmericans 7.05 
ratios) 7.05 
(TL) 7.05 
(index 7.05 
cartridge 7.05 
Cytyc 7.05 
Atherosclerotic 7.05 
15/16 7.05 
algorithmic 7.05 
0/26 7.05 
MeSHAcromion 7.05 
plaque 7.05 
corresponds 7.04 
infarction 7.04 
Orthopedic 7.03 
Before 7.03 
modes 7.03 
HCT 7.02 
3-week 7.02 
invalid 7.02 
originating 7.02 
ray 7.01 
gas 7.01 
newly 7.01 
Intervention 7.01 
thromboplastin 7.01 
lumen 7.01 
MeSHAutomation 7.01 
475 7.01 
MeSHMicrobialSensitivityTests 7.01 
MeSHPatientSelection 7.01 
(81%) 7.00 
pose 7.00 
ruptures 7.00 
14% 6.99 
20-24 6.99 
spurs 6.99 
proform 6.99 
strategies: 6.99 
Downs 6.99 
757 6.99 
acquired 6.99 
SN 6.99 
functions 6.99 
nucleotide 6.99 
Bronchoalveolar 6.98 
donors 6.98 
delivery 6.98 
racial 6.97 
narrow 6.97 
somatic 6.96 
causal 6.96 
(91 6.96 
(85%) 6.95 
address 6.95 
XDR 6.95 
alleles 6.95 
7-8 6.95 
(74% 6.95 
note 6.94 
2002 6.94 
stiffness 6.93 
Fallopian 6.93 
MeSHCholedocholithiasis 6.93 
serologic 6.92 
defense 6.92 
incision 6.92 
inter- 6.91 
tandem 6.91 
MeSHKeratins 6.91 
(odds 6.90 
Delayed 6.90 
transit 6.90 
MeSHStrokeVolume 6.90 
MeSHFungemia 6.90 
deeply 6.89 
2-9 6.89 
MeSHRNA 6.88 
fast 6.88 
non-invasive 6.88 
manifested 6.88 
possibility 6.88 
clinically 6.87 
MeSHDigestiveSystem 6.87 
Fifty-two 6.87 
6-month 6.86 
MeSHPlateletAggregation 6.85 
occasionally 6.85 
micrometastases 6.85 
(58%) 6.85 
Twenty-seven 6.85 
mole 6.84 
(normal 6.84 
150 6.83 
(greater 6.83 
augment 6.83 
hydrosalpinx 6.83 
21-affected 6.83 
MeSHLeftVentricular 6.83 
aspergillosis] 6.83 
'normal 6.83 
laparoscopies 6.83 
tools 6.82 
professionals 6.82 
CRP 6.82 
survivors 6.82 
Women's 6.82 
PATIENTS 6.81 
(77% 6.81 
Cytologic 6.80 
karyotypically 6.80 
velocimetry 6.80 
ventriculography 6.80 
arithmetic 6.80 
(analysis 6.80 
technetium-99m-labeled 6.80 
Midline 6.80 
Cytopathology 6.80 
(MACE) 6.80 
(2-5 6.80 
relative 6.80 
variance 6.79 
MeSHAnesthetics 6.79 
MeSHDNAMutationalAnalysis 6.79 
obese 6.79 
translation 6.79 
Large 6.79 
(CT 6.78 
CV 6.78 
massively 6.78 
MeSHPatientAdmission 6.78 
muscle 6.77 
surgery: 6.76 
follows: 6.76 
hip 6.76 
196 6.76 
arrest 6.76 
removing 6.76 
evaluates 6.76 
Obstructive 6.75 
resuscitation 6.74 
thromboelastometry 6.74 
standardized 6.74 
isosulfan 6.74 
bands 6.73 
epidermal 6.73 
ever 6.72 
isolated 6.72 
requires 6.71 
baseline 6.71 
Between 6.71 
serous 6.71 
cranial 6.71 
appointment 6.70 
Admission 6.70 
Alteration 6.70 
certified 6.70 
periampullary 6.70 
ng/mL 6.70 
MeSHThrombosis 6.70 
PARTICIPANTS: 6.69 
subcutaneous 6.69 
parity 6.69 
Platelets 6.69 
provides 6.68 
immunosuppressive 6.68 
exhibit 6.67 
put 6.67 
NTDs 6.67 
cancer-associated 6.67 
appointments 6.67 
township 6.67 
cytohistologic 6.67 
Enzyme 6.67 
Alzheimer's 6.67 
(31%) 6.67 
sonographical 6.66 
MeSHSpain 6.66 
62%) 6.66 
Ninety-four 6.65 
(partial 6.65 
379 6.65 
645 6.65 
clinician 6.65 
first-line 6.65 
Typing 6.65 
lapse 6.64 
Dutch 6.64 
C 6.64 
diaphragm 6.64 
nonthrowing 6.63 
non-fungal 6.63 
kU/l 6.63 
1557 6.63 
(taken 6.63 
498) 6.63 
catching 6.63 
clicking 6.63 
disregarding 6.63 
fat-saturation 6.63 
Salzburg 6.63 
refrigeration 6.63 
(11/13) 6.63 
0049) 6.63 
DS-affected 6.63 
1467 6.63 
3450 6.63 
Correspondence 6.63 
creatinine) 6.63 
14/40 6.63 
6-8% 6.63 
[64 6.63 
Hospital's 6.63 
sub-units 6.63 
caesarian 6.63 
Chromosomally 6.63 
Margaret 6.63 
combined; 6.63 
1034 6.63 
1444 6.63 
U-test) 6.63 
fucosylated 6.63 
noncontributory 6.63 
fashion; 6.63 
endoscopy; 6.63 
abduction) 6.63 
Overhead 6.63 
MeSHTime-to-Treatment 6.63 
rule-out 6.63 
pellets 6.63 
(58%); 6.63 
(Institute 6.63 
Tc-99m-labeled 6.63 
Laboratories) 6.63 
Chulalongkorn 6.63 
Spanish-speaking 6.63 
MeSHProblemSolving 6.63 
multicultural 6.63 
b-values 6.63 
MeSHGatedBlood-PoolImaging 6.63 
Suitability 6.63 
1375 6.63 
7/53 6.63 
(259 6.63 
(W) 6.63 
Cancer) 6.63 
(99m)Technetium 6.63 
1/9) 6.63 
MeSHSutureTechniques 6.63 
raising 6.63 
dated 6.63 
lag 6.63 
trocar 6.62 
relevant 6.62 
analyse 6.61 
ROTEM) 6.61 
Western 6.60 
rehabilitation 6.60 
minimize 6.60 
traffic 6.60 
MeSHHematoma 6.60 
Pediatric 6.60 
online 6.60 
?/nMeSHAntitubercularAgents 6.59 
supporting 6.58 
Pathological 6.58 
etc 6.58 
formula 6.58 
minimum 6.58 
von 6.57 
arthroplasty 6.57 
MeSHPatientCompliance 6.57 
(BMI) 6.57 
MeSH"PracticePatterns 6.57 
tubular 6.57 
MeSHLymphocytic 6.57 
73) 6.57 
developing 6.57 
MeSHPeritonealDiseases 6.57 
MY09/11 6.56 
(n=34) 6.56 
224) 6.56 
women? 6.56 
Belgian 6.56 
oncofetal 6.56 
Trisomies 6.56 
bursae 6.56 
MeSHEcho-PlanarImaging 6.56 
(low-grade 6.56 
smears: 6.56 
drift 6.56 
sensitivity/specificity 6.56 
Raised 6.56 
HPV6 6.56 
Bio-Rad 6.56 
MeSHHeart 6.56 
MeSHCD4LymphocyteCount 6.56 
deposits 6.56 
mutant 6.56 
MeSHNeoplasmProteins 6.56 
(18 6.55 
bear 6.54 
MeSHOpioid 6.54 
Transabdominal 6.54 
13th 6.54 
483 6.54 
(P= 6.54 
hour 6.53 
Quality 6.53 
neuropsychologic 6.53 
Matrix 6.53 
echoes 6.53 
(ICSI) 6.53 
exception 6.52 
existence 6.52 
longer 6.52 
995 6.52 
to 6.52 
length) 6.51 
fetuses) 6.51 
ANSWER: 6.51 
infarctions 6.51 
369 6.51 
427 6.51 
MD 6.51 
immunoreactive 6.51 
(pl 6.51 
MeSHAutologous 6.51 
depicted 6.50 
cycles 6.50 
minute 6.50 
supports 6.50 
Implementation 6.49 
accumulation 6.49 
156 6.49 
absent 6.48 
mentioned 6.48 
MeSHNon-Steroidal 6.47 
dominance 6.45 
mention 6.45 
Wilcoxon 6.45 
MeSHHumerus 6.45 
(high 6.45 
trial 6.45 
Scapula 6.45 
bias 6.44 
MeSHDoppler 6.44 
MeSHAccidents 6.44 
exclusion 6.43 
overexpression 6.43 
palpable 6.43 
patients 6.43 
critical 6.42 
Reproductive 6.42 
Limitations 6.42 
661 6.42 
testicular 6.42 
limit 6.42 
downward 6.41 
413 6.41 
26; 6.41 
Nomogram 6.41 
7-10 6.41 
leukocytes 6.41 
past 6.41 
(73 6.40 
(93% 6.40 
>6 6.39 
seventeen 6.38 
(98%) 6.38 
MeSHEthnicGroups 6.38 
99) 6.38 
71) 6.38 
MeSHBacterialProteins 6.38 
MeSHLymphedema 6.38 
999 6.37 
Kaplan-Meier 6.37 
syndrome) 6.37 
MeSHEndometriosis 6.36 
delirium 6.36 
negative; 6.36 
Ninety-nine 6.36 
seventy-five 6.36 
MeSHBaseball 6.36 
(GGT) 6.36 
chronological 6.36 
Technetium-99m 6.36 
turned 6.36 
congenital 6.35 
172 6.35 
MeSHInterventional 6.34 
piperacillin-tazobactam 6.34 
interexaminer 6.34 
(r(s) 6.34 
14-19 6.34 
irresectable 6.34 
signal-to-noise 6.34 
concluding 6.34 
impairment: 6.34 
endometrioma: 6.34 
3mm 6.34 
1-36 6.34 
high-or 6.34 
(58% 6.34 
context 6.33 
MeSHMuscle 6.33 
subsets 6.33 
Both 6.33 
971 6.33 
Patients 6.32 
facilitate 6.32 
all-cause 6.32 
twenty-two 6.32 
Adding 6.32 
(BAL 6.32 
Intravenous 6.32 
sarcomas 6.32 
89) 6.31 
hand-held 6.31 
201 6.31 
Virus 6.31 
071 6.31 
MeSHPeritonealLavage 6.31 
631 6.31 
slide 6.30 
trials 6.30 
lethal 6.29 
nonspecific 6.29 
wild-type 6.28 
MeSHCultureMedia 6.28 
MeSHPublicHealth 6.28 
Perioperative 6.28 
lobectomy 6.28 
pancreatic 6.28 
adds 6.28 
partially 6.27 
45%) 6.27 
118 6.26 
This 6.26 
suggesting 6.26 
peripancreatic 6.26 
adapt 6.26 
randomly 6.26 
MeSHDNA-DirectedRNAPolymerases 6.25 
actively 6.25 
PCR-based 6.24 
counseled 6.23 
MeSHCoronaryStenosis 6.23 
Australia 6.23 
validate 6.23 
Congenital 6.23 
-84 6.22 
MeSHEndothelium 6.22 
replication 6.22 
mp 6.22 
small-for-gestational 6.22 
50th 6.22 
thickness) 6.22 
test' 6.22 
80-90% 6.22 
644 6.22 
893 6.22 
613 6.22 
guideline 6.21 
list 6.20 
DPC 6.20 
screen: 6.20 
hrHPV-positive 6.20 
L1-positive 6.20 
fbetahCG 6.20 
immunoassay) 6.20 
overhead-throwing 6.20 
TERC 6.20 
MOI 6.20 
HPV33 6.20 
=CIN3 6.20 
1360 6.20 
consultative 6.20 
'increased 6.20 
3050 6.20 
multi-variate 6.20 
Chorionicity 6.20 
Chinese) 6.20 
1942 6.20 
log-normal 6.20 
Songkla 6.20 
>95th 6.20 
(Diagnostic 6.20 
gestations: 6.20 
miscarriages) 6.20 
(Mr 6.20 
MeSHDehydroepiandrosteroneSulfate 6.20 
exactness 6.20 
1:274 6.20 
alpha-fetoprotein: 6.20 
calcium-binding 6.20 
women); 6.20 
3-4% 6.20 
polymalformation 6.20 
syndromal 6.20 
oestriol) 6.20 
Jerusalem 6.20 
1/270) 6.20 
analyses) 6.20 
(PDA) 6.20 
assay] 6.20 
45XO 6.20 
(exact 6.20 
adducted 6.20 
retrospectively; 6.20 
subgrouping 6.20 
surgically-treated 6.20 
(euploid 6.20 
(pregnancy-associated 6.20 
(reflecting 6.20 
Disadvantages 6.20 
surface) 6.20 
small) 6.20 
MeSHRhodeIsland 6.20 
colposcopists 6.20 
(Brazil) 6.20 
sevenfold 6.20 
(SPM2) 6.20 
fragment: 6.20 
Wellcome 6.20 
Astler-Coller 6.20 
00004) 6.20 
(CIN2/3 6.20 
HC2- 6.20 
0038) 6.20 
High-grade 6.19 
two-fold 6.19 
lesion) 6.19 
idea 6.19 
hepatocellular 6.19 
granulocyte 6.19 
arose 6.19 
cholecystostomy 6.19 
blunt 6.19 
(62%) 6.19 
describes 6.19 
changes 6.18 
placental 6.18 
models 6.17 
MeSHAnti-HIVAgents 6.16 
vitamin 6.16 
SM 6.16 
antimicrobial 6.16 
MeSHSwine 6.16 
compensation 6.16 
antigen-specific 6.16 
anaplastic 6.16 
Thirty-two 6.16 
continues 6.15 
range 6.15 
428 6.14 
Open 6.14 
deviations 6.14 
TM 6.13 
TBS 6.13 
(CI: 6.13 
Scottish 6.13 
urines 6.13 
(white 6.13 
diagnosed; 6.13 
obscuring 6.13 
MeSHOccultBlood 6.13 
INVESTIGATION: 6.13 
laparoscopy; 6.13 
cuff] 6.13 
ICER 6.13 
epicardial 6.13 
text] 6.13 
elsewhere 6.13 
161 6.11 
passage 6.11 
phases 6.11 
interval: 6.11 
285 6.11 
MeSHTrophoblasts 6.11 
aggregate 6.11 
MeSHUreter 6.11 
adjunctive 6.11 
386 6.10 
MeSHPolyps 6.10 
MeSHPatientEducationasTopic 6.10 
MeSHTreatmentFailure 6.09 
accelerate 6.09 
cervicovaginal 6.09 
Dec 6.08 
relieved 6.08 
unclear 6.08 
(difference 6.07 
harms 6.07 
SELECTION: 6.07 
MeSHMichigan 6.07 
Nottingham 6.07 
MeSHBronchoalveolarLavage 6.07 
extended 6.06 
IIa 6.06 
MeSHCisplatin 6.05 
upper 6.05 
planned 6.04 
World 6.03 
MeSHDiet 6.02 
inherited 6.02 
135 6.02 
Polymerase 6.02 
R: 6.02 
pl 6.02 
Forty-six 6.02 
dataset 6.02 
carcinomas 6.02 
cord 6.01 
026 6.01 
numerical 6.01 
gel 6.01 
MeSHCesareanSection 6.00 
Significance 6.00 
MeSHSurgicalProcedures 6.00 
Endometriosis 5.99 
However 5.99 
years 5.98 
31st 5.98 
XYY 5.98 
probes 5.98 
summarize 5.97 
Kaplan 5.97 
extremely 5.97 
cardiopulmonary 5.97 
cellularity 5.97 
carriage 5.96 
uptake 5.96 
endemic 5.96 
MeSHIntestine 5.96 
monochorionic 5.96 
MeSHBrazil 5.96 
R2 5.96 
How 5.96 
TL 5.96 
attention 5.95 
exceeds 5.95 
frequencies 5.94 
infiltrate 5.94 
formulas 5.94 
XXY) 5.94 
623 5.94 
835 5.94 
A7 5.94 
singly 5.93 
asked 5.93 
isotropic 5.93 
HC-II 5.93 
Johannesburg 5.93 
installed 5.93 
five-point 5.93 
unsure 5.93 
0-4) 5.93 
rifampin 5.92 
AMP 5.92 
grading 5.92 
29% 5.92 
00001 5.91 
(nine 5.91 
slope 5.91 
eosin 5.90 
MeSHOrthopedic 5.90 
technetium-99 5.89 
emerging 5.89 
Evaluation 5.89 
Nineteen 5.89 
Corp 5.89 
perioperative 5.88 
detail 5.88 
Within 5.88 
cyclic 5.88 
MeSHFactorV 5.88 
quarter 5.87 
miscarriage 5.87 
084 5.87 
MeSH16-18 5.87 
(BPD) 5.87 
conservatively 5.87 
fill 5.86 
Follow 5.86 
platelet 5.86 
MeSHNucleicAcidHybridization 5.86 
coverage 5.86 
recurrent 5.86 
16) 5.85 
variety 5.85 
IIB 5.85 
leukaemia 5.85 
courses 5.84 
C2 5.84 
(28 5.84 
325 5.84 
hypothesized 5.84 
CR 5.83 
subtype 5.83 
intravenous 5.83 
Data 5.83 
else 5.82 
(85% 5.82 
studied 5.82 
Herein 5.81 
wedge 5.81 
NASBA 5.81 
Alexandria 5.81 
CBDs 5.81 
intertester 5.81 
16-23 5.81 
non-culture-based 5.81 
rule-in 5.81 
1:150 5.81 
1994-2007 5.81 
Dividing 5.81 
18-34 5.81 
1018 5.81 
trivariate 5.81 
2-step 5.81 
Differing 5.81 
small; 5.81 
seven-fold 5.81 
aliquoted 5.81 
(MMS) 5.81 
Princess 5.81 
MeSHMaine 5.81 
(10-12 5.81 
(S-100 5.81 
self-reporting 5.81 
gestation] 5.81 
chronologically 5.81 
(15/16) 5.81 
ERPC 5.81 
poor: 5.81 
visualising 5.81 
bifida) 5.81 
tenderness; 5.81 
Getting 5.81 
tendons; 5.81 
fruitful 5.81 
Repeatability 5.81 
terminations) 5.81 
812) 5.81 
(therapeutic 5.81 
superconducting 5.81 
severity; 5.81 
(value 5.81 
program: 5.81 
POINTS: 5.81 
adhesions; 5.81 
Bio-Rad) 5.81 
N0: 5.81 
traversed 5.81 
450) 5.81 
RNA-based 5.81 
300% 5.81 
9/46 5.81 
MIs 5.81 
163 5.81 
450 5.81 
(55% 5.81 
pure 5.81 
endometriosis 5.81 
(38 5.80 
(Pearson 5.80 
596 5.80 
defects: 5.80 
(AMA) 5.80 
scrape 5.80 
931 5.80 
3-fold 5.80 
orally 5.80 
406 5.79 
cingulate 5.79 
(91%) 5.79 
display 5.79 
Calcium 5.79 
rarity 5.78 
high-dose 5.78 
hippocampal 5.78 
Images 5.78 
Potential 5.78 
Recurrences 5.77 
561 5.77 
111) 5.77 
flexed 5.77 
sm 5.77 
regional 5.76 
controlling 5.76 
Thrombelastograph 5.76 
P= 5.76 
MeSHJaundice 5.75 
modulation 5.75 
kidneys 5.75 
stopped 5.75 
MeSHBronchoscopy 5.75 
fraction 5.75 
bilateral 5.75 
processed 5.75 
178 5.74 
aide 5.74 
sustained 5.73 
LightCycler 5.73 
25-34 5.73 
ineligible 5.73 
Alabama 5.73 
efficacies 5.73 
pathology; 5.73 
pre-emptive 5.73 
sum 5.73 
(67 5.73 
distributed 5.72 
ROTEM 5.72 
districts 5.72 
proportion 5.72 
employment 5.72 
osteoarthritis 5.72 
MeSHPalpation 5.72 
(DFS) 5.72 
users 5.72 
subacute 5.72 
MeSHTumorSuppressorProteinp53 5.72 
subgroup 5.71 
capacity 5.71 
18% 5.70 
postnatal 5.70 
75) 5.70 
they 5.70 
limitations 5.70 
(69% 5.69 
confirms 5.68 
39%) 5.68 
fumigatus 5.67 
osseous 5.67 
year 5.67 
evolves 5.67 
789 5.67 
ingrowth 5.67 
752 5.67 
extrapancreatic 5.67 
KNOWN 5.67 
847 5.67 
913 5.67 
transducers 5.67 
49; 5.67 
thawed 5.67 
gastroesophageal 5.66 
pyelectasis 5.66 
discriminatory 5.65 
visual 5.65 
exclusive 5.65 
though 5.65 
relate 5.65 
showing 5.65 
MeSHAmpullaofVater 5.65 
west 5.64 
approximately 5.64 
infections 5.64 
carried 5.63 
lipoma 5.63 
05% 5.62 
restaging 5.62 
members 5.62 
filling 5.62 
02) 5.61 
LG 5.61 
rest 5.61 
biopsies 5.61 
Metastatic 5.61 
hospitalized 5.61 
MeSHProgesterone 5.61 
(the 5.61 
infer 5.60 
Biochemical 5.60 
Accident 5.60 
Delay 5.60 
MeSHImmunoglobulinA 5.60 
Sum 5.59 
Reliability 5.59 
MeSHOutcomeAssessment(HealthCare) 5.58 
agenesis 5.58 
Thrombelastography 5.58 
descriptive 5.57 
emergence 5.57 
065 5.57 
uremic 5.57 
(RCTs) 5.57 
Michigan 5.57 
supported 5.57 
osteolytic 5.57 
Scale 5.56 
DM 5.56 
guidelines 5.56 
INTERVENTIONS: 5.56 
A 5.56 
histopathologic 5.56 
predominantly 5.56 
MeSHAbdomen 5.56 
99%) 5.55 
MeSHGeneral 5.55 
multifocal 5.55 
MeSHMEDLINE 5.55 
MeSHGlobins 5.55 
deceleration 5.55 
MeSHPennsylvania 5.55 
one-side 5.55 
Medium 5.55 
CTR 5.54 
analyser 5.54 
others) 5.54 
counselled 5.54 
(red 5.54 
>or=5 5.54 
lesions; 5.54 
planar 5.54 
(four 5.54 
(92% 5.54 
morphine 5.53 
elected 5.53 
two-stage 5.53 
warrants 5.53 
variants 5.53 
reviews 5.53 
pilot 5.53 
emergency 5.52 
(HD) 5.52 
geometric 5.52 
(19%) 5.51 
cases] 5.51 
followed 5.51 
suppression 5.51 
QuantiFERON-TB 5.50 
MeSHEugenic 5.50 
Electric 5.50 
menstruation 5.50 
waves 5.50 
(87 5.50 
(35% 5.50 
retain 5.50 
MeSHCanada 5.50 
minutes 5.49 
enhancement 5.49 
Rest 5.49 
line 5.49 
model 5.49 
plus 5.49 
warrant 5.49 
(97% 5.48 
misdiagnosis 5.47 
attached 5.47 
exceptional 5.47 
sharp 5.47 
apoptotic 5.47 
tests) 5.47 
11th 5.47 
545 5.47 
ventricular 5.47 
MeSHStroke 5.47 
sign' 5.47 
fetus-specific 5.47 
gastro-esophageal 5.47 
heat-stable 5.47 
b-value 5.47 
RSD 5.47 
pancreas-kidney 5.47 
Miniprobe 5.47 
multisite 5.47 
(PRC) 5.47 
(predictive 5.47 
malignant-appearing 5.47 
retroflexed 5.47 
RTR 5.47 
(reduced 5.47 
(U) 5.47 
miscarry 5.47 
10-14-week 5.47 
32-month 5.47 
daunting 5.47 
Kings 5.47 
30/35 5.47 
(IGFBP-1 5.47 
IGFBP-1 5.47 
translocations) 5.47 
'true' 5.47 
downwards 5.47 
program) 5.47 
MeSHIowa 5.47 
Downs' 5.47 
chromosomes; 5.47 
fifths 5.47 
MeSHVegetarian 5.47 
reanalysed 5.47 
analysed; 5.47 
Omitting 5.47 
hygroma: 5.47 
Single-step 5.47 
maternal-serum 5.47 
baby' 5.47 
1451 5.47 
MeSHAngiogenesisInducingAgents 5.47 
serum-screening 5.47 
fluorimetric 5.47 
Mid-trimester 5.47 
(routine 5.47 
EUS; 5.47 
229) 5.47 
(n=47) 5.47 
parameterized 5.47 
Diagnostics) 5.47 
HBP 5.47 
supraspinous 5.47 
tesla 5.47 
vulva: 5.47 
(INTEM 5.47 
micrograms/l 5.47 
efficient: 5.47 
"test 5.47 
3/21) 5.47 
1/18) 5.47 
cardiological 5.47 
91%; 5.47 
3)-beta-d-glucan 5.47 
speed 5.47 
proceed 5.47 
setting 5.47 
94%) 5.47 
temporoparietal 5.46 
349 5.46 
Ho 5.46 
includes 5.46 
attended 5.46 
MeSHPractice 5.46 
admitted 5.45 
unrelated 5.45 
visceral 5.45 
MeSHMyeloid 5.45 
obstructive 5.45 
MeSHHypertrophy 5.44 
Conversion 5.44 
inclusion 5.44 
postoperatively 5.44 
grades 5.43 
illustrate 5.43 
concordant 5.43 
enrollment 5.43 
losses 5.43 
percentages 5.43 
ascites 5.42 
nonlinear 5.42 
EMR 5.42 
889 5.42 
582 5.42 
prognostic 5.42 
painless 5.41 
brains 5.41 
(INH) 5.41 
cleft 5.41 
see 5.41 
D) 5.40 
utilize 5.40 
month 5.40 
outpatient 5.40 
splenectomy 5.39 
cumulative 5.39 
123 5.39 
sex 5.39 
MeSHContactTracing 5.38 
400 5.38 
(47 5.38 
=18 5.38 
benchmark 5.38 
explain 5.38 
MACE 5.37 
T-staging 5.37 
ICD-10 5.37 
(new 5.37 
Knowing 5.37 
(corrected 5.37 
peculiarity 5.37 
(SIS) 5.37 
heralded 5.37 
(SL) 5.37 
(BMT) 5.37 
797 5.37 
assay: 5.37 
Yield 5.37 
236) 5.37 
Dako 5.37 
Chip 5.37 
04) 5.37 
rigid 5.37 
rearrangement 5.37 
Thirty-five 5.37 
Selection 5.36 
choice 5.35 
bronchoscopy 5.35 
FA 5.35 
MeSHHistory 5.34 
entered 5.34 
sexual 5.34 
numbers 5.34 
implants 5.34 
assure 5.34 
MeSHThrombelastography 5.33 
endogenous 5.33 
(83 5.33 
diffusion 5.32 
(71% 5.32 
series 5.31 
125) 5.31 
4+ 5.31 
MTBDRplus 5.30 
EXTEM 5.30 
(cases) 5.30 
culture-based 5.30 
causative 5.30 
certainty 5.30 
articles 5.30 
dorsal 5.29 
Pattern 5.29 
25%) 5.29 
high-frequency 5.28 
culture-negative 5.28 
9-12 5.28 
397 5.28 
(RCT) 5.28 
MeSHIntensiveCare 5.28 
FUNDING 5.28 
Forty-three 5.28 
verification 5.28 
infertility 5.28 
enough 5.28 
986 5.28 
contraceptive 5.28 
Surgeon 5.28 
VII 5.27 
ought 5.27 
Prognosis 5.27 
accident 5.27 
MeSHHypertension 5.27 
MeSHPregnancyComplications 5.26 
feeding 5.26 
ligament 5.25 
lowest 5.25 
anesthetic 5.25 
MeSHPrognosis 5.24 
their 5.24 
variability 5.24 
widespread 5.23 
items 5.23 
Trophoblast 5.23 
diastolic 5.23 
2000 5.23 
nonsignificant 5.23 
intraarticular 5.23 
16; 5.23 
biomarker 5.23 
MeSHVirulence 5.23 
Gel 5.23 
subpopulation 5.22 
Crass 5.22 
AHPV 5.22 
bear-hug 5.22 
carcinoembryionic 5.22 
belly-off 5.22 
MSCTe 5.22 
TA-EUS 5.22 
L-EUS 5.22 
CEA-dt 5.22 
(+LR: 5.22 
GHBP 5.22 
double-screening 5.22 
GSCS 5.22 
p16(ink4a) 5.22 
3D-US 5.22 
HCGbetacf 5.22 
-LR: 5.22 
FLRG 5.22 
low-field-strength 5.22 
MCI/MCI 5.22 
alpha-Angle 5.22 
reassayed 5.22 
beta-hCG/total 5.22 
(Sens 5.22 
waterpolo 5.22 
MS-hCG 5.22 
mosaic-T21 5.22 
2-plex 5.22 
8-plex 5.22 
CTA-MRA 5.22 
124I-PET/CT 5.22 
124I-PET 5.22 
cotests 5.22 
post-Imager 5.22 
samples); 5.22 
significance-favour 5.22 
CE-MR-C 5.22 
AoC 5.22 
Burnet's 5.22 
tyrosines 5.22 
TEG-directed 5.22 
beta-core/estriol 5.22 
180; 5.22 
GGCS 5.22 
transverse-array 5.22 
SLAC 5.22 
NPAs 5.22 
U/microL 5.22 
8(+0) 5.22 
int-FISH 5.22 
DSSP 5.22 
16-23-week 5.22 
side-to-side/margin 5.22 
D-MRA 5.22 
Isotropic 5.22 
unexercised 5.22 
ultra-staging 5.22 
Thin-prep 5.22 
E2/E6 5.22 
DNA-ICM 5.22 
EC/TZS 5.22 
CCNA1 5.22 
rule") 5.22 
elastosonography 5.22 
pre-stress 5.22 
Coleman 5.22 
LMCI 5.22 
hemato-oncological 5.22 
VHAs 5.22 
coagulation-related 5.22 
MT-related 5.22 
blood-brain-barrier 5.22 
ADPtest 5.22 
TRAPtest 5.22 
97th 5.22 
LGC 5.22 
<or=T2 5.22 
(denoting 5.22 
hornblower's 5.22 
kayaking 5.22 
unresisted 5.22 
Intratester 5.22 
(cut-point 5.22 
ALARA 5.22 
LVIDd 5.22 
plasma-CEA 5.22 
microgram/1 5.22 
Tissular 5.22 
IEV 5.22 
(r(DS) 5.22 
5809) 5.22 
MSpMBP 5.22 
9737 5.22 
(h-hCG) 5.22 
Quad; 5.22 
Sequential-Combined 5.22 
obs/exp 5.22 
4373 5.22 
CE-certified 5.22 
13(+4) 5.22 
7534 5.22 
combined-screening 5.22 
follistatin-related 5.22 
gonadotophin 5.22 
MLPA/rtPCR 5.22 
74-93%) 5.22 
110948 5.22 
JOY-Software 5.22 
area/head 5.22 
DV-RAV 5.22 
Beta-globin 5.22 
Geq/ml 5.22 
11-0/7 5.22 
12-6/7 5.22 
Nicolaides' 5.22 
23/34 5.22 
subacromioclavicular 5.22 
(Ellman 5.22 
end-to-bone 5.22 
SSP-ISP 5.22 
High-field-strength 5.22 
TGO(AST) 5.22 
"no/low" 5.22 
CBDIA 5.22 
pts-group 5.22 
technetium(99) 5.22 
124I 5.22 
lymphoscyntygraphy 5.22 
(42/50 5.22 
ARTISTIC 5.22 
qualifier 5.22 
acid-washed 5.22 
P16INK4a 5.22 
borderline/mildly 5.22 
CIN-III 5.22 
mRNA-based 5.22 
LINEAR 5.22 
cytotechnologists' 5.22 
(MAPS) 5.22 
cytopathologists' 5.22 
sub-category 5.22 
DAPK1 5.22 
PAX1 5.22 
B-ADL 5.22 
PSDE 5.22 
MCI-patients 5.22 
SMMSE 5.22 
TMSE 5.22 
nodule/s 5.22 
noncompressible 5.22 
LC-CUSUM 5.22 
'tissue' 5.22 
sample); 5.22 
(99mTc-MIBI) 5.22 
CVAs 5.22 
microgram/L 5.22 
RTCs 5.22 
CDR-SB 5.22 
(p-tau(181)) 5.22 
p-tau(181) 5.22 
Macfarlane 5.22 
Medawar 5.22 
BLF 5.22 
'static' 5.22 
pg/L 5.22 
3703 5.22 
(LY60) 5.22 
MeSHFactorXIa 5.22 
MEDLINE; 5.22 
Science; 5.22 
CINAHL; 5.22 
MeSHIraqWar 5.22 
MeSH2003-2011 5.22 
(2-9) 5.22 
>2000 5.22 
burn) 5.22 
Normotest 5.22 
r-times 5.22 
(adrenaline 5.22 
noradrenaline) 5.22 
(tissue-type 5.22 
units/6 5.22 
neurointensive 5.22 
thromboplastine 5.22 
15+/-4 5.22 
fibrinogens 5.22 
TATs 5.22 
MeSHMassCasualtyIncidents 5.22 
(was 5.22 
MCF<40 5.22 
10(9)l(-1)) 5.22 
(mA) 5.22 
no-PE 5.22 
(RapidTEG) 5.22 
Reagent-supported 5.22 
(compatible 5.22 
nonovert 5.22 
nonadditive 5.22 
mm/min) 5.22 
(11th 5.22 
(74-1700 5.22 
(mean=53 5.22 
sto/nMeSHBiomarkers 5.22 
(</=5%) 5.22 
fragment/total 5.22 
fragment-total 5.22 
immunoassay: 5.22 
syndrome-directed 5.22 
urine-serum 5.22 
(HCGbetacf) 5.22 
pregnanci2es 5.22 
6585 5.22 
(nmom/mmol 5.22 
Kellner 5.22 
retrospectives 5.22 
Isozaki 5.22 
(creatinine-independent) 5.22 
fragment:total 5.22 
(tE) 5.22 
11(+6) 5.22 
hand-carried 5.22 
fragment/estriol 5.22 
[ITA; 5.22 
(2023 5.22 
enzyme-immunometric 5.22 
beta152 5.22 
"automatic" 5.22 
beta-Core-hCG 5.22 
(34/69) 5.22 
(27/69) 5.22 
(24/69) 5.22 
Bi-weekly 5.22 
multi-trauma 5.22 
1485) 5.22 
(T0-2 5.22 
2/118 5.22 
[German 5.22 
non-superficial 5.22 
Tuen 5.22 
intramediastinal 5.22 
(DCUS) 5.22 
propria: 5.22 
(accuracy) 5.22 
(HGS) 5.22 
(LGC) 5.22 
(TA-EUS) 5.22 
(L-EUS) 5.22 
nodes/subject) 5.22 
nodes/subject 5.22 
L-EUS) 5.22 
0852 5.22 
maximum/minimum 5.22 
part/distal 5.22 
third/whole 5.22 
proximal/cardioesophageal) 5.22 
multi-layered 5.22 
>or=T3 5.22 
(22/29) 5.22 
hyperenhancement 5.22 
(mucosa) 5.22 
(T-staging) 5.22 
(N-staging) 5.22 
N+/- 5.22 
(involvement 5.22 
(EUS)] 5.22 
EU-M3 5.22 
antrum: 5.22 
44/65 5.22 
(42/56) 5.22 
Imagistic 5.22 
embedding) 5.22 
Endogastric 5.22 
'lift-off 5.22 
palm-up 5.22 
non-impingement 5.22 
Kibler 5.22 
tensiometer 5.22 
total: 5.22 
(Suretac; 5.22 
Acufex 5.22 
screw-type 5.22 
cortico-steroidal 5.22 
posterior-evaluation 5.22 
corticosteroid) 5.22 
Variational 5.22 
over-reported 5.22 
pseudoparalysis) 5.22 
slight' 5.22 
(636 5.22 
1999;27(3):300-3] 5.22 
LR>10 5.22 
(TPRs) 5.22 
(SROCs) 5.22 
(IRRT) 5.22 
Jerk 5.22 
Mechanically 5.22 
re-creating 5.22 
particular--supraspinatus 5.22 
impingement--or 5.22 
(MRI)-and 5.22 
findings-to 5.22 
severity-dependent 5.22 
kayaker's 5.22 
Kayaker's 5.22 
portaging 5.22 
arthroscopy) 5.22 
Pascal 5.22 
maneuvers; 5.22 
competition-level 5.22 
former-but-not-current 5.22 
critiqued 5.22 
(95/243) 5.22 
(5/243) 5.22 
(17/89) 5.22 
(4/89) 5.22 
test/Napoleon 5.22 
complete/near 5.22 
arthroscopists 5.22 
"anchor" 5.22 
synovial/bursal 5.22 
importantly) 5.22 
66-92) 5.22 
Waterpolo 5.22 
fine-needle-aspiration 5.22 
smear-negative/culture-positive 5.22 
one-off 5.22 
6648 5.22 
(796 5.22 
BACTEC-MGIT-960 5.22 
organisms) 5.22 
incorporation; 5.22 
0-0) 5.22 
(5/18) 5.22 
(fifth 5.22 
Xpert's 5.22 
95-100) 5.22 
pelleting 5.22 
Two-month 5.22 
6893 5.22 
[RIF] 5.22 
(41/63) 5.22 
SS(+) 5.22 
purified-protein-derivative 5.22 
mycobacteriuria 5.22 
(LPAs) 5.22 
LPAs 5.22 
(n=111) 5.22 
323; 5.22 
(61/62) 5.22 
9-30) 5.22 
System's 5.22 
hands-free 5.22 
tuberculosis-negative 5.22 
Sultan 5.22 
accurate: 5.22 
CFU/m(3) 5.22 
impactor 5.22 
BioSampler 5.22 
Assay: 5.22 
assay? 5.22 
LODs 5.22 
preconcentration 5.22 
TB-LAM; 5.22 
(Alere 5.22 
outperforming 5.22 
(35%vs 5.22 
0-625 5.22 
9600 5.22 
laboratory-defined 5.22 
4228 5.22 
Perforation: 5.22 
rectocolic 5.22 
Sorine 5.22 
07/2007 5.22 
reresected 5.22 
patients--is 5.22 
(NT-proBNP) 5.22 
(LVIDd) 5.22 
LVEDV 5.22 
look' 5.22 
value(s) 5.22 
chi-squared) 5.22 
dependences 5.22 
61-67 5.22 
CEA's 5.22 
18F-fluoro-deoxyglucose 5.22 
(TPM) 5.22 
(1/72) 5.22 
2-[(18)F]fluoro-2-deoxy-D-glucose-positron 5.22 
Resectable 5.22 
(31/49) 5.22 
(31/79) 5.22 
Wangensteen 5.22 
Redmond 5.22 
hundred-sixty 5.22 
proporation 5.22 
CEA-values 5.22 
(21/74) 5.22 
PET's 5.22 
(CEA-dt) 5.22 
Kung 5.22 
fungemic 5.22 
one-fold 5.22 
Kingdom; 5.22 
310; 5.22 
CEA/l 5.22 
entodermally 5.22 
(534 5.22 
10ng/ml 5.22 
(IIc) 5.22 
tumor-tissue 5.22 
eight% 5.22 
catcher 5.22 
patient-basis 5.22 
(12-37 5.22 
(2-12 5.22 
Reresection 5.22 
CEA-EIA 5.22 
non-correspondence 5.22 
markers--CEA 5.22 
Prolifigen 5.22 
antigen-M 5.22 
Rises 5.22 
(JSCCR) 5.22 
Slope 5.22 
histologictype 5.22 
A-B-C1 5.22 
spine-tumor 5.22 
LPB 5.22 
study--that 5.22 
centile--is 5.22 
Afro-Caribbeans) 5.22 
rate-for 5.22 
5%--by 5.22 
2529 5.22 
2427; 5.22 
(detection) 5.22 
beta/alpha 5.22 
'cost' 5.22 
4585 5.22 
(noninferior) 5.22 
(-47 5.22 
cryptate 5.22 
99(th) 5.22 
73-89%) 5.22 
56-72%) 5.22 
84-96%) 5.22 
unchanged: 5.22 
Log10MoM 5.22 
complex-bound 5.22 
(MSpMBP) 5.22 
5-9; 5.22 
MSpMBP</=cut-off) 5.22 
MSpMBP>/=cut-off) 5.22 
7284 5.22 
hyperglycosylated-hCG 5.22 
56-93%) 5.22 
aneuloidy] 5.22 
aneuloidy 5.22 
Screening" 5.22 
DeltaNT 5.22 
participiants 5.22 
examinied 5.22 
3845 5.22 
10/3845 5.22 
3727) 5.22 
options' 5.22 
dominant: 5.22 
(FB-hCG) 5.22 
(125/9424) 5.22 
(6577/12 5.22 
(1514/13 5.22 
(2212/13181) 5.22 
(1130/13181) 5.22 
(159/558) 5.22 
chromosomes-in 5.22 
(Nooman) 5.22 
zero/reverse) 5.22 
time-window 5.22 
drifts 5.22 
(DQASS) 5.22 
DQASS 5.22 
abortion-influence 5.22 
(MS-hCG) 5.22 
schwangerschaftsprotein 5.22 
(MSSP1) 5.22 
gave--in 5.22 
(cf)DNA 5.22 
(DYS14) 5.22 
8514 5.22 
Screen-maternal 5.22 
Quad-maternal 5.22 
First-nuchal 5.22 
Integrated-nuchal 5.22 
Integrated-PAPP-A 5.22 
abnormalities--the 5.22 
Jbo 5.22 
crownr-rump 5.22 
ojf 5.22 
iwere 5.22 
only--(sensitivity 5.22 
(CCDR) 5.22 
CCDR 5.22 
period-dated 5.22 
(858/1083) 5.22 
(756/858) 5.22 
(238/756) 5.22 
(25/223) 5.22 
(72/102) 5.22 
(obs/exp) 5.22 
11th+0 5.22 
11+6 5.22 
sonograms? 5.22 
100(1 5.22 
p)% 5.22 
Pr(Down 5.22 
exp(W)/ 5.22 
exp(W)] 5.22 
5-9-MHz 5.22 
4-8-MHz 5.22 
(mosaic-T21) 5.22 
(MDR: 5.22 
'missing'/N) 5.22 
3936 5.22 
choriogonadotrophin 5.22 
Province] 5.22 
(f-betaHCG) 5.22 
f-betaHCG 5.22 
population--comparison 5.22 
protein--A 5.22 
beta--human 5.22 
(ProMBP) 5.22 
pregnancy-specific-beta-1-glycoprotein 5.22 
(SP(1)) 5.22 
SP(1); 5.22 
10-12) 5.22 
SP(1) 5.22 
Calculation) 5.22 
"degree 5.22 
extremeness" 5.22 
(1994-2007) 5.22 
359/973) 5.22 
151/973) 5.22 
[detection 5.22 
throughput: 5.22 
amniocenteses/detected 5.22 
(66/1297) 5.22 
(25/1297) 5.22 
(99/695) 5.22 
(11/695) 5.22 
(42/730) 5.22 
(GHBP) 5.22 
10(+1) 5.22 
(14/370) 5.22 
[beta-hCG]) 5.22 
10+0-12+6 5.22 
screening-alone 5.22 
(FLRG) 5.22 
MeSHFollistatin-RelatedProteins 5.22 
unrecognised? 5.22 
1/2500 5.22 
(11-55) 5.22 
(11-67) 5.22 
(45-89) 5.22 
6896 5.22 
Down-screening 5.22 
(int-FISH) 5.22 
mid-pregnancy] 5.22 
(16-20 5.22 
karyotpying 5.22 
weeks-the 5.22 
(DSFN) 5.22 
(DSTN) 5.22 
DSFN 5.22 
DSTN 5.22 
(BPD)/NB 5.22 
26-69) 5.22 
91%-93%) 5.22 
38%-80%) 5.22 
82%-85%) 5.22 
-5-31) 5.22 
1994-2007] 5.22 
aberrations" 5.22 
(MLPA/rtPCR) 5.22 
delta-free 5.22 
7543 5.22 
CRL(mm)) 5.22 
NBL(mm) 5.22 
log(10)(NBL 5.22 
Log-regression 5.22 
quarter] 5.22 
"Cuza-Voda" 5.22 
diameter/HL 5.22 
(DSSP) 5.22 
(RAD: 5.22 
(QF-PCR)) 5.22 
$24084 5.22 
$27898 5.22 
$66608 5.22 
Down's-affected 5.22 
'nasal 5.22 
fetuses--with: 5.22 
(AFS): 5.22 
[measurement 5.22 
(fbetaB-Hcg) 5.22 
(Papp-A)] 5.22 
(FMF)-Software 5.22 
(JOY-Software) 5.22 
test-strategies 5.22 
FMF-Software 5.22 
significant-reduced 5.22 
AFS-algorithm 5.22 
28/45) 5.22 
SAFER 5.22 
(four-marker) 5.22 
(five-marker) 5.22 
(six-marker) 5.22 
six-marker 5.22 
73-98%) 5.22 
[(P/hCG)(free 5.22 
ahCG/hCG)] 5.22 
gestation--a 5.22 
"Maichin 5.22 
(4/36) 5.22 
(1--trisomy 5.22 
1--trisomy 5.22 
1--triplody) 5.22 
(BPD:NBL) 5.22 
BPD:NBL 5.22 
crown-rump-lengths 5.22 
6897) 5.22 
3840) 5.22 
practices/prenatal 5.22 
monoclonal-based 5.22 
Alfa-fetoprotein 5.22 
disparity: 5.22 
Hispanics; 5.22 
FTSs 5.22 
Roskilde 5.22 
Storstrom 5.22 
CVS/AC 5.22 
beta-hGC 5.22 
anormalies 5.22 
(590/10 5.22 
hypoplasia? 5.22 
AFP-uE3-free 5.22 
8811 5.22 
(21/64; 5.22 
(41/64; 5.22 
(30/63; 5.22 
(42/63; 5.22 
(ThCG)] 5.22 
assesement 5.22 
gestation--Polish 5.22 
gestation--Poland's 5.22 
multi-centers 5.22 
Nomogrames 5.22 
23(rd) 5.22 
offline; 5.22 
perimeter/head 5.22 
(FL/HL) 5.22 
FL/HL 5.22 
BPD/long 5.22 
Elucigene 5.22 
(Tepnel 5.22 
D13S634 5.22 
1/1600 5.22 
1/1600; 5.22 
(DNBH) 5.22 
DNBH 5.22 
Holbaek 5.22 
Centralregistry 5.22 
absent/reversed 5.22 
(DV-RAV; 5.22 
RESULTS/DISCUSSION: 5.22 
FlashFISH 5.22 
based-screening 5.22 
3169 5.22 
1:2368 5.22 
diandric) 5.22 
(99/109) 5.22 
(ASTRAIA) 5.22 
(38/88) 5.22 
(12/88) 5.22 
(26/88) 5.22 
(63/88) 5.22 
polyhydramnios/oligohydramnios) 5.22 
polyhydramnios/oligohydramnios 5.22 
(inhA) 5.22 
Republic--the 5.22 
minimal/maximal 5.22 
maternal) 5.22 
NICHD-sponsored 5.22 
(12p13) 5.22 
(7p15-12) 5.22 
Sequence-specific 5.22 
Can$3815 5.22 
(Biochemistry 5.22 
"sequential 5.22 
contingency" 5.22 
11-6/7 5.22 
12-0/7 5.22 
(55-66 5.22 
13-0/7 5.22 
13-6/7 5.22 
(67-84 5.22 
45-66 5.22 
14-23 5.22 
(FMF(bone)) 5.22 
(FMF(skin)) 5.22 
FMF(bone) 5.22 
FMF(skin) 5.22 
3019 5.22 
(2885/3019) 5.22 
(89/2833) 5.22 
NT-risk 5.22 
(NT-risk 5.22 
NT-Module) 5.22 
module) 5.22 
level:13 5.22 
Down-Syndrome 5.22 
Klinefelter-Syndrome 5.22 
strategy-in 5.22 
adjusted? 5.22 
risk)/(risk 5.22 
(3)Of 5.22 
11-13+6 5.22 
"indicators" 5.22 
1472 5.22 
reference; 5.22 
monitored; 5.22 
carcinoma?/nMeSHAngiography 5.22 
fullfill 5.22 
(resectability 5.22 
(locally 5.22 
(34/38) 5.22 
(7/21) 5.22 
(22/36) 5.22 
hospital-free 5.22 
therapy--particularly 5.22 
trials--is 5.22 
peek 5.22 
Going 5.22 
De-identified 5.22 
biopsy/fine 5.22 
RNM 5.22 
non-resected 5.22 
LAPAROSCOPIC 5.22 
Nontumor 5.22 
(log-rank) 5.22 
non-resectability 5.22 
(<40%) 5.22 
arthrotomic 5.22 
FTRCT; 5.22 
resonance-imaging 5.22 
(35/45)] 5.22 
grade1) 5.22 
synovitic 5.22 
(gadodiamide 5.22 
iobitridol 5.22 
(CTA-MRA) 5.22 
95%/100% 5.22 
(luxation 5.22 
(ninety-nine 5.22 
rotator-cuff-related 5.22 
arthrotomy) 5.22 
discontinuities 5.22 
Arthro-MRI 5.22 
mechanism: 5.22 
excitations) 5.22 
MRI/arthroscopy 5.22 
short-wide 5.22 
long-narrow 5.22 
long-wide 5.22 
end-to-bone; 5.22 
(D-MRA) 5.22 
(SSP-ISP) 5.22 
79/80% 5.22 
71/80% 5.22 
64/75% 5.22 
64/100% 5.22 
100/86% 5.22 
67/100% 5.22 
78/100% 5.22 
86/80% 5.22 
71/100% 5.22 
100/83% 5.22 
64/88% 5.22 
82/100% 5.22 
92/86% 5.22 
78/90% 5.22 
89/100% 5.22 
D-MRI 5.22 
assessing: 5.22 
one-hundred-and-ninety 5.22 
(38/40) 5.22 
65-96%) 5.22 
82-100%) 5.22 
COT2 5.22 
two-plane 5.22 
(distinguishing 5.22 
86-93% 5.22 
(forty-nine 5.22 
honestly 5.22 
Rudolph 5.22 
interslice 5.22 
(120% 5.22 
gadodiamide) 5.22 
loop-gap 5.22 
resonator 5.22 
128XP 5.22 
Choledocholithisis 5.22 
"vibratory" 5.22 
(US)(dilation 5.22 
(CBD)) 5.22 
prospectively) 5.22 
Peri-umbilical 5.22 
(70-81%) 5.22 
31-67% 5.22 
nonexcretion 5.22 
(reference: 5.22 
Loayza"] 5.22 
intraoperatorycholangiography 5.22 
ecographyc 5.22 
peopleunder 5.22 
cholangytis 5.22 
deshidrogenasa 5.22 
postoperated 5.22 
(8/129) 5.22 
cholangiopacreatography 5.22 
(26%): 5.22 
choledocholithiasis-sonography 5.22 
cholangiography-have 5.22 
management--result 5.22 
(cholangitis) 5.22 
Pre-ERCP 5.22 
(n=61); 5.22 
radiological: 5.22 
89/167 5.22 
ACC/CDL 5.22 
22-89 5.22 
renaissance?] 5.22 
(side-viewing 5.22 
[formula: 5.22 
mU/mL 5.22 
selectors 5.22 
(H&P) 5.22 
63-92) 5.22 
53-98) 5.22 
67-92) 5.22 
34-59) 5.22 
78-97) 5.22 
54-73) 5.22 
Bilirrubin 5.22 
TGO(ALT) 5.22 
58(23%) 5.22 
187(77%) 5.22 
IOC-derived 5.22 
1983-1984 5.22 
cholangiography-percutaneous 5.22 
predictors; 5.22 
"CBD 5.22 
data-splitting 5.22 
"test") 5.22 
5%-19%; 5.22 
30%-47% 5.22 
(GSCS) 5.22 
nondilatation 5.22 
aminotranferase 5.22 
(ER-CP) 5.22 
positive--two 5.22 
glutamic-oxalacetic 5.22 
Addis-Ababa 5.22 
(CBDIA) 5.22 
(AMY) 5.22 
(260/370) 5.22 
(356/370) 5.22 
under-evaluate 5.22 
Inguinofemoral 5.22 
(>2cm 5.22 
LSGs 5.22 
((9)(9)m)Tc 5.22 
post-study 5.22 
124I- 5.22 
blue/radioactive 5.22 
(SLB) 5.22 
(SSDR) 5.22 
dye+ 5.22 
Pre-surgical 5.22 
methylene-blue 5.22 
3-17) 5.22 
50/64 5.22 
(midline 5.22 
=grade 5.22 
=CIN-2 5.22 
LR-positive 5.22 
77-90%) 5.22 
8621 5.22 
(hc2; 5.22 
(RLUs) 5.22 
curettage; 5.22 
[ASCUS]) 5.22 
(ASCUS)-favor 5.22 
(deemed 5.22 
(633 5.22 
25-34-year 5.22 
(ASCUS-L) 5.22 
(HELP) 5.22 
$3003 5.22 
coloposcopic 5.22 
[ISH] 5.22 
(23/29) 5.22 
(30/250) 5.22 
(43/50) 5.22 
regression/persistence 5.22 
persistence) 5.22 
3517 5.22 
Reserving 5.22 
Trial) 5.22 
hr-HPV-positive 5.22 
province's 5.22 
genotyping' 5.22 
(n=131) 5.22 
papillomavirus-induced 5.22 
HPV16/HPV18 5.22 
Capture-II 5.22 
HPV39 5.22 
Ki-67-positivity 5.22 
p16-positivity 5.22 
(<3%) 5.22 
(DNA-ICM) 5.22 
RNA-DNA 5.22 
Repetition 5.22 
3735 5.22 
HARNET 5.22 
7458) 5.22 
4201 5.22 
travel) 5.22 
(FUTURE 5.22 
Serologically 5.22 
autostainer 5.22 
46/66 5.22 
53/60 5.22 
(non-neoplastic 5.22 
(HR-HPVs) 5.22 
analyte-specific 5.22 
8380 5.22 
5x10(3) 5.22 
[SIL] 5.22 
[ACIS] 5.22 
co-testing 5.22 
(minichromosome 5.22 
E6-E7 5.22 
correlated) 5.22 
(Argentina) 5.22 
significancy 5.22 
"preferred" 5.22 
(EC/TZS) 5.22 
(BNC) 5.22 
high-risk-type 5.22 
ASC] 5.22 
(MeSH) 5.22 
Gp5+/6+ 5.22 
ASC+ 5.22 
CIN2+cases 5.22 
(NLM) 5.22 
CIN-II 5.22 
CIN-2/CIN-3 5.22 
capture: 5.22 
cells--cannot 5.22 
Papillomaviruses 5.22 
trichomonas 5.22 
utility? 5.22 
HPV42 5.22 
precancer) 5.22 
7651 5.22 
CDC6 5.22 
HPV54 5.22 
11-18%) 5.22 
(19%; 5.22 
(rs396991) 5.22 
test--a 5.22 
(28%; 5.22 
(n=228) 5.22 
95-99%) 5.22 
Zhongshan 5.22 
Whittington 5.22 
37/66 5.22 
HC-1 5.22 
(AHPV) 5.22 
Papanicoloau 5.22 
pathologists: 5.22 
high/intermediate-risk 5.22 
intraepitelial 5.22 
(reflex 5.22 
ASC:SIL 5.22 
dysplasia/neoplasia 5.22 
[ASC-US] 5.22 
Products) 5.22 
(14/43) 5.22 
(22/47) 5.22 
(13/27) 5.22 
(35/42) 5.22 
(24/46) 5.22 
Province) 5.22 
inexistent 5.22 
12-81 5.22 
optimises 5.22 
(LCB) 5.22 
(HR-) 5.22 
triage: 5.22 
(pap) 5.22 
18-35) 5.22 
Significance-Low-grade 5.22 
4948 5.22 
reviewer's 5.22 
intercomparison 5.22 
70-93 5.22 
"Informant 5.22 
Elderly" 5.22 
Mulligan 5.22 
(PSDE) 5.22 
decline: 5.22 
1015) 5.22 
2-parameter 5.22 
(theta) 5.22 
CIDS 5.22 
(Standardized 5.22 
MeSHMentalCompetency 5.22 
(CCRs) 5.22 
0956 5.22 
(TMSE) 5.22 
(n=160 5.22 
gadget 5.22 
MeSHMultilingualism 5.22 
uterinum 5.22 
3/39) 5.22 
dysnomia 5.22 
Kissing 5.22 
22-54 5.22 
64-row 5.22 
endometriomata) 5.22 
79-97%) 5.22 
post-Gd 5.22 
21-45 5.22 
vaginam 5.22 
(3D-US) 5.22 
Fleiss' 5.22 
"fat-saturation" 5.22 
Izumo 5.22 
nonnegligible 5.22 
76/83 5.22 
12/83 5.22 
28/126 5.22 
recognition" 5.22 
452; 5.22 
158; 5.22 
Digitally 5.22 
(84-94%) 5.22 
(74-83%) 5.22 
(TR)/echo 5.22 
80/81 5.22 
(CE-MR-C) 5.22 
(46/48) 5.22 
(48/50) 5.22 
(47/48) 5.22 
(47/50) 5.22 
"tenderness-guided" 5.22 
up-and-down 5.22 
42/59 5.22 
morphologic- 5.22 
(2004-2010) 5.22 
Extraovarian 5.22 
(MSCTe) 5.22 
119/143 5.22 
(quadratic 5.22 
MeSHLubrication 5.22 
discarded; 5.22 
perlaparoscopic 5.22 
color; 5.22 
width; 5.22 
vascularization; 5.22 
retrouterine 5.22 
confirmation) 5.22 
(REU) 5.22 
66/71 5.22 
ischemia; 5.22 
hemodyalisis 5.22 
2338 5.22 
258; 5.22 
HD-patients 5.22 
CAD-positive 5.22 
Massachusetts] 5.22 
(PCE) 5.22 
infarctions) 5.22 
Discontinuing 5.22 
(cardiac) 5.22 
azotemic 5.22 
diseased) 5.22 
recipient) 5.22 
iodophenylpentadecanoic 5.22 
(201Tl) 5.22 
Arteriosclerotic 5.22 
nephropathic 5.22 
chronotropic 5.22 
(+/-10) 5.22 
LVESD 5.22 
American; 5.22 
isovolumic 5.22 
EF% 5.22 
(MCI/MCI) 5.22 
three-group 5.22 
(IFC) 5.22 
(18)F-fluoro-2-deoxy-d-glucose 5.22 
MeSHHalluxValgus 5.22 
(parahippocampal 5.22 
hippocampus) 5.22 
(converters) 5.22 
cingulated 5.22 
(FAQ) 5.22 
'group 5.22 
LMCI) 5.22 
EMCI 5.22 
74+/-6 5.22 
17/42 5.22 
1511 5.22 
reaction-enzyme-linked 5.22 
reasoning" 5.22 
Kit) 5.22 
agglutination) 5.22 
(50-80%) 5.22 
krusei) 5.22 
hinted 5.22 
hematopoetic 5.22 
(BLF) 5.22 
oncohematologic 5.22 
(GMEIA) 5.22 
sandwich-enzyme 5.22 
beta-D-glucan) 5.22 
G/(1 5.22 
2059 5.22 
ELISA-positive 5.22 
(GM-ELISA) 5.22 
MeSHConnexin26 5.22 
(GEI) 5.22 
?/nMeSHAcademicMedicalCenters 5.22 
exo-antigen 5.22 
lightcycler 5.22 
onco-haematological 5.22 
(13%): 5.22 
seven-transmembrane 5.22 
Interferon-gamma-inducible 5.22 
Transfected 5.22 
N-termini 5.22 
widely 5.21 
decade 5.21 
Central 5.21 
costs 5.20 
(36 5.20 
(29%) 5.20 
(increased 5.20 
(+/-SD) 5.20 
cent); 5.20 
values: 5.20 
traverse 5.20 
(Kappa 5.20 
(1994 5.20 
case-control 5.20 
residual 5.20 
sensation 5.20 
infrequently 5.20 
facilitates 5.19 
RT) 5.19 
404 5.19 
aliquot 5.19 
5-50 5.19 
placentae 5.18 
666 5.18 
LEEP 5.18 
WHAT 5.18 
haematopoietic 5.18 
false-positives 5.18 
thirty-five 5.18 
forty-nine 5.18 
risk) 5.18 
(kappa= 5.18 
brush 5.18 
ill 5.18 
fifteen 5.18 
3-9 5.18 
380 5.18 
merging 5.17 
attempt 5.17 
Service 5.17 
single-center 5.17 
worsening 5.17 
Thrombosis 5.17 
thirty 5.17 
tubes 5.17 
sides 5.17 
6; 5.16 
betaA 5.16 
18-22 5.16 
EGCs 5.16 
(PIA) 5.16 
cardiologists 5.16 
moderate-risk 5.16 
agreement) 5.16 
(FIBTEM) 5.16 
population-specific 5.16 
7200 5.16 
1133 5.16 
Noonan's 5.16 
computationally 5.16 
underascertainment 5.16 
259) 5.16 
univariately 5.16 
IRMA 5.16 
attempts) 5.16 
line-probe 5.16 
(solid 5.16 
Yearly 5.16 
(TPS) 5.16 
(n=37) 5.16 
unrevealing 5.16 
nonstandard 5.16 
low-signal-intensity 5.16 
anterior-to-posterior 5.16 
age-stratified 5.16 
contemporaneously 5.16 
(HPV)-DNA 5.16 
Systems) 5.16 
threshold) 5.16 
Independently 5.16 
utero-sacral 5.16 
INTEREST(S): 5.16 
mold-active 5.16 
PO2 5.16 
EXTEM) 5.16 
98%; 5.16 
(16/18 5.16 
(histology 5.16 
Medium- 5.16 
48) 5.15 
BPD 5.15 
AIS 5.15 
Seventy-four 5.15 
admit 5.15 
2008 5.14 
applicability 5.14 
killed 5.13 
BMI 5.13 
MeSHPancreaticDucts 5.13 
1995 5.13 
returned 5.12 
characteristics 5.11 
MeSHHeartDiseases 5.11 
[HR] 5.11 
average 5.11 
papers 5.10 
documentation 5.10 
02% 5.10 
categorical 5.10 
(z 5.10 
NHS 5.10 
383 5.10 
491 5.10 
waveform 5.10 
054 5.10 
computed 5.10 
None 5.10 
attempts 5.09 
temporary 5.09 
reviewer 5.09 
women; 5.08 
038) 5.08 
MeSHExtrahepatic 5.08 
omitted 5.07 
MeSHMedicalHistoryTaking 5.07 
MeSHAspergillusfumigatus 5.07 
fused 5.07 
capsid 5.07 
blinding 5.07 
resolves 5.07 
practised 5.07 
cheaper 5.07 
Tl 5.07 
Analytic 5.07 
818 5.07 
(80%) 5.06 
64%) 5.06 
significant) 5.06 
MeSHFinland 5.06 
scanned 5.05 
72%) 5.05 
DNA- 5.05 
thoracolumbar 5.05 
responsiveness 5.04 
restored 5.04 
presumably 5.04 
immunocytochemical 5.04 
insignificant 5.04 
gastro-oesophageal 5.04 
high-sensitivity 5.04 
MeSHRibonucleases 5.04 
(confirmed 5.04 
(n=27) 5.04 
'normal' 5.04 
(146 5.04 
GAPDH 5.04 
(T 5.03 
Nuclear 5.03 
112 5.02 
careful 5.01 
774 5.01 
Planar 5.01 
9/9 5.01 
spondylosis 5.01 
chloride 5.01 
peritoneum 5.01 
gravid 5.01 
capsular 5.01 
repetitive 5.00 
cholangiographic 5.00 
Investigation 5.00 
arteriography 5.00 
lysis 5.00 
30) 5.00 
closed 5.00 
cytogenetic 5.00 
suggests 5.00 
becomes 4.99 
Extensive 4.99 
moderate 4.99 
undertake 4.99 
BAL 4.99 
masked 4.99 
292 4.99 
tendinous 4.99 
Noninvasive 4.99 
tier 4.99 
branch 4.98 
?/nMeSHCholelithiasis 4.98 
supportive 4.98 
thrombocytopenia 4.98 
loading 4.98 
enhancing 4.98 
suspension 4.98 
os 4.98 
187 4.98 
2; 4.97 
217 4.97 
31) 4.97 
modest 4.97 
(B 4.97 
18- 4.97 
IT 4.96 
ultrasonograms 4.96 
(AST) 4.96 
Karyotypes 4.96 
Noonan 4.96 
609 4.96 
(3%) 4.95 
granule 4.95 
(50 4.95 
provider 4.95 
23% 4.95 
104 4.95 
located 4.94 
MeSHGeneticMarkers 4.94 
stations 4.93 
diagnostics 4.93 
follow-up; 4.93 
(early 4.93 
(25 4.92 
Constant 4.92 
hemangioma 4.92 
LIMITATIONS: 4.92 
numeric 4.92 
atypia 4.90 
diaphragmatic 4.90 
47% 4.89 
MeSHBloodCellCount 4.89 
pharmacological 4.89 
large 4.89 
hampered 4.89 
throughput 4.89 
one-stop 4.88 
scene 4.88 
(ISS) 4.88 
(135 4.88 
method; 4.88 
EXTRACTION: 4.88 
markers; 4.88 
MeSHSigmoidoscopy 4.88 
(although 4.88 
FUNDING/COMPETING 4.88 
7/30 4.88 
772 4.88 
bone) 4.88 
(pregnancy 4.88 
Utah 4.88 
003) 4.88 
involves 4.88 
Repeat 4.88 
related 4.88 
open 4.88 
April 4.88 
fifth 4.87 
18/13 4.87 
socioeconomically 4.87 
endometriomata 4.87 
quadruplets 4.87 
(category 4.87 
evaluators 4.87 
PSD 4.87 
end-systolic 4.87 
233) 4.87 
first-generation 4.87 
Haemostasis 4.87 
diabetes: 4.87 
MeSHGravidity 4.87 
MeSHInsulin-LikeGrowthFactorBindingProtein3 4.87 
?/nMeSHCostsandCostAnalysis 4.87 
3200 4.87 
meta-analytic 4.87 
(older 4.87 
kD) 4.87 
amniocentesis? 4.87 
(5/14 4.87 
similar; 4.87 
twins) 4.87 
16/20 4.87 
marker; 4.87 
(proximal 4.87 
(middle 4.87 
sub-district 4.87 
2000-2002 4.87 
(CPCs) 4.87 
hyperchromasia 4.87 
multinucleation 4.87 
HPV-based 4.87 
(repeat 4.87 
(regression 4.87 
Planned 4.87 
clarifies 4.87 
US$3 4.87 
299) 4.87 
glance 4.87 
30); 4.87 
rescreened 4.87 
=82 4.87 
(fixed 4.87 
onto 4.87 
neutral 4.87 
ureteral 4.87 
danger 4.87 
round 4.87 
classical 4.87 
Recently 4.86 
20) 4.86 
preclinical 4.86 
expectancy 4.86 
MeSHMicrosatelliteRepeats 4.86 
opting 4.86 
MeSHEngland 4.86 
junction 4.85 
(all 4.85 
reassessed 4.85 
fourfold 4.85 
onwards 4.85 
period; 4.85 
tomography) 4.85 
923 4.85 
5-17 4.85 
MeSHRemissionInduction 4.85 
respectively; 4.84 
TBI 4.84 
MeSHCellCycleProteins 4.84 
555 4.84 
Abeta 4.84 
Ultrasonic 4.83 
3-4 4.83 
production 4.83 
sediment 4.82 
Thirty-seven 4.82 
importance 4.82 
theory 4.81 
tolerance 4.81 
worldwide 4.81 
MeSHMultiple 4.81 
research 4.81 
p53 4.80 
267 4.80 
adversely 4.80 
right-sided 4.80 
Countries 4.80 
contribute 4.80 
arthrosis 4.79 
discussion 4.79 
(CI): 4.79 
locating 4.79 
evolving 4.79 
(20 4.78 
MeSHWest 4.78 
(93%) 4.78 
U/ml 4.78 
pressure 4.78 
divided 4.77 
MeSHGlucocorticoids 4.77 
avoiding 4.77 
School 4.77 
infant 4.77 
score 4.77 
(ODI) 4.76 
cohorts 4.76 
pretherapeutic 4.76 
Otherwise 4.76 
twenty-six 4.76 
MeSHBloodSpecimenCollection 4.76 
formed: 4.76 
Pelvic 4.76 
88) 4.75 
applied 4.75 
cholecystolithiasis 4.74 
double-blind 4.74 
endorectal 4.74 
641 4.74 
(LV) 4.74 
886 4.74 
arrival 4.74 
creation 4.74 
colo-rectal 4.73 
[interquartile 4.73 
(true 4.73 
substituting 4.73 
million) 4.73 
questions: 4.73 
Rotational 4.73 
sodium 4.73 
Compliance 4.73 
circulation 4.73 
miscarriages 4.72 
(77%) 4.72 
classify 4.72 
recognition 4.72 
irrespective 4.72 
facial 4.71 
undiagnosed 4.71 
MeSHHepatomegaly 4.71 
prone 4.71 
5-year 4.71 
lytic 4.71 
198 4.70 
75-year 4.70 
access 4.69 
ages 4.69 
locoregional 4.69 
obtaining 4.69 
sparing 4.68 
cysts 4.68 
4%; 4.68 
982 4.67 
(O 4.67 
(28% 4.67 
103) 4.67 
transpeptidase 4.67 
plotted 4.67 
Totally 4.67 
T-stage 4.67 
Bilirubin 4.67 
app 4.66 
detector 4.66 
transformation 4.66 
symptomatology 4.65 
stillbirths 4.65 
Seventy-six 4.65 
028) 4.65 
MeSHPostoperativeCare 4.65 
compressed 4.65 
July 4.65 
preferred 4.65 
SD 4.65 
carrying 4.64 
31%) 4.64 
10-year 4.64 
opinion 4.64 
12-week 4.64 
Hispanics 4.64 
averted 4.64 
bicipital 4.64 
5/15 4.64 
colonic 4.64 
(S) 4.64 
MeSHArm 4.63 
demonstrate 4.63 
SAT 4.63 
(92%) 4.62 
demise 4.62 
FV 4.62 
MeSHThorax 4.62 
osteomyelitis 4.62 
II) 4.62 
volume 4.62 
RRT 4.61 
tear; 4.61 
desirability 4.61 
40-45 4.61 
software) 4.61 
Helsinki 4.61 
MeSHCaribbeanRegion 4.61 
microtitre 4.61 
karyotype] 4.61 
2800 4.61 
Moving 4.61 
weeks); 4.61 
MeSHHydrothorax 4.61 
Singleton 4.61 
ng/l 4.61 
Bristol 4.61 
hCGbeta) 4.61 
optimizes 4.61 
MeSHRadiologyDepartment 4.61 
positive: 4.61 
(n=41) 4.61 
CPCs 4.61 
(ICER) 4.61 
(DF) 4.61 
gammaglutamyl 4.61 
1005 4.61 
equated 4.61 
"high-risk 4.61 
videolaparoscopy 4.61 
single-positive 4.61 
non-neutropenic 4.61 
73%; 4.61 
Consultant 4.61 
0049 4.61 
semiannual 4.61 
pathologists' 4.61 
Hologic 4.61 
211) 4.61 
polyp 4.61 
Method 4.61 
distinguishing 4.60 
MeSHSequenceAnalysis 4.60 
empty 4.60 
conclude 4.60 
candidate 4.60 
thorax 4.60 
20% 4.59 
(ROTEM) 4.59 
approaching 4.59 
dynamometer 4.59 
coagulopathic 4.59 
pairwise 4.59 
SETTINGS: 4.59 
threatened 4.59 
reasoning 4.59 
abuse 4.59 
contraindications 4.59 
(ERCP 4.58 
Manual 4.58 
Indians 4.58 
239 4.58 
living 4.58 
(11%) 4.58 
pain: 4.57 
108 4.57 
51) 4.57 
(90% 4.56 
sequence 4.56 
aberrant 4.56 
Children 4.56 
3-year 4.56 
new 4.56 
February 4.56 
MeSHClinicalCompetence 4.55 
foci 4.55 
(95%) 4.55 
TR) 4.55 
defining 4.55 
phone 4.55 
32% 4.55 
ampulla 4.55 
(GA) 4.54 
parturient 4.54 
tests; 4.54 
632 4.54 
659 4.54 
I/II 4.53 
classic 4.53 
MeSHLeiomyoma 4.53 
MeSHCirculating 4.53 
(40 4.53 
extracted 4.52 
90%) 4.52 
(SD 4.52 
191 4.51 
prophylaxis 4.51 
Further 4.51 
angiogram 4.51 
leave 4.50 
Recent 4.50 
Design 4.50 
presents 4.50 
worsened 4.50 
MeSHUnknownPrimary 4.50 
Histopathologic 4.50 
easier 4.49 
42) 4.49 
fixed 4.48 
207 4.48 
eighty 4.48 
dermoid 4.47 
associated 4.47 
Cardiac 4.47 
MeSHImmunocompromisedHost 4.47 
Italy 4.47 
angles 4.47 
profiling 4.47 
pathophysiologic 4.47 
MeSHNeoplasticCells 4.47 
MeSHAtrophy 4.47 
angular 4.47 
AIM: 4.47 
Correlations 4.46 
cortex 4.46 
PE 4.46 
it 4.46 
existing 4.45 
(140 4.45 
electrocardiographic 4.45 
optimised 4.45 
ICCs 4.45 
gender-specific 4.45 
ninety-four 4.45 
PARTICIPANTS/MATERIALS 4.45 
brachii 4.45 
(reference 4.45 
134) 4.45 
054) 4.45 
awaiting 4.45 
interphase 4.44 
ischemia 4.44 
Conversely 4.44 
colitis 4.44 
communities 4.44 
sheath 4.44 
mg/dl 4.44 
government 4.44 
conducted 4.44 
specimens) 4.44 
070 4.44 
097 4.44 
years); 4.44 
tearing 4.44 
(33% 4.43 
Corresponding 4.43 
persisted 4.43 
en 4.42 
locate 4.42 
* 4.42 
MeSHHealthServicesAccessibility 4.41 
routes 4.41 
MeSHCytodiagnosis 4.40 
associate 4.40 
(24 4.40 
reasonable 4.40 
inadequate 4.40 
Cytogenetic 4.40 
Indications 4.40 
comfort 4.40 
(relative 4.39 
(61%) 4.39 
s; 4.39 
LBP 4.39 
aorta 4.39 
diversity 4.39 
Histopathological 4.38 
echocardiographic 4.38 
true-positive 4.38 
Sixty-three 4.38 
pathology 4.38 
ovary 4.38 
22%) 4.38 
arc 4.38 
Antenatal 4.38 
wk 4.38 
MeSHDuodenoscopy 4.38 
carcinoid 4.38 
stabilized 4.38 
precursors 4.38 
Mixed 4.38 
burned 4.38 
SP-1 4.38 
signaled 4.38 
nonsurvivors 4.38 
multigravid 4.38 
XYY) 4.38 
MeSHInsulin-LikeGrowthFactorBindingProtein1 4.38 
older: 4.38 
preeclamptic 4.38 
Unconjugated 4.38 
post-delivery 4.38 
genetics; 4.38 
(natural 4.38 
imbalanced 4.38 
a-wave 4.38 
222) 4.38 
authorized 4.38 
Semi-quantitative 4.38 
multiplicative 4.38 
CVS: 4.38 
malignancy) 4.38 
MeSHBibliographic 4.38 
sign: 4.38 
into: 4.38 
(PIA 4.38 
planners 4.38 
prelaparoscopic 4.38 
MeSHAdolescentHealthServices 4.38 
baseline; 4.38 
(sd 4.38 
MeSHTouch 4.38 
noncyclic 4.38 
99mTc-MIBI 4.38 
perfusion) 4.38 
TLS 4.38 
flexion) 4.38 
PRC) 4.38 
2/32 4.38 
(biopsy 4.38 
role 4.37 
spare 4.37 
Department 4.36 
pre-operatively 4.36 
academic 4.36 
Image 4.36 
platelets 4.36 
aetiology 4.36 
Eighty-five 4.36 
Paired 4.36 
resistance 4.35 
PCR 4.35 
mouth 4.35 
MeSHThrombin 4.35 
spectrum 4.35 
Immunocompromised 4.34 
posterosuperior 4.34 
(time 4.34 
twenty-nine 4.34 
MeSHCriticalIllness 4.34 
803 4.34 
overview 4.34 
accelerated 4.34 
TEM 4.33 
span 4.32 
proceeded 4.32 
syndrome; 4.32 
MeSHEarlyDetectionofCancer 4.32 
2-10 4.32 
MeSHResearchDesign 4.32 
vulval 4.32 
(19) 4.32 
(MT) 4.32 
MeSHResuscitation 4.32 
points; 4.32 
inappropriately 4.32 
(superior 4.32 
817 4.32 
16] 4.32 
transitional 4.32 
microm 4.31 
MeSHElectrophoresis 4.31 
analysis 4.31 
(64 4.31 
7-9 4.31 
western 4.31 
IIA 4.31 
VIII 4.31 
affecting 4.31 
implication 4.30 
uncertainty 4.29 
96%) 4.29 
ms 4.29 
considerably 4.29 
alive 4.29 
appeared 4.29 
mycobacterium 4.29 
Communication 4.29 
elimination 4.29 
adhesion 4.29 
MeSHProbability 4.29 
aimed 4.29 
disadvantages 4.28 
Bilateral 4.28 
reclassified 4.28 
410 4.28 
esophagus 4.27 
discriminant 4.26 
uterine 4.26 
means 4.26 
source 4.26 
3-5 4.26 
surfaces 4.26 
olds 4.25 
Functional 4.25 
Patient 4.25 
pragmatic 4.25 
CINAHL 4.25 
(ALT) 4.25 
476 4.25 
563 4.25 
sac 4.24 
counts 4.24 
healthcare 4.24 
Developing 4.24 
DISCUSSION 4.24 
Range 4.24 
tumoral 4.23 
Final 4.23 
MeSHIntraductal 4.23 
ruptured 4.23 
similarities 4.23 
vena 4.23 
policies 4.22 
marginally 4.22 
multiplanar 4.22 
ultrasonic 4.22 
implications 4.22 
disrupt 4.22 
Five-year 4.21 
FDG-PET) 4.21 
notes 4.21 
kayakers 4.21 
NT-proBNP 4.21 
endogastric 4.21 
non-sentinel-node 4.21 
WMA 4.21 
glycocalyx 4.21 
TPA-M 4.21 
gynaecologists' 4.21 
co-screening 4.21 
CPI/IIG 4.21 
MRI-e 4.21 
10(-3)/mm(2)/s 4.21 
CCTA 4.21 
"advanced" 4.21 
(SOR: 4.21 
H&P 4.21 
unjaundiced 4.21 
WMHs 4.21 
"self" 4.21 
secretors 4.21 
CEA-levels 4.21 
I-MRA 4.21 
rim-rent 4.21 
FOCAL 4.21 
(samples 4.21 
PGMY09/PGMY11 4.21 
MAPS 4.21 
ACE-R 4.21 
sum' 4.21 
Patient-level 4.21 
BP(ND) 4.21 
2-deoxy-2-[18F]-fluoro-D-glucose 4.21 
/2N0) 4.21 
(T3/4 4.21 
pathPR 4.21 
(704 4.21 
Cyriax's 4.21 
Mumford 4.21 
time-to-detection 4.21 
pro-brain 4.21 
thorax-abdominal 4.21 
break-through 4.21 
carcino-embryonal 4.21 
CA50 4.21 
recidivations 4.21 
hindsight 4.21 
a-priori 4.21 
race-based 4.21 
8571 4.21 
(nonsignificantly) 4.21 
software: 4.21 
3073 4.21 
Delamination 4.21 
less-experienced 4.21 
(in-transit 4.21 
E6*II 4.21 
negative/HPV 4.21 
ASC/SIL 4.21 
LG-SIL 4.21 
SiHa 4.21 
DakoCytomation 4.21 
cytologic-histologic 4.21 
(ACE-R) 4.21 
Japanese-American 4.21 
hysterosalpingo-contrast 4.21 
compartment: 4.21 
2-tiered 4.21 
postexercise 4.21 
Disease's 4.21 
(PET+ 4.21 
ADAS-Cog) 4.21 
Burnet 4.21 
non-fumigatus 4.21 
allo-SCT 4.21 
(MA)) 4.21 
>15%) 4.21 
EMBASE; 4.21 
LILACS; 4.21 
[MA]) 4.21 
disincentives 4.21 
Handbook 4.21 
(histone-complexed 4.21 
high-degree 4.21 
ng/mL]) 4.21 
TEG-derived 4.21 
(estradiol 4.21 
open-chest 4.21 
multiplate 4.21 
peptide-6 4.21 
5%-67%) 4.21 
sensitivities/specificities 4.21 
MOIs 4.21 
injuries? 4.21 
(suggestive 4.21 
(n=122) 4.21 
88-89%) 4.21 
(T-stage) 4.21 
echo-rich 4.21 
IM1) 4.21 
(CT-PET) 4.21 
gastroscopy: 4.21 
(32/32) 4.21 
(Kw) 4.21 
00042) 4.21 
(27/29 4.21 
ultrasongraphy 4.21 
46-87 4.21 
(SMG) 4.21 
five-layered 4.21 
april 4.21 
(24/28 4.21 
reputedly 4.21 
T2-T4) 4.21 
over-staging 4.21 
(accuracy: 4.21 
air-filled 4.21 
mL/sec 4.21 
expediently 4.21 
(10/23) 4.21 
EGD/EUS 4.21 
(fixation 4.21 
non-upper 4.21 
(acromioplasty 4.21 
(SRT) 4.21 
Linvatec 4.21 
(MTrPs) 4.21 
MTrPs 4.21 
MTrP 4.21 
top" 4.21 
cuff? 4.21 
weakness: 4.21 
stage-3 4.21 
avulsion; 4.21 
non-throwing 4.21 
result? 4.21 
claviculectomy 4.21 
down) 4.21 
tenorrhaphy 4.21 
fail-safe 4.21 
[SOR]: 4.21 
same-subject 4.21 
(N=37) 4.21 
(test-retest) 4.21 
twists 4.21 
tearing: 4.21 
?/nMeSHBursitis 4.21 
(SSB) 4.21 
bedside: 4.21 
variations; 4.21 
replication) 4.21 
cartridge) 4.21 
assay--a 4.21 
H37RV 4.21 
~100 4.21 
>97% 4.21 
(4/18) 4.21 
(23/25) 4.21 
Biosafety 4.21 
setting? 4.21 
Clearview 4.21 
sputum-scarce 4.21 
CD4<50 4.21 
[42% 4.21 
CONSECUTIVE 4.21 
+6% 4.21 
(MTBDR) 4.21 
sub-study 4.21 
kits: 4.21 
Molecular-based 4.21 
ground-breaking 4.21 
33/39 4.21 
38/53 4.21 
patient-important 4.21 
MeSHContainmentofBiohazards 4.21 
tools; 4.21 
emanates 4.21 
Herault 4.21 
1478 4.21 
seedlings 4.21 
unbiopsied 4.21 
(pT1N0M0) 4.21 
(Dutch 4.21 
(Abbott) 4.21 
(103/117) 4.21 
acute/chronic 4.21 
Inadequacy 4.21 
polypeptide-specific 4.21 
[CEA] 4.21 
examination(s) 4.21 
(1/20) 4.21 
Solid-phase 4.21 
octanoyl 4.21 
carcinome 4.21 
(IDT) 4.21 
antigen-directed 4.21 
tumor-biological 4.21 
IInd 4.21 
acuteness 4.21 
CEA-measurement 4.21 
meta-static 4.21 
assessments; 4.21 
(FOBT) 4.21 
FOBT) 4.21 
(IIa) 4.21 
(IIb) 4.21 
CEA-test 4.21 
(living 4.21 
Wagner 4.21 
thereto 4.21 
10-56 4.21 
(5/22) 4.21 
results" 4.21 
18-th 4.21 
non-relapse 4.21 
Abdominopelvic 4.21 
resectable) 4.21 
2121 4.21 
(one-sided 4.21 
(IMM) 4.21 
screenings) 4.21 
(21/26) 4.21 
DNA-and 4.21 
Formaldehyde-treated 4.21 
week] 4.21 
(1999-2002) 4.21 
2245 4.21 
5694 4.21 
35-years-old 4.21 
14/49 4.21 
MSMs 4.21 
1/240 4.21 
Turnaround 4.21 
(27-73) 4.21 
(late) 4.21 
efficacy? 4.21 
3634 4.21 
7517 4.21 
Obversely 4.21 
gonadotropine 4.21 
23/42 4.21 
(largely 4.21 
$99 4.21 
7642 4.21 
diagnostics?] 4.21 
4412 4.21 
(127) 4.21 
(98/109) 4.21 
numbers: 4.21 
(45-54 4.21 
16-28 4.21 
Database) 4.21 
opponents 4.21 
nonresectional 4.21 
(23/44) 4.21 
(80%); 4.21 
resectable" 4.21 
"doubtful" 4.21 
(15%): 4.21 
8/87 4.21 
11/72 4.21 
ingrowing 4.21 
Extrapancreatic 4.21 
(benign) 4.21 
micro-peritoneal 4.21 
infragastric 4.21 
offsetting 4.21 
resectability) 4.21 
comparable: 4.21 
35%-44% 4.21 
capsulo-ligamentous 4.21 
(arthro-CT 4.21 
records] 4.21 
[78% 4.21 
(complete) 4.21 
1/reader 4.21 
(repetition 4.21 
msec/echo 4.21 
observers' 4.21 
Cohens 4.21 
Bankart- 4.21 
(nonconsecutive 4.21 
stitching 4.21 
(I-MRA) 4.21 
I-MRI 4.21 
ultrasonographically; 4.21 
Rim-rent 4.21 
arthroscopy: 4.21 
retraction) 4.21 
nonretracted 4.21 
(bursal 4.21 
partial-tear 4.21 
expounded 4.21 
impingement] 4.21 
(tendinitis) 4.21 
imbibition 4.21 
(4/30 4.21 
(PIR) 4.21 
SONOLINE 4.21 
AlkPh 4.21 
peri-umbilical 4.21 
(BUS) 4.21 
(n=38); 4.21 
biochemical: 4.21 
clinical-imaging 4.21 
middle-distal 4.21 
WORDS)/nMeSHAbdomen 4.21 
21-91 4.21 
examiners) 4.21 
1981-1982 4.21 
9%-36% 4.21 
17-93) 4.21 
methylene) 4.21 
(non-SNs) 4.21 
14/64 4.21 
34/39 4.21 
90-180 4.21 
19/31 4.21 
(planar 4.21 
Karolinska 4.21 
quality-controlled 4.21 
subserously 4.21 
(application 4.21 
(T1-T2) 4.21 
(micrometastasis) 4.21 
METHODS/MATERIALS: 4.21 
Tc99m-nanocolloid 4.21 
9-123 4.21 
(HSIL); 4.21 
14-29 4.21 
30-77 4.21 
Inc) 4.21 
8170 4.21 
subset) 4.21 
[Hazards 4.21 
unit/cutoff 4.21 
Biopsy-confirmed 4.21 
(Digene) 4.21 
(Gen-Probe) 4.21 
Beltsville 4.21 
(ECA) 4.21 
(n=121) 4.21 
2019 4.21 
1908 4.21 
interpretation: 4.21 
(GAA) 4.21 
1776 4.21 
1676 4.21 
=atypical 4.21 
ASCUS/AGUS 4.21 
16-83) 4.21 
0281) 4.21 
21-60) 4.21 
(n=89) 4.21 
>55% 4.21 
4075 4.21 
skews 4.21 
reaction-reverse 4.21 
water-bath 4.21 
Cotesting 4.21 
(455 4.21 
flat; 4.21 
(hTR) 4.21 
hTR 4.21 
LBPs 4.21 
(ASCUS/LSIL) 4.21 
16-25) 4.21 
(ASCUS): 4.21 
moderate-grade 4.21 
subtler 4.21 
past) 4.21 
"reflex 4.21 
109% 4.21 
(Bethesda 4.21 
4273 4.21 
SurePath) 4.21 
98/100 4.21 
(ASC-H); 4.21 
(Milan 4.21 
uncertainty: 4.21 
AGCs 4.21 
not-otherwise-specified 4.21 
HPV-PCR 4.21 
HC2-negative 4.21 
(28/48) 4.21 
L1/p16 4.21 
(Cytyc) 4.21 
4792 4.21 
MeSHSelf-SustainedSequenceReplication 4.21 
HR-HPV-negative 4.21 
parakeratosis 4.21 
biobanks 4.21 
trial-based 4.21 
Age-stratified 4.21 
(AGCUS) 4.21 
HG-SIL 4.21 
p16ink4a 4.21 
smears? 4.21 
n=156) 4.21 
1757 4.21 
?/nMeSHColposcopy 4.21 
primer-mediated 4.21 
(28/60) 4.21 
manufacturer-recommended 4.21 
(NPVs) 4.21 
second-hand 4.21 
adjudication 4.21 
papillomavirus] 4.21 
12/56 4.21 
significant? 4.21 
(NISH) 4.21 
3619 4.21 
accessions 4.21 
(Dakocytomation) 4.21 
[CIN2+] 4.21 
[LSIL]) 4.21 
format) 4.21 
MeSHCyclinA1 4.21 
mid-April 4.21 
interpathologist 4.21 
2237 4.21 
cross-validated 4.21 
DSM-IV-TR 4.21 
MeSHCommunityMentalHealthServices 4.21 
periurban 4.21 
Culturally 4.21 
Jorm's 4.21 
(AMT) 4.21 
Relatives 4.21 
(controls: 4.21 
'don't 4.21 
Informant-based 4.21 
(z-score) 4.21 
minutes] 4.21 
Noncontrast 4.21 
(5/12) 4.21 
4-8%) 4.21 
pelvis' 4.21 
KNOWN: 4.21 
(substantial 4.21 
not-for-profit 4.21 
Shimane 4.21 
19-49 4.21 
(ovaries 4.21 
(SSH) 4.21 
pouch; 4.21 
ADDS: 4.21 
managment 4.21 
"pattern 4.21 
obliteration) 4.21 
(DPE) 4.21 
(45/48) 4.21 
irregularly-shaped 4.21 
sonograms; 4.21 
84%-92%) 4.21 
67-100% 4.21 
33/201 4.21 
childless 4.21 
signal-void 4.21 
magnetom 4.21 
(observers 4.21 
gel: 4.21 
unbearable) 4.21 
20-71 4.21 
to; 4.21 
list; 4.21 
>or=1000 4.21 
puzzled 4.21 
low-to-intermediate 4.21 
pancreas/kidney 4.21 
(DPM) 4.21 
(TRs) 4.21 
(2/11) 4.21 
(CVE) 4.21 
<75% 4.21 
>or=70% 4.21 
(6-48 4.21 
MHZ 4.21 
CIMT> 4.21 
hypertrophy) 4.21 
(amputation 4.21 
noncoronary 4.21 
(fatal 4.21 
(DPT) 4.21 
(documented 4.21 
201thallium 4.21 
Angiographically 4.21 
antibody-sensitized 4.21 
cineangiography 4.21 
(reversible 4.21 
Reversibility 4.21 
mug/kg/min 4.21 
(LVSD) 4.21 
First-year 4.21 
IVRT 4.21 
MeSHLeukoencephalopathies 4.21 
stereotactically 4.21 
(Abeta(1-42) 4.21 
cingulate-precuneus 4.21 
Reminding 4.21 
memory; 4.21 
mnemonics 4.21 
diaschisis) 4.21 
(BP(ND)) 4.21 
(MCI-AD) 4.21 
Florbetapir 4.21 
"stable" 4.21 
75+/-8 4.21 
inclusion: 4.21 
(NASBA) 4.21 
spp) 4.21 
mensuration 4.21 
297; 4.21 
Fundeni 4.21 
fungus-derived 4.21 
per-test 4.21 
Pasteur) 4.21 
(6/14) 4.21 
G/M 4.21 
non-infective 4.21 
(6/28) 4.21 
(14/28) 4.21 
Childrens 4.21 
[European 4.21 
(real-time 4.21 
'probable' 4.21 
ELISA: 4.21 
foothold 4.21 
positivity: 4.21 
(125)I-labeled 4.21 
much 4.21 
tricuspid 4.21 
ng/mL) 4.21 
irregularity 4.21 
electrosurgical 4.21 
REGISTRATION: 4.21 
passed 4.20 
clavicular 4.20 
sufficient 4.20 
MeSHCalcium 4.20 
example 4.19 
regularity 4.19 
approximation 4.19 
MShCG 4.19 
distracting 4.19 
community-dwelling 4.19 
fifty-two 4.19 
specimens; 4.19 
laparoscopy] 4.19 
cytopathologists 4.19 
849 4.19 
831 4.19 
neuropsychological 4.19 
MeSHSexDistribution 4.18 
decision 4.18 
(43 4.18 
MeSHContact 4.18 
Statistics 4.17 
localize 4.17 
negligible 4.17 
specialists 4.17 
expressions 4.17 
modulated 4.17 
clips 4.17 
remote 4.17 
Americans 4.17 
stillbirth 4.17 
59% 4.16 
DSL 4.16 
interpersonal 4.16 
28-day 4.16 
hydrosalpinges 4.16 
LOD 4.16 
267) 4.16 
summation 4.16 
N-acetylglucosamine 4.16 
343) 4.16 
corrects 4.16 
feto-protein 4.16 
retrieving 4.16 
mm: 4.16 
Papers 4.16 
Policies 4.16 
MeSHExtraembryonicMembranes 4.16 
series: 4.16 
foreseeable 4.16 
south-east 4.16 
70%; 4.16 
MeSHSkiing 4.16 
inadequacies 4.16 
(DOR) 4.16 
(TPA) 4.16 
(FDG-PET/CT) 4.16 
Equally 4.16 
(alkaline 4.16 
characterising 4.16 
finding; 4.16 
muscle: 4.16 
(cytology 4.16 
Endocervical 4.16 
MeSHPersonalityInventory 4.16 
psychiatrist 4.16 
INTERESTS: 4.16 
ST-segment 4.16 
HTA 4.16 
1/39 4.16 
2-5) 4.16 
0038 4.16 
1/160 4.16 
accuracy) 4.16 
18/19 4.16 
detection) 4.16 
9/50 4.16 
isonitrile 4.16 
unknown 4.16 
MeSHYoungAdult 4.15 
(ERCP) 4.15 
096 4.15 
521 4.15 
abnormalities; 4.15 
sponsored 4.15 
scanner 4.15 
goal 4.15 
derived 4.15 
Eye 4.14 
individual 4.14 
failures 4.13 
differentiated 4.13 
ECG 4.13 
discriminative 4.13 
504 4.13 
athletic 4.13 
(ICC 4.13 
prevalent 4.13 
Obstetrics 4.13 
scattered 4.13 
MeSHNoninfiltrating 4.13 
stable 4.13 
encouraged 4.12 
45) 4.12 
(LC) 4.11 
323 4.11 
275 4.11 
<4 4.11 
Analysis 4.11 
MeSHPressure 4.11 
NM 4.11 
MeSHForecasting 4.10 
artificial 4.10 
contra 4.10 
precursor 4.10 
true 4.09 
two-dimensional 4.09 
operated 4.09 
constitute 4.08 
Research 4.08 
physiotherapy 4.08 
MeSHIntellectualDisability 4.08 
ERCP) 4.08 
Population 4.08 
our 4.08 
anastomotic 4.07 
MeSHGenitalNeoplasms 4.07 
keep 4.07 
concurrent 4.07 
dying 4.07 
diabetics 4.07 
proton 4.07 
McNemar 4.07 
many 4.07 
(including 4.07 
stimulated 4.07 
CAG 4.07 
778 4.07 
period: 4.07 
samples: 4.07 
(NB) 4.07 
CHANCE: 4.07 
REASONS 4.07 
controls: 4.07 
Resting 4.07 
781 4.07 
127) 4.07 
DISCUSSION: 4.06 
nondiabetic 4.06 
retaining 4.06 
twenty-seven 4.06 
cancers] 4.06 
invited 4.06 
436 4.06 
-20 4.06 
inguinal 4.05 
ethanol 4.05 
endothelium 4.05 
(IL) 4.05 
outlet 4.05 
HIV-positive 4.05 
grafts 4.05 
attenuated 4.05 
(PTB) 4.05 
correlations 4.05 
received 4.04 
certain 4.04 
depressed 4.04 
3); 4.04 
contrast-enhanced 4.03 
anatomic 4.03 
MeSHIntravenous 4.02 
Africa 4.02 
slowly 4.02 
goals 4.02 
MeSHTh1Cells 4.02 
MeSHSacroiliacJoint 4.02 
cytokeratin 4.02 
supplemented 4.02 
(12% 4.01 
expectation 4.01 
61%) 4.01 
laparoscopic 4.01 
AFS 4.01 
307 4.01 
335 4.01 
MeSHBoneMarrowTransplantation 4.01 
Recurrent 4.01 
Genetic 4.00 
encourage 4.00 
(52% 4.00 
Seventeen 3.99 
(11% 3.99 
MeSHIntestinalNeoplasms 3.99 
Almost 3.99 
45; 3.99 
2-24 3.99 
undertaken 3.99 
extrahepatic 3.98 
Twenty-six 3.98 
77) 3.98 
recruit 3.98 
MeSHFluorodeoxyglucoseF18 3.98 
Significantly 3.98 
rheumatologist 3.97 
endorsed 3.97 
septated 3.97 
recommending 3.97 
Dilated 3.97 
568 3.97 
(serum 3.97 
towns 3.97 
(89 3.97 
trends 3.97 
neither 3.96 
TME 3.96 
LOS 3.96 
mistaken 3.96 
Severe 3.96 
PTB 3.96 
herein 3.96 
dimension 3.96 
grouped 3.96 
prognosis 3.96 
GA) 3.96 
presurgical 3.95 
Well 3.95 
LHB 3.95 
SBP 3.95 
nicked 3.95 
septae 3.95 
(model 3.95 
miniprobes 3.95 
16-24 3.95 
broncho-alveolar 3.95 
happy 3.95 
measurement) 3.95 
inconvenient 3.95 
weight-corrected 3.95 
measurement: 3.95 
(ET) 3.95 
MeSHHaptoglobins 3.95 
Bayes' 3.95 
Foetal 3.95 
Pyelectasis 3.95 
MeSHHealthServicesMisuse 3.95 
Presurgical 3.95 
pathomechanics 3.95 
(2-D) 3.95 
69%; 3.95 
HPV; 3.95 
load) 3.95 
poststroke 3.95 
(LVH) 3.95 
27%; 3.95 
088) 3.95 
301) 3.95 
denoting 3.95 
k= 3.95 
(99) 3.95 
calcifications 3.95 
gamma-detecting 3.94 
919 3.94 
CAUTION: 3.94 
[13 3.94 
terms 3.94 
ICC 3.93 
paired 3.93 
thigh 3.93 
Informed 3.93 
MeSHSouthern 3.93 
sensitization 3.93 
assessments 3.93 
(12%) 3.93 
cycle 3.93 
calcification 3.93 
calcific 3.92 
intraobserver 3.92 
351 3.92 
423 3.92 
evidenced 3.92 
agreed 3.92 
Little 3.92 
MeSHCross-SectionalStudies 3.91 
conversion 3.91 
L 3.91 
impact 3.91 
high-quality 3.91 
253 3.91 
Superior 3.91 
attain 3.90 
74) 3.90 
spectroscopy 3.90 
MeSHMorbidity 3.90 
MeSHSurgicalWoundInfection 3.90 
arises 3.90 
telephone 3.90 
spasm 3.90 
spiral 3.90 
repaired 3.89 
transformed 3.89 
487 3.89 
contamination 3.89 
habits 3.89 
(45%) 3.88 
intracytoplasmic 3.88 
MeSHRangeofMotion 3.88 
nephrectomy 3.87 
serosal 3.87 
F18 3.87 
DFS 3.87 
hypothesize 3.86 
definitive 3.86 
commonest 3.86 
dividing 3.86 
persistently 3.86 
separated 3.85 
microl 3.85 
counselling 3.85 
complaint 3.85 
57) 3.85 
24% 3.85 
MeSHPrevalence 3.85 
10% 3.85 
volunteer 3.85 
clustered 3.84 
echogenic 3.84 
extracts 3.84 
MeSHHIVSeropositivity 3.84 
quad 3.84 
expensive 3.84 
discovered 3.84 
markedly 3.84 
Real-Time 3.83 
none 3.83 
perimenopausal 3.83 
MeSHPulsed 3.83 
anomalies) 3.83 
145) 3.83 
(CE) 3.83 
Analytical 3.83 
considered: 3.83 
Stockholm 3.83 
MeSHGyrusCinguli 3.83 
MeSHLatexFixationTests 3.83 
oncologic 3.83 
512 3.83 
trigger 3.83 
MeSHHepatectomy 3.83 
MeSHAdenoma 3.83 
opted 3.82 
Approximately 3.82 
(21% 3.82 
parenchymal 3.82 
ligation 3.82 
evoked 3.82 
dietary 3.82 
R0 3.81 
multi-center 3.80 
pregnancy; 3.80 
formally 3.80 
482 3.80 
limitation 3.80 
longitudinal 3.80 
took 3.80 
essential 3.79 
impairment 3.79 
13% 3.79 
India 3.79 
pharmacologic 3.79 
225 3.79 
fluorouracil 3.79 
M1 3.79 
exclusively 3.79 
weak 3.79 
possibilities 3.79 
occurring 3.79 
MeSHSpectrometry 3.79 
dermis 3.79 
inheritance 3.79 
MeSHHispanicAmericans 3.78 
test-retest 3.78 
407 3.78 
in: 3.78 
MDCT 3.78 
SPM 3.78 
saline 3.77 
infertile 3.77 
etiological 3.77 
diverse 3.77 
evidence-based 3.77 
cross 3.76 
T18 3.76 
(x) 3.76 
Geneva 3.76 
Normalization 3.76 
Echocardiographic 3.76 
cytology-based 3.76 
transplantation; 3.76 
disagreements 3.76 
trauma-induced 3.76 
(TBI) 3.76 
1157 3.76 
father's 3.76 
'G 3.76 
MeSHMacrophageColony-StimulatingFactor 3.76 
lines; 3.76 
average: 3.76 
specifying 3.76 
85-90% 3.76 
"screen 3.76 
MeSHDehydroepiandrosterone 3.76 
1944 3.76 
Distributions 3.76 
47%; 3.76 
Shoulders 3.76 
Probable 3.76 
resective 3.76 
(recurrent 3.76 
(PlGF) 3.76 
(grades 3.76 
cholangio-pancreaticography 3.76 
Consenting 3.76 
25-64 3.76 
<45 3.76 
17-month 3.76 
dysplasia: 3.76 
atropine 3.76 
(MPS) 3.76 
(FDG)-positron 3.76 
Meier) 3.76 
(PRC 3.76 
197) 3.76 
nanogram 3.76 
=50%) 3.76 
(cardiac 3.76 
F-fluorodeoxyglucose-positron 3.76 
MeSHLatentTuberculosis 3.76 
shortly 3.76 
demented 3.76 
capability 3.75 
c) 3.75 
phenotypically 3.74 
(36%) 3.74 
appears 3.74 
point 3.74 
49) 3.73 
Technique 3.73 
PATIENTS: 3.73 
MeSHBronchogenic 3.73 
generating 3.73 
dialysis 3.73 
066 3.72 
tachycardia 3.72 
449 3.72 
hindered 3.72 
Estimation 3.72 
[CI]: 3.72 
651 3.72 
556 3.72 
letter 3.72 
105) 3.72 
=9) 3.72 
328 3.72 
blindly 3.72 
manufacturer 3.72 
S/M 3.72 
motion 3.72 
1997 3.72 
population: 3.72 
Seventy-seven 3.72 
(36% 3.72 
EGD 3.72 
sialic 3.72 
junior 3.72 
1930 3.72 
(mild 3.72 
SIZE 3.72 
WIDER 3.72 
(rCMRglc) 3.72 
positive" 3.72 
766 3.72 
897 3.72 
parahippocampal 3.72 
(127 3.72 
639 3.72 
beta-d 3.72 
MeSHPalliativeCare 3.72 
Complete 3.72 
rationale 3.71 
qualitative 3.71 
modalities 3.71 
care 3.71 
fewer 3.71 
ANOVA 3.71 
MeSHHeartDefects 3.71 
year) 3.71 
MeSHFever 3.70 
Importantly 3.70 
confused 3.70 
lacked 3.70 
nevi 3.70 
contraceptives 3.70 
need 3.70 
LNs 3.70 
(17 3.70 
postmenopausal 3.69 
actual 3.69 
choledochus 3.69 
MeSHIntraoperativePeriod 3.69 
shadow 3.68 
leads 3.68 
MeSHGeneExpressionProfiling 3.68 
stimulating 3.68 
label 3.68 
activating 3.67 
MeSHKnee 3.67 
gonadal 3.67 
Progressive 3.67 
Complementary 3.67 
159 3.67 
(25%) 3.67 
Sonographic 3.67 
loco-regional 3.67 
parenteral 3.66 
MeSHAlanineTransaminase 3.66 
partner 3.66 
elbow 3.66 
virtually 3.65 
MeSHIntestinalMucosa 3.65 
Seventy-two 3.65 
47) 3.65 
August 3.65 
(51 3.65 
trunk 3.65 
b) 3.65 
CDR 3.64 
MeSHEmergencyMedicalServices 3.64 
IU/L 3.64 
Best 3.64 
467 3.64 
MeSHSubtractionTechnique 3.64 
474 3.64 
minutes) 3.64 
lactate 3.64 
framework 3.64 
helped 3.64 
Thai 3.64 
041) 3.64 
SCC 3.64 
MeSHSexFactors 3.63 
verify 3.63 
specified 3.63 
symptomatic 3.62 
236 3.62 
034 3.62 
ideal 3.62 
recent 3.61 
ROM 3.61 
shows 3.61 
273 3.61 
continuously 3.61 
Morphological 3.61 
mg) 3.61 
Many 3.61 
6); 3.61 
thin-section 3.61 
drug-susceptibility 3.61 
older) 3.61 
MSCT 3.61 
haematology 3.61 
902 3.61 
30-50 3.61 
impossible 3.61 
variables 3.60 
(SD) 3.60 
five-year 3.60 
HYPOTHESIS: 3.60 
MeSHGenetic 3.60 
MeSHMultidrug-Resistant 3.60 
hours 3.59 
chemistry 3.59 
MeSHStatistics 3.59 
evidence 3.59 
equations 3.59 
simulations 3.59 
394 3.59 
distress 3.59 
serology 3.59 
learning 3.59 
Accordingly 3.58 
sitting 3.58 
believe 3.58 
vegetarian 3.58 
jelly 3.58 
countrywide 3.58 
(182 3.58 
INNO-LiPA 3.58 
enteroclysis 3.58 
45-54 3.58 
specificity; 3.58 
(PTT) 3.58 
17-19 3.58 
immunofluorometric 3.58 
neural-tube 3.58 
non-insulin-dependent 3.58 
nonchromosomal 3.58 
dehydroepiandrosterone 3.58 
70-90% 3.58 
included) 3.58 
MeSHS100CalciumBindingProteinbetaSubunit 3.58 
BACKGROUND/OBJECTIVE: 3.58 
1127 3.58 
week's 3.58 
fewest 3.58 
endosonographically 3.58 
reinsertion 3.58 
84%; 3.58 
60%; 3.58 
?/nMeSHColoringAgents 3.58 
Followup 3.58 
Papanicolaou-stained 3.58 
Permanente 3.58 
higher) 3.58 
person's 3.58 
(EXTEM 3.58 
[TR 3.58 
Gated 3.58 
1/31 3.58 
3-beta-D 3.58 
MeSHIntraoperativeCare 3.58 
Five 3.58 
technetium-99m 3.58 
260 3.58 
mind 3.58 
(9%) 3.57 
reports 3.57 
relapses 3.57 
assurance 3.57 
ASTRAIA 3.57 
114% 3.57 
h-hCG 3.57 
dual-echo 3.57 
Zlatkin 3.57 
CFU/ml) 3.57 
ceCT 3.57 
MSSP1 3.57 
1463 3.57 
HhCG 3.57 
100/100% 3.57 
SMG 3.57 
screening-related 3.57 
ProExC 3.57 
HyCoSy 3.57 
GM-ELISA 3.57 
6U 3.57 
1141 3.57 
oesophago-gastric 3.57 
overhand 3.57 
1321 3.57 
AFS-3D 3.57 
(serum) 3.57 
phospho-tau 3.57 
LSV 3.57 
138% 3.57 
A&E 3.57 
Patlak 3.57 
non-traversable 3.57 
non-painful 3.57 
Snyder's 3.57 
HIV-prevalent 3.57 
low-birth-weight 3.57 
nonhepatic 3.57 
(AFS-3D) 3.57 
Multiplexed 3.57 
well-dated 3.57 
(HhCG) 3.57 
fronto-maxillary 3.57 
(JOY) 3.57 
hepatopancreatobiliary 3.57 
supragastric 3.57 
SOJ 3.57 
false-positive; 3.57 
(ProEx 3.57 
bias-adjusted 3.57 
<CIN2 3.57 
1290 3.57 
WNL 3.57 
minor-grade 3.57 
ASCUS/LGSIL 3.57 
Elena 3.57 
SS-IQCODE 3.57 
(RSD) 3.57 
fundus) 3.57 
IU/mL; 3.57 
multilocularity 3.57 
narrowing) 3.57 
mg%) 3.57 
coronarography 3.57 
MCI-AD 3.57 
non-hematological 3.57 
MeSHAirAmbulances 3.57 
nonbleeding 3.57 
(INTEM) 3.57 
(R: 3.57 
(burn 3.57 
RECA 3.57 
(syndecan 3.57 
sympathoadrenal 3.57 
(addition 3.57 
(E(2)) 3.57 
amiodarone 3.57 
downregulates 3.57 
MeSHHypovolemia 3.57 
battlefield 3.57 
(A10) 3.57 
(TEGs) 3.57 
(fresh-frozen 3.57 
"G" 3.57 
Goal-directed 3.57 
1448 3.57 
two-tail) 3.57 
later: 3.57 
best-fitting 3.57 
(TLJ) 3.57 
(TLJ 3.57 
98-100%) 3.57 
(N-stage) 3.57 
21/29 3.57 
(59/60) 3.57 
non-solid 3.57 
(N0: 3.57 
advanced) 3.57 
T1/2N0 3.57 
?/nMeSHGastroscopy 3.57 
unquestionably 3.57 
pT2-4 3.57 
(16/29 3.57 
radial-type 3.57 
MeSHSesameOil 3.57 
Misdiagnosing 3.57 
Endosonography-guided 3.57 
(644 3.57 
(transabdominal 3.57 
exists; 3.57 
HBC) 3.57 
drop-arm 3.57 
abductions 3.57 
springing 3.57 
Test: 3.57 
MeSHArthroscopes 3.57 
entraps 3.57 
prohibiting 3.57 
sprint 3.57 
scapula) 3.57 
non-athletic 3.57 
short: 3.57 
1449 3.57 
(>/=18 3.57 
easy-to-handle 3.57 
(RIF)-resistant 3.57 
BMIs 3.57 
(C(T)) 3.57 
(C(T) 3.57 
324; 3.57 
unconcentrated 3.57 
cells/microl; 3.57 
Sputa 3.57 
1730 3.57 
(3/28) 3.57 
Culture-confirmed 3.57 
(n=94) 3.57 
x32 3.57 
reaction-positive 3.57 
Killing 3.57 
63/64 3.57 
respiratory) 3.57 
89-100%) 3.57 
(smear-negative 3.57 
counts: 3.57 
mobility: 3.57 
(ceCT) 3.57 
antigen's 3.57 
(97%); 3.57 
Post-test 3.57 
(1)(8)F-FDG-PET 3.57 
n=79 3.57 
unconnected 3.57 
(SLT 3.57 
phosphatidylglycerol 3.57 
(Kendall's 3.57 
tumour-marker 3.57 
cross-checked 3.57 
Univariately 3.57 
non-early 3.57 
indicate: 3.57 
242; 3.57 
(29/33) 3.57 
metastasation 3.57 
1-156 3.57 
aren't 3.57 
twice) 3.57 
Arcitumomab 3.57 
(8/43) 3.57 
McAb 3.57 
22-86 3.57 
Tochigi 3.57 
transaminase) 3.57 
1378 3.57 
Reviewers 3.57 
11-13-week 3.57 
"Advanced 3.57 
therefrom 3.57 
prescreened 3.57 
(NCR) 3.57 
7/118 3.57 
NT-multiples 3.57 
(low-risk) 3.57 
polymalformed 3.57 
analysis--a 3.57 
trisomies) 3.57 
21-screening 3.57 
4580 3.57 
cancelling 3.57 
10-49% 3.57 
logMoMs 3.57 
15-19) 3.57 
(DoE) 3.57 
20-yr 3.57 
sequencing: 3.57 
Between-pregnancy 3.57 
Log(10) 3.57 
[Correction 3.57 
4765 3.57 
namely; 3.57 
Governments 3.57 
inversions) 3.57 
(ICBDSR 3.57 
EUROCAT) 3.57 
log(10)(NT 3.57 
58-67 3.57 
11(+0)-13(+6) 3.57 
MoM' 3.57 
dom" 3.57 
2000-April 3.57 
(1:300) 3.57 
(362 3.57 
PAAP-A 3.57 
5478 3.57 
protein-A: 3.57 
24/54 3.57 
Diagnostica) 3.57 
non-ultrasound 3.57 
2006-December 3.57 
Turners 3.57 
flow: 3.57 
11/42 3.57 
(Trisomy 3.57 
1602 3.57 
FMF-certified 3.57 
PAPPA 3.57 
non-chromosome 3.57 
second-most 3.57 
NT-certified 3.57 
optionally 3.57 
Turner-Syndrome 3.57 
subglissonian 3.57 
omentalis 3.57 
redirecting 3.57 
(76%); 3.57 
incurability 3.57 
semiflexible 3.57 
swiftly 3.57 
sufficed 3.57 
VLS 3.57 
situation: 3.57 
extraorgan 3.57 
(LCU) 3.57 
(favorable 3.57 
(SVA) 3.57 
?/nMeSHDigestiveSystemDiseases 3.57 
non-resection 3.57 
(6/56 3.57 
surgically-proven 3.57 
[63%] 3.57 
Office-based 3.57 
Esaote 3.57 
15-84 3.57 
(consultant 3.57 
compared] 3.57 
(SSC) 3.57 
report; 3.57 
reviewers' 3.57 
intrasurgical 3.57 
Rotator-cuff 3.57 
In: 3.57 
interpretation; 3.57 
(16/30 3.57 
microlesions 3.57 
muscles] 3.57 
duct--the 3.57 
extrahepatically 3.57 
Yields 3.57 
choloedocholithiasis 3.57 
(SOJ) 3.57 
scanner; 3.57 
66%); 3.57 
1985-1986 3.57 
false-normal 3.57 
Accepted 3.57 
subicterus 3.57 
(sensibility 3.57 
(significance 3.57 
Male-to-female 3.57 
(isosulfan 3.57 
interrogates 3.57 
smaller; 3.57 
(124)I-PET/CT 3.57 
groin: 3.57 
nannocolloid 3.57 
Klinik 3.57 
unilateral; 3.57 
gammaprobe 3.57 
single-head 3.57 
planoepithelial 3.57 
transpired 3.57 
primary; 3.57 
Technetium-99m-labeled 3.57 
(15/17) 3.57 
genotypes: 3.57 
Trial: 3.57 
see-and-treat 3.57 
(LBA) 3.57 
Locked 3.57 
ISRCTN81678807 3.57 
(H-SIL) 3.57 
overcalled 3.57 
(28/29) 3.57 
(NILM) 3.57 
(HR)-HPV 3.57 
(clade 3.57 
MeSHTumorProteinp73 3.57 
4233 3.57 
gained) 3.57 
prediluted 3.57 
Significance-Low-Grade 3.57 
P16(INK4a) 3.57 
detrimentally 3.57 
arbitration 3.57 
(SUS) 3.57 
SIL/cervical 3.57 
acetowhitening 3.57 
"low-grade 3.57 
(3/29 3.57 
(6/29 3.57 
testing" 3.57 
koilocytotic 3.57 
2192 3.57 
Assay) 3.57 
exploded 3.57 
NLM 3.57 
(LSIL); 3.57 
<1) 3.57 
disease-positive 3.57 
(RLU/CO) 3.57 
HPV-testing 3.57 
treat; 3.57 
2309 3.57 
PCR-DNA 3.57 
BIRC5 3.57 
discordant: 3.57 
65-70% 3.57 
51-73 3.57 
19-67 3.57 
(14%; 3.57 
=CIN2) 3.57 
single-type 3.57 
euro5 3.57 
(colposcopy 3.57 
consensus) 3.57 
smear? 3.57 
39/92 3.57 
nonadvanced 3.57 
(TIS) 3.57 
MeSHStudentHealthServices 3.57 
referral-based 3.57 
(PPVs) 3.57 
(18/43) 3.57 
verbally 3.57 
(n=172) 3.57 
(n=106) 3.57 
4799 3.57 
spanish 3.57 
82/83 3.57 
(DSM) 3.57 
(dementia 3.57 
education: 3.57 
(407 3.57 
740) 3.57 
MeSHReading 3.57 
partner) 3.57 
French-language 3.57 
(IQCODE-SF) 3.57 
PsychINFO 3.57 
24/30) 3.57 
Syndrome: 3.57 
rule" 3.57 
?/nMeSHDementia 3.57 
94-100%) 3.57 
aphasia: 3.57 
(DMI) 3.57 
23-48 3.57 
10(-3)mm(2)/s) 3.57 
)mm(2)/s) 3.57 
interreader 3.57 
(kappa=1 3.57 
coil) 3.57 
STARD 3.57 
re-analyzed 3.57 
observers) 3.57 
PAPER 3.57 
(n=83) 3.57 
accuracy? 3.57 
shadow) 3.57 
infiltrating) 3.57 
intestine) 3.57 
MeSH"DouglasPouch" 3.57 
(TVU) 3.57 
(83%); 3.57 
85-100% 3.57 
88); 3.57 
Hypointense 3.57 
ovaries: 3.57 
15/46 3.57 
(LHR) 3.57 
(HyCoSy) 3.57 
Habib 3.57 
Duh 3.57 
(IOTA) 3.57 
concordances 3.57 
Mangiagalli 3.57 
1689 3.57 
1833 3.57 
>or=100 3.57 
CVE 3.57 
MeSHC-Peptide 3.57 
(Tl-201) 3.57 
(123I-BMIPP) 3.57 
=75%) 3.57 
(+/-11) 3.57 
3-minute 3.57 
Doppler-derived 3.57 
beta-blockade 3.57 
[(1)(8)F]fluorodeoxyglucose 3.57 
(E4 3.57 
fronto-temporo-parietal 3.57 
Initiative) 3.57 
Fritz 3.57 
observer-independent 3.57 
Osaki-Tajiri 3.57 
pseudodementia 3.57 
non-amnestic 3.57 
amygdala) 3.57 
(PCR-ELISA) 3.57 
organism's 3.57 
MeSHEgo 3.57 
(beta-glucan 3.57 
(GM-EIA) 3.57 
test-based 3.57 
recipients) 3.57 
galactomannan: 3.57 
(748 3.57 
(CT)-based 3.57 
haemato-oncological 3.57 
(galactomannan) 3.57 
(25/28) 3.57 
definitions) 3.57 
(NSHL) 3.57 
neutropenia: 3.57 
500/mm(3) 3.57 
GM-negative 3.57 
clinical/radiological 3.57 
MeSHVentilator-Associated 3.57 
Saint-Louis 3.57 
1-108 3.57 
fungaemia 3.57 
293T 3.57 
prevents 3.56 
(OR 3.56 
amplified 3.56 
justification 3.56 
trainees 3.56 
uni- 3.56 
curability 3.56 
948 3.56 
risk" 3.56 
Australian 3.56 
MeSHPrimaryHealthCare 3.56 
208 3.55 
methylation 3.55 
synthase 3.55 
retroperitoneum 3.55 
Real-time 3.55 
selected 3.55 
FE 3.54 
placebo-controlled 3.54 
revascularization 3.54 
b 3.54 
(78%) 3.53 
37%) 3.53 
unsuitable 3.53 
425 3.53 
Frank 3.52 
oestrogen 3.52 
directions 3.52 
3rd 3.52 
undertook 3.52 
dosage 3.52 
ask 3.52 
disappearance 3.52 
progesterone 3.52 
MeSHDigestiveSystemNeoplasms 3.52 
(MTB) 3.51 
ease 3.51 
pathologist 3.51 
entry 3.51 
fund 3.51 
MeSHMultipleTrauma 3.50 
>or=1 3.50 
choledocholithiasis 3.50 
microg/L 3.50 
118) 3.50 
(MODS) 3.50 
Scans 3.50 
nonetheless 3.50 
747 3.50 
ALREADY 3.50 
(p< 3.50 
MeSHTraffic 3.50 
MeSHDermatitis 3.50 
maneuver 3.50 
transmitted 3.49 
today 3.49 
(74%) 3.49 
MeSHPositron-EmissionTomography 3.49 
lead 3.49 
pH 3.49 
veins 3.49 
MRIs 3.49 
MeSHBursa 3.49 
resection) 3.49 
0001; 3.49 
484 3.49 
economic 3.48 
original 3.48 
predispose 3.47 
compares 3.47 
justify 3.47 
perinatal 3.47 
rate) 3.47 
criteria: 3.47 
mere 3.47 
3; 3.47 
RAS 3.47 
successive 3.47 
demanding 3.47 
Operation 3.47 
vulnerable 3.47 
methodology 3.46 
Sixty-nine 3.46 
(GI) 3.46 
961 3.46 
MeSHOsteoarthritis 3.46 
characterization 3.46 
MeSHClinicalLaboratoryTechniques 3.45 
reciprocal 3.45 
converting 3.45 
Fifteen 3.45 
Technology 3.45 
25+ 3.45 
recommended 3.44 
his 3.44 
Hospital 3.44 
Motion 3.44 
MeSHMorphine 3.44 
Gy) 3.44 
doing 3.44 
gauge 3.44 
MeSHColectomy 3.44 
81) 3.44 
AFB 3.44 
palliation 3.44 
suspicion 3.44 
different 3.43 
Multivariate 3.43 
volunteers 3.43 
geographic 3.43 
statin 3.43 
NOS 3.43 
increasingly 3.42 
MeSHRenalDialysis 3.42 
(GA 3.42 
P; 3.42 
PlGF 3.41 
articular-sided 3.41 
non-survivors 3.41 
three-stage 3.41 
ng/mg 3.41 
RIF-resistant 3.41 
cytology) 3.41 
non-fatal 3.41 
inspired 3.41 
different: 3.41 
Metalloprotease 3.41 
MeSHPerinatalCare 3.41 
auspices 3.41 
forms: 3.41 
venipuncture 3.41 
correction) 3.41 
good-quality 3.41 
pattern; 3.41 
eight; 3.41 
delivery) 3.41 
14-21 3.41 
unmatched 3.41 
catchment 3.41 
abstraction 3.41 
MeSHLimitofDetection 3.41 
pyruvic 3.41 
probe) 3.41 
(BE) 3.41 
LVH 3.41 
EMC 3.41 
possible) 3.41 
(1-5) 3.41 
092) 3.41 
Pentax 3.41 
(187 3.41 
3-48 3.41 
203) 3.41 
intrinsically 3.41 
positivity) 3.41 
caveat 3.41 
TR/TE 3.41 
including 3.41 
Finally 3.41 
518 3.41 
MeSHDouble-BlindMethod 3.41 
Tyrosine 3.41 
parous 3.41 
repairs 3.41 
sulfate 3.41 
birthweight 3.41 
(N) 3.41 
Norwegian 3.41 
MeSHIntensiveCareUnits 3.41 
MeSHInsemination 3.41 
scan) 3.41 
Strict 3.41 
453 3.41 
others 3.41 
MeSHGastricMucosa 3.41 
Size 3.41 
Gynaecology 3.40 
rotate 3.40 
rCMRglc 3.40 
minutes; 3.40 
646 3.40 
postinjection 3.40 
low-resource 3.40 
erroneously 3.40 
optimistic 3.40 
practicable 3.40 
rifampicin-resistant 3.40 
sonography; 3.40 
gradient-echo 3.40 
cellulitis 3.40 
DURATION: 3.40 
chi-squared 3.40 
anechoic 3.40 
UNLABELLED: 3.40 
rater 3.40 
undergone 3.40 
shift 3.39 
Thirty-six 3.39 
components 3.39 
smaller 3.39 
retrieve 3.38 
exercise 3.38 
thickened 3.38 
MeSHDysmenorrhea 3.38 
deteriorated 3.38 
probably 3.38 
matching 3.38 
Active 3.38 
create 3.38 
axial 3.37 
el 3.37 
palliative 3.37 
2009 3.37 
013) 3.37 
MeSHHealthServices 3.37 
anaesthesia 3.36 
MeSHFollow-UpStudies 3.36 
text 3.36 
deterioration 3.36 
halo 3.36 
Basel 3.36 
DIC 3.35 
curvature 3.35 
emotional 3.35 
Menstrual 3.35 
Prevalence 3.35 
recorded 3.35 
Generally 3.35 
298 3.35 
allowing 3.35 
maintaining 3.35 
Whereas 3.35 
Oncology 3.34 
stress 3.34 
MeSHEmergencyService 3.34 
16th 3.34 
(RIF) 3.34 
were: 3.34 
MeSHCerebral 3.34 
highlighted 3.34 
lobes 3.34 
MeSHImmunosuppressiveAgents 3.34 
curatively 3.34 
HPV-associated 3.34 
confounded 3.34 
biases 3.34 
Coma 3.34 
MTBDR 3.34 
534 3.34 
assay) 3.34 
459 3.34 
08% 3.33 
Karyotype 3.33 
6-19 3.33 
264 3.33 
PET 3.33 
most 3.33 
colour 3.32 
keeping 3.32 
choices 3.32 
MeSHSurgery 3.32 
(89%) 3.32 
multimodal 3.32 
channel 3.32 
hematopoietic 3.32 
injection 3.31 
comprehensive 3.31 
ambulatory 3.31 
MeSHGenitalDiseases 3.31 
MeSHReferralandConsultation 3.31 
deal 3.31 
concluded 3.31 
Stage 3.31 
1991 3.31 
Young 3.31 
connection 3.30 
forty-seven 3.30 
Hannover 3.30 
sign) 3.30 
(preoperative 3.30 
(LEEP) 3.30 
MeSHAmnesia 3.30 
5/14 3.30 
4/12 3.30 
TaqMan 3.30 
861 3.30 
(Fisher 3.30 
980 3.30 
titre 3.30 
obstructed 3.30 
fear 3.30 
5' 3.30 
lift 3.29 
MeSHContrastMedia 3.29 
alanine 3.29 
precisely 3.29 
Twenty-one 3.29 
Careful 3.29 
MeSHCadaver 3.29 
MeSHCellNucleus 3.28 
Concord 3.28 
staff 3.28 
scales 3.28 
technetium 3.28 
Following 3.28 
force 3.27 
memory 3.27 
MeSHNonparametric 3.27 
preparation 3.27 
contained 3.27 
073 3.26 
434 3.26 
MeSHAustria 3.26 
625 3.26 
546 3.26 
profit 3.26 
median: 3.26 
(= 3.26 
0/8 3.26 
delay 3.26 
64) 3.26 
Errors 3.26 
cTnT 3.26 
"early" 3.26 
Ulm 3.26 
intrarater 3.26 
labels 3.26 
LVEF 3.26 
Amplicor 3.26 
electron-beam 3.26 
MeSHTraumatic 3.26 
33%; 3.26 
(versus 3.26 
delta-NT 3.26 
[AFP] 3.26 
MeSHNeuraminidase 3.26 
attainable 3.26 
high-order 3.26 
(3/4) 3.26 
counterbalance 3.26 
pregnancy? 3.26 
trisomy-18 3.26 
MeSHPlacentalInsufficiency 3.26 
Chiang 3.26 
MeSHHydantoins 3.26 
exclusions 3.26 
preselected 3.26 
reconsideration 3.26 
Biparietal 3.26 
MeSHEnzymeStability 3.26 
preoperatively; 3.26 
presumption 3.26 
1/300 3.26 
Iasi 3.26 
post-contrast 3.26 
stricter 3.26 
14/16 3.26 
excellence 3.26 
turn-around 3.26 
CA72-4 3.26 
Frontomaxillary 3.26 
Edition 3.26 
preterm 3.26 
Thirty-one 3.26 
muscles 3.25 
help 3.25 
Pancreas 3.25 
U/l 3.25 
RATIONALE 3.24 
Aug 3.24 
manage 3.24 
permitted 3.24 
patency 3.24 
</= 3.24 
39) 3.24 
pseudocysts 3.24 
MeSHNephrectomy 3.24 
Asthma 3.24 
complementary 3.24 
age-adjusted 3.22 
transcriptase 3.22 
Circulating 3.22 
N0 3.22 
MeSHFamily 3.22 
age-specific 3.22 
valuations 3.22 
Methylation 3.21 
necessitating 3.21 
grew 3.21 
WITH 3.21 
borne 3.21 
Sequences 3.21 
draw 3.21 
626 3.21 
second-generation 3.21 
insufficiently 3.21 
712 3.21 
malignancies: 3.21 
N-staging 3.21 
MeSHElbowJoint 3.21 
fifty-six 3.21 
paucibacillary 3.21 
<or=1 3.21 
898 3.21 
appearing 3.20 
elective 3.20 
phenotypical 3.20 
FIGO 3.20 
277 3.20 
known 3.20 
retrieved 3.20 
adopting 3.19 
MeSHConfoundingFactors(Epidemiology) 3.19 
Johns 3.19 
bcl-2 3.19 
expanding 3.19 
LDH 3.18 
except 3.18 
Special 3.18 
amyloid 3.18 
Interestingly 3.18 
MeSHNeoadjuvantTherapy 3.18 
dynamic 3.18 
multidisciplinary 3.17 
room 3.17 
acquisition 3.17 
(21%) 3.17 
SP 3.17 
equally 3.17 
perfect 3.17 
mesenteric 3.17 
372 3.17 
336 3.17 
There 3.17 
IS6110 3.17 
special 3.16 
(with 3.16 
311 3.16 
laparoscopically 3.16 
Chain 3.16 
light 3.15 
cognition 3.15 
kinds 3.15 
opened 3.15 
MeSHOvariectomy 3.15 
standards 3.15 
instead 3.15 
collecting 3.15 
MeSHGeneticPredispositiontoDisease 3.15 
Secondary 3.15 
MeSHEdema 3.14 
MeSHPapillomavirusVaccines 3.14 
herpes 3.14 
disruption 3.14 
sudden 3.14 
mild 3.13 
reviewers 3.13 
two-thirds 3.13 
scintigraphy 3.13 
(15% 3.13 
technology 3.13 
unresponsive 3.12 
neurosurgical 3.12 
palate 3.12 
CBDE 3.12 
faced 3.12 
proliferations 3.12 
latex 3.12 
MeSHDizygotic 3.12 
Curative 3.12 
computational 3.12 
0009 3.12 
n=8) 3.12 
953 3.12 
2-year 3.12 
disease) 3.12 
MeSHEpithelium 3.12 
therapeutical 3.12 
right-side 3.12 
155 3.12 
CTA 3.11 
nonsmokers 3.11 
BMT 3.11 
MPI 3.11 
uniformity 3.11 
clinician's 3.11 
672 3.11 
938 3.11 
(22%) 3.11 
week) 3.11 
418 3.11 
challenging 3.11 
T2*-weighted 3.11 
videotapes 3.11 
images; 3.11 
pre-defined 3.11 
convexity 3.11 
Unenhanced 3.11 
ultrasensitive 3.11 
unscreened 3.11 
Supervised 3.11 
radioimmunoassays 3.11 
positive' 3.11 
MeSHMathematicalComputing 3.11 
mellitus: 3.11 
consanguinity 3.11 
smoothed 3.11 
18-19 3.11 
(6/7) 3.11 
inter-assay 3.11 
MeSHGlasgowComaScale 3.11 
coincidentally 3.11 
pretherapy 3.11 
molecular-based 3.11 
Relapses 3.11 
(sensitivity: 3.11 
Used 3.11 
Intergroup 3.11 
1999-2004 3.11 
first-stage 3.11 
(CTA) 3.11 
061) 3.11 
wholly 3.11 
?/nMeSHCervicalIntraepithelialNeoplasia 3.11 
Bangkok 3.11 
Hippocampal 3.11 
MeSHTunicaMedia 3.11 
Second-look 3.11 
209) 3.11 
MeSHCellulitis 3.11 
4-26 3.11 
071) 3.11 
mucosa) 3.11 
entities 3.10 
259 3.10 
294 3.10 
RapidTEG 3.10 
function-related 3.10 
99mTc-phytate 3.10 
GJB2 3.10 
S-CT 3.10 
(lesion 3.10 
FOBT 3.10 
LHBT 3.10 
prefracture 3.10 
CIMT 3.10 
</=35 3.10 
kg(-)(1) 3.10 
urine-based 3.10 
SLN's 3.10 
Ecuadorian 3.10 
deep-infiltrating 3.10 
susceptibility-weighted 3.10 
rectouterine 3.10 
FAQ 3.10 
NSHL 3.10 
pathCR 3.10 
parameter) 3.10 
955) 3.10 
turn-around-time 3.10 
(curative 3.10 
arcitumomab 3.10 
1048 3.10 
acid-specific 3.10 
laterolateral 3.10 
prognosis) 3.10 
proton-density- 3.10 
one-shot 3.10 
nonsuspicious 3.10 
HC2-positive 3.10 
AGCUS 3.10 
HC-2 3.10 
log(10)) 3.10 
TFPI2 3.10 
17-24 3.10 
uterovesical 3.10 
rectosigmoidal 3.10 
CUSUM 3.10 
99mTc-methoxyisobutylisonitrile 3.10 
123I-BMIPP 3.10 
E4+ 3.10 
(SSV) 3.10 
plasmin-antiplasmin 3.10 
'moderate' 3.10 
participants; 3.10 
(VHA) 3.10 
(ODN) 3.10 
(2-6) 3.10 
hand-searched 3.10 
trialists 3.10 
lung" 3.10 
ng/mL] 3.10 
(LY30) 3.10 
(2-5) 3.10 
Hypocoagulability 3.10 
MeSHOrganizationalInnovation 3.10 
Proactive 3.10 
(MTP) 3.10 
MRTG 3.10 
tightened 3.10 
(15th 3.10 
(urine 3.10 
(Glasgow 3.10 
TLJ 3.10 
thoracic/lumbar 3.10 
x-rays: 3.10 
(MDT) 3.10 
under-treated 3.10 
(poorly 3.10 
echo-endoscope 3.10 
(arterial 3.10 
undifferentiated-type 3.10 
(HPE) 3.10 
Bundang 3.10 
ultrasound-fine 3.10 
(submucosa) 3.10 
SM2 3.10 
(pathCR) 3.10 
cardia: 3.10 
(17/17) 3.10 
nonrepresentative 3.10 
586) 3.10 
pylorus) 3.10 
mL/kg) 3.10 
(SpR 3.10 
(spiral 3.10 
furnishes 3.10 
arc) 3.10 
Mansfield 3.10 
pathomechanical 3.10 
recognised: 3.10 
posterior-superior 3.10 
symptoms? 3.10 
[Kim 3.10 
audible 3.10 
attention; 3.10 
tear? 3.10 
(strength 3.10 
54-month 3.10 
lengthens 3.10 
Anterosuperior 3.10 
lesion? 3.10 
studies' 3.10 
designers 3.10 
(labral 3.10 
outstretched 3.10 
(296 3.10 
(441 3.10 
July-September 3.10 
7-29) 3.10 
Lifescience) 3.10 
(11/18) 3.10 
234; 3.10 
beset 3.10 
Andersen 3.10 
launching 3.10 
exhaustively 3.10 
LVMI) 3.10 
making? 3.10 
[CA] 3.10 
LLT 3.10 
Carcino-embryonic 3.10 
surmounted 3.10 
(Ref 3.10 
CA72-4) 3.10 
22-87 3.10 
three-monthly 3.10 
six-monthly 3.10 
(ovary 3.10 
(n=82) 3.10 
concentration: 3.10 
(GICA) 3.10 
1358 3.10 
salvageable 3.10 
(3/21) 3.10 
postrecurrence 3.10 
recidivation 3.10 
employed) 3.10 
signalled 3.10 
(n=105) 3.10 
(high-risk) 3.10 
1257 3.10 
postive 3.10 
MeSHNail-PatellaSyndrome 3.10 
(weeks) 3.10 
multifrequency 3.10 
(kg/m(2)) 3.10 
(PGH) 3.10 
bioavailable 3.10 
3197 3.10 
brackets) 3.10 
20/37 3.10 
misidentifying 3.10 
screening-positive 3.10 
2246 3.10 
(12/19) 3.10 
$77 3.10 
13(6) 3.10 
19(th) 3.10 
indications-- 3.10 
Risk-benefit 3.10 
"same 3.10 
?/nMeSHADAMProteins 3.10 
diagnostic] 3.10 
transitioning 3.10 
precociously 3.10 
ecographic 3.10 
under-estimate 3.10 
initially; 3.10 
Inception 3.10 
(ERCP; 3.10 
enteroenterostomy 3.10 
Multi-detector 3.10 
(HBP) 3.10 
SVA 3.10 
94%-98% 3.10 
readers' 3.10 
hook-shaped 3.10 
rupture] 3.10 
gradient-recalled 3.10 
retrospectivly 3.10 
paracoronal 3.10 
(LHBT) 3.10 
(22/24) 3.10 
Bigliani 3.10 
(subacromial 3.10 
tear] 3.10 
tendonopathy 3.10 
frayed 3.10 
positive); 3.10 
joint's 3.10 
gap) 3.10 
(8/30 3.10 
registered; 3.10 
Fundamentally 3.10 
(n=59) 3.10 
1264 3.10 
(c-index 3.10 
decade) 3.10 
31/31 3.10 
(wound 3.10 
disection 3.10 
(technetium-99 3.10 
Wiesbaden 3.10 
lower-third 3.10 
(ILND) 3.10 
(pre-operative 3.10 
posteriori 3.10 
Patente 3.10 
Blue-V) 3.10 
"older" 3.10 
subcategorization 3.10 
PGMY09/11 3.10 
predecessor 3.10 
technologies: 3.10 
cost? 3.10 
rinses 3.10 
cytometry] 3.10 
centres: 3.10 
(CGIN) 3.10 
Veneto 3.10 
HSIL" 3.10 
Madison 3.10 
recalls 3.10 
(biopsy) 3.10 
noncervical 3.10 
polymer-based 3.10 
Brazil's 3.10 
(henceforth 3.10 
behavior: 3.10 
colposcopy? 3.10 
Heading 3.10 
pap- 3.10 
5/97 3.10 
E7) 3.10 
(private 3.10 
(ASM) 3.10 
(AMP) 3.10 
Geminin 3.10 
(ICERs) 3.10 
suppliers 3.10 
moderate/strong 3.10 
DNA; 3.10 
(follow-up) 3.10 
ViraPap 3.10 
digene 3.10 
delay: 3.10 
MeSHDeath-AssociatedProteinKinases 3.10 
System: 3.10 
Interpretive 3.10 
update] 3.10 
item-total 3.10 
Leukoaraiosis 3.10 
(DSM-IV) 3.10 
(IRT) 3.10 
(urban 3.10 
5/77 3.10 
IQCODE-SF 3.10 
Conceptual 3.10 
Hawai'i 3.10 
abdominus 3.10 
(25/25) 3.10 
Dataset 3.10 
power-Doppler 3.10 
surgicopathological 3.10 
findings? 3.10 
high-spatial-resolution 3.10 
(project 3.10 
50/59 3.10 
[with 3.10 
ligaments: 3.10 
22/46 3.10 
15-59 3.10 
postmenopausal) 3.10 
ureters; 3.10 
equating 3.10 
(CDE) 3.10 
(TRS) 3.10 
(ETT) 3.10 
(4/22) 3.10 
nonuremic 3.10 
(CIMT) 3.10 
(QCA) 3.10 
arteriographic 3.10 
prerenal 3.10 
angor 3.10 
cerebro-vascular 3.10 
AD-specific 3.10 
two-factor 3.10 
29]) 3.10 
NEUROSTAT 3.10 
(18)F-2-fluoro-2-deoxy-D-glucose 3.10 
MeSHTarsalBones 3.10 
(n=150) 3.10 
colleagues' 3.10 
Nobel 3.10 
MeSHNobelPrize 3.10 
[ELISA] 3.10 
12/98 3.10 
time-PCR 3.10 
(1->3)-beta-D-glucan 3.10 
(optical 3.10 
candidaemia 3.10 
(>or=6 3.10 
sulfotransferases 3.10 
digestive 3.10 
Bill 3.10 
adherent 3.10 
MeSHProteinBinding 3.10 
MeSHImageInterpretation 3.10 
54%) 3.10 
(76% 3.10 
194 3.09 
176 3.09 
fibrinolytic 3.09 
reacted 3.09 
bovine 3.09 
tried 3.09 
MeSHDevelopingCountries 3.09 
revealing 3.09 
follows 3.09 
Abnormalities 3.09 
fluids 3.09 
novo 3.08 
-31 3.08 
Rapid 3.08 
definitely 3.07 
417 3.07 
MeSHHabitual 3.07 
luteal 3.07 
67%) 3.07 
Gynecology 3.06 
serving 3.06 
requirement 3.06 
(low 3.06 
discomfort 3.06 
serological 3.06 
aspergillus 3.06 
high-throughput 3.06 
18th 3.06 
SOURCES: 3.06 
population) 3.06 
laxity 3.05 
468 3.05 
multislice 3.05 
launch 3.05 
hypoplastic 3.05 
progressively 3.05 
why 3.05 
intraperitoneal 3.05 
(60 3.05 
46) 3.04 
patients' 3.04 
dehydrogenase 3.04 
predictable 3.04 
estradiol 3.04 
heavily 3.04 
chromatin 3.04 
paucity 3.04 
unremarkable 3.04 
surgery) 3.04 
indicators 3.04 
Nonparametric 3.04 
GP 3.04 
143 3.03 
labeling 3.03 
track 3.03 
existed 3.03 
sentinel-node 3.03 
642 3.03 
nondilated 3.03 
imprecise 3.03 
recurrence: 3.03 
transversal 3.03 
802 3.03 
Two-hundred 3.03 
managing 3.02 
consisted 3.02 
clinicians 3.02 
MeSHBilirubin 3.02 
lengths 3.02 
medium 3.02 
delineation 3.02 
MeSHExerciseTherapy 3.02 
Less 3.02 
T4 3.02 
side 3.01 
glycoprotein 3.01 
Public 3.01 
cooperation 3.01 
Very 3.01 
gall-bladder 3.01 
descending 3.01 
ileal 3.01 
extreme 3.01 
1999 3.01 
157 3.01 
choledocholithiasis: 3.01 
capsule 3.01 
leiomyoma 3.00 
intensity 3.00 
[1 3.00 
represent 3.00 
umbilical 3.00 
164 3.00 
>2 3.00 
MeSHSurgicalInstruments 2.99 
Plain 2.99 
jaundice 2.99 
efficacy 2.99 
Forty-nine 2.99 
062 2.99 
MeSHErythrocyteTransfusion 2.99 
Eighty-four 2.99 
378 2.99 
MeSHDirect 2.99 
while 2.99 
demonstration 2.99 
strengthening 2.98 
genotypic 2.98 
output 2.98 
foetal 2.98 
028 2.98 
partly 2.98 
actuarial 2.97 
E' 2.97 
boards 2.97 
nontuberculosis 2.97 
10-11 2.97 
positives) 2.97 
group); 2.97 
(n=22) 2.97 
lighter 2.97 
(primarily 2.97 
of) 2.97 
MeSHInformationSystems 2.97 
(26) 2.97 
Thanks 2.97 
scapulohumeral 2.97 
?/nMeSHAntibiotics 2.97 
177) 2.97 
239) 2.97 
Correlative 2.97 
(PET)/computed 2.97 
(male/female 2.97 
spares 2.97 
uncinate 2.97 
injury] 2.97 
ninety-eight 2.97 
hypointensity 2.97 
MeSHMyocardialContraction 2.97 
stem-cell 2.97 
Blunt 2.97 
tumours) 2.97 
4/13 2.97 
Rise 2.97 
allogeneic 2.97 
(71%) 2.97 
introduced 2.97 
deposition 2.96 
continuation 2.96 
endoscopist 2.96 
Genotyping 2.96 
practical 2.96 
Clinically 2.96 
stones; 2.96 
Network 2.96 
achieve 2.95 
radiocolloid 2.95 
aminotransferase 2.95 
18-month 2.95 
playing 2.95 
(PTC) 2.95 
Thailand 2.94 
reduces 2.94 
attenuation 2.94 
despite 2.94 
statistics 2.94 
ESD 2.94 
justifying 2.94 
same-day 2.94 
140) 2.94 
SYNTHESIS: 2.94 
comply 2.94 
MeSHApolipoproteinE4 2.94 
8-15 2.94 
811 2.94 
epsilon4 2.94 
583 2.94 
(mean 2.93 
localized 2.93 
kg 2.93 
indicative 2.93 
CONCLUSION(S): 2.93 
virtual 2.93 
expand 2.92 
representative 2.92 
MeSHSingle-Photon 2.92 
Earlier 2.92 
four-year 2.92 
datasets 2.92 
patients); 2.92 
incurable 2.92 
(either 2.92 
abdominoperineal 2.92 
sonography] 2.92 
antrum 2.92 
73%) 2.92 
MeSHPancreas 2.92 
stronger 2.92 
(60%) 2.91 
(6) 2.91 
starting 2.91 
(51% 2.91 
absence 2.91 
formal 2.90 
parametric 2.90 
few 2.90 
MeSHCytogenetics 2.90 
choledocholithotomy 2.90 
cloned 2.90 
MeSHSepsis 2.90 
grade 2.90 
012 2.90 
MeSHRetroperitonealNeoplasms 2.90 
fascia 2.90 
mainly 2.90 
demographic 2.90 
publications 2.90 
colony 2.90 
views 2.89 
perigastric 2.89 
breakdown 2.89 
width 2.89 
rear 2.89 
Referral 2.89 
Oncol 2.89 
objective 2.89 
MeSHJapan 2.89 
degrees 2.88 
introduce 2.88 
(22% 2.88 
464 2.88 
130 2.88 
Organization 2.88 
(37 2.88 
nasopharyngeal 2.87 
MeSH20thCentury 2.87 
Portal 2.87 
incubated 2.87 
males; 2.87 
MeSHHysterosalpingography 2.87 
MeSHAngioplasty 2.87 
cholestasis 2.87 
MeSHDilatation 2.87 
battery 2.87 
340 2.87 
21; 2.87 
227 2.87 
Trials 2.87 
SD) 2.87 
basic 2.86 
antigen) 2.86 
emission 2.86 
kind 2.85 
MODS 2.85 
medicolegal 2.85 
MeSHPregnancyTrimesters 2.85 
737 2.85 
forty-three 2.85 
SGOT 2.85 
MeSHCzechRepublic 2.85 
691 2.85 
noting 2.85 
hazard 2.85 
disease-free 2.85 
Coagulation 2.85 
attitudes 2.85 
passing 2.85 
MeSHAged 2.85 
weakness 2.85 
Unlike 2.84 
cone 2.84 
(72% 2.84 
consolidation 2.84 
MeSHPatientCareTeam 2.84 
nodes; 2.84 
suspensions 2.84 
bladder: 2.84 
167 2.84 
Netherlands 2.84 
single-photon 2.84 
MeSHHippocampus 2.84 
346 2.84 
431 2.84 
Forty-four 2.84 
MeSHThailand 2.84 
malformations 2.84 
lists 2.84 
KK 2.84 
(cutoff 2.84 
(G) 2.84 
intratendinous 2.84 
triaged 2.84 
AUCs 2.84 
interrogated 2.84 
advantages: 2.84 
NICE 2.84 
urged 2.84 
Peer 2.84 
index: 2.84 
caught 2.84 
withholding 2.84 
eighty-six 2.84 
(pancreatic 2.84 
(active 2.84 
(sputum 2.84 
expectorated 2.84 
(132 2.84 
(hepatic 2.84 
embalmed 2.84 
(STIR) 2.84 
jaundice) 2.84 
Groningen 2.84 
cervicitis 2.84 
Technologies 2.84 
AD; 2.84 
DOR 2.84 
(phase 2.84 
264) 2.84 
essentially 2.83 
co-infection 2.83 
salvage 2.83 
102 2.83 
MeSHQualityControl 2.83 
038 2.83 
(99m)Tc 2.83 
ASA 2.83 
eighteen 2.82 
MeSHAssisted 2.82 
318 2.82 
MRC 2.82 
operate 2.82 
1985 2.82 
controversial 2.82 
Ziehl-Neelsen 2.82 
progression 2.82 
Chronic 2.82 
bilirubin 2.81 
2nd 2.81 
electrophoresis 2.81 
MeSHBrainMapping 2.80 
thyroidectomy 2.80 
oocyte 2.80 
(diameter 2.80 
performed: 2.80 
establishes 2.80 
Retrospectively 2.80 
(first 2.80 
State 2.79 
distance 2.79 
Descriptive 2.79 
MeSHElectrocardiography 2.79 
MeSHOpportunisticInfections 2.79 
continuity 2.79 
376 2.79 
32; 2.79 
MeSHChoristoma 2.79 
appendix 2.79 
quantitatively 2.79 
exhibited 2.79 
gross 2.78 
Previous 2.78 
atherosclerotic 2.78 
Larger 2.78 
optimum 2.78 
Reflex 2.78 
intracranial 2.78 
pain) 2.78 
brought 2.78 
metabolism 2.78 
applicable 2.77 
0009) 2.77 
intermediate-risk 2.77 
T1/T2 2.77 
imaging] 2.77 
choledocholithiasis; 2.77 
chromogenic 2.77 
stenosis) 2.77 
risk' 2.77 
673 2.77 
946 2.77 
hypothesise 2.77 
58; 2.77 
MeSHClinicalProtocols 2.77 
045 2.77 
resources 2.77 
ending 2.77 
released 2.77 
65) 2.76 
(39 2.76 
rejection 2.76 
lasted 2.76 
(52%) 2.76 
in-vitro 2.75 
244 2.75 
(64% 2.75 
L3 2.75 
focused 2.75 
suboptimal 2.75 
203 2.75 
Change 2.75 
dramatic 2.74 
dilatation 2.74 
MeSHPathology 2.74 
72) 2.74 
radically 2.74 
MeSHFunctionalLaterality 2.74 
MeSHOrganometallicCompounds 2.74 
8-10 2.74 
death) 2.73 
MeSHLondon 2.73 
impending 2.73 
498 2.73 
MeSHStomachUlcer 2.73 
Evaluating 2.73 
Mary 2.73 
triple-screening 2.73 
logMoM 2.73 
QCA 2.73 
florbetapir 2.73 
non-MT 2.73 
imagistic 2.73 
REU 2.73 
short-lasting 2.73 
20-minute 2.73 
LAGC 2.73 
large-to-massive 2.73 
Rh-positive 2.73 
E6*I 2.73 
p73 2.73 
CCTs 2.73 
(288 2.73 
852) 2.73 
differentiated-type 2.73 
pericancerous 2.73 
SM1 2.73 
supraspinatous 2.73 
bioaerosols 2.73 
flotation 2.73 
1279 2.73 
non-therapeutic 2.73 
Arzobispo 2.73 
LR-HPV 2.73 
(Ptrend 2.73 
reimbursements 2.73 
ARRAY 2.73 
=CIN2 2.73 
L1+ 2.73 
NISH 2.73 
amplimers 2.73 
IIIR 2.73 
nonovarian 2.73 
WMH 2.73 
"possible" 2.73 
"proven" 2.73 
immunoabsorbent 2.73 
Polytrauma 2.73 
MeSHRegionalMedicalPrograms 2.73 
Ill) 2.73 
(>16 2.73 
K-time 2.73 
(ELT) 2.73 
(NICU) 2.73 
haemorrhage: 2.73 
[PT] 2.73 
hematocrit) 2.73 
(metabolic 2.73 
A10) 2.73 
MeSHAfghanCampaign2001- 2.73 
MeSHBlastInjuries 2.73 
visco-elastic 2.73 
mean+/-SEM 2.73 
Fresh-frozen 2.73 
triple-X 2.73 
(hCG)] 2.73 
2404 2.73 
23/32 2.73 
expect? 2.73 
(blinded 2.73 
(LAGC) 2.73 
surgeon; 2.73 
(DFS; 2.73 
EUS-FNAs 2.73 
tumour's 2.73 
Operable 2.73 
corpus: 2.73 
first-tier 2.73 
echoprobe 2.73 
T1sm 2.73 
MeSHProctoscopes 2.73 
non-specialist 2.73 
Hawkins' 2.73 
?/nMeSHArthroscopy 2.73 
(dynamic) 2.73 
Cinahl 2.73 
(horizontal 2.73 
bursa; 2.73 
labrum: 2.73 
intratester 2.73 
(hand 2.73 
reliability) 2.73 
cocking 2.73 
(Adjusted 2.73 
MeSH"PatientsRooms" 2.73 
sublabral 2.73 
(subluxation 2.73 
Melinda 2.73 
fluids: 2.73 
T-SPOT-TB 2.73 
MeSHReagentStrips 2.73 
tuberculosis-positive 2.73 
(NRL) 2.73 
1238 2.73 
WORDS)/nMeSHAneuploidy 2.73 
important? 2.73 
nonstandardized 2.73 
marker-positive 2.73 
matched-pairs 2.73 
[96 2.73 
(specificity: 2.73 
(17/32) 2.73 
(First 2.73 
enemas 2.73 
(CEA-Scan 2.73 
LIA-mat 2.73 
'classical' 2.73 
(79%); 2.73 
50(th) 2.73 
Xpress 2.73 
[maternal 2.73 
Down-syndrome-affected 2.73 
mid-phalanx 2.73 
849) 2.73 
(n=90) 2.73 
1813 2.73 
1799 2.73 
(FASTER) 2.73 
Zp 2.73 
(ARSA) 2.73 
subdistricts 2.73 
1988-2003 2.73 
(15-18 2.73 
equivalently 2.73 
1996-2007 2.73 
(8/14) 2.73 
balanced) 2.73 
(IGFBP) 2.73 
Proteolytic 2.73 
departures 2.73 
Republic: 2.73 
record-linkage 2.73 
purposely 2.73 
14+0 2.73 
amniocenteses) 2.73 
$116 2.73 
triploidies) 2.73 
MeSHForehead 2.73 
femur/humerus 2.73 
(O/E) 2.73 
omfalocele 2.73 
Laparotomies 2.73 
nonlocal 2.73 
27-month 2.73 
nonpancreatic 2.73 
NS); 2.73 
arthrographically 2.73 
"frozen 2.73 
[21%] 2.73 
(reader 2.73 
Lunar 2.73 
magnetic-resonance 2.73 
bankart 2.73 
only? 2.73 
indeterminant 2.73 
(articular 2.73 
(n=92 2.73 
errors] 2.73 
arm; 2.73 
(FOV) 2.73 
Acuson 2.73 
ultrasound-assisted 2.73 
CT/US 2.73 
choledocolithiasis] 2.73 
Loayza 2.73 
ERCP/sphincterotomy 2.73 
reliability] 2.73 
cholesystectomy 2.73 
TRACT] 2.73 
TGP 2.73 
bearers 2.73 
measured; 2.73 
(slightly 2.73 
radionuclear 2.73 
phophatase 2.73 
liver-specific 2.73 
Combined-modality 2.73 
Mercy 2.73 
nonblue 2.73 
(4%; 2.73 
co-registration 2.73 
melanomas) 2.73 
Schmidt 2.73 
Tampere 2.73 
(activity 2.73 
2114 2.73 
low-positive 2.73 
(1-10) 2.73 
Nicaragua 2.73 
(1/9) 2.73 
25-65 2.73 
diagnostics) 2.73 
0925 2.73 
(148) 2.73 
HPV18-positive 2.73 
'atypical 2.73 
streptavidin-biotin-peroxidase 2.73 
CGIN 2.73 
cervigrams 2.73 
Pairs 2.73 
>92% 2.73 
naked-eye 2.73 
peroxidase) 2.73 
HPV-DNA-positive 2.73 
(6/15) 2.73 
visit; 2.73 
womens 2.73 
(29/31) 2.73 
malignancy" 2.73 
31/33/35 2.73 
(ThinPrep) 2.73 
HPV53 2.73 
algorithms: 2.73 
(31%; 2.73 
biotin-labeled 2.73 
(15/18) 2.73 
overburdened 2.73 
(P=NS) 2.73 
INTEGRATION 2.73 
time-interval 2.73 
exonuclease 2.73 
(TaqMan 2.73 
corollary 2.73 
(CASI) 2.73 
hold' 2.73 
(Informant 2.73 
MeSHBriefPsychiatricRatingScale 2.73 
CCRs 2.73 
[the 2.73 
cut-points 2.73 
recognition) 2.73 
18/21) 2.73 
tenderness) 2.73 
blueberry 2.73 
(fair 2.73 
(functional) 2.73 
cystoma 2.73 
bifocal 2.73 
'poor' 2.73 
non-ESRD 2.73 
endstage 2.73 
Electron-beam 2.73 
vessel) 2.73 
(ABI) 2.73 
(myocardial 2.73 
ESRF 2.73 
uptake; 2.73 
circulation; 2.73 
Ischaemic 2.73 
(TLS) 2.73 
Post-transplant 2.73 
1-vessel 2.73 
interpretability 2.73 
PC12 2.73 
BAs 2.73 
21]) 2.73 
predementia 2.73 
self-perception 2.73 
interregional 2.73 
[11C]PIB 2.73 
MeSH28S 2.73 
renovation 2.73 
workable 2.73 
(9/11) 2.73 
Diseased 2.73 
GM-positive 2.73 
MeSHPatientIsolators 2.73 
(Se) 2.73 
2026 2.73 
1691 2.73 
admission; 2.73 
lead-time 2.73 
double-direct 2.73 
ligand-receptor 2.73 
metastasized 2.73 
pancreatitis] 2.73 
MeSHSpiralComputed 2.73 
Progesterone 2.73 
Tc99m 2.73 
neutrophils 2.73 
(RT-PCR) 2.73 
frozen 2.73 
HIV-infected 2.73 
Initial 2.73 
confusion 2.73 
specialized 2.72 
differentiate 2.72 
optical 2.72 
enzyme 2.71 
(PCR) 2.71 
Klinefelter 2.71 
posttest 2.71 
ECC 2.71 
non-selected 2.71 
excision) 2.71 
hours; 2.71 
scan: 2.71 
outcome? 2.71 
15-17 2.71 
'low 2.71 
Expectant 2.71 
MeSHMenotropins 2.71 
goodness 2.71 
(presence 2.71 
eighty-one 2.71 
Choosing 2.71 
(Mycobacterium 2.71 
Ib) 2.71 
DELFIA 2.71 
1/200 2.71 
screening] 2.71 
BUN 2.71 
(LAP) 2.71 
non-operated 2.71 
four-point 2.71 
94%; 2.71 
(IHD) 2.71 
(99m)Tc-nanocolloid 2.71 
Kaiser 2.71 
(CAS) 2.71 
Hypometabolism 2.71 
anti-fungal 2.71 
191) 2.71 
immunometric 2.71 
"other 2.71 
fibrin 2.71 
retrieval 2.71 
lymphnode 2.71 
cured 2.71 
043 2.71 
MeSHOrganSize 2.71 
MeSHBalloon 2.71 
MeSHEvidence-BasedMedicine 2.70 
precision 2.70 
livebirth 2.69 
September 2.69 
Polish 2.69 
jointly 2.69 
(n=9) 2.69 
MeSHOsmolarConcentration 2.69 
MeSHCoronaryCirculation 2.69 
replicated 2.69 
524 2.69 
less) 2.69 
cancers) 2.69 
694 2.69 
low: 2.69 
756 2.69 
695 2.69 
MeSHFrance 2.69 
316 2.69 
to: 2.69 
Increased 2.68 
?/nMeSHAbdomen 2.68 
throughout 2.68 
MeSHClinical 2.68 
Anatomic 2.68 
1974 2.68 
relapsing 2.68 
CT-guided 2.68 
Under 2.68 
lack 2.68 
regressed 2.68 
Sports 2.68 
gray-scale 2.67 
rotated 2.67 
Concentrations 2.67 
(ICC) 2.67 
MeSHEsophagoscopy 2.67 
(PV) 2.67 
omental 2.67 
Tc99 2.67 
76%) 2.67 
MeSHEducation 2.67 
board 2.67 
33%) 2.67 
untreated 2.66 
misdiagnosed 2.66 
?/nMeSHCarcinoma 2.66 
(60% 2.66 
majority 2.66 
hand 2.65 
forceps 2.65 
sub-Saharan 2.65 
metastases: 2.65 
MeSHResidual 2.65 
mutants 2.65 
injected 2.64 
B-mode 2.64 
deviation) 2.64 
MeSHHungary 2.64 
309 2.64 
harbored 2.64 
infancy 2.64 
hence 2.64 
MeSHEsophagus 2.63 
adolescents 2.63 
fashion 2.63 
managed 2.62 
(RA) 2.62 
protected 2.62 
advisable 2.62 
Baseline 2.62 
MeSHViralLoad 2.62 
Additionally 2.62 
material 2.62 
210 2.62 
angiographically 2.61 
MeSHThrombophilia 2.61 
329 2.61 
517 2.61 
(GP) 2.61 
629 2.61 
(TEM 2.61 
5-11 2.61 
3/13 2.61 
N1) 2.61 
0/4 2.61 
demonstrated 2.61 
volumes 2.60 
(97%) 2.60 
245 2.60 
reveals 2.60 
7; 2.60 
Late 2.60 
focuses 2.60 
Clinicopathologic 2.60 
Invasive 2.60 
hemolysis 2.60 
Upon 2.60 
MeSHCoinfection 2.60 
MeSHCellSurface 2.60 
shadowing 2.60 
MeSHElectrocoagulation 2.60 
Prophylactic 2.60 
hosts 2.60 
inhibiting 2.60 
MeSHBloodCoagulationTests 2.60 
Major 2.60 
Ischemia 2.59 
bypass 2.59 
non-respiratory 2.59 
electrocardiography 2.59 
Biceps 2.59 
goal-directed 2.59 
approximated 2.59 
Publications 2.59 
Fractions 2.59 
reformatted 2.59 
side-by-side 2.59 
weeks: 2.59 
(six) 2.59 
Smokers 2.59 
(T1-2 2.59 
manufactured 2.59 
86%; 2.59 
MeSHMissouri 2.59 
68%; 2.59 
DNA-based 2.59 
oncoproteins 2.59 
(CDR) 2.59 
Point-of-care 2.59 
(EGD 2.59 
specificity: 2.59 
fluoro-2-deoxy-d-glucose 2.59 
[18F]FDG 2.59 
esophagectomy 2.59 
Materials 2.59 
175 2.59 
27) 2.59 
induction 2.59 
December 2.58 
solution 2.58 
pre- 2.58 
metabolite 2.58 
steps 2.58 
render 2.58 
premenopausal 2.58 
poses 2.58 
906 2.58 
immature 2.58 
equivalent 2.57 
precancerous 2.57 
Minor 2.57 
flexion 2.57 
indicates 2.56 
genotype 2.56 
transaminase 2.56 
produce 2.56 
<30 2.56 
ignored 2.56 
(ten 2.56 
(patient 2.56 
(18F 2.56 
evolved 2.56 
Mycobacteria 2.56 
(54 2.55 
adenocarcinoma 2.55 
?/nMeSHHumans 2.55 
investigated 2.55 
recurred 2.55 
sufficiently 2.55 
general 2.55 
regurgitation 2.54 
treatment-related 2.54 
globally 2.54 
killing 2.54 
ancillary 2.54 
degrees) 2.54 
radiolabeled 2.54 
irreversible 2.54 
registries 2.54 
MeSHAnxiety 2.54 
long-standing 2.54 
argument 2.54 
077 2.54 
080 2.54 
>12 2.54 
Hill-Sachs 2.54 
FIBTEM 2.54 
percentile) 2.54 
DNA-positive 2.54 
547 2.54 
1993) 2.54 
Validity 2.54 
Wave 2.54 
Besides 2.53 
dominate 2.53 
MeSHTumor 2.53 
219 2.53 
(FDG-PET) 2.53 
hydrocephalus 2.53 
262 2.53 
object 2.53 
portal 2.53 
152 2.52 
makes 2.52 
ensure 2.52 
111 2.52 
sedation 2.52 
appreciate 2.52 
isotope 2.52 
101 2.52 
tyrosine 2.52 
side-effects 2.52 
treatment] 2.52 
MeSHFallopianTubeDiseases 2.52 
conduct 2.51 
elicit 2.51 
-67 2.51 
Instrument 2.51 
1986 2.50 
easily 2.50 
uniform 2.50 
447 2.50 
readings 2.50 
reassurance 2.50 
confronted 2.50 
re-examined 2.50 
Applying 2.50 
395 2.50 
CMRglc 2.50 
441 2.50 
393 2.50 
pregnancy] 2.50 
spur 2.50 
intrinsic 2.49 
aborted 2.49 
give 2.49 
andover 2.49 
escape 2.49 
pre-existing 2.49 
revision 2.49 
varied 2.49 
working 2.48 
improve 2.48 
viruses 2.48 
multidetector-row 2.48 
1:250) 2.48 
deepest 2.48 
MeSHThoracicInjuries 2.48 
Scandinavian 2.48 
toxemia 2.48 
?/nMeSHAsia 2.48 
MeSHVitaminB12 2.48 
MeSHCalcium-BindingProteins 2.48 
matrices 2.48 
habitus 2.48 
reduction) 2.48 
MeSHProctoscopy 2.48 
futile 2.48 
(vascular 2.48 
bisected 2.48 
MeSHMultidetectorComputedTomography 2.48 
rims 2.48 
Distinction 2.48 
MeSHTennis 2.48 
MeSHTenosynovitis 2.48 
laboratory-based 2.48 
Expenditures 2.48 
25-50 2.48 
achieving 2.48 
(or 2.48 
pancreas 2.47 
instrumental 2.47 
XI 2.47 
(range: 2.47 
convergence 2.47 
MeSHFreezing 2.47 
Peking 2.47 
104) 2.47 
(CV) 2.47 
intensively 2.47 
>35 2.47 
571 2.47 
927 2.47 
settings 2.46 
outline 2.46 
middle-aged 2.46 
expectant 2.46 
(CD) 2.46 
MeSHHistologicalTechniques 2.46 
(EST) 2.46 
infused 2.46 
description 2.46 
anticipate 2.46 
resulting 2.46 
35%) 2.46 
11) 2.46 
238 2.46 
(control 2.46 
extra- 2.45 
priority 2.45 
MeSHLipids 2.45 
pay 2.45 
malformation 2.45 
culture-confirmed 2.45 
precise 2.45 
By 2.45 
(37% 2.44 
Ninety-six 2.44 
programmatic 2.44 
398 2.44 
580 2.44 
Neoadjuvant 2.44 
advantages 2.44 
coagulation 2.44 
Glucose 2.44 
comprised 2.44 
CT-PET 2.44 
defect(s) 2.44 
ILND 2.44 
Imager 2.44 
non-haematological 2.44 
3DUS 2.44 
angiocardiography 2.44 
peri-intestinal 2.44 
risk-adjusted 2.44 
(GPT) 2.44 
trans-vaginal 2.44 
TRS 2.44 
non-CAD 2.44 
polytraumatised 2.44 
hypovolemic 2.44 
HPE 2.44 
Reposition 2.44 
1033 2.44 
RD1-specific 2.44 
cure" 2.44 
surgical/pathologic 2.44 
harmonics 2.44 
(subscapularis 2.44 
scar) 2.44 
Reid 2.44 
1256 2.44 
time-intensity 2.44 
fusariosis 2.44 
>/=16 2.44 
ellagic 2.44 
trauma-associated 2.44 
6730 2.44 
2055 2.44 
scout 2.44 
Ming 2.44 
(T3/T4) 2.44 
T3/T4) 2.44 
26/32 2.44 
uT1 2.44 
Restaging 2.44 
esophagoscopy 2.44 
Odense 2.44 
(30/31) 2.44 
fan-shaped 2.44 
1847 2.44 
EGJ 2.44 
Severance 2.44 
water-filled 2.44 
(depth 2.44 
winding 2.44 
stiffness) 2.44 
pair-wise 2.44 
taut 2.44 
twitch 2.44 
strain: 2.44 
Over-all 2.44 
0084 2.44 
mismanagement 2.44 
positive-predictive 2.44 
0%-25% 2.44 
better) 2.44 
entity; 2.44 
SSB 2.44 
Gerber 2.44 
insufficiencies 2.44 
Andrews 2.44 
control? 2.44 
695) 2.44 
HIV-status 2.44 
[60% 2.44 
antigenuria 2.44 
(30/30) 2.44 
2220 2.44 
(SGPT) 2.44 
TPM 2.44 
(SLO) 2.44 
antigen] 2.44 
structure-function 2.44 
MeSHSystemsIntegration 2.44 
(PRL) 2.44 
MeSHLiverRegeneration 2.44 
Norway: 2.44 
needed) 2.44 
Immunomedics 2.44 
(10-16 2.44 
proctosigmoidoscopy 2.44 
(inguinal 2.44 
proctoscopy 2.44 
"successful" 2.44 
(CT); 2.44 
walk-in 2.44 
polynomials 2.44 
options: 2.44 
1348 2.44 
reality?] 2.44 
(2003-2005) 2.44 
7-9) 2.44 
uneffected 2.44 
noninterventional 2.44 
(Multiple 2.44 
century] 2.44 
centers] 2.44 
ultrasound-proven 2.44 
1564 2.44 
1382 2.44 
(Brahms 2.44 
20/32 2.44 
fontanelles 2.44 
day" 2.44 
(differences 2.44 
1370 2.44 
(44%); 2.44 
numbers) 2.44 
8500 2.44 
field; 2.44 
intervention] 2.44 
(EL) 2.44 
(68%); 2.44 
ampulla; 2.44 
non-conclusive 2.44 
Peritoneoscopic 2.44 
review; 2.44 
nonhomogeneous 2.44 
fluid-like 2.44 
MeSHPubMed 2.44 
correlations] 2.44 
first; 2.44 
(22/22) 2.44 
TE] 2.44 
gallstone) 2.44 
iotroxate 2.44 
bilirrubin 2.44 
ethiologic 2.44 
clinical: 2.44 
'acute 2.44 
ASAT 2.44 
(EHD) 2.44 
'routine' 2.44 
MeSHDuodenitis 2.44 
collimated 2.44 
two-center 2.44 
FICT 2.44 
Stopping 2.44 
35-70 2.44 
immunhistochemistry 2.44 
clitoral 2.44 
1990-2007 2.44 
ILND) 2.44 
(1/15) 2.44 
EUA 2.44 
self-sample 2.44 
3488 2.44 
(LNA) 2.44 
NTCC 2.44 
16-50 2.44 
downgrade 2.44 
(11/15) 2.44 
"special 2.44 
GAA 2.44 
P63 2.44 
amplification) 2.44 
0091) 2.44 
longer) 2.44 
347) 2.44 
1998-2001 2.44 
AZ) 2.44 
120% 2.44 
Reclassification 2.44 
BNC 2.44 
HPV66 2.44 
"wait-and-see" 2.44 
1371 2.44 
MWP 2.44 
5060 2.44 
3q26 2.44 
colposcope 2.44 
nonproductive 2.44 
(tested 2.44 
(26/27) 2.44 
(incomplete 2.44 
Marlborough 2.44 
(QC) 2.44 
stark 2.44 
(PSD) 2.44 
(family 2.44 
(CIND) 2.44 
Thinking 2.44 
4/24) 2.44 
laparoscopy? 2.44 
(hard 2.44 
antenna 2.44 
Sonographers 2.44 
non-gynaecological 2.44 
(March 2.44 
(SVG) 2.44 
3-37% 2.44 
(3DUS) 2.44 
ligaments) 2.44 
discerning 2.44 
MeSHGynecologicalExamination 2.44 
83-100% 2.44 
seventeenth 2.44 
septum: 2.44 
(MUC) 2.44 
31/37 2.44 
18-45 2.44 
absent; 2.44 
>or=45 2.44 
>or=25 2.44 
Turin 2.44 
CKMB 2.44 
single-vessel 2.44 
kingdom 2.44 
(22%); 2.44 
MeSHTherapeuticEquivalency 2.44 
mellitus) 2.44 
non-q 2.44 
(IPC) 2.44 
E4- 2.44 
IFC 2.44 
Whole-brain 2.44 
self-ratings 2.44 
precuneus/posterior 2.44 
1(1/2) 2.44 
(1-->3)-beta-d-glucan 2.44 
substantively 2.44 
Infiltrates 2.44 
nonpulmonary 2.44 
Neutropenic 2.44 
MeSHChromogenicCompounds 2.44 
(mortality: 2.44 
heart) 2.44 
(Sp) 2.44 
nonneutropenic 2.44 
Hunan 2.44 
1109 2.44 
unexplainable 2.44 
MeSHAntibiotics 2.44 
impairments 2.43 
floor 2.43 
melanomas 2.43 
immediately 2.43 
originated 2.43 
pancreatitis: 2.43 
probe 2.43 
937 2.43 
thin 2.42 
peri- 2.42 
125 2.42 
(87%) 2.42 
women) 2.41 
Emergency 2.41 
participation 2.41 
aspirates 2.41 
doubtful 2.41 
Continuous 2.41 
(OC) 2.41 
Axial 2.41 
configuration 2.41 
moving 2.41 
extent 2.41 
Biomed 2.40 
counseling 2.40 
MeSHRegistries 2.40 
biomarkers 2.40 
(57 2.40 
pediatric 2.40 
urgent 2.40 
association 2.40 
OR 2.39 
092 2.39 
N-stage 2.39 
derangements 2.39 
restricting 2.39 
destined 2.39 
MeSHOutpatientClinics 2.39 
estimations 2.39 
values) 2.39 
754 2.39 
T1-T2 2.39 
716 2.39 
neurologist 2.39 
examines 2.39 
(82% 2.39 
externally 2.39 
resource-poor 2.39 
shortcomings 2.39 
groups) 2.39 
Regular 2.39 
426 2.39 
Forty-eight 2.39 
25th 2.39 
932 2.39 
801 2.39 
interview 2.39 
Computer 2.39 
amongst 2.39 
000) 2.39 
Feasibility 2.38 
Thrombin 2.38 
(eg 2.38 
041 2.38 
shear 2.38 
isochromosome 2.38 
cholangiography: 2.38 
(MB 2.38 
Changes 2.38 
MRCP 2.38 
strengthen 2.37 
Up 2.37 
national 2.37 
packages 2.37 
thyroid-stimulating 2.37 
(M1) 2.37 
disintegrin 2.37 
(ADAM 2.37 
contacting 2.37 
MeSHClomiphene 2.37 
Established 2.37 
Integrating 2.37 
gender-matched 2.37 
classification: 2.37 
(FP) 2.37 
11%; 2.37 
ninety-one 2.37 
inexperienced 2.37 
(smear 2.37 
Immediate 2.37 
U/ml) 2.36 
MeSHOrthopedics 2.36 
options 2.36 
MeSHBrainDiseases 2.36 
paradigm 2.36 
RT 2.36 
urinary 2.36 
360 2.36 
PM 2.36 
MeSHDNAPrimers 2.36 
came 2.36 
Activated 2.35 
MeSHCarcinoidTumor 2.35 
MeSHDeoxyglucose 2.35 
MeSHColitis 2.35 
rescue 2.35 
sixteen 2.35 
MeSHPhysicians" 2.35 
Rates 2.35 
established 2.35 
in; 2.35 
plan 2.35 
histopathological 2.35 
Trial 2.35 
MeSHStatistical 2.35 
rise 2.34 
death 2.34 
exceeding 2.34 
expertise 2.34 
urgently 2.34 
remarkably 2.34 
arm 2.34 
live-born 2.34 
MeSHMethyleneBlue 2.34 
strengths 2.34 
=8) 2.34 
364 2.34 
59) 2.34 
N 2.33 
MeSH80andover 2.33 
meta-analysis 2.33 
regardless 2.33 
60%) 2.33 
EGFR 2.33 
brace 2.33 
MeSHCerebrospinalFluid 2.33 
devastating 2.33 
transforming 2.33 
hybridisation 2.33 
construct 2.32 
lipoarabinomannan 2.32 
obtainable 2.32 
ominous 2.32 
ROLE 2.32 
6-14 2.32 
598 2.32 
Hill- 2.32 
videotape 2.32 
simple 2.32 
alter 2.32 
quick 2.32 
Learning 2.32 
post-operative 2.31 
alternatives 2.31 
?/nMeSHDiagnosis 2.31 
requirements 2.31 
metabolic 2.31 
chi(2) 2.31 
653 2.31 
682 2.31 
behind 2.31 
(at 2.31 
in 2.31 
dysmenorrhea 2.31 
Nodal 2.31 
oncogene 2.31 
MeSHFeasibilityStudies 2.31 
06) 2.31 
005 2.31 
lines 2.30 
stones] 2.30 
MeSHDNAMethylation 2.30 
Adenomyosis 2.30 
hemisphere 2.30 
covering 2.30 
Ib 2.30 
electric 2.30 
microg 2.30 
interstitial 2.30 
multidetector 2.29 
PE) 2.29 
MeSHEsophagectomy 2.29 
Lower 2.29 
23) 2.29 
seeking 2.29 
gradual 2.29 
expressed 2.29 
cases: 2.29 
FOR 2.29 
unstimulated 2.28 
transfers 2.28 
modeled 2.28 
broad-spectrum 2.28 
pg/mL 2.28 
nodes: 2.28 
focusing 2.28 
choroid 2.28 
15%) 2.28 
MeSHMolecular 2.28 
universal 2.28 
(PCR 2.28 
circulating 2.28 
RCTs 2.27 
MeSHReal-TimePolymeraseChainReaction 2.27 
tasks 2.27 
oligonucleotide 2.27 
thalamus 2.27 
701 2.27 
cleavage 2.27 
recurrence-free 2.27 
MeSHManipulation 2.27 
partners 2.27 
studying 2.27 
jerk 2.27 
test-positive 2.27 
celiotomy 2.27 
echocardiograms 2.27 
(double 2.27 
increase) 2.27 
University-based 2.27 
MeSHConnecticut 2.27 
customized 2.27 
variances 2.27 
sums 2.27 
(NTDs) 2.27 
Minneapolis 2.27 
1082 2.27 
Clomiphene 2.27 
governed 2.27 
MeSHMacromolecularSubstances 2.27 
ultrasound; 2.27 
model: 2.27 
T1-T3 2.27 
sixty-three 2.27 
shoulder] 2.27 
exeresis 2.27 
immunocytochemically 2.27 
s/mm(2) 2.27 
10/12 2.27 
(142 2.27 
10(2) 2.27 
1700 2.27 
stretched 2.27 
utilization 2.27 
allowed 2.26 
poorly 2.26 
(log-rank 2.26 
follow-up: 2.26 
cautiously 2.26 
537 2.26 
(SE) 2.26 
validating 2.26 
663 2.26 
PCR-positive 2.26 
539 2.26 
bacillary 2.25 
235 2.25 
helical 2.25 
<or= 2.25 
karyotypic 2.25 
states 2.25 
MeSHUterus 2.25 
(15%) 2.25 
intrathoracic 2.25 
Cape 2.25 
seronegative 2.25 
insurance 2.25 
MeSHCandida 2.25 
Evidence 2.25 
pounds 2.24 
natural 2.24 
724 2.24 
AIMS: 2.24 
tau 2.23 
former 2.23 
Epidemiology 2.23 
spite 2.23 
327 2.23 
Performing 2.23 
403 2.23 
359 2.23 
503 2.23 
(live 2.23 
3-10 2.23 
lasting 2.23 
carcinoma; 2.23 
non-sentinel 2.23 
126 2.23 
MeSHKinetics 2.23 
complexity 2.23 
MeSHAngiography 2.23 
FS 2.23 
haemorrhage 2.22 
Technical 2.22 
(LBP) 2.22 
Observation 2.22 
(both 2.22 
MeSHPostoperativeHemorrhage 2.22 
Clinicopathological 2.22 
Today 2.22 
cholangiography] 2.22 
thalami 2.22 
(3) 2.22 
MeSHCalcinosis 2.22 
Gynecol 2.21 
eliminated 2.21 
looked 2.21 
at 2.21 
aware 2.21 
recommend 2.21 
co-infected 2.20 
dealing 2.20 
repair 2.20 
local 2.20 
caliber 2.19 
INR 2.19 
Milan 2.19 
MeSHHematologicTests 2.19 
30-60 2.19 
series; 2.19 
MeSH13-15 2.19 
useless 2.19 
layered 2.19 
Echography 2.19 
anticipated 2.19 
panel 2.19 
Specimen 2.19 
graph 2.19 
syndromes 2.19 
relatively 2.19 
old 2.19 
narrowing 2.19 
compromising 2.19 
splitting 2.19 
ARSA 2.19 
self-administration 2.19 
subacromial/subdeltoid 2.19 
sulfation 2.19 
microstaging 2.19 
first-ever 2.19 
fatal) 2.19 
PlateletMapping 2.19 
acromions 2.19 
amniocentesis-related 2.19 
LSE 2.19 
units/l 2.19 
pre-LC 2.19 
anucleate 2.19 
low-resolution 2.19 
mechanistically 2.19 
17beta-estradiol 2.19 
Intrarater 2.19 
high-HIV 2.19 
LVMI 2.19 
cost/effective 2.19 
Pisa 2.19 
2515 2.19 
diandric 2.19 
(set 2.19 
arm: 2.19 
Addenbrooke's 2.19 
Douglas' 2.19 
84-100% 2.19 
thickness; 2.19 
SSV 2.19 
(proven 2.19 
(2-7) 2.19 
quality) 2.19 
activator) 2.19 
MeSHCardiopulmonaryResuscitation 2.19 
(MEA) 2.19 
?/nMeSHDeliveryofHealthCare 2.19 
(matched 2.19 
(pTNM) 2.19 
Underestimation 2.19 
overestimating 2.19 
reconstruction) 2.19 
Locations 2.19 
ultrasonography? 2.19 
Physiotherapists 2.19 
assessment? 2.19 
anterior-superior 2.19 
MeSHIothalamateMeglumine 2.19 
noncontact 2.19 
follow-through 2.19 
imaging-confirmed 2.19 
US$6 2.19 
organisms; 2.19 
David 2.19 
(8/8) 2.19 
?/nMeSHAutomation 2.19 
MeSHMutantProteins 2.19 
0-16) 2.19 
MeSHBacteriuria 2.19 
(Ct) 2.19 
bioaerosol 2.19 
Pham 2.19 
Ngoc 2.19 
Thach 2.19 
Persistently 2.19 
(rectal 2.19 
99Tcm-labelled 2.19 
(SGOT) 2.19 
0042) 2.19 
NR: 2.19 
SLT 2.19 
coloscopy 2.19 
nanograms 2.19 
PET; 2.19 
antigen(CEA) 2.19 
0003); 2.19 
Plains 2.19 
1356 2.19 
presurgically 2.19 
1190 2.19 
(unaffected 2.19 
MeSHNewHampshire 2.19 
(wave 2.19 
(391 2.19 
MeSHMaternalBehavior 2.19 
(90%); 2.19 
townships 2.19 
IGFBP-5 2.19 
aneuplodies 2.19 
(329 2.19 
Equations 2.19 
(14/16) 2.19 
$98 2.19 
trimesters: 2.19 
1796 2.19 
used? 2.19 
population-at 2.19 
sonogram: 2.19 
viscera; 2.19 
resected; 2.19 
pathology-proven 2.19 
1988-1992 2.19 
Supplementing 2.19 
8-15% 2.19 
395) 2.19 
Recursive 2.19 
1992: 2.19 
endosurgical 2.19 
(Magnetom 2.19 
plenty 2.19 
(16/18) 2.19 
Austria) 2.19 
939) 2.19 
peritendinous 2.19 
Estimations 2.19 
(discriminant 2.19 
(aspartate 2.19 
"Hospital 2.19 
ecography 2.19 
characterizations 2.19 
september 2.19 
standard: 2.19 
indentified 2.19 
(GOT) 2.19 
preoperatively: 2.19 
sonographist 2.19 
upper-abdominal 2.19 
(Tc-99m) 2.19 
(distant 2.19 
(84%); 2.19 
pathogeneses 2.19 
(non-SLN 2.19 
coloring 2.19 
40/50 2.19 
(H-E) 2.19 
RT-PCR-based 2.19 
(15/15) 2.19 
unaided 2.19 
second) 2.19 
centres) 2.19 
H-SIL 2.19 
?/nMeSHAfricanAmericans 2.19 
glacial 2.19 
weakens 2.19 
semiannually 2.19 
samplers 2.19 
(n=58) 2.19 
brushes 2.19 
(signal 2.19 
haphazard 2.19 
(204 2.19 
(EBC) 2.19 
unaffordable 2.19 
gonorrhea 2.19 
MeSHHerpesvirus2 2.19 
497) 2.19 
>64 2.19 
personalised 2.19 
(18/20) 2.19 
NPVs 2.19 
(Human 2.19 
immunolocalized 2.19 
non-isotopic 2.19 
TABULATION 2.19 
(namely 2.19 
(594 2.19 
(34%); 2.19 
Interagency 2.19 
hinges 2.19 
strange 2.19 
harnessing 2.19 
Abilities 2.19 
MeSHJudgment 2.19 
delirious 2.19 
11/29 2.19 
full-text 2.19 
Elderly) 2.19 
MCI; 2.19 
remembering 2.19 
endometrioma) 2.19 
endometriomas) 2.19 
right/left 2.19 
shaving 2.19 
nodularities 2.19 
VPP 2.19 
(intensity 2.19 
Visibility 2.19 
Doppler) 2.19 
(CDE 2.19 
uterus; 2.19 
essential? 2.19 
(TTE) 2.19 
(DMS) 2.19 
stratifies 2.19 
MeSHMBForm 2.19 
MeSHAngiocardiography 2.19 
Sensibility 2.19 
64); 2.19 
repolarization 2.19 
444) 2.19 
Examination) 2.19 
Two-tailed 2.19 
[18F]-2-fluoro-2-deoxy-D-glucose 2.19 
Benton 2.19 
(18FDG-PET) 2.19 
12-d 2.19 
predating 2.19 
(FUO) 2.19 
(FUO 2.19 
antibody-negative 2.19 
positivity; 2.19 
Hopital 2.19 
shRNA 2.19 
(2%) 2.19 
well-differentiated 2.19 
MeSHRemission 2.19 
Working 2.18 
283 2.18 
expectations 2.18 
six-month 2.18 
hydatidiform 2.18 
MeSHOntario 2.18 
LJ 2.18 
three) 2.18 
and/or 2.18 
men; 2.18 
management 2.18 
2-month 2.17 
cleared 2.17 
Aboriginal 2.17 
067) 2.17 
echotexture 2.17 
subtracted 2.17 
preparative 2.17 
risk; 2.17 
practicability 2.17 
MeSHGrowthSubstances 2.17 
MeSHTriplets 2.17 
MeSHFetalProteins 2.17 
MeSHDiatrizoateMeglumine 2.17 
not? 2.17 
defects) 2.17 
capsulolabral 2.17 
colorectum 2.17 
806 2.17 
localisations 2.17 
second-stage 2.17 
Immunochemical 2.17 
microplate 2.17 
literacy 2.17 
KEY 2.17 
Thickening 2.17 
unrecognised 2.17 
(Tc-99m 2.17 
chlamydia 2.17 
moderate/ 2.17 
MeSHPre-Eclampsia 2.17 
skip 2.17 
maintained 2.16 
tail 2.16 
566 2.16 
929 2.16 
MeSHNetherlands 2.16 
recessive 2.16 
MeSHGenome 2.16 
arrays 2.16 
community-based 2.16 
doctor 2.15 
Fourteen 2.15 
error 2.15 
Ovarian 2.15 
=35 2.15 
moreover 2.15 
deliveries 2.15 
4); 2.15 
developments 2.15 
disadvantage 2.15 
MeSHPatientAcceptanceofHealthCare 2.14 
During 2.14 
abolish 2.14 
potency 2.14 
MeSHSynovialCyst 2.14 
MeSHElectiveSurgicalProcedures 2.14 
cholecystogram 2.14 
orthopaedic 2.14 
neonates 2.14 
(ES) 2.13 
imbalance 2.13 
age; 2.13 
Eighty-eight 2.13 
Free 2.13 
mobile 2.13 
elucidating 2.13 
intra-operatively 2.13 
(n=15) 2.13 
MeSHMarkovChains 2.13 
extrapolate 2.13 
MeSHBiologicalAssay 2.13 
SG 2.12 
h) 2.12 
decreasing 2.12 
along 2.12 
714 2.12 
efficacious 2.12 
Wide 2.12 
postural 2.12 
Fluorine 2.12 
miscellaneous 2.12 
flap 2.12 
Ethiopia 2.12 
MeSHMucousMembrane 2.12 
modern 2.11 
MeSHClinicalTrialsasTopic 2.11 
pointed 2.11 
outlined 2.11 
synthesized 2.11 
MeSHCauseofDeath 2.11 
(37%) 2.11 
MeSHImageEnhancement 2.11 
quickly 2.11 
Force 2.11 
small 2.11 
donation 2.11 
TRIAL 2.11 
Silver 2.11 
recommendation 2.11 
advancing 2.11 
Interpretation 2.10 
full 2.10 
sd 2.10 
Questionnaire 2.10 
mucosal 2.09 
19) 2.09 
(33%) 2.09 
record 2.09 
spreading 2.09 
(ER) 2.09 
circumferential 2.09 
reproducible 2.09 
firmness 2.09 
Strong 2.09 
anorexia 2.09 
qualified 2.09 
laminar 2.09 
(ART) 2.09 
educational 2.09 
(76%) 2.09 
649 2.08 
palm 2.08 
hypointense 2.08 
338 2.08 
MeSHSingapore 2.08 
improvements 2.08 
fundamental 2.08 
(average 2.08 
49%) 2.08 
deprived 2.08 
noncardiac 2.08 
scrapes 2.08 
(chi-square 2.08 
step-wise 2.08 
60-70% 2.08 
heavier 2.08 
imminent 2.08 
multimarker 2.08 
mathematically 2.08 
Ullrich-Turner 2.08 
superiorly 2.08 
osteoarthrosis 2.08 
accredited 2.08 
T1W 2.08 
MeSHTunicaIntima 2.08 
defect) 2.08 
rheumatologists 2.08 
215) 2.08 
phylogenetically 2.08 
(tissue 2.08 
lamination 2.08 
(>8 2.08 
mumol/L 2.08 
(histologic 2.08 
135) 2.08 
HPV-16 2.08 
male; 2.08 
U/L 2.08 
never 2.07 
MeSHSkeletal 2.07 
obvious 2.07 
attractive 2.07 
MeSHSecondPrimary 2.07 
unrecognized 2.07 
fungus 2.07 
432 2.07 
317 2.07 
logistical 2.07 
milliliter 2.07 
Elevation 2.07 
2010) 2.07 
572 2.07 
Isometric 2.07 
790 2.07 
529 2.07 
54; 2.07 
Salvage 2.06 
Malformation 2.06 
predominated 2.06 
treatment: 2.06 
Trend 2.06 
constipation 2.06 
(70 2.06 
subtle 2.06 
call 2.06 
metastases 2.05 
Inclusion 2.05 
smear-positive 2.05 
stage 2.05 
atrophy 2.05 
x-ray 2.05 
comment 2.05 
Ann 2.05 
science 2.05 
05-1 2.05 
99m 2.04 
?/nMeSHAntigens 2.04 
perineural 2.04 
electrode 2.04 
ulcers 2.04 
MeSHInterphase 2.04 
illnesses 2.04 
post-ERCP 2.04 
hydronephrosis 2.04 
(10%) 2.04 
(25% 2.04 
962 2.04 
economically 2.04 
selection 2.03 
document 2.03 
appropriately 2.03 
layers 2.03 
addressed 2.03 
Singapore 2.03 
steady 2.02 
polypoid 2.02 
similarity 2.02 
121 2.02 
translocations 2.01 
sampled 2.01 
contains 2.01 
Symptom 2.01 
MeSHHand 2.01 
cell-free 2.01 
contiguous 2.01 
localizations 2.01 
aggressiveness 2.01 
1960 2.01 
household 2.01 
read 2.01 
estimating 2.01 
65; 2.01 
711 2.01 
Without 2.01 
MeSHLowBirthWeight 2.01 
Articles 2.01 
levels; 2.01 
true-negative 2.01 
IRB 2.01 
MeSHPulmonaryAspergillosis 2.01 
normal; 2.01 
612 2.01 
83; 2.01 
MeSHTraumaSeverityIndices 2.01 
till 2.00 
MeSHPortalVein 2.00 
transfer 2.00 
NC) 2.00 
questions 2.00 
MeSHDiagnosticErrors 2.00 
20th 2.00 
MeSHMucinous 1.99 
MeSHHepatocellular 1.99 
babies 1.99 
ineffective 1.99 
MeSHTaiwan 1.99 
Contrary 1.99 
fertilized 1.99 
508 1.99 
reconsider 1.99 
399 1.99 
930 1.99 
PRC 1.99 
A10 1.99 
Johnson 1.99 
(Fisher's 1.99 
cross-validation 1.99 
antifungals 1.99 
(CENTRAL) 1.99 
gaussian 1.99 
inconsistencies 1.99 
9-16 1.99 
maximized 1.99 
IVF/ICSI 1.99 
9-13 1.99 
eighty-two 1.99 
withheld 1.99 
augmenting 1.99 
pre-surgical 1.99 
solution) 1.99 
MeSHPapillomavirusE7Proteins 1.99 
quadratic 1.99 
infra- 1.99 
sings 1.99 
avidin-biotin-peroxidase 1.99 
142) 1.99 
853 1.99 
(191 1.99 
MeSHAbdominalNeoplasms 1.99 
persistence 1.99 
might 1.99 
requiring 1.99 
debilitating 1.99 
scenarios 1.99 
uninvolved 1.99 
month-old 1.99 
colectomy 1.98 
looking 1.98 
Another 1.98 
fungi 1.98 
percentage 1.98 
white 1.98 
utilized 1.98 
Where 1.98 
cfDNA 1.98 
fontanelle 1.98 
SVG 1.98 
[(11)C]PIB 1.98 
LDN 1.98 
ethnic-specific 1.98 
TEG((R)) 1.98 
BMIPP 1.98 
piglets 1.98 
1083 1.98 
ALAT 1.98 
7-item 1.98 
enterography 1.98 
"probable" 1.98 
RMP-susceptible 1.98 
1202 1.98 
unsuspicious 1.98 
trocar-site 1.98 
subscapularis) 1.98 
melanocortin 1.98 
cycle-related 1.98 
Thin-section 1.98 
=40% 1.98 
allocations 1.98 
naturalistic 1.98 
anti-aspergillus 1.98 
piperacillin/tazobactam 1.98 
MeSHEpoprostenol 1.98 
days: 1.98 
ELT 1.98 
plasma/serum 1.98 
(international 1.98 
MeSHIntracranialHemorrhages 1.98 
14+/-3 1.98 
data-driven 1.98 
(normalized 1.98 
others: 1.98 
(n=84) 1.98 
thirdly 1.98 
esophagography 1.98 
2961 1.98 
Understaging 1.98 
Verona 1.98 
(Pentax 1.98 
T1m 1.98 
MeSHMicrobubbles 1.98 
MeSHEsophagoscopes 1.98 
categories) 1.98 
Studied 1.98 
Pending 1.98 
Throwing 1.98 
DARE 1.98 
test); 1.98 
bursography 1.98 
peeled 1.98 
nonathlete 1.98 
paralabral 1.98 
Unclear 1.98 
decentralised 1.98 
1041 1.98 
810) 1.98 
(0-1) 1.98 
MeSHLuminescence 1.98 
decision-makers 1.98 
5-35) 1.98 
TWO 1.98 
N-acetyl-L-cysteine 1.98 
smear-microscopy 1.98 
endorsement 1.98 
29/29 1.98 
NAAT 1.98 
(15; 1.98 
recurrence? 1.98 
relapse; 1.98 
(life 1.98 
females] 1.98 
(-)] 1.98 
antigen; 1.98 
(Dukes' 1.98 
1160 1.98 
reoperation) 1.98 
lungs; 1.98 
survival? 1.98 
4-57 1.98 
92%); 1.98 
(5/21) 1.98 
t2) 1.98 
FNR) 1.98 
milliseconds 1.98 
child) 1.98 
28/34 1.98 
Non-parametric 1.98 
(AMC) 1.98 
nonsignificant) 1.98 
Translocations 1.98 
(resulting 1.98 
multi-parameter 1.98 
Separately 1.98 
Proponents 1.98 
1996-2003 1.98 
(PAC) 1.98 
Peritoneoscopy 1.98 
peribursal 1.98 
(3-6 1.98 
[16%] 1.98 
subluxation) 1.98 
arthrographies 1.98 
Genoa 1.98 
re-tears 1.98 
Periarticular 1.98 
amd 1.98 
bursal-side 1.98 
information: 1.98 
reinterpreted 1.98 
undamaged 1.98 
joint; 1.98 
postlaparoscopic 1.98 
1996-2002 1.98 
(x2 1.98 
(GOG) 1.98 
(1/16) 1.98 
technique-related 1.98 
49/50 1.98 
Ultrastaging 1.98 
trisulfide 1.98 
reticulo-endothelial 1.98 
(18/19) 1.98 
intraparenchymatous 1.98 
interstitially 1.98 
(1/10) 1.98 
smears; 1.98 
(n=55) 1.98 
eightfold 1.98 
cross-protection 1.98 
MeSHHumanpapillomavirus11 1.98 
(generally 1.98 
unfeasible 1.98 
non-cervical 1.98 
reports: 1.98 
severity: 1.98 
smear: 1.98 
587) 1.98 
Misclassification 1.98 
Monolayer 1.98 
20/24 1.98 
ectocervical 1.98 
(currently 1.98 
reclassify 1.98 
ACG 1.98 
1871 1.98 
curve; 1.98 
informs 1.98 
(VF) 1.98 
adhesions) 1.98 
convolution 1.98 
analyzed) 1.98 
T1w 1.98 
(CI)] 1.98 
14-28 1.98 
MeSHPhotofluorography 1.98 
ST-T 1.98 
<70% 1.98 
(RRT) 1.98 
incurring 1.98 
4/53 1.98 
(21%); 1.98 
donors) 1.98 
All-cause 1.98 
pre-RT 1.98 
echocardiography: 1.98 
t-tau 1.98 
MeSHMetatarsalBones 1.98 
segmentations 1.98 
(rCMRGlu) 1.98 
[18F]FDG-PET 1.98 
(9/14) 1.98 
purposed 1.98 
2071 1.98 
Group] 1.98 
malignity 1.98 
Early 1.97 
emphasis 1.97 
MeSHAntiretroviralTherapy 1.97 
MeSHHighlyActive 1.97 
MeSHSpeciesSpecificity 1.97 
(48 1.97 
(three 1.97 
599 1.97 
?/nMeSHDownSyndrome 1.97 
(4% 1.97 
Canada 1.97 
shown 1.96 
observe 1.96 
MeSHBloodCoagulationFactors 1.96 
MeSHEstrogens 1.96 
tuberculosis) 1.96 
transcriptase-polymerase 1.96 
persists 1.96 
cells: 1.96 
proposal 1.96 
MeSHEpidermalGrowthFactor 1.96 
residence 1.96 
complaining 1.96 
computerized 1.96 
Chromosomal 1.96 
providers 1.96 
(OR) 1.96 
laboratories 1.95 
(17% 1.95 
experience] 1.95 
Sciences 1.95 
patients) 1.95 
circumstances 1.95 
prepared 1.95 
hyperfibrinolysis 1.95 
(three) 1.95 
pathologically 1.94 
terminology 1.94 
discrepant 1.94 
452 1.94 
concomitant 1.94 
460 1.94 
perineal 1.94 
211 1.94 
C1 1.94 
aid 1.94 
sought 1.94 
chain 1.94 
postcholecystectomy 1.94 
MeSHRuralPopulation 1.94 
largely 1.94 
outcomes 1.94 
MeSHNeurons 1.93 
(WHO) 1.93 
MeSHHost-PathogenInteractions 1.93 
microarrays 1.93 
relaxation 1.93 
cerebrospinal 1.93 
want 1.93 
Hemoglobin 1.93 
(SLN) 1.93 
collection 1.92 
cancers 1.92 
discrepancies 1.92 
vector 1.92 
augmented 1.92 
community 1.91 
whole 1.91 
deserves 1.91 
exams 1.91 
516 1.91 
core 1.91 
sacroiliitis 1.91 
cascade 1.91 
ordered 1.91 
non-tuberculous 1.91 
appearances 1.90 
timely 1.90 
strategies 1.90 
AGA 1.90 
(rho 1.90 
Determine 1.90 
cancer-free 1.90 
radiologist's 1.90 
(FA) 1.90 
transvaginally 1.90 
imprecision 1.90 
MeSHBoston 1.90 
(spontaneous 1.90 
MeSHPolicyMaking 1.90 
MeSHPublicPolicy 1.90 
inequality 1.90 
Expressed 1.90 
1400 1.90 
(TSH) 1.90 
0-I 1.90 
(EMR) 1.90 
surgical-pathologic 1.90 
posterior) 1.90 
passively 1.90 
144) 1.90 
detected; 1.90 
hyperplasia) 1.90 
benign-appearing 1.90 
195) 1.90 
Haemoscope 1.90 
Kaolin 1.90 
845 1.90 
ABI 1.90 
fifty 1.90 
disparities 1.90 
ruling 1.90 
impressive 1.90 
firstly 1.90 
(PI) 1.90 
meant 1.90 
seek 1.90 
MeSHDrugCombinations 1.89 
(AT 1.89 
uniformly 1.89 
Unfortunately 1.89 
washing 1.89 
095 1.89 
sub-group 1.89 
TSE 1.89 
(POC) 1.89 
constructing 1.89 
64; 1.89 
screening) 1.89 
event-free 1.89 
Collaborative 1.89 
(<10 1.89 
501 1.89 
810 1.89 
inside 1.89 
dilemma 1.89 
MeSHPancreaticCyst 1.88 
LDL 1.88 
pressures 1.88 
user 1.88 
Thirteen 1.88 
Fluid 1.88 
clearly 1.88 
counterpart 1.88 
intravenously 1.88 
annually 1.88 
255 1.88 
inpatients 1.87 
MeSHPartialThromboplastinTime 1.87 
313 1.87 
all) 1.87 
-66 1.87 
collaboration 1.87 
Determination 1.87 
discriminate 1.87 
evaluations 1.86 
hydrops 1.86 
MeSHFactorVIII 1.86 
Morris 1.86 
entail 1.86 
promptly 1.86 
(105 1.86 
715 1.86 
153) 1.86 
892 1.86 
triplet 1.85 
MeSHElectrosurgery 1.85 
metastasis) 1.85 
squared 1.85 
really 1.85 
reinforce 1.85 
IGRA 1.85 
heparin 1.85 
deliver 1.85 
carry 1.85 
devices 1.84 
manner 1.84 
Although 1.84 
projection 1.84 
00001) 1.84 
study; 1.84 
Automated 1.84 
Differences 1.84 
RESULT(S): 1.84 
08) 1.84 
dramatically 1.83 
cadaver 1.83 
MeSHHealthStatus 1.83 
Either 1.83 
Suspected 1.83 
FSE 1.83 
alpha-2 1.83 
Gynecological 1.83 
pre-treatment 1.83 
mesentery 1.83 
SEARCH 1.83 
nationally 1.83 
incisions 1.83 
candidiasis 1.83 
link 1.83 
Then 1.83 
personnel 1.83 
doctors 1.83 
afferent 1.83 
SPECT 1.83 
251 1.82 
forms 1.82 
reduction 1.82 
hepatobiliary 1.82 
General 1.82 
MPS 1.82 
beta-globin 1.82 
non-curative 1.82 
A9 1.82 
intima-media 1.82 
MeSHPovertyAreas 1.82 
MeSHPregnancyReduction 1.82 
MeSHMultifetal 1.82 
counselors 1.82 
deformations 1.82 
voluntarily 1.82 
dictates 1.82 
examination: 1.82 
hypothesised 1.82 
masses: 1.82 
Tau 1.82 
(ACC) 1.82 
INTEM 1.82 
002] 1.82 
phalanx 1.82 
location 1.82 
794 1.82 
20-40 1.82 
persisting 1.82 
accounts 1.82 
PATIENT(S): 1.82 
attitude 1.82 
towards 1.82 
differentiating 1.82 
(35%) 1.82 
611 1.82 
beam 1.82 
practices 1.81 
B2 1.81 
newer 1.81 
07) 1.81 
each) 1.81 
scanty 1.81 
transplantation: 1.81 
lost 1.81 
lymphedema 1.81 
MeSHAsciticFluid 1.81 
Blue 1.81 
cancer-related 1.81 
demand 1.80 
MeSHChorionicVilliSampling 1.80 
transferred 1.80 
2-3 1.80 
carcinoma) 1.80 
(16% 1.79 
prenasal 1.79 
nuchal-translucency 1.79 
MDT 1.79 
CNPA 1.79 
marathon 1.79 
BPD/NB 1.79 
digynic 1.79 
acetowhite 1.79 
retrosplenial 1.79 
093) 1.79 
35-44 1.79 
CIND 1.79 
NICU 1.79 
"routine" 1.79 
postero-superior 1.79 
Cobas 1.79 
stage-oriented 1.79 
496) 1.79 
O/E 1.79 
10(5)) 1.79 
0037) 1.79 
(CND) 1.79 
vaccine) 1.79 
Naming 1.79 
intrarectal 1.79 
proxies 1.79 
alpha-angle) 1.79 
R-time 1.79 
(ICP) 1.79 
piglet 1.79 
Decreases 1.79 
surpasses 1.79 
1120 1.79 
editions 1.79 
(9/18 1.79 
EUS-based 1.79 
Consultants 1.79 
rupture) 1.79 
manages 1.79 
protraction 1.79 
(PLR) 1.79 
(rotator 1.79 
players: 1.79 
(LHB) 1.79 
Gates 1.79 
oxazolidinones 1.79 
Editors' 1.79 
(2/7 1.79 
urine) 1.79 
(Cellestis 1.79 
powering 1.79 
low-burden 1.79 
pharmacogenetic 1.79 
10%-15% 1.79 
allocating 1.79 
(DA) 1.79 
<or=10 1.79 
cognizant 1.79 
1079 1.79 
(CRLM) 1.79 
(global 1.79 
Oulu 1.79 
noncompliant 1.79 
"other" 1.79 
placenta-derived 1.79 
protein-a 1.79 
pre-CVS 1.79 
DYS14 1.79 
one-tail 1.79 
Sad 1.79 
nonoverlapping 1.79 
(>or=10 1.79 
1490 1.79 
uptake) 1.79 
centre) 1.79 
811) 1.79 
accustomed 1.79 
(table 1.79 
(QF)-PCR 1.79 
1173 1.79 
(karyotype 1.79 
1445 1.79 
11-13(+6) 1.79 
benefitted 1.79 
nonresectability 1.79 
Rounds 1.79 
instigated 1.79 
fiscal 1.79 
Scan) 1.79 
(NM) 1.79 
fraying 1.79 
shoulder" 1.79 
medial-lateral 1.79 
echography] 1.79 
DIR 1.79 
(SAB) 1.79 
(SAA) 1.79 
units; 1.79 
(223 1.79 
endoscopic/laparoscopic 1.79 
(ERCP); 1.79 
recount 1.79 
cholangiotomography 1.79 
nonvisualizing 1.79 
sonogram) 1.79 
SLB 1.79 
(23%); 1.79 
2-66 1.79 
agreeing 1.79 
11/14 1.79 
commercialized 1.79 
(considered 1.79 
Were 1.79 
sample: 1.79 
(5/9) 1.79 
decision-analytic 1.79 
393) 1.79 
cervico-vaginal 1.79 
group-specific 1.79 
cancer-screening 1.79 
MeSHPerimenopause 1.79 
Alegre 1.79 
(5000 1.79 
reminders 1.79 
(E6 1.79 
micro-invasive 1.79 
MeSHSulfotransferases 1.79 
strong) 1.79 
System) 1.79 
1996-1998 1.79 
1998; 1.79 
post-stroke 1.79 
individuals' 1.79 
Ramathibodi 1.79 
(CA-125) 1.79 
della 1.79 
arcs 1.79 
18FDG) 1.79 
ankle-brachial 1.79 
5500 1.79 
inter-group 1.79 
42-month 1.79 
depressions 1.79 
hemodialysis] 1.79 
Cox-regression 1.79 
genotype: 1.79 
hyperphosphorylated 1.79 
decliners 1.79 
community: 1.79 
18F-fluorodeoxyglucose-positron 1.79 
antedate 1.79 
MeSHStilbenes 1.79 
(MTL) 1.79 
1-16) 1.79 
1205 1.79 
recipients] 1.79 
gap 1.79 
brief 1.79 
earliest 1.79 
seropositive 1.79 
(RT) 1.79 
RC 1.79 
Taking 1.79 
(OD 1.78 
permitting 1.78 
hematoxylin-eosin 1.78 
MeSHNose 1.78 
mutated 1.78 
radiographically 1.78 
243 1.78 
310 1.78 
Fifty-five 1.78 
participants 1.78 
(liver 1.78 
MeSHCephalometry 1.78 
weeks; 1.78 
discarded 1.78 
cecum 1.78 
investigating 1.78 
26% 1.77 
strong 1.77 
ml 1.77 
contributor 1.77 
asymmetrical 1.77 
(LS) 1.77 
Bias 1.77 
transport 1.77 
lives 1.77 
uninfected 1.77 
myomas 1.77 
cytogenetically 1.77 
287 1.77 
MeSHFetalBlood 1.77 
interrupt 1.77 
scoring 1.76 
MeSHCentralNervousSystem 1.76 
century 1.76 
immunoperoxidase 1.76 
implemented 1.76 
Q 1.76 
necropsy 1.76 
acutely 1.76 
disproportionate 1.76 
angiograms 1.75 
maintain 1.75 
36) 1.75 
257 1.75 
Ambulatory 1.75 
032 1.75 
mainstay 1.75 
14; 1.75 
corresponded 1.74 
836 1.74 
787 1.74 
decreased 1.74 
Scapular 1.74 
fbeta-hCG 1.74 
Stratification 1.74 
simplest 1.74 
MeSHUrbanHealthServices 1.74 
left) 1.74 
5/20 1.74 
anticoagulated 1.74 
922 1.74 
unassociated 1.74 
impingement: 1.74 
SGPT 1.74 
2005-2006 1.74 
(n=17) 1.74 
Investigators 1.74 
reviewed; 1.74 
preneoplastic 1.74 
sestamibi 1.74 
LILACS 1.74 
"negative 1.74 
Uncertainty 1.74 
aged 1.74 
attained 1.74 
experiences 1.74 
excellent 1.74 
coupled 1.74 
objectives 1.74 
(b) 1.74 
separation 1.73 
served 1.73 
following 1.73 
Canadian 1.73 
she 1.73 
interleukin-6 1.73 
bactericidal 1.73 
Nodular 1.73 
DV 1.73 
nephropathy 1.73 
dictate 1.73 
(16%) 1.73 
But 1.73 
precluded 1.73 
designs 1.73 
Paulo 1.73 
Rank 1.73 
obviating 1.73 
(n=8) 1.73 
(n=10) 1.73 
effected 1.73 
Difference 1.73 
diameters 1.72 
cited 1.72 
typically 1.72 
63) 1.72 
reflect 1.72 
At 1.72 
heterogeneity 1.71 
Forty-one 1.71 
Altogether 1.71 
regarded 1.71 
Direct 1.71 
opportunity 1.71 
MEASURE(S): 1.71 
(69%) 1.71 
IHC 1.71 
folds 1.71 
primitive 1.71 
transpapillary 1.71 
Indeed 1.71 
conditional 1.71 
Duration 1.71 
MeSHFrontalLobe 1.71 
aids 1.71 
tumour 1.71 
655 1.71 
0002) 1.70 
Library 1.70 
chemotherapeutic 1.70 
005) 1.70 
cholecystectomy: 1.70 
filled 1.70 
antithrombin 1.70 
types: 1.70 
affects 1.69 
Depending 1.69 
Psychological 1.69 
techniques 1.69 
MeSHBirthWeight 1.69 
stage) 1.69 
posttransplant 1.69 
(>2 1.69 
relations 1.68 
operative 1.68 
acetic 1.68 
microscopically 1.68 
adaptation 1.68 
TB/HIV 1.68 
MeSHThoracicNeoplasms 1.68 
laparoscope 1.68 
coexistent 1.68 
Neither 1.68 
controversy 1.68 
Wall 1.68 
(less 1.67 
700 1.67 
monolayer 1.67 
temperatures 1.67 
EDTA 1.67 
(UICC 1.67 
forty-two 1.67 
MeSHSignetRingCell 1.67 
pancreatoduodenectomy 1.67 
Pulsed 1.67 
536 1.67 
DD 1.67 
attributed 1.67 
emphasizes 1.67 
AIMS 1.67 
intramucosal 1.67 
conspicuity 1.67 
(aPTT) 1.67 
Connecticut 1.67 
MeSHGonadalSteroidHormones 1.67 
neck) 1.67 
IMM 1.67 
multiplexed 1.67 
recipients: 1.67 
multivessel 1.67 
orbitofrontal 1.67 
Supraspinatus 1.67 
908 1.67 
indentation 1.67 
micromol/l 1.67 
759 1.67 
M0 1.66 
deletions 1.66 
BE 1.66 
lacks 1.66 
Pregnant 1.66 
constant 1.66 
multivariable 1.66 
192 1.66 
reagent 1.66 
51% 1.66 
typed 1.66 
cholangiograms 1.66 
smooth 1.66 
dark 1.66 
(PPD) 1.66 
2:1 1.66 
lifting 1.66 
MeSHCarrierProteins 1.66 
roentgenographic 1.66 
electrical 1.66 
MeSHMembraneProteins 1.66 
United 1.65 
versions 1.65 
conization 1.65 
millimeter 1.65 
interfere 1.64 
needed 1.64 
(50%) 1.64 
intravascular 1.64 
branches 1.64 
validated 1.64 
debate 1.64 
underestimate 1.64 
Load 1.64 
(MRCP) 1.64 
INTERPRETATION: 1.63 
sectional 1.63 
cisplatin 1.63 
constitutes 1.63 
Technic 1.63 
Bleeding 1.63 
MeSHAnti-InfectiveAgents 1.63 
MeSHEosinophils 1.63 
MeSHBodyHeight 1.63 
instituted 1.63 
indexes 1.63 
Teaching 1.63 
distinguished 1.63 
0004 1.63 
221 1.63 
15T 1.63 
688 1.63 
uteri 1.63 
MeSHPair21 1.63 
searched 1.63 
streaming 1.63 
AFR 1.63 
kissing 1.63 
460TB 1.63 
CRLM 1.63 
heuristic 1.63 
labroligamentous 1.63 
case-specific 1.63 
false-negative) 1.63 
rCMRGlu 1.63 
BDG 1.63 
endosonography-guided 1.63 
bioluminescence 1.63 
near-patient 1.63 
49%; 1.63 
0067) 1.63 
transparietohepatic 1.63 
self-sampling 1.63 
nonendometriotic 1.63 
haemopoietic 1.63 
Antigenemia 1.63 
state; 1.63 
(EXTEM) 1.63 
fibrin-based 1.63 
humidity 1.63 
preset 1.63 
(ARDS) 1.63 
fragments) 1.63 
Limiting 1.63 
pre-hospital 1.63 
(1994) 1.63 
significant" 1.63 
differentiation) 1.63 
junction) 1.63 
0121 1.63 
perifocal 1.63 
peri-tumor 1.63 
Obstructing 1.63 
369) 1.63 
semiotics 1.63 
SRT 1.63 
MeSHMuscleStrengthDynamometer 1.63 
Abduction 1.63 
type-III 1.63 
resisting 1.63 
radionucleotide 1.63 
(WORC) 1.63 
motion; 1.63 
(IAP) 1.63 
dropouts 1.63 
underpowered 1.63 
(MTD) 1.63 
assays; 1.63 
anthropological 1.63 
?/nMeSHAttitudetoHealth 1.63 
culturable 1.63 
Dickinson) 1.63 
ml-1) 1.63 
quantitating 1.63 
oscillating 1.63 
heralds 1.63 
lungs) 1.63 
(n=49 1.63 
Hansen 1.63 
2-69 1.63 
sign; 1.63 
Cheng 1.63 
1993-2002 1.63 
non-symptomatic 1.63 
normal: 1.63 
A-C) 1.63 
Cohorts 1.63 
0089 1.63 
algorithm: 1.63 
dream 1.63 
(2/2) 1.63 
Unselected 1.63 
Definitions 1.63 
research] 1.63 
(BUN) 1.63 
(GAPDH) 1.63 
cost/benefit 1.63 
22/34 1.63 
billing 1.63 
pre-therapeutic 1.63 
obliquely 1.63 
thinned 1.63 
restudied 1.63 
echotomographic 1.63 
TESTS 1.63 
center] 1.63 
pronostic 1.63 
?/nMeSHCholedocholithiasis 1.63 
demonstrated: 1.63 
Tikur 1.63 
(USI) 1.63 
mute 1.63 
(RIT) 1.63 
lymphscintigraphy 1.63 
clitoris 1.63 
Restricting 1.63 
controversial; 1.63 
preparations: 1.63 
reflexive 1.63 
(ASCCP) 1.63 
ablation) 1.63 
cytology] 1.63 
SYBR 1.63 
(hybrid 1.63 
Twelve-month 1.63 
Mississippi 1.63 
Accepting 1.63 
treat" 1.63 
1021 1.63 
subclassifications 1.63 
lesions? 1.63 
analyses: 1.63 
[CIN] 1.63 
progression) 1.63 
cell's 1.63 
MeSHCalcium-Calmodulin-DependentProteinKinases 1.63 
Abbreviated 1.63 
uncontaminated 1.63 
MeSHPersonalityAssessment 1.63 
non-English 1.63 
(10/10) 1.63 
T(1)-w 1.63 
2012) 1.63 
(adenomyosis 1.63 
grayscale 1.63 
space; 1.63 
MeSHBiomedicalTechnology 1.63 
(TV) 1.63 
scanning; 1.63 
system's 1.63 
(157 1.63 
transplantation) 1.63 
Four-year 1.63 
vasodilatation 1.63 
16-slice 1.63 
micromol/l) 1.63 
Uremic 1.63 
events; 1.63 
coefficient: 1.63 
"self 1.63 
(enzyme-linked 1.63 
(BDG) 1.63 
BDG) 1.63 
(8/11) 1.63 
Sanofi 1.63 
incidence: 1.63 
sera) 1.63 
MeSHConnexins 1.63 
replicate 1.63 
ITA 1.62 
hemodialysis 1.62 
compromise 1.62 
MeSHBloodCoagulation 1.62 
preservation 1.62 
underestimation 1.62 
thirty-two 1.62 
102) 1.62 
(PE) 1.62 
complements 1.62 
tendonitis 1.62 
detectability 1.62 
505 1.62 
Heterogeneity 1.62 
1997) 1.62 
fellow 1.62 
Philippines 1.62 
thereof 1.62 
Immunocytochemical 1.62 
restriction 1.62 
MeSHGlucose 1.62 
entering 1.62 
presently 1.62 
next 1.62 
1; 1.62 
over- 1.62 
characterised 1.61 
MeSHKidneyDiseases 1.61 
tomography 1.61 
paid 1.61 
cytoplasm 1.61 
BUS 1.61 
supervised 1.61 
In-Tube 1.61 
mimics 1.61 
perceptions 1.61 
MeSHHLA-DRAntigens 1.61 
angioplasty 1.61 
shifted 1.61 
411 1.61 
MeSHFetalDeath 1.60 
tuberosity 1.60 
diluted 1.60 
radioactivity 1.60 
MeSHFetalGrowthRetardation 1.60 
adequate 1.60 
(28%) 1.60 
fossa 1.60 
immunosuppression 1.60 
lacking 1.60 
inconclusive 1.60 
differentially 1.60 
05- 1.60 
days' 1.60 
checks 1.60 
(124 1.60 
(respectively 1.60 
judging 1.60 
nominal 1.60 
comparisons) 1.60 
hypocoagulability 1.60 
Jefferson 1.60 
non-parametric 1.60 
midwife 1.60 
sixty-one 1.60 
ways: 1.60 
extramural 1.60 
MeSHGastroscopes 1.60 
specializing 1.60 
sulcus 1.60 
prognosis; 1.60 
IHD 1.60 
Charles 1.60 
preventative 1.60 
MeSHMycology 1.60 
(ultrasonography 1.60 
clot 1.60 
disseminated 1.60 
uneventful 1.59 
excess 1.59 
pelvis 1.59 
SR 1.59 
obscure 1.59 
Models 1.59 
sequencing 1.58 
immediate 1.58 
MeSHHemostasis 1.58 
overcome 1.58 
F-beta 1.58 
FL) 1.58 
drawbacks 1.58 
Short-term 1.58 
Anatomical 1.58 
dysplastic 1.58 
bulk 1.58 
Does 1.58 
Instruments 1.58 
another 1.58 
Ratio 1.58 
602 1.57 
Humeral 1.57 
utilizes 1.57 
MeSHApolipoproteinsE 1.57 
10(3) 1.57 
fluorodeoxyglucose-positron 1.57 
main 1.57 
accounted 1.57 
team 1.57 
disease: 1.57 
197 1.57 
screens 1.57 
MeSHArthralgia 1.57 
MeSHAmyloidbeta-Peptides 1.57 
510 1.57 
IFI 1.56 
conflict 1.56 
(18)F-FDG 1.56 
Fifty-six 1.56 
accordingly 1.56 
263 1.56 
MeSHSports 1.56 
312 1.56 
collections 1.56 
clue 1.56 
employed 1.56 
morphometric 1.56 
excretion 1.56 
micrometastatic 1.56 
023) 1.56 
Concerning 1.56 
15-year 1.56 
mosaics 1.56 
trocars 1.56 
differed 1.56 
86) 1.56 
on 1.56 
obstruction] 1.55 
embolism 1.55 
basin 1.55 
20- 1.55 
does 1.55 
(eight 1.54 
searches 1.54 
Spearman 1.54 
Characteristics 1.54 
cytogenetics 1.54 
Umbilical 1.54 
105 1.54 
agglutinin 1.54 
green 1.54 
standardization 1.54 
largest 1.54 
MeSHCommonBileDuctNeoplasms 1.54 
unsuspected 1.54 
gradually 1.54 
duct] 1.53 
Unilateral 1.53 
visually 1.53 
alternate 1.53 
regard 1.53 
(13 1.53 
facilitated 1.53 
204 1.53 
gyrus 1.53 
custom 1.53 
Effect 1.53 
twenty-four 1.53 
reoperated 1.53 
8-12 1.53 
Meanwhile 1.53 
extraovarian 1.53 
pathohistological 1.53 
haptoglobin 1.53 
bradycardia 1.53 
intimal 1.53 
Collaboration 1.53 
4500 1.53 
?/nMeSHChromosomeAberrations 1.53 
MeSHNerveGrowthFactors 1.53 
extremes 1.53 
Karyotypic 1.53 
Palm 1.53 
refining 1.53 
(n=18) 1.53 
MeSHDiagnosticTechniquesandProcedures 1.53 
75%; 1.53 
node; 1.53 
ALREADY: 1.53 
(HRCT) 1.53 
transplantation] 1.53 
(<4 1.53 
agency 1.53 
558 1.53 
meets 1.53 
norms 1.53 
precludes 1.53 
voxel-based 1.53 
30; 1.53 
underlying 1.53 
MeSHCollagen 1.52 
signal 1.52 
79) 1.52 
MeSHChi-SquareDistribution 1.52 
confound 1.52 
MeSHUnitedStates 1.52 
al: 1.52 
tracing 1.52 
Neelsen 1.52 
seventy 1.52 
6%; 1.52 
anti 1.52 
conduction 1.51 
IGRAs 1.51 
MeSHRadioimmunodetection 1.51 
mono- 1.51 
notion 1.51 
Thirty-four 1.51 
Biomedica 1.51 
bowel 1.51 
elect 1.50 
thereafter 1.50 
identified: 1.50 
refined 1.50 
classifying 1.50 
MeSHMammalian 1.50 
MeSHPostmenopause 1.50 
quantitative 1.50 
179 1.50 
184 1.50 
MeSHLigaments 1.50 
985 1.50 
MeSHMonitoring 1.49 
015 1.49 
follow-up) 1.49 
296 1.49 
Translocation 1.49 
+/-1 1.49 
played 1.49 
compass 1.49 
wanted 1.49 
MeSHDiploidy 1.49 
seventh 1.49 
MeSHMexico 1.49 
cross-reactivity 1.49 
topography 1.49 
UMP 1.48 
LBA 1.48 
55-64 1.48 
65-74 1.48 
Mainland 1.48 
pupillary 1.48 
094) 1.48 
Snyder 1.48 
Simulations 1.48 
detections 1.48 
1171 1.48 
attendees 1.48 
beta-blockers 1.48 
48-month 1.48 
'late 1.48 
hippocampi 1.48 
sequence-based 1.48 
Taqman 1.48 
MeSHVenousThromboembolism 1.48 
databases: 1.48 
hypofibrinogenemia 1.48 
MeSHThrombomodulin 1.48 
MeSHColorado 1.48 
trauma-related 1.48 
Analyte 1.48 
staging] 1.48 
IL2) 1.48 
wide-spread 1.48 
(hazards 1.48 
(mp 1.48 
histo-pathological 1.48 
3cm 1.48 
TN-staging 1.48 
sectorial 1.48 
Referring 1.48 
Acromial 1.48 
10-minute 1.48 
negative-predictive 1.48 
(worse 1.48 
pathoanatomy 1.48 
(AOR) 1.48 
dislocation) 1.48 
athlete's 1.48 
restraints 1.48 
badly 1.48 
complex; 1.48 
samples] 1.48 
1-hour 1.48 
monitoring] 1.48 
unreliability 1.48 
unquestionable 1.48 
hyperalimentation 1.48 
extraabdominal 1.48 
(NED) 1.48 
MeSHComputerGraphics 1.48 
377) 1.48 
(NFT) 1.48 
Lagos 1.48 
model-predicted 1.48 
enhancements 1.48 
>30) 1.48 
(restricted 1.48 
1069 1.48 
(2/5) 1.48 
(2/14) 1.48 
(IGF) 1.48 
(early) 1.48 
(MoM)) 1.48 
marker' 1.48 
1341 1.48 
(11-13 1.48 
Gender-specific 1.48 
Genzyme 1.48 
Patau's 1.48 
fetal) 1.48 
Hypoplastic 1.48 
unit's 1.48 
body-tail 1.48 
classifies 1.48 
bloc" 1.48 
7/27 1.48 
millimeters) 1.48 
trocar- 1.48 
(11%); 1.48 
(5%); 1.48 
(TR/TE 1.48 
arthrography: 1.48 
Hyperechoic 1.48 
given; 1.48 
history-taking 1.48 
(AG) 1.48 
free-hand 1.48 
1640 1.48 
Figures 1.48 
ethiology 1.48 
GGTP 1.48 
pancreatitis); 1.48 
basketing 1.48 
biochemistries 1.48 
Anbessa 1.48 
Specificities 1.48 
(blue 1.48 
H-E 1.48 
nodal-negative 1.48 
substudy 1.48 
(experimental 1.48 
382) 1.48 
motivating 1.48 
polymerase-chain 1.48 
performance; 1.48 
spatula 1.48 
Dacron 1.48 
(inflammation 1.48 
PCR-negative 1.48 
"high-risk" 1.48 
Boxborough 1.48 
II-III) 1.48 
point: 1.48 
MeSHAlabama 1.48 
cytotechnologists 1.48 
collected: 1.48 
(HPV)-positive 1.48 
association? 1.48 
MeSHNonlinearDynamics 1.48 
MeSHPsychoticDisorders 1.48 
people: 1.48 
MeSHPersonalityDisorders 1.48 
non-Caucasian 1.48 
MeSHFats 1.48 
THIS 1.48 
coitus 1.48 
(echogenic 1.48 
ultrasound? 1.48 
15/19 1.48 
Masses 1.48 
1938 1.48 
MeSHPhosphodiesteraseInhibitors 1.48 
mofetil 1.48 
(diabetes 1.48 
MeSHRenalReplacementTherapy 1.48 
hypokinetic 1.48 
(CMRgl) 1.48 
(IE) 1.48 
MeSHEthyleneGlycols 1.48 
troubled 1.48 
1311 1.48 
bronchoscopies 1.48 
1-18) 1.48 
antigen-negative 1.48 
Th1-mediated 1.48 
income 1.48 
impair 1.48 
overlapping 1.48 
Sequencing 1.48 
(Tc 1.48 
A-C 1.48 
"high 1.48 
=15) 1.48 
supplementation 1.48 
non-surgical 1.48 
variably 1.48 
therapy: 1.48 
669 1.48 
invasion 1.48 
15) 1.47 
females) 1.47 
carcinoma 1.47 
MeSHPelvicPain 1.47 
quantification 1.47 
premalignant 1.47 
MeSHRadiology 1.47 
024) 1.47 
roles 1.47 
self-report 1.47 
Score 1.47 
option 1.46 
ratio 1.46 
definition 1.46 
physical 1.46 
suggest 1.46 
inhalation 1.46 
vasculature 1.46 
rows 1.46 
MeSHMuscularAtrophy 1.46 
hazardous 1.46 
risen 1.46 
MeSHSecondaryPrevention 1.46 
lymphotropic 1.46 
?/nMeSHAgeFactors 1.46 
PRESENTATION: 1.46 
over-all 1.46 
bilateral) 1.46 
enthusiasm 1.46 
Complicated 1.46 
oligosaccharides 1.46 
underlined 1.46 
15-month 1.46 
microparticle 1.46 
10-cm 1.46 
thirty-eight 1.46 
10(8) 1.46 
arbitrarily 1.46 
technique] 1.46 
digitized 1.46 
retinopathy 1.46 
synchronously 1.46 
(RIA 1.46 
822 1.46 
apart 1.46 
painful 1.46 
1976 1.46 
(66%) 1.46 
001; 1.46 
8th 1.46 
dissected 1.46 
benefited 1.46 
Sao 1.46 
MeSHMonozygotic 1.46 
DNA) 1.46 
chains 1.45 
profound 1.45 
attempted 1.45 
radiography 1.44 
visible 1.44 
037 1.44 
avoids 1.44 
notably 1.44 
part 1.44 
visualizing 1.44 
tolerability 1.44 
stresses 1.44 
outflow 1.44 
inhabitants 1.44 
self-administered 1.44 
dimensions 1.44 
lymphadenectomies 1.43 
21] 1.43 
P< 1.43 
about 1.43 
MeSHTranslocation 1.43 
26%) 1.43 
degree 1.43 
severely 1.43 
thromboelastography 1.43 
believed 1.43 
035 1.43 
flex 1.43 
determinant 1.42 
carefully 1.42 
unbalanced 1.42 
somewhat 1.42 
(39% 1.42 
malformed 1.42 
>30 1.42 
ischemic 1.42 
Symptoms 1.42 
MeSHBinding 1.42 
MeSHExtensivelyDrug-ResistantTuberculosis 1.42 
genotyped 1.42 
amenable 1.42 
195 1.42 
surgery 1.42 
MEDLINE 1.42 
injured 1.41 
leiomyomas 1.41 
objectively 1.41 
MeSHEndometrialHyperplasia 1.41 
hysteroscopy 1.41 
rolled 1.41 
MeSHInterviewsasTopic 1.41 
echogenicity 1.41 
type 1.41 
Comparative 1.41 
Forty-seven 1.41 
imaged 1.41 
Interviews 1.41 
section) 1.41 
MeSHImmunoenzymeTechniques 1.41 
may 1.40 
simulate 1.40 
attributable 1.40 
(131) 1.40 
1940 1.40 
915 1.40 
0025 1.40 
Union 1.40 
3-month 1.40 
unsatisfactory 1.40 
5-10 1.40 
69%) 1.40 
EUS-guided 1.40 
MeSHReconstructiveSurgicalProcedures 1.40 
MeSHProto-OncogeneProteinsc-bcl-2 1.40 
MeSHAllergicBronchopulmonary 1.40 
exacerbation 1.40 
122) 1.40 
normalised 1.40 
(expressed 1.40 
Maternity 1.40 
(five) 1.40 
squares 1.40 
cubic 1.40 
examination) 1.40 
(NF) 1.40 
births) 1.40 
(secondary 1.40 
(n=12) 1.40 
(ND) 1.40 
(diagnostic 1.40 
selective 1.40 
ovaries 1.40 
direction 1.40 
characteristic 1.39 
Subjects 1.39 
esophagogastric 1.39 
MeSHTechnetiumTc99mSestamibi 1.39 
echocardiogram 1.39 
v2 1.39 
N-terminal 1.39 
synergistic 1.39 
MeSHMilitary 1.39 
Individuals 1.39 
MeSHLeucovorin 1.39 
charges 1.39 
MeSHRibosomal 1.39 
intercellular 1.39 
Birth 1.39 
portion 1.39 
SEM 1.39 
departments 1.38 
undetectable 1.38 
Simultaneous 1.38 
anterior 1.38 
MeSHMuscularDiseases 1.38 
elevations 1.38 
246 1.38 
depends 1.38 
closure 1.38 
genital 1.38 
173 1.38 
grossly 1.38 
formulate 1.38 
maneuvers 1.38 
categories: 1.38 
scatter 1.38 
MeSHSputum 1.37 
mRNA 1.37 
mean 1.37 
paediatric 1.37 
summarized 1.37 
027) 1.37 
disabled 1.37 
387 1.37 
germline 1.37 
MeSHDextrans 1.37 
primarily 1.37 
894 1.36 
0018 1.36 
also 1.36 
189 1.36 
hypothesis 1.36 
via 1.36 
Combinations 1.36 
structured 1.36 
Rh-negative 1.36 
HCM 1.36 
intraindividual 1.36 
head) 1.36 
363) 1.36 
WORC 1.36 
1035 1.36 
crescent-shaped 1.36 
aminotransferase) 1.36 
operator's 1.36 
ensemble 1.36 
post-RT 1.36 
(Haemoscope 1.36 
Niles 1.36 
Oslo 1.36 
vivo; 1.36 
10%); 1.36 
(GCS) 1.36 
(trauma 1.36 
(A5 1.36 
1016 1.36 
radiographs) 1.36 
MeSHChicago 1.36 
(ECC) 1.36 
arguably 1.36 
Siena 1.36 
N-category 1.36 
=55) 1.36 
(5/5) 1.36 
repositioned 1.36 
arthroscope 1.36 
(despite 1.36 
taping 1.36 
MeSHConsumerBehavior 1.36 
conjoined 1.36 
(PLR 1.36 
tendinopathies 1.36 
etiology; 1.36 
VII) 1.36 
OVID 1.36 
(236 1.36 
Please 1.36 
investigated; 1.36 
Spontaneously 1.36 
(Funded 1.36 
non-progressive 1.36 
(AN) 1.36 
metastases? 1.36 
day-case 1.36 
decisively 1.36 
hypokalemia 1.36 
overall; 1.36 
profitable 1.36 
298) 1.36 
DNCB 1.36 
non-contributory 1.36 
proviso 1.36 
privately 1.36 
MeSHLaser-DopplerFlowmetry 1.36 
MeSHRiskAdjustment 1.36 
(MSM) 1.36 
were; 1.36 
effective? 1.36 
non-visualized 1.36 
581) 1.36 
Turbo 1.36 
3000) 1.36 
Hepatology 1.36 
(lithiasis 1.36 
(alanine 1.36 
trans-abdominal 1.36 
insofar 1.36 
(57) 1.36 
bile-ducts 1.36 
(14/15) 1.36 
lifestyles 1.36 
believing 1.36 
abnormal; 1.36 
MeSHObstetricsandGynecologyDepartment 1.36 
(hTERT) 1.36 
recurrent) 1.36 
HPV31 1.36 
biomolecular 1.36 
meaningfully 1.36 
{CI} 1.36 
(2%); 1.36 
(<25 1.36 
23/24 1.36 
comparison) 1.36 
DNA: 1.36 
nononcogenic 1.36 
MeSHEcuador 1.36 
57%; 1.36 
nonclinical 1.36 
MeSHFrontotemporalDementia 1.36 
0/5) 1.36 
(TRUS) 1.36 
1058 1.36 
exist? 1.36 
(ASRM) 1.36 
bowels 1.36 
100-point 1.36 
(CSE) 1.36 
arteries) 1.36 
electrocardiograms 1.36 
(3-year 1.36 
vasodilatory 1.36 
coronaries 1.36 
supramarginal 1.36 
(FE) 1.36 
SVM 1.36 
engendered 1.36 
proven/probable 1.36 
28S 1.36 
Bucharest 1.36 
Episodes 1.36 
signs; 1.36 
purifying 1.36 
Pastorex 1.36 
MeSHSulfates 1.36 
questionnaire 1.35 
previous 1.35 
endpoint 1.35 
albumin 1.35 
Czech 1.35 
livebirths 1.35 
cordocentesis 1.35 
Biopsies 1.35 
357 1.35 
Threshold 1.35 
constituted 1.35 
contents 1.35 
leaving 1.35 
MeSHLiverFunctionTests 1.35 
relevance 1.35 
forearm 1.35 
choriocarcinoma 1.35 
502 1.35 
409 1.35 
results; 1.35 
noninvasively 1.35 
cocktail 1.35 
nothing 1.35 
nonsurgical 1.35 
males) 1.34 
long-lasting 1.34 
prognoses 1.34 
Hepatobiliary 1.34 
elusive 1.34 
resolving 1.34 
MeSHHysteroscopy 1.34 
ventral 1.34 
monosomy 1.34 
pigmented 1.34 
diagnosis: 1.34 
MeSHMagneticResonanceSpectroscopy 1.34 
Any 1.34 
(11) 1.34 
III 1.34 
cushion 1.34 
928 1.34 
summed 1.34 
777 1.34 
(102 1.34 
CCT 1.34 
MeSHPhilippines 1.34 
valued 1.34 
[hazard 1.34 
Prague 1.34 
adjuncts 1.34 
MeSHPsychologicalTests 1.34 
crash 1.34 
699 1.34 
MeSHAirMicrobiology 1.34 
=90 1.34 
Line 1.33 
Medline 1.33 
MeSHIodineRadioisotopes 1.33 
think 1.33 
MeSHProthrombinTime 1.33 
accessible 1.33 
Institute 1.33 
55) 1.33 
indices 1.33 
power 1.33 
274) 1.33 
MeSHIntestines 1.33 
produced 1.32 
anteroposterior 1.32 
microgram 1.32 
PSA 1.32 
interface 1.32 
indistinguishable 1.32 
Ziehl- 1.32 
magnitude 1.32 
Can 1.32 
positively 1.32 
periods 1.32 
MeSHRespiration 1.32 
aiming 1.32 
electromyography 1.32 
Yet 1.32 
MeSHUlcerative 1.32 
investigational 1.32 
45-year-old 1.32 
MeSHGuidelinesasTopic 1.32 
guiding 1.32 
(49% 1.32 
standardise 1.32 
07% 1.32 
322 1.32 
RATIONALE: 1.32 
psychometric 1.32 
MeSHBloodChemicalAnalysis 1.32 
99mTc 1.32 
Quantitative 1.32 
gynaecologic 1.32 
consistent 1.31 
velocity 1.31 
lose 1.31 
edema 1.31 
pT2 1.31 
069 1.30 
(human 1.30 
altogether 1.30 
consented 1.30 
cervix: 1.30 
MeSHPatternRecognition 1.30 
explicit 1.30 
fitting 1.30 
(PET/CT) 1.30 
repetition 1.30 
prudent 1.30 
34; 1.30 
radial 1.30 
old) 1.30 
menopausal 1.30 
injuries 1.30 
BNA 1.30 
(not 1.30 
belief 1.30 
operational 1.30 
side-effect 1.30 
Failure 1.30 
therapy) 1.30 
although 1.30 
MeSHIntralesional 1.30 
posteriorly 1.30 
longest 1.30 
MeSHBleomycin 1.30 
non-mosaic 1.30 
complications: 1.30 
MeSHUniversity 1.29 
chronically 1.29 
package 1.29 
contributing 1.29 
resections 1.29 
chosen 1.29 
France 1.29 
100000 1.29 
864 1.29 
143) 1.29 
photon 1.29 
intradermal 1.28 
AMA 1.28 
(0%) 1.28 
preventable 1.28 
cf 1.28 
rotational 1.28 
hyperechoic 1.28 
MeSHAntifungalAgents 1.28 
45X 1.28 
occured 1.28 
MeSHFetalMonitoring 1.28 
857 1.28 
respectively); 1.28 
sampling) 1.28 
884 1.28 
slopes 1.28 
25%; 1.28 
(size 1.28 
assists 1.28 
paradoxically 1.28 
(LFT) 1.28 
MeSHHistocytologicalPreparationTechniques 1.28 
retested 1.28 
MeSHSupinePosition 1.28 
63%) 1.28 
produces 1.28 
advance 1.27 
Bcl-2 1.27 
ANALYSIS: 1.27 
modulating 1.27 
MeSHInterferon-gammaReleaseTests 1.27 
duplicate 1.27 
specialty 1.27 
sex-matched 1.27 
165 1.26 
Though 1.26 
warranted 1.26 
063 1.26 
calibration 1.26 
compelling 1.26 
MeSHKidneyPelvis 1.26 
Fresh 1.26 
MeSHCross-OverStudies 1.26 
peculiar 1.26 
LH 1.26 
=50 1.26 
050 1.26 
Traumatic 1.26 
pain; 1.26 
Finding 1.26 
guide 1.26 
Proportion 1.26 
duration 1.25 
prevented 1.25 
(20%) 1.25 
157) 1.25 
074) 1.25 
5; 1.25 
suitability 1.25 
needs 1.25 
MeSHCardiacSurgicalProcedures 1.25 
Willebrand 1.25 
mm3 1.25 
Vietnam 1.25 
defines 1.25 
MeSHIminoAcids 1.25 
MeSHIran 1.25 
Parkinson's 1.25 
White 1.25 
wall 1.25 
MeSHFrozenSections 1.25 
relates 1.25 
palpation 1.25 
MeSHEndoscopes 1.25 
section 1.25 
episode 1.24 
signed 1.24 
Eastern 1.24 
Transient 1.24 
Development 1.24 
TIC 1.24 
carbohydrate 1.24 
impression 1.24 
(39%) 1.24 
Simulation 1.24 
1); 1.24 
spontaneously 1.24 
DPT 1.24 
prestroke 1.24 
rotators 1.24 
>11 1.24 
D-type 1.24 
non-AD 1.24 
syndecan 1.24 
00003) 1.24 
0062 1.24 
radiographs; 1.24 
anterior-inferior 1.24 
on-demand 1.24 
0028) 1.24 
p16-positive 1.24 
adenofibromas 1.24 
Zagreb 1.24 
(kidney 1.24 
uninterpretable 1.24 
antifibrinolytics 1.24 
(TSA) 1.24 
bpm 1.24 
MeSHIntracranialAneurysm 1.24 
casualties 1.24 
(53) 1.24 
crashes 1.24 
(NLR) 1.24 
esophagojejunostomy 1.24 
Accompanying 1.24 
1-7) 1.24 
(10/13 1.24 
(gender 1.24 
pathology? 1.24 
Non-steroidal 1.24 
rotation; 1.24 
inquiries 1.24 
securely 1.24 
chronology 1.24 
instability) 1.24 
1996-2006 1.24 
inclusion/exclusion 1.24 
hands-on 1.24 
Lusaka 1.24 
definition) 1.24 
MeSHParacentesis 1.24 
inaccurately 1.24 
3/45 1.24 
unforeseen 1.24 
Minh 1.24 
abdomino-pelvic 1.24 
95%; 1.24 
seric 1.24 
(every 1.24 
defensins 1.24 
near-diploid 1.24 
recurrences; 1.24 
(5th 1.24 
results? 1.24 
272) 1.24 
standalone 1.24 
(8/10) 1.24 
triallelic 1.24 
trimester? 1.24 
neoplasm; 1.24 
acquires 1.24 
orthopaedist 1.24 
Supplemental 1.24 
'high-risk' 1.24 
EHD 1.24 
mumol/L) 1.24 
specifies 1.24 
25/26 1.24 
17/20 1.24 
method's 1.24 
biopsy? 1.24 
(CIN3+) 1.24 
criteria] 1.24 
Aberdeen 1.24 
Binomial 1.24 
MeSHHumanpapillomavirus6 1.24 
(229 1.24 
Malignancies 1.24 
invitation 1.24 
321) 1.24 
post-hoc 1.24 
grade; 1.24 
"benign" 1.24 
"low-risk" 1.24 
Trichomonas 1.24 
gamble 1.24 
MCM 1.24 
Corporation) 1.24 
triennial 1.24 
Equivalent 1.24 
extraneous 1.24 
dermoids 1.24 
technique? 1.24 
examinations: 1.24 
Single-shot 1.24 
II-1) 1.24 
rectoscopy 1.24 
shading 1.24 
kappa: 1.24 
MeSHBroadLigament 1.24 
indentations 1.24 
(189 1.24 
25-75 1.24 
diabetes) 1.24 
(PSV) 1.24 
arteriosclerotic 1.24 
2-vessel 1.24 
SPM5 1.24 
IPC 1.24 
resting-state 1.24 
elders 1.24 
CART 1.24 
(10/12) 1.24 
Lowering 1.24 
tomography-based 1.24 
episodes) 1.24 
non-Aspergillus 1.24 
considered; 1.24 
exploitation 1.24 
(MS) 1.24 
MeSHNeoplasmInvasiveness 1.23 
sources 1.23 
effect 1.23 
Whether 1.23 
identifiable 1.23 
translate 1.23 
citrate 1.23 
spinous 1.23 
MeSHAustralia 1.23 
Advanced 1.23 
bled 1.23 
edition 1.23 
MeSHHemodynamics 1.23 
failing 1.23 
well-being 1.23 
image-guided 1.23 
burn 1.23 
Good 1.23 
Part 1.22 
438 1.22 
(TNM) 1.22 
computer-assisted 1.22 
Medicare 1.22 
Concordance 1.22 
interpretable 1.22 
facilities 1.22 
advent 1.22 
MeSHTechnetium 1.22 
091 1.22 
interrater 1.22 
enrolling 1.22 
NED 1.22 
Candidate 1.22 
cryoprecipitate 1.22 
MeSHCalibration 1.22 
mosaicisms 1.22 
Caution 1.22 
liveborns 1.22 
pooling 1.22 
(ESD) 1.22 
treatment? 1.22 
nodularity 1.22 
gadolinium-enhanced 1.22 
Existing 1.22 
polypectomy 1.22 
assigning 1.22 
(patients 1.22 
Medial 1.22 
(L) 1.22 
gyri 1.22 
MeSHLungTransplantation 1.22 
Organisation 1.22 
(110 1.22 
681 1.22 
053) 1.22 
nadir 1.22 
(general 1.22 
expenditures 1.22 
Science 1.22 
Several 1.22 
whole-blood 1.22 
method) 1.22 
Activities 1.22 
which 1.21 
0015 1.21 
866 1.21 
incomplete 1.21 
INTERVENTION(S): 1.21 
Published 1.21 
237 1.21 
(197 1.21 
referring 1.21 
224 1.21 
CA-125 1.21 
MeSHCardia 1.21 
positive) 1.21 
done 1.21 
(up 1.21 
Initially 1.21 
resembled 1.21 
expense 1.21 
LV 1.21 
(50% 1.21 
patient) 1.20 
patient's 1.20 
thyroglobulin 1.20 
MeSHBloodSedimentation 1.20 
MeSHElectroencephalography 1.20 
Angeles 1.20 
aims 1.20 
lymphoscintigraphy 1.20 
MeSHMycoses 1.20 
formation 1.20 
MeSHDiseaseProgression 1.20 
desirable 1.20 
tendency 1.20 
air 1.19 
(94% 1.19 
macroscopic 1.19 
117 1.19 
classification 1.19 
fall 1.19 
fragment 1.19 
MeSHMuscleContraction 1.19 
recognizing 1.19 
High-resolution 1.19 
dysplasias 1.19 
consent 1.19 
(AIS) 1.18 
fourteen 1.18 
whose 1.18 
assumptions 1.18 
Drugs 1.18 
re-evaluate 1.18 
perforations 1.18 
underlie 1.18 
chapter 1.18 
navigation 1.18 
marginal 1.18 
enhance 1.18 
(128 1.17 
0014 1.17 
207) 1.17 
056) 1.17 
155) 1.17 
refuse 1.17 
Low- 1.17 
IOC 1.17 
as 1.17 
TAT 1.17 
differing 1.17 
realize 1.17 
039 1.17 
0000) 1.17 
(101 1.17 
692 1.17 
data) 1.17 
perfectly 1.17 
waveforms 1.17 
well-described 1.17 
828 1.17 
anatomopathological 1.17 
Practitioners 1.17 
traumas 1.17 
788 1.17 
117) 1.17 
prompting 1.17 
surgeons' 1.17 
averages 1.17 
ducts; 1.17 
Relatively 1.17 
kappa) 1.17 
schooling 1.17 
T2W 1.17 
MeSHOrganophosphorusCompounds 1.17 
thumb 1.17 
Oncogenic 1.17 
916 1.17 
Reading 1.17 
beta-glucan 1.17 
summarizes 1.17 
lean 1.17 
Adherence 1.16 
AG 1.16 
?/nMeSHAneuploidy 1.16 
closely 1.16 
represented 1.16 
services 1.16 
neighboring 1.16 
tract] 1.16 
MeSHFamilyPractice 1.16 
transthoracic 1.16 
amputation 1.16 
352 1.16 
405 1.16 
ultrasonogram 1.16 
intra-articular 1.16 
verified 1.15 
cryo 1.15 
MeSHAmyloid 1.15 
(a) 1.15 
Adequate 1.15 
statement 1.15 
Characterization 1.15 
116 1.15 
titres 1.15 
(if 1.15 
echoendoscope 1.15 
(MI) 1.15 
MeSHTissuePlasminogenActivator 1.15 
059 1.15 
Markov 1.15 
selectively 1.15 
deaths 1.15 
remain 1.14 
varying 1.14 
Four 1.14 
tumors] 1.14 
153 1.14 
149 1.14 
establishing 1.14 
dilution 1.14 
(117 1.14 
center 1.14 
anxiety 1.14 
CRITERIA: 1.13 
MeSHCausality 1.13 
disrupted 1.13 
convincing 1.13 
pain] 1.13 
MeSHCondylomataAcuminata 1.13 
unexpectedly 1.13 
progresses 1.13 
delamination 1.13 
>> 1.13 
TRUS 1.13 
PIH 1.13 
(177 1.13 
1066 1.13 
oesophagogastric 1.13 
IDT 1.13 
curative-intent 1.13 
324) 1.13 
MY09/MY11 1.13 
prostacyclin 1.13 
(202 1.13 
miniaturized 1.13 
manuscripts 1.13 
Istituto 1.13 
1030 1.13 
1390 1.13 
GP5+/GP6+ 1.13 
yrs; 1.13 
interpreter 1.13 
spiculated 1.13 
solid-organ 1.13 
Posttraumatic 1.13 
curve: 1.13 
Recorded 1.13 
exogenously 1.13 
41%; 1.13 
(UGI) 1.13 
MeSHGastricFundus 1.13 
repair) 1.13 
AMED 1.13 
pronation 1.13 
non-dominant 1.13 
whipple 1.13 
acumen 1.13 
article: 1.13 
(Oxford 1.13 
labor-intensive 1.13 
(172 1.13 
bilary 1.13 
(LVEF) 1.13 
exploration) 1.13 
Analyzed 1.13 
fulfills 1.13 
302) 1.13 
PATIENTS/METHODS: 1.13 
nonrecurrent 1.13 
(40) 1.13 
25-50% 1.13 
TMs 1.13 
pain--a 1.13 
segmentally 1.13 
(n=46) 1.13 
(screening 1.13 
France] 1.13 
rates) 1.13 
'triple 1.13 
MeSHPatientPreference 1.13 
karyotype; 1.13 
redesigned 1.13 
(DBS) 1.13 
14-24 1.13 
peripartum 1.13 
Adopting 1.13 
organs; 1.13 
?/nMeSHBiliaryTractNeoplasms 1.13 
Nebraska 1.13 
EXPERIENCES 1.13 
(Cox) 1.13 
higher-risk 1.13 
partitioned 1.13 
disorder: 1.13 
Siemens) 1.13 
mismatches 1.13 
Intra-articular 1.13 
Tukey 1.13 
79%; 1.13 
(SAT) 1.13 
(metastasis 1.13 
(OR): 1.13 
question: 1.13 
(EBM) 1.13 
(>30 1.13 
stain) 1.13 
expecting 1.13 
coinfections 1.13 
indefinitely 1.13 
subcategorize 1.13 
unidimensional 1.13 
spiculation 1.13 
invalidating 1.13 
4/5) 1.13 
stranding 1.13 
(3/3) 1.13 
Written 1.13 
discoid 1.13 
bowel) 1.13 
non-endometriosis 1.13 
pre-surgery 1.13 
fluid; 1.13 
(2003) 1.13 
mycophenolate 1.13 
Single-photon 1.13 
MeSHIodobenzenes 1.13 
work-ups 1.13 
calcium-phosphate 1.13 
cardiomegaly 1.13 
(cTnT) 1.13 
83%; 1.13 
logrank 1.13 
(European 1.13 
usability 1.13 
(IP-10) 1.13 
ERCPs 1.13 
competitive 1.13 
relies 1.13 
students 1.13 
Literature 1.13 
RIT 1.13 
case) 1.13 
scheme 1.13 
recommendations 1.13 
offers 1.13 
stomach 1.13 
cervix 1.13 
referable 1.13 
doubling 1.13 
immunoassays 1.13 
notch 1.13 
15; 1.13 
plexus 1.13 
35) 1.12 
-12 1.12 
reoperation 1.12 
(18) 1.12 
Similar 1.12 
benefits 1.12 
avoidance 1.12 
846 1.12 
injury; 1.12 
(biliary 1.12 
proxy 1.12 
anti-Aspergillus 1.12 
anomalies: 1.12 
+7 1.12 
race/ethnicity 1.12 
Discrepancies 1.12 
overestimation 1.12 
(DTC) 1.12 
omitting 1.12 
showed: 1.12 
perpendicular 1.12 
echotomography 1.12 
MeSHGels 1.12 
726 1.12 
(MGIT 1.12 
don't 1.12 
(follow-up 1.12 
MEASUREMENTS: 1.11 
encouraging 1.11 
strongest 1.11 
contralateral 1.11 
RBC 1.11 
surprising 1.11 
Awareness 1.11 
therapeutics 1.11 
downstream 1.11 
glycoproteins 1.11 
official 1.11 
Pneumoperitoneum 1.11 
nowadays 1.11 
defer 1.11 
unpredictable 1.11 
caudate 1.11 
anatomical 1.11 
infiltrates 1.11 
MeSHFibrinolysis 1.11 
stand-alone 1.11 
checking 1.11 
rate: 1.11 
lateral) 1.11 
6/11 1.11 
close 1.11 
4th 1.11 
MeSHHomologous 1.11 
States 1.11 
rising 1.11 
intramural 1.10 
(min 1.10 
Pre-operative 1.10 
S100 1.10 
Important 1.10 
rather 1.10 
LBC 1.10 
065) 1.10 
(133 1.10 
178) 1.10 
vice 1.10 
mitral 1.10 
front 1.10 
Severity 1.10 
cholestatic 1.09 
MeSHTheoretical 1.09 
MeSHBloodFlowVelocity 1.09 
Green 1.09 
120 1.09 
consist 1.09 
junctional 1.09 
granulation 1.09 
investigations 1.09 
(63% 1.09 
hemorrhagic 1.09 
subluxation 1.08 
timing 1.08 
delineate 1.08 
polyps 1.08 
intracardiac 1.08 
WE 1.08 
cancer] 1.08 
Model 1.08 
MeSHEmbryonicandFetalDevelopment 1.08 
vehicle 1.08 
niger 1.08 
sheet 1.08 
Sputum 1.08 
compatible 1.08 
gastroscopy 1.07 
investigative 1.07 
(<3 1.07 
2001) 1.07 
MeSHProportionalHazardsModels 1.07 
catheterization 1.07 
dedicated 1.07 
orient 1.07 
Northern 1.07 
tends 1.07 
residents 1.07 
MeSHLaparoscopes 1.07 
subclinical 1.07 
022) 1.07 
SNPs 1.07 
encephalitis 1.07 
transduction 1.07 
subcarinal 1.07 
MeSHLidocaine 1.07 
Black 1.07 
virologic 1.07 
Sixty-eight 1.07 
356 1.07 
MRA 1.07 
executed 1.07 
(TEM) 1.07 
Citation 1.07 
fortuitous 1.07 
twinning 1.07 
11] 1.07 
Expected 1.07 
alike 1.07 
MeSHIopamidol 1.07 
conversely 1.07 
esophagogastroduodenoscopy 1.07 
MeSHHealthResources 1.07 
Pregnancy-associated 1.07 
sixty-two 1.07 
laparoscopy) 1.07 
malignancy: 1.07 
peer-reviewed 1.07 
Sonographically 1.07 
confidently 1.07 
points: 1.07 
caregivers 1.07 
IIIb 1.07 
577 1.07 
bones 1.06 
approached 1.06 
(96%) 1.06 
183) 1.06 
0016) 1.06 
(152 1.06 
moderately 1.06 
years) 1.06 
suspicious 1.06 
Apr 1.06 
egg 1.06 
collate 1.06 
Formal 1.06 
surface 1.06 
request 1.06 
MeSHPracticeGuidelinesasTopic 1.06 
upward 1.05 
discordance 1.05 
listed 1.05 
168 1.05 
relapsed 1.05 
107 1.05 
briefly 1.05 
exogenous 1.05 
tenderness 1.05 
felt 1.05 
020 1.05 
comparative 1.05 
min) 1.05 
Isolated 1.05 
explore 1.05 
048) 1.05 
fluoroquinolones 1.05 
completeness 1.05 
incompletely 1.05 
Aggressive 1.05 
in-depth 1.05 
10-20 1.05 
centrally 1.05 
dissolved 1.05 
concomitantly 1.05 
MeSHEmployment 1.05 
disappointing 1.05 
One 1.04 
vital 1.04 
irregular 1.04 
restrict 1.04 
training 1.04 
suited 1.04 
50%) 1.04 
episodic 1.04 
MeSHMagneticResonanceAngiography 1.04 
SAA 1.04 
lymphazurin 1.04 
pRb 1.04 
IU/mL) 1.04 
range] 1.04 
LY30 1.04 
High-frequency 1.04 
(lymphatic 1.04 
partial) 1.04 
patient-oriented 1.04 
1-30) 1.04 
osteochondritis 1.04 
debulked 1.04 
credibility 1.04 
markers' 1.04 
post-transplantation 1.04 
cTnI 1.04 
Whole-blood 1.04 
extrinsically 1.04 
wrote 1.04 
Clauss 1.04 
12-48 1.04 
(TIC) 1.04 
heparin-like 1.04 
MeSHMobileHealthUnits 1.04 
concentration) 1.04 
(167 1.04 
(N-) 1.04 
IM2 1.04 
stage-dependent 1.04 
periesophageal 1.04 
246) 1.04 
primary) 1.04 
Early-stage 1.04 
catheter-based 1.04 
cornerstones 1.04 
hampers 1.04 
type-II 1.04 
Nonrandomized 1.04 
user-friendly 1.04 
HIV-prevalence 1.04 
specimen; 1.04 
(18F-FDG) 1.04 
cost-effectively 1.04 
(1972 1.04 
intentionally 1.04 
units/ml 1.04 
MeSHHeterocyclicCompounds 1.04 
translating 1.04 
[20] 1.04 
assaying 1.04 
Pia 1.04 
minimised 1.04 
outcomes) 1.04 
10(-7)) 1.04 
(chorionic 1.04 
(structural 1.04 
exemplify 1.04 
changes] 1.04 
evaluation; 1.04 
possible: 1.04 
abandoning 1.04 
MR-cholangiopancreatography 1.04 
(SG) 1.04 
recorded; 1.04 
?/nMeSHBiliaryDyskinesia 1.04 
malpositioned 1.04 
Wire-guided 1.04 
postoperative) 1.04 
experience) 1.04 
transcutaneously 1.04 
theater 1.04 
them; 1.04 
Croatian 1.04 
(VIA) 1.04 
undertreatment 1.04 
test-negative 1.04 
2003-2004 1.04 
Study) 1.04 
ACIS 1.04 
paralleling 1.04 
Programmes 1.04 
MeSHRNAProbes 1.04 
42] 1.04 
undermined 1.04 
(6%); 1.04 
11-mo 1.04 
(VaD) 1.04 
VaD 1.04 
clinic-based 1.04 
subtests 1.04 
MeSHHerpesvirus1 1.04 
(third 1.04 
MeSHCorpusLuteum 1.04 
nonpigmented 1.04 
inaccuracies 1.04 
MeSHBrachialArtery 1.04 
52%; 1.04 
PCE 1.04 
micromol/L) 1.04 
MeSHMyocardialPerfusionImaging 1.04 
MeSHNeurology 1.04 
MeSHOrthopedicEquipment 1.04 
image-based 1.04 
neuropsychology 1.04 
immunologist 1.04 
MeSHHost-ParasiteInteractions 1.04 
heart-lung 1.04 
(EORTC) 1.04 
findings: 1.04 
(125 1.04 
(MDCT) 1.04 
obscured 1.04 
depicting 1.04 
506 1.04 
-- 1.04 
eleven 1.04 
166 1.04 
(8%) 1.03 
question 1.03 
Japanese 1.03 
both) 1.03 
continuing 1.03 
participant 1.03 
capabilities 1.03 
MeSHShoulderDislocation 1.03 
easy 1.03 
MeSHDataInterpretation 1.03 
(n=1) 1.02 
nitrogen 1.02 
(tumor 1.02 
reconstructive 1.02 
unspecific 1.02 
tumors) 1.02 
colloidal 1.02 
Controversy 1.02 
MeSHGraftRejection 1.02 
0045 1.02 
(145 1.02 
(195 1.02 
(169 1.02 
23%; 1.02 
tobacco 1.02 
juvenile 1.02 
002) 1.02 
RESULT: 1.02 
private 1.02 
MeSHMessenger 1.02 
(48%) 1.02 
dorsolateral 1.02 
MeSHSmallforGestationalAge 1.02 
MeSHIsoelectricFocusing 1.02 
fetuses: 1.02 
institutes 1.02 
684 1.02 
MeSHNorthAmerican 1.02 
legislation 1.02 
unnecessarily 1.02 
exponentially 1.02 
Innovative 1.02 
chemistries 1.02 
intra-epithelial 1.02 
culture) 1.02 
polytrauma 1.02 
resectional 1.02 
Row 1.02 
698 1.02 
fell 1.02 
reflecting 1.02 
014 1.02 
MeSHPremenopause 1.01 
314 1.01 
>8 1.01 
1984 1.01 
became 1.01 
age-matched 1.01 
databases 1.01 
univariate 1.01 
pregnancy: 1.01 
MeSHSigmoidNeoplasms 1.01 
underestimated 1.01 
2); 1.01 
MeSHRandomAllocation 1.01 
self-reported 1.01 
MeSHHospitalization 1.01 
MeSHCoronaryArteryBypass 1.01 
1990 1.01 
Stress 1.00 
MeSHMolecularWeight 1.00 
Weekly 1.00 
Rehabilitation 1.00 
?/nMeSHBloodCoagulation 1.00 
nonvisualization 1.00 
560 1.00 
MD) 1.00 
reducing 1.00 
immunoscintigraphy 1.00 
Profile 1.00 
MeSHClavicle 1.00 
behave 1.00 
neurodegenerative 1.00 
Due 1.00 
Brazil 1.00 
actually 1.00 
laterally 1.00 
primer 1.00 
600 1.00 
visualization 0.99 
122 0.99 
altered 0.99 
a) 0.99 
Regarding 0.99 
mural 0.99 
coming 0.99 
lymphadenectomy 0.99 
suspects 0.99 
MeSHCellCycle 0.99 
ventilation 0.99 
Memorial 0.99 
relatives 0.99 
MeSHPrecursorCellLymphoblasticLeukemia-Lymphoma 0.99 
MeSHMechanical 0.99 
invade 0.99 
gradient 0.99 
148 0.99 
endoscopic 0.99 
(>20 0.99 
0025) 0.99 
00005 0.99 
785 0.99 
1900 0.99 
1945 0.99 
989 0.98 
pronounced 0.98 
(standard 0.98 
allocation 0.98 
3-dimensional 0.98 
Spanish 0.98 
saved 0.98 
MeSHReferenceStandards 0.98 
128 0.98 
Center 0.98 
concentrate 0.98 
nulliparous 0.98 
COLLECTION 0.98 
combat 0.98 
XIII 0.98 
restrictions 0.98 
outlines 0.98 
compensatory 0.98 
single-stage 0.98 
qualitatively 0.98 
infiltration 0.98 
still 0.98 
Fisher 0.97 
MeSHMuscles 0.97 
reflected 0.97 
university 0.97 
declined 0.97 
IUI 0.97 
078 0.97 
(130 0.97 
informations 0.97 
safest 0.97 
830 0.97 
Native 0.97 
136) 0.97 
MeSHCompetitive 0.97 
731 0.97 
efficiencies 0.97 
Italy) 0.97 
MeSHDilatationandCurettage 0.97 
phased 0.97 
endometriosis? 0.97 
transplantations 0.97 
Hematology 0.97 
refute 0.97 
Normalized 0.97 
795 0.97 
sigma 0.97 
10%; 0.97 
(1-4 0.97 
groups: 0.97 
(as 0.97 
vary 0.97 
cytopathologic 0.97 
Eighty-six 0.97 
only) 0.97 
male/female 0.97 
507 0.97 
pivotal 0.97 
voluntary 0.97 
within 0.97 
(52 0.96 
preparations 0.96 
MeSHMulticenterStudiesasTopic 0.96 
peptide 0.96 
conflicting 0.96 
cavitary 0.96 
integrity 0.96 
sheets 0.96 
Saudi 0.96 
(1-3 0.96 
practically 0.96 
laceration 0.96 
MeSHPeritonealCavity 0.96 
biliopancreatic 0.96 
Investigations 0.96 
Glandular 0.96 
37-year-old 0.96 
Emerging 0.96 
analysis) 0.96 
doubled 0.96 
cautious 0.96 
promise 0.96 
990 0.95 
MeSHDuodenalNeoplasms 0.95 
digit 0.95 
misinterpretations 0.95 
Jiangsu 0.95 
heparinization 0.95 
1:1:1 0.95 
248) 0.95 
1(st) 0.95 
myogenic 0.95 
"for 0.95 
microg/L) 0.95 
226) 0.95 
teens 0.95 
scrapings 0.95 
koilocytosis 0.95 
inner-city 0.95 
struma 0.95 
ovarii 0.95 
time-varying 0.95 
onsite 0.95 
plasma-based 0.95 
death: 0.95 
inhibitor) 0.95 
(</=1 0.95 
esophagus] 0.95 
(distal 0.95 
continental 0.95 
EUS: 0.95 
20-MHz 0.95 
"large 0.95 
Normative 0.95 
activity-related 0.95 
fragmentary 0.95 
Confirmed 0.95 
invention 0.95 
(Hain 0.95 
?/nMeSHCanada 0.95 
hospital; 0.95 
"classical" 0.95 
letters 0.95 
47); 0.95 
Identifier: 0.95 
Metachronous 0.95 
Means 0.95 
recumbent 0.95 
therein 0.95 
NFT 0.95 
(5/6) 0.95 
0042 0.95 
Selecting 0.95 
MeSHFluoroimmunoassay 0.95 
certification 0.95 
systole 0.95 
hybridization] 0.95 
Thereby 0.95 
MeSHRepublicofBelarus 0.95 
woman) 0.95 
10/21 0.95 
DBS 0.95 
Peripancreatic 0.95 
patient? 0.95 
encircling 0.95 
recumbency 0.95 
examiner's 0.95 
correlational 0.95 
onset) 0.95 
Lund 0.95 
stone" 0.95 
ERCP? 0.95 
step-sectioning 0.95 
palpably 0.95 
nanocolloids 0.95 
Manchester 0.95 
Unified 0.95 
smears) 0.95 
Virologic 0.95 
(315 0.95 
segregating 0.95 
reliabilities 0.95 
interviewers 0.95 
Two-stage 0.95 
MeSHIntelligenceTests 0.95 
(effect 0.95 
generalizable 0.95 
implants) 0.95 
gadolinium-DTPA 0.95 
infiltration) 0.95 
recognising 0.95 
minimal-mild 0.95 
signs: 0.95 
retroverted 0.95 
masses) 0.95 
(crude 0.95 
amnesic 0.95 
Critically 0.95 
(CPA) 0.95 
criterium 0.95 
jirovecii 0.95 
caveats 0.95 
(34%) 0.95 
interquartile 0.95 
pulse 0.95 
MeSHSexChromosomeAberrations 0.95 
mL 0.95 
139) 0.95 
052) 0.95 
(<50 0.95 
thirds 0.95 
031 0.95 
Forty-five 0.95 
(0% 0.95 
economical 0.95 
sector 0.94 
titers 0.94 
substitution 0.94 
230 0.94 
Human 0.94 
bases 0.94 
(Ca 0.94 
situations 0.94 
quite 0.94 
frame 0.94 
Current 0.94 
subjects 0.94 
replace 0.94 
rose 0.94 
(two) 0.94 
760 0.94 
433 0.94 
bivariate 0.94 
Amongst 0.94 
Parameters 0.94 
Estimated 0.94 
evaluated: 0.94 
knowing 0.94 
Nomograms 0.94 
448 0.94 
(R0 0.94 
into 0.94 
arena 0.94 
classification) 0.94 
optimally 0.94 
freedom 0.94 
cold 0.93 
feet 0.93 
questionable 0.93 
informed 0.93 
familiar 0.93 
Excluding 0.93 
re-operation 0.93 
Patte 0.93 
responders 0.93 
surgery] 0.93 
MeSHPulmonaryA 0.93 
labelled 0.93 
094 0.93 
18FDG 0.93 
933 0.93 
662 0.93 
bibliographies 0.93 
Perhaps 0.93 
analysis; 0.93 
ovum 0.93 
758 0.93 
weighting 0.93 
robustness 0.93 
Two-dimensional 0.93 
study's 0.93 
Hopkins 0.93 
mmol/L 0.93 
775 0.93 
707 0.93 
window 0.93 
design 0.92 
MeSHAntigens 0.92 
Progression 0.92 
graphical 0.92 
limited 0.92 
MeSHMedical 0.92 
yields 0.92 
conclusive 0.92 
anatomy 0.92 
complement 0.92 
angiogenic 0.92 
harboring 0.92 
STR 0.92 
transplanted 0.92 
(of 0.92 
ratings 0.92 
PTT 0.92 
282 0.92 
broader 0.92 
Issue 0.92 
laparoscopy- 0.92 
MeSHL-LactateDehydrogenase 0.92 
hyper- 0.92 
devoid 0.92 
papillosphincterotomy 0.92 
Prophylaxis 0.92 
hyphae 0.92 
MeSHChronic 0.91 
adequacy 0.91 
intestinal 0.91 
Unit 0.91 
Lateral 0.91 
069) 0.91 
0014) 0.91 
etc) 0.91 
(96 0.91 
drop 0.91 
MeSHPostpartumPeriod 0.91 
accessed 0.91 
Meta-analysis 0.91 
adenocarcinoma: 0.91 
periodically 0.91 
Summary 0.91 
groove 0.91 
choledocolithiasis 0.91 
997) 0.91 
(2) 0.91 
MeSHColoringAgents 0.91 
kept 0.90 
hypercoagulable 0.90 
refers 0.90 
Selected 0.90 
319 0.90 
MeSHPatientCarePlanning 0.90 
Stages 0.90 
grey 0.90 
two) 0.90 
Laparosc 0.90 
designed 0.90 
coexistence 0.90 
Detailed 0.90 
transcripts 0.90 
MeSHGlycoproteins 0.90 
infiltrative 0.90 
grounds 0.90 
College 0.90 
96) 0.90 
FINDINGS: 0.90 
4; 0.90 
microbiologic 0.90 
MeSHHumans 0.89 
039) 0.89 
MeSHPeru 0.89 
achieves 0.89 
MeSHLymphoscintigraphy 0.89 
MeSHUreteralDiseases 0.89 
MeSHEmbryonicDevelopment 0.89 
survey 0.89 
030 0.89 
thrombelastography 0.89 
=2 0.89 
Amniotic 0.89 
Education 0.89 
BMD 0.89 
dominated 0.89 
themselves 0.89 
Obstet 0.89 
MeSHHuman 0.89 
miss 0.89 
compensate 0.89 
016) 0.89 
Until 0.88 
MeSHDNA-BindingProteins 0.88 
(73% 0.88 
History 0.88 
kaolin 0.88 
638 0.88 
paraclinical 0.88 
647 0.88 
MeSHNeedsAssessment 0.88 
multiplication 0.88 
1000) 0.88 
modifiers 0.88 
subject's 0.88 
invasion) 0.88 
ultrasonography] 0.88 
prerequisites 0.88 
physiotherapist 0.88 
MeSHIntestinalPolyps 0.88 
fifty-five 0.88 
condom 0.88 
(201 0.88 
ERCP; 0.88 
=17) 0.88 
randomisation 0.88 
occasions 0.88 
achieved 0.88 
004) 0.88 
charts 0.88 
methodological 0.88 
predictions 0.88 
nineteen 0.88 
alpha1 0.88 
Year 0.88 
MeSHFibrinogen 0.88 
(6% 0.88 
genetically 0.88 
roentgen 0.88 
27% 0.88 
oldest 0.87 
intoxication 0.87 
clavicle 0.87 
low-cost 0.87 
node) 0.87 
extra-hepatic 0.87 
EUR 0.87 
33; 0.87 
declare 0.87 
transfusion 0.87 
paralleled 0.87 
durable 0.87 
drug-susceptible 0.87 
antegrade 0.87 
furthermore 0.87 
lymphoma) 0.87 
MeSHIschemia 0.87 
Chi-square 0.87 
maxilla 0.87 
SELECTION 0.87 
0013) 0.87 
075) 0.87 
0201 0.87 
063) 0.87 
072) 0.87 
077) 0.87 
(139 0.87 
0015) 0.87 
tissular 0.87 
ODN 0.87 
mmol/L) 0.87 
186) 0.87 
(version 0.87 
FNB 0.87 
dubious 0.87 
'soft 0.87 
(ROTEM(R)) 0.87 
mg; 0.87 
objectivity 0.87 
(single- 0.87 
four-fold 0.87 
accuracy; 0.87 
first-choice 0.87 
undergraduate 0.87 
postgraduate 0.87 
milligrams 0.87 
PLR 0.87 
curriculum 0.87 
expedited 0.87 
-21% 0.87 
sediments 0.87 
roll-out 0.87 
lateral-flow 0.87 
(SPET) 0.87 
carcinosis 0.87 
41); 0.87 
MeSHColorectalSurgery 0.87 
"blind" 0.87 
gastroenteric 0.87 
Roentgenograms 0.87 
developers 0.87 
comprehend 0.87 
AFP; 0.87 
Hypoplasia 0.87 
outweighs 0.87 
case-series 0.87 
ADAM12s 0.87 
gleaned 0.87 
assessors 0.87 
low-lying 0.87 
tears] 0.87 
spoiled 0.87 
(cholangitis 0.87 
calculi; 0.87 
Applied 0.87 
AMY 0.87 
(3-5 0.87 
subdermally 0.87 
incriminated 0.87 
SNL 0.87 
staining; 0.87 
Extending 0.87 
sub-population 0.87 
vials 0.87 
over-treatment 0.87 
Type-specific 0.87 
MeSHUncertainty 0.87 
Twice 0.87 
overwhelmingly 0.87 
(estrogen 0.87 
(RR: 0.87 
8q24 0.87 
nurses' 0.87 
Cache 0.87 
(age: 0.87 
glide 0.87 
interrogation 0.87 
worthwhile? 0.87 
Intraobserver 0.87 
phases: 0.87 
left/right 0.87 
test's 0.87 
obstruction) 0.87 
[HP 0.87 
informational 0.87 
201Tl 0.87 
trajectories 0.87 
timepoint 0.87 
MeSHRibosomalSpacer 0.87 
agrees 0.87 
0011) 0.87 
fluid 0.87 
operatively 0.87 
viable 0.87 
Cardiovascular 0.87 
competence 0.87 
epitopes 0.87 
(64%) 0.87 
South 0.87 
OI 0.87 
Committee 0.87 
cavities 0.87 
Nearly 0.87 
(CSF) 0.87 
oriented 0.87 
N1 0.86 
1981 0.86 
checked 0.86 
amniotic 0.86 
Various 0.86 
frontal 0.86 
278 0.85 
intensified 0.85 
RQ 0.85 
MeSHPlateletFunctionTests 0.85 
MeSHPhospholipids 0.85 
Participation 0.85 
Arabia 0.85 
distinctly 0.85 
gastroenterology 0.85 
MeSHGeneAmplification 0.85 
frontotemporal 0.85 
files 0.85 
positioning 0.85 
unilateral 0.85 
1979 0.85 
(seven 0.85 
290 0.85 
have 0.85 
thus 0.85 
non-specific 0.85 
diffusely 0.85 
PAC 0.85 
integration 0.85 
MeSHMovement 0.85 
Relative 0.85 
021 0.85 
await 0.85 
2010 0.85 
Information 0.84 
17%) 0.84 
fractional 0.84 
crossover 0.84 
twenty-three 0.84 
MeSHMuscleStrength 0.84 
necessary? 0.84 
MeSHParietalLobe 0.84 
416 0.84 
years-old 0.84 
reevaluated 0.84 
Dermoid 0.84 
(32% 0.84 
92) 0.84 
Verbal 0.84 
579 0.84 
914 0.84 
platforms 0.84 
diagram 0.84 
abruptio 0.84 
IVF-ET 0.84 
clomiphene 0.84 
867 0.84 
Two-thirds 0.84 
751 0.84 
associates 0.84 
probabilistic 0.84 
obviated 0.84 
intraparenchymal 0.84 
(sentinel 0.84 
productivity 0.84 
(NC) 0.84 
MeSHAnilineCompounds 0.84 
(ICU) 0.84 
554 0.84 
DTC) 0.84 
evaluable 0.84 
tight 0.84 
bronchoalveolar 0.84 
format 0.84 
085) 0.83 
0069 0.83 
definite 0.83 
origins 0.83 
improved 0.83 
include: 0.83 
warts 0.83 
thromboelastographic 0.83 
subserosa 0.83 
quantifying 0.83 
anchors 0.83 
therapeutically 0.83 
22; 0.83 
047) 0.83 
(CHD) 0.83 
extraperitoneal 0.83 
depressive 0.83 
CAP 0.83 
MeSHMissense 0.83 
positioned 0.83 
MeSHAmnioticFluid 0.83 
lowering 0.83 
026) 0.83 
265 0.83 
PET-CT 0.83 
tomography/computed 0.83 
Absence 0.83 
344 0.83 
satisfactorily 0.83 
costly 0.83 
Because 0.83 
MeSHGel 0.82 
Centre 0.82 
INTERPRETATION 0.82 
technologies 0.82 
productive 0.82 
70%) 0.82 
arch 0.82 
interesting 0.82 
(8% 0.82 
other 0.82 
early-stage 0.82 
ER 0.82 
RAD 0.82 
Previously 0.82 
Statistically 0.82 
MeSHArtifacts 0.82 
21st 0.82 
maximum 0.82 
captured 0.81 
Eighty-three 0.81 
473 0.81 
depending 0.81 
(20% 0.81 
Gene 0.81 
(95%CI 0.81 
218 0.81 
platform 0.81 
deserve 0.81 
Systematic 0.81 
usage 0.81 
[OR] 0.81 
distention 0.81 
contracted 0.81 
colloids 0.81 
occlusive 0.81 
transfected 0.81 
(SS 0.81 
(T1 0.81 
3000 0.81 
jaundiced 0.81 
created 0.81 
1-3 0.81 
Frozen 0.81 
visualise 0.81 
assignment 0.81 
Sixty-two 0.81 
non-SLN 0.81 
mapping 0.81 
ART 0.81 
moot 0.80 
(46 0.80 
HRCT 0.80 
mechanism(s) 0.80 
outcomes: 0.80 
understaged 0.80 
(RC) 0.80 
TB-endemic 0.80 
rapidity 0.80 
reproductive-age 0.80 
quadrivalent 0.80 
Experiments 0.80 
patterns: 0.80 
(DWI) 0.80 
2013 0.80 
fusiform 0.80 
706 0.80 
652 0.80 
Idea 0.80 
2/13 0.80 
Dept 0.80 
hospitals 0.80 
chart 0.80 
Cochrane 0.80 
Duke's 0.80 
denatured 0.80 
084) 0.80 
062) 0.80 
fungemia 0.80 
>or=35 0.80 
office-based 0.80 
cholescintigraphic 0.80 
(referred 0.80 
L(-1)) 0.80 
(>40 0.80 
parameters; 0.80 
MeSHNeuroprotectiveAgents 0.80 
(TAT) 0.80 
(invasive 0.80 
bruising 0.80 
bodyweight 0.80 
(1992) 0.80 
(n=36) 0.80 
R0-resection 0.80 
(n=26) 0.80 
MeSHMiniaturization 0.80 
detectors 0.80 
(1997) 0.80 
microbubbles 0.80 
(SIT) 0.80 
athletics 0.80 
resistance) 0.80 
(>/=2 0.80 
pre-ART 0.80 
(Stages 0.80 
MeSHNatriureticPeptide 0.80 
"second 0.80 
(CA19-9) 0.80 
study)] 0.80 
precancers 0.80 
secondaries 0.80 
duties 0.80 
back-up 0.80 
MeSHFrontalBone 0.80 
(DV) 0.80 
handicaps 0.80 
MeSHLebanon 0.80 
(multivariate 0.80 
undiscovered 0.80 
celioscopy 0.80 
micro-metastases 0.80 
athletes: 0.80 
cross-talk 0.80 
MeSHOfficeVisits 0.80 
perforating 0.80 
gadopentetate 0.80 
nonjaundiced 0.80 
(bilirubin 0.80 
custom-made 0.80 
abutting 0.80 
Peritumoral 0.80 
semiautomated 0.80 
Campinas 0.80 
underscored 0.80 
exposure) 0.80 
chlamydial 0.80 
356) 0.80 
Calculations 0.80 
(>100 0.80 
Ottawa 0.80 
neoplasia) 0.80 
Conflicting 0.80 
well-accepted 0.80 
recto-sigmoid 0.80 
anyone 0.80 
guarantees 0.80 
81%; 0.80 
TTE 0.80 
events: 0.80 
(peak 0.80 
(CCS) 0.80 
AD-like 0.80 
(Aspergillus 0.80 
[95%CI 0.80 
candidemia 0.80 
MeSHMycologicalTypingTechniques 0.80 
Elisa 0.80 
posttranslational 0.80 
gives 0.80 
(IHC) 0.80 
MeSHEpidemiologicMethods 0.80 
disabling 0.80 
adenomas 0.80 
excisional 0.80 
kg) 0.80 
025) 0.80 
1-8 0.80 
00002 0.80 
082) 0.80 
182) 0.80 
0021 0.80 
081) 0.80 
008 0.80 
properly 0.79 
missing 0.79 
MeSHSerum 0.79 
011 0.79 
042 0.79 
decision-making 0.79 
lesser 0.79 
radiology 0.79 
video 0.79 
chip 0.79 
multimodality 0.79 
Pathogenesis 0.79 
MeSHFeces 0.79 
1968 0.79 
washings 0.79 
parameters: 0.79 
Localization 0.79 
displays 0.79 
Attention 0.79 
24-month 0.79 
Organ 0.79 
18) 0.79 
HIV-associated 0.79 
Fifty-four 0.79 
Analyse 0.79 
adherence 0.79 
NR 0.79 
citrated 0.79 
3/7 0.79 
Sachs 0.79 
Improving 0.79 
inherent 0.79 
demographics 0.78 
meaning 0.78 
750 0.78 
inactivation 0.78 
B: 0.78 
structurally 0.78 
131 0.78 
01; 0.78 
Few 0.78 
check 0.78 
SLN 0.78 
TEG 0.78 
repeatedly 0.78 
223 0.78 
traditional 0.77 
342 0.77 
Rio 0.77 
MeSHRareDiseases 0.77 
reaches 0.77 
leiomyosarcoma 0.77 
Town 0.77 
symptoms; 0.77 
roentgenologic 0.77 
MeSHGammaCameras 0.77 
intellectual 0.77 
deals 0.77 
additive 0.77 
abandoned 0.77 
grouping 0.77 
range: 0.77 
gynaecological 0.77 
MeSHMultivariateAnalysis 0.77 
MeSHPelvis 0.77 
external 0.77 
situated 0.77 
(AFB) 0.77 
vascularity 0.77 
physician 0.77 
Oriental 0.76 
(four) 0.76 
677 0.76 
CPC 0.76 
(ranging 0.76 
aliquots 0.76 
MeSHAntithrombinIII 0.76 
Ellis 0.76 
tremor 0.76 
portend 0.76 
Slide 0.76 
checklist 0.76 
ahead 0.76 
reassessment 0.76 
panels 0.76 
II-2) 0.76 
knew 0.76 
(local 0.76 
friendly 0.76 
Nam 0.76 
Proton 0.76 
These 0.76 
Audit 0.76 
recording 0.76 
oncological 0.76 
abstracted 0.76 
MeSHNeoplasmSeeding 0.76 
afterward 0.76 
mold 0.76 
worthy 0.76 
Span 0.76 
survived 0.76 
(120 0.76 
fecal 0.76 
permeability 0.76 
(excluding 0.76 
sensibility 0.76 
005); 0.76 
-121 0.76 
089) 0.76 
095) 0.76 
-02 0.76 
010 0.76 
RR 0.76 
because 0.76 
helps 0.75 
pulsed 0.75 
microscope 0.75 
effectively 0.75 
correlates 0.75 
(1) 0.75 
II 0.75 
clues 0.75 
supplementary 0.75 
exploratory 0.75 
rhesus 0.75 
speculated 0.75 
MeSHRepublicofKorea 0.75 
MeSHSyphilis 0.75 
Update 0.75 
exocrine 0.75 
seeding 0.75 
Notably 0.75 
2008) 0.75 
follow-ups 0.75 
(HIV-1) 0.75 
MeSHArteriosclerosis 0.75 
disease? 0.75 
hospitalisation 0.75 
implementing 0.75 
(65%) 0.75 
MeSHResearch 0.75 
walls 0.75 
intended 0.75 
stepwise 0.75 
theoretical 0.75 
(SLN 0.74 
emerged 0.74 
becoming 0.74 
fallopian 0.74 
simulated 0.74 
microscopy 0.74 
unfavourable 0.74 
funding 0.74 
reoperations 0.74 
249 0.74 
Fertility 0.74 
entirely 0.74 
nitric 0.73 
reflection 0.73 
hallmark 0.73 
sexes 0.73 
(LV 0.73 
TRUNCATED 0.73 
acromiale 0.73 
083) 0.73 
items) 0.73 
thrombomodulin 0.73 
pathoanatomical 0.73 
Santiago 0.73 
82%; 0.73 
Tumori 0.73 
FASTER 0.73 
1050 0.73 
HPV-6 0.73 
Verification 0.73 
N-terminus 0.73 
thromboprophylaxis 0.73 
curve) 0.73 
(rather 0.73 
(axial 0.73 
down-staging 0.73 
eighty-three 0.73 
Pretherapeutic 0.73 
T-category 0.73 
MeSHSulfurHexafluoride 0.73 
lessening 0.73 
meta-regression 0.73 
(coefficient 0.73 
MeSHDrugApproval 0.73 
tested) 0.73 
cells/ml 0.73 
profiled 0.73 
stages) 0.73 
asymptomatic) 0.73 
"real 0.73 
(previously 0.73 
2001-2006 0.73 
noninferiority 0.73 
(geometric 0.73 
wrongly 0.73 
aneuploidies) 0.73 
glyceraldehyde-3-phosphate 0.73 
Asan 0.73 
forecasting 0.73 
modalities: 0.73 
quantifies 0.73 
joint) 0.73 
One-way 0.73 
Philips 0.73 
(associated 0.73 
potentiality 0.73 
choledocholitiasis 0.73 
opacify 0.73 
99m-Tc 0.73 
judiciously 0.73 
2001-2003 0.73 
Switzerland) 0.73 
hTERT 0.73 
6-monthly 0.73 
21-month 0.73 
preservative 0.73 
(HPV)-related 0.73 
(reduction 0.73 
immunolocalization 0.73 
higher-grade 0.73 
unimportant 0.73 
189) 0.73 
bowel: 0.73 
junction: 0.73 
colon) 0.73 
(185 0.73 
(proportion 0.73 
MeSHNitrates 0.73 
pancreas) 0.73 
spurious 0.73 
uraemic 0.73 
92%; 0.73 
MTL 0.73 
busy 0.73 
infection-related 0.73 
MeSHPenicillanicAcid 0.73 
not) 0.73 
fluid: 0.73 
mycoplasma 0.73 
site-directed 0.73 
condyloma 0.73 
gynecologists 0.73 
(mainly 0.73 
463 0.73 
Determining 0.73 
OUTCOMES 0.73 
Office 0.73 
09; 0.73 
(pT 0.73 
UCLA 0.73 
B3 0.73 
organisation 0.73 
Key 0.73 
tumor) 0.73 
MeSHSexuallyTransmittedDiseases 0.73 
MeSHFattyAcids 0.73 
10000 0.73 
IU/l 0.73 
downstaging 0.73 
time; 0.73 
prematurely 0.73 
005; 0.73 
chemotherapy) 0.73 
U/L) 0.73 
MeSHOligonucleotideProbes 0.73 
multi-centre 0.73 
analyzed: 0.73 
MeSHAutomated 0.73 
thirty-four 0.73 
(mRNA 0.73 
Posterior 0.73 
(72%) 0.72 
214 0.72 
genetic 0.72 
camera 0.72 
1-4 0.72 
Guidelines 0.72 
068) 0.72 
003] 0.72 
(174 0.72 
12-fold 0.72 
244) 0.72 
MeSHHemoglobins 0.72 
places 0.72 
histopathology 0.72 
cm) 0.72 
MeSHAgeDistribution 0.72 
facts 0.72 
6-week 0.71 
MeSHHydropsFetalis 0.71 
teams 0.71 
strength 0.71 
(BMD) 0.71 
orientation 0.71 
elucidate 0.71 
Odds 0.71 
rules 0.71 
Typical 0.71 
fulfilled 0.71 
driven 0.71 
exists 0.71 
definitively 0.71 
generic 0.71 
MeSHDisseminatedIntravascularCoagulation 0.71 
absolutely 0.71 
viscosity 0.71 
stock 0.71 
circular 0.71 
MeSHRetreatment 0.71 
biopsy: 0.71 
utmost 0.71 
infection] 0.71 
MeSHChorionicVilli 0.71 
dual 0.71 
inducible 0.71 
standardised 0.71 
NB 0.71 
MeSHRadiopharmaceuticals 0.71 
(TEG 0.71 
contraction 0.71 
without 0.70 
delineating 0.70 
03% 0.70 
?/nMeSHAbdominalNeoplasms 0.70 
Impairment 0.70 
(<2 0.70 
Genotype 0.70 
unexplained 0.70 
(54%) 0.70 
024 0.70 
(GI 0.70 
corpus 0.70 
cortices 0.70 
(32%) 0.70 
MeSHSweden 0.70 
initial 0.70 
reversed 0.70 
linkage 0.70 
March 0.70 
phenotypic 0.70 
nonsentinel 0.69 
thirteen 0.69 
scant 0.69 
genders 0.69 
MeSHEgypt 0.69 
fifty-seven 0.69 
diminishes 0.69 
drug-sensitive 0.69 
573 0.69 
MeSHHalf-Life 0.69 
closest 0.69 
qualify 0.69 
bladder) 0.69 
luteum 0.69 
aspergillosis: 0.69 
Penetrating 0.69 
(TM) 0.69 
594 0.69 
meglumine 0.69 
62; 0.69 
thinner 0.69 
Criteria 0.69 
indeterminate 0.69 
disease; 0.69 
lots 0.69 
wish 0.69 
methodologies 0.69 
9-month 0.69 
Marked 0.69 
nosocomial 0.69 
invaluable 0.69 
MeSHTumorSuppressorProteins 0.69 
intercourse 0.69 
faint 0.69 
milder 0.69 
Intermediate 0.69 
Plasmids 0.69 
Fisher's 0.69 
Brazilian 0.69 
sterile 0.69 
SPSS 0.69 
forward 0.69 
PubMed 0.69 
Therefore 0.69 
CONTEXT: 0.68 
027 0.68 
integral 0.68 
argue 0.68 
External 0.68 
physicians 0.68 
justified 0.68 
00005) 0.68 
205) 0.68 
(183 0.68 
Residual 0.68 
background 0.68 
Contrast-enhanced 0.68 
risky 0.68 
(single 0.68 
2003) 0.68 
choose 0.68 
approval 0.68 
MeSHAspartateAminotransferases 0.68 
presumptive 0.67 
Revised 0.67 
ALT) 0.67 
Radical 0.67 
Average 0.67 
classes 0.67 
Denmark 0.67 
overexpressed 0.67 
ratio) 0.67 
MeSHDelayedDiagnosis 0.67 
genomes 0.67 
organizations 0.67 
traced 0.67 
medium-sized 0.67 
merely 0.67 
Regardless 0.67 
opacified 0.67 
Reported 0.67 
wounds 0.67 
facets 0.67 
Chlamydia 0.67 
13-year 0.67 
MeSHTransplantationImmunology 0.67 
PSV 0.67 
residual/recurrent 0.67 
moderate/severe 0.67 
(P-value 0.67 
hypocoagulation 0.67 
mitigated 0.67 
Marseille 0.67 
anti-Mullerian 0.67 
misses 0.67 
LNE 0.67 
parameters) 0.67 
MeSHSanFrancisco 0.67 
(HF) 0.67 
state) 0.67 
thromboelastograms 0.67 
PROCEDURES: 0.67 
splenectomies 0.67 
T2-T3 0.67 
(MPR) 0.67 
218) 0.67 
hyperechogenicity 0.67 
(EGD) 0.67 
echoendoscopy 0.67 
forceful 0.67 
MeSHFibrocartilage 0.67 
[median 0.67 
differentiation: 0.67 
MeSHHypertrophic 0.67 
3-72 0.67 
membrane-associated 0.67 
Windows 0.67 
Concurrently 0.67 
antigens: 0.67 
(30) 0.67 
ensues 0.67 
(17%); 0.67 
(equivalent 0.67 
Aiming 0.67 
(129 0.67 
cost-utility 0.67 
11-15 0.67 
observed-to-expected 0.67 
Belarus 0.67 
Anteroposterior 0.67 
(RAS) 0.67 
2006-2008 0.67 
supplanted 0.67 
(final 0.67 
staging; 0.67 
(3-D) 0.67 
needless 0.67 
Difficulty 0.67 
171) 0.67 
suspecting 0.67 
injection: 0.67 
seromas 0.67 
mg/mL) 0.67 
(30%); 0.67 
MeSHNanostructures 0.67 
anti-apoptotic 0.67 
(cost 0.67 
debut 0.67 
(LLETZ) 0.67 
PCR: 0.67 
(borderline 0.67 
reviewed: 0.67 
dysplasia) 0.67 
?/nMeSHCervixUteri 0.67 
Ecuador 0.67 
pre-invasive 0.67 
change) 0.67 
semistructured 0.67 
(here 0.67 
MeSHLearningCurve 0.67 
incidence) 0.67 
(TE) 0.67 
protocol: 0.67 
septations 0.67 
regions: 0.67 
pretransplantation 0.67 
(chest 0.67 
MeSHCardiacOutput 0.67 
masks 0.67 
MeSHBenzothiazoles 0.67 
Implementing 0.67 
aspergilli 0.67 
began 0.67 
unless 0.67 
matter 0.67 
pitfall 0.67 
rises 0.67 
limits 0.66 
newborns 0.66 
black 0.66 
scenario 0.66 
GE 0.66 
until 0.66 
hypometabolic 0.66 
725 0.66 
(n=11) 0.66 
coagulopathies 0.66 
dichotomous 0.66 
observed; 0.66 
lends 0.66 
Autosomal 0.66 
MeSHTechnologyAssessment 0.66 
MeSHIsometricContraction 0.66 
ninth 0.66 
unequivocally 0.66 
bigger 0.66 
(Spearman 0.66 
presence/absence 0.66 
size) 0.66 
L(-1) 0.66 
Thoracolumbar 0.66 
957 0.66 
(>4 0.66 
618 0.66 
123) 0.66 
16-positive 0.66 
MeSHGeneticVariation 0.66 
psychosocial 0.66 
dropped 0.66 
inappropriate 0.66 
clotting 0.66 
14) 0.66 
choosing 0.65 
bulky 0.65 
Economic 0.65 
MeSHImageProcessing 0.65 
viscoelastic 0.65 
Finnish 0.65 
Paris 0.65 
470 0.65 
5-month 0.65 
MeSHHospitals 0.65 
MeSHGastrectomy 0.65 
universally 0.65 
MeSHDigestiveSystemDiseases 0.65 
bank 0.65 
(12) 0.65 
324 0.65 
propagation 0.65 
marking 0.65 
MeSHTanzania 0.65 
protects 0.65 
FDA 0.65 
Eighty-two 0.65 
serodiagnosis 0.65 
53%) 0.65 
MeSHGastrointestinalDiseases 0.65 
LIMITATIONS 0.65 
protease 0.65 
recognised 0.65 
WORDS)/nMeSHAdult 0.64 
opposite 0.64 
style 0.64 
0034) 0.64 
0029) 0.64 
0024 0.64 
0045) 0.64 
073) 0.64 
(67%) 0.64 
convenient 0.64 
Ki-67 0.64 
BD 0.64 
Clinic 0.64 
acceptance 0.64 
hypercoagulability 0.64 
endoprosthesis 0.64 
eliminating 0.64 
Certain 0.64 
1973 0.64 
collective 0.64 
gynecology 0.64 
Host 0.64 
mixture 0.64 
6-8 0.64 
confined 0.64 
gastrointestinal 0.63 
immunocompromised 0.63 
Twenty-four 0.63 
revised 0.63 
Randomized 0.63 
interim 0.63 
043) 0.63 
distances 0.63 
MeSHPlacebos 0.63 
revisited 0.63 
short-course 0.63 
WA 0.63 
avoidable 0.63 
Lymphadenectomy 0.63 
Available 0.63 
MeSHCerebrovascularDisorders 0.63 
MeSHIsoenzymes 0.63 
functionally 0.63 
Genetics 0.63 
outpatients 0.63 
far 0.63 
minus 0.63 
anterior-posterior 0.63 
transfuse 0.63 
utilizing 0.63 
Also 0.63 
instance 0.63 
balanced 0.63 
experience 0.63 
MeSHBrainInjuries 0.63 
fulfilling 0.63 
AML 0.63 
Glasgow 0.63 
Assurance 0.63 
Clin 0.63 
gonosomal 0.63 
hyperintensity 0.63 
dysgenesis 0.63 
621 0.63 
nonresponders 0.63 
by: 0.63 
trough 0.63 
sensitivity) 0.63 
MeSHQuebec 0.63 
ischaemia 0.63 
(PCA) 0.63 
3/9 0.63 
millimeters 0.63 
Troponin 0.63 
days; 0.62 
opacification 0.62 
tumors: 0.62 
MeSHBloodGlucose 0.62 
immunodetection 0.62 
emphasize 0.62 
major 0.62 
generally 0.62 
inability 0.62 
scintigraphic 0.62 
analyzed 0.62 
critically 0.62 
endoscope 0.62 
Anterior 0.62 
GT 0.62 
resting 0.62 
(six 0.62 
intraoperative 0.61 
MATERIALS: 0.61 
micrometastasis 0.61 
TN 0.61 
06% 0.61 
visualised 0.61 
STRATEGY: 0.61 
Immediately 0.61 
MeSHMilitaryPersonnel 0.61 
constraints 0.61 
ethics 0.61 
People 0.61 
Subgroup 0.61 
TB-HIV 0.61 
jaundice] 0.61 
cholecystectomy) 0.61 
lymphoscintigraphic 0.61 
biomedical 0.61 
MeSHSexualBehavior 0.61 
laparotomic 0.61 
Generalized 0.61 
cryptococcosis 0.61 
reviewing 0.61 
lavage 0.61 
pelvic 0.61 
months; 0.61 
overt 0.61 
feasible 0.61 
Twenty-five 0.61 
ROTEM((R)) 0.61 
098) 0.61 
torsional 0.61 
laparoscopist 0.61 
spiking 0.61 
inhibitor-1 0.61 
MeSHSyndecan-1 0.61 
MeSHPostgastrectomySyndromes 0.61 
MPR) 0.61 
MeSHSerousMembrane 0.61 
D0 0.61 
>/=30 0.61 
Glenoid 0.61 
subjacent 0.61 
resistance: 0.61 
MeSH16thCentury 0.61 
assays: 0.61 
Fab' 0.61 
Consistently 0.61 
hyponatremia 0.61 
-26% 0.61 
liver; 0.61 
(colon 0.61 
evaluation) 0.61 
cardiopathy 0.61 
Intact 0.61 
replaces 0.61 
ante- 0.61 
dependant 0.61 
non-contrast 0.61 
msec 0.61 
PIR 0.61 
(McNemar 0.61 
Southwestern 0.61 
1002 0.61 
uncomfortable 0.61 
outweighed 0.61 
re-excision 0.61 
MeSHRNASplicing 0.61 
proposition 0.61 
demographically 0.61 
diversified 0.61 
taxonomic 0.61 
banks 0.61 
"true 0.61 
1924 0.61 
MeSHPairedBoxTranscriptionFactors 0.61 
(focal 0.61 
subsample 0.61 
common; 0.61 
difference) 0.61 
Ancillary 0.61 
underrecognized 0.61 
(166 0.61 
mass; 0.61 
Annular 0.61 
occurred: 0.61 
(young 0.61 
prespecified 0.61 
64-slice 0.61 
voxel-wise 0.61 
distinctions 0.61 
(GVHD) 0.61 
MeSHPiperacillin 0.61 
genus-specific 0.61 
(4) 0.61 
job 0.61 
Carotid 0.61 
0046 0.61 
(207 0.61 
(156 0.61 
71%; 0.61 
290) 0.61 
0017) 0.61 
-174 0.61 
1934 0.61 
51%; 0.61 
0039 0.61 
nuclei) 0.61 
=35) 0.61 
MeSHGenotype 0.61 
urea 0.61 
MeSHGynecologicSurgicalProcedures 0.61 
MeSHCandidiasis 0.61 
Collective 0.60 
Anomalies 0.60 
(chi(2) 0.60 
isotopic 0.60 
Chart 0.60 
0007 0.60 
concrements 0.60 
aspartate 0.60 
MeSHDecisionTrees 0.60 
differs 0.60 
Occult 0.60 
documented 0.60 
coexisting 0.60 
ulceration 0.60 
following: 0.60 
adenocarcinomas 0.60 
permit 0.60 
months) 0.60 
overlooked 0.60 
wave 0.60 
participated 0.60 
diameter 0.60 
non-malignant 0.59 
Danish 0.59 
thoroughly 0.59 
Mycobacterial 0.59 
archival 0.59 
yrs 0.59 
Object 0.59 
vial 0.59 
95%CI 0.59 
principal 0.59 
(196 0.59 
answers 0.59 
ventriculomegaly 0.59 
longitudinally 0.59 
helping 0.59 
hidden 0.59 
time) 0.59 
089 0.59 
reimbursement 0.59 
understage 0.59 
Patau 0.59 
One-hundred 0.59 
<100 0.59 
2T 0.59 
isoelectric 0.59 
triplets 0.59 
(21) 0.59 
musculotendinous 0.59 
(LJ) 0.59 
(median: 0.59 
favors 0.59 
cases)] 0.59 
graft-versus-host 0.59 
>80 0.59 
Nevertheless 0.59 
stroke 0.59 
dead 0.59 
"gold 0.59 
(clinic 0.59 
septal 0.59 
peritumoral 0.59 
3-mo 0.59 
outcome 0.59 
20%) 0.59 
(82%) 0.59 
(Tr 0.59 
displayed 0.59 
women's 0.59 
8; 0.59 
nodule 0.58 
pT1 0.58 
Thirty-eight 0.58 
resolution 0.58 
possibly 0.58 
unreported 0.58 
4-fold 0.58 
supplied 0.58 
capsulitis 0.58 
Assays 0.58 
Operating 0.58 
MeSHCerebralCortex 0.58 
Random 0.58 
anatomically 0.58 
contacted 0.58 
optimization 0.58 
MeSHGeneDeletion 0.58 
artifacts 0.58 
determinate 0.58 
stability 0.58 
119 0.58 
(23% 0.58 
Web 0.57 
engaged 0.57 
communicate 0.57 
pulsatility 0.57 
MeSHKlinefelterSyndrome 0.57 
fissure 0.57 
more) 0.57 
MeSHHipFractures 0.57 
overload 0.57 
muscular 0.57 
MeSHBiomechanicalPhenomena 0.57 
pool 0.57 
abort 0.57 
comprise 0.57 
MeSHAreaUnderCurve 0.57 
versa 0.57 
(6%) 0.57 
radical 0.57 
Reduced 0.57 
Indirect 0.57 
thickening 0.57 
advantage 0.57 
Database 0.57 
75-84 0.57 
012; 0.57 
0027) 0.57 
(58) 0.57 
0002; 0.57 
311) 0.57 
0023) 0.57 
0036 0.57 
filter 0.57 
East 0.57 
weakly 0.57 
atherosclerosis 0.57 
(79%) 0.57 
>50 0.57 
patent 0.57 
skeletal 0.57 
GICA 0.56 
Gross 0.56 
superiority 0.56 
VI) 0.56 
averaged 0.56 
dizygotic 0.56 
microinvasion 0.56 
pectoris 0.56 
674 0.56 
proficiency 0.56 
period) 0.56 
ANOVA) 0.56 
1-2% 0.56 
4p 0.56 
949 0.56 
MeSHIntelligence 0.56 
76; 0.56 
g) 0.56 
fails 0.56 
1983 0.56 
BG 0.56 
suggested 0.56 
populations 0.56 
indirect 0.56 
(99%) 0.56 
declines 0.56 
assistant 0.56 
(RMP) 0.56 
MeSHMaxilla 0.56 
IU/ml 0.56 
424 0.56 
A5 0.56 
LPA 0.56 
Non-invasive 0.56 
076) 0.56 
FOV 0.56 
(IQR: 0.56 
microcolloid 0.56 
aerosolized 0.56 
"positive" 0.56 
stage-specific 0.56 
dropping 0.56 
cells/mul 0.56 
t-test) 0.56 
1/1000 0.56 
perimeter 0.56 
discounted 0.56 
mm(3)) 0.56 
moderate-severe 0.56 
MeSHBloodGasAnalysis 0.56 
present: 0.56 
"negative" 0.56 
unblinded 0.56 
58%; 0.56 
three-step 0.56 
Goutallier 0.56 
85%; 0.56 
testing; 0.56 
MeSHNucleicAcids 0.56 
unilobar 0.56 
>18 0.56 
outnumbered 0.56 
immunoscintigraphic 0.56 
imagery 0.56 
board-certified 0.56 
malignancy; 0.56 
median; 0.56 
mothers' 0.56 
fashioned 0.56 
nodal) 0.56 
legitimate 0.56 
Node-positive 0.56 
HPB 0.56 
his/her 0.56 
(twenty 0.56 
Verify 0.56 
FUNCTION 0.56 
duodenitis 0.56 
signifies 0.56 
4/32 0.56 
"hot" 0.56 
Arizona 0.56 
1-yr 0.56 
cytohistological 0.56 
changes; 0.56 
managements 0.56 
HPV-infected 0.56 
MeSHObstetricalandGynecological 0.56 
Concordant 0.56 
(Cronbach's 0.56 
illiterate 0.56 
short-form 0.56 
membership 0.56 
paraovarian 0.56 
CHU 0.56 
179) 0.56 
Irish 0.56 
adapting 0.56 
fumigatus-specific 0.56 
surveying 0.56 
direct 0.56 
Other 0.56 
elicited 0.56 
79%) 0.56 
elapsed 0.56 
precipitating 0.56 
Alternatively 0.56 
10-mm 0.56 
Multivariable 0.56 
subhepatic 0.56 
sphincterotomies 0.56 
upstaged 0.56 
bulging 0.56 
substrates 0.56 
embryogenesis 0.56 
airways 0.56 
comprising 0.56 
stenoses 0.55 
Cytogenetics 0.55 
>4 0.55 
registration 0.55 
MeSHClinicalEnzymeTests 0.55 
fluorodeoxyglucose 0.55 
pretreatment 0.55 
1989 0.55 
minority 0.55 
MeSHComputer-Assisted 0.55 
30%) 0.55 
044 0.55 
ESS 0.55 
MeSHDecisionSupportTechniques 0.55 
MeSHSteroids 0.55 
office 0.55 
MeSHTransplantation 0.55 
posture 0.55 
cartilage 0.55 
IOC) 0.55 
therefore 0.54 
elderly 0.54 
neuroimaging 0.54 
inoperable 0.54 
Standards 0.54 
MeSHRespiratoryFunctionTests 0.54 
24-hour 0.54 
RBCs 0.54 
Swiss 0.54 
Description 0.54 
altering 0.54 
Quantification 0.54 
disorders: 0.54 
haematoxylin 0.54 
MeSHDrugDeliverySystems 0.54 
MeSHCommunityHealthServices 0.54 
Anderson 0.54 
inactivated 0.54 
MeSHPyrimidines 0.54 
Controlled 0.54 
Subsequent 0.54 
09% 0.54 
overuse 0.54 
twenty-five 0.54 
resumption 0.54 
asymmetry 0.54 
popularity 0.54 
alert 0.54 
syndrome] 0.53 
(23%) 0.53 
saturation 0.53 
072 0.53 
GenoType 0.53 
667 0.53 
aPTT 0.53 
operation) 0.53 
(ages 0.53 
intra-uterine 0.53 
assumes 0.53 
(OI) 0.53 
cryopreservation 0.53 
643 0.53 
MeSHUmbilicalCord 0.53 
ESS) 0.53 
UK) 0.53 
longterm 0.53 
anamnestic 0.53 
homes 0.53 
MeSHDepressiveDisorder 0.53 
U/mL) 0.53 
up] 0.53 
954) 0.53 
(239 0.53 
(13%); 0.53 
(39) 0.53 
200% 0.53 
0032 0.53 
invasiveness 0.53 
belonged 0.53 
adhesive 0.53 
suite 0.53 
Pre- 0.53 
rearrangements 0.53 
57%) 0.53 
CA) 0.52 
(14% 0.52 
surviving 0.52 
change 0.52 
allograft 0.52 
cross-section 0.52 
Novel 0.52 
happen 0.52 
(especially 0.52 
indirectly 0.52 
mug 0.52 
one-third 0.52 
T1a 0.52 
lidocaine 0.52 
epinephrine 0.52 
Victoria 0.52 
dioxide 0.52 
infection; 0.52 
primaries 0.52 
hematomas 0.52 
(iv) 0.52 
Characteristic 0.52 
(67% 0.52 
version 0.52 
women: 0.52 
?/nMeSHFemale 0.52 
cadaveric 0.52 
echographic 0.52 
asks 0.52 
MeSHSeverityofIllnessIndex 0.52 
(27 0.52 
enable 0.52 
namely 0.52 
MeSHStress 0.52 
(except 0.51 
summarise 0.51 
detachment 0.51 
(Canadian 0.51 
0-25 0.51 
(an 0.51 
Services 0.51 
loads 0.51 
UICC 0.51 
Classification 0.51 
007 0.51 
obviate 0.51 
And 0.51 
I(2) 0.51 
mortality) 0.51 
effectivity 0.51 
retropancreatic 0.51 
gantry 0.51 
IU/L) 0.51 
(via 0.51 
Overt 0.51 
10-19 0.51 
Aneuploidies 0.51 
reluctant 0.51 
undocumented 0.51 
sonolucent 0.51 
40%; 0.51 
acetonide 0.51 
osteochondral 0.51 
12B 0.51 
13/14 0.51 
allied 0.51 
(survival 0.51 
176) 0.51 
disease--a 0.51 
DS; 0.51 
fetuses; 0.51 
Serbia 0.51 
Edward's 0.51 
respecting 0.51 
problems: 0.51 
Basing 0.51 
nonselected 0.51 
underdiagnosis 0.51 
2cm 0.51 
Disease-specific 0.51 
1-9) 0.51 
edemas 0.51 
nulliparity 0.51 
(n=24) 0.51 
Analyzing 0.51 
(QALY) 0.51 
interrelationships 0.51 
excluded) 0.51 
intervention; 0.51 
MeSHMolecularProbeTechniques 0.51 
[Am 0.51 
cross-cultural 0.51 
Scale) 0.51 
64%; 0.51 
cramps 0.51 
sonomorphologic 0.51 
depicts 0.51 
none) 0.51 
non-cardiac 0.51 
(Univ 0.51 
categorizing 0.51 
chemotherapy-induced 0.51 
years' 0.51 
endoscopists 0.51 
epidermoid 0.51 
24-h 0.51 
008) 0.51 
predictability 0.51 
872 0.51 
MeSHProteinC 0.51 
116) 0.51 
chorionicity 0.51 
instabilities 0.51 
symptoms: 0.51 
(EPTB) 0.51 
colostomy 0.51 
Assuming 0.51 
pancreatitis; 0.51 
SAB 0.51 
cumbersome 0.51 
99mTc-labeled 0.51 
735 0.51 
Telomerase 0.51 
MeSHTelomerase 0.51 
MeSHCross-CulturalComparison 0.51 
MeSHCarotidArteries 0.51 
496 0.51 
forced 0.51 
National 0.50 
Reoperation 0.50 
purposes 0.50 
viral 0.50 
Injury 0.50 
wash 0.50 
scintigrams 0.50 
Mexican 0.50 
MeSHThromboembolism 0.50 
MeSHHemodilution 0.50 
Observational 0.50 
MeSHVietnam 0.50 
omphalocele 0.50 
AE1/AE3 0.50 
Columbia 0.50 
married 0.50 
(about 0.50 
MeSHTriazoles 0.50 
consuming 0.50 
METHODOLOGY: 0.50 
life-threatening 0.50 
MeSHPloidies 0.50 
confers 0.50 
overlying 0.50 
289 0.50 
expanded 0.50 
029 0.50 
Sera 0.50 
unstable 0.49 
POC 0.49 
intraclass 0.49 
Precise 0.49 
361 0.49 
simplicity 0.49 
(>5 0.49 
07; 0.49 
anticoagulation 0.49 
voids 0.49 
classifications 0.49 
choledocholithiasis] 0.49 
g/L 0.49 
MeSHTerminologyasTopic 0.49 
0026) 0.49 
097) 0.49 
0064 0.49 
46%; 0.49 
1023 0.49 
46XX 0.49 
1073 0.49 
(225 0.49 
(203 0.49 
0078 0.49 
0048) 0.49 
0065 0.49 
1931 0.49 
1897 0.49 
inferior 0.49 
While 0.49 
perfusion 0.49 
2-4 0.49 
Prior 0.49 
organization 0.49 
MeSHRadionuclideImaging 0.49 
Making 0.49 
however 0.49 
GI 0.49 
sacral 0.49 
subtypes 0.49 
appearance 0.49 
seems 0.49 
examining 0.49 
Tc-99 0.48 
04% 0.48 
senile 0.48 
military 0.48 
Distal 0.48 
Satisfactory 0.48 
shortest 0.48 
cystadenocarcinoma 0.48 
analysis: 0.48 
breath-hold 0.48 
sparse 0.48 
performing 0.48 
MeSHStatisticsasTopic 0.48 
concerns 0.48 
diminished 0.48 
162 0.48 
Incidence 0.48 
reflects 0.48 
initiating 0.48 
explorations 0.48 
>/= 0.48 
shaped 0.48 
resolved 0.48 
nontuberculous 0.48 
Periodic 0.48 
cancel 0.48 
MRT 0.48 
087 0.48 
troponin 0.48 
DTC 0.48 
velocities 0.48 
judgement 0.48 
arrived 0.48 
MeSHMicrospheres 0.48 
Whilst 0.48 
isoenzyme 0.48 
basically 0.48 
irregularly 0.48 
Location 0.48 
exhaustive 0.48 
37; 0.48 
therapist 0.48 
foetus 0.48 
excessive 0.48 
favour 0.48 
number 0.48 
32%) 0.47 
2-D 0.47 
>/=2 0.47 
SN) 0.47 
Modified 0.47 
neonatal 0.47 
intraluminal 0.47 
4-month 0.47 
historical 0.47 
parametrial 0.47 
044) 0.47 
subtraction 0.47 
min; 0.47 
inhaled 0.47 
Institutes 0.47 
MeSHBodyFluids 0.47 
MeSHChemoradiotherapy 0.47 
MeSHIndiumRadioisotopes 0.47 
dismal 0.47 
conditioned 0.47 
MeSHAntimony 0.47 
17; 0.47 
Sagittal 0.47 
(DM) 0.47 
conference 0.47 
salt 0.47 
tumorous 0.47 
drawing 0.47 
Lowenstein-Jensen 0.47 
prolongation 0.47 
Swedish 0.47 
Clot 0.47 
wards 0.47 
subset 0.46 
MeSHBloodProteins 0.46 
implies 0.46 
Lanka 0.46 
milliliters 0.46 
Hypercoagulability 0.46 
critique 0.46 
decontaminated 0.46 
MSM 0.46 
1949 0.46 
admission) 0.46 
(those 0.46 
Quick 0.46 
Limits 0.46 
(MD) 0.46 
injuries) 0.46 
thromboelastometric 0.46 
scirrhous 0.46 
included; 0.46 
GOALS: 0.46 
cubital 0.46 
standardizing 0.46 
MeSHCompressiveStrength 0.46 
ingredients 0.46 
hydroxide 0.46 
30-50% 0.46 
amounting 0.46 
(plasma 0.46 
(k) 0.46 
MRI; 0.46 
oncology] 0.46 
non-compliance 0.46 
Anomaly 0.46 
?/nMeSHFollow-UpStudies 0.46 
MRI] 0.46 
Ultrasonographically 0.46 
routines 0.46 
specifity 0.46 
indiscriminate 0.46 
diffused 0.46 
(AE1/AE3) 0.46 
position) 0.46 
cytospin 0.46 
Community-based 0.46 
monolayers 0.46 
(p53 0.46 
culled 0.46 
biopsy-proved 0.46 
(1000 0.46 
169) 0.46 
dot-blot 0.46 
(32) 0.46 
(squamous 0.46 
well-demarcated 0.46 
adenomyomas 0.46 
inhomogeneity 0.46 
justified? 0.46 
usefully 0.46 
Z-scores 0.46 
bullous 0.46 
Prize 0.46 
MeSHMyelodysplasticSyndromes 0.46 
PROCEDURE: 0.46 
13-month 0.46 
(ANC 0.46 
MeSHCXCR3 0.46 
perhaps 0.46 
Experience 0.46 
2011 0.46 
shortening 0.46 
(AP 0.46 
doubt 0.46 
apply 0.46 
What 0.46 
prothrombin 0.46 
patients; 0.46 
CA 0.46 
District 0.46 
directly 0.46 
Laparotomy 0.46 
indicate 0.46 
shape 0.46 
changing 0.46 
0024) 0.45 
(230 0.45 
0043) 0.45 
1242 0.45 
0063 0.45 
0044 0.45 
0020 0.45 
1096 0.45 
(49) 0.45 
clinic 0.45 
spatial 0.45 
hazards 0.45 
337 0.45 
MeSHLaboratories 0.45 
MeSHMusculoskeletalDiseases 0.45 
MeSHMetaplasia 0.45 
Ia) 0.45 
Subject 0.45 
MeSHPair14 0.45 
Military 0.45 
IMPLICATIONS 0.45 
[range 0.45 
r/l 0.45 
17th 0.45 
proximally 0.45 
Anastomotic 0.45 
subepithelial 0.45 
MeSHPainThreshold 0.45 
centralized 0.45 
increments 0.45 
<25 0.45 
(>6 0.45 
(anterior 0.45 
exercised 0.45 
moves 0.45 
87; 0.45 
UI 0.45 
Presence 0.45 
(five 0.45 
303 0.45 
appropriateness 0.45 
cm; 0.45 
coincidence 0.45 
simplify 0.45 
MeSHCentrifugation 0.45 
TB: 0.45 
Much 0.45 
Reducing 0.45 
MeSHIntradermal 0.45 
promotion 0.45 
extrapelvic 0.45 
dysmenorrhoea 0.45 
transiently 0.45 
antibacterial 0.45 
Quad 0.45 
(>1 0.45 
cross-sectional 0.45 
provision 0.45 
g/dL 0.45 
procedure-related 0.45 
shortened 0.45 
days) 0.45 
interviewed 0.45 
penetration 0.45 
Metastases 0.45 
ovarian 0.44 
ran 0.44 
embryos 0.44 
Twenty-three 0.44 
(90%) 0.44 
87) 0.44 
subjected 0.44 
4] 0.44 
City 0.44 
MeSHCardiac 0.44 
complaints 0.44 
Breslow 0.44 
achievement 0.44 
Modern 0.44 
174 0.44 
specially 0.44 
(68 0.44 
load 0.44 
(13%) 0.44 
solve 0.44 
Task 0.43 
dyspareunia 0.43 
annular 0.43 
?/nMeSHAIDS-RelatedOpportunisticInfections 0.43 
homogeneity 0.43 
dependency 0.43 
tabulated 0.43 
exactly 0.43 
Faculty 0.43 
Angina 0.43 
judicious 0.43 
itching 0.43 
0006) 0.43 
T1b 0.43 
Chile 0.43 
haemorrhagic 0.43 
aggressively 0.43 
single-institution 0.43 
inhA 0.43 
check-up 0.43 
MeSHSacrococcygealRegion 0.43 
loops 0.43 
Collectively 0.43 
connections 0.43 
10-fold 0.43 
110 0.43 
summary 0.43 
optimized 0.43 
geographical 0.43 
empirical 0.43 
Cross-sectional 0.43 
refused 0.43 
institution 0.43 
half 0.43 
male-to-female 0.43 
MeSHEmergencyTreatment 0.43 
primigravid 0.43 
glycemic 0.43 
687 0.43 
unaltered 0.43 
thirty-six 0.43 
567 0.43 
visibility 0.43 
consenting 0.43 
Exact 0.43 
ureters 0.43 
Alterations 0.43 
features: 0.43 
superficial 0.43 
showed 0.43 
mins 0.43 
colonization 0.43 
declining 0.43 
tables 0.43 
tumor-associated 0.43 
fundus 0.42 
extra-pulmonary 0.42 
stool 0.42 
dislocations 0.42 
monitored 0.42 
[(18)F]FDG 0.42 
AMT 0.42 
aminotransferases 0.42 
competency 0.42 
18FDG-PET 0.42 
U; 0.42 
veteran 0.42 
(CACS) 0.42 
(clot 0.42 
GRADE 0.42 
concealment 0.42 
complex) 0.42 
(October 0.42 
(iNOS) 0.42 
2300 0.42 
MeSHLaboratory 0.42 
MeSHKaolin 0.42 
rank-sum 0.42 
(176 0.42 
abrasion 0.42 
carcinoma--a 0.42 
described; 0.42 
Intraclass 0.42 
MeSHIndomethacin 0.42 
Trust 0.42 
Immunotec 0.42 
8-hour 0.42 
RX 0.42 
MeSHCardiomyopathy 0.42 
[33 0.42 
PET-positive 0.42 
<80 0.42 
antibody) 0.42 
WORDS)/nMeSHAdenocarcinoma 0.42 
(PND) 0.42 
(IT) 0.42 
circulation: 0.42 
(observed 0.42 
trimester] 0.42 
non-Down 0.42 
outcome] 0.42 
Excluded 0.42 
Neonates 0.42 
risk-benefit 0.42 
(metastatic 0.42 
mainstays 0.42 
nonobstructive 0.42 
16-month 0.42 
treated; 0.42 
0019) 0.42 
(health 0.42 
basing 0.42 
immunochemistry 0.42 
papillomavirus-associated 0.42 
instructive 0.42 
T(2)-w 0.42 
wall; 0.42 
Acquisition 0.42 
unintended 0.42 
dyschezia 0.42 
185) 0.42 
proposed: 0.42 
fever) 0.42 
88%; 0.42 
antigen-positive 0.42 
plasmids 0.42 
suggestive 0.42 
digital 0.42 
endoscopy 0.42 
12-month 0.42 
extrinsic 0.42 
0036) 0.42 
262) 0.42 
0010) 0.42 
(48) 0.42 
0098) 0.42 
263) 0.42 
-05 0.42 
1289 0.42 
0625 0.42 
indicating 0.42 
tended 0.42 
540 0.42 
tethered 0.42 
encompassing 0.42 
MeSHMetaphase 0.42 
20-30 0.42 
manipulations 0.42 
predisposed 0.42 
MeSHContinuing 0.42 
technics 0.42 
Urgent 0.42 
MeSHPepticUlcer 0.42 
plausible 0.42 
replicating 0.42 
appreciable 0.42 
accounting 0.42 
valve 0.42 
CAC 0.42 
MeSHDiseaseManagement 0.42 
unacceptable 0.42 
(A) 0.42 
unresolved 0.42 
MeSHPosture 0.41 
MeSHTechnetiumCompounds 0.41 
supervise 0.41 
totally 0.41 
Eleven 0.41 
More 0.41 
Since 0.41 
MeSHMiddleAged 0.41 
appraisal 0.41 
infiltrated 0.41 
placing 0.41 
updated 0.41 
years; 0.41 
47%) 0.41 
kit 0.41 
Symptomatic 0.41 
Given 0.41 
obstetrics 0.40 
posttrauma 0.40 
147 0.40 
(131 0.40 
prodromal 0.40 
essay 0.40 
(300 0.40 
(R0) 0.40 
involvement; 0.40 
forty-one 0.40 
edges 0.40 
lengthen 0.40 
calibrated 0.40 
150) 0.40 
puts 0.40 
recalled 0.40 
II-III 0.40 
Selective 0.40 
points 0.40 
get 0.40 
distinction 0.40 
nonoperative 0.40 
uncomplicated 0.40 
invaded 0.40 
MeSHCystadenoma 0.40 
cystadenoma 0.40 
Number 0.40 
974 0.40 
delivered 0.40 
electromagnetic 0.40 
dextran 0.40 
Substantial 0.40 
Efforts 0.40 
MeSHEconomic 0.40 
inhomogeneous 0.40 
afterwards 0.40 
projected 0.40 
1200 0.40 
ridging 0.40 
MeSHPulmonaryDisease 0.40 
MeSHChronicObstructive 0.40 
subarachnoid 0.40 
packed 0.40 
promoted 0.40 
pT3 0.40 
Comprehensive 0.40 
(interquartile 0.40 
035) 0.40 
are: 0.40 
foetuses 0.40 
MeSHMeta-AnalysisasTopic 0.40 
15th 0.40 
oligohydramnios 0.40 
T4) 0.40 
balance 0.40 
ultrasonographically 0.40 
atrial 0.40 
advantageous 0.40 
mounted 0.40 
takes 0.39 
Serologic 0.39 
errors 0.39 
loci 0.39 
(P< 0.39 
MeSHKaplan-MeierEstimate 0.39 
met 0.39 
spots 0.39 
contour 0.39 
landmarks 0.39 
Specifically 0.39 
METHODOLOGY/PRINCIPAL 0.39 
Aim 0.39 
PCR) 0.39 
work-up 0.39 
stones) 0.39 
misleading 0.39 
Patients' 0.39 
DST 0.39 
incidentally 0.39 
MeSHEpithelialCells 0.39 
About 0.38 
Partial 0.38 
pound 0.38 
around 0.38 
aggregometry 0.38 
high-level 0.38 
TRs 0.38 
transported 0.38 
Macroscopic 0.38 
Confirmation 0.38 
(ESR) 0.38 
Seventy-three 0.38 
MeSH21stCentury 0.38 
conditioning 0.38 
unidentified 0.38 
imaging: 0.38 
intra- 0.38 
amphotericin 0.38 
(136 0.38 
(134 0.38 
(168 0.38 
sucrose 0.38 
dementing 0.38 
connectivity 0.38 
seconds) 0.38 
MTD 0.38 
fundal 0.38 
(interleukin 0.38 
iNOS) 0.38 
tested: 0.38 
urinalysis 0.38 
Endoscopical 0.38 
Poorly 0.38 
sixty-nine 0.38 
sports-related 0.38 
(groups 0.38 
spinoglenoid 0.38 
MeSHHealthExpenditures 0.38 
0-1) 0.38 
concentrating 0.38 
oxaloacetic 0.38 
Edinburgh 0.38 
Monthly 0.38 
161) 0.38 
Left-side 0.38 
(RIGS 0.38 
12-13 0.38 
nonsmoking 0.38 
MeSHPopulationGroups 0.38 
2006-2007 0.38 
(119 0.38 
articulated 0.38 
non-visualization 0.38 
intracapsular 0.38 
measurements: 0.38 
mg/100 0.38 
rates; 0.38 
(DNA) 0.38 
(DD) 0.38 
Decreasing 0.38 
landscape 0.38 
seventy-one 0.38 
elderly] 0.38 
neurologists 0.38 
MeSHFemaleUrogenitalDiseases 0.38 
pararectal 0.38 
(18)FDG 0.38 
OBSERVATIONS: 0.38 
intravaginal 0.38 
MeSHColonography 0.38 
MeSHComputedTomographic 0.38 
0001] 0.38 
Fixed 0.38 
dialysis-dependent 0.38 
censored 0.38 
hyperintensities 0.38 
noncarriers 0.38 
fludeoxyglucose 0.38 
frameshift 0.38 
cell-wall 0.38 
X) 0.38 
radiologically 0.38 
modeling 0.38 
Mean 0.38 
homogeneous 0.38 
affinity 0.38 
greatly 0.38 
correspondence 0.38 
discourage 0.38 
Exploratory 0.38 
metastasis; 0.38 
end-point 0.38 
MeSHPerineum 0.38 
module 0.38 
Infants 0.38 
ultrasound) 0.38 
MeSHAplastic 0.38 
128) 0.38 
Croatia 0.38 
conventionally 0.38 
in-house 0.38 
Sixty-six 0.38 
(January 0.38 
(H&E) 0.38 
25; 0.38 
Identifying 0.38 
discrete 0.38 
unexpected 0.38 
V20 0.38 
080) 0.38 
0053) 0.38 
(333 0.38 
0031) 0.38 
099) 0.38 
0099 0.38 
(235 0.38 
1003 0.38 
1880 0.38 
(265 0.38 
(OS) 0.38 
MeSHItaly 0.38 
" 0.38 
2007 0.38 
assign 0.37 
acoustic 0.37 
questioned 0.37 
North 0.37 
surrogate 0.37 
recurring 0.37 
304 0.37 
(aged 0.37 
mmol 0.37 
fourth 0.37 
(i) 0.37 
extending 0.37 
0-6 0.37 
inner 0.37 
MeSHGeneticCounseling 0.37 
activator 0.37 
originally 0.37 
May 0.37 
MeSHHealthCare 0.37 
apparently 0.37 
LAM 0.37 
accumulated 0.37 
MeSHAnthropometry 0.37 
Half 0.37 
ended 0.37 
MeSHReoperation 0.37 
presacral 0.37 
Turkish 0.37 
Olympus 0.37 
Relevant 0.37 
Rifampicin 0.37 
Document 0.37 
18-year 0.37 
MeSHIndirect 0.37 
(CABG) 0.37 
popular 0.37 
publication 0.37 
eventual 0.36 
included: 0.36 
Register 0.36 
2D 0.36 
sulfur 0.36 
MeSHObstetricLabor 0.36 
anencephaly 0.36 
that: 0.36 
cornerstone 0.36 
running 0.36 
focally 0.36 
viability 0.36 
future 0.36 
MeSHGuidelineAdherence 0.36 
Institutional 0.36 
Resistance 0.36 
MeSHAging 0.36 
viewed 0.36 
Application 0.36 
meaningful 0.36 
constrain 0.36 
Consensus 0.36 
residues 0.36 
088 0.36 
holoprosencephaly 0.36 
nontrauma 0.36 
Being 0.36 
ASM 0.36 
OUTCOMES: 0.36 
21-year-old 0.36 
thirty-three 0.36 
72; 0.36 
tethering 0.36 
(rs 0.36 
478 0.36 
optional 0.36 
I-II 0.35 
belonging 0.35 
Currently 0.35 
Medical 0.35 
g 0.35 
(iii) 0.35 
preferentially 0.35 
threefold 0.35 
Janeiro 0.35 
broadly 0.35 
ranked 0.35 
exceptions 0.35 
leaves 0.35 
acceleration 0.35 
Advantages 0.35 
time-dependent 0.35 
(B) 0.35 
(GB) 0.35 
Apparent 0.35 
simpler 0.35 
almost 0.35 
problematic 0.35 
certainly 0.35 
stimulus 0.35 
MeSHSmooth 0.35 
decisive 0.35 
Tc 0.35 
Sentinel 0.35 
rifampicin 0.35 
Pathology 0.35 
villous 0.35 
contemporary 0.35 
debated 0.35 
Records 0.35 
Gy 0.35 
al 0.35 
breadth 0.35 
167) 0.35 
mm); 0.35 
natriuretic 0.35 
pancytokeratin 0.35 
(confidence 0.35 
MeSHEmergencyMedicine 0.35 
(maximal 0.35 
(28) 0.35 
(prothrombin 0.35 
1+2 0.35 
battle 0.35 
NLR 0.35 
(n=33) 0.35 
aortopulmonary 0.35 
imitate 0.35 
Examine 0.35 
plasmas 0.35 
IMPORTANCE: 0.35 
colectomies 0.35 
complementarity 0.35 
translates 0.35 
(MShCG) 0.35 
fivefold 0.35 
data] 0.35 
MeSHFetalMembranes 0.35 
MeSHPrematureRupture 0.35 
Tunisian 0.35 
frontomaxillary 0.35 
value] 0.35 
MeSHPeriarthritis 0.35 
underestimates 0.35 
evaluation: 0.35 
non-SNs 0.35 
(LSG) 0.35 
practice? 0.35 
case: 0.35 
Setting 0.35 
Buenos 0.35 
Aires 0.35 
Epigenetic 0.35 
29%; 0.35 
face-to-face 0.35 
Online 0.35 
Aloka 0.35 
evaluative 0.35 
MeSHUnstable 0.35 
MeSHMaryland 0.35 
Increasingly 0.35 
13%; 0.35 
CT-scans 0.35 
quantifiable 0.35 
HEK 0.35 
used: 0.35 
Variables 0.35 
Preoperatively 0.35 
CFU 0.35 
simultaneously 0.35 
historic 0.34 
Eighteen 0.34 
Aging 0.34 
during 0.34 
inversion 0.34 
individualized 0.34 
Recognition 0.34 
0033) 0.34 
(295 0.34 
1095 0.34 
0044) 0.34 
0039) 0.34 
1263 0.34 
(47) 0.34 
0030 0.34 
(224 0.34 
106% 0.34 
1123 0.34 
(53 0.34 
carcinogenesis 0.34 
(IOC) 0.34 
(40% 0.34 
(30% 0.34 
mm; 0.34 
requested 0.34 
incorporation 0.34 
Mexico 0.34 
passes 0.34 
protein-1 0.34 
groups; 0.34 
vague 0.34 
tuberculosis-specific 0.34 
sequentially 0.34 
Every 0.34 
Gastric 0.34 
061 0.34 
anorectal 0.34 
DWI 0.34 
EPTB 0.34 
MeSHCollagenTypeI 0.34 
discernible 0.34 
QALY 0.34 
(CAC) 0.34 
>/=10 0.34 
Electronic 0.34 
microbiological 0.34 
PCI 0.34 
classically 0.34 
dilemmas 0.34 
MeSHHIVSeronegativity 0.34 
ZN 0.34 
MeSHChoiceBehavior 0.34 
crossed 0.34 
Fewer 0.34 
creates 0.34 
II; 0.34 
Event 0.34 
delaying 0.34 
28; 0.34 
infecting 0.34 
MeSHHeartTransplantation 0.34 
fresh 0.33 
minimizing 0.33 
Outpatient 0.33 
intermediate- 0.33 
sectioning 0.33 
orthopedic 0.33 
adoption 0.33 
theories 0.33 
II: 0.33 
MeSHTemporalLobe 0.33 
lifetime 0.33 
its 0.33 
practiced 0.33 
metastasis: 0.33 
study: 0.33 
low-income 0.33 
metastases; 0.33 
(within 0.33 
=4) 0.33 
U) 0.33 
MeSHAmbulatoryCare 0.33 
Lack 0.33 
resolve 0.33 
observed 0.33 
wider 0.32 
visited 0.32 
reagents 0.32 
968 0.32 
MeSHNitricOxide 0.32 
Government 0.32 
Such 0.32 
even 0.32 
MeSHRandomizedControlledTrialsasTopic 0.32 
maximize 0.32 
N+ 0.32 
052 0.32 
MeSHBacterialLoad 0.32 
endoprostheses 0.32 
intrapancreatic 0.32 
MeSHThyroglobulin 0.32 
indocyanin 0.32 
durations 0.32 
underdiagnose 0.32 
menorrhagia 0.32 
vascularized 0.32 
Sjogren's 0.32 
precedes 0.32 
MeSHBacteremia 0.32 
MeSHOvarianCysts 0.32 
supposed 0.32 
eligibility 0.32 
330 0.32 
Radiographs 0.32 
prerequisite 0.32 
sited 0.32 
086 0.32 
mini-open 0.32 
R1) 0.32 
Bayesian 0.32 
2]) 0.32 
noteworthy 0.32 
(AJCC) 0.32 
disparity 0.32 
(ISH) 0.32 
Healthy 0.32 
>100 0.32 
998) 0.32 
[18F]fluorodeoxy 0.32 
lesional 0.32 
intense 0.32 
language 0.32 
socioeconomic 0.31 
join 0.31 
54) 0.31 
mutual 0.31 
Demonstration 0.31 
401 0.31 
designing 0.31 
ultrasounds 0.31 
Counseling 0.31 
mo 0.31 
S-phase 0.31 
(defined 0.31 
diagnostically 0.31 
Causes 0.31 
conspicuous 0.31 
disease-specific 0.31 
recruitment 0.31 
twelve 0.31 
CACS 0.31 
fluorography 0.31 
tennis 0.31 
ARDS 0.31 
(137 0.31 
(143 0.31 
PND 0.31 
proficient 0.31 
biweekly 0.31 
unpaired 0.31 
(women 0.31 
cytochalasin 0.31 
altitude 0.31 
simulates 0.31 
T3/T4 0.31 
MeSHRadioWaves 0.31 
potentialities 0.31 
out) 0.31 
inferences 0.31 
costing 0.31 
setting: 0.31 
two-month 0.31 
7000 0.31 
non-invasively 0.31 
spending 0.31 
disposal 0.31 
Becton 0.31 
tumour-free 0.31 
arteriosus 0.31 
age? 0.31 
MeSHMetalloendopeptidases 0.31 
(advanced 0.31 
gravidas 0.31 
(AMH) 0.31 
2/21 0.31 
Exocrine 0.31 
(HP) 0.31 
diagnosable 0.31 
?/nMeSHDiagnosticImaging 0.31 
(MSCT) 0.31 
188) 0.31 
short-lived 0.31 
138) 0.31 
correspondingly 0.31 
MeSHHealthPlanningGuidelines 0.31 
Khan 0.31 
(PMR 0.31 
inter-rater 0.31 
ASRM 0.31 
parathyroidectomy 0.31 
(147 0.31 
Reductions 0.31 
(IFIs) 0.31 
assay; 0.31 
convince 0.31 
batches 0.31 
MeSHProteinProcessing 0.31 
MeSHPost-Translational 0.31 
carcinoma: 0.31 
CBDS 0.31 
localised 0.31 
correlating 0.31 
THE 0.31 
(TEG) 0.31 
processing 0.31 
temporal 0.31 
Fibrinogen 0.31 
Demographic 0.31 
MeSHSynovial 0.31 
translocation 0.31 
psychiatric 0.31 
echography 0.31 
bad 0.31 
?/nMeSHAmniocentesis 0.31 
comparatively 0.31 
assesses 0.31 
narrowed 0.30 
elasticity 0.30 
(PA) 0.30 
Assessing 0.30 
spanning 0.30 
MeSHSurgicalFlaps 0.30 
alleviating 0.30 
pediatrician 0.30 
historically 0.30 
hyperlipidemia 0.30 
Lewy 0.30 
Majority 0.30 
underscores 0.30 
125% 0.30 
0054) 0.30 
(227 0.30 
2660 0.30 
2339 0.30 
902) 0.30 
605) 0.30 
-223 0.30 
046; 0.30 
711) 0.30 
0021) 0.30 
1068 0.30 
6800 0.30 
999] 0.30 
0073 0.30 
(16%); 0.30 
(26%); 0.30 
1223 0.30 
1374 0.30 
887) 0.30 
1089 0.30 
(82) 0.30 
(29%; 0.30 
0046) 0.30 
1199 0.30 
age: 0.30 
ED 0.30 
one-stage 0.30 
morphometry 0.30 
non-operative 0.30 
post-operatively 0.30 
smallest 0.30 
ANALYSIS 0.30 
radioactive 0.30 
Republic 0.30 
Korea 0.30 
diagnosis] 0.30 
liveborn 0.30 
046 0.30 
(after 0.30 
transcutaneous 0.30 
three-year 0.30 
necessitates 0.30 
discriminated 0.30 
metaplastic 0.30 
distortion 0.30 
optic 0.30 
(53% 0.30 
(53%) 0.30 
delays 0.30 
bring 0.30 
Advances 0.30 
references 0.30 
atrophic 0.30 
According 0.30 
arteries 0.30 
079 0.30 
101) 0.30 
telomerase 0.30 
declared 0.30 
unenhanced 0.30 
Absolute 0.30 
syndrome? 0.30 
(before 0.30 
manoeuvre 0.30 
surgery? 0.30 
(number 0.30 
?/nMeSHAlgorithms 0.30 
two-sided 0.30 
527 0.30 
ileocecal 0.30 
competing 0.30 
angle) 0.30 
lags 0.30 
directing 0.30 
constructed 0.29 
malignancy 0.29 
4-5 0.29 
mucosa 0.29 
intensities 0.29 
MeSHSamplingStudies 0.29 
(over 0.29 
methylene 0.29 
183 0.29 
four- 0.29 
MeSHPulmonaryEmbolism 0.29 
MeSHTwo-Dimensional 0.29 
interdisciplinary 0.29 
Improvements 0.29 
what 0.29 
056 0.29 
SIT 0.29 
AUTHORS' 0.29 
495 0.29 
gastritis 0.29 
Nonsurgical 0.29 
predisposes 0.29 
MeSHDNATransposableElements 0.29 
(SS) 0.29 
Clearance 0.29 
Having 0.29 
(CS) 0.29 
(STR) 0.29 
BILIARY 0.29 
MeSHIndocyanineGreen 0.29 
MeSHResidenceCharacteristics 0.29 
filamentous 0.29 
abortions 0.29 
substance 0.29 
regularly 0.29 
52%) 0.29 
MeSHMyocardialInfarction 0.29 
MeSHPeritoneum 0.29 
insufficient 0.29 
185 0.29 
America 0.29 
investigators 0.29 
Community 0.29 
Moreover 0.29 
nondiagnostic 0.28 
(CNS) 0.28 
Measures 0.28 
18F-fluorodeoxyglucose 0.28 
Implication 0.28 
immunostaining 0.28 
fatal 0.28 
confirming 0.28 
LCU 0.28 
sample) 0.28 
RIGS 0.28 
VIA 0.28 
spliced 0.28 
CDE 0.28 
25-29 0.28 
LLETZ 0.28 
actinomycosis 0.28 
MeSHInternationalNormalizedRatio 0.28 
Bland-Altman 0.28 
pg/mL) 0.28 
MeSHFlorida 0.28 
(N+) 0.28 
mucosae 0.28 
?/nMeSHColonicNeoplasms 0.28 
biodegradable 0.28 
subcoracoid 0.28 
complains 0.28 
complexities 0.28 
investments 0.28 
outlier 0.28 
IS6110-based 0.28 
SPET 0.28 
seventy-seven 0.28 
imaging; 0.28 
inputs 0.28 
2007; 0.28 
Grand 0.28 
(LPD) 0.28 
?/nMeSHAdiposeTissue 0.28 
dimeglumine 0.28 
problems] 0.28 
morbility 0.28 
(n=28) 0.28 
(mean) 0.28 
2X 0.28 
1-mm 0.28 
horseradish 0.28 
EBM 0.28 
cyclin-dependent 0.28 
signify 0.28 
MeSHDelirium 0.28 
abbreviated 0.28 
phased-array 0.28 
acquisitions 0.28 
eighty-five 0.28 
hyperemia 0.28 
(death 0.28 
diuretics 0.28 
fraction) 0.28 
upgraded 0.28 
8/15 0.28 
217) 0.28 
allocated 0.28 
Sweden 0.28 
illustrated 0.28 
Future 0.28 
affiliated 0.28 
MeSHRegionalBloodFlow 0.28 
posttreatment 0.28 
eventually 0.28 
MeSHMedicalAudit 0.28 
Neonatal 0.28 
MeSHNationalHealthPrograms 0.28 
B; 0.28 
665 0.28 
didn't 0.28 
947 0.28 
>60 0.28 
535 0.28 
MeSHLifeTables 0.28 
state-of-the-art 0.28 
Seventy-nine 0.28 
gentle 0.28 
MeSHMicrotomy 0.28 
coarse 0.28 
2002) 0.28 
>90 0.28 
amylase 0.28 
issued 0.28 
0008 0.28 
theta 0.28 
irreparable 0.28 
tuberculosis? 0.28 
commencing 0.28 
microliter 0.28 
MeSHSterilization 0.28 
underway 0.28 
Federal 0.28 
societal 0.28 
findings] 0.28 
septicemia 0.28 
caesarean 0.28 
MeSHMotorActivity 0.28 
Even 0.27 
adapted 0.27 
(73%) 0.27 
MeSHNuclearProteins 0.27 
soft-tissue 0.27 
roughly 0.27 
enhances 0.27 
(57% 0.27 
patient 0.27 
allows 0.27 
distinguish 0.27 
applying 0.27 
435 0.27 
334 0.27 
12th 0.27 
x 0.27 
savings 0.27 
271 0.27 
favorably 0.27 
sixth 0.27 
EMBASE 0.27 
contaminated 0.27 
-69 0.27 
functioning 0.27 
collaborative 0.27 
MeSHBloodPressure 0.27 
Terminology 0.27 
biomechanics 0.27 
Germany) 0.27 
nonmetastatic 0.27 
Nonetheless 0.27 
characterizing 0.27 
obstructions 0.27 
purely 0.27 
nuclei 0.27 
(9) 0.27 
max 0.27 
spot 0.27 
1125 0.27 
1090 0.27 
(556 0.27 
034; 0.27 
1170 0.27 
930) 0.27 
00006 0.27 
1656 0.27 
504) 0.27 
402) 0.27 
(408 0.27 
(375 0.27 
3047 0.27 
509) 0.27 
479) 0.27 
4156 0.27 
2750 0.27 
(121) 0.27 
1870 0.27 
accordance 0.27 
chemoradiotherapy 0.26 
kidney 0.26 
MEASUREMENTS 0.26 
(17%) 0.26 
MeSHBloodTransfusion 0.26 
owing 0.26 
warm 0.26 
HIV+ 0.26 
Extrapulmonary 0.26 
(LDH) 0.26 
MeSHBloodDonors 0.26 
>/=5 0.26 
nicotin 0.26 
overgrowth 0.26 
quadrants 0.26 
firmly 0.26 
Features 0.26 
profoundly 0.26 
sequences 0.26 
disclosed 0.26 
terminate 0.26 
MLPA 0.26 
longstanding 0.26 
Rather 0.26 
averaging 0.26 
repair: 0.26 
MeSHMicroarrayAnalysis 0.26 
microinvasive 0.26 
CFT 0.26 
MeSHTransaminases 0.26 
mg/dL 0.26 
MeSHPelvicNeoplasms 0.26 
MeSHPhysiologic 0.26 
roentgenogram 0.26 
Radionuclide 0.26 
1500 0.26 
learned 0.26 
slices 0.26 
Texas 0.26 
MeSHDepression 0.26 
transplants 0.26 
>20 0.26 
Associations 0.26 
mid 0.26 
age] 0.26 
therapists 0.26 
Pretreatment 0.26 
Multiple 0.25 
gastrectomy 0.25 
joint 0.25 
burns 0.25 
000001) 0.25 
(138 0.25 
FNR 0.25 
Delirium 0.25 
22%; 0.25 
Framingham 0.25 
(percent 0.25 
(160 0.25 
speculative 0.25 
(CFT) 0.25 
MRI: 0.25 
(male: 0.25 
gathering 0.25 
resorting 0.25 
location: 0.25 
osteoarthritic 0.25 
triamcinolone 0.25 
anteroinferior 0.25 
participants) 0.25 
147) 0.25 
sputum-smear 0.25 
amplicons 0.25 
resource-constrained 0.25 
isothermal 0.25 
diseases) 0.25 
hints 0.25 
Intense 0.25 
inflammations 0.25 
Prefecture 0.25 
quarterly 0.25 
windows 0.25 
MeSHAnti-MullerianHormone 0.25 
anomalies; 0.25 
one-fifth 0.25 
periumbilical 0.25 
orthogonal 0.25 
noninflammatory 0.25 
Blinded 0.25 
friable 0.25 
stumps 0.25 
fluid) 0.25 
diameter: 0.25 
accrual 0.25 
envisaged 0.25 
peritumorally 0.25 
MeSHNear-Infrared 0.25 
MeSHSurgicalWoundDehiscence 0.25 
cells/microL 0.25 
(QALYs) 0.25 
immunoexpression 0.25 
Adolescents 0.25 
(higher 0.25 
intolerable 0.25 
(CAP) 0.25 
sets 0.25 
handling 0.25 
Efficacy 0.25 
responded 0.25 
importantly 0.25 
possible 0.25 
traditionally 0.25 
computerised 0.25 
LES 0.25 
v1 0.25 
964 0.25 
(GC) 0.25 
640 0.25 
level) 0.25 
conditions: 0.25 
system) 0.25 
12-year-old 0.25 
MeSHVisual 0.25 
ancient 0.25 
Infiltration 0.25 
MeSHAntibioticProphylaxis 0.25 
Analyses 0.25 
(BD 0.25 
lifestyle 0.25 
pericardial 0.25 
logs 0.25 
(which 0.25 
institutions 0.24 
isoforms 0.24 
=40 0.24 
Dual 0.24 
MeSHHemorrhage 0.24 
082 0.24 
085 0.24 
051 0.24 
ligation-dependent 0.24 
iodinated 0.24 
tetraploidy 0.24 
MeSHBias(Epidemiology) 0.24 
551 0.24 
Including 0.24 
Charts 0.24 
alongside 0.24 
hysterectomies 0.24 
intrauterine 0.24 
very 0.24 
indeed 0.24 
strictly 0.24 
poor 0.24 
Massachusetts 0.24 
skills 0.24 
designated 0.24 
(per 0.24 
MeSHPoland 0.24 
MeSHArtificial 0.24 
299 0.24 
prostate-specific 0.24 
minimized 0.24 
Ossification 0.24 
emphasizing 0.24 
(CR) 0.24 
incisional 0.24 
IA: 0.24 
times 0.23 
reaching 0.23 
adopted 0.23 
CXR 0.23 
(18)F-fluorodeoxyglucose 0.23 
total) 0.23 
Treatments 0.23 
Partnership 0.23 
administering 0.23 
cholecystosonography 0.23 
squamous-cell 0.23 
histomorphologic 0.23 
(OR: 0.23 
MeSHLifeStyle 0.23 
effusions 0.23 
Thirty-nine 0.23 
biopsied 0.23 
delineated 0.23 
endometriosis] 0.23 
burden 0.23 
split 0.23 
satisfied 0.23 
faster 0.23 
ADC 0.23 
RMP 0.23 
supplemental 0.23 
diagnosis; 0.23 
38%) 0.23 
Cooperative 0.23 
Third 0.23 
500% 0.23 
CA199 0.23 
0324 0.23 
108% 0.23 
073; 0.23 
2227 0.23 
1029 0.23 
(IO) 0.23 
(23%; 0.23 
(359 0.23 
124; 0.23 
0062) 0.23 
0058) 0.23 
00-45 0.23 
1266 0.23 
00007 0.23 
0055 0.23 
>10 0.23 
influenced 0.23 
Findings 0.23 
006) 0.23 
education 0.23 
AMH 0.23 
CSE 0.23 
noncurative 0.23 
utilities 0.23 
thrombin-antithrombin 0.23 
mg/m(2)) 0.23 
p63 0.23 
10mm 0.23 
>/=15 0.23 
Paradoxically 0.23 
ROTEM(R) 0.23 
MeSHSubarachnoidHemorrhage 0.23 
Vasopressin 0.23 
bay 0.23 
mmHg) 0.23 
MeSHGonads 0.23 
10-month 0.23 
tenosynovitis 0.23 
trial) 0.23 
definable 0.23 
proprioceptive 0.23 
day; 0.23 
tuberculosis-endemic 0.23 
(RIA) 0.23 
detected: 0.23 
radioimmunoguided 0.23 
solid-phase 0.23 
origin; 0.23 
syndromes: 0.23 
formats 0.23 
meantime 0.23 
metastatic) 0.23 
partitioning 0.23 
MeSHRheumatology 0.23 
anchored 0.23 
rotatory 0.23 
halves 0.23 
(CDL) 0.23 
cytometer 0.23 
verifying 0.23 
care) 0.23 
sending 0.23 
exfoliated 0.23 
Pathogenic 0.23 
inaccuracy 0.23 
(MIS) 0.23 
wall: 0.23 
hypermetabolic 0.23 
respectively: 0.23 
Known 0.23 
numerically 0.23 
fugal 0.23 
(SCT) 0.23 
MeSHMannosidases 0.23 
integrative 0.23 
MeSHHearingLoss 0.23 
mucositis 0.23 
cure 0.23 
067 0.23 
MIB-1 0.23 
videos 0.23 
activity) 0.23 
553 0.23 
side-to-side 0.23 
underlines 0.23 
955 0.23 
contractile 0.23 
(P) 0.23 
seroma 0.23 
mechanistic 0.23 
hands 0.22 
MeSHPair22 0.22 
emphasise 0.22 
score) 0.22 
MeSHMothers 0.22 
CT-scan 0.22 
scar 0.22 
(ii) 0.22 
prompted 0.22 
MeSHSerologicTests 0.22 
detectable 0.22 
radioisotope 0.22 
surgery; 0.22 
ALI 0.22 
spontaneous 0.22 
Grade 0.22 
& 0.22 
MeSHChina 0.22 
MeSHSpecimenHandling 0.22 
readily 0.22 
ensures 0.22 
signet 0.22 
chiefly 0.22 
(T4 0.22 
coping 0.22 
adenomatous 0.22 
license 0.22 
670 0.22 
dilatations 0.22 
transaminases 0.22 
Ultimately 0.22 
Vater's 0.22 
died; 0.22 
uniquely 0.22 
+/- 0.22 
(57%) 0.22 
metaplasia 0.22 
tailored 0.22 
(group 0.22 
MeSHIncidence 0.22 
MCF 0.22 
(CKD) 0.22 
eliminate 0.22 
Intra- 0.22 
races 0.22 
study] 0.22 
cultural 0.22 
genetical 0.21 
MeSHPancreatectomy 0.21 
IVC 0.21 
Korean 0.21 
32-year-old 0.21 
trophoblastic 0.21 
devised 0.21 
macroscopically 0.21 
MeSHOutcomeandProcessAssessment(HealthCare) 0.21 
simply 0.21 
241 0.21 
MeSHAmylases 0.21 
Asymptomatic 0.21 
pg/ml 0.21 
308 0.21 
Weakness 0.21 
French 0.21 
1988 0.21 
equipment 0.21 
Two 0.21 
TSH 0.21 
sputa 0.21 
Demographics 0.21 
unpublished 0.21 
lectins 0.21 
thousands 0.21 
MeSHMathematics 0.21 
MeSHIohexol 0.21 
studied: 0.21 
unacceptably 0.21 
999) 0.21 
(>3 0.21 
educated 0.21 
(hazard 0.21 
dependence 0.21 
pars 0.21 
MeSHPlateletCount 0.21 
exhibiting 0.21 
976 0.21 
presumed 0.21 
Standard 0.21 
057 0.21 
meta-analyses 0.21 
evidences 0.21 
sustaining 0.21 
MeSHMatrixMetalloproteinase9 0.21 
erosions 0.21 
motivation 0.21 
ensured 0.21 
inception 0.21 
biochemically 0.21 
Delhi 0.21 
stratifying 0.21 
behavioural 0.21 
Bruce 0.21 
(E) 0.21 
ejection 0.21 
Whole 0.21 
IMI 0.21 
damaged 0.21 
demonstrates 0.21 
loses 0.20 
PCs 0.20 
fat 0.20 
prototype 0.20 
df 0.20 
cholangiopancreaticography 0.20 
hypothetical 0.20 
h] 0.20 
haemoglobin 0.20 
MeSHEmission-Computed 0.20 
TIS 0.20 
Cancer 0.20 
explanation 0.20 
chance 0.20 
(5%) 0.20 
SLO 0.20 
057) 0.20 
Ct 0.20 
CT/MRI 0.20 
CPA 0.20 
downstaged 0.20 
UGI 0.20 
old; 0.20 
Mp 0.20 
re-treated 0.20 
Nordic 0.20 
DMS 0.20 
Watch 0.20 
euglobulin 0.20 
(UICC) 0.20 
forward-view 0.20 
multidirectional 0.20 
isotonic 0.20 
seventy-two 0.20 
responsibilities 0.20 
doctor's 0.20 
(Hb) 0.20 
NJ) 0.20 
unfamiliar 0.20 
Wiley 0.20 
affections 0.20 
RAS) 0.20 
(R(2) 0.20 
mesocolon 0.20 
tendon: 0.20 
(MRA) 0.20 
Smaller 0.20 
curtail 0.20 
Melbourne 0.20 
2/16 0.20 
unstained 0.20 
20-month 0.20 
present; 0.20 
MeSHInhibitorofApoptosisProteins 0.20 
attainment 0.20 
(deep 0.20 
MeSHRoundLigamentofUterus 0.20 
electrolytes 0.20 
MeSHHLA-AAntigens 0.20 
MeSHHLA-BAntigens 0.20 
(Abeta) 0.20 
PCRs 0.20 
nonsense 0.20 
826 0.20 
973 0.20 
Optimal 0.20 
(BMD 0.20 
uncertain 0.20 
(c) 0.20 
66) 0.20 
metallic 0.20 
PET/CT 0.20 
various 0.20 
project 0.20 
interest 0.20 
IUGR 0.20 
transferase 0.20 
Outcomes 0.20 
seldom 0.19 
contrary 0.19 
Programme 0.19 
service 0.19 
Children's 0.19 
formulated 0.19 
degenerated 0.19 
bright 0.19 
cecal 0.19 
Kim 0.19 
0007) 0.19 
specialised 0.19 
(n=7) 0.19 
pictorial 0.19 
alpha-1 0.19 
MeSHIndians 0.19 
MeSHPreoperativePeriod 0.19 
tumoural 0.19 
Eighty-seven 0.19 
MeSHGraftSurvival 0.19 
allografts 0.19 
<15 0.19 
(<5 0.19 
investigates 0.19 
pole 0.19 
degradation 0.19 
CPP 0.19 
MUC 0.19 
fibrillation 0.19 
ultrasound: 0.19 
Rome 0.19 
Ninety-one 0.19 
denied 0.19 
Distant 0.19 
(SNPs) 0.19 
MeSHNomograms 0.19 
Giemsa 0.19 
atraumatic 0.19 
stones? 0.19 
qualities 0.19 
cystadenomas 0.19 
Romania 0.19 
(particularly 0.19 
immunoprecipitation 0.19 
levels) 0.19 
anteriorly 0.19 
Fifty-nine 0.19 
mm(2) 0.19 
158 0.19 
terminated 0.19 
subdivided 0.19 
MeSHQualityAssurance 0.19 
Clinicians 0.19 
bifida 0.19 
comparisons 0.19 
MeSHHospital 0.19 
107% 0.19 
103% 0.19 
0451) 0.19 
0352 0.19 
15000 0.19 
85-94 0.19 
000004 0.19 
217% 0.19 
142% 0.19 
2070 0.19 
(483 0.19 
579) 0.19 
136; 0.19 
1359 0.19 
1525 0.19 
1000; 0.19 
(387 0.19 
1342 0.19 
0345 0.19 
(269 0.19 
1309 0.19 
1011 0.19 
135% 0.19 
764) 0.19 
>15) 0.19 
Switzerland 0.19 
Chemistry 0.19 
audit 0.19 
regards 0.19 
mA 0.19 
(26%) 0.19 
confer 0.19 
MeSHPremature 0.19 
shot 0.19 
Monitoring 0.19 
cholescintigraphy 0.18 
(PT) 0.18 
(IUGR) 0.18 
MeSHIntra-Articular 0.18 
cancer-specific 0.18 
reading 0.18 
(5% 0.18 
seconds 0.18 
L1- 0.18 
Biomedical 0.18 
biopsy 0.18 
adopt 0.18 
sports 0.18 
necessitate 0.18 
feel 0.18 
FF 0.18 
-30 0.18 
harbour 0.18 
coinfection 0.18 
indicated 0.18 
(30%) 0.18 
familiarity 0.18 
(The 0.18 
subjectively 0.18 
Considerable 0.18 
gastroschisis 0.18 
evenly 0.18 
duct; 0.18 
pretreated 0.18 
reinfection 0.18 
sensorimotor 0.18 
visiting 0.18 
incorporates 0.18 
002; 0.18 
receipt 0.18 
Twenty-eight 0.18 
quantified 0.18 
scored 0.18 
GIT 0.18 
names 0.18 
controls; 0.18 
outcome: 0.18 
MeSHMolecularStructure 0.18 
Eligible 0.18 
observed: 0.18 
(C) 0.18 
Lastly 0.18 
scanners 0.18 
(IVC) 0.18 
identified; 0.18 
4000 0.18 
565 0.18 
initially 0.18 
CDL 0.18 
000001 0.18 
colonoscopic 0.18 
heparinized 0.18 
antiplasmin 0.18 
MeSHHeartArrest 0.18 
Clotting 0.18 
hypocoagulable 0.18 
T3-T4 0.18 
misdiagnoses 0.18 
(USG) 0.18 
wherever 0.18 
(MGIT) 0.18 
complied 0.18 
stage; 0.18 
60-80 0.18 
multicystic 0.18 
MeSHSubclavianArtery 0.18 
(mm) 0.18 
factors; 0.18 
Nacional 0.18 
LIVER 0.18 
grey-scale 0.18 
cholangiography? 0.18 
cells" 0.18 
(PCR)-based 0.18 
(population 0.18 
MeSHContraceptiveAgents 0.18 
=23) 0.18 
MeSHAphasia 0.18 
retroversion 0.18 
amputations 0.18 
MeSHPrincipalComponentAnalysis 0.18 
(CMRglc) 0.18 
MeSHBodyBurden 0.18 
wall) 0.18 
WI 0.18 
2005 0.18 
restricted 0.18 
men) 0.18 
Tc-99m 0.18 
gadolinium 0.18 
monthly 0.18 
impacts 0.18 
name 0.18 
U/mL 0.17 
beds 0.17 
981 0.17 
047 0.17 
MeSHProgramEvaluation 0.17 
determines 0.17 
represents 0.17 
elucidated 0.17 
aberrations 0.17 
ossification 0.17 
Indicators 0.17 
IS 0.17 
visualisation 0.17 
misinterpreted 0.17 
Mun 0.17 
Relapse 0.17 
informative 0.17 
apparent 0.17 
subgroups 0.17 
events 0.17 
Increasing 0.17 
ranging 0.17 
effusion 0.17 
01% 0.17 
(111 0.17 
insulin-like 0.17 
OCG 0.17 
OLT 0.17 
freezing 0.17 
Percentage 0.17 
cm2 0.17 
523 0.17 
geographically 0.17 
10(7) 0.17 
(14) 0.17 
plasmatic 0.17 
yrs) 0.17 
African-American 0.17 
Porto 0.17 
excisions 0.17 
binary 0.17 
Serious 0.17 
ageing 0.17 
neurodegeneration 0.17 
mid-term 0.17 
endpoints 0.17 
xpert 0.17 
Massive 0.17 
gastroenterologist 0.17 
Repair 0.17 
650 0.17 
exploring 0.17 
(MRC) 0.17 
exhibits 0.17 
melanoma: 0.17 
FDG-PET/CT 0.17 
crystalloid 0.17 
081 0.17 
D-dimer 0.17 
MeSHEndopeptidases 0.17 
Kw 0.17 
perirectal 0.17 
accessibility 0.17 
cardiomyopathy 0.17 
retracted 0.17 
paramagnetic 0.17 
Academy 0.17 
MeSHConization 0.17 
(Stage 0.17 
10(4) 0.17 
MeSHCounseling 0.17 
MeSHDebridement 0.17 
MeSHUrinaryBladderDiseases 0.17 
maker 0.17 
MeSHAscites 0.17 
basins 0.17 
backs 0.17 
beyond 0.17 
assigned 0.16 
SLNs 0.16 
Enhancement 0.16 
(43%) 0.16 
late 0.16 
practitioners 0.16 
set 0.16 
hyperintense 0.16 
multi-institutional 0.16 
(pain 0.16 
plasmid 0.16 
randomised 0.16 
Array 0.16 
disclose 0.16 
trophoblast 0.16 
semiquantitative 0.16 
female) 0.16 
Adhesions 0.16 
Ascites 0.16 
male) 0.16 
generated 0.16 
contributions 0.16 
months' 0.16 
traumatized 0.16 
IUD 0.16 
MeSHBurns 0.16 
cross-linking 0.16 
demography 0.16 
MeSHLipidPeroxidation 0.16 
Nx 0.16 
clinicopathologically 0.16 
gastroscope 0.16 
emphasises 0.16 
type-I 0.16 
region) 0.16 
100-fold 0.16 
small-sized 0.16 
sixty-six 0.16 
levator 0.16 
months); 0.16 
denoted 0.16 
abnormalities] 0.16 
pancreas] 0.16 
2000; 0.16 
(23) 0.16 
choledocus 0.16 
SURGERY 0.16 
immunoreaction 0.16 
MeSHAceticAcid 0.16 
MeSHPublicSector 0.16 
equals 0.16 
MeSHChlamydiatrachomatis 0.16 
payer 0.16 
(SMC) 0.16 
6-mm 0.16 
sulfated 0.16 
MeSHOddsRatio 0.16 
nonrandomized 0.16 
MeSHCalifornia 0.16 
building 0.16 
Fifty-seven 0.16 
post-mortem 0.16 
Viet 0.16 
technological 0.16 
discern 0.16 
assumption 0.16 
007) 0.16 
465 0.16 
topographical 0.16 
(control) 0.16 
queried 0.16 
cohesive 0.16 
clarifying 0.16 
postsurgery 0.16 
Difficulties 0.16 
MeSHJointCapsule 0.16 
Why 0.16 
statements 0.16 
stopping 0.16 
industrialized 0.16 
commencement 0.16 
autosomes 0.16 
MeSHLeiomyosarcoma 0.16 
MeSHAbdominalInjuries 0.16 
biopsy] 0.16 
Multicentric 0.16 
lymphoscintigram 0.16 
MeSHArgentina 0.16 
MeSHAmbulatoryCareFacilities 0.16 
MeSHAnginaPectoris 0.16 
SIS 0.16 
multivariate 0.15 
electively 0.15 
crucial 0.15 
pharmaceutical 0.15 
Subsequently 0.15 
anomaly 0.15 
cytoplasmic 0.15 
semi-quantitative 0.15 
055 0.15 
triggers 0.15 
up-to-date 0.15 
glycosylation 0.15 
sulphate 0.15 
Controls 0.15 
Pathologically 0.15 
MeSHCumulativeTraumaDisorders 0.15 
Emphasis 0.15 
Maximal 0.15 
variables: 0.15 
automatically 0.15 
Degradation 0.15 
610 0.15 
MeSHDeath 0.15 
Mild 0.15 
sexually 0.15 
?/nMeSHAmpullaofVater 0.15 
(45X) 0.15 
0378 0.15 
(321 0.15 
172; 0.15 
0050) 0.15 
0110 0.15 
130% 0.15 
(338 0.15 
1249 0.15 
1648 0.15 
001)/nMeSHAdult 0.15 
(90%; 0.15 
1703 0.15 
1698 0.15 
0225 0.15 
110% 0.15 
(237 0.15 
0489) 0.15 
0275 0.15 
45X/46XX 0.15 
0177 0.15 
1543 0.15 
2168 0.15 
1788 0.15 
113% 0.15 
105% 0.15 
(982 0.15 
400% 0.15 
1268 0.15 
140% 0.15 
Md) 0.15 
(353 0.15 
(716 0.15 
797) 0.15 
arthritis" 0.15 
255; 0.15 
0000001) 0.15 
21-fold 0.15 
(508 0.15 
(484 0.15 
232; 0.15 
0268 0.15 
0093) 0.15 
0144 0.15 
127% 0.15 
1244 0.15 
(120) 0.15 
104% 0.15 
0005] 0.15 
=112) 0.15 
117% 0.15 
102; 0.15 
200000 0.15 
224% 0.15 
0127 0.15 
1849 0.15 
(24%); 0.15 
049; 0.15 
0927 0.15 
0454 0.15 
0370 0.15 
3135 0.15 
2983 0.15 
(456 0.15 
(66) 0.15 
137; 0.15 
231% 0.15 
composite 0.15 
clarified 0.15 
(one 0.15 
exploration 0.15 
[OR 0.15 
2004 0.15 
graded 0.15 
diminish 0.15 
angiographic 0.15 
interruption 0.15 
proximity 0.15 
polycystic 0.15 
analysing 0.15 
cysts: 0.15 
ana 0.15 
BACKGROUND/AIMS: 0.15 
receiving 0.15 
in-hospital 0.15 
centrifugation 0.15 
corner 0.15 
040 0.15 
mmHg 0.15 
2006) 0.15 
hypometabolism 0.15 
nil 0.15 
Cross 0.15 
Delta 0.15 
Section 0.15 
outer 0.15 
ICU 0.14 
Bowel 0.14 
532 0.14 
Lima 0.14 
702 0.14 
MeSHFibrinolyticAgents 0.14 
(also 0.14 
leucovorin 0.14 
protecting 0.14 
doubts 0.14 
one-step 0.14 
[RR] 0.14 
522 0.14 
MeSHAnkle 0.14 
(IC) 0.14 
(94%) 0.14 
undifferentiated 0.14 
real 0.14 
Program 0.14 
comprises 0.14 
desired 0.14 
MeSHRenalInsufficiency 0.14 
MeSHBiomedical 0.14 
ambiguous 0.14 
exist 0.14 
pitfalls 0.14 
margin 0.14 
66%) 0.14 
articular 0.14 
motions 0.14 
(clinical 0.14 
MeSHChoroidPlexus 0.14 
(base 0.14 
provocative 0.14 
FFP 0.14 
glutamic 0.14 
(range) 0.14 
multiplicity 0.14 
regimes 0.14 
(MTBC) 0.14 
442 0.14 
post-surgical 0.14 
results) 0.14 
MTBC) 0.14 
543 0.14 
ISS 0.14 
Day 0.14 
well-established 0.14 
spp 0.14 
hearing 0.14 
conferred 0.14 
instances 0.14 
188 0.14 
diseased 0.14 
(from 0.14 
141 0.14 
occult 0.14 
138 0.14 
robust 0.14 
(116 0.14 
879 0.14 
fatalities 0.14 
(Type 0.14 
(AOR 0.14 
obliterated 0.14 
removes 0.14 
conditions; 0.14 
(104 0.14 
worker's 0.14 
physiotherapists 0.14 
subluxations 0.14 
impediment 0.14 
anti-carcinoembryonic 0.14 
characters 0.14 
009; 0.14 
sensible 0.14 
formulating 0.14 
unsuccessfully 0.14 
collated 0.14 
Ideally 0.14 
Respective 0.14 
(computed 0.14 
citizens 0.14 
(BT) 0.14 
scrutinized 0.14 
cholangiopancreatographies 0.14 
McNemar's 0.14 
2mm 0.14 
Carcinomas 0.14 
modifies 0.14 
MeSHImageCytometry 0.14 
offices 0.14 
(types 0.14 
reverted 0.14 
archives 0.14 
amplifications 0.14 
life-table 0.14 
MeSHAwareness 0.14 
MeSHHawaii 0.14 
outdoor 0.14 
MeSHTroponinT 0.14 
(lateral 0.14 
Parametric 0.14 
MeSHLipopeptides 0.14 
followed-up 0.14 
linked 0.14 
concentrated 0.14 
loop 0.14 
immunoreactivity 0.14 
harbor 0.14 
32) 0.14 
BP 0.14 
caution 0.14 
Society 0.13 
opposed 0.13 
studies) 0.13 
prolactin 0.13 
TAC 0.13 
MeSHSchools 0.13 
divisions 0.13 
reappraisal 0.13 
Mucosal 0.13 
wax 0.13 
vacuum 0.13 
favoring 0.13 
Conclusion 0.13 
tests: 0.13 
containment 0.13 
(based 0.13 
cholecystocholedocholithiasis 0.13 
Scintigraphy 0.13 
exploited 0.13 
MeSHMenorrhagia 0.13 
"normal" 0.13 
MeSHHeartVentricles 0.13 
(38% 0.13 
profiles 0.13 
normalization 0.13 
student 0.13 
initiation 0.13 
Candida 0.13 
compliance 0.13 
reductions 0.13 
006 0.13 
cytokeratins 0.13 
045) 0.13 
Excel 0.13 
(CPM) 0.13 
MeSHCrossInfection 0.13 
localizing 0.13 
MeSHUganda 0.13 
changed 0.13 
Sixty-one 0.13 
analogous 0.13 
calculi] 0.13 
geriatric 0.13 
tertiary 0.13 
elder 0.13 
especially 0.13 
solely 0.13 
million 0.13 
13; 0.13 
quality-adjusted 0.13 
MeSHCriticalCare 0.13 
457 0.13 
MeSHSuperoxideDismutase 0.13 
(only 0.13 
Ninety-three 0.13 
whatever 0.13 
(n=5) 0.13 
demarcated 0.13 
10(-3 0.13 
(7) 0.13 
reviewed 0.13 
025 0.13 
authors' 0.13 
consequent 0.13 
(24%) 0.13 
respondents 0.13 
Except 0.13 
Collection 0.13 
Is 0.13 
seemed 0.13 
ring 0.13 
determinants 0.13 
province 0.13 
Prothrombin 0.13 
(68% 0.13 
records 0.13 
genetics 0.13 
Personal 0.12 
gray 0.12 
registers 0.12 
individualize 0.12 
MMP-9 0.12 
446 0.12 
SSC 0.12 
found: 0.12 
tumor-related 0.12 
gastro-intestinal 0.12 
MeSHSynovitis 0.12 
MeSHNasopharynx 0.12 
reliance 0.12 
agencies 0.12 
transitory 0.12 
tumor; 0.12 
MeSHHyperbilirubinemia 0.12 
methods: 0.12 
Completion 0.12 
Tobacco 0.12 
96; 0.12 
regressive 0.12 
endometriosis-related 0.12 
quicker 0.12 
x-rays 0.12 
(type 0.12 
966 0.12 
0004) 0.12 
OR: 0.12 
MeSHSurvivalAnalysis 0.12 
ward 0.12 
hormones 0.12 
3+ 0.12 
concept 0.12 
CXCR3 0.12 
habitual 0.12 
PRL 0.12 
E(2) 0.12 
883 0.12 
IAP 0.12 
hypermetabolism 0.12 
MeSHMilitaryMedicine 0.12 
postinjury 0.12 
T/N 0.12 
unexplored 0.12 
provoking 0.12 
Amplified 0.12 
Riyadh 0.12 
monoresistant 0.12 
Vienna 0.12 
20-50 0.12 
prominently 0.12 
non-tumor 0.12 
0013 0.12 
skinfold 0.12 
MeSHTomographyScanners 0.12 
venography 0.12 
(internal 0.12 
warranting 0.12 
sensors 0.12 
187) 0.12 
postoperatively; 0.12 
MeSHPreventiveHealthServices 0.12 
MeSHUterineCervicitis 0.12 
friends 0.12 
pedunculated 0.12 
888 0.12 
Panel 0.12 
LHR 0.12 
Inducible 0.12 
preformed 0.12 
tendencies 0.12 
MeSHNitriles 0.12 
infections: 0.12 
MeSHTyrosine 0.12 
LS) 0.12 
annual 0.12 
asymptomatic 0.12 
explained 0.12 
(FDG) 0.12 
(stage 0.12 
Persistent 0.12 
USG 0.12 
microdissection 0.12 
reportedly 0.12 
constituting 0.12 
MeSHProteinIsoforms 0.12 
Missed 0.12 
regressions 0.12 
MeSHDermoidCyst 0.12 
III: 0.12 
Liquid 0.12 
localise 0.12 
Specimens 0.12 
input 0.12 
investigation 0.12 
Effective 0.12 
(age 0.12 
necessity 0.12 
Process 0.12 
constituent 0.12 
conclusion 0.12 
demonstrable 0.12 
quantity 0.12 
whenever 0.11 
-28 0.11 
patients/nMeSHAdult 0.11 
242% 0.11 
375% 0.11 
118% 0.11 
0375) 0.11 
0070 0.11 
Ltd) 0.11 
6090 0.11 
21mm 0.11 
1777 0.11 
(172) 0.11 
0405 0.11 
0375 0.11 
2086 0.11 
0291) 0.11 
(04 0.11 
132% 0.11 
119% 0.11 
027; 0.11 
600% 0.11 
(449 0.11 
(795 0.11 
=271) 0.11 
(309 0.11 
0796 0.11 
1684 0.11 
547) 0.11 
1181 0.11 
881) 0.11 
4865 0.11 
005% 0.11 
658) 0.11 
843) 0.11 
-001 0.11 
3620 0.11 
00006) 0.11 
(889 0.11 
014); 0.11 
162% 0.11 
0109) 0.11 
307% 0.11 
=67) 0.11 
147% 0.11 
180% 0.11 
31-fold 0.11 
2232 0.11 
00001] 0.11 
012% 0.11 
209% 0.11 
5416 0.11 
534) 0.11 
1612 0.11 
1393 0.11 
00001); 0.11 
0623 0.11 
0291 0.11 
-007 0.11 
105; 0.11 
0907 0.11 
069; 0.11 
(327 0.11 
01-02 0.11 
168; 0.11 
053; 0.11 
-018 0.11 
129% 0.11 
332 0.11 
congestive 0.11 
steadily 0.11 
MeSHHealthStatusIndicators 0.11 
Consistent 0.11 
English- 0.11 
(38%) 0.11 
(47% 0.11 
sputum 0.11 
INO 0.11 
Changing 0.11 
APACHE 0.11 
MeSHTaxoids 0.11 
MeSHShoulderFractures 0.11 
flare 0.11 
954 0.11 
1967 0.11 
False-negative 0.11 
interposition 0.11 
ERCP: 0.11 
obviates 0.11 
advancements 0.11 
5-10% 0.11 
socio-demographic 0.11 
colorimetric 0.11 
live 0.11 
decreases 0.11 
worst 0.11 
demands 0.11 
rigorous 0.11 
(grade 0.11 
gynecologist 0.11 
introduction 0.11 
evolve 0.11 
English 0.11 
advocate 0.11 
carotid 0.11 
(by 0.11 
Thromboelastography 0.11 
gaining 0.11 
advancement 0.11 
masses 0.11 
otherwise 0.11 
scarce 0.11 
Forty-two 0.11 
<2 0.11 
retreatment 0.11 
tumours 0.11 
insemination 0.11 
cases; 0.11 
(SN) 0.11 
MeSHCommunity 0.11 
MeSHDiagnosticImaging 0.11 
429 0.11 
fluorine-18 0.11 
reproduced 0.11 
strengthened 0.11 
dilated 0.11 
ulcer 0.11 
0003) 0.11 
amplify 0.11 
injecting 0.11 
proceeding 0.11 
MeSHThromboplastin 0.11 
reality 0.11 
MeSHColonicDiseases 0.10 
relating 0.10 
raters 0.10 
beta-actin 0.10 
(PAP) 0.10 
faculty 0.10 
involvement) 0.10 
volume) 0.10 
Depth 0.10 
microtrauma 0.10 
MeSHHumeralFractures 0.10 
non-tuberculosis 0.10 
Background 0.10 
(SR) 0.10 
(modified 0.10 
70-80% 0.10 
resection] 0.10 
noncompliance 0.10 
researched 0.10 
alone) 0.10 
retroduodenal 0.10 
disease' 0.10 
choledocholithiasis) 0.10 
(moderate 0.10 
symphysis 0.10 
(combined 0.10 
MeSHPhyticAcid 0.10 
staining) 0.10 
Check 0.10 
(conventional 0.10 
world-wide 0.10 
nondemented 0.10 
university-based 0.10 
Thickness 0.10 
submucous 0.10 
174) 0.10 
(>50% 0.10 
ideas 0.10 
stage: 0.10 
negativity 0.10 
accomplish 0.10 
18F-FDG 0.10 
stratify 0.10 
down 0.10 
nationwide 0.10 
scintigram 0.10 
HIV-uninfected 0.10 
bloody 0.10 
machines 0.10 
unadjusted 0.10 
activators 0.10 
Munich 0.10 
Morphology 0.10 
microglobulin 0.10 
observing 0.10 
MeSHQuality-AdjustedLifeYears 0.10 
polyploidy 0.10 
nearby 0.10 
radioguided 0.10 
pools 0.10 
=13) 0.10 
Loop 0.10 
high-intensity 0.10 
(ADC) 0.10 
(small 0.10 
implied 0.10 
massive 0.10 
Transfusion 0.10 
slides 0.10 
mo) 0.10 
266 0.10 
Double 0.10 
femur 0.10 
B 0.10 
(for 0.10 
teaching 0.10 
048 0.10 
concrement 0.10 
favourable 0.10 
Their 0.10 
adequately 0.10 
normally 0.10 
(46% 0.10 
CKD 0.10 
Intraoperatively 0.10 
MeSHUrbanHealth 0.10 
compile 0.10 
4- 0.10 
endoluminal 0.10 
foundation 0.10 
inaccessible 0.10 
mixtures 0.10 
angiography) 0.10 
Carolina 0.10 
Case-control 0.10 
ITS 0.10 
British 0.10 
mL) 0.10 
immunostained 0.10 
supplement 0.10 
labeled 0.10 
MA) 0.10 
given 0.10 
luminal 0.09 
plans 0.09 
036 0.09 
<10 0.09 
SAMPLE: 0.09 
900 0.09 
333 0.09 
standard" 0.09 
fibroids 0.09 
enormous 0.09 
Exclusion 0.09 
buffer 0.09 
built 0.09 
oncologists 0.09 
MeSHFace 0.09 
oncogenes 0.09 
Digital 0.09 
survivals 0.09 
Enlarged 0.09 
missense 0.09 
MeSHElectrodes 0.09 
procedure) 0.09 
cells/mm(3) 0.09 
osteoblastic 0.09 
shapes 0.09 
(CP) 0.09 
Along 0.09 
immunochemical 0.09 
(PCI) 0.09 
postulated 0.09 
beside 0.09 
remains 0.09 
how 0.09 
rupture 0.09 
diameter) 0.09 
therapy; 0.09 
Consequently 0.09 
MeSHMultimodalImaging 0.09 
quantities 0.09 
explains 0.09 
pale 0.09 
nonbiliary 0.09 
phytate 0.09 
smoothly 0.09 
(ADP) 0.09 
>75 0.09 
interleukin-8 0.09 
slowed 0.09 
(delta 0.09 
Locally 0.09 
scarcely 0.09 
Forearm 0.09 
sufferers 0.09 
inadvertently 0.09 
case; 0.09 
(LDP) 0.09 
?/nMeSHEndoscopy 0.09 
inferiorly 0.09 
three-level 0.09 
(n=14) 0.09 
Erlangen 0.09 
(bile 0.09 
723 0.09 
9/12 0.09 
copies/mL 0.09 
types; 0.09 
Tehran 0.09 
generalization 0.09 
Universal 0.09 
MeSHElasticityImagingTechniques 0.09 
bowl 0.09 
(CRF) 0.09 
MeSHStereotaxicTechniques 0.09 
proposed 0.09 
distant 0.09 
MeSHSurveysandQuestionnaires 0.09 
population-based 0.09 
meet 0.09 
quality 0.09 
answer 0.09 
compartments 0.09 
Arthroscopic 0.09 
(PET) 0.09 
hematoxylin 0.09 
permits 0.09 
060 0.09 
Pearson's 0.09 
Philadelphia 0.09 
insufflation 0.09 
itraconazole 0.09 
N+) 0.09 
471 0.09 
Brief 0.09 
amplitude 0.09 
171 0.09 
kinetics 0.09 
realistic 0.09 
explanations 0.09 
ill-defined 0.09 
269 0.09 
infrastructure 0.09 
Concentration 0.09 
varies 0.09 
specifically 0.09 
analyze 0.08 
MeSHType2 0.08 
positions 0.08 
institute 0.08 
(SCC 0.08 
surgically 0.08 
(51%) 0.08 
010) 0.08 
appear 0.08 
NS) 0.08 
4-6 0.08 
076 0.08 
Francisco 0.08 
scale-up 0.08 
(LAM) 0.08 
congestion 0.08 
continuum 0.08 
Production 0.08 
non-SLNs 0.08 
575 0.08 
serve 0.08 
febrile 0.08 
Wald 0.08 
conscious 0.08 
Robertsonian 0.08 
Board 0.08 
optimizing 0.08 
consultant 0.08 
MBq 0.08 
INTRODUCTION 0.08 
mandatory 0.08 
C) 0.08 
Gastrointestinal 0.08 
maintenance 0.08 
registry 0.08 
(MT 0.08 
trend 0.08 
stages 0.08 
strip 0.08 
Thereafter 0.08 
(PSA) 0.08 
276 0.08 
paramount 0.08 
NMR 0.08 
?/nMeSHEndometriosis 0.08 
MeSHEnergyMetabolism 0.08 
049 0.08 
MeSHKi-67Antigen 0.08 
058 0.08 
COPD 0.08 
MeSHPlateletTransfusion 0.08 
strikingly 0.08 
rate; 0.08 
Journal 0.08 
low) 0.08 
samplings 0.08 
lobule 0.08 
interrelations 0.08 
upon 0.08 
assisted 0.08 
274 0.08 
transfusions 0.08 
chemoradiation 0.08 
expert 0.08 
Hospitals 0.08 
009 0.08 
curettage 0.08 
thereby 0.08 
fair 0.08 
MeSHHealthCareCosts 0.08 
limiting 0.08 
reversible 0.08 
greatest 0.08 
arms 0.08 
Preliminary 0.08 
enhanced 0.08 
LSG 0.08 
[(18)F]fluorodeoxyglucose 0.08 
GmbH 0.08 
Days 0.08 
6F 0.08 
mm3) 0.08 
MeSHEpinephrine 0.08 
fifty-one 0.08 
decontamination 0.08 
Evaluate 0.08 
Degree 0.08 
denominator 0.08 
MeSHMusculoskeletalSystem 0.08 
explicitly 0.08 
entrapped 0.08 
concurrence 0.08 
intercurrent 0.08 
Three-year 0.08 
pubis 0.08 
preparing 0.08 
homologues 0.08 
(false-negative 0.08 
HPV16- 0.08 
(115 0.08 
postponed 0.08 
24h 0.08 
uremia 0.08 
subjects: 0.08 
twentieth 0.08 
2/15 0.08 
15-T 0.08 
47XXY 0.08 
625% 0.08 
225% 0.08 
30-T 0.08 
999% 0.08 
556% 0.08 
0700 0.08 
115% 0.08 
96127 0.08 
144% 0.08 
950% 0.08 
945% 0.08 
112% 0.08 
(413 0.08 
313% 0.08 
169% 0.08 
143% 0.08 
868% 0.08 
700% 0.08 
angiography/nMeSHAdult 0.08 
0875 0.08 
(+/-35) 0.08 
0283) 0.08 
0151) 0.08 
0221) 0.08 
51-70) 0.08 
0578 0.08 
0320 0.08 
0675) 0.08 
22-40 0.08 
186% 0.08 
3411 0.08 
45X0 0.08 
46XY/47XY 0.08 
95476 0.08 
2196 0.08 
3939 0.08 
95-104 0.08 
0320) 0.08 
1455 0.08 
(5/75 0.08 
tear" 0.08 
0510 0.08 
(719 0.08 
098; 0.08 
9333 0.08 
342; 0.08 
490% 0.08 
823% 0.08 
x12 0.08 
37-83 0.08 
-147) 0.08 
(72%); 0.08 
1519 0.08 
0181 0.08 
0173 0.08 
0263 0.08 
(674 0.08 
0040) 0.08 
8333 0.08 
0365 0.08 
-208 0.08 
30-140) 0.08 
166% 0.08 
250% 0.08 
1545 0.08 
0334) 0.08 
(424 0.08 
0772; 0.08 
0611 0.08 
193%) 0.08 
0123) 0.08 
348% 0.08 
2537 0.08 
3090 0.08 
300; 0.08 
25-100) 0.08 
134% 0.08 
(684 0.08 
087; 0.08 
1308 0.08 
(351 0.08 
(109) 0.08 
024% 0.08 
238% 0.08 
101% 0.08 
080; 0.08 
101; 0.08 
07%; 0.08 
4204 0.08 
00009) 0.08 
107%) 0.08 
(149) 0.08 
10875 0.08 
137% 0.08 
cholangiography/nMeSHAdult 0.08 
0145) 0.08 
00-110 0.08 
2628 0.08 
0459 0.08 
10-48) 0.08 
102% 0.08 
004]) 0.08 
014% 0.08 
1767 0.08 
Abnormalities" 0.08 
240% 0.08 
1679 0.08 
2603 0.08 
3552 0.08 
220; 0.08 
0217 0.08 
2659 0.08 
122% 0.08 
380% 0.08 
Corp) 0.08 
0317 0.08 
3308 0.08 
086; 0.08 
354; 0.08 
0060) 0.08 
=330) 0.08 
2689 0.08 
x15 0.08 
0942 0.08 
0883 0.08 
4667 0.08 
2456 0.08 
322; 0.08 
0821 0.08 
5150 0.08 
0030) 0.08 
0008; 0.08 
(555 0.08 
135%) 0.08 
0118) 0.08 
058; 0.08 
0605 0.08 
3327 0.08 
1365 0.08 
[103 0.08 
MeSHNorway 0.08 
transfused 0.08 
MeSHKorea 0.08 
412 0.08 
531 0.08 
Its 0.08 
consistency 0.08 
Single 0.07 
8] 0.07 
hemodilution 0.07 
cholangiographies 0.07 
[18F]fluorodeoxyglucose 0.07 
576 0.07 
homocysteine 0.07 
(RFS) 0.07 
transmural 0.07 
lens 0.07 
debatable 0.07 
physician's 0.07 
(GS) 0.07 
funded 0.07 
588 0.07 
MeSHAspergillusflavus 0.07 
practitioner 0.07 
making 0.07 
contributed 0.07 
southern 0.07 
preeclampsia 0.07 
(SLNs) 0.07 
Products 0.07 
rule 0.07 
international 0.07 
(24% 0.07 
concerned 0.07 
safer 0.07 
Variable 0.07 
exact 0.07 
970 0.07 
turbo 0.07 
provocation 0.07 
weaker 0.07 
clarification 0.07 
makers 0.07 
1987 0.07 
Addition 0.07 
30-day 0.07 
MeSHFetalHeart 0.07 
progressing 0.07 
(CBDS) 0.07 
10; 0.07 
ex 0.07 
index 0.07 
pT4 0.07 
contrasted 0.07 
396 0.07 
Fibrinolytic 0.07 
exit 0.07 
(70%) 0.07 
(RR 0.07 
intra-operative 0.07 
MeSHDatabases 0.07 
recently 0.07 
roentgenograms 0.07 
principally 0.07 
wrong 0.07 
T1-2 0.07 
(IQR 0.07 
profile 0.07 
representing 0.07 
medically 0.07 
Adverse 0.07 
unable 0.07 
show 0.07 
portions 0.07 
gathered 0.07 
PI 0.07 
>5 0.07 
neoplasias 0.07 
MeSHShock 0.07 
begins 0.07 
nonoperatively 0.07 
slower 0.07 
MeSHDiffusionMagneticResonanceImaging 0.07 
tilt 0.07 
kits 0.07 
=14 0.07 
prime 0.07 
modify 0.07 
(103 0.07 
456 0.07 
coracoid 0.07 
correlative 0.07 
widened 0.07 
injury: 0.07 
systemically 0.07 
QFT-GIT 0.07 
MeSHDistrict 0.07 
Isolates 0.07 
Historically 0.07 
pg/ml) 0.07 
HLs 0.07 
pieces 0.07 
MeSHCarcinosarcoma 0.07 
Histopathologically 0.07 
Simplex 0.07 
MeSHMagnetiteNanoparticles 0.07 
MeSHPrecipitinTests 0.07 
inversely 0.07 
priori 0.06 
reasons 0.06 
employing 0.06 
Sri 0.06 
baseball 0.06 
coils 0.06 
664 0.06 
Methodologic 0.06 
metastasectomy 0.06 
MeSHCreatineKinase 0.06 
172) 0.06 
(BD) 0.06 
extracranial 0.06 
deployed 0.06 
MeSHContracture 0.06 
fifty-nine 0.06 
fared 0.06 
disruptions 0.06 
dropout 0.06 
MeSHCriticalPathways 0.06 
10(-6) 0.06 
Cancers 0.06 
Coronal 0.06 
(IDUS) 0.06 
monitors 0.06 
groupings 0.06 
complications] 0.06 
7/18 0.06 
METHODS/DESIGN: 0.06 
MeSHCryotherapy 0.06 
reaction) 0.06 
molds 0.06 
manufacturer's 0.06 
Timely 0.06 
coinciding 0.06 
validates 0.06 
compartment 0.06 
MeSHDenmark 0.06 
array 0.06 
Mini 0.06 
gradation 0.06 
maximal 0.06 
newborn 0.06 
Clinical 0.06 
study) 0.06 
Comparisons 0.06 
<50 0.06 
arrive 0.06 
Additional 0.06 
Lymphoscintigraphy 0.06 
Possible 0.06 
075 0.06 
388 0.06 
decidual 0.06 
959 0.06 
tumors; 0.06 
stringent 0.06 
vascularization 0.06 
manual 0.06 
213 0.06 
proving 0.06 
consciousness 0.06 
CONCLUSIONS/SIGNIFICANCE: 0.06 
59%) 0.06 
MeSHAgeFactors 0.06 
(18%) 0.06 
bilaterally 0.06 
northern 0.06 
innovative 0.06 
Derived 0.06 
passive 0.06 
DR 0.06 
immunostain 0.06 
022 0.06 
MeSHGermany 0.06 
13%) 0.06 
SMC 0.06 
knees 0.06 
subclavian 0.06 
third-trimester 0.06 
MeSHFibrinFibrinogenDegradationProducts 0.06 
Spearman's 0.06 
ensuing 0.06 
multitude 0.06 
Frequently 0.06 
docetaxel 0.06 
MeSHFolicAcid 0.06 
diminution 0.06 
dislocated 0.06 
empirically 0.06 
strata 0.06 
pancreatico-biliary 0.06 
undertaking 0.06 
MeSHExudatesandTransudates 0.06 
radiopharmaceuticals 0.06 
(overall 0.06 
gravity 0.06 
MeSHConsensus 0.06 
Polymorphisms 0.06 
non-Hispanic 0.06 
MeSHInflammatoryBowelDiseases 0.06 
MeSHConstipation 0.06 
myocardium 0.06 
Progress 0.06 
isolation 0.06 
conducting 0.06 
de 0.06 
group; 0.06 
refinement 0.06 
indispensable 0.06 
6-12 0.06 
unreliable 0.06 
covariate 0.06 
Norway 0.06 
add 0.06 
efficiently 0.06 
locally 0.06 
intra-abdominal 0.06 
preceding 0.06 
fairly 0.06 
592 0.06 
492 0.06 
companies 0.06 
monozygotic 0.06 
English-language 0.06 
Staff 0.06 
Quebec 0.06 
5:1 0.06 
biopsy) 0.06 
MeSHNeonatal 0.06 
Siemens 0.06 
final 0.05 
Indicator 0.05 
ACC 0.05 
centered 0.05 
preferences 0.05 
MeSHTemperature 0.05 
imperfect 0.05 
highlighting 0.05 
Gastroenterology 0.05 
9); 0.05 
extirpation 0.05 
compensated 0.05 
S' 0.05 
Cases 0.05 
MeSHGastrointestinal 0.05 
beta) 0.05 
drawn 0.05 
CND 0.05 
004; 0.05 
(N1) 0.05 
Santa 0.05 
mandates 0.05 
tightness 0.05 
discoveries 0.05 
50-100 0.05 
exacerbations 0.05 
antigenicity 0.05 
Adoption 0.05 
populated 0.05 
?/nMeSHDNA 0.05 
(lower 0.05 
MeSHSampleSize 0.05 
excludes 0.05 
18-20 0.05 
Lethal 0.05 
(IOUS) 0.05 
centimeters 0.05 
MeSHReviewLiteratureasTopic 0.05 
studies; 0.05 
preinvasive 0.05 
picked 0.05 
MeSHStateMedicine 0.05 
subclassified 0.05 
Inactivation 0.05 
adenocarcinoma) 0.05 
-70) 0.05 
summer 0.05 
pattern) 0.05 
entorhinal 0.05 
(DAT) 0.05 
minor 0.05 
SLNB 0.05 
hemostatic 0.05 
182 0.05 
CSF 0.05 
transverse 0.05 
electronic 0.05 
MeSHUterineDiseases 0.05 
devise 0.05 
renal 0.05 
MeSHThird 0.05 
grown 0.05 
hospital-based 0.05 
MeSHDecisionMaking 0.05 
trade 0.05 
larger 0.05 
progressed 0.05 
MeSHPopulationSurveillance 0.05 
>25 0.05 
068 0.05 
shortness 0.05 
patient; 0.05 
thrombelastometry 0.05 
Hemolysis 0.05 
deranged 0.05 
contusion 0.05 
operation; 0.05 
"en 0.05 
affords 0.05 
(according 0.05 
technique) 0.05 
One-third 0.05 
specification 0.05 
commentary 0.05 
MeSHLanguage 0.05 
site-specific 0.05 
endometriosis) 0.05 
Kruskal-Wallis 0.05 
influx 0.05 
(5) 0.05 
009) 0.05 
experiencing 0.05 
surgeon's 0.05 
Independent 0.05 
repeated 0.05 
tracers 0.05 
(13) 0.05 
cytotrophoblast 0.05 
intubation 0.05 
carcinomatous 0.05 
0006 0.05 
analyzer 0.05 
Historical 0.05 
<20 0.05 
MeSHDissection 0.05 
inexpensive 0.05 
MeSHCA-125Antigen 0.05 
BT 0.05 
institutional 0.05 
meeting 0.05 
Authors 0.05 
Urinary 0.05 
college 0.05 
(NS) 0.05 
29-year-old 0.05 
favourably 0.05 
seated 0.05 
inclusive 0.05 
dynamically 0.05 
(HL) 0.05 
MeSHPenteticAcid 0.05 
[odds 0.05 
511 0.05 
Concept 0.05 
gynaecologist 0.05 
centers 0.05 
Death 0.05 
INTRODUCTION: 0.05 
leading 0.05 
visualize 0.05 
time 0.05 
zero 0.05 
anchor 0.05 
Effectiveness 0.05 
little 0.05 
subject 0.05 
metastases) 0.05 
pertaining 0.05 
RELEVANCE: 0.05 
nonmalignant 0.05 
preferable 0.05 
molar 0.05 
AST 0.05 
histopathologically 0.05 
Twelve 0.05 
(63%) 0.05 
biased 0.04 
negatively 0.04 
planning 0.04 
native 0.04 
Mayo 0.04 
assuming 0.04 
non-significant 0.04 
analyzes 0.04 
MeSHColloids 0.04 
MeSHHeartFailure 0.04 
guarantee 0.04 
premature 0.04 
1975 0.04 
build 0.04 
(95%CI: 0.04 
per-operative 0.04 
CT-based 0.04 
orientate 0.04 
comet 0.04 
pregnancy-related 0.04 
phase) 0.04 
(initial 0.04 
tumor-node-metastasis 0.04 
taught 0.04 
non-traumatic 0.04 
transosseous 0.04 
damages 0.04 
population; 0.04 
drives 0.04 
887 0.04 
liver) 0.04 
tomography-computed 0.04 
carcinomas] 0.04 
present) 0.04 
(LMP) 0.04 
11/12 0.04 
artificially 0.04 
encephalocele 0.04 
cholecystojejunostomy 0.04 
probe-guided 0.04 
researches 0.04 
Across 0.04 
extraordinary 0.04 
misclassification 0.04 
'gold 0.04 
ml/kg 0.04 
foremost 0.04 
disconnection 0.04 
posttransplantation 0.04 
Molecular 0.04 
0008) 0.04 
mg/ml 0.04 
488 0.04 
thoraco-lumbar 0.04 
culture-proven 0.04 
pipeline 0.04 
consulting 0.04 
certificate 0.04 
924 0.04 
port-site 0.04 
(open 0.04 
Extreme 0.04 
videolaparoscopic 0.04 
IU/mL 0.04 
MeSHAorticDiseases 0.04 
reevaluation 0.04 
neuropathology 0.04 
yearly 0.04 
chances 0.04 
Bank 0.04 
pathologies 0.04 
MeSHSouthAfrica 0.04 
Tertiary 0.04 
MeSHDrugResistance 0.04 
MTBC 0.04 
schools 0.04 
rheumatology 0.04 
(n=6) 0.04 
test; 0.04 
unfit 0.04 
claimed 0.04 
(n=4) 0.04 
3T 0.04 
It 0.04 
surveyed 0.04 
answered 0.04 
providing 0.04 
MeSHHospitalMortality 0.04 
MeSH"WomensHealth" 0.04 
complete 0.04 
postpartum 0.04 
disturbed 0.04 
231 0.04 
stenotic 0.04 
contradict 0.04 
05; 0.04 
011) 0.04 
Italian 0.04 
particularly 0.04 
Laboratory 0.04 
(43% 0.04 
simultaneous 0.04 
cytomorphologic 0.04 
prefrontal 0.04 
contradictory 0.04 
lessons 0.04 
Mediterranean 0.04 
replacing 0.04 
amounted 0.04 
yellow 0.04 
Tanzania 0.04 
MeSHPhysicalTherapyModalities 0.04 
800 0.04 
whole-body 0.04 
Latin 0.04 
Wales 0.04 
EXPERIMENTAL 0.04 
N0) 0.04 
endoscopically 0.04 
gynecological 0.04 
advised 0.04 
skill 0.04 
h 0.04 
(p<0001) 0.04 
p<0001) 0.04 
<001) 0.04 
933% 0.04 
111% 0.04 
1000% 0.04 
750% 0.04 
897% 0.04 
patients/nMeSHAged 0.04 
surgery/nMeSHAdult 0.04 
116% 0.04 
188% 0.04 
969% 0.04 
lesions/nMeSHAdult 0.04 
30T 0.04 
632% 0.04 
(07%) 0.04 
(02%) 0.04 
124% 0.04 
731% 0.04 
146% 0.04 
165% 0.04 
215% 0.04 
995% 0.04 
308% 0.04 
226% 0.04 
289% 0.04 
(227%) 0.04 
423% 0.04 
128% 0.04 
cuff/nMeSHAdult 0.04 
533% 0.04 
(04%) 0.04 
765% 0.04 
974% 0.04 
<0001) 0.04 
(13)-beta-D-glucan 0.04 
needed/nMeSHAdult 0.04 
0936 0.04 
0872 0.04 
(+/-14) 0.04 
01/40 0.04 
(476 0.04 
-008) 0.04 
(106% 0.04 
02291 0.04 
00001; 0.04 
2853 0.04 
38000 0.04 
(605 0.04 
2497 0.04 
3125 0.04 
2803 0.04 
4443 0.04 
00097 0.04 
10605 0.04 
0209 0.04 
0226 0.04 
on/nMeSHAdolescent 0.04 
0840 0.04 
500000 0.04 
21-42) 0.04 
0228) 0.04 
0090) 0.04 
14000 0.04 
51206 0.04 
312% 0.04 
574% 0.04 
0546) 0.04 
717% 0.04 
088; 0.04 
(171%) 0.04 
280% 0.04 
(228%) 0.04 
182% 0.04 
(345%) 0.04 
353% 0.04 
8116 0.04 
0991 0.04 
328% 0.04 
196% 0.04 
141% 0.04 
(02 0.04 
687% 0.04 
371% 0.04 
171% 0.04 
246% 0.04 
(106%) 0.04 
474% 0.04 
0961 0.04 
525; 0.04 
0873 0.04 
0624 0.04 
0368 0.04 
0986 0.04 
00005; 0.04 
37-100) 0.04 
<001 0.04 
0491 0.04 
702% 0.04 
tears" 0.04 
0771 0.04 
7804 0.04 
5452 0.04 
19-120) 0.04 
=203) 0.04 
p<0001 0.04 
-040 0.04 
(739 0.04 
(717%) 0.04 
516] 0.04 
1000] 0.04 
-1000) 0.04 
(1000) 0.04 
0495 0.04 
0781 0.04 
0909) 0.04 
0001% 0.04 
851% 0.04 
35:1 0.04 
(59%; 0.04 
154; 0.04 
081; 0.04 
4548 0.04 
264%) 0.04 
3288 0.04 
6528 0.04 
150-360) 0.04 
(70) 0.04 
168% 0.04 
-001) 0.04 
1183 0.04 
495% 0.04 
0368) 0.04 
37-65 0.04 
(05 0.04 
3559 0.04 
4508 0.04 
(264% 0.04 
(474% 0.04 
-0201 0.04 
-0116 0.04 
(08%) 0.04 
0774 0.04 
01842 0.04 
(1013 0.04 
(303% 0.04 
289%) 0.04 
0009; 0.04 
(250) 0.04 
II-2/nMeSHAdolescent 0.04 
624) 0.04 
263% 0.04 
089% 0.04 
+/-01 0.04 
11659 0.04 
0251 0.04 
0338) 0.04 
0421 0.04 
142%; 0.04 
2505 0.04 
5713 0.04 
205% 0.04 
557% 0.04 
(09 0.04 
(264%) 0.04 
577% 0.04 
(137%) 0.04 
685% 0.04 
252% 0.04 
650% 0.04 
(217%) 0.04 
12-21) 0.04 
3335) 0.04 
782% 0.04 
populations" 0.04 
0898 0.04 
0982 0.04 
230% 0.04 
567% 0.04 
287% 0.04 
1559 0.04 
0784 0.04 
048% 0.04 
1458% 0.04 
(266% 0.04 
=0005) 0.04 
293; 0.04 
(249% 0.04 
(205% 0.04 
0003; 0.04 
2856 0.04 
0264) 0.04 
0536 0.04 
106; 0.04 
629% 0.04 
0667 0.04 
458% 0.04 
4590 0.04 
3890 0.04 
(793 0.04 
228% 0.04 
037); 0.04 
0280 0.04 
0354 0.04 
0646 0.04 
0560 0.04 
0916 0.04 
0833 0.04 
0834 0.04 
0802 0.04 
(592 0.04 
0789 0.04 
07087 0.04 
infiltration/nMeSHAdult 0.04 
0913) 0.04 
4291 0.04 
8851 0.04 
0816 0.04 
575% 0.04 
1429 0.04 
9206 0.04 
7250 0.04 
25+/-10 0.04 
188; 0.04 
345% 0.04 
(101+/- 0.04 
005)) 0.04 
-042 0.04 
0242) 0.04 
05-13 0.04 
3294 0.04 
164% 0.04 
0857 0.04 
0913 0.04 
0015); 0.04 
teratoma 0.04 
empiric 0.04 
wide 0.04 
40%) 0.04 
MeSHCytogeneticAnalysis 0.04 
MeSHTeratoma 0.04 
0003 0.04 
adenosine 0.04 
peptic 0.04 
tomography- 0.04 
Poor 0.04 
feeling 0.04 
factors: 0.04 
(AC) 0.04 
(more 0.04 
074 0.04 
IP-10 0.04 
hrs 0.04 
extrathoracic 0.04 
thinking 0.04 
cryotherapy 0.04 
92; 0.04 
oxygenation 0.04 
544 0.04 
co-existing 0.04 
hospitalised 0.04 
inferred 0.04 
Tumours 0.04 
remissions 0.04 
unfortunately 0.04 
blood: 0.04 
SRY 0.04 
women] 0.04 
southeast 0.04 
inconspicuous 0.04 
precocious 0.04 
encompasses 0.04 
cholecystitis; 0.04 
Strategy 0.04 
MeSHChromatin 0.04 
Encephalitis 0.04 
inspected 0.04 
120) 0.04 
MeSHAmputation 0.04 
mycobacteriosis 0.04 
ribosomal 0.04 
018 0.04 
MeSHLectins 0.04 
GS 0.04 
girdle 0.04 
Superoxide 0.04 
Fatigue 0.04 
MeSHRepressorProteins 0.04 
MeSHWholeBloodCoagulationTime 0.04 
appraise 0.04 
Indian 0.04 
silent 0.04 
46%) 0.04 
chest 0.04 
severity 0.04 
DMI 0.04 
manoeuvres 0.04 
Bactec 0.04 
iNOS 0.04 
NCR 0.04 
fractures; 0.04 
subjects' 0.04 
MeSHLivingDonors 0.04 
PROBLEM: 0.04 
poorest 0.04 
clarity 0.04 
FUNDING: 0.04 
(2; 0.04 
criteria; 0.04 
appraised 0.04 
dissection; 0.04 
(Tg) 0.04 
unifocal 0.04 
contracting 0.04 
MeSHAntinuclear 0.04 
worsens 0.04 
personalized 0.04 
waste 0.04 
MeSHPrivateSector 0.04 
level; 0.04 
standard' 0.04 
treadmill 0.04 
Reversible 0.04 
896 0.04 
tertiary-care 0.04 
MeSHDiagnosticTechniques 0.03 
as: 0.03 
obstetricians 0.03 
MeSHIsrael 0.03 
mailed 0.03 
(PC) 0.03 
046) 0.03 
037) 0.03 
medial 0.03 
016 0.03 
rhythm 0.03 
generate 0.03 
(14%) 0.03 
synchronous 0.03 
theoretic 0.03 
Area 0.03 
ten 0.03 
resource-limited 0.03 
operable 0.03 
unchanged 0.03 
ruled 0.03 
Higher 0.03 
Fifty-eight 0.03 
286 0.03 
Past 0.03 
DI 0.03 
MeSHPancreaticoduodenectomy 0.03 
MeSHInguinalCanal 0.03 
Regional 0.03 
Impact 0.03 
reached 0.03 
horizontal 0.03 
CA125 0.03 
verbal 0.03 
Together 0.03 
ns 0.03 
dismutase 0.03 
compliant 0.03 
seriously 0.03 
MeSHProgramDevelopment 0.03 
reach 0.03 
poorer 0.03 
sperm 0.03 
compromised 0.03 
glucose 0.03 
098 0.03 
branched 0.03 
risk: 0.03 
well-designed 0.03 
radicality 0.03 
(mostly 0.03 
Transcutaneous 0.03 
gamma-probe 0.03 
telomere 0.03 
elderly: 0.03 
MeSHWholeBodyImaging 0.03 
indigenous 0.03 
MeSHPhysicalExertion 0.03 
Pharmacologic 0.03 
003; 0.03 
beta-amyloid 0.03 
MeSHAnalysisofVariance 0.03 
28-year-old 0.03 
5/10 0.03 
MeSHOsteogenesis 0.03 
MeSHPregnantWomen 0.03 
MTC 0.03 
renewed 0.03 
Washington 0.03 
volumetric 0.03 
arrhythmia 0.03 
already 0.03 
regular 0.03 
QF-PCR 0.03 
MeSHPair16 0.03 
powerful 0.03 
explored 0.03 
episodes 0.03 
helpful 0.03 
27%) 0.03 
detailed 0.03 
quantitation 0.03 
DQ 0.03 
MeSHLipopolysaccharides 0.03 
6/10 0.03 
972 0.03 
IDUS 0.03 
culturally 0.03 
MeSHFibrinolysin 0.03 
disputed 0.03 
Controlling 0.03 
Klinefelter's 0.03 
chemotherapy; 0.03 
subdiaphragmatic 0.03 
Predominant 0.03 
varieties 0.03 
undue 0.03 
(baseline 0.03 
endotracheal 0.03 
auxiliary 0.03 
Numbers 0.03 
intergroup 0.03 
submicroscopic 0.03 
lifespan 0.03 
respected 0.03 
pancreatocholangiography 0.03 
10/11 0.03 
cribriform 0.03 
adolescents: 0.03 
linearity 0.03 
cervix] 0.03 
Pertinent 0.03 
MeSHFactorAnalysis 0.03 
Confusion 0.03 
1988) 0.03 
MeSHMyocardialRevascularization 0.03 
MeSHPeripheralVascularDiseases 0.03 
disease-modifying 0.03 
fluency 0.03 
Positivity 0.03 
2006 0.03 
carcinoma] 0.03 
Participants 0.03 
MeSHTissueAdhesions 0.03 
worse 0.03 
celiac 0.03 
additionally 0.03 
Significant 0.03 
decided 0.03 
haemodialysis 0.03 
weighing 0.03 
hypertrophic 0.03 
imaging) 0.03 
ischaemic 0.03 
anamnesis 0.03 
(endoscopic 0.03 
diseases: 0.03 
Eighty-one 0.03 
Bankart 0.03 
needing 0.03 
IIa) 0.03 
EUS-FNA 0.03 
293 0.03 
disabilities 0.03 
tumor-free 0.03 
histories 0.03 
modifications 0.03 
offering 0.03 
diffusion-weighted 0.03 
Ki67 0.03 
(n=2) 0.03 
MeSHMonosomy 0.03 
practicing 0.03 
Royal 0.03 
recommends 0.03 
adipose 0.03 
MeSHComputerSimulation 0.03 
contrast 0.03 
search 0.03 
MeSHMedicalRecords 0.03 
improving 0.02 
modifying 0.02 
liberal 0.02 
36; 0.02 
mg/dL) 0.02 
MeSHBloodComponentTransfusion 0.02 
nontraumatic 0.02 
staging: 0.02 
dilutions 0.02 
1998) 0.02 
intra-hepatic 0.02 
exposing 0.02 
aneuploidy: 0.02 
diagnosis? 0.02 
unilaterally 0.02 
near-infrared 0.02 
infarcts 0.02 
arrhythmias 0.02 
Consortium 0.02 
(OLT) 0.02 
Prognostic 0.02 
players 0.02 
polypeptide 0.02 
claims 0.02 
That 0.02 
exponential 0.02 
hippocampus 0.02 
relapse 0.02 
(59%) 0.02 
(68%) 0.02 
MeSHOrganotechnetiumCompounds 0.02 
MeSHCardiovascularDiseases 0.02 
anomalous 0.02 
A-D 0.02 
sized 0.02 
220 0.02 
MeSHOligonucleotideArraySequenceAnalysis 0.02 
register 0.02 
consisting 0.02 
ongoing 0.02 
posterior 0.02 
Gynecologic 0.02 
pathologists 0.02 
intraabdominal 0.02 
(RR) 0.02 
liver 0.02 
considerable 0.02 
kinetic 0.02 
third 0.02 
pair 0.02 
parallel 0.02 
hours) 0.02 
documenting 0.02 
substituted 0.02 
pancreatitis) 0.02 
handicap 0.02 
signs 0.02 
rpoB 0.02 
postsurgical 0.02 
SNs 0.02 
(46%) 0.02 
secure 0.02 
isometric 0.02 
integrating 0.02 
Classic 0.02 
Minnesota 0.02 
eliminates 0.02 
(primary 0.02 
WORDS)/nMeSHAdolescent 0.02 
MeSHAntiviralAgents 0.02 
undefined 0.02 
washed 0.02 
instruments 0.02 
adhesions 0.02 
GA 0.02 
(13% 0.02 
angled 0.02 
MPR 0.02 
628 0.02 
jump 0.02 
trend) 0.02 
accommodate 0.02 
type-1 0.02 
manufacturers 0.02 
anterosuperior 0.02 
introduces 0.02 
compounded 0.02 
re-operated 0.02 
MeSHHealthcareDisparities 0.02 
(Table 0.02 
factual 0.02 
(AR) 0.02 
hundreds 0.02 
motivated 0.02 
scientists 0.02 
worry 0.02 
MeSHIgG 0.02 
virus-1 0.02 
(F) 0.02 
sites: 0.02 
248 0.02 
senior 0.02 
flavus 0.02 
detrimental 0.02 
Renal 0.02 
(CBD 0.02 
stated 0.02 
nephrosis 0.02 
0-3 0.02 
aberration 0.02 
Total 0.02 
questionnaires 0.02 
neoadjuvant 0.02 
(ie 0.02 
advice 0.02 
stays 0.02 
2012 0.02 
pancreatobiliary 0.02 
any) 0.02 
Cumulative 0.02 
?/nMeSHAdenocarcinoma 0.02 
083 0.02 
colored 0.02 
Evidence-based 0.02 
Proximal 0.02 
flags 0.02 
(CXR) 0.02 
anti-retroviral 0.02 
601 0.02 
arbitrary 0.02 
small-bowel 0.02 
rewarding 0.02 
MeSHUmbilicalVeins 0.02 
co-morbidity 0.02 
pancreas: 0.02 
pathology] 0.02 
including: 0.02 
dictated 0.02 
McGill 0.02 
(SNs) 0.02 
MeSHFerrosoferricOxide 0.02 
18: 0.02 
vigilance 0.02 
Endometriotic 0.02 
hemosiderin 0.02 
(16) 0.02 
hypercholesterolemia 0.02 
Matched 0.02 
mycelial 0.02 
accompanying 0.02 
menstrual 0.02 
nearly 0.02 
042) 0.02 
derivation 0.02 
Greater 0.02 
(15) 0.02 
gender 0.02 
department 0.02 
relationships 0.02 
describing 0.02 
intention 0.02 
(18% 0.02 
modification 0.02 
MeSHAdiposeTissue 0.02 
haemostatic 0.02 
albeit 0.02 
messenger 0.02 
covariates 0.02 
results] 0.02 
S-P 0.02 
systematically 0.02 
Scores 0.02 
dose-response 0.02 
projects 0.02 
security 0.02 
independence 0.02 
behaviors 0.02 
unspecified 0.02 
017 0.02 
(83%) 0.02 
any 0.02 
evident 0.02 
Dynamic 0.02 
enabled 0.02 
influence 0.02 
rendered 0.02 
omentum 0.02 
time-consuming 0.02 
977 0.02 
raises 0.02 
well-defined 0.02 
thorough 0.02 
EST 0.02 
Resection 0.02 
cancer? 0.02 
256 0.02 
Mycosis 0.02 
landmark 0.02 
China 0.02 
(range 0.02 
positron 0.02 
localisation 0.02 
substances 0.02 
subfertile 0.02 
825 0.02 
NaCl 0.02 
899 0.02 
reaction-based 0.02 
tumor's 0.02 
compression) 0.02 
Surgically 0.02 
utilised 0.02 
(AML) 0.02 
Periodicals 0.02 
MeSH"PhysiciansRole" 0.02 
MeSHEosineYellowish-(YS) 0.02 
MeSHMicrotubule-AssociatedProteins 0.02 
Slides 0.02 
doesn't 0.02 
MeSHCerebralHemorrhage 0.02 
finds 0.02 
community-acquired 0.02 
penicillin 0.02 
moieties 0.02 
primers 0.02 
substitute 0.02 
them 0.02 
(27%) 0.02 
0002 0.02 
3-D 0.02 
MeSHHydronephrosis 0.02 
dealt 0.02 
explores 0.02 
restoring 0.02 
victims 0.01 
874 0.01 
722 0.01 
IOUS 0.01 
Helical 0.01 
entrance 0.01 
random-effects 0.01 
omission 0.01 
weight) 0.01 
samples; 0.01 
iminodiacetic 0.01 
selectivity 0.01 
(LND) 0.01 
macrometastasis 0.01 
EQ-5D 0.01 
78; 0.01 
Radiologist 0.01 
MeSHSudden 0.01 
Retention 0.01 
MeSHLewyBodyDisease 0.01 
beneficial 0.01 
posttraumatic 0.01 
Fifty-three 0.01 
C: 0.01 
experts 0.01 
Food 0.01 
concepts 0.01 
(83% 0.01 
interference 0.01 
hypertensive 0.01 
superoxide 0.01 
MeSHGynecology 0.01 
getting 0.01 
Randomised 0.01 
ratio: 0.01 
consistently 0.01 
Limited 0.01 
Academic 0.01 
019) 0.01 
California 0.01 
admission 0.01 
(47%) 0.01 
inconsistent 0.01 
machine 0.01 
MeSHFactual 0.01 
polymerase 0.01 
treatable 0.01 
quantify 0.01 
(EUS-FNA) 0.01 
high-burden 0.01 
documents 0.01 
confident 0.01 
intraoperatively 0.01 
154 0.01 
San 0.01 
ulcerative 0.01 
merits 0.01 
D] 0.01 
resource 0.01 
emphasized 0.01 
discrepancy 0.01 
Whipple 0.01 
symmetrical 0.01 
<1 0.01 
Identification 0.01 
recur 0.01 
(40%) 0.01 
studies 0.01 
peroperative 0.01 
5c 0.01 
late-stage 0.01 
DIC) 0.01 
QFT-GIT) 0.01 
intestines 0.01 
(ED) 0.01 
FVIII 0.01 
designation 0.01 
it? 0.01 
Departments 0.01 
survival: 0.01 
precluding 0.01 
teenagers 0.01 
golden 0.01 
enrolment 0.01 
trachomatis 0.01 
retinoblastoma 0.01 
backgrounds 0.01 
ovoid 0.01 
baseline) 0.01 
visuospatial 0.01 
Peter 0.01 
MeSHChemokineCXCL10 0.01 
Tumor 0.01 
latter 0.01 
deleted 0.01 
HPV-related 0.01 
cognitively 0.01 
2-microglobulin 0.01 
postcontrast 0.01 
1100 0.01 
continually 0.01 
injuries: 0.01 
MeSHPyloricAntrum 0.01 
implantable 0.01 
988) 0.01 
INH-resistant 0.01 
time: 0.01 
likewise 0.01 
MeSHProlactin 0.01 
587 0.01 
compulsory 0.01 
Amsterdam 0.01 
frozen-section 0.01 
Adjunct 0.01 
technique: 0.01 
MeSHGlucans 0.01 
antemortem 0.01 
caspofungin 0.01 
911 0.01 
MeSHFetus 0.01 
participate 0.01 
Twenty-two 0.01 
MeSHCarcinomainSitu 0.01 
claim 0.01 
seem 0.01 
proportional 0.01 
988 0.01 
tracer 0.01 
(SCC) 0.01 
reporting 0.01 
periodic 0.01 
infants 0.01 
extrapulmonary 0.01 
Close 0.01 
avulsion 0.01 
Israel 0.01 
incidences 0.01 
thrombin 0.01 
patients] 0.01 
133 0.01 
plasminogen 0.01 
SOD 0.01 
acidic 0.01 
half-life 0.01 
PCA 0.01 
group: 0.01 
constructs 0.01 
overwhelming 0.01 
(QF-PCR) 0.01 
quantitate 0.01 
Steril 0.01 
decide 0.01 
contributes 0.01 
specialist 0.01 
MeSHTechnetiumTc99mSulfurColloid 0.01 
necessarily 0.01 
INTERVENTION: 0.01 
Hence 0.01 
unfavorable 0.01 
2] 0.01 
promising 0.01 
admissions 0.01 
micrograms 0.01 
Inc 0.01 
is 0.01 
non 0.01 
died 0.01 
experienced 0.01 
executive 0.01 
fatality 0.01 
pursued 0.01 
26-year-old 0.01 
contracture 0.01 
(MTC) 0.01 
warn 0.01 
colleagues 0.01 
83%) 0.01 
abnormally 0.01 
enabling 0.01 
structural 0.01 
?/nMeSHBiliaryTract 0.01 
automatic 0.01 
IMPLICATION 0.01 
propose 0.01 
nevertheless 0.01 
County 0.01 
repositioning 0.01 
myofascial 0.01 
case-finding 0.01 
110) 0.01 
MeSHPatientDischarge 0.01 
biopsy; 0.01 
decubitus 0.01 
conclusively 0.01 
fibromyalgia 0.01 
Challenges 0.01 
discretion 0.01 
<200 0.01 
argues 0.01 
mCi) 0.01 
cyst) 0.01 
24-48 0.01 
hypoalbuminemia 0.01 
classifiable 0.01 
launched 0.01 
(n=13) 0.01 
[SD] 0.01 
(SP) 0.01 
incipient 0.01 
MeSHCellNucleolus 0.01 
complicates 0.01 
sectors 0.01 
MeSHMedicalIllustration 0.01 
coexisted 0.01 
punctate 0.01 
(ERC) 0.01 
MeSHFemur 0.01 
chromosome 0.01 
you 0.01 
r 0.01 
implying 0.01 
justifies 0.01 
facing 0.01 
dosages 0.01 
metropolitan 0.01 
Moderate 0.01 
asking 0.01 
2007) 0.01 
SEM) 0.01 
viewing 0.01 
intermediate 0.01 
fulfill 0.01 
(107 0.01 
823 0.01 
preemptive 0.01 
sterilizing 0.01 
fluctuating 0.01 
GPs 0.01 
detrusor 0.01 
proceedings 0.01 
951 0.01 
pTNM 0.01 
infectiousness 0.01 
countries: 0.01 
Objectives 0.01 
resection; 0.01 
MeSHLong-TermCare 0.01 
Whole-body 0.01 
reexploration 0.01 
extra-articular 0.01 
comparably 0.01 
tomography] 0.01 
MeSHSpectroscopy 0.01 
>90% 0.01 
your 0.01 
Fortunately 0.01 
5-point 0.01 
draws 0.01 
refusal 0.01 
impressions 0.01 
redistribution 0.01 
two-tailed 0.01 
Physiology 0.01 
MeSHEchinocandins 0.01 
analyses 0.01 
associations 0.01 
H&E 0.01 
aided 0.01 
make 0.01 
alternative 0.01 
1st 0.01 
Thus 0.01 
Despite 0.01 
sentinel 0.01 
an 0.01 
rated 0.01 
visualized 0.01 
multiplex 0.01 
Histopathology 0.01 
IS) 0.01 
pictures 0.01 
TR 0.01 
technically 0.01 
observation 0.01 
Insurance 0.01 
MeSHMuscleWeakness 0.01 
MeSHSodiumChloride 0.01 
made 0.01 
taking 0.01 
counties 0.01 
MeSHExternal 0.01 
boundaries 0.01 
Nonoperative 0.01 
355 0.01 
Immunostaining 0.01 
MeSHAngina 0.01 
blocker 0.01 
(and 0.01 
heart 0.01 
patients: 0.01 
International 0.01 
abortion 0.01 
head 0.01 
d 0.01 
followup 0.01 
023 0.01 
skull 0.01 
teres 0.01 
RFS 0.01 
harmful 0.01 
labour 0.01 
Embase 0.01 
hepatis 0.01 
misinterpretation 0.01 
compiled 0.01 
CBD 0.00 
?/nMeSHBloodCoagulationDisorders 0.00 
hemodynamics 0.00 
cycles) 0.00 
"on 0.00 
occupations 0.00 
keywords 0.00 
causation 0.00 
(IS) 0.00 
Zambia 0.00 
stayed 0.00 
litigation 0.00 
(IQR) 0.00 
MeSHPair3 0.00 
Tunisia 0.00 
ultrasonography) 0.00 
hepatoma 0.00 
usable 0.00 
analysis] 0.00 
Berlin 0.00 
(OCG) 0.00 
Queen 0.00 
791 0.00 
extracardiac 0.00 
(400 0.00 
(COPD) 0.00 
trauma 0.00 
supine 0.00 
Expert 0.00 
Recommendations 0.00 
CA19-9 0.00 
circumference 0.00 
spectral 0.00 
addresses 0.00 
Microbiology 0.00 
adverse 0.00 
MeSHProstate-SpecificAntigen 0.00 
besides 0.00 
closer 0.00 
(two 0.00 
persistent 0.00 
(CBD) 0.00 
assist 0.00 
Han 0.00 
save 0.00 
606 0.00 
incarceration 0.00 
palpated 0.00 
resection: 0.00 
Medicina 0.00 
eroded 0.00 
Targeting 0.00 
Gd-DTPA 0.00 
(out 0.00 
supraduodenal 0.00 
bivalent 0.00 
bringing 0.00 
(mRNA) 0.00 
Cyclins 0.00 
appreciably 0.00 
Original 0.00 
thick-walled 0.00 
BACKGROUND/AIM: 0.00 
medium-term 0.00 
test] 0.00 
care: 0.00 
832 0.00 
1978 0.00 
(PET 0.00 
MeSHSentinelLymphNodeBiopsy 0.00 
M-CSF 0.00 
female; 0.00 
subscale 0.00 
manifests 0.00 
362 0.00 
increasing 0.00 
gynecologic 0.00 
radionuclide 0.00 
IU 0.00 
preexisting 0.00 
distension 0.00 
manually 0.00 
system: 0.00 
Included 0.00 
23; 0.00 
eight) 0.00 
Univariate 0.00 
500 0.00 
advocated 0.00 
clinical 0.00 
Once 0.00 
1966 0.00 
wart 0.00 
(SE 0.00 
ethical 0.00 
variable 0.00 
variations 0.00 
instability 0.00 
reproduce 0.00 
Falls 0.00 
traumatic 0.00 
temperature 0.00 
avoid 0.00 
093 0.00 
pN+ 0.00 
(MCF) 0.00 
expired 0.00 
gemcitabine 0.00 
hyperextension 0.00 
internally 0.00 
isolating 0.00 
(1966 0.00 
Details 0.00 
Adults 0.00 
(ZN) 0.00 
741 0.00 
Benefits 0.00 
Others 0.00 
Simultaneously 0.00 
fathers 0.00 
Reliable 0.00 
switching 0.00 
series) 0.00 
745 0.00 
gynaecology 0.00 
clade 0.00 
Iranian 0.00 
A); 0.00 
(left 0.00 
angiography; 0.00 
scintiscan 0.00 
Arbor 0.00 
mutagenesis 0.00 
methionine 0.00 
perspective 0.00 
240 0.00 
saving 0.00 
heightened 0.00 
3:1 0.00 
seemingly 0.00 
>15 0.00 
bundle 0.00 
353 0.00 
Introduction 0.00 
(most 0.00 
assumed 0.00 
dissections 0.00 
(OS 0.00 
particular 0.00 
channels 0.00 
margins 0.00 
hysterosalpingography 0.00 
health-care 0.00 
extends 0.00 
characterisation 0.00 
weights 0.00 
exploit 0.00 
(Group 0.00 
proof 0.00 
CRF 0.00 
fluctuations 0.00 
keratin-positive 0.00 
Barrett's 0.00 
non-palpable 0.00 
LNA 0.00 
848 0.00 
fundamentally 0.00 
local-regional 0.00 
5-yr 0.00 
MeSHAlbumins 0.00 
(17) 0.00 
MeSHElectrodiagnosis 0.00 
Antimicrobial 0.00 
handled 0.00 
delayed-type 0.00 
738 0.00 
midsagittal 0.00 
MeSHNeonatalScreening 0.00 
(SLND) 0.00 
assessable 0.00 
biodistribution 0.00 
18-24 0.00 
lymphoedema 0.00 
Saphenous 0.00 
MeSHCroatia 0.00 
neoplasia: 0.00 
Relationships 0.00 
671 0.00 
appendicular 0.00 
dyslipidemia 0.00 
MeSHDominance 0.00 
serodiagnostic 0.00 
(66 0.00 
t 0.00 
MeSHVenaCava 0.00 
cerebrovascular 0.00 
targeted 0.00 
American 0.00 
optimize 0.00 
pairs 0.00 
Germany 0.00 
nodules 0.00 
(49%) 0.00 
Long 0.00 
flexible 0.00 
pack 0.00 
void 0.00 
shorten 0.00 
tomographic 0.00 
registered 0.00 
imply 0.00 
p 0.00 
multifactorial 0.00 
inverse 0.00 
fibrinogen 0.00 
potassium 0.00 
residing 0.00 
suddenly 0.00 
years] 0.00 
confusing 0.00 
MIS 0.00 
MeSHDemography 0.00 
erroneous 0.00 
Cure 0.00 
019 0.00 
icterus 0.00 
Variations 0.00 
Nowadays 0.00 
complemented 0.00 
simplex 0.00 
415 0.00 
awake 0.00 
interstitium 0.00 
gradients 0.00 
762 0.00 
host's 0.00 
MeSHNitricOxideSynthaseTypeI 0.00 
MeSHNitricOxideSynthaseTypeII 0.00 
(DIC) 0.00 
interferes 0.00 
tactile 0.00 
Virtual 0.00 
616 0.00 
double-blinded 0.00 
(5-year 0.00 
(MLPA) 0.00 
6000 0.00 
(<or= 0.00 
forehead 0.00 
coeliac 0.00 
50%; 0.00 
(SM) 0.00 
MeSHHematoxylin 0.00 
rigorously 0.00 
duty 0.00 
cell/ 0.00 
findings; 0.00 
90; 0.00 
circumflex 0.00 
positron-emission 0.00 
MeSHOccupations 0.00 
Starting 0.00 
weakened 0.00 
MeSHOvary 0.00 
south 0.00 
titer 0.00 
Uganda 0.00 
306 0.00 
1972 0.00 
Immunology 0.00 
capable 0.00 
Not 0.00 
reconstructed 0.00 
(1%) 0.00 
strongly 0.00 
organized 0.00 
(+/- 0.00 
decrease 0.00 
identical 0.00 
absolute 0.00 
106 0.00 
(<1 0.00 
young 0.00 
(M) 0.00 
814 0.00 
KwaZulu-Natal 0.00 
units) 0.00 
haematocrit 0.00 
peroxidation 0.00 
kilogram 0.00 
amniocentesis: 0.00 
Newly 0.00 
eliciting 0.00 
MeSHFootball 0.00 
forty-four 0.00 
statically 0.00 
techniques: 0.00 
amplicon 0.00 
FACS 0.00 
Ohio 0.00 
941 0.00 
(LOS) 0.00 
calculi: 0.00 
saphenous 0.00 
management: 0.00 
bioptic 0.00 
C-positive 0.00 
MeSHOncogenes 0.00 
requesting 0.00 
MeSHBrainIschemia 0.00 
MeSHHerpesSimplex 0.00 
(CPP) 0.00 
MeSHCardiacCatheterization 0.00 
Revascularization 0.00 
(EF) 0.00 
segmented 0.00 
scores) 0.00 
Similarly 0.00 
?/nMeSHBiliaryTractDiseases 0.00 
sm) 0.00 
247 0.00 
MeSHLaparotomy 0.00 
(4%) 0.00 
proportions 0.00 
workup 0.00 
enables 0.00 
satisfactory 0.00 
Histology 0.00 
financial 0.00 
Inguinal 0.00 
authorities 0.00 
Instead 0.00 
377 0.00 
synaptic 0.00 
Tumour 0.00 
crude 0.00 
IC 0.00 
atrioventricular 0.00 
control) 0.00 
unequivocal 0.00 
agglutination 0.00 
Now 0.00 
peritoneal 0.00 
two-step 0.00 
mRNAs 0.00 
bedside 0.00 
374 0.00 
teratomas 0.00 
twofold 0.00 
23-year-old 0.00 
afforded 0.00 
Seventy-one 0.00 
sociodemographic 0.00 
967 0.00 
influencing 0.00 
rank 0.00 
soft 0.00 
I-III 0.00 
Comparing 0.00 
5-mm 0.00 
depression 0.00 
After 0.00 
hybrid 0.00 
[IQR 0.00 
cholangiolithiasis 0.00 
sixty-five 0.00 
with/without 0.00 
neocortical 0.00 
reflective 0.00 
040) 0.00 
(IM) 0.00 
(SEM) 0.00 
periarticular 0.00 
Discussion 0.00 
re-examination 0.00 
Utilizing 0.00 
Agencies 0.00 
forty-five 0.00 
7-14 0.00 
port) 0.00 
superficially 0.00 
stationary 0.00 
organised 0.00 
MeSHEncephalitis 0.00 
configurations 0.00 
classifier 0.00 
differentiates 0.00 
MeSHMicrobiologicalTechniques 0.00 
oedema 0.00 
hematocrit 0.00 
early- 0.00 
consequently 0.00 
(SLNB) 0.00 
step 0.00 
systematic 0.00 
(adjusted 0.00 
Conservative 0.00 
inpatient 0.00 
demonstrating 0.00 
investigator 0.00 
MGIT 0.00 
dislocation 0.00 
hemoglobin 0.00 
232 0.00 
written 0.00 
MeSHBiliaryTractNeoplasms 0.00 
m 0.00 
remained 0.00 
dissociation 0.00 
Intra-operative 0.00 
armamentarium 0.00 
it's 0.00 
fibrinolysis 0.00 
pooled 0.00 
Registry 0.00 
relationship 0.00 
accomplished 0.00 
proximal 0.00 
drug-resistance 0.00 
diphosphate 0.00 
formulations 0.00 
schemes 0.00 
MeSHHotTemperature 0.00 
one-half 0.00 
Owing 0.00 
MeSHEmbryo 0.00 
IMT 0.00 
cases); 0.00 
Acoustic 0.00 
cuts 0.00 
(lung 0.00 
5-min 0.00 
MeSHFluidTherapy 0.00 
outstanding 0.00 
926 0.00 
(HE) 0.00 
fellows 0.00 
skewed 0.00 
average) 0.00 
brushing 0.00 
re-exploration 0.00 
use: 0.00 
multiplied 0.00 
binomial 0.00 
MeSHTunisia 0.00 
diminishing 0.00 
IV: 0.00 
radioiodine 0.00 
MBq) 0.00 
superparamagnetic 0.00 
(HC) 0.00 
seeks 0.00 
L1) 0.00 
tune 0.00 
reassuring 0.00 
extrapolated 0.00 
oncology 0.00 
amplification 0.00 
PC 0.00 
water 0.00 
III) 0.00 
German 0.00 
decisions 0.00 
o 0.00 
simplified 0.00 
Peru 0.00 
pancreaticoduodenectomy 0.00 
017) 0.00 
type) 0.00 
s 0.00 
y 0.00 
a 0.00 
n 0.00 
MeSHalpha-FetoproteinsMaternal 0.00 
M 0.00 
MeSHPrenatalMaternal 0.00 
667% 0.00 
875% 0.00 
MeSHalpha-FetoproteinsScreening 0.00 
screening/nMeSHAdult 0.00 
MeSHalpha-FetoproteinsFirst-trimester 0.00 
cancer/nMeSHAdult 0.00 
833% 0.00 
endometriosis/nMeSHAdult 0.00 
MeSHPrenatalThe 0.00 
857% 0.00 
MeSHalpha-FetoproteinsThe 0.00 
MeSHVulvarNeoplasmsSentinel 0.00 
MeSHPrenatalFirst-trimester 0.00 
rate/nMeSHAdult 0.00 
889% 0.00 
MeSHVaginalSmearsHuman 0.00 
patients/nMeSHAdolescent 0.00 
syndrome/nMeSHAdult 0.00 
results/nMeSHAdult 0.00 
MeSHalpha-FetoproteinsSecond-trimester 0.00 
population/nMeSHAdult 0.00 
women/nMeSHAdult 0.00 
MeSHVaginalSmearsComparison 0.00 
333% 0.00 
952% 0.00 
abnormalities/nMeSHAdult 0.00 
MeSHalpha-FetoproteinsFirst 0.00 
screening/nMeSHAdolescent 0.00 
MeSHUltrasonographyDiagnostic 0.00 
975% 0.00 
MeSHalpha-FetoproteinsFetal 0.00 
MeSHalpha-FetoproteinsCombined 0.00 
testing/nMeSHAdult 0.00 
MeSHPrenatalFirst 0.00 
test/nMeSHAdult 0.00 
983% 0.00 
818% 0.00 
926% 0.00 
167% 0.00 
pregnancies/nMeSHAdult 0.00 
cases/nMeSHAdult 0.00 
lesions/nMeSHAdolescent 0.00 
S 0.00 
944% 0.00 
714% 0.00 
disease/nMeSHAdult 0.00 
846% 0.00 
895% 0.00 
fetuses/nMeSHAdult 0.00 
MeSHRetrospectiveStudiesMaternal 0.00 
pregnancies/nMeSHChorionicGonadotropin 0.00 
(P<00001) 0.00 
346% 0.00 
984% 0.00 
MeSHPrenatalSecond-trimester 0.00 
769% 0.00 
(P<001) 0.00 
824% 0.00 
treatment/nMeSHAdult 0.00 
MeSHUltrasonographyThe 0.00 
tears/nMeSHAdult 0.00 
882% 0.00 
956% 0.00 
MeSHYoungAdultThe 0.00 
928% 0.00 
963% 0.00 
909% 0.00 
IIIII 0.00 
MeSHPrenatalDiagnosisFirst-trimester 0.00 
MeSHalpha-FetoproteinsSequential 0.00 
923% 0.00 
syndrome/nMeSHBiomarkers 0.00 
954% 0.00 
778% 0.00 
922% 0.00 
538% 0.00 
989% 0.00 
967% 0.00 
MeSHUltrasonographyEndoscopic 0.00 
P<0001) 0.00 
(P<0001) 0.00 
tears/nMeSHAdolescent 0.00 
947% 0.00 
978% 0.00 
follow-up/nMeSHAdult 0.00 
964% 0.00 
p<005) 0.00 
levels/nMeSHAdult 0.00 
<05 0.00 
(857%) 0.00 
MeSHSensitivityandSpecificityThe 0.00 
MeSHalpha-FetoproteinsSecond 0.00 
MeSHalpha-FetoproteinsNuchal 0.00 
153% 0.00 
917% 0.00 
MeSHSensitivityandSpecificityMaternal 0.00 
pregnancy/nMeSHAdult 0.00 
994% 0.00 
MeSHReferenceValuesMaternal 0.00 
666% 0.00 
MeSHalpha-FetoproteinsCombining 0.00 
age/nMeSHAdult 0.00 
942% 0.00 
MeSHalpha-FetoproteinsIs 0.00 
(308%) 0.00 
rates/nMeSHAdult 0.00 
(03%) 0.00 
648% 0.00 
p<0005) 0.00 
727% 0.00 
trimester/nMeSHAdult 0.00 
MeSHUltrasonographyDiagnosis 0.00 
965% 0.00 
cancer/nMeSHAdenocarcinoma 0.00 
739% 0.00 
941% 0.00 
MeSHUltrasonographyPreoperative 0.00 
management/nMeSHAdult 0.00 
968% 0.00 
986% 0.00 
957% 0.00 
<075 0.00 
979% 0.00 
MeSHUltrasonographyMagnetic 0.00 
MeSHVaginalSmearsTriage 0.00 
MeSHVaginalSmearsThe 0.00 
AD/nMeSHAged 0.00 
848% 0.00 
(P=001) 0.00 
(084 0.00 
MeSHalpha-FetoproteinsNasal 0.00 
tests/nMeSHAdult 0.00 
(P<005) 0.00 
MeSHalpha-FetoproteinsEffect 0.00 
MeSHPrenatalNuchal 0.00 
/ 0.00 
MeSHalpha-FetoproteinsDown 0.00 
(625%) 0.00 
investigation/nMeSHAdult 0.00 
185% 0.00 
(114%) 0.00 
syndrome/nMeSHDownSyndrome 0.00 
test/nMeSHAdolescent 0.00 
MeSHPrenatalDiagnosisMaternal 0.00 
MeSHTrisomyMaternal 0.00 
915% 0.00 
performed/nMeSHAdult 0.00 
screening/nMeSHBiomarkers 0.00 
747% 0.00 
MeSHStomachNeoplasmsEndoscopic 0.00 
837% 0.00 
905% 0.00 
417% 0.00 
976% 0.00 
813% 0.00 
955% 0.00 
MeSHUltrasonographyRotator 0.00 
MeSHUltrasonographyMR 0.00 
982% 0.00 
MeSHYoungAdultEvaluation 0.00 
988% 0.00 
953% 0.00 
675% 0.00 
762% 0.00 
877% 0.00 
826% 0.00 
(286%) 0.00 
MeSHUltrasonographyUltrasonography 0.00 
692% 0.00 
02-T 0.00 
MeSHVaginalSmearsClinical 0.00 
care/nMeSHAdult 0.00 
p=0001) 0.00 
defects/nMeSHAdult 0.00 
(333%) 0.00 
MeSHalpha-FetoproteinsComparison 0.00 
DS/nMeSHAdult 0.00 
=0001) 0.00 
trials/nMeSHAdult 0.00 
MeSHalpha-FetoproteinsInfluence 0.00 
MeSHalpha-FetoproteinsUrinary 0.00 
852% 0.00 
385% 0.00 
467% 0.00 
MeSHPrenatalDiagnosisFirst 0.00 
21/nMeSHAdult 0.00 
MeSHPrenatalPrenatal 0.00 
MeSHalpha-FetoproteinsPrenatal 0.00 
MeSHPrenatalScreening 0.00 
period/nMeSHAdult 0.00 
outcome/nMeSHAdult 0.00 
719% 0.00 
programs/nMeSHAdult 0.00 
(067) 0.00 
455% 0.00 
population/nMeSHAdolescent 0.00 
913% 0.00 
176% 0.00 
MeSHPrenatalDiagnosisThe 0.00 
(108%) 0.00 
MeSHalpha-FetoproteinsSerum 0.00 
152% 0.00 
abnormalities/nMeSHAdolescent 0.00 
47XYY 0.00 
pregnancies/nMeSHBiomarkers 0.00 
615% 0.00 
795% 0.00 
596% 0.00 
706% 0.00 
(067 0.00 
21/nMeSHAdolescent 0.00 
(p<00001) 0.00 
use/nMeSHAdult 0.00 
patients/nMeSHAdenocarcinoma 0.00 
772% 0.00 
MeSHUltrasonographyA 0.00 
774% 0.00 
MeSHTreatmentOutcomeThe 0.00 
286% 0.00 
diagnosis/nMeSHAdult 0.00 
75-MHz 0.00 
MeSHUltrasonographyAccuracy 0.00 
878% 0.00 
725% 0.00 
294% 0.00 
MeSHShoulderJointThe 0.00 
800% 0.00 
P<001) 0.00 
921% 0.00 
MeSHTuberculosisRapid 0.00 
996% 0.00 
991% 0.00 
906% 0.00 
214% 0.00 
951% 0.00 
981% 0.00 
919% 0.00 
(111%) 0.00 
636% 0.00 
planning/nMeSHAdult 0.00 
30-Tesla 0.00 
stones/nMeSHAdult 0.00 
MeSHUltrasonography[The 0.00 
972% 0.00 
MeSHVulvarNeoplasmsThe 0.00 
MeSHVaginalSmearsReflex 0.00 
MeSHYoungAdultHuman 0.00 
908% 0.00 
971% 0.00 
939% 0.00 
decline/nMeSHAged 0.00 
873% 0.00 
transplantation/nMeSHAdult 0.00 
findings/nMeSHAdult 0.00 
(088 0.00 
treatment/nMeSHAdolescent 0.00 
810% 0.00 
(988%) 0.00 
39572 0.00 
001/33; 0.00 
(725%) 0.00 
MeSHalpha-FetoproteinsHuman 0.00 
(049 0.00 
weeks/nMeSHAneuploidy 0.00 
858% 0.00 
determined/nMeSHAdult 0.00 
MeSHalpha-FetoproteinsPredictive 0.00 
332% 0.00 
MeSHalpha-FetoproteinsAnalysis 0.00 
groups/nMeSHAdult 0.00 
(096 0.00 
appropriate/nMeSHAdult 0.00 
marker/nMeSHAdult 0.00 
trisomies/nMeSHAdult 0.00 
syndrome/nMeSHAdolescent 0.00 
MeSHReferenceValuesScreening 0.00 
anomalies/nMeSHAdolescent 0.00 
207% 0.00 
(097 0.00 
617% 0.00 
440% 0.00 
448% 0.00 
rates/nMeSHBiomarkers 0.00 
735% 0.00 
768% 0.00 
(889%) 0.00 
(259%) 0.00 
MeSHalpha-FetoproteinsAssessment 0.00 
(467%) 0.00 
programs/nMeSHAdolescent 0.00 
931% 0.00 
57614 0.00 
(034 0.00 
A/nMeSHAdult 0.00 
MeSHUltrasonographyMaternal 0.00 
alone/nMeSHAmniocentesis 0.00 
576% 0.00 
(905%) 0.00 
studies/nMeSHAdult 0.00 
(326 0.00 
563% 0.00 
18712 0.00 
alone/nMeSHAdult 0.00 
MeSHPrenatalCombined 0.00 
(<05 0.00 
(06%) 0.00 
trimester/nMeSHAdolescent 0.00 
(167%) 0.00 
MeSHPrenatalElevated 0.00 
(187%) 0.00 
used/nMeSHAdult 0.00 
(-07k) 0.00 
23369 0.00 
syndrome/nMeSHAfricanContinentalAncestryGroup 0.00 
855% 0.00 
513% 0.00 
47053 0.00 
procedures/nMeSHAdult 0.00 
870% 0.00 
529% 0.00 
MeSHPrenatalIntegrated 0.00 
69XXX 0.00 
MeSHPrenatalA 0.00 
839% 0.00 
weeks/nMeSHAdult 0.00 
(357%) 0.00 
854902 0.00 
rate/nMeSHBiomarkers 0.00 
procedure/nMeSHAdult 0.00 
175% 0.00 
444% 0.00 
(089 0.00 
MeSHPrenatalDiagnosisA 0.00 
MeSHPrenatalDiagnosisComparison 0.00 
12170 0.00 
age/nMeSHAdolescent 0.00 
group/nMeSHAdult 0.00 
884% 0.00 
506% 0.00 
MeSHX-RayComputedPreoperative 0.00 
893% 0.00 
cancer/nMeSHAged 0.00 
786% 0.00 
(p=00001) 0.00 
777% 0.00 
429% 0.00 
MeSHX-RayComputedComparison 0.00 
722% 0.00 
surgery/nMeSHAdenocarcinoma 0.00 
811% 0.00 
901% 0.00 
571% 0.00 
tear/nMeSHAdult 0.00 
pathology/nMeSHAdult 0.00 
cases/nMeSHAdolescent 0.00 
985% 0.00 
(976%) 0.00 
(v20) 0.00 
993% 0.00 
935% 0.00 
cancer/nMeSHAntigens 0.00 
<005) 0.00 
program/nMeSHAdult 0.00 
MeSHX-RayComputed[The 0.00 
(193%) 0.00 
888% 0.00 
MeSHX-RayComputedThe 0.00 
MeSHUltrasonographyValue 0.00 
MeSHRectalNeoplasmsThe 0.00 
MeSHTimeFactorsThe 0.00 
risk/nMeSHAdult 0.00 
CA724 0.00 
808% 0.00 
864% 0.00 
MeSHSensitivityandSpecificityFirst-trimester 0.00 
31615 0.00 
(875%) 0.00 
(080 0.00 
364% 0.00 
MeSHX-RayComputedLaparoscopic 0.00 
MeSHX-RayComputedStaging 0.00 
MeSHUltrasonographyRole 0.00 
(727%) 0.00 
903% 0.00 
diagnosis/nMeSHAdolescent 0.00 
MeSHSensitivityandSpecificityComparison 0.00 
948% 0.00 
900% 0.00 
442% 0.00 
835% 0.00 
(135%) 0.00 
842% 0.00 
colposcopy/nMeSHAdult 0.00 
886% 0.00 
MeSHUterineCervicalNeoplasmsHPV 0.00 
788% 0.00 
MeSHVaginalSmearsHigh-risk 0.00 
MeSHVaginalSmearsAtypical 0.00 
colposcopy/nMeSHAdolescent 0.00 
949% 0.00 
958% 0.00 
737% 0.00 
(423%) 0.00 
MeSHSurveysandQuestionnairesThe 0.00 
endometriosis/nMeSHAdolescent 0.00 
involvement/nMeSHAdult 0.00 
05/converters 0.00 
c235delC 0.00 
MeSHWoundsandInjuriesThe 0.00 
required/nMeSHAdult 0.00 
III/nMeSHAdult 0.00 
(093) 0.00 
(087 0.00 
studies/nMeSHAlgorithms 0.00 
937% 0.00 
protocols/nMeSHAdult 0.00 
(099 0.00 
(934%) 0.00 
619% 0.00 
MeSHalpha-FetoproteinsMeasurement 0.00 
712% 0.00 
(081 0.00 
(902%) 0.00 
486% 0.00 
838% 0.00 
0768) 0.00 
MeSHPrenatalAccuracy 0.00 
justified/nMeSHAdult 0.00 
268% 0.00 
387% 0.00 
0827 0.00 
0542 0.00 
level/nMeSHAdult 0.00 
MeSHSmokingMaternal 0.00 
findings/nMeSHAdolescent 0.00 
796% 0.00 
(226%) 0.00 
reduced/nMeSHAdolescent 0.00 
respectively/nMeSHAdult 0.00 
MeSHGeneticMaternal 0.00 
634% 0.00 
culture/nMeSHAdult 0.00 
155% 0.00 
590% 0.00 
526% 0.00 
available/nMeSHAdult 0.00 
830% 0.00 
(231% 0.00 
examination/nMeSHAdult 0.00 
defects/nMeSHAdolescent 0.00 
MeSHalpha-FetoproteinsImproved 0.00 
MeSHalpha-FetoproteinsDetection 0.00 
342% 0.00 
191% 0.00 
159% 0.00 
screen/nMeSHAdult 0.00 
MeSHalpha-FetoproteinsMultiple 0.00 
useful/nMeSHAdult 0.00 
markers/nMeSHBiomarkers 0.00 
(242%) 0.00 
MeSHSensitivityandSpecificityEvaluation 0.00 
799% 0.00 
815% 0.00 
MeSHPrenatalDiagnosisIntegrated 0.00 
outcomes/nMeSHAdolescent 0.00 
MeSHalpha-FetoproteinsTriple-marker 0.00 
35/nMeSHAdult 0.00 
927% 0.00 
(304%) 0.00 
markers/nMeSHChorionicGonadotropin 0.00 
729% 0.00 
751% 0.00 
(125%) 0.00 
(571%) 0.00 
(818%) 0.00 
189% 0.00 
(083 0.00 
690% 0.00 
181% 0.00 
MeSHalpha-FetoproteinsPopulation 0.00 
MeSHalpha-FetoproteinsRisk 0.00 
MeSHalpha-FetoproteinsUrine 0.00 
245% 0.00 
MeSHProspectiveStudiesMaternal 0.00 
(682%) 0.00 
(p<005 0.00 
(326%) 0.00 
aneuploidy/nMeSHAdult 0.00 
(192%) 0.00 
II-3/nMeSHAdolescent 0.00 
MeSHPrenatalSecond 0.00 
amniocentesis/nMeSHAdult 0.00 
MeSHUltrasonographyScreening 0.00 
(594%) 0.00 
587% 0.00 
677% 0.00 
(375% 0.00 
611% 0.00 
evaluation/nMeSHAdult 0.00 
(476%) 0.00 
(558%) 0.00 
value/nMeSHAdolescent 0.00 
MeSHStomachNeoplasmsThe 0.00 
911% 0.00 
MeSHStomachNeoplasmsPreoperative 0.00 
tumors/nMeSHAdenocarcinoma 0.00 
378% 0.00 
784% 0.00 
carcinoma/nMeSHAdenocarcinoma 0.00 
resection/nMeSHAdenocarcinoma 0.00 
295% 0.00 
741% 0.00 
MeSHUltrasonographyComputed 0.00 
683% 0.00 
836% 0.00 
936% 0.00 
MeSHShoulderPainThe 0.00 
standard/nMeSHAdolescent 0.00 
871% 0.00 
(731%) 0.00 
(583%) 0.00 
(981%) 0.00 
joint/nMeSHAdolescent 0.00 
565% 0.00 
(923%) 0.00 
shoulder/nMeSHAdult 0.00 
surgery/nMeSHAdolescent 0.00 
assessment/nMeSHAdolescent 0.00 
MeSHShoulderJointEvaluation 0.00 
MeSHPulmonaryXpert 0.00 
MeSHTuberculosisClinical 0.00 
929% 0.00 
733% 0.00 
973% 0.00 
626% 0.00 
902% 0.00 
916% 0.00 
174% 0.00 
977% 0.00 
recurrence/nMeSHCarcinoembryonicAntigen 0.00 
recurrence/nMeSHAdult 0.00 
MeSHRectalNeoplasmsRole 0.00 
-044 0.00 
MeSHRectalNeoplasms[Clinical 0.00 
(P=0001) 0.00 
value/nMeSHAdult 0.00 
MeSHRectalNeoplasmsValue 0.00 
892% 0.00 
959% 0.00 
894% 0.00 
924% 0.00 
metastases/nMeSHAdult 0.00 
(450%) 0.00 
794% 0.00 
adenocarcinoma/nMeSHAdenocarcinoma 0.00 
recurrences/nMeSHCarcinoembryonicAntigen 0.00 
736% 0.00 
775% 0.00 
cancer/nMeSHAdolescent 0.00 
961% 0.00 
(375%) 0.00 
583% 0.00 
887% 0.00 
940% 0.00 
825% 0.00 
detection/nMeSHAdolescent 0.00 
(947%) 0.00 
946% 0.00 
MeSHSensitivityandSpecificityScreening 0.00 
complications/nMeSHAdult 0.00 
476% 0.00 
(666%) 0.00 
MeSHUltrasonographyComparison 0.00 
179% 0.00 
laparotomy/nMeSHAdult 0.00 
MeSHUltrasonography[Value 0.00 
MeSHUltrasonographyEvaluation 0.00 
647% 0.00 
235% 0.00 
MeSHYoungAdultDiagnostic 0.00 
disease/nMeSHAdolescent 0.00 
413% 0.00 
732% 0.00 
763% 0.00 
MeSHUltrasonography[Ultrasonography 0.00 
816% 0.00 
cholangiography/nMeSHCholangiography 0.00 
914% 0.00 
962% 0.00 
MeSHVulvarNeoplasmsIntraoperative 0.00 
MeSHVulvarNeoplasmsLymphatic 0.00 
(269%) 0.00 
MeSHVulvarNeoplasmsDetection 0.00 
MeSHVulvarNeoplasmsRe: 0.00 
MeSHVaginalSmearsDetection 0.00 
MeSHVaginalSmearsValue 0.00 
MeSHUterineCervicalNeoplasmsA 0.00 
MeSHUterineCervicalNeoplasmsComparison 0.00 
356% 0.00 
437% 0.00 
403% 0.00 
MeSHViralLoadHuman 0.00 
MeSHVaginalSmearsA 0.00 
645% 0.00 
MeSHUterineCervicalNeoplasmsThe 0.00 
(728%) 0.00 
(09%) 0.00 
MeSHUterineCervicalNeoplasmsHuman 0.00 
MeSHVaginalSmearsHPV 0.00 
206% 0.00 
274% 0.00 
MeSHYoungAdultHigh-risk 0.00 
(833% 0.00 
>331 0.00 
dementia/nMeSHAged 0.00 
912% 0.00 
MeSHUltrasonographyDeep 0.00 
987% 0.00 
960% 0.00 
MeSHUltrasonographyTransvaginal 0.00 
MeSHVaginaThe 0.00 
endometrioma/nMeSHAdult 0.00 
locations/nMeSHAdult 0.00 
agreement/nMeSHAdult 0.00 
(769%) 0.00 
events/nMeSHAdult 0.00 
CAD/nMeSHAdult 0.00 
05/non-converters 0.00 
"tolerance" 0.00 
therapy/nMeSHAdolescent 0.00 
discussed/nMeSHAdult 0.00 
interventions/nMeSHAdult 0.00 
improved/nMeSHAdult 0.00 
-8505 0.00 
-14068 0.00 
MeSHWoundsandInjuriesA 0.00 
ClinicalTrialsgov 0.00 
finding/nMeSHAdult 0.00 
trauma/nMeSHAdult 0.00 
p=0003) 0.00 
P=0008) 0.00 
P=002) 0.00 
P=0006; 0.00 
797% 0.00 
(123%) 0.00 
p<00001) 0.00 
(P=002) 0.00 
541% 0.00 
mellitus/nMeSHChorionicGonadotropin 0.00 
MeSHRiskAssessmentPrenatal 0.00 
diagnosed/nMeSHBloodSpecimenCollection 0.00 
MeSHReferenceValuesAlpha-fetoprotein: 0.00 
(675%) 0.00 
echocardiography/nMeSHAdolescent 0.00 
minimal/nMeSHBodyWeight 0.00 
use/nMeSHCost-BenefitAnalysis 0.00 
MeSHSensitivityandSpecificityMidtrimester 0.00 
-0345; 0.00 
0499; 0.00 
(45/19796) 0.00 
MeSHPregnancyOutcomeThe 0.00 
<002) 0.00 
MeSHalpha-FetoproteinsMULTISCAN--a 0.00 
27844 0.00 
10264 0.00 
(621-913); 0.00 
(421-996); 0.00 
(08-208) 0.00 
(245-915) 0.00 
(349-968); 0.00 
(94-992) 0.00 
(292-1000); 0.00 
(02-360) 0.00 
(192-749) 0.00 
(794%) 0.00 
DS/nMeSHAbdominalMuscles 0.00 
sonogram/nMeSHAdult 0.00 
samples/nMeSHAlkalinePhosphatase 0.00 
non-smokers/nMeSHBiomarkers 0.00 
MeSHPrenatalCorrelations 0.00 
44272 0.00 
20321 0.00 
(r=054 0.00 
(p=0007) 0.00 
bone/nMeSHAdult 0.00 
MeSHPrenatalUrinary 0.00 
p=0004) 0.00 
gonadotrophin/nMeSHAlgorithms 0.00 
MeSHalpha-FetoproteinsElevated 0.00 
11281 0.00 
condition/nMeSHAdult 0.00 
obscure/nMeSHBiomarkers 0.00 
MeSHPregnancyinDiabeticsMaternal 0.00 
anomalies/nMeSHChorionicGonadotropin 0.00 
156-176) 0.00 
identified/nMeSHAdolescent 0.00 
11974 0.00 
small/nMeSHAmniocentesis 0.00 
use/nMeSHActivins 0.00 
MeSHProteinPrecursorsDouble-positive 0.00 
170394 0.00 
identified/nMeSHCase-ControlStudies 0.00 
MeSHalpha-FetoproteinsADAM 0.00 
00049) 0.00 
03734 0.00 
03353 0.00 
0251) 0.00 
models/nMeSHADAMProteins 0.00 
MeSHPregnancy-AssociatedPlasmaProtein-ASecond-trimester 0.00 
084-093) 0.00 
(091-099) 0.00 
(080-101) 0.00 
(088-108) 0.00 
(089-110) 0.00 
16096 0.00 
detected/nMeSHDownSyndrome 0.00 
MeSHalpha-FetoproteinsA 0.00 
cost/nMeSHBiomarkers 0.00 
41528(gestational 0.00 
13649(gestational 0.00 
12949] 0.00 
variations/nMeSHBiomarkers 0.00 
(333%); 0.00 
(178%) 0.00 
(422%) 0.00 
=002) 0.00 
0139 0.00 
0134) 0.00 
head/nMeSHAdolescent 0.00 
660% 0.00 
(AFP-L23) 0.00 
AFP-L23 0.00 
0835 0.00 
(P=0106) 0.00 
(r=0006) 0.00 
DS/nMeSHAmnioticFluid 0.00 
MeSHalpha-FetoproteinsPractical 0.00 
protocols/nMeSHBiomarkers 0.00 
disorder/nMeSHAbortion 0.00 
performance/nMeSHDownSyndrome 0.00 
MeSHSoftwareFirst-trimester 0.00 
programs/nMeSHDownSyndrome 0.00 
MeSHUnitedKingdom[The 0.00 
156-179) 0.00 
164-207) 0.00 
197-231) 0.00 
963%/nMeSHChorionicGonadotropin 0.00 
MeSHalpha-FetoproteinsEthnicity 0.00 
-0012 0.00 
investigated/nMeSHAdult 0.00 
MeSHTwinsThe 0.00 
00358 0.00 
defects/nMeSHAneuploidy 0.00 
present(ABSTRACT 0.00 
MeSHPrenatalHyperglycosylated 0.00 
MeSHRegressionAnalysisMaternal 0.00 
marker/nMeSHDownSyndrome 0.00 
(076 0.00 
MeSHTurnerSyndromeCorrelation 0.00 
00487) 0.00 
<02 0.00 
MeSHalpha-FetoproteinsCigarette 0.00 
23668 0.00 
015-15) 0.00 
4935 0.00 
advantages/nMeSHBloodSpecimenCollection 0.00 
MeSHTimeFactorsScreening 0.00 
premature/nMeSHAdult 0.00 
264481 0.00 
this/nMeSHBiomarkers 0.00 
088-103) 0.00 
MoM=104) 0.00 
23-fold 0.00 
p<005 0.00 
MeSHSexFirst-trimester 0.00 
08-21) 0.00 
index/nMeSHAdult 0.00 
MeSHRetrospectiveStudiesDoes 0.00 
MeSHTrophoblastsRepeat 0.00 
delay/nMeSHBiomarkers 0.00 
7392 0.00 
0890 0.00 
performance/nMeSHChorionicGonadotropin 0.00 
MeSHUltrasonographyAn 0.00 
3862 0.00 
precisely/nMeSHBodyWeight 0.00 
MeSHalpha-FetoproteinsDoppler 0.00 
(0604 0.00 
0011; 0.00 
0581 0.00 
(0330 0.00 
(0301 0.00 
fetuses/nMeSHChromosomeAberrations 0.00 
09357 0.00 
20%/nMeSHAdult 0.00 
conception/nMeSHChorionicGonadotropin 0.00 
offered/nMeSHAmniocentesis 0.00 
32730 0.00 
(053 0.00 
(011 0.00 
376% 0.00 
17200 0.00 
timing/nMeSHAdult 0.00 
MeSHUltrasonographyAlteration 0.00 
testing/nMeSHAgeFactors 0.00 
MeSHalpha-FetoproteinsAgreement 0.00 
programme/nMeSHAmniocentesis 0.00 
(283%) 0.00 
MeSHPrenatal[Fetal 0.00 
images/nMeSHAbnormalities 0.00 
(955% 0.00 
point/nMeSHAdult 0.00 
MeSHPrenatalRole 0.00 
3157 0.00 
358% 0.00 
243% 0.00 
control/nMeSHAbnormalities 0.00 
rate)/nMeSHChorionicGonadotropin 0.00 
14934 0.00 
7118 0.00 
MeSHalpha-FetoproteinsMidtrimester 0.00 
149-1485 0.00 
014-247) 0.00 
056-184) 0.00 
(936%) 0.00 
(197%) 0.00 
(434%) 0.00 
(862%) 0.00 
(138%) 0.00 
(613%) 0.00 
absent/nMeSHAdolescent 0.00 
screening/nMeSHChromosomeAberrations 0.00 
25207 0.00 
MeSHalpha-FetoproteinsEstimates 0.00 
MeSHalpha-FetoproteinsApplication 0.00 
abnormalities/nMeSHAneuploidy 0.00 
MeSHInferiorChanges 0.00 
(774%) 0.00 
17-40) 0.00 
pregnancy/nMeSHChorionicGonadotropin 0.00 
(06071) 0.00 
(04255) 0.00 
21/nMeSHActivins 0.00 
exp(02718 0.00 
09425) 0.00 
MeSHUnitedKingdomEvaluation 0.00 
7696% 0.00 
5180-100%) 0.00 
9407% 0.00 
8447-100%) 0.00 
systems/nMeSHAdult 0.00 
Asians/nMeSHAdult 0.00 
(039 0.00 
CVS/nMeSHBiomarkers 0.00 
MeSHPrenatalDiagnosisAgreement 0.00 
11847 0.00 
accurate/nMeSHAdolescent 0.00 
MeSHPrenatalAcceptability 0.00 
(443%) 0.00 
investigated/nMeSHChorionicGonadotropin 0.00 
MeSHSensitivityandSpecificityPredicting 0.00 
trimester/nMeSHAfrica 0.00 
MeSHUnitedKingdom[Maternal 0.00 
MeSHPrenatalDiagnosisFetal 0.00 
15428 0.00 
11428 0.00 
sex/nMeSHBiomarkers 0.00 
trimester/nMeSHAntigens 0.00 
MeSHalpha-Fetoproteins[First 0.00 
95%/nMeSHAdult 0.00 
036-281 0.00 
05482 0.00 
008-1187 0.00 
MeSHalpha-Fetoproteins[Screening 0.00 
199611-20013 0.00 
6338 0.00 
(233%) 0.00 
MeSHPrenatalThree-dimensional 0.00 
(r=043 0.00 
r=028 0.00 
r=010 0.00 
measurements/nMeSHChorionicGonadotropin 0.00 
MeSHUltrasonographySimilarity 0.00 
18639 0.00 
18088) 0.00 
programs/nMeSHAfricanAmericans 0.00 
MeSHPrenatalInhibin 0.00 
A-subunits/nMeSHDownSyndrome 0.00 
MeSHReferenceValuesSerum 0.00 
MeSHPrenatalDiagnosisScreening 0.00 
(028%) 0.00 
measurement/nMeSHBiomarkers 0.00 
rate/nMeSHAdolescent 0.00 
9177 0.00 
(201%) 0.00 
465-724) 0.00 
677-892) 0.00 
274-604) 0.00 
212-528) 0.00 
(570%; 0.00 
abandoned/nMeSHChromosomeAberrations 0.00 
MeSHPrenatalAntenatal 0.00 
12603 0.00 
27140 0.00 
quality/nMeSHBiomarkers 0.00 
MeSHUltrasonographyPlacental 0.00 
(656%)/nMeSHAdult 0.00 
predicted/nMeSHAdult 0.00 
261% 0.00 
(P=0025) 0.00 
2000/nMeSHBiomarkers 0.00 
MeSHSensitivityandSpecificityEffect 0.00 
(p=000004) 0.00 
fetus/nMeSHBiomarkers 0.00 
271-1257); 0.00 
084-340); 0.00 
530% 0.00 
later/nMeSHDownSyndrome 0.00 
MeSHReferenceValuesDual 0.00 
programmes/nMeSHAdolescent 0.00 
view/nMeSHAdult 0.00 
022-163 0.00 
033-224 0.00 
approach/nMeSHADAMProteins 0.00 
MeSHTrisomyInfluence 0.00 
22169 0.00 
18876 0.00 
(1147 0.00 
habits/nMeSHAdult 0.00 
48XXXY 0.00 
MeSHalpha-FetoproteinsUltrasound 0.00 
(112%) 0.00 
412% 0.00 
MeSHPrenatalMeasurement 0.00 
-0097 0.00 
-0481 0.00 
-0369 0.00 
0819) 0.00 
ultrasound/nMeSHCross-OverStudies 0.00 
91000 0.00 
MeSHVaginaSerum 0.00 
16666 0.00 
(32-57 0.00 
negligible/nMeSHAdolescent 0.00 
MeSHUnitedKingdomSerial 0.00 
[096 0.00 
77273 0.00 
well/nMeSHAdult 0.00 
(082) 0.00 
performed/nMeSHAdolescent 0.00 
2420) 0.00 
poor/nMeSHAdult 0.00 
controls/nMeSHAdult 0.00 
MeSHUreaFetuses 0.00 
indicators/nMeSHChromosomeAberrations 0.00 
183-216] 0.00 
13486 0.00 
outcome/nMeSHAdolescent 0.00 
MeSHalpha-FetoproteinsFree 0.00 
0991; 0.00 
proved/nMeSHAdult 0.00 
MeSHSecondUrinary 0.00 
008-082 0.00 
03-474 0.00 
48XXY 0.00 
(098) 0.00 
MeSHPrenatal[Increased 0.00 
hygromas/nMeSHAbnormalities 0.00 
MeSHTurnerSyndromeMaternal 0.00 
MeSHTrisomyFirst 0.00 
465% 0.00 
P=09) 0.00 
(alpha=005 0.00 
beta=020) 0.00 
screening/nMeSHAmniocentesis 0.00 
MeSHalpha-FetoproteinsVariation 0.00 
NBL/nMeSHAfricanAmericans 0.00 
MeSHPrenatalNormal 0.00 
46XX/47XXX 0.00 
846%) 0.00 
35150 0.00 
twins/nMeSHAdult 0.00 
MeSHalpha-FetoproteinsProspective 0.00 
(66/59696) 0.00 
fetoprotein/nMeSHAdult 0.00 
MeSHalpha-FetoproteinsTriple 0.00 
MeSHalpha-FetoproteinsPregnancy 0.00 
MeSHPrenatalVariability 0.00 
028-090 0.00 
acceptable/nMeSHDownSyndrome 0.00 
(578% 0.00 
464%) 0.00 
073); 0.00 
MeSHalpha-FetoproteinsSonography 0.00 
078-100) 0.00 
21/nMeSHBodyWeight 0.00 
MeSHReproducibilityofResultsClinical 0.00 
assay/nMeSHAdult 0.00 
MeSHalpha-Fetoproteins[Fetal 0.00 
MeSHUltrasonographySensitivity 0.00 
pregnancies/nMeSHBodyWeight 0.00 
combination/nMeSHBiomarkers 0.00 
MeSHPrenatalTriple-test 0.00 
ones/nMeSHCase-ControlStudies 0.00 
-00657 0.00 
03792 0.00 
syndrome/nMeSHChorionicGonadotropin 0.00 
syndrome/nMeSHAnalysisofVariance 0.00 
themselves/nMeSHAneuploidy 0.00 
performance/nMeSHAutoanalysis 0.00 
MeSHTrophoblastsIs 0.00 
MeSHSensitivityandSpecificityAntenatal 0.00 
150000 0.00 
range/nMeSHBiomarkers 0.00 
EC11511) 0.00 
12+/-073 0.00 
(220+/-07 0.00 
significance/nMeSHAdult 0.00 
29360 0.00 
older/nMeSHAmniocentesis 0.00 
MeSHSingaporePrenatal 0.00 
cost-effective/nMeSHBiomarkers 0.00 
groups/nMeSHAneuploidy 0.00 
MeSHSensitivityandSpecificityNuchal 0.00 
imprudent/nMeSHAdult 0.00 
MeSHalpha-FetoproteinsExtent 0.00 
(009%) 0.00 
CVS/nMeSHChorionicGonadotropin 0.00 
MeSHRiskAssessmentThe 0.00 
PPV/nMeSHAdult 0.00 
MeSHSmokingFirst 0.00 
15-3-fold 0.00 
085-122) 0.00 
095-137) 0.00 
089-105) 0.00 
076-105) 0.00 
093-125) 0.00 
095-111) 0.00 
conception/nMeSHAdult 0.00 
MeSHUltrasonographyMedically 0.00 
MeSHalpha-Fetoproteins[Antenatal 0.00 
3776 0.00 
(20/3776) 0.00 
completed(ABSTRACT 0.00 
performance/nMeSHAdult 0.00 
MeSHalpha-FetoproteinsChoice 0.00 
subunit/nMeSHActivins 0.00 
MeSHMessengerPrenatal 0.00 
6197 0.00 
NTD/nMeSHAmniocentesis 0.00 
discussed/nMeSHChorionicGonadotropin 0.00 
age/nMeSHBiomarkers 0.00 
194326 0.00 
significance/nMeSHActivins 0.00 
MeSHPrenatalDiagnosisIdentification 0.00 
(-13k)--believed 0.00 
(-13k) 0.00 
001)/nMeSHAgeFactors 0.00 
MeSHSecondThe 0.00 
198-100%) 0.00 
903-946%) 0.00 
891% 0.00 
(863-914%) 0.00 
determination/nMeSHAdult 0.00 
(104; 0.00 
pregnancies/nMeSHCase-ControlStudies 0.00 
MeSHalpha-FetoproteinsKaryotypes 0.00 
(525%) 0.00 
(798%) 0.00 
population/nMeSHDownSyndrome 0.00 
MeSHSouthAustraliaEnhanced 0.00 
00012) 0.00 
gestation/nMeSHBiomarkers 0.00 
63110 0.00 
minimal/nMeSHAdult 0.00 
second/nMeSHBiomarkers 0.00 
MeSHRiskFactorsDo 0.00 
(21549) 0.00 
715-743%) 0.00 
671-83%) 0.00 
715-723%) 0.00 
628-668%) 0.00 
356-670%) 0.00 
595% 0.00 
512-668%) 0.00 
769-927%) 0.00 
207-273%) 0.00 
Syndrome/nMeSHAntigens 0.00 
21/nMeSHAmnioticFluid 0.00 
population/nMeSHCase-ControlStudies 0.00 
MeSHPrenatal[Significance 0.00 
(1087%) 0.00 
(319%) 0.00 
MeSHPregnancyComplicationsDifferential 0.00 
258885 0.00 
singletons/nMeSHBiomarkers 0.00 
MeSHalpha-FetoproteinsSP1 0.00 
lie/nMeSHBiomarkers 0.00 
32%/nMeSHAdult 0.00 
13-687]) 0.00 
13-687) 0.00 
08-44) 0.00 
ultrasonography/nMeSHDownSyndrome 0.00 
MeSHPrenatalRaised 0.00 
(p=0014) 0.00 
(072 0.00 
fluid/nMeSHAdult 0.00 
200868 0.00 
44613 0.00 
15822 0.00 
assurance/nMeSHAdult 0.00 
15132 0.00 
1133% 0.00 
1291% 0.00 
values/nMeSHAdolescent 0.00 
MeSHTaiwanRisk 0.00 
(p=0003) 0.00 
p<002) 0.00 
088% 0.00 
measurements/nMeSHAdult 0.00 
MeSHPrivatePractice[Proposed 0.00 
SD/nMeSHAdult 0.00 
MeSHalpha-FetoproteinsEarly 0.00 
045-087); 0.00 
(133-266); 0.00 
(170-322) 0.00 
rate/nMeSHAneuploidy 0.00 
222-223 0.00 
(p<010) 0.00 
(r(s)=027 0.00 
p=007) 0.00 
(r(s)=-017 0.00 
p=07) 0.00 
(r(s)=-0013 0.00 
p=09) 0.00 
MeSHS100ProteinsThe 0.00 
46XXins(2)(q21p13p15)mat 0.00 
reevaluated/nMeSHAdolescent 0.00 
serum/nMeSHChemistry 0.00 
199-513) 0.00 
(008 0.00 
normal/nMeSHAdult 0.00 
21/nMeSHAntibodies 0.00 
MeSHalpha-FetoproteinsCalifornia's 0.00 
275000 0.00 
2552 0.00 
(47XXY) 0.00 
amniocenteses/nMeSHAdult 0.00 
MeSHalpha-FetoproteinsLevels 0.00 
urine/nMeSHAdult 0.00 
MeSHPrenatalDiagnosisRelationship 0.00 
21/nMeSHDownSyndrome 0.00 
birth/nMeSHChromosomes 0.00 
outcomes/nMeSHAbortion 0.00 
year/nMeSHChorionicGonadotropin 0.00 
(30727) 0.00 
incidence/nMeSHAdult 0.00 
MeSHalpha-FetoproteinsEstimating 0.00 
36645 0.00 
alone/nMeSHAgeFactors 0.00 
-014288log10MoM; 0.00 
035034 0.00 
028548 0.00 
(<065 0.00 
-018853 0.00 
<033 0.00 
-047727 0.00 
<0005) 0.00 
(078 0.00 
investigation/nMeSHChorionicGonadotropin 0.00 
(908%) 0.00 
discussed/nMeSHDownSyndrome 0.00 
MeSHStatisticsasTopic[Sonographic 0.00 
placenta/nMeSHAdult 0.00 
MeSHPrenatalPregnant 0.00 
(05-10%) 0.00 
17084 0.00 
years/nMeSHAdult 0.00 
results/nMeSHBiochemistry 0.00 
129-182) 0.00 
(r=073 0.00 
(r=056 0.00 
protocol/nMeSHAdult 0.00 
MeSHalpha-FetoproteinsEvaluation 0.00 
MeSHTrisomyMedians 0.00 
screening/nMeSHAfricanContinentalAncestryGroup 0.00 
MeSHPrenatalDiagnosis[Prenatal 0.00 
defects/nMeSHAfricanContinentalAncestryGroup 0.00 
MeSHalpha-FetoproteinsTrisomy 0.00 
hygromas/nMeSHAdult 0.00 
00071 0.00 
(03228) 0.00 
respectively/nMeSHBiomarkers 0.00 
(p=008) 0.00 
rates/nMeSHChorionicGonadotropin 0.00 
<005 0.00 
MeSHPrenatalEstimating 0.00 
113000 0.00 
pregnancies/nMeSHAdolescent 0.00 
MeSHalpha-FetoproteinsRefinements 0.00 
47585 0.00 
indicated/nMeSHBodyWeight 0.00 
11434 0.00 
592%) 0.00 
369% 0.00 
identified/nMeSHAdult 0.00 
MeSHalpha-Fetoproteins[Clinical 0.00 
MeSHalpha-FetoproteinsDimeric 0.00 
150-219 0.00 
MeSHalpha-FetoproteinsAge 0.00 
reproduction/nMeSHChorionicGonadotropin 0.00 
population/nMeSHChromosomeAberrations 0.00 
MeSHPrenatalUmbilical 0.00 
(r=0620; 0.00 
(r=0555; 0.00 
y=-0604+0051*x 0.00 
y=1962+0029*x 0.00 
aneuploidies/nMeSHAdult 0.00 
MeSHVeinsNicked 0.00 
MeSHalpha-FetoproteinsSingle-step 0.00 
177% 0.00 
Belgium/nMeSHAdult 0.00 
MeSHReproducibilityofResultsPrenatal 0.00 
04022 0.00 
05635 0.00 
collection/nMeSHAdult 0.00 
MeSHalpha-Fetoproteins[Low 0.00 
(083) 0.00 
A/nMeSHChorionicGonadotropin 0.00 
184-268 0.00 
(43/57)) 0.00 
(32/46)) 0.00 
28897 0.00 
658% 0.00 
63-1000) 0.00 
(654%) 0.00 
child/nMeSHCase-ControlStudies 0.00 
(845%) 0.00 
acceptable/nMeSHCongenitalAbnormalities 0.00 
karyotype/nMeSHDownSyndrome 0.00 
MeSHPrenatalExpanded 0.00 
presented/nMeSHDownSyndrome 0.00 
Syndrome/nMeSHCase-ControlStudies 0.00 
(143% 0.00 
MeSHPrenatalDiagnosisPregnancy 0.00 
198% 0.00 
142-618]) 0.00 
anatomy/nMeSHAdolescent 0.00 
MeSHPrenatalDown's 0.00 
(093 0.00 
reproduction/nMeSHBiomarkers 0.00 
(104-111) 0.00 
(101-102); 0.00 
(094-099) 0.00 
(093-106) 0.00 
(p>005 0.00 
-1118 0.00 
variables/nMeSHAdult 0.00 
MeSHalpha-Fetoproteins2nd-trimester 0.00 
sensitivity/nMeSHChorionicGonadotropin 0.00 
MeSHAssistedScreening 0.00 
10600 0.00 
AFP/hCG/nMeSHBiomarkers 0.00 
complications/nMeSHBiomarkers 0.00 
MeSHProspectiveStudiesComparison 0.00 
reports/nMeSHChorionicGonadotropin 0.00 
MeSHTrisomyCombining 0.00 
134-196 0.00 
cent/nMeSHBiomarkers 0.00 
MeSHalpha-FetoproteinsAccuracy 0.00 
(r=09995) 0.00 
risk/nMeSHAlgorithms 0.00 
MeSHalpha-FetoproteinsResults 0.00 
9343 0.00 
feasible/nMeSHAdult 0.00 
MeSHalpha-FetoproteinsTotal 0.00 
(403% 0.00 
(398% 0.00 
(466%) 0.00 
(415%) 0.00 
MeSHPrenatalPreliminary 0.00 
34368 0.00 
death/nMeSHChorionicGonadotropin 0.00 
pregnancy/nMeSHAbortion 0.00 
MeSHPrenatalDiagnosisRelation 0.00 
105-114 0.00 
11315 0.00 
MeSHPrenatal[A 0.00 
384% 0.00 
algorithms/nMeSHAdult 0.00 
837765 0.00 
54321 0.00 
(648%; 0.00 
642-653%) 0.00 
(708%; 0.00 
678-738%) 0.00 
13891 0.00 
32010 0.00 
(r2=0986 0.00 
0980) 0.00 
(r2=0991 0.00 
0985) 0.00 
02675 0.00 
02605 0.00 
02545 0.00 
02336 0.00 
serum/nMeSHAdult 0.00 
MeSHRadioimmunoassayRacial 0.00 
women/nMeSHAfricanContinentalAncestryGroup 0.00 
transfer/nMeSHCase-ControlStudies 0.00 
secretion/nMeSHAdult 0.00 
screen/nMeSHAmniocentesis 0.00 
(803%) 0.00 
gestations/nMeSHBiomarkers 0.00 
40490 0.00 
(944% 0.00 
224%) 0.00 
analyte/nMeSHAdult 0.00 
trimester/nMeSHAneuploidy 0.00 
MeSHalpha-Fetoproteins[Biochemical 0.00 
(>1:1001-1:10000) 0.00 
681%-778% 0.00 
similar/nMeSHAdult 0.00 
stage/nMeSHAbortion 0.00 
32925 0.00 
MeSHalpha-FetoproteinsHigher 0.00 
program/nMeSHBiomarkers 0.00 
MeSHPrenatalEar 0.00 
0753) 0.00 
MeSHPrenatalImproved 0.00 
MeSHalpha-FetoproteinsLow 0.00 
2819 0.00 
21/nMeSHAlgorithms 0.00 
0008); 0.00 
464% 0.00 
later/nMeSHAdolescent 0.00 
MeSHUnitedKingdom[Screening 0.00 
(05%) 0.00 
208257 0.00 
155142 0.00 
62121 0.00 
weeks-312 0.00 
weeks-347 0.00 
screening/nMeSHChorionicGonadotropin 0.00 
67904 0.00 
(67904/78501) 0.00 
(3466/67904; 0.00 
(956/36371; 0.00 
(475/67904; 0.00 
judged/nMeSHAdult 0.00 
34354 0.00 
defect/nMeSHAbnormalities 0.00 
MeSHPrognosisUltrasound 0.00 
procedures/nMeSHChromosomeAberrations 0.00 
(0889 0.00 
(p=0064) 0.00 
(r=+01024) 0.00 
(r=+02288) 0.00 
(r=+02629) 0.00 
(r=+00038) 0.00 
(r=+01028) 0.00 
(r=+00339) 0.00 
beta-hCG/nMeSHAdult 0.00 
MeSHUltrasonographyNuchal 0.00 
pregnancy/nMeSHAneuploidy 0.00 
markers/nMeSHAdolescent 0.00 
trimester/nMeSHBiologicalAssay 0.00 
MeSHProcollagenThe 0.00 
01995 0.00 
01993) 0.00 
00026 0.00 
02129) 0.00 
0590) 0.00 
054% 0.00 
termination/nMeSHBiomarkers 0.00 
levels/nMeSHAmniocentesis 0.00 
5%/nMeSHChorionicGonadotropin 0.00 
MeSHPrenatalHeat-stable 0.00 
screening/nMeSHAlkalinePhosphatase 0.00 
MeSHTrisomyEffectiveness 0.00 
beta-hCG/nMeSHChorionicGonadotropin 0.00 
(065 0.00 
defects/nMeSHBiomarkers 0.00 
938-948%) 0.00 
necessary/nMeSHBodyWeight 0.00 
MeSHTrisomyFirst-trimester 0.00 
(p=050 0.00 
p=043 0.00 
-021 0.00 
(p=002 0.00 
-038 0.00 
-003) 0.00 
MeSHThyrotropinSecond-trimester 0.00 
25359 0.00 
(6)/nMeSHAdult 0.00 
AFP=097 0.00 
hCG=104; 0.00 
AFP=104 0.00 
hCG=080 0.00 
AFP=069 0.00 
hCG=249; 0.00 
AFP=070 0.00 
hCG=153 0.00 
AFP=067 0.00 
hCG=229; 0.00 
AFP=073 0.00 
hCG=199 0.00 
760%) 0.00 
693% 0.00 
MeSHalpha-FetoproteinsAn 0.00 
strategy/nMeSHCohortStudies 0.00 
MeSHSensitivityandSpecificityClinical 0.00 
4-499 0.00 
complications/nMeSHChorionicGonadotropin 0.00 
414% 0.00 
therapy/nMeSHAdenocarcinoma 0.00 
(829%) 0.00 
682% 0.00 
726% 0.00 
831% 0.00 
MeSHUltrasonographyClinical 0.00 
(132%) 0.00 
MeSHUltrasonographyCurrent 0.00 
MeSHStomachNeoplasmsEndosonographic 0.00 
822% 0.00 
MeSHUltrasonographyPre-operative 0.00 
MeSHStomachNeoplasmsUsefulness 0.00 
detection/nMeSHAdult 0.00 
MeSHStomachNeoplasmsAccuracy 0.00 
importance/nMeSHAdult 0.00 
MeSHUltrasonographyStaging 0.00 
MeSHUltrasonographyUsefulness 0.00 
691% 0.00 
791% 0.00 
880% 0.00 
stage/nMeSHAdult 0.00 
MeSHUltrasonographyRelationship 0.00 
<01 0.00 
MeSHTreatmentOutcomeEndoscopic 0.00 
resection/nMeSHAdult 0.00 
MeSHUltrasonographyEfficacy 0.00 
malignancies/nMeSHAged 0.00 
(p=0016) 0.00 
638% 0.00 
804% 0.00 
742% 0.00 
(916%) 0.00 
stage/nMeSHAged 0.00 
determined/nMeSHAdenocarcinoma 0.00 
462% 0.00 
results/nMeSHAdenocarcinoma 0.00 
carcinoma/nMeSHAdult 0.00 
MeSHStomachNeoplasmsExperience 0.00 
setting/nMeSHAged 0.00 
MeSHUltrasonographyEndosonography 0.00 
MeSHX-RayComputedUsefulness 0.00 
757% 0.00 
(565%) 0.00 
(929%) 0.00 
(439%) 0.00 
244% 0.00 
metastases/nMeSHEsophagealNeoplasms 0.00 
807% 0.00 
(833 0.00 
(022 0.00 
767% 0.00 
435% 0.00 
examinations/nMeSHAdult 0.00 
(P=012) 0.00 
90%/nMeSHAdolescent 0.00 
979%; 0.00 
665% 0.00 
604% 0.00 
MeSHTendonInjuriesThe 0.00 
MeSHTendonInjuriesSuperior 0.00 
department/nMeSHAdult 0.00 
tear/nMeSHAdolescent 0.00 
(833%) 0.00 
(825%) 0.00 
MeSHShoulderJointA 0.00 
9375% 0.00 
0815 0.00 
arthroscopy/nMeSHArthroscopy 0.00 
MeSHTendinopathyThe 0.00 
MeSHWoundsandInjuriesShoulder 0.00 
injury/nMeSHAdult 0.00 
MeSHShoulderJointClinical 0.00 
MeSHYoungAdultRotator 0.00 
tear/nMeSHAcromion 0.00 
(972%) 0.00 
MeSHShoulderJointAccuracy 0.00 
specificity/nMeSHAged 0.00 
MeSHWoundsandInjuriesAnterior 0.00 
MeSHYoungAdultRapid 0.00 
1000%) 0.00 
990% 0.00 
MeSHTuberculosisComparison 0.00 
p=002) 0.00 
MeSHPulmonaryGeneXpert(R) 0.00 
MeSHPulmonaryComparison 0.00 
(385%) 0.00 
MeSHYoungAdultXpert 0.00 
920% 0.00 
(182%) 0.00 
MeSHTuberculosisThe 0.00 
173%) 0.00 
(172%) 0.00 
MeSHTuberculosisPerformance 0.00 
assay/nMeSHAdolescent 0.00 
(982%) 0.00 
(163%) 0.00 
(952%) 0.00 
(762%) 0.00 
(263%) 0.00 
MeSHTuberculosisEvaluation 0.00 
861% 0.00 
163% 0.00 
Mtuberculosis 0.00 
study/nMeSHAdolescent 0.00 
MeSHYoungAdultA 0.00 
998% 0.00 
997% 0.00 
(846%) 0.00 
773% 0.00 
943% 0.00 
863% 0.00 
992% 0.00 
MeSHPulmonaryEvaluation 0.00 
390% 0.00 
689% 0.00 
910% 0.00 
MeSHUltrasonographySerum 0.00 
(584%) 0.00 
MeSHRectalNeoplasmsCarcinoembryonic 0.00 
MeSHSensitivityandSpecificitySerum 0.00 
management/nMeSHCarcinoembryonicAntigen 0.00 
(p<005) 0.00 
MeSHYoungAdultIs 0.00 
MeSHRectalNeoplasmsIs 0.00 
survival/nMeSHBiomarkers 0.00 
disease/nMeSHAged 0.00 
(CEA<50) 0.00 
(CEA<25) 0.00 
CEA/nMeSHAdult 0.00 
MeSHRetrospectiveStudiesIs 0.00 
(807%) 0.00 
MeSHRectalNeoplasmsCEA 0.00 
disease/nMeSHCarcinoembryonicAntigen 0.00 
(731 0.00 
MeSHSensitivityandSpecificity[Value 0.00 
MeSHTimeFactorsSerum 0.00 
MeSHSensitivityandSpecificityDetection 0.00 
evidence/nMeSHAdenocarcinoma 0.00 
1667% 0.00 
8636% 0.00 
603% 0.00 
8333% 0.00 
315% 0.00 
531% 0.00 
343% 0.00 
patient/nMeSHCarcinoembryonicAntigen 0.00 
tumor/nMeSHCarcinoembryonicAntigen 0.00 
(206%) 0.00 
MeSHProspectiveStudiesSerum 0.00 
groups/nMeSHAdenocarcinoma 0.00 
(218%) 0.00 
389% 0.00 
MeSHSensitivityandSpecificityCEA 0.00 
(533%) 0.00 
MeSHSurvivalRate18F-FDG 0.00 
MeSHRectalNeoplasmsPostoperative 0.00 
MeSHTreatmentOutcomeClinical 0.00 
(273%) 0.00 
(265%) 0.00 
(647%) 0.00 
(636%) 0.00 
641% 0.00 
cancer/nMeSHBiomarkers 0.00 
MeSHSensitivityandSpecificityUsefulness 0.00 
MeSHRectalNeoplasmsClinical 0.00 
3042 0.00 
213% 0.00 
316% 0.00 
10%-79%; 0.00 
803% 0.00 
789% 0.00 
CEA/nMeSHAntigens 0.00 
patient/nMeSHAdult 0.00 
(232%) 0.00 
(113%) 0.00 
(305%) 0.00 
792% 0.00 
591% 0.00 
192+/-203 0.00 
6554+/-3396 0.00 
121%) 0.00 
MeSHTreatmentOutcomeValue 0.00 
patients/nMeSHCarcinoembryonicAntigen 0.00 
agents/nMeSHAdult 0.00 
469% 0.00 
screened/nMeSHAdult 0.00 
516% 0.00 
475% 0.00 
MeSHSensitivityandSpecificityA 0.00 
(512%) 0.00 
syndrome/nMeSHAbortion 0.00 
285% 0.00 
340% 0.00 
tests/nMeSHAdolescent 0.00 
(989%) 0.00 
644% 0.00 
10017 0.00 
812% 0.00 
MeSHFirstFirst 0.00 
(051 0.00 
MeSHPrenatalFetal 0.00 
III/nMeSHAdolescent 0.00 
MeSHYoungAdultNuchal 0.00 
11107 0.00 
553% 0.00 
MeSHYoungAdultComparison 0.00 
(216%) 0.00 
698% 0.00 
26803 0.00 
27313 0.00 
70030 0.00 
MeSHYoungAdultFirst 0.00 
966% 0.00 
avoided/nMeSHAdult 0.00 
MeSHalpha-FetoproteinsClinical 0.00 
885% 0.00 
(P>05) 0.00 
MeSHPrenatalDiagnosisNuchal 0.00 
MeSHPrenatal[Prenatal 0.00 
2244 0.00 
alone/nMeSHAdolescent 0.00 
35-39%) 0.00 
MeSHYoungAdultScreening 0.00 
189MoM 0.00 
169MoM 0.00 
048MoM 0.00 
pregnancies/nMeSHAneuploidy 0.00 
result/nMeSHAdult 0.00 
5%/nMeSHAdult 0.00 
(975% 0.00 
(857% 0.00 
(928%) 0.00 
977%; 0.00 
697% 0.00 
779% 0.00 
39004 0.00 
(154%) 0.00 
(026%) 0.00 
(393%) 0.00 
(455%) 0.00 
(103%) 0.00 
758% 0.00 
MeSHYoungAdultTriple 0.00 
approach/nMeSHAdult 0.00 
MeSHX-RayComputed[Diagnostic 0.00 
(236%) 0.00 
MeSHX-RayComputedLaparoscopy 0.00 
(429%) 0.00 
829% 0.00 
MeSHPancreaticNeoplasmsLaparoscopy 0.00 
(312%) 0.00 
MeSHSensitivityandSpecificityLaparoscopic 0.00 
carcinoma/nMeSHAged 0.00 
region/nMeSHAdult 0.00 
MeSHSurvivalAnalysisStaging 0.00 
MeSHX-RayComputedAssessment 0.00 
(566%) 0.00 
malignancies/nMeSHAdult 0.00 
(757%) 0.00 
MeSHSensitivityandSpecificityPreoperative 0.00 
201% 0.00 
MeSHUltrasonographyLaparoscopy 0.00 
MeSHSensitivityandSpecificityRole 0.00 
393% 0.00 
effective/nMeSHAdult 0.00 
415% 0.00 
exploration/nMeSHAdult 0.00 
MeSHX-RayComputedMR 0.00 
MeSHWoundsandInjuries[Magnetic 0.00 
observed/nMeSHAdult 0.00 
surface/nMeSHAdolescent 0.00 
MeSHTendonInjuriesSonographic 0.00 
MeSHUltrasonographySonography 0.00 
(094) 0.00 
MeSHUltrasonographyUltrasound 0.00 
898% 0.00 
02-Tesla 0.00 
ultrasonography/nMeSHAdult 0.00 
negative/nMeSHAdult 0.00 
images/nMeSHAdult 0.00 
MeSHUltrasonography[Lesions 0.00 
MeSHUltrasonographyShoulder 0.00 
MeSHUltrasonographyUS 0.00 
tendon/nMeSHArthroscopy 0.00 
MeSHTendonInjuriesCorrelation 0.00 
MeSHShoulderJointSonography 0.00 
required/nMeSHArthrography 0.00 
MeSHTendonInjuriesMagnetic 0.00 
MeSHWoundsandInjuriesSonography 0.00 
time/nMeSHAdult 0.00 
(143%) 0.00 
accurately/nMeSHAdult 0.00 
MeSHUltrasonographyIndirect 0.00 
procedure/nMeSHAdolescent 0.00 
368% 0.00 
536% 0.00 
853%) 0.00 
MeSHShoulderJoint[Contribution 0.00 
MeSHTendonInjuriesMR 0.00 
MeSHUltrasonographyEffect 0.00 
MeSHUltrasonographyCan 0.00 
(063 0.00 
exercise/nMeSHAdult 0.00 
MeSHUltrasonography[Ultrasonics 0.00 
MeSHUltrasonography[Ultrasonic 0.00 
cholecystitis/nMeSHAcuteDisease 0.00 
MeSHUltrasonographyPrediction 0.00 
MeSHUltrasonographySelection 0.00 
MeSHSensitivityandSpecificityPredictive 0.00 
ERCP/nMeSHAdult 0.00 
MeSHUltrasonographyProspective 0.00 
745% 0.00 
MeSHUltrasonographyComparative 0.00 
(p<001) 0.00 
(837%) 0.00 
H 0.00 
559% 0.00 
441% 0.00 
MeSHUltrasonographyCommon 0.00 
MeSHRiskFactorsA 0.00 
(841%) 0.00 
MeSHgamma-Glutamyltransferase[Value 0.00 
(p=00009) 0.00 
stones/nMeSHAdolescent 0.00 
out/nMeSHAdult 0.00 
(975%) 0.00 
intervention/nMeSHAged 0.00 
918% 0.00 
932% 0.00 
MeSHVulvarNeoplasmsFurther 0.00 
surgeons/nMeSHAdult 0.00 
161% 0.00 
688% 0.00 
MeSHVulvarNeoplasmsA 0.00 
MeSHVulvarNeoplasmsEvaluation 0.00 
MeSHVulvarNeoplasmsInguinal 0.00 
MeSHVulvarNeoplasmsCombined 0.00 
MeSHVulvarNeoplasmsVulvar 0.00 
MeSHVulvarNeoplasmsComparison 0.00 
MeSHVulvarNeoplasmsValidation 0.00 
MeSHVulvarNeoplasms[Sentinel 0.00 
practice/nMeSHAdult 0.00 
entities/nMeSHAdult 0.00 
594% 0.00 
781% 0.00 
853% 0.00 
446% 0.00 
(420%) 0.00 
MeSHYoungAdult[The 0.00 
ASCUS/nMeSHCervicalIntraepithelialNeoplasia 0.00 
utility/nMeSHAdult 0.00 
MeSHVaginalSmearsPrediction 0.00 
cytology/nMeSHDNA 0.00 
586% 0.00 
156% 0.00 
173% 0.00 
849% 0.00 
402% 0.00 
MeSHVaginalSmearsCytological 0.00 
399% 0.00 
523% 0.00 
377% 0.00 
MeSHVaginalSmearsOutcome 0.00 
MeSHVaginalSmearsRole 0.00 
397% 0.00 
(945%) 0.00 
970% 0.00 
MeSHVaginalSmearsShould 0.00 
smears/nMeSHCervicalIntraepithelialNeoplasia 0.00 
582% 0.00 
204% 0.00 
cancer/nMeSHAlphapapillomavirus 0.00 
MeSHUterineCervicalNeoplasmsAtypical 0.00 
MeSHVaginalSmearsImmunocytochemical 0.00 
844% 0.00 
862% 0.00 
MeSHVaginalSmearsFive-year 0.00 
MeSHVaginalSmearsPrevalence 0.00 
MeSHVaginalSmearsUse 0.00 
(252%) 0.00 
MeSHVaginalSmearsEvaluation 0.00 
MeSHVaginalSmearsCervical 0.00 
cytology/nMeSHAdolescent 0.00 
436% 0.00 
MeSHYoungAdultCorrelation 0.00 
dyskaryosis/nMeSHAdult 0.00 
(405%) 0.00 
(153%) 0.00 
MeSHYoungAdultHPV 0.00 
199% 0.00 
MeSHVaginalSmearsQuantitative 0.00 
(368%) 0.00 
specificity/nMeSHAdolescent 0.00 
sampling/nMeSHAdolescent 0.00 
smears/nMeSHAdolescent 0.00 
25203 0.00 
(144%) 0.00 
454% 0.00 
(692%) 0.00 
(086 0.00 
930% 0.00 
881% 0.00 
smears/nMeSHAdult 0.00 
233% 0.00 
MeSHVaginalSmearsPredicting 0.00 
smear/nMeSHAdult 0.00 
656% 0.00 
319% 0.00 
(727% 0.00 
766% 0.00 
established/nMeSHAdult 0.00 
711% 0.00 
infections/nMeSHAlphapapillomavirus 0.00 
MeSHVaginalSmearsImpact 0.00 
34841617/nMeSHAdult 0.00 
31000 0.00 
872% 0.00 
391% 0.00 
MeSHVaginalSmearsIs 0.00 
0739 0.00 
0606) 0.00 
strategy/nMeSHAdolescent 0.00 
684% 0.00 
testing/nMeSHAdolescent 0.00 
764% 0.00 
801% 0.00 
(967%) 0.00 
710% 0.00 
MeSHYoungAdultAtypical 0.00 
481% 0.00 
MeSHSurveysandQuestionnairesA 0.00 
MeSHSurveysandQuestionnairesCombining 0.00 
MeSHSurveysandQuestionnairesPerformance 0.00 
MeSHUtahThe 0.00 
elderly/nMeSHAged 0.00 
907% 0.00 
905%) 0.00 
(729%) 0.00 
(649%) 0.00 
785% 0.00 
pelvis/nMeSHAdult 0.00 
MeSHVaginaCan 0.00 
resolution=075 0.00 
MeSHYoungAdultAccuracy 0.00 
891%); 0.00 
(432%) 0.00 
lesions/nMeSHAdnexalDiseases 0.00 
DIE/nMeSHAdult 0.00 
MeSHVaginaDiagnosis 0.00 
9458% 0.00 
709% 0.00 
MeSHRetrospectiveStudiesTransvaginal 0.00 
MeSHYoungAdultUltrasound 0.00 
806% 0.00 
(847%) 0.00 
MeSHYoungAdultEndometriosis 0.00 
MeSHSensitivityandSpecificityValue 0.00 
(10000%) 0.00 
793% 0.00 
847% 0.00 
candidates/nMeSHAdult 0.00 
(P=005) 0.00 
0895 0.00 
cTnT>01 0.00 
MeSHbeta-GlucansProspective 0.00 
malignancies/nMeSHAspergillosis 0.00 
MeSHSensitivityandSpecificity[The 0.00 
disorders/nMeSHAdolescent 0.00 
055/093/040/096 0.00 
MeSHYoungAdultProspective 0.00 
MeSHSensitivityandSpecificityGalactomannan 0.00 
IA/nMeSHAdolescent 0.00 
MeSHRetrospectiveStudiesDetection 0.00 
IPA/nMeSHAdolescent 0.00 
HSCT/nMeSHAdolescent 0.00 
MeSHSensitivityandSpecificityAspergillus 0.00 
recipients/nMeSHAdult 0.00 
patients/nMeSHAntigens 0.00 
MeSHSensitivityandSpecificityProspective 0.00 
aspergillosis/nMeSHAntifungalAgents 0.00 
(13)beta-D-glucan 0.00 
beta-D-(13)-glucan 0.00 
c109G>A 0.00 
c344T>G 0.00 
MeSHHomologousValue 0.00 
MeSHTraumaCentersEarly 0.00 
11618 0.00 
MeSHWoundsandInjuriesThromboelastography 0.00 
MeSHWoundsandInjuriesRotational 0.00 
activity/nMeSHAdult 0.00 
MeSHalpha-2-AntiplasminThrombelastography 0.00 
(378% 0.00 
511% 0.00 
-2942; 0.00 
MeSHThrombelastographyHypercoagulability 0.00 
state/nMeSHAdult 0.00 
MeSHTraumaCentersFIBTEM 0.00 
(789% 0.00 
(084) 0.00 
MeSHWoundsandInjuriesPrehospital 0.00 
outcome/nMeSHBloodCoagulationDisorders 0.00 
(>or=15) 0.00 
requirements/nMeSHBloodCoagulation 0.00 
MeSHPenetratingEvaluation 0.00 
MeSHWoundsandInjuriesRandomized 0.00 
(06(07) 0.00 
03(05); 0.00 
transplant/nMeSHAnalgesics 0.00 
MeSHTissueandOrganHarvestingFunctional 0.00 
transfusion/nMeSHAcuteDisease 0.00 
MeSHYoungAdultEvidence 0.00 
ControlledTrialscom 0.00 
5551 0.00 
1591 0.00 
2356) 0.00 
-2942) 0.00 
MeSHNitricOxideThe 0.00 
044-061) 0.00 
MeSHNonpenetratingCombining 0.00 
0891 0.00 
0997 0.00 
MeSHWoundsandInjuriesFibrinogen 0.00 
MeSHWoundsandInjuriesCoagulation 0.00 
MeSHWoundsandInjuriesSplenectomy 0.00 
MeSHWoundsandInjuriesEndothelial 0.00 
MeSHWoundsandInjuriesPoint 0.00 
sensitivity/nMeSHBloodCoagulation 0.00 
MeSHWoundsandInjuriesHyperfibrinolysis 0.00 
(09% 0.00 
HF/nMeSHAdult 0.00 
MeSHWoundsandInjuriesViscoelastic 0.00 
(089; 0.00 
MeSHYoungAdultMulticenter 0.00 
819; 0.00 
3152132; 0.00 
670; 0.00 
1742578; 0.00 
p=0006) 0.00 
2061340; 0.00 
TBI/nMeSHBloodCoagulationDisorders 0.00 
MeSHX-RayComputedCoagulation 0.00 
MeSHThromboplastinNeuroprotective 0.00 
injury/nMeSHAnimals 0.00 
MeSHVentricularFibrillationThe 0.00 
(22-1001) 0.00 
(11-15) 0.00 
(13-223) 0.00 
P=002] 0.00 
coagulopathy/nMeSHBloodCoagulationDisorders 0.00 
MeSHTreatmentOutcomeDevelopment 0.00 
laboratory/nMeSHAlgorithms 0.00 
MeSHTimeFactorsPlatelet 0.00 
(181000/mul 0.00 
212000/mul; 0.00 
p=001) 0.00 
p=00019) 0.00 
vs103 0.00 
p=00012) 0.00 
(p=00017 0.00 
p=00002 0.00 
management/nMeSHAdenosineDiphosphate 0.00 
MeSHWoundsandInjuriesMilitary 0.00 
MeSHWarfareHyperfibrinolysis 0.00 
P=0001 0.00 
P=0009 0.00 
(P=0017) 0.00 
MeSHYoungAdultUtility 0.00 
096/058 0.00 
100/070 0.00 
affected/nMeSHAdult 0.00 
MeSHWholeBloodCoagulationTimeEarly 0.00 
(p=02) 0.00 
hypoperfusion/nMeSHAdult 0.00 
MeSHWoundsandInjuriesAdmission 0.00 
(2017) 0.00 
MeSHYoungAdultTEG-guided 0.00 
IV/nMeSHAdult 0.00 
MeSHPenetratingCan 0.00 
care/nMeSHAdolescent 0.00 
MeSHYoungAdultDiagnosis 0.00 
transfusion/nMeSHBloodCoagulationDisorders 0.00 
0957 0.00 
data/nMeSHAlgorithms 0.00 
MeSHThromboplastinInitial 0.00 
(-130 0.00 
(p=010) 0.00 
(p=003) 0.00 
(p=003 0.00 
(p=0048 0.00 
p=003 0.00 
p=004 0.00 
requirements/nMeSHAdult 0.00 
MeSHYoungAdultThree-stage 0.00 
MeSHalpha-FetoproteinsAbsent 0.00 
78-fold 0.00 
practice/nMeSHChorionicGonadotropin 0.00 
(r2=004) 0.00 
(360-20500 0.00 
(r2=0998) 0.00 
MeSHSensitivityandSpecificityDimeric 0.00 
08744 0.00 
07504 0.00 
=1116) 0.00 
00212 0.00 
00133 0.00 
<05) 0.00 
=012) 0.00 
MeSHPrenatalDiagnosisSecond 0.00 
expenditures/nMeSHAdult 0.00 
MeSHTurnerSyndromeEvaluation 0.00 
MeSHWestIndiesIncorporation 0.00 
MeSHPrenatalAlpha-fetoprotein 0.00 
MeSHPrenatalComparison 0.00 
(935%) 0.00 
09337 0.00 
07887; 0.00 
=02) 0.00 
542% 0.00 
screen/nMeSHChorionicGonadotropin 0.00 
MeSHPrenatalUltrasonography 0.00 
95-fold 0.00 
MeSHalpha-FetoproteinsStability 0.00 
MeSHPrenatalSialic 0.00 
MeSHalpha-FetoproteinsAdjustment 0.00 
MeSHPrenatalUltrasound 0.00 
MeSHalpha-Fetoproteins[AFP 0.00 
MeSHSensitivityandSpecificityIncreased 0.00 
(p<00001 0.00 
MoM/nMeSHCase-ControlStudies 0.00 
MeSHRegressionAnalysisFirst-trimester 0.00 
MeSHPrenatalLens 0.00 
(1289) 0.00 
(822 0.00 
MeSHalpha-FetoproteinsCA-125 0.00 
MeSHPrenatalCollaborative 0.00 
126-230); 0.00 
drawn/nMeSHBiomarkers 0.00 
MeSHPrenatalDiagnosisMultiple 0.00 
MeSHSensitivityandSpecificityAge-specific 0.00 
MeSHRiskFactorsScreening 0.00 
995th 0.00 
MeSHROCCurveSix 0.00 
MeSHSmokingEvaluation 0.00 
beta-core-hCG/nMeSHAdult 0.00 
MeSHReferenceValuesInsulin-dependent 0.00 
pregnancy/nMeSHBiomarkers 0.00 
MeSHFirstCombining 0.00 
MeSHalpha-FetoproteinsNew 0.00 
MeSHPrenatalDiagnosisInfluence 0.00 
MeSHTurnerSyndromeFree 0.00 
MeSHalpha-FetoproteinsInvasive 0.00 
usage/nMeSHAdult 0.00 
MeSHTrophoblastsUrine 0.00 
MeSHPregnancyNuchal 0.00 
MeSHUltrasonographyElevated 0.00 
MeSHPrenatalDiagnosisUrine 0.00 
0941 0.00 
<02) 0.00 
MeSHalpha-FetoproteinsCan 0.00 
MeSHSensitivityandSpecificitySecond 0.00 
MeSHNonparametricAbnormal 0.00 
MeSHalpha-FetoproteinsRepeat 0.00 
MeSHReferenceValuesPrenatal 0.00 
MeSHalpha-FetoproteinsSURUSS 0.00 
MeSHRegressionAnalysisElevated 0.00 
MeSHProspectiveStudiesPhenotypic 0.00 
MeSHPrenatalMidtrimester 0.00 
MeSHProspectiveStudiesUrinary 0.00 
(002 0.00 
(064 0.00 
aneuploidies/nMeSHAdolescent 0.00 
MeSHalpha-FetoproteinsTemporal 0.00 
informed/nMeSH?The 0.00 
MeSHHigh-RiskMaternal 0.00 
MeSHS100ProteinsAppropriate 0.00 
MeSHTaiwanNuchal 0.00 
MeSHPrenatalSURUSS 0.00 
MeSHReferenceValuesFirst 0.00 
MeSHTwinsSerum 0.00 
MeSHTwinsEvaluation 0.00 
reality/nMeSHAdult 0.00 
MeSHReferenceValuesCombining 0.00 
MeSHalpha-FetoproteinsMid-gestation 0.00 
248-468) 0.00 
(387-862) 0.00 
(055-080) 0.00 
biochemistry/nMeSHAdult 0.00 
marker/nMeSHAntibodies 0.00 
MeSHPrenatalTriple 0.00 
MeSHSecondA 0.00 
MeSHalpha-FetoproteinsRace-ethnicity-specific 0.00 
MeSHXChromosomeTriple 0.00 
MeSHProspectiveStudies[Measurement 0.00 
MeSHTrisomyA 0.00 
3649) 0.00 
MeSHPrenatalSelective 0.00 
radiography/nMeSHAdolescent 0.00 
MeSHNonpenetratingEvidence 0.00 
MeSHRetrospectiveStudiesEvaluation 0.00 
MeSHNonpenetratingEvaluation 0.00 
trauma/nMeSHAccidentalFalls 0.00 
MeSHNonpenetratingThoracolumbar 0.00 
621% 0.00 
915%) 0.00 
986%) 0.00 
958%) 0.00 
MeSHNonpenetratingIndications 0.00 
MeSHNonpenetratingRadiography 0.00 
discussed/nMeSHAdolescent 0.00 
MeSHRadiographyLumbar 0.00 
(524%) 0.00 
(725% 0.00 
412%) 0.00 
(425% 0.00 
207%) 0.00 
0005)/nMeSHAdolescent 0.00 
MeSHWoundsandInjuriesProspective 0.00 
MeSHNonpenetrating'Routine' 0.00 
MeSHNonpenetratingUse 0.00 
318% 0.00 
(642%) 0.00 
studies/nMeSHAdolescent 0.00 
MeSHSpinalNeoplasmsPositron 0.00 
(P=0008) 0.00 
NLR/nMeSHEsophagealNeoplasms 0.00 
MeSHEmission-ComputedEndoscopic 0.00 
(p=0001) 0.00 
MeSHSurvivalAnalysisMRI 0.00 
infiltration/nMeSHAged 0.00 
MeSHX-RayComputed[Endosonographic 0.00 
metastases/nMeSHEndoscopes 0.00 
MeSHUltrasonographyDoes 0.00 
0766) 0.00 
mandatory/nMeSHEndosonography 0.00 
MeSHTreatmentOutcomeAnalysis 0.00 
possible/nMeSHCarcinoma 0.00 
MeSHUltrasonographyEpidemiology 0.00 
825%/715%) 0.00 
274%); 0.00 
426%) 0.00 
798%/711%) 0.00 
(361%) 0.00 
8%/89%) 0.00 
709%) 0.00 
therapy/nMeSHAdult 0.00 
MeSHStomachNeoplasmsRegional 0.00 
821% 0.00 
metastasis/nMeSHAdolescent 0.00 
one/nMeSHFemale 0.00 
(841%; 0.00 
EGC/nMeSHAdenocarcinoma 0.00 
disease/nMeSHGastroscopy 0.00 
MeSHUltrasonographyYou 0.00 
information/nMeSHDigestiveSystemNeoplasms 0.00 
MeSHVideotapeRecordingLaparoscopy 0.00 
lesions/nMeSHEvaluationStudiesasTopic 0.00 
indications/nMeSHEndosonography 0.00 
cancer/nMeSHChemotherapy 0.00 
MeSHX-RayComputedMultimodal 0.00 
place/nMeSHAdult 0.00 
0850) 0.00 
MeSHX-RayComputedEndosonography 0.00 
respectively/nMeSHEndoscopy 0.00 
MeSHStomachNeoplasmsImpact 0.00 
countries/nMeSHEndoscopy 0.00 
resection/nMeSH?Double 0.00 
895%; 0.00 
MeSHX-RayComputedGastric 0.00 
MeSHSurvivalRateUlcerous 0.00 
(514%) 0.00 
(459%) 0.00 
00284) 0.00 
changes/nMeSHAdenocarcinoma 0.00 
MeSHStomachUlcerEndoscopic 0.00 
MeSHStomachNeoplasmsInfluence 0.00 
taken/nMeSHAdenocarcinoma 0.00 
MeSHStomachNeoplasmsEfficacy 0.00 
546% 0.00 
MeSHStomachNeoplasmsVideo-endoscopic 0.00 
ultrasonography/nMeSHAdenocarcinoma 0.00 
MeSHVideoRecordingThe 0.00 
up/nMeSHAged 0.00 
MeSHInterventionalClinical 0.00 
LGC/nMeSHAdult 0.00 
studies/nMeSHAdenocarcinoma 0.00 
MeSHStomachNeoplasmsRole 0.00 
understood/nMeSHAdult 0.00 
(P=0033) 0.00 
(P=0035) 0.00 
(P=0029 0.00 
OR=2873) 0.00 
(P=0035 0.00 
OR=2151) 0.00 
morphology/nMeSH?A 0.00 
MeSHStomachNeoplasmsEUS 0.00 
MeSHTransducersProspective 0.00 
(p=0087) 0.00 
(p=0206) 0.00 
(p=0376) 0.00 
(p=0195) 0.00 
(p=0031) 0.00 
treatment/nMeSHAdenocarcinoma 0.00 
628% 0.00 
MeSHX-RayComputedMorphometric 0.00 
fibrosis/nMeSHAdult 0.00 
6313 0.00 
854% 0.00 
0873) 0.00 
028)/nMeSHAdenocarcinoma 0.00 
MeSHUltrasonographyLocal 0.00 
extended/nMeSHFibrosis 0.00 
MeSHUltrasonographyTransendoscopic 0.00 
depth/nMeSHEndosonography 0.00 
MeSHTransducersIs 0.00 
patients/nMeSHEndosonography 0.00 
MeSHStomachNeoplasmsClinical 0.00 
MeSHRetrospectiveStudiesLymph 0.00 
(776%) 0.00 
West/nMeSHGastroscopy 0.00 
(994%vs 0.00 
754% 0.00 
intervention/nMeSHAdolescent 0.00 
8095% 0.00 
7302% 0.00 
9522% 0.00 
552% 0.00 
759% 0.00 
(931%) 0.00 
invasion/nMeSHAdenocarcinoma 0.00 
MeSHUltrasonography[Comparison 0.00 
867% 0.00 
9031 0.00 
MeSHUltrasonographyCT 0.00 
shooting/nMeSHAged 0.00 
317% 0.00 
future/nMeSHEndoscopy 0.00 
(922%) 0.00 
241% 0.00 
239%) 0.00 
body/nMeSHAdult 0.00 
MeSHStomachNeoplasms[How 0.00 
investigations/nMeSHAdenocarcinoma 0.00 
MeSHUltrasonographyImpact 0.00 
125-MHz 0.00 
MeSHStomachNeoplasms[Endoscopic 0.00 
(1992-2001)we 0.00 
cancer)When 0.00 
suggest/nMeSHAdenocarcinoma 0.00 
MeSHStomachNeoplasmsEnlarged 0.00 
required/nMeSHEndoscopy 0.00 
MeSHUltrasonographyPretreatment 0.00 
nodes/nMeSHAdenocarcinoma 0.00 
MeSHStomachNeoplasmsClinicopathologic 0.00 
staging/nMeSHDiagnosticErrors 0.00 
HCT/nMeSHAdenocarcinoma 0.00 
MeSHSpiralComputedPreoperative 0.00 
cancer/nMeSHGastroscopy 0.00 
874% 0.00 
S-CT/nMeSHAdult 0.00 
MeSHX-RayComputedEndoscopic 0.00 
MeSHStomachNeoplasmsPre-operative 0.00 
achieved/nMeSHAdenocarcinoma 0.00 
surgically/nMeSHAdenocarcinoma 0.00 
MeSHStomachNeoplasms[Preoperative 0.00 
cases/nMeSHAged 0.00 
stomach/nMeSHAged 0.00 
MeSHStomachNeoplasmsMulti-institutional 0.00 
<01) 0.00 
(639 0.00 
=03) 0.00 
chemoradiotherapy/nMeSHAdenocarcinoma 0.00 
MeSHTreatmentOutcome[Progress 0.00 
analysis/nMeSHAdenocarcinoma 0.00 
MeSHSurvivalRateEndoscopic 0.00 
tumours/nMeSHAdenocarcinoma 0.00 
MeSHStomachNeoplasmsAn 0.00 
patients/nMeSHAgeFactors 0.00 
than05 0.00 
>99) 0.00 
MeSHSpiralComputedAccuracy 0.00 
(571%); 0.00 
(175% 0.00 
(263% 0.00 
aspiration/nMeSHAdult 0.00 
unsatisfactory/nMeSHAdult 0.00 
cancer/nMeSHEndosonography 0.00 
MeSHStomachNeoplasms[Laparoscopy 0.00 
spread/nMeSHEsophagealNeoplasms 0.00 
lesions/nMeSHAdenocarcinoma 0.00 
MeSHTransducersEsophagogastric 0.00 
ES/nMeSHAdolescent 0.00 
41475 0.00 
78-26838 0.00 
2617 0.00 
1444-3429) 0.00 
p=00001; 0.00 
p=00216; 0.00 
p=00121) 0.00 
p=0011 0.00 
coefficient=0104; 0.00 
p=0020 0.00 
coefficient=30414) 0.00 
MeSHStomachNeoplasms[Diagnosis 0.00 
examinations/nMeSHGastroscopy 0.00 
moderate/nMeSHAdenocarcinoma 0.00 
MeSHStomachNeoplasmsProspective 0.00 
category/nMeSHBiopsy 0.00 
(792% 0.00 
staging/nMeSHAdenocarcinoma 0.00 
17364 0.00 
(6981 0.00 
(8571 0.00 
(8556 0.00 
(9394 0.00 
9211 0.00 
9876 0.00 
MeSHUltrasonography[Electronic 0.00 
carcinomas/nMeSHAdult 0.00 
MeSHStomachUlcer[Possibilities 0.00 
load/nMeSHAdenocarcinoma 0.00 
MeSHUltrasonography[Endosonography 0.00 
excision/nMeSHEndoscopes 0.00 
EUS/nMeSHAdenocarcinoma 0.00 
MeSHTumorBurdenEvaluation 0.00 
0394) 0.00 
MeSHStomachNeoplasmsInvasion 0.00 
specimens/nMeSHAdenocarcinoma 0.00 
nondiagnostic/nMeSHAdenocarcinoma 0.00 
MeSHStomachNeoplasmsComparison 0.00 
6389%; 0.00 
9891%) 0.00 
instability/nMeSHFear 0.00 
MeSHShoulderJointCorrelation 0.00 
MeSHShoulderJointIsolated 0.00 
nerve/nMeSHAdult 0.00 
MeSHTreatmentOutcomeIndications 0.00 
challenge/nMeSHAgeFactors 0.00 
MeSH"WorkersCompensation"Diagnostic 0.00 
MeSHSyndromeEffect 0.00 
problems/nMeSHAdult 0.00 
MeSHSportsMedicineThe 0.00 
MeSHTendonInjuriesSubacromial 0.00 
MeSHTreatmentOutcomeSurgical 0.00 
MeSHTenosynovitisA 0.00 
tear/nMeSHAged 0.00 
176%) 0.00 
917%) 0.00 
MeSHWoundsandInjuriesMost 0.00 
test/nMeSHDiagnosticTests 0.00 
MeSHShoulderImpingementSyndromeInterobserver 0.00 
value>or=060 0.00 
ICC>or=075 0.00 
reliability/nMeSHAcromioclavicularJoint 0.00 
MeSHShoulderPainCurrent 0.00 
MeSHShoulderJointUnstable 0.00 
group/nMeSHAbsorbableImplants 0.00 
MeSHTreatmentOutcomeReliability 0.00 
subjects/nMeSHAdult 0.00 
MeSHShoulderDislocationSuperior 0.00 
athletes/nMeSHAthleticInjuries 0.00 
MeSHShoulderImpingementSyndromeInterrater 0.00 
pain/nMeSH?The 0.00 
group/nMeSHAcromioclavicularJoint 0.00 
MeSHTendonInjuriesValidity 0.00 
insignificant/nMeSHAdult 0.00 
MeSHShoulderImpingementSyndromeMeasurement 0.00 
(X=300 0.00 
SD=111) 0.00 
[11]) 0.00 
dysfunction/nMeSHAdult 0.00 
joint/nMeSHAdult 0.00 
MeSHShoulderJointInternal 0.00 
presented/nMeSHAlgorithms 0.00 
MeSHSportsArthroscopy 0.00 
uncertain/nMeSHAdult 0.00 
MeSHShoulderJointAre 0.00 
weakness/nMeSHAdolescent 0.00 
(P=008) 0.00 
syndrome/nMeSHAcromion 0.00 
MeSHTreatmentOutcomeIsolated 0.00 
repair/nMeSHAdult 0.00 
MeSHWorkCapacityEvaluationScapular 0.00 
strategies/nMeSHHumans 0.00 
MeSHShoulderImpingementSyndromeClinical 0.00 
299% 0.00 
instability/nMeSHAdolescent 0.00 
MeSHShoulderInjuriesPhysical 0.00 
9885% 0.00 
3684% 0.00 
7818% 0.00 
9333% 0.00 
high/nMeSHAdolescent 0.00 
MeSHShoulderImpingementSyndromePainful 0.00 
MeSHTreatmentFailureShoulder 0.00 
407% 0.00 
subgroups/nMeSHAdult 0.00 
provided/nMeSHArthroscopy 0.00 
MeSHShoulderDislocationRegional 0.00 
treatments/nMeSHBiomechanicalPhenomena 0.00 
clearance/nMeSHAdult 0.00 
MeSHX-RayComputedTears 0.00 
outcomes/nMeSHArthroscopy 0.00 
identified/nMeSHArthroscopy 0.00 
MeSHTendonInjuriesShoulder 0.00 
intact/nMeSHActivitiesofDailyLiving 0.00 
MeSHTreatmentOutcomeTemporal 0.00 
MeSHTreatmentOutcomeSubscapularis 0.00 
delayed/nMeSHArthroscopy 0.00 
MeSHTendonInjuriesClinical 0.00 
investigations/nMeSHArthrography 0.00 
MeSHUltrasonographySpecificity 0.00 
MeSHTennisArthroscopic 0.00 
score/nMeSHAdult 0.00 
MeSHTreatmentOutcomeType 0.00 
MeSHSeverityofIllnessIndexReliability 0.00 
MeSHShoulderJointExamination 0.00 
athlete/nMeSHArm 0.00 
MeSHShoulderPainLack 0.00 
populations/nMeSHAbstractingandIndexingasTopic 0.00 
MeSHTerminologyasTopicMagnetic 0.00 
MeSHTendonInjuriesShoulder: 0.00 
diagnosticians/nMeSHAcromioclavicularJoint 0.00 
MeSHTendonsSpecial 0.00 
lesion/nMeSHHumans 0.00 
MeSHWoundsandInjuriesIncidence 0.00 
pain/nMeSHAcromion 0.00 
MeSHShoulderPainSubacromial 0.00 
experienced/nMeSHAdult 0.00 
MeSHTreatmentOutcomeRotator 0.00 
(355%) 0.00 
lesion(ABSTRACT 0.00 
MeSHTendonsDiagnostic 0.00 
MeSHUltrasonographyIntroduction 0.00 
available/nMeSHAcromioclavicularJoint 0.00 
MeSHShoulderPainNon-operative 0.00 
0555 0.00 
respectively)/nMeSHAdolescent 0.00 
resection/nMeSHAcromioclavicularJoint 0.00 
MeSHTreatmentFailureThe 0.00 
LR<02 0.00 
2909; 0.00 
2632; 0.00 
2477; 0.00 
646; 0.00 
1262; 0.00 
-LR:021) 0.00 
3471; 0.00 
confidence/nMeSHCartilage 0.00 
MeSHShoulderPainImpingement 0.00 
syndrome/nMeSHBiomechanicalPhenomena 0.00 
MeSHSyndromeA 0.00 
arthrosis/nMeSHArthroscopy 0.00 
(828%) 0.00 
(643%) 0.00 
diagnosed/nMeSHAcromioclavicularJoint 0.00 
MeSHSupinationPartial-thickness 0.00 
essential/nMeSHAdult 0.00 
shoulder/nMeSHActivitiesofDailyLiving 0.00 
MeSHTriamcinoloneAcetonidePainful 0.00 
1436) 0.00 
standard)/nMeSHAdult 0.00 
MeSHTendonInjuriesBiceps 0.00 
lesions/nMeSHAcromioclavicularJoint 0.00 
MeSHWeight-BearingIdentifying 0.00 
studies/nMeSHDecisionMaking 0.00 
MeSHTendonInjuriesDiagnosing 0.00 
studies)/nMeSHHumans 0.00 
proposed/nMeSHHumans 0.00 
15-67) 0.00 
02-08) 0.00 
00-25) 0.00 
04-09) 0.00 
signs/nMeSHAdult 0.00 
=358) 0.00 
=270) 0.00 
suggests/nMeSHAdult 0.00 
MeSHTreatmentOutcomeInterpreting 0.00 
MeSHSportsUltrasonographic 0.00 
MeSHSupinePositionThe 0.00 
MeSHShoulderJointContribution 0.00 
needed/nMeSHDatabases 0.00 
MeSHTendonsShoulder 0.00 
MeSHShoulderPainReliability 0.00 
function/nMeSHAdult 0.00 
rupture/nMeSHAdolescent 0.00 
MeSHTendonInjuriesAnterior 0.00 
MeSHTendonInjuriesIntra- 0.00 
091-100) 0.00 
discriminators/nMeSHAcromioclavicularJoint 0.00 
MeSHTendonsArthroscopic 0.00 
symptoms/nMeSHAcromioclavicularJoint 0.00 
MeSHShoulderJointUltrasonographic 0.00 
effusion/nMeSHAdult 0.00 
MeSHUltrasonographyAnterior 0.00 
MeSHTreatmentOutcomePhysical 0.00 
shoulder/nMeSHHumans 0.00 
lesion/nMeSHAdolescent 0.00 
variance/nMeSHArthroscopy 0.00 
MeSHShoulderJointAn 0.00 
MeSHTendonInjuriesRe: 0.00 
pathology/nMeSHAdolescent 0.00 
MeSHSodiumChlorideThe 0.00 
755% 0.00 
athletics/nMeSHAdult 0.00 
MeSHShoulderPainPartial-thickness 0.00 
(921%) 0.00 
(887%) 0.00 
(820%) 0.00 
(861%) 0.00 
(805%) 0.00 
MeSHShoulderImpingementSyndromeIntraarticular 0.00 
lesion/nMeSHAthleticInjuries 0.00 
MeSHShoulderJointShoulder 0.00 
management/nMeSHAlgorithms 0.00 
MeSHWoundsandInjuriesReturning 0.00 
(672%) 0.00 
1303)) 0.00 
405(247 0.00 
1607)) 0.00 
(1004 0.00 
739)) 0.00 
MeSHWoundsandInjuriesPartial-thickness 0.00 
approaches/nMeSHAgeFactors 0.00 
MeSHWoundsandInjuriesSLAP 0.00 
MeSHTendonsInternal 0.00 
15-Tesla 0.00 
caution/nMeSHAdult 0.00 
weakness/nMeSHAdult 0.00 
standard/nMeSHActivitiesofDailyLiving 0.00 
MeSHTendonInjuriesDoes 0.00 
36-19) 0.00 
73-1150 0.00 
86-800) 0.00 
16-320) 0.00 
81-760) 0.00 
tests/nMeSHCartilage 0.00 
MeSHShoulderJointSLAP 0.00 
patients/nMeSHAccidentalFalls 0.00 
MeSHMechanicalInterobserver 0.00 
>060 0.00 
(kappa=018-021) 0.00 
pain/nMeSHAlgorithms 0.00 
MeSHSportsCurrent 0.00 
MeSHShoulderImpingementSyndromeShoulder 0.00 
instability/nMeSHExerciseTherapy 0.00 
MeSHShoulderDislocationDiagnostic 0.00 
36-521); 0.00 
00-03) 0.00 
13-161) 0.00 
01-05) 0.00 
needed/nMeSHHumans 0.00 
MeSHShoulderJointPosterosuperior 0.00 
athletes/nMeSHAdolescent 0.00 
MeSHShoulderJointPoint-of-care 0.00 
US$998 0.00 
practices/nMeSHAdult 0.00 
949%) 0.00 
(589% 0.00 
999%) 0.00 
MeSHSputumFeasibility 0.00 
(903%) 0.00 
(671%) 0.00 
(TA200740200009) 0.00 
Development/nMeSHAdolescent 0.00 
MeSHYoungAdultGeneXpert--a 0.00 
MeSHPulmonaryPre-screening 0.00 
MeSHTuberculosisEffectiveness 0.00 
269%) 0.00 
(765%) 0.00 
diagnosis/nMeSHHumans 0.00 
threshold/nMeSHColonyCount 0.00 
MeSHPolymeraseChainReactionIs 0.00 
conditions/nMeSHCost-BenefitAnalysis 0.00 
MeSHPulmonary[Treatment 0.00 
forward/nMeSHAntibiotics 0.00 
?/nMeSH?Time 0.00 
mortality/nMeSHAdult 0.00 
Summary/nMeSHAdult 0.00 
625%) 0.00 
settings/nMeSHAntibiotics 0.00 
MeSHMultidrug-ResistantIncreased 0.00 
590%-100%) 0.00 
430%-854%) 0.00 
(547% 0.00 
427%-662%]) 0.00 
infrastructure/nMeSHAdolescent 0.00 
(753%) 0.00 
simplicity/nMeSHBacterialProteins 0.00 
MeSHTuberculosisXpert 0.00 
endemic/nMeSHAdolescent 0.00 
MeSHYoungAdultPerformance 0.00 
variable/nMeSHBacteriologicalTechniques 0.00 
reads/nMeSHBacteriologicalTechniques 0.00 
</=202; 0.00 
323% 0.00 
971%) 0.00 
>318; 0.00 
800%) 0.00 
>318 0.00 
318; 0.00 
strategies/nMeSHAutomation 0.00 
MeSHPulmonaryDo 0.00 
settings/nMeSHCostsandCostAnalysis 0.00 
p<0001] 0.00 
sensitivity/nMeSHAIDS-RelatedOpportunisticInfections 0.00 
MeSHUrinalysisImpact 0.00 
p=006) 0.00 
p=078) 0.00 
p=080) 0.00 
p=077) 0.00 
phases/nMeSHAdult 0.00 
MeSHUgandaAn 0.00 
cases/nMeSHAntitubercularAgents 0.00 
MeSHMultidrug-ResistantSuitability 0.00 
-048 0.00 
load/nMeSHAdolescent 0.00 
MeSHYoungAdultXpert((R)) 0.00 
assay/nMeSHAnti-BacterialAgents 0.00 
MeSHMultidrug-ResistantScreening 0.00 
992%) 0.00 
434% 0.00 
623% 0.00 
941%; 0.00 
sub-optimal/nMeSHAdult 0.00 
MeSHMultidrug-ResistantRapid 0.00 
TB/nMeSHFemale 0.00 
(994 0.00 
(986 0.00 
988); 0.00 
(997 0.00 
$165690 0.00 
$115360 0.00 
MeSHMultidrug-ResistantComparison 0.00 
(992%) 0.00 
Diagnostics)/nMeSHAdolescent 0.00 
culture/nMeSHAntitubercularAgents 0.00 
MeSHPleuralRapid 0.00 
(219%) 0.00 
(151%) 0.00 
966%) 0.00 
701% 0.00 
(176%) 0.00 
(367%) 0.00 
(981-100) 0.00 
(968-996) 0.00 
feasible/nMeSHBacteriologicalTechniques 0.00 
MeSHPulmonaryCorrelation 0.00 
(TSPOTTB 0.00 
(TSPOTTB; 0.00 
TSPOTTB 0.00 
p<001] 0.00 
prognostication/nMeSHAdolescent 0.00 
cultureand 0.00 
924%-968%)and 0.00 
803%-904%) 0.00 
646%-828%) 0.00 
microscopyA 0.00 
(162%) 0.00 
tuberculosisThe 0.00 
537%-950%) 0.00 
CI904%-996%) 0.00 
[corrected]/nMeSHAdult 0.00 
MeSHZambiaThe 0.00 
treatment/nMeSHBacteriologicalTechniques 0.00 
MeSHTuberculosisCharacteristics 0.00 
MeSHPulmonaryRapid 0.00 
331% 0.00 
391-862) 0.00 
646-985) 0.00 
952-996) 0.00 
963-999) 0.00 
areas/nMeSHChile 0.00 
MeSHPulmonary[Evaluation 0.00 
0943; 0.00 
hours/nMeSHAntibiotics 0.00 
MeSHTuberculosisDetecting 0.00 
thereof/nMeSHCommunicableDiseaseControl 0.00 
MeSHMultidrug-ResistantDelay 0.00 
TB/nMeSHAntitubercularAgents 0.00 
MeSHMultidrug-ResistantEvaluation 0.00 
(P=009) 0.00 
-077) 0.00 
=-071) 0.00 
-056) 0.00 
tuberculosis/nMeSHAlgorithms 0.00 
(1476 0.00 
(869% 0.00 
suboptimal/nMeSHAdolescent 0.00 
MeSHMultidrug-ResistantXpert(R) 0.00 
settings/nMeSHClinicalTrialsasTopic 0.00 
MeSHTuberculosisNeed 0.00 
MeSHWorldHealthOrganizationThe 0.00 
pHis526Tyr 0.00 
sensitivity/nMeSHAntitubercularAgents 0.00 
(984%) 0.00 
h/nMeSHAdolescent 0.00 
occur/nMeSHAntibiotics 0.00 
MeSHSputumRapid 0.00 
respectively/nMeSHAutomation 0.00 
MeSHTuberculosisHigh 0.00 
population/nMeSHAIDS-RelatedOpportunisticInfections 0.00 
MeSHUrinalysisSyphilis 0.00 
MeSHTreponemalInfectionsComparison 0.00 
specimens/nMeSHAntitubercularAgents 0.00 
(246%) 0.00 
936-100%) 0.00 
902-985) 0.00 
958-100%) 0.00 
876-100) 0.00 
924-100%) 0.00 
time/nMeSHAbscess 0.00 
MeSHRespiratoryTractInfectionsCepheid 0.00 
samples/nMeSHAntitubercularAgents 0.00 
-982% 0.00 
programs/nMeSHCost-BenefitAnalysis 0.00 
MeSHWorldHealthOrganizationXpert(R) 0.00 
MeSHMultidrug-ResistantXpert 0.00 
MeSHPulmonaryContainment 0.00 
131-day 0.00 
user/nMeSHAerosols 0.00 
MeSHPulmonaryImplementation 0.00 
support/nMeSHHIVInfections 0.00 
tuberculosis/nMeSHBacteriologicalTechniques 0.00 
MeSHUnitedStatesShould 0.00 
tuberculosis/nMeSHAntitubercularAgents 0.00 
MeSHMultidrug-ResistantCan 0.00 
samples/nMeSHBacteriologicalTechniques 0.00 
MeSHTuberculosisTuberculosis 0.00 
TB/nMeSHAntibodies 0.00 
MeSHPulmonaryAntigen 0.00 
US$350 0.00 
282% 0.00 
counts/nMeSHAntigens 0.00 
[382; 0.00 
650] 0.00 
[366; 0.00 
634] 0.00 
(P=0046) 0.00 
[880; 0.00 
[205; 0.00 
499] 0.00 
[833; 0.00 
[196; 0.00 
495] 0.00 
algorithms/nMeSHAdolescent 0.00 
MeSHTuberculosisAn 0.00 
?/nMeSH?The 0.00 
children/nMeSHChild 0.00 
147-947) 0.00 
4781-1000) 0.00 
context/nMeSHAdolescent 0.00 
(344%) 0.00 
884-996) 0.00 
919-994) 0.00 
855-988) 0.00 
936-998) 0.00 
[978% 0.00 
00002] 0.00 
610-1000) 0.00 
764-969) 0.00 
354-879) 0.00 
microscopy/nMeSHAntitubercularAgents 0.00 
0380) 0.00 
MeSHProspectiveStudiesA 0.00 
duct/nMeSHAdolescent 0.00 
MeSHSensitivityandSpecificityPrognostic 0.00 
MeSHStatisticsasTopicCarcinoembryonic 0.00 
value/nMeSHAntineoplasticAgents 0.00 
MeSHRectalNeoplasmsPostherapeutic 0.00 
CRC/nMeSHAged 0.00 
(142%) 0.00 
MeSHTimeFactorsCost 0.00 
(p=025) 0.00 
22615 0.00 
MeSHUltrasonographyCEA 0.00 
scheme/nMeSHCarcinoembryonicAntigen 0.00 
benefit/nMeSHCarcinoembryonicAntigen 0.00 
MeSHSensitivityandSpecificityLocal 0.00 
remained/nMeSHAdenocarcinoma 0.00 
MeSHRisk[Indications 0.00 
MeSHRectalNeoplasms[Carcinoembryonic 0.00 
MeSHSurvivalAnalysisSerum 0.00 
elevation/nMeSHCarcinoembryonicAntigen 0.00 
MeSHX-RayComputedClinical 0.00 
(0978) 0.00 
(0740 0.00 
0628-0852) 0.00 
(0833) 0.00 
(0900) 0.00 
0376-0644) 0.00 
(0904 0.00 
0786-1000) 0.00 
(0869 0.00 
0744-0994) 0.00 
CA19-9/nMeSHAdenocarcinoma 0.00 
MeSHSurvivalRateShould 0.00 
developed/nMeSHAdult 0.00 
(p=034) 0.00 
MeSHTimeFactors[Clinical 0.00 
MeSHRectalNeoplasmsResults 0.00 
<00001) 0.00 
MeSHTreatmentOutcomeComparison 0.00 
operation(ABSTRACT 0.00 
MeSHRadioimmunoassay[Increased 0.00 
cause/nMeSHAdenocarcinoma 0.00 
MeSHProspectiveStudiesThe 0.00 
MeSHTissuePolypeptideAntigenVariation 0.00 
MeSHSigmoidNeoplasmsUtility 0.00 
criteria/nMeSHAdenocarcinoma 0.00 
MeSHTimeFactorsCEA 0.00 
MeSHRectalNeoplasms[Prospective 0.00 
cases/nMeSHCarcinoembryonicAntigen 0.00 
carcinomas/nMeSHBoneNeoplasms 0.00 
MeSHTimeFactorsPersistent 0.00 
(593%) 0.00 
(406%) 0.00 
curable/nMeSHAlanineTransaminase 0.00 
MeSHgamma-GlutamyltransferaseAmount 0.00 
7752 0.00 
9942 0.00 
331-47290 0.00 
-031p 0.00 
MeSHLeft[The 0.00 
MeSHRectalNeoplasms99Tcm-IMMU4 0.00 
MeSHSingle-PhotonPostoperative 0.00 
stage/nMeSHCarcinoembryonicAntigen 0.00 
MeSHTissuePlasminogenActivatorCost-effectiveness 0.00 
(2735%) 0.00 
139-211) 0.00 
MeSHTimeFactors[Carcinoembryonic 0.00 
resection/nMeSHCarcinoembryonicAntigen 0.00 
288%) 0.00 
MeSHX-RayComputedCarcinoembryonic 0.00 
MeSHRadioimmunoassayThe 0.00 
tumour/nMeSHAdenocarcinoma 0.00 
MeSHRectalNeoplasmsEvaluating 0.00 
MeSHUnitedStatesCEA 0.00 
staging/nMeSHAdult 0.00 
MeSHProspectiveStudiesRole 0.00 
accuracy/nMeSHAdenocarcinoma 0.00 
MeSHRetrospectiveStudiesFollow-up 0.00 
MeSHUltrasonographyMultivariate 0.00 
(428%) 0.00 
MeSHPrognosisDetection 0.00 
MeSHTimeFactorsDoes 0.00 
MeSHSensitivityandSpecificityCarcinoembryonic 0.00 
(295%) 0.00 
treatment/nMeSHAbdominalNeoplasms 0.00 
MeSHUltrasonographyCarcinoembryonic 0.00 
MeSHRectalNeoplasmsTumor 0.00 
colonoscopy/nMeSHBiomarkers 0.00 
MeSHRetrospectiveStudies[Significance 0.00 
markers/nMeSHAntigens 0.00 
MeSHTissuePolypeptideAntigen[The 0.00 
(489%) 0.00 
(465%) 0.00 
(776%); 0.00 
(224%) 0.00 
(792%) 0.00 
+099) 0.00 
+097) 0.00 
MeSHalpha-FetoproteinsSurveillance 0.00 
rate/nMeSHAged 0.00 
MeSHTimeFactors[CEA 0.00 
MeSHReoperationA 0.00 
MeSHReferenceValuesThe 0.00 
levels/nMeSHAdolescent 0.00 
MeSHRectalNeoplasmsPreoperative 0.00 
MeSHSurvivalAnalysisFDG-PET 0.00 
MeSHSensitivityandSpecificityAccuracy 0.00 
760%; 0.00 
0633 0.00 
0047] 0.00 
0654 0.00 
0982) 0.00 
level/nMeSHAdenocarcinoma 0.00 
MeSHYoungAdultCarcinoembryonic 0.00 
MeSHTimeFactorsSurveillance 0.00 
nonsecretors/nMeSHCarcinoembryonicAntigen 0.00 
MeSHSmokingAn 0.00 
MeSHSurvivalAnalysisPredictive 0.00 
progression/nMeSHCarcinoembryonicAntigen 0.00 
MeSHRectalNeoplasmsSixty 0.00 
MeSHRectalNeoplasmsStrict 0.00 
MeSHTissuePolypeptideAntigenPreoperative 0.00 
procedure/nMeSHCarcinoembryonicAntigen 0.00 
MeSHTimeFactors[Evaluation 0.00 
6363% 0.00 
6212% 0.00 
1121% 0.00 
4074% 0.00 
4444% 0.00 
592% 0.00 
8879% 0.00 
MeSHRectalNeoplasms[Value 0.00 
cancer/nMeSHActuarialAnalysis 0.00 
MeSHTreatmentOutcomeSecond-look 0.00 
survival/nMeSHActuarialAnalysis 0.00 
MeSHSurvivalAnalysisLong-term 0.00 
survivors/nMeSHAged 0.00 
MeSHTimeFactors[Diagnostic 0.00 
cancers/nMeSHAged 0.00 
MeSHbeta2-MicroglobulinValue 0.00 
MeSHSurvivalRateFirst 0.00 
performed/nMeSHBiomarkers 0.00 
MeSHX-RayComputedDetection 0.00 
484% 0.00 
633% 0.00 
392% 0.00 
(p=0008) 0.00 
(p=0004) 0.00 
MeSHTreatmentOutcome[Value 0.00 
years/nMeSHAdenocarcinoma 0.00 
MeSHRetrospectiveStudiesSerial 0.00 
005%) 0.00 
002%) 0.00 
MeSHRectalNeoplasmsLead 0.00 
(728%)before 0.00 
(272%) 0.00 
201%) 0.00 
needed/nMeSHCarcinoembryonicAntigen 0.00 
MeSHTimeFactorsRaised 0.00 
MeSHPostoperativePeriodCEA 0.00 
(7/9)/nMeSHAlkalinePhosphatase 0.00 
MeSHPrognosisDiagnostic 0.00 
(078) 0.00 
(091) 0.00 
limited/nMeSHAdenocarcinoma 0.00 
MeSHSensitivityandSpecificityTool 0.00 
(http://apsunmcedu/AP/mainhtml) 0.00 
bioinformatics/nMeSHAminoAcidSequence 0.00 
MeSHStructure-ActivityRelationship[Carcino-embryonic 0.00 
(67%)/nMeSHCarcinoembryonicAntigen 0.00 
MeSHPrognosis[The 0.00 
0812; 0.00 
0001)/nMeSHCarcinoembryonicAntigen 0.00 
MeSHStomachNeoplasmsEvaluation 0.00 
MeSHSurvivalRateSecond 0.00 
useful/nMeSHCarcinoembryonicAntigen 0.00 
MeSHSurvivalRate[Effect 0.00 
extirpation/nMeSHCarcinoembryonicAntigen 0.00 
MeSHReoperationRole 0.00 
370% 0.00 
544% 0.00 
366% 0.00 
(326% 0.00 
metastasis/nMeSHAdult 0.00 
(741%) 0.00 
28)/nMeSHAdult 0.00 
MeSHRetrospectiveStudiesA 0.00 
MeSHRetrospectiveStudiesCarcinoembryonic 0.00 
levels/nMeSHCarcinoembryonicAntigen 0.00 
MeSHTimeFactors[Colorectal 0.00 
MeSHReoperationCarcinoembryonic 0.00 
MeSHRectalNeoplasms[A 0.00 
(421%) 0.00 
MeSHUltrasonographyDetection 0.00 
value/nMeSHAged 0.00 
MeSHRectalNeoplasmsCharacteristics 0.00 
MeSHTimeFactors[Serum 0.00 
resection/nMeSHBiomarkers 0.00 
scan/nMeSHAdult 0.00 
MeSHX-RayComputedUnnecessary 0.00 
MeSHUnnecessaryProceduresCarcinoembryonic 0.00 
MeSHRectalNeoplasmsUsefulness 0.00 
carcinoma/nMeSHAdrenalGlandNeoplasms 0.00 
judgment/nMeSHAdenocarcinoma 0.00 
MeSHLocal[The 0.00 
plasma/nMeSHCarcinoembryonicAntigen 0.00 
confirmed/nMeSHCarcinoembryonicAntigen 0.00 
MeSHPrognosisPredictive 0.00 
(542%) 0.00 
(591%) 0.00 
00091) 0.00 
MeSHRetrospectiveStudiesPredictive 0.00 
MeSHTissuePlasminogenActivatorComparison 0.00 
0931) 0.00 
MeSHSensitivityandSpecificityFluorodeoxyglucose 0.00 
MeSHEmission-ComputedFollow-up 0.00 
polyps/nMeSHAdenocarcinoma 0.00 
MeSHX-RayComputedSignificance 0.00 
(255%) 0.00 
00224) 0.00 
738% 0.00 
00261) 0.00 
CEA/nMeSHAdolescent 0.00 
MeSHRetrospectiveStudies[Interest 0.00 
evidence/nMeSHCarcinoembryonicAntigen 0.00 
factor/nMeSHAdult 0.00 
MeSHSurvivalAnalysisClinical 0.00 
1065-6042 0.00 
0035] 0.00 
1405-6795 0.00 
MeSHProportionalHazardsModelsCarcinoembryonic 0.00 
(232% 0.00 
MeSHPrognosisSystemic 0.00 
infants/nMeSHAmphotericinB 0.00 
MeSHRetrospectiveStudiesUsefulness 0.00 
values/nMeSHBiomarkers 0.00 
MeSHPreoperativeCareA 0.00 
limits/nMeSHAdult 0.00 
(677%) 0.00 
(2075% 0.00 
1887% 0.00 
surveillance/nMeSHCarcinoembryonicAntigen 0.00 
MeSHRetrospectiveStudiesModelling 0.00 
MeSHLocal[Value 0.00 
MeSHTimeFactorsIndividual 0.00 
surveillance/nMeSHAdult 0.00 
MeSHSensitivityandSpecificityEvaluating 0.00 
suggested/nMeSHCarcinoembryonicAntigen 0.00 
MeSHRiskSerial 0.00 
unequivocal/nMeSHAdult 0.00 
MeSHX-RayComputedMonitoring 0.00 
<euro>2196 0.00 
<euro>6721 0.00 
MeSHX-RayComputedResults 0.00 
months/nMeSHAdenocarcinoma 0.00 
MeSHReoperationAssessment 0.00 
MeSHTimeFactors[Determination 0.00 
antigen--196 0.00 
ineffective/nMeSHAdenocarcinoma 0.00 
MeSHTimeFactorsEffect 0.00 
(166%; 0.00 
145%-187%) 0.00 
46%-72%) 0.00 
123-733) 0.00 
22%-95%; 0.00 
363; 0.00 
151-869) 0.00 
110-871) 0.00 
(159% 0.00 
isrctnorg 0.00 
41458548/nMeSHAged 0.00 
MeSHX-RayComputed[CEA 0.00 
MeSHRectalNeoplasmsDifferent 0.00 
cancers/nMeSHAdult 0.00 
MeSHStomachNeoplasmsPre- 0.00 
MeSHSurvivalRateRole 0.00 
925% 0.00 
548% 0.00 
advocated/nMeSHAged 0.00 
MeSHX-RayComputed[Carcinoembryonic 0.00 
metastases/nMeSHCarcinoembryonicAntigen 0.00 
MeSHStomachNeoplasmsSerum 0.00 
MeSHRectalNeoplasmsUse 0.00 
MeSHRecurrenceCEA 0.00 
MeSHSensitivityandSpecificityResults 0.00 
MeSHSigmoidNeoplasmsCarcinoembryonic 0.00 
armamentarium/nMeSHAdult 0.00 
MeSHUrinaryBladderNeoplasmsReoperation 0.00 
MeSHReoperationSerum 0.00 
(P=0003 0.00 
P<0001 0.00 
changed/nMeSHAdenocarcinoma 0.00 
MeSHYoungAdultSystematic 0.00 
228117 0.00 
280994 0.00 
20530 0.00 
25289 0.00 
debated/nMeSHAdenocarcinoma 0.00 
MeSHTreatmentOutcomeCEA 0.00 
05ng/ml 0.00 
154%) 0.00 
510%): 0.00 
337%): 0.00 
(155%) 0.00 
179+/-38 0.00 
(121% 0.00 
MeSHReoperationPrognostic 0.00 
(426%) 0.00 
MeSHSurvivalRateLimitations 0.00 
disease/nMeSHAntibodies 0.00 
MeSHStomachNeoplasmsBiologic 0.00 
techniques/nMeSHBiocompatibleMaterials 0.00 
MeSHTreatmentOutcomeRe-operation 0.00 
time821% 0.00 
581% 0.00 
(527%) 0.00 
MeSHSurvivalRateSerum 0.00 
relapse/nMeSHAdult 0.00 
MeSHMiddleAgedIs 0.00 
(268%) 0.00 
(444%) 0.00 
intent/nMeSHAdenocarcinoma 0.00 
MeSHTreatmentOutcome[Colorectal 0.00 
MeSHReoperationUsefulness 0.00 
MeSHTissuePolypeptideAntigenRecurrence 0.00 
sign/nMeSHAdolescent 0.00 
redundant/nMeSHAntigens 0.00 
(511%) 0.00 
MeSHRetrospectiveStudies[Value 0.00 
benefit/nMeSHBreastNeoplasms 0.00 
MeSHTimeFactorsRole 0.00 
carcinoma/nMeSHCarcinoembryonicAntigen 0.00 
MeSHTransaminasesNegative 0.00 
recurrence/nMeSHAged 0.00 
MeSHRetrospectiveStudiesCan 0.00 
undertaken/nMeSHAdenocarcinoma 0.00 
MeSHSensitivityandSpecificityUse 0.00 
defined/nMeSHAdult 0.00 
least/nMeSHAdult 0.00 
MeSHUltrasonographyFollow-up 0.00 
study/nMeSHAged 0.00 
MeSHSurvivalRateClinical 0.00 
218% 0.00 
questioned/nMeSHAdenocarcinoma 0.00 
MeSHRectalNeoplasmsFive-year 0.00 
survival/nMeSHAbdominalNeoplasms 0.00 
MeSHX-RayComputedA 0.00 
neoplasms/nMeSHAdult 0.00 
MeSHRetrospectiveStudiesFDG-PET 0.00 
treatment/nMeSHAbdomen 0.00 
MeSHX-RayComputed[Clinical 0.00 
379% 0.00 
780% 0.00 
MeSHPrognosisFollow-up 0.00 
MeSHTissuePolypeptideAntigenThe 0.00 
proven/nMeSHAftercare 0.00 
MeSHTimeFactorsCorrelation 0.00 
control/nMeSHBreastNeoplasms 0.00 
MeSHRectalNeoplasms[Usefulness 0.00 
(894%) 0.00 
(8085%) 0.00 
(9574) 0.00 
MeSHSensitivityandSpecificityPostoperative 0.00 
(359% 0.00 
(291% 0.00 
374%) 0.00 
(236% 0.00 
(127% 0.00 
(1922 0.00 
(663 0.00 
(4427 0.00 
recurrence/nMeSHAdenocarcinoma 0.00 
MeSHPredictiveValueofTestsA 0.00 
MeSHRetrospectiveStudies[Clinical 0.00 
MeSHStomachNeoplasms[Prognostic 0.00 
005/nMeSHCarcinoembryonicAntigen 0.00 
MeSHRectalNeoplasmsImaging 0.00 
817; 0.00 
113-5929) 0.00 
survival/nMeSHAged 0.00 
MeSHX-RayComputedRadioimmunoguided 0.00 
tumors/nMeSHAdolescent 0.00 
MeSHX-RayComputedPostsurgical 0.00 
$418615 0.00 
$170880 0.00 
$5696 0.00 
$120934 0.00 
$10078 0.00 
$641344 0.00 
$45810 0.00 
benefit/nMeSHAntineoplasticAgents 0.00 
MeSHUnitedStates[Follow-up 0.00 
CRC/nMeSHAdenocarcinoma 0.00 
MeSHX-RayComputed[Follow 0.00 
biopsy/nMeSHCA-19-9Antigen 0.00 
MeSHUltrasonographyPostoperative 0.00 
patient(ABSTRACT 0.00 
advantage/nMeSHActuarialAnalysis 0.00 
MeSHTreatmentOutcomePlasma 0.00 
discussed/nMeSHCarcinoembryonicAntigen 0.00 
MeSHRectalNeoplasmsEighty-four 0.00 
growth/nMeSHActuarialAnalysis 0.00 
MeSHStomachNeoplasms[Importance 0.00 
292%; 0.00 
881%) 0.00 
MeSHNeoplasmMetastasisCEA 0.00 
MeSHTimeFactorsValue 0.00 
(195%) 0.00 
programme/nMeSHAdult 0.00 
MeSHSurvivalAnalysisIntensive 0.00 
344% 0.00 
survival/nMeSHAdult 0.00 
MeSHDopplerThe 0.00 
226; 0.00 
186; 0.00 
spine/nMeSHAdolescent 0.00 
MeSHSingle-PhotonThe 0.00 
concern/nMeSHAdolescent 0.00 
MeSHScoliosisUse 0.00 
lesions/nMeSHAged 0.00 
MeSHSpinalNeoplasmsSpinal 0.00 
MeSHX-RayComputedSelective 0.00 
(211%); 0.00 
(461%) 0.00 
analgesics/nMeSHAdolescent 0.00 
MeSHSacrumEvaluating 0.00 
LBP/nMeSHAdult 0.00 
MeSHSurveysandQuestionnairesMusculoskeletal 0.00 
symptoms/nMeSHAdult 0.00 
MeSHRetrospectiveStudiesThree-stage 0.00 
MeSHSensitivityandSpecificityPrenasal 0.00 
MeSHYoungAdultADAM 0.00 
(02678) 0.00 
(04318) 0.00 
second-trimester/nMeSHADAMProteins 0.00 
MeSHSecondMidtrimester 0.00 
85%/nMeSHAdolescent 0.00 
MeSHPrenatalAbsent 0.00 
10251) 0.00 
069%) 0.00 
MeSHPrenatalProspective 0.00 
NT/nMeSHAdolescent 0.00 
MeSHProspectiveStudiesDimeric 0.00 
56771 0.00 
56376 0.00 
step/nMeSHAdolescent 0.00 
MeSHRiskMeasurement 0.00 
MeSHRetrospectiveStudiesFirst-trimester 0.00 
MeSHPrenatalDiagnosisMeasurement 0.00 
(P=016) 0.00 
(P=02) 0.00 
4497 0.00 
099-10) 0.00 
096-10) 0.00 
0999-10) 0.00 
(002%) 0.00 
(P<001 0.00 
143-146) 0.00 
II/nMeSHAmniocentesis 0.00 
stress/nMeSHAdolescent 0.00 
MeSHUnitedKingdomProspective 0.00 
(959%) 0.00 
(770%) 0.00 
(783%) 0.00 
01-294) 0.00 
02-33) 0.00 
MeSHRiskAssessmentClinical 0.00 
101%) 0.00 
screens/nMeSHAdult 0.00 
21/nMeSHBiomarkers 0.00 
MeSHRetrospectiveStudiesADAM 0.00 
-01621 0.00 
cases/nMeSHADAMProteins 0.00 
MeSHPrenatalCareNuchal 0.00 
MeSHTurnerSyndromeThe 0.00 
(049-079) 0.00 
(071-197) 0.00 
(118-198) 0.00 
trimester/nMeSHAging 0.00 
MeSHRiskFactorsEvaluation 0.00 
MeSHWestIndiesMaternal 0.00 
MeSHalpha-FetoproteinsIncorporation 0.00 
MeSHPrenatalQF-PCR 0.00 
0069% 0.00 
anxiety/nMeSHAlgorithms 0.00 
MeSHRetrospectiveStudiesHyperglycosylated-hCG 0.00 
MeSHPrenatalDiagnosis[Three-dimensional 0.00 
wwwfirsttrimesternet 0.00 
MeSHSensitivityandSpecificityAlpha-fetoprotein 0.00 
MeSHPrenatalAre 0.00 
FTS/nMeSHAdult 0.00 
MeSHRetrospectiveStudiesAccuracy 0.00 
($C26833 0.00 
$C30963 0.00 
(7781%) 0.00 
(2105%) 0.00 
$C26833 0.00 
$C37260 0.00 
$C35215 0.00 
$C45314 0.00 
MeSHYoungAdultFirst-trimester 0.00 
MeSHPrenatalHuman 0.00 
149-3903) 0.00 
(053-788) 0.00 
midtrimester/nMeSHAdolescent 0.00 
MeSHRetrospectiveStudiesUltrasonography 0.00 
MeSHPrenatalStability 0.00 
09-239) 0.00 
29-1105) 0.00 
61-1458) 0.00 
26-1547) 0.00 
95-3828) 0.00 
delay/nMeSHAdult 0.00 
MeSHPrenatalInvasive 0.00 
MeSHTrophoblastsSialic 0.00 
-015) 0.00 
thickness/nMeSHChorionicGonadotropin 0.00 
325% 0.00 
170-938) 0.00 
125-982) 0.00 
(894-999) 0.00 
MeSHPrenatalDiagnosisAn 0.00 
MeSHalpha-Fetoproteins[Predictive 0.00 
test/nMeSHCross-SectionalStudies 0.00 
MeSHInferiorAdjustment 0.00 
MeSHPrenatalMedian 0.00 
61368 0.00 
programmes/nMeSHBiomarkers 0.00 
MeSHPrenatalPractical 0.00 
practice/nMeSHAdolescent 0.00 
MeSHPrenatalDiagnosisImproved 0.00 
(-222%) 0.00 
2008/nMeSHAdolescent 0.00 
21/nMeSHAbortion 0.00 
MeSHRiskFactorsUltrasound 0.00 
MeSHTrisomy[AFP 0.00 
(058 0.00 
(054 0.00 
(090 0.00 
PE/nMeSHArteries 0.00 
MeSHUterusIncreased 0.00 
MeSHPrenatalSchwangerschaftsprotein 0.00 
011-059] 0.00 
111-149) 0.00 
020-209) 0.00 
respectively/nMeSHDownSyndrome 0.00 
MeSHPrenatalFree 0.00 
MeSHSex-DeterminingRegionYProteinLens 0.00 
MeSHalpha-Fetoproteins[Non 0.00 
MeSHGeneticPrenatal 0.00 
(939% 0.00 
441%) 0.00 
approach/nMeSHAdolescent 0.00 
MeSHYoungAdultCombining 0.00 
practice/nMeSHBiomarkers 0.00 
authors/nMeSHBiomarkers 0.00 
rate/nMeSHChorionicGonadotropin 0.00 
MeSHalpha-FetoproteinsFirst- 0.00 
1:1500 0.00 
38033 0.00 
($719675 0.00 
$690427) 0.00 
screening/nMeSHClinicalTrialsasTopic 0.00 
MeSHPrenatalDiagnosis[Ultrasound 0.00 
069)/nMeSHAdult 0.00 
policy/nMeSHAdult 0.00 
752686 0.00 
(N=1217) 0.00 
624% 0.00 
360% 0.00 
614% 0.00 
262% 0.00 
MeSHRiskFactorsCA-125 0.00 
MeSHPrenatalDiagnosisEffect 0.00 
18/nMeSHAdult 0.00 
MeSHTrisomyMultiple 0.00 
MeSHalpha-FetoproteinsHumerus 0.00 
LMP/nMeSHAdolescent 0.00 
MeSHPrenatalExamination 0.00 
10668 0.00 
881%; 0.00 
798-964 0.00 
45-53) 0.00 
813%; 0.00 
678-948 0.00 
05-09) 0.00 
MeSHTrisomyDo 0.00 
=091 0.00 
=089 0.00 
58710 0.00 
MeSHYoungAdultDown 0.00 
exp(358 0.00 
062-480 0.00 
pregnancy/nMeSHAdolescent 0.00 
MeSHUltrasonographyFirst 0.00 
908-1946) 0.00 
MeSHPrenatal[Specificity 0.00 
23000 0.00 
70000 0.00 
1044% 0.00 
specificity/nMeSHAdult 0.00 
19614 0.00 
598% 0.00 
528% 0.00 
450% 0.00 
494163) 0.00 
T21/nMeSHAdult 0.00 
MeSHRetrospectiveStudiesInfluence 0.00 
(784%; 0.00 
773-795%) 0.00 
917%; 0.00 
901-932%) 0.00 
06-09; 0.00 
anomalies/nMeSHAdult 0.00 
MeSHPrenatalAge-specific 0.00 
MeSHRiskFactorsComparison 0.00 
708% 0.00 
(<10%)/nMeSHAdult 0.00 
MeSHalpha-Fetoproteins[Serum 0.00 
MeSHalpha-FetoproteinsAre 0.00 
8038); 0.00 
all/nMeSHAdolescent 0.00 
MeSHalpha-Fetoproteins[Noninvasive 0.00 
MeSHYoungAdultSix 0.00 
(043 0.00 
MeSHalpha-FetoproteinsEfficiency 0.00 
40568 0.00 
Germany/nMeSHChromosomeAberrations 0.00 
MeSHPrenatal[Screening 0.00 
MeSHSmokingProspective 0.00 
MeSHPrenatalClinical 0.00 
(354%) 0.00 
(369% 0.00 
(155% 0.00 
Korea/nMeSHAdult 0.00 
MeSHYoungAdultInsulin-dependent 0.00 
094-100] 0.00 
065-090) 0.00 
MeSHPrenatalDiagnosisNon-invasive 0.00 
MeSHSexDeterminationProcessesSonographical 0.00 
(9921%) 0.00 
(9973%) 0.00 
MeSHUltrasonographyGradual 0.00 
542/10000 0.00 
366/10000 0.00 
2066/10000 0.00 
2373 0.00 
3852 0.00 
MeSHRegistriesSecond 0.00 
56951 0.00 
patient/nMeSHAdolescent 0.00 
MeSHPrenatalPlacental 0.00 
(0373) 0.00 
(0265) 0.00 
publication]/nMeSHAdult 0.00 
MeSHPrenatalSpecificity 0.00 
009-329 0.00 
137-170 0.00 
fetuses/nMeSHAdolescent 0.00 
062-098) 0.00 
054-109) 0.00 
marker/nMeSHBiomarkers 0.00 
MeSHPrenatalDiagnosisGenetic 0.00 
warranted/nMeSHBiomarkers 0.00 
MeSHPrenatalCosts 0.00 
98000 0.00 
191000 0.00 
73000 0.00 
MeSHRiskAssessmentUsing 0.00 
technologies/nMeSHAustralia 0.00 
MeSHVictoriaRacial 0.00 
MeSHalpha-Fetoproteins[Rapid 0.00 
signs/nMeSHAneuploidy 0.00 
MeSHProspectiveStudiesMultiple 0.00 
MeSHalpha-Fetoproteins[Analysis 0.00 
MeSHPrenatalADAM12: 0.00 
(001-076) 0.00 
syndrome/nMeSHADAMProteins 0.00 
MeSHPrenatalDiagnosisPrediction 0.00 
36014 0.00 
rates/nMeSHAbortion 0.00 
MeSHTurnerSyndromeInhibin 0.00 
-01754 0.00 
(03712) 0.00 
(02145) 0.00 
trimester/nMeSHBiomarkers 0.00 
MeSHReferenceValuesFree 0.00 
MeSHPregnancyFirst 0.00 
studies/nMeSHChorionicGonadotropin 0.00 
MeSHPrenatalPerformance 0.00 
44537 0.00 
00035) 0.00 
triploidy/nMeSHAdult 0.00 
MeSHPrenatalDiagnosisContingent 0.00 
843% 0.00 
cost-effective/nMeSHAdult 0.00 
MeSHalpha-FetoproteinsIntegrated 0.00 
(0961 0.00 
(0697 0.00 
(0577 0.00 
(0426 0.00 
(0747 0.00 
PAPP-A/nMeSHADAMProteins 0.00 
12517 0.00 
adjustment/nMeSHBiomarkers 0.00 
MeSHSmokingCessationCombined 0.00 
MeSHUltrasonographyDefining 0.00 
75-95) 0.00 
specificity/nMeSHAneuploidy 0.00 
(0707 0.00 
(0483 0.00 
(0404 0.00 
(0531 0.00 
(0534 0.00 
(1658) 0.00 
6337% 0.00 
(385) 0.00 
7993% 0.00 
6887% 0.00 
(281) 0.00 
7989% 0.00 
(045) 0.00 
5974% 0.00 
7365% 0.00 
(016) 0.00 
5476% 0.00 
diagnoses/nMeSHChromosomeAberrations 0.00 
MeSHPrenatalDiagnosisElevated 0.00 
MeSHalpha-FetoproteinsSimultaneous 0.00 
samples/nMeSHChromosomes 0.00 
MeSHFirst[Trisomy 0.00 
MeSHPrenatalCan 0.00 
04593 0.00 
(00186 0.00 
02392 0.00 
(00027 0.00 
MeSHReferenceValuesSecond 0.00 
01040 0.00 
(00956) 0.00 
00109 0.00 
(01661) 0.00 
MeSHProgesterone[Prenatal 0.00 
MeSHPrenatalCareMaternal 0.00 
MeSHalpha-Fetoproteins[FISH 0.00 
(1630%) 0.00 
(125% 0.00 
(2615% 0.00 
(714% 0.00 
results/nMeSHAmniocentesis 0.00 
MeSHPrenatalReevaluating 0.00 
studied/nMeSHCase-ControlStudies 0.00 
22280) 0.00 
22280 0.00 
MeSHWesternAustraliaRapid 0.00 
karyotypingIn 0.00 
karyotyping/nMeSHAdult 0.00 
FPR/nMeSHAdult 0.00 
MeSHNonparametricEvaluation 0.00 
211-326 0.00 
MeSHSensitivityandSpecificityAbnormal 0.00 
MeSHPrenatalRepeat 0.00 
MeSHReferenceValues[Abnormal 0.00 
MeSHRiskAssessmentAdvanced 0.00 
performance/nMeSHAlgorithms 0.00 
MeSHSensitivityandSpecificitySURUSS 0.00 
17229) 0.00 
(26/1000) 0.00 
33-51%) 0.00 
MeSHRiskAssessmentMaternal 0.00 
MeSHRetrospectiveStudiesScreening 0.00 
MeSHalpha-Fetoproteins[Ultrasound 0.00 
pregnancy/nMeSHChromosomeAberrations 0.00 
MeSHPrenatal[First 0.00 
131% 0.00 
MeSHPrenatalPhenotypic 0.00 
MeSHPrenatalSerum 0.00 
(031 0.00 
022-065 0.00 
089-120) 0.00 
093-263 0.00 
079-103) 0.00 
547-876 0.00 
649-928 0.00 
gestation/nMeSHAdult 0.00 
22695 0.00 
1351) 0.00 
4391) 0.00 
MeSHYoungAdult[Combined 0.00 
MeSHTrisomySerum 0.00 
MeSHPrenatalAnalysis 0.00 
15228 0.00 
MeSHYoungAdultComparing 0.00 
15026 0.00 
112000 0.00 
31122003 0.00 
684/692 0.00 
421/654 0.00 
789/885 0.00 
centre/nMeSHBloodChemicalAnalysis 0.00 
(296%) 0.00 
(109%) 0.00 
practice/nMeSHChromosomeAberrations 0.00 
MeSHPrenatalLow 0.00 
046-084 0.00 
MeSHTrisomyAbnormal 0.00 
(333% 0.00 
277% 0.00 
positivity/nMeSHAdult 0.00 
MeSHProspectiveStudiesUse 0.00 
539% 0.00 
329% 0.00 
405% 0.00 
MeSHalpha-FetoproteinsHow 0.00 
10116 0.00 
-02-mm 0.00 
possible/nMeSHAdolescent 0.00 
13477 0.00 
issues/nMeSHAdult 0.00 
MeSHSexChromosomeAberrationsThe 0.00 
MeSHalpha-Fetoproteins[Evaluation 0.00 
markers/nMeSHAdult 0.00 
MeSHYoungAdultMaternal 0.00 
available/nMeSHAdolescent 0.00 
MeSHYoungAdultTemporal 0.00 
characteristics/nMeSHAdolescent 0.00 
MeSHRiskFactorsDetection 0.00 
informed/nMeSH?Likelihood 0.00 
14612 0.00 
MeSHHigh-RiskComparison 0.00 
216-457%) 0.00 
511-757%) 0.00 
349-606) 0.00 
537-780%) 0.00 
abandoned/nMeSHAdult 0.00 
MeSHS100ProteinsMaternal 0.00 
009-167 0.00 
006-145 0.00 
010-062 0.00 
009-248 0.00 
-019 0.00 
thickness/nMeSHCrown-RumpLength 0.00 
MeSHPrenatalAppropriate 0.00 
(r=0536) 0.00 
MeSHPrenatal[Evaluation 0.00 
demonstrated/nMeSHAdult 0.00 
MeSHPrenatal[Share 0.00 
MeSHPrenatalDiagnosisSecond-trimester 0.00 
(485%) 0.00 
625%; 0.00 
807%; 0.00 
syndrome/nMeSHChromosomeDisorders 0.00 
groups/nMeSHBiomarkers 0.00 
MeSHRh-HrBlood-GroupSystemSURUSS 0.00 
MeSHPrenatalFetuses 0.00 
scan/nMeSHCranialSutures 0.00 
MeSHPrenatalValidation 0.00 
populations/nMeSHAneuploidy 0.00 
MeSHProspectiveStudies[Advanced 0.00 
karyotype/nMeSHAdult 0.00 
MeSHTrisomyComparison 0.00 
MeSHTrisomyAdvanced 0.00 
87241 0.00 
43303 0.00 
(092%) 0.00 
considers/nMeSHAdult 0.00 
MeSHRiskAssessmentCombining 0.00 
MeSHalpha-Fetoproteins[Quality 0.00 
programme/nMeSHChromosomeAberrations 0.00 
MeSHTwinsMaternal 0.00 
MeSHalpha-FetoproteinsAbnormal 0.00 
(262%) 0.00 
MeSHRiskFactorsFetal 0.00 
MeSHPrenatalPregnancy 0.00 
outcomes/nMeSHCase-ControlStudies 0.00 
MeSHFirst[Prenatal 0.00 
MeSHReferenceValuesFlashFISH: 0.00 
"FlashFISH" 0.00 
laboratory/nMeSHAdult 0.00 
MeSHTimeFactorsFirst 0.00 
MeSHPrenatalDiagnosisEvaluation 0.00 
serum/nMeSHAdolescent 0.00 
MeSHalpha-FetoproteinsStepwise 0.00 
(768%) 0.00 
1:10301 0.00 
MeSHPrenatalImplications 0.00 
258% 0.00 
malformations/nMeSHCongenitalAbnormalities 0.00 
MeSHPrenatal[Efficiency 0.00 
MeSHTwinsFirst- 0.00 
MeSHSecondMaternal 0.00 
002-095) 0.00 
002-047) 0.00 
283-470) 0.00 
032-151) 0.00 
triploidy/nMeSHAdolescent 0.00 
MeSHYoungAdultSerum 0.00 
0976 0.00 
0975 0.00 
(177%) 0.00 
ethnicity/nMeSHAdult 0.00 
MeSHTrisomyIs 0.00 
063% 0.00 
ultrasounds/nMeSHAmniocentesis 0.00 
MeSHTwinsDoes 0.00 
necessary/nMeSHAdult 0.00 
MeSHPrenatalMid-gestation 0.00 
MeSHPrenatalRisk 0.00 
359% 0.00 
077% 0.00 
CPCs/nMeSHCentralNervousSystemCysts 0.00 
MeSHXYYKaryotypeImpact 0.00 
MeSHYoungAdultSecond-trimester 0.00 
MeSHalpha-FetoproteinsRole 0.00 
MeSHPrenatal[Birth 0.00 
3935209 0.00 
83970 0.00 
21338 0.00 
7398 0.00 
74%/nMeSHAbortion 0.00 
MeSHPrenatalComplete 0.00 
534795) 0.00 
(11p155) 0.00 
(17p131) 0.00 
MeSHPrenatalDiagnosisCombined 0.00 
MeSHPrenatalCost-effectiveness 0.00 
Can$26833 0.00 
(Can$47358) 0.00 
limitations/nMeSHCanada 0.00 
MeSHPrenatalDiagnosisTriple 0.00 
MeSHSecondFirst 0.00 
MeSHUltrasonographyOptimal 0.00 
(818% 0.00 
844%) 0.00 
(669%) 0.00 
MeSHalpha-FetoproteinsFrontomaxillary 0.00 
879% 0.00 
MeSHPrenatalRace-ethnicity-specific 0.00 
MeSHalpha-FetoproteinsUltrasonographic 0.00 
04337 0.00 
(<25th 0.00 
(9877%) 0.00 
(089%) 0.00 
(014%) 0.00 
(007% 0.00 
(150%) 0.00 
(-228%) 0.00 
(-220%) 0.00 
MeSHSoftwareFirst 0.00 
MeSHSensitivityandSpecificitySchwangerschafts 0.00 
(049) 0.00 
alone/nMeSHBiomarkers 0.00 
MeSHXChromosomeTricuspid 0.00 
MeSHProspectiveStudiesShould 0.00 
MeSHRisk[Measurement 0.00 
589%-904%) 0.00 
150%-211%) 0.00 
786%-992%) 0.00 
309%-384%) 0.00 
MeSHalpha-FetoproteinsDose 0.00 
0989 0.00 
0733; 0.00 
385%) 0.00 
risk/nMeSHAdolescent 0.00 
favourable/nMeSHAdult 0.00 
MeSHTrisomyThe 0.00 
cancer/nMeSHAlgorithms 0.00 
MeSHX-RayComputedDiagnostic-staging 0.00 
surgery/nMeSHAbdomen 0.00 
MeSHStomachNeoplasms[The 0.00 
cancer/nMeSHBiopsy 0.00 
MeSHPreoperativeCareLaparoscopy 0.00 
discussed/nMeSHAbdominalNeoplasms 0.00 
MeSHSensitivityandSpecificityComputed 0.00 
CT/nMeSHHumans 0.00 
neoplasms/nMeSHAdenocarcinoma 0.00 
MeSHX-RayComputedRefining 0.00 
D/nMeSHAdult 0.00 
MeSHPreoperativeCare[Prediction 0.00 
grading/nMeSHActuarialAnalysis 0.00 
MeSHNeoplasmStagingImproved 0.00 
(184%) 0.00 
MeSHStomachNeoplasmsLaparoscopy 0.00 
cancer/nMeSHCost-BenefitAnalysis 0.00 
MeSHInterventional[Current 0.00 
MeSHLiverNeoplasms[Is 0.00 
(925%) 0.00 
(780%) 0.00 
tumors/nMeSHAdenoma 0.00 
MeSHPeritonealNeoplasmsExperience 0.00 
cure/nMeSHAged 0.00 
MeSHX-RayComputedDiagnostic 0.00 
laparotomy/nMeSHAbdomen 0.00 
MeSHReproducibilityofResultsValue 0.00 
(343%) 0.00 
EL/nMeSHAbdominalNeoplasms 0.00 
MeSHNeoplasmStagingPreoperative 0.00 
techniques/nMeSHEndosonography 0.00 
MeSHSensitivityandSpecificity[Efficacy 0.00 
MeSHSensitivityandSpecificityMultimodality 0.00 
MeSHPrognosis[Laparoscopic 0.00 
emphasized/nMeSHHumans 0.00 
MeSHPeritonealNeoplasmsPretreatment 0.00 
MeSHPreoperativeCareImpact 0.00 
(440%) 0.00 
(364%) 0.00 
(382%) 0.00 
742%) 0.00 
P<001 0.00 
benefit/nMeSHAged 0.00 
MeSHSurvivalAnalysisLaparoscopy 0.00 
MeSHPancreaticNeoplasmsPreoperative 0.00 
MeSHUnnecessaryProceduresDoes 0.00 
utilization/nMeSHAdenocarcinoma 0.00 
MeSHPreoperativeCareLaparoscopic 0.00 
laparotomy/nMeSHCarcinoma 0.00 
MeSHProspectiveStudiesTNM 0.00 
algorithm/nMeSHAged 0.00 
024-053) 0.00 
selectively/nMeSHAdult 0.00 
MeSHRadiographyDiagnosing 0.00 
987%; 0.00 
(564 0.00 
MeSHUltrasonographyMedicine 0.00 
MeSHSplenicDiseasesLaparoscopic 0.00 
MeSHInterventional[Is 0.00 
tumor/nMeSHAdult 0.00 
MeSHUnnecessaryProceduresStaging 0.00 
MeSHProspectiveStudiesValue 0.00 
MeSHPancreaticNeoplasms[Value 0.00 
(5-75 0.00 
cancer/nMeSHCarcinoma 0.00 
MeSHColorThe 0.00 
malignancy/nMeSHHumans 0.00 
MeSHSpiralComputedThe 0.00 
P=001) 0.00 
P=0006) 0.00 
disease/nMeSHAdenocarcinoma 0.00 
MeSHReproducibilityofResultsWhat 0.00 
impact/nMeSHAdenocarcinoma 0.00 
MeSHRadiotherapy[Comparison 0.00 
MeSHPancreaticNeoplasmsProblems 0.00 
tumors/nMeSHAdult 0.00 
MeSHSensitivityandSpecificityPancreatic 0.00 
metastases/nMeSHAsciticFluid 0.00 
MeSHPeritonealNeoplasmsDiagnostic 0.00 
$91805 0.00 
$90888 0.00 
$93134 0.00 
MeSHRetrospectiveStudiesLaparoscopy 0.00 
contemplated/nMeSHAdult 0.00 
MeSHPancreaticNeoplasmsLaparoscopic 0.00 
carcinomatosis/nMeSHColorectalNeoplasms 0.00 
MeSHX-RayComputedValue 0.00 
31860 0.00 
31270 0.00 
19-9/nMeSHHumans 0.00 
MeSHUnitedStatesEvolving 0.00 
(276%) 0.00 
resectability/nMeSHAdenocarcinoma 0.00 
MeSHRetrospectiveStudiesUtility 0.00 
MeSHMiddleAgedPreoperative 0.00 
ampulla/nMeSHAngiography 0.00 
MeSHX-RayComputedSubaquatic 0.00 
070): 0.00 
investigation/nMeSHEndosonography 0.00 
MeSHSensitivityandSpecificityPatients 0.00 
(243%) 0.00 
143%) 0.00 
rate/nMeSHAdenocarcinoma 0.00 
performed/nMeSHHumans 0.00 
MeSHPostoperativeComplicationsThe 0.00 
MeSHX-RayComputedUltrasound-guided 0.00 
investigation/nMeSHBiopsy 0.00 
MeSHRandomizedControlledTrialsasTopicThe 0.00 
(30%)/nMeSHBileDuctNeoplasms 0.00 
MeSHUltrasonography[Preoperative 0.00 
stay/nMeSHAdenocarcinoma 0.00 
MeSHProspectiveStudiesCombined 0.00 
approach/nMeSHEndosonography 0.00 
MeSHX-RayComputedEpidemiology 0.00 
MeSHRiskFactors[Diagnostic-operative 0.00 
neoplasms/nMeSHAbdomen 0.00 
MeSHMiddleAgedManagement 0.00 
?/nMeSH?Staging 0.00 
92%MRI 0.00 
inspectionMRI 0.00 
given/nMeSHAdenocarcinoma 0.00 
MeSHSensitivityandSpecificityLaparoscopy 0.00 
technique/nMeSHAdenocarcinoma 0.00 
MeSHSensitivityandSpecificityCA 0.00 
183; 0.00 
103-324; 0.00 
267% 0.00 
laparoscopy/nMeSHAged 0.00 
MeSHRetrospectiveStudiesThe 0.00 
MeSHSurvivalCytology 0.00 
patients/nMeSHGastrointestinalNeoplasms 0.00 
MeSHSensitivityandSpecificity[Diagnosis 0.00 
MeSHPrognosis[OUR 0.00 
MeSHPeritoneumMinimally 0.00 
MeSHStomachNeoplasmsLesser 0.00 
9622 0.00 
patients/nMeSHAcuteDisease 0.00 
MeSHStomachNeoplasmsLimitation 0.00 
MeSHTreatmentOutcomeLaparoscopy 0.00 
patients/nMeSHEndoscopy 0.00 
survivals/nMeSHAdenocarcinoma 0.00 
MeSHVascularNeoplasmsThe 0.00 
important/nMeSHAged 0.00 
MeSHTreatmentOutcome[Evaluation 0.00 
MeSHUltrasonographyPeritoneoscopy 0.00 
complications/nMeSHAcuteDisease 0.00 
MeSHPancreatitis[Place 0.00 
MeSHX-RayComputed[Contribution 0.00 
MeSHUltrasonographyLaparoscopic 0.00 
MeSHSplenomegalyStaging 0.00 
morbidity/nMeSHAdult 0.00 
dissemination/nMeSHAdult 0.00 
MeSHUltrasonography[Laparoscopy 0.00 
MeSHLaparoscopyPreoperative 0.00 
134-544; 0.00 
laparoscopy/nMeSHAdenocarcinoma 0.00 
patients/nMeSHBiliaryTractNeoplasms 0.00 
MeSHStomachNeoplasms[Laparoscopic 0.00 
357% 0.00 
laparotomy/nMeSHAged 0.00 
MeSHInterventionalRoutine 0.00 
malignancy/nMeSHAdult 0.00 
MeSHInterventional[Laparoscopy 0.00 
MeSHMiddleAged[Laparoscopy 0.00 
MeSHPancreaticDiseasesCurrent 0.00 
adenocarcinoma/nMeSHCarcinoma 0.00 
696% 0.00 
involvement/nMeSHAged 0.00 
MeSHUltrasonographyCombined 0.00 
resection/nMeSH?Diagnostic 0.00 
307%) 0.00 
procedure/nMeSHEndosonography 0.00 
MeSHSpiralComputed[Adenocarcinomas 0.00 
MeSHPancreaticNeoplasmsThe 0.00 
0731-0881; 0.00 
0168-0443) 0.00 
poor/nMeSHAdolescent 0.00 
MeSHUltrasonography[Status 0.00 
MeSHUltrasonography[Rotator 0.00 
00148) 0.00 
06238) 0.00 
01611) 0.00 
MeSHShoulderImpingementSyndrome[The 0.00 
MeSHTendinopathyRotator 0.00 
MeSHWoundsandInjuries[Shoulder 0.00 
MeSHShoulderJointImaging 0.00 
improve/nMeSHAdult 0.00 
interpretation/nMeSHAdult 0.00 
MeSHUltrasonographyFull-thickness 0.00 
finding/nMeSHArthroscopy 0.00 
MeSHTendonInjuriesIs 0.00 
rheumatologists/nMeSHAdult 0.00 
injuries/nMeSHAdult 0.00 
classification/nMeSHAdult 0.00 
MeSHShoulderMR 0.00 
retracted/nMeSHAdult 0.00 
MeSHTendonInjuries[MRI 0.00 
MeSHTendonsRotator 0.00 
margins/nMeSHAdolescent 0.00 
MeSHTendonInjuriesDistinction 0.00 
951-993; 0.00 
857-971; 0.00 
938-981) 0.00 
MeSHUltrasonography[Echography 0.00 
improvement/nMeSHAdult 0.00 
MeSHUltrasonographyOne-shot 0.00 
233+/-062 0.00 
247+/-052 0.00 
267+/-049 0.00 
(p=00281) 0.00 
(p=00277) 0.00 
separately/nMeSHAdult 0.00 
MeSHX-RayComputedHorizontal 0.00 
06-45 0.00 
component/nMeSHAdult 0.00 
MeSHShoulderJoint[Role 0.00 
trauma/nMeSHArthroscopy 0.00 
systems/nMeSHAdolescent 0.00 
arthrography/nMeSHAdult 0.00 
labrum/nMeSHAdolescent 0.00 
MeSHUltrasonographyAcute 0.00 
MeSHUltrasonographyIs 0.00 
MeSHTendonInjuriesSubscapularis 0.00 
MeSHTendonInjuriesAccuracy 0.00 
approach/nMeSHArthroscopy 0.00 
available/nMeSHArthrography 0.00 
described/nMeSHAcromion 0.00 
tendon/nMeSHAdolescent 0.00 
MeSHTendonsMR 0.00 
MeSHShoulderJointRotator 0.00 
2500/20 0.00 
(2000/80) 0.00 
MeSHTendonInjuries[Echography 0.00 
integrity/nMeSHAdult 0.00 
high-field-strengths/nMeSHAdolescent 0.00 
MeSHWoundsandInjuriesUltrasonography 0.00 
tears/nMeSHHumans 0.00 
instability/nMeSHAcromioclavicularJoint 0.00 
MeSHWoundsandInjuries[Contribution 0.00 
cases)(ABSTRACT 0.00 
rheumatologist/nMeSHAdult 0.00 
MeSHUltrasonographyUltrasonographic 0.00 
MeSHUltrasonography[Shoulder 0.00 
SLAP-Lasionen/nMeSHAdolescent 0.00 
MeSHShoulderJointMR 0.00 
200/2575; 0.00 
(3500-5000/2290; 0.00 
ratio/nMeSHAdolescent 0.00 
MeSHRotatorCuffInjuriesFat-suppression 0.00 
MeSHShoulderJoint[Ultrasonography 0.00 
manner/nMeSHHumans 0.00 
performed/nMeSHDiagnosis 0.00 
MeSHUltrasonographyUse 0.00 
765%) 0.00 
patients)/nMeSHAdult 0.00 
MeSHRotatorCuffInjuriesMagnetic 0.00 
MeSHShoulder[Rotator 0.00 
7619% 0.00 
1428% 0.00 
made/nMeSHAged 0.00 
operator-dependent/nMeSHAdolescent 0.00 
MeSHWoundsandInjuriesComparison 0.00 
artifacts/nMeSHAdult 0.00 
MeSHShoulderJointMagnetic 0.00 
MeSHShoulderImpingementSyndromeMR 0.00 
MeSHTendonInjuries[Sonography 0.00 
established/nMeSHAustralia 0.00 
anatomy/nMeSHAdult 0.00 
MeSHTraumaSeverityIndicesUltrasonography 0.00 
muscle/nMeSHClinicalCompetence 0.00 
MeSHShoulderJoint[Arthroscopy 0.00 
618% 0.00 
871%) 0.00 
MeSHTendinopathyComparative 0.00 
(056) 0.00 
pain/nMeSHAdolescent 0.00 
MeSHVideotapeRecordingA 0.00 
MeSHTendinopathyMR 0.00 
(kappa=90) 0.00 
(kappa=98) 0.00 
(kappa=70) 0.00 
(kappa=53) 0.00 
tears/nMeSHConfidenceIntervals 0.00 
MeSHTimeFactorsMR 0.00 
suspected/nMeSHAdolescent 0.00 
MeSHRuptureIndirect 0.00 
09137 0.00 
09773 0.00 
0383-0571) 0.00 
0873-0936) 0.00 
MeSHTraumaSeverityIndicesDiagnosis 0.00 
MeSHUltrasonographyAssociation 0.00 
symptoms/nMeSHFemale 0.00 
MeSHUltrasonographyDiagnosing 0.00 
impact/nMeSHAdult 0.00 
MeSHShoulderJointDetection 0.00 
tears/nMeSHArthroscopy 0.00 
MeSHUltrasonographyIsolated 0.00 
surgery/nMeSHAcromion 0.00 
MeSHTendinopathyShoulder 0.00 
syndrome/nMeSHBursitis 0.00 
avoided/nMeSHFemale 0.00 
(15-T) 0.00 
(02-T) 0.00 
treatment/nMeSHArthroscopy 0.00 
MeSHWoundsandInjuriesSite 0.00 
worse/nMeSHAdult 0.00 
MeSHUltrasonographySupraspinatus 0.00 
functions/nMeSHAdult 0.00 
random/nMeSHAdult 0.00 
MeSHWoundsandInjuries[Rotator 0.00 
edges/nMeSHArthroscopy 0.00 
MeSHTendonInjuriesThree-dimensional 0.00 
MeSHUltrasonographyWhat 0.00 
study/nMeSHAdult 0.00 
MeSHUltrasonographyNot-so-fast 0.00 
MeSHTendonInjuriesSonography 0.00 
making/nMeSHAdult 0.00 
MeSHTendonInjuries[Possibilities 0.00 
MeSHX-RayComputedShoulder 0.00 
MeSHShoulderJointUltrasonography 0.00 
tendon/nMeSHAdult 0.00 
MeSHUltrasonography[Diagnostic 0.00 
MeSHTendonInjuriesAssessment 0.00 
158%) 0.00 
251% 0.00 
340%) 0.00 
559%) 0.00 
661% 0.00 
745%) 0.00 
<001; 0.00 
<001-002 0.00 
226%); 0.00 
404%); 0.00 
431% 0.00 
642%); 0.00 
823%); 0.00 
</=001) 0.00 
=261) 0.00 
muscles/nMeSHAdult 0.00 
MeSHTendonInjuries[The 0.00 
MeSHUltrasonography[Normal 0.00 
95)/nMeSHHumans 0.00 
MeSHTendonsImages 0.00 
MeSHTendonInjuriesRotator 0.00 
067-084) 0.00 
074-092) 0.00 
012-060) 0.00 
035-078) 0.00 
difficult/nMeSHFemale 0.00 
MeSHTendonInjuriesSymptomatic 0.00 
intervention/nMeSHFemale 0.00 
MeSHWoundsandInjuriesDirect 0.00 
CT/nMeSHAdolescent 0.00 
MeSHX-RayComputedRotator 0.00 
MeSHTendonInjuriesIntraarticular 0.00 
MeSHWoundsandInjuriesRole 0.00 
MeSHUltrasonography[On: 0.00 
MeSHTendonInjuriesFull-thickness 0.00 
MeSHUltrasonography30-T 0.00 
planning/nMeSHFemale 0.00 
arthrotomy/nMeSHAdult 0.00 
MeSHTendonInjuriesEvaluation 0.00 
ultrasound/nMeSHAdult 0.00 
MeSHUltrasonographyImaging 0.00 
MeSHUltrasonography[Sonography 0.00 
MeSHTendonInjuries[Ultrasound 0.00 
possible/nMeSHCost-BenefitAnalysis 0.00 
MeSHTendonInjuries[Ultrasound--a 0.00 
minutes/nMeSHAdolescent 0.00 
MeSHTendonInjuries[Normal 0.00 
MeSHUltrasonographyAngled 0.00 
mm/02 0.00 
(P=004) 0.00 
MeSHRotatorCuffInjuriesAssociation 0.00 
avoided/nMeSHHumans 0.00 
MeSHTendons[Chronic 0.00 
(148%) 0.00 
(244%) 0.00 
(2075%) 0.00 
(909%) 0.00 
MRI/nMeSHChronicDisease 0.00 
causes--eg 0.00 
MeSHTendonsMagnetic 0.00 
MRI/nMeSHArthrography 0.00 
MeSHTendonInjuriesMRI 0.00 
injury/nMeSHAdolescent 0.00 
MeSHUltrasonography[Diagnosis 0.00 
MeSHUltrasonography[MRI 0.00 
muscle/nMeSHAcromioclavicularJoint 0.00 
MeSHX-RayComputed[Ultrasonography 0.00 
difference/nMeSHHumans 0.00 
MeSHTendonInjuries3-T 0.00 
clinically/nMeSHAdolescent 0.00 
disease/nMeSHArthrography 0.00 
(809%) 0.00 
(149%) 0.00 
analyzed/nMeSHAdult 0.00 
MeSHUltrasonography[Conventional 0.00 
7839% 0.00 
7222% 0.00 
reinforced/nMeSHAdult 0.00 
MeSHProspectiveStudiesExploration 0.00 
MeSHRetrospectiveStudies[The 0.00 
(767%); 0.00 
ERCP/nMeSHAbdomen 0.00 
508% 0.00 
MeSHgamma-GlutamyltransferaseDetection 0.00 
selection/nMeSHAdolescent 0.00 
MeSHUltrasonographyAbnormal 0.00 
MeSHProspectiveStudiesAre 0.00 
302564 0.00 
MeSHSwedenSerum 0.00 
obstruction/nMeSHAcuteDisease 0.00 
indicated/nMeSHAmpullaofVater 0.00 
essential/nMeSHAdolescent 0.00 
MeSHUltrasonography[Choledocolithiasis 0.00 
country/nMeSHAdolescent 0.00 
MeSHRiskFactorsYield 0.00 
(946%) 0.00 
(623%) 0.00 
needed/nMeSHCase-ControlStudies 0.00 
MeSHEndoscopicDiagnosis 0.00 
MeSHMale[Diagnostic 0.00 
obstruction/nMeSHCholangiography 0.00 
(792%): 0.00 
211% 0.00 
examination/nMeSHCholangiography 0.00 
MeSHUltrasonography[Critical 0.00 
869% 0.00 
ethiology/nMeSHAdult 0.00 
era/nMeSHAdult 0.00 
MeSHPreoperativeCarePreoperative 0.00 
accuracy/nMeSHAdolescent 0.00 
MeSHTimeFactors[Results 0.00 
exam/nMeSHAdult 0.00 
present/nMeSHAdult 0.00 
unreliable/nMeSHAcuteDisease 0.00 
MeSHgamma-GlutamyltransferaseAbnormal 0.00 
cholecystectomy/nMeSHAdult 0.00 
827% 0.00 
MeSHUltrasonographyLiver 0.00 
CDL/nMeSHAdult 0.00 
investigations/nMeSHAdult 0.00 
(p<001 0.00 
duct/nMeSHAdult 0.00 
MeSHUltrasonographyIndication 0.00 
ERC/nMeSHAdolescent 0.00 
MeSHYoungAdultPreoperative 0.00 
cholecystectomy/nMeSHCholecystectomy 0.00 
duct/nMeSHCholelithiasis 0.00 
875%; 0.00 
875%) 0.00 
963%) 0.00 
(179%) 0.00 
(821%) 0.00 
death(ABSTRACT 0.00 
MeSHUltrasonographyGallstone 0.00 
2/nMeSHAPACHE 0.00 
MeSHProspectiveStudiesRapid 0.00 
gallstones/nMeSHAdult 0.00 
MeSHPredictiveValueofTestsSelective 0.00 
MeSHEndoscopicRoutine 0.00 
measured/nMeSHAdult 0.00 
MeSHUnnecessaryProcedures[VALUE 0.00 
MeSHOperativeImpact 0.00 
choledocholithiasis/nMeSHAdolescent 0.00 
pancreatitis/nMeSHAdult 0.00 
studies/nMeSHCholestasis 0.00 
MeSHUltrasonographyFactors 0.00 
MeSHSensitivityandSpecificity[Selective 0.00 
today/nMeSHCholangiography 0.00 
MeSHRetrospectiveStudies[Ultrasonography 0.00 
reserve/nMeSHCholangiopancreatography 0.00 
cholelithiasis/nMeSHAlkalinePhosphatase 0.00 
MeSHRiskUltrasonic 0.00 
modality/nMeSHBileDuctDiseases 0.00 
MeSHUltrasonography[Alterations 0.00 
p<001 0.00 
MeSHRetrospectiveStudiesPreoperative 0.00 
evaluation/nMeSHAged 0.00 
MeSHUltrasonographyReliability 0.00 
equivocal/nMeSHBileDuctDiseases 0.00 
evolve/nMeSHAdolescent 0.00 
complementary/nMeSHAdenoma 0.00 
obstruction/nMeSHAdolescent 0.00 
MeSHUltrasonographyRadiology 0.00 
LC/nMeSHBileDucts 0.00 
MeSHVideotapeRecordingAssessment 0.00 
cholangiography/nMeSHAdolescent 0.00 
MeSHReoperationRelative 0.00 
planned/nMeSHAdolescent 0.00 
MeSHUltrasonographyBiochemical 0.00 
(960%) 0.00 
(991%) 0.00 
(1073) 0.00 
(980%) 0.00 
(274%) 0.00 
(979%) 0.00 
values/nMeSHAdult 0.00 
MeSHgamma-GlutamyltransferaseUseful 0.00 
MeSHgamma-GlutamyltransferaseSelective 0.00 
(537 0.00 
ERCPs/nMeSHAdult 0.00 
0808 0.00 
889%) 0.00 
MeSHInterventionalUltrasound 0.00 
MeSHUltrasonographyLimitations 0.00 
stones(ABSTRACT 0.00 
ERCP/nMeSHAbdominalPain 0.00 
MeSHUltrasonographyTotal 0.00 
MeSHRetrospectiveStudiesPredicting 0.00 
"training" 0.00 
choledocholithiasis/nMeSHCase-ControlStudies 0.00 
papillotomy/nMeSHAdolescent 0.00 
MeSHInterventionalLaparoscopic 0.00 
(576%); 0.00 
CBDE/nMeSHAdult 0.00 
MeSHRetrospectiveStudiesGammaglutamyl 0.00 
MeSHUltrasonographyUseful 0.00 
(p=00008) 0.00 
(p=00012) 0.00 
factors/nMeSHAdolescent 0.00 
patient/nMeSHBiliaryTractDiseases 0.00 
MeSHUltrasonographyGrey 0.00 
jaundice/nMeSHAdolescent 0.00 
MeSHUltrasonography[Upper-abdominal 0.00 
(702%) 0.00 
respectively/nMeSHBiliaryTractDiseases 0.00 
pancreatitis/nMeSHAcuteDisease 0.00 
MeSHgamma-GlutamyltransferaseUltrasound 0.00 
(721%) 0.00 
chledocholithiasis/nMeSHAlkalinePhosphatase 0.00 
(KWM) 0.00 
cent/nMeSHAlgorithms 0.00 
MeSHTimeFactors[Sonographic 0.00 
appropriate/nMeSHAdolescent 0.00 
0898) 0.00 
(65%)/nMeSHAdult 0.00 
technique/nMeSHEvaluationStudiesasTopic 0.00 
MeSHUltrasonographySelective 0.00 
(095%) 0.00 
(695%) 0.00 
(047%) 0.00 
695% 0.00 
MeSHProspectiveStudiesPredictors 0.00 
MeSHMiddleAgedEndoscopic 0.00 
choledocholithiasis/nMeSHAdult 0.00 
MeSHX-RayComputedValidity 0.00 
calculi/nMeSHAdult 0.00 
MeSHSensitivityandSpecificityEndoscopic 0.00 
examination--845%/nMeSHAdolescent 0.00 
(971%) 0.00 
tools)/nMeSHBileDucts 0.00 
MeSHRetrospectiveStudiesProposed 0.00 
MeSHRetrospectiveStudies[Comparative 0.00 
703% 0.00 
stone/nMeSHAdolescent 0.00 
cholangiograms/nMeSHAdolescent 0.00 
(685%) 0.00 
recommended/nMeSHCarcinoma 0.00 
MeSHYoungAdultReliability 0.00 
(548% 0.00 
cholecystectomy/nMeSHFemale 0.00 
surgery/nMeSHCholangiography 0.00 
MeSHUltrasonographyAssessment 0.00 
CBD/nMeSHAdult 0.00 
MeSHVulvarNeoplasms[Interpretation 0.00 
groin/nMeSHAdult 0.00 
SLNs/nMeSHAdult 0.00 
MeSHVulvarNeoplasms[Feasibility 0.00 
(267%) 0.00 
concepts/nMeSHCarcinoma 0.00 
MeSHVulvarNeoplasmsPathologic 0.00 
03mm 0.00 
vulva/nMeSHCarcinoma 0.00 
prognosis/nMeSHAdult 0.00 
MeSHVulvarNeoplasmsIs 0.00 
SLN/nMeSHCarcinoma 0.00 
(872%) 0.00 
(166%) 0.00 
MeSHVulvarNeoplasmsOutcomes 0.00 
excellent/nMeSHAdult 0.00 
scans/nMeSHAdult 0.00 
867%) 0.00 
vulva/nMeSHAged 0.00 
MeSHVulvarNeoplasmsEffects 0.00 
small/nMeSHAged 0.00 
chain/nMeSHCarcinoma 0.00 
safe/nMeSHAdult 0.00 
technique/nMeSHFemale 0.00 
(70%)/nMeSHAged 0.00 
MeSHVulvarNeoplasmsIdentification 0.00 
0953 0.00 
warranted/nMeSHAdult 0.00 
concepts/nMeSHAdult 0.00 
demonstrated/nMeSHAged 0.00 
metastases/nMeSHCarcinoma 0.00 
MeSHVulvarNeoplasmsSize 0.00 
(695%vs 0.00 
applied/nMeSHAdult 0.00 
MeSHX-RayComputedSentinel 0.00 
females/nMeSHAdult 0.00 
(2222%) 0.00 
(7777%) 0.00 
II/nMeSHAged 0.00 
melanoma/nMeSHAdult 0.00 
MeSHVulvarNeoplasms[Lymph 0.00 
(8787%) 0.00 
cancer/nMeSHEndometrialNeoplasms 0.00 
(P=08) 0.00 
lymphadenectomy/nMeSHAdult 0.00 
MeSHVulvarNeoplasmsAssessment 0.00 
oncology/nMeSHAdult 0.00 
accordingly/nMeSHCarcinoma 0.00 
basis/nMeSHAdult 0.00 
MeSHYoungAdultSentinel 0.00 
MeSHVulvarNeoplasmsPreliminary 0.00 
malignancy/nMeSHAged 0.00 
MeSHVulvarNeoplasmsNodal 0.00 
(737%); 0.00 
MeSHVulvarNeoplasmsRadioguided 0.00 
confirmed/nMeSHAdult 0.00 
(307%) 0.00 
923%) 0.00 
relapses/nMeSHAdult 0.00 
MeSHVulvarNeoplasmsPotential 0.00 
variations/nMeSHAdult 0.00 
0996; 0.00 
midline/nMeSHAdult 0.00 
warranted/nMeSHCarcinoma 0.00 
(983%) 0.00 
MeSHVulvarNeoplasmsLymphoscintigraphy 0.00 
technique/nMeSHAged 0.00 
mapping/nMeSHAdult 0.00 
MeSHVulvarNeoplasmsMorbidity 0.00 
technique/nMeSHCellulitis 0.00 
060-710) 0.00 
(18-60) 0.00 
nodes/nMeSHDisease-FreeSurvival 0.00 
MeSHVulvarNeoplasmsIsolated 0.00 
lymphadenectomy/nMeSHAged 0.00 
MeSHVulvarNeoplasmsMultimodal 0.00 
MeSHSingle-Photon[An 0.00 
0652;t 0.00 
-0421 0.00 
0717) 0.00 
basins/nMeSHAdult 0.00 
determined/nMeSHAged 0.00 
MeSHVulvarNeoplasmsReliability 0.00 
surgery/nMeSHAged 0.00 
mm)/nMeSHAdult 0.00 
MeSHVulvarNeoplasmsCervical 0.00 
631% 0.00 
713% 0.00 
strategies/nMeSHAdult 0.00 
MeSHYoungAdultp16(INK4a) 0.00 
817% 0.00 
509% 0.00 
(412% 0.00 
trials/nMeSHCervicalIntraepithelialNeoplasia 0.00 
MeSHUterineCervicalDysplasiaAtypical 0.00 
(211% 0.00 
446%) 0.00 
HSIL/nMeSHAlgorithms 0.00 
colposcopies/nMeSHAdolescent 0.00 
infections/nMeSHCervixUteri 0.00 
(101%) 0.00 
(000%) 0.00 
515% 0.00 
(P>005) 0.00 
229% 0.00 
>005) 0.00 
(Kappa=0314 0.00 
U=0064 0.00 
(chi2=2988 0.00 
old/nMeSHAdult 0.00 
algorithmA 0.00 
(252% 0.00 
664% 0.00 
073% 0.00 
self-test/nMeSHAdult 0.00 
(173%) 0.00 
=0047) 0.00 
MeSHRiskAssessmentA 0.00 
(119% 0.00 
510% 0.00 
281% 0.00 
(388%) 0.00 
18-285; 0.00 
705% 0.00 
22-483) 0.00 
months/nMeSHAdult 0.00 
MeSHYoungAdultIncreased 0.00 
12000 0.00 
(165%) 0.00 
10-19] 0.00 
16-98) 0.00 
15-86) 0.00 
cessation/nMeSHAdult 0.00 
[07-27%]) 0.00 
[30-59%] 0.00 
[257-324%] 0.00 
[176-235%] 0.00 
[605-662%] 0.00 
[695-748%] 0.00 
005)/nMeSHAdolescent 0.00 
(923% 0.00 
871%; 0.00 
(482% 0.00 
540%; 0.00 
MeSHUterineNeoplasmsComparison 0.00 
988%) 0.00 
561% 0.00 
529%) 0.00 
908%) 0.00 
above/nMeSHAdult 0.00 
MeSHUterineCervicalNeoplasmsOptimal 0.00 
18386 0.00 
934% 0.00 
(503% 0.00 
(787% 0.00 
threshold/nMeSHAdult 0.00 
MeSHYoungAdultHigh-throughput 0.00 
vaccines/nMeSHEurope 0.00 
MeSHSensitivityandSpecificity[Assessment 0.00 
(617%) 0.00 
449% 0.00 
30/nMeSHAdult 0.00 
MeSHUterineCervicalDiseasesGenital 0.00 
negative/nMeSHAdolescent 0.00 
discussed/nMeSHCervixUteri 0.00 
MeSHUterineCervicalNeoplasmsUse 0.00 
115-202) 0.00 
(096-121) 0.00 
(182-517) 0.00 
(096-137) 0.00 
(120-368) 0.00 
(046-073) 0.00 
MeSHUterineCervicalNeoplasmsPrevalence 0.00 
AGC-NOS/nMeSHCervicalIntraepithelialNeoplasia 0.00 
infection/nMeSHAdolescent 0.00 
MeSHYoungAdultComparative 0.00 
8349 0.00 
9083 0.00 
9113 0.00 
8468 0.00 
(052) 0.00 
colposcopyimproving 0.00 
resources/nMeSHColposcopy 0.00 
(202%) 0.00 
284% 0.00 
361% 0.00 
335% 0.00 
520% 0.00 
422% 0.00 
809% 0.00 
330%/nMeSHAdult 0.00 
327% 0.00 
29475 0.00 
(336%) 0.00 
(022%) 0.00 
evaluation/nMeSHAdolescent 0.00 
consequences/nMeSHAdolescent 0.00 
MeSHVaginalSmearsIdentifying 0.00 
784%-952%) 0.00 
609%-672%) 0.00 
635%-857%) 0.00 
883%-995%) 0.00 
disease/nMeSHCervicalIntraepithelialNeoplasia 0.00 
types/nMeSHAdolescent 0.00 
MeSHVaginalSmearsAssessment 0.00 
(377% 0.00 
164%; 0.00 
3095 0.00 
(165-582)] 0.00 
(692% 0.00 
615%) 0.00 
(632% 0.00 
930%) 0.00 
(300% 0.00 
667%) 0.00 
(900% 0.00 
914%) 0.00 
MeSHUterineCervicalNeoplasmsCost-effectiveness 0.00 
20370 0.00 
analyses/nMeSHAdult 0.00 
MeSHUterineCervicalNeoplasmsContribution 0.00 
women/nMeSHAdolescent 0.00 
33000 0.00 
(235%) 0.00 
ISRCTN79347302/nMeSHAdult 0.00 
MeSHUterineCervicalNeoplasmsDiagnostic 0.00 
(516%) 0.00 
(29-615%) 0.00 
298-414%) 0.00 
319-563%); 0.00 
MeSHYoungAdultReflex 0.00 
(504%) 0.00 
interpretation/nMeSHAcetates 0.00 
(P=0019) 0.00 
MeSHVaginalSmearsOncogenic 0.00 
positive(+)In 0.00 
"acceptable"/nMeSHAdolescent 0.00 
(p=0678) 0.00 
MeSHUterineCervicalDiseases[Application 0.00 
662% 0.00 
0748 0.00 
0779 0.00 
HSIL/nMeSHCarcinoma 0.00 
(p=00355) 0.00 
(p=00084) 0.00 
350% 0.00 
284-421) 0.00 
583-703) 0.00 
cytology/nMeSHAdult 0.00 
MeSHUterineCervicalNeoplasmsAn 0.00 
39684 0.00 
10716 0.00 
MeSHVaginalSmearsUsefulness 0.00 
11792) 0.00 
MeSHViralLoadMolecular 0.00 
management/nMeSHFemale 0.00 
MeSHVaginalSmearsCo-expression 0.00 
257% 0.00 
(359%) 0.00 
(282%) 0.00 
11008 0.00 
MeSHVaginalSmearsAge-specific 0.00 
vaccination/nMeSHAdult 0.00 
MeSHVaginalSmears[Contribution 0.00 
[123]; 0.00 
ratio=189; 0.00 
109-331) 0.00 
9852%) 0.00 
AGUS/nMeSHAdolescent 0.00 
MeSHVaginalSmearsWomen 0.00 
(549%) 0.00 
(139% 0.00 
(399%) 0.00 
MeSHVaginalSmears[Detection 0.00 
(168%) 0.00 
(745%) 0.00 
0595) 0.00 
(687%) 0.00 
cytology/nMeSHBiomarkers 0.00 
(p=001) 0.00 
MeSHYoungAdult[Assessment 0.00 
865% 0.00 
540% 0.00 
651% 0.00 
lesions/nMeSHAneuploidy 0.00 
(771%) 0.00 
recall/nMeSHAdolescent 0.00 
MeSHVirologyVisual 0.00 
weak/nMeSHAdolescent 0.00 
MeSHUterineCervicalNeoplasmsClinical 0.00 
care/nMeSHCervicalIntraepithelialNeoplasia 0.00 
HC2/nMeSHAdolescent 0.00 
MeSHYoungAdultP634A4 0.00 
(P=0031) 0.00 
(P=0006) 0.00 
(P=0016) 0.00 
(P=0038) 0.00 
613% 0.00 
(485%-709%) 0.00 
(789%-938%) 0.00 
(831%-958%) 0.00 
(818%-831%) 0.00 
(779%-797%) 0.00 
(694%-750%) 0.00 
(613% 0.00 
(824% 0.00 
(753%-910%) 0.00 
(851%-873%) 0.00 
(294%) 0.00 
(342%) 0.00 
(786%) 0.00 
(149%)/nMeSHAdult 0.00 
ASC-US/nMeSHBiomarkers 0.00 
MeSHViralLoadLifetime 0.00 
consideration/nMeSHAdult 0.00 
(n=580289) 0.00 
cotests=812598) 0.00 
627% 0.00 
621-632%) 0.00 
394-403%) 0.00 
518% 0.00 
513-523%) 0.00 
284-291%) 0.00 
atypia/nMeSHAcetates 0.00 
(645%) 0.00 
MeSHUterineCervicalNeoplasmsOptions 0.00 
pound15020 0.00 
pound24030 0.00 
pound24110 0.00 
pound20440 0.00 
pound33990 0.00 
pound32750 0.00 
34841617/nMeSHBiopsy 0.00 
(806%) 0.00 
diagnoses/nMeSHAdenocarcinoma 0.00 
463% 0.00 
12490 0.00 
occurs/nMeSHDNA 0.00 
MeSHVirologyEvaluation 0.00 
(491%) 0.00 
(554%) 0.00 
(241%) 0.00 
(214%) 0.00 
(414%) 0.00 
MeSHVaginalSmearsProEx 0.00 
9804% 0.00 
8235% 0.00 
7450% 0.00 
7315% 0.00 
ASC-US/nMeSHAdolescent 0.00 
0065] 0.00 
MeSHUterineCervicalNeoplasmsMultiplex 0.00 
treatment/nMeSHBiomarkers 0.00 
MeSHSensitivityandSpecificityDoes 0.00 
108371 0.00 
104555 0.00 
(P>0124) 0.00 
01690) 0.00 
01471) 0.00 
significance/nMeSH?A 0.00 
(332%) 0.00 
(208%) 0.00 
screening/nMeSHAlphapapillomavirus 0.00 
(866%) 0.00 
subtyping/nMeSHCarcinoma 0.00 
MeSHVaginalSmearsCombining 0.00 
colposcopy/nMeSHAntibodies 0.00 
visits/nMeSHAdolescent 0.00 
MeSHVaginalSmearsRisk 0.00 
(152%) 0.00 
(9970% 0.00 
9982% 0.00 
MeSHVaginalSmearsHybrid 0.00 
(214% 0.00 
(154% 0.00 
674% 0.00 
testing/nMeSHAlphapapillomavirus 0.00 
MeSHVirologyRole 0.00 
61320 0.00 
5473 0.00 
70409 0.00 
future/nMeSHAdult 0.00 
MeSHUterineCervicalNeoplasmsIntroducing 0.00 
MeSH"WomensHealth"Papillary 0.00 
discarded/nMeSHAdolescent 0.00 
(622%) 0.00 
CIN/nMeSHCervicalIntraepithelialNeoplasia 0.00 
MeSHUterineCervicalNeoplasmsNucliSENS 0.00 
23x10(2) 0.00 
30x10(4) 0.00 
assay/nMeSHCervixUteri 0.00 
652%-748%) 0.00 
733%-940%) 0.00 
650%-1000%) 0.00 
887%-997%) 0.00 
178994 0.00 
(01045%) 0.00 
8740 0.00 
(48828%) 0.00 
patients/nMeSHCervicalIntraepithelialNeoplasia 0.00 
50668 0.00 
(019%) 0.00 
(058%) 0.00 
41024 0.00 
(338%) 0.00 
(419%) 0.00 
(338% 0.00 
14-573 0.00 
smear/nMeSHAdolescent 0.00 
MeSHViralLoadLongitudinal 0.00 
progress/nMeSHAntibodies 0.00 
0-21%) 0.00 
cytology/nMeSH?Utilization 0.00 
9286% 0.00 
6667% 0.00 
9474% 0.00 
MeSHVaginalSmearsLack 0.00 
evaluations/nMeSHAdult 0.00 
44102 0.00 
visit/nMeSHAlgorithms 0.00 
MeSHVaginalSmearsHistologic 0.00 
247131 0.00 
(041%) 0.00 
93%/nMeSHAdenocarcinoma 0.00 
prevention/nMeSHAdolescent 0.00 
comparedHCII 0.00 
256% 0.00 
31694200 0.00 
36948400 0.00 
MeSHUterineCervicalDysplasiaTime 0.00 
discussed/nMeSH?Human 0.00 
progression/nMeSHAdenocarcinoma 0.00 
(1059%) 0.00 
(1523%) 0.00 
(45%-85%) 0.00 
treat/nMeSHAdult 0.00 
216% 0.00 
lesions/nMeSHAlgorithms 0.00 
grade/nMeSHAdult 0.00 
MeSHUterineCervicalNeoplasmsDysplasia 0.00 
subclassification/nMeSHAdenocarcinoma 0.00 
MeSHVaginalSmearsSignificance 0.00 
(254%) 0.00 
309% 0.00 
(074%) 0.00 
752% 0.00 
688-810%) 0.00 
699% 0.00 
617-773%) 0.00 
(713%; 0.00 
685-741%) 0.00 
(469%; 0.00 
422-516%) 0.00 
(945%; 0.00 
929-960%) 0.00 
MeSHYoungAdultManagement 0.00 
MeSHUterineCervicalDiseasesThe 0.00 
9355% 0.00 
9065% 0.00 
1034% 0.00 
1168% 0.00 
differently/nMeSHCellNucleus 0.00 
MeSHVaginalSmearsDoes 0.00 
MeSHVaginalSmearsSmoking 0.00 
111-943) 0.00 
p=033) 0.00 
040-133) 0.00 
(p=004) 0.00 
biopsy/nMeSHAdult 0.00 
MeSHVaginalSmearsTest 0.00 
reliably/nMeSHAdolescent 0.00 
570% 0.00 
ASCUS/nMeSHAdult 0.00 
(442%) 0.00 
SIL/nMeSHCervicalIntraepithelialNeoplasia 0.00 
MeSHVaginalSmearsFollow-up 0.00 
results/nMeSHAdolescent 0.00 
P<005) 0.00 
SIL/nMeSHBiopsy 0.00 
services/nMeSHCellNucleus 0.00 
MeSHVaginalSmearsASC-US 0.00 
(231%) 0.00 
(526%) 0.00 
MeSHVaginalSmearsEffect 0.00 
13-20] 0.00 
19-36]) 0.00 
08-36) 0.00 
SIL/nMeSHCD4LymphocyteCount 0.00 
MeSHVaginalSmearsGenomic 0.00 
(877%) 0.00 
(851%) 0.00 
(957%) 0.00 
disorders/nMeSHDiagnosis 0.00 
MeSHUterineCervicalDiseasesRisk 0.00 
(077 0.00 
(048 0.00 
(094 0.00 
=01) 0.00 
specificity/nMeSHBlotting 0.00 
MeSHUterineCervicalNeoplasmsIs 0.00 
(638%) 0.00 
tests/nMeSHBiopsy 0.00 
MeSHVaginalSmears[The 0.00 
672% 0.00 
473% 0.00 
MeSHYoungAdultLiving 0.00 
future/nMeSHCervicalIntraepithelialNeoplasia 0.00 
"HPV" 0.00 
179-874 0.00 
04%; 0.00 
=016) 0.00 
considered/nMeSHFemale 0.00 
(546%) 0.00 
(234%) 0.00 
421-996) 0.00 
739-925) 0.00 
374-626) 0.00 
43-11373) 0.00 
06-520) 0.00 
MeSHVaginalSmearsAre 0.00 
interpretationA 0.00 
MeSHVaginalSmearsDo 0.00 
MeSHScotlandHPV 0.00 
2225) 0.00 
1265) 0.00 
status/nMeSHAdult 0.00 
579% 0.00 
850% 0.00 
333%) 0.00 
(212%) 0.00 
colposcopy/nMeSHCervicalIntraepithelialNeoplasia 0.00 
MeSHVaginalSmearsDistribution 0.00 
(590% 0.00 
555% 0.00 
(600% 0.00 
485% 0.00 
(735%) 0.00 
(180%) 0.00 
395% 0.00 
195% 0.00 
(275%) 0.00 
(500%) 0.00 
sensitivity/nMeSHAdult 0.00 
circumstances/nMeSHAdult 0.00 
578% 0.00 
514% 0.00 
324% 0.00 
562% 0.00 
(593% 0.00 
referral/nMeSHCarcinomainSitu 0.00 
(SD=34 0.00 
(187% 0.00 
group/nMeSHAdolescent 0.00 
MeSHYoungAdultLong-term 0.00 
(93-316)) 0.00 
(45-171)) 0.00 
023% 0.00 
prevalence/nMeSHAdult 0.00 
MeSHVaginalSmearsResolution 0.00 
(974%) 0.00 
cases/nMeSHCervixUteri 0.00 
MeSHVaginalSmearsRelevance 0.00 
(k=049) 0.00 
(k=088) 0.00 
virus/nMeSHAdolescent 0.00 
MeSHYoungAdult[Contribution 0.00 
MeSHUterineCervicalNeoplasmsMorphologic 0.00 
vs-negative 0.00 
indicator/nMeSHAdult 0.00 
numbers/nMeSHBiomarkers 0.00 
8022 0.00 
7334 0.00 
3410% 0.00 
5846% 0.00 
(114% 0.00 
=0007) 0.00 
(316% 0.00 
=009) 0.00 
1000000 0.00 
2861 0.00 
ratio=27 0.00 
ratio=32 0.00 
smoke/nMeSHAdenocarcinoma 0.00 
114-149) 0.00 
103-125) 0.00 
109-132) 0.00 
072-103) 0.00 
031-103) 0.00 
MeSHVaginalSmearsUtility 0.00 
warranted/nMeSHBiopsy 0.00 
09967 0.00 
(09957-09978) 0.00 
09972 0.00 
(09964-09980) 0.00 
09354 0.00 
(08544-10) 0.00 
09656 0.00 
(09081-10) 0.00 
thereof/nMeSHAdult 0.00 
MeSHVaginalSmearsLinear 0.00 
117%) 0.00 
312-2593) 0.00 
126-7417) 0.00 
395-21806) 0.00 
(927%) 0.00 
0547; 0.00 
0435-659) 0.00 
745; 0.00 
2736-20272) 0.00 
MeSHUterineCervicalNeoplasmsManagement 0.00 
(971% 0.00 
p=0002) 0.00 
(933% 0.00 
MeSHVaginalSmearsDetecting 0.00 
MeSHUterineCervicalNeoplasmsTrial 0.00 
trial/nMeSHAlphapapillomavirus 0.00 
(813%) 0.00 
(844% 0.00 
06419) 0.00 
(840% 0.00 
06341) 0.00 
(978% 0.00 
09441) 0.00 
MeSHVaginalSmearsLongitudinal 0.00 
group/nMeSHCervicalIntraepithelialNeoplasia 0.00 
3215; 0.00 
922%) 0.00 
epidemiology/nMeSHAdult 0.00 
(749% 0.00 
825%) 0.00 
(721% 0.00 
812%) 0.00 
(+/-130) 0.00 
(079-611 0.00 
decisions/nMeSHAdult 0.00 
25164 0.00 
MeSHVaginalSmearsImmunohistochemical 0.00 
(p=0021) 0.00 
progression/nMeSHBiomarkers 0.00 
MeSHUterineCervicalNeoplasmsGene 0.00 
immunohistochemistry/nMeSHAntigens 0.00 
663% 0.00 
668% 0.00 
(966%) 0.00 
MeSHVaginalSmearsCost-effectiveness 0.00 
$34074 0.00 
$33807 0.00 
States/nMeSHAdolescent 0.00 
756% 0.00 
527% 0.00 
3340; 0.00 
1189-9397; 0.00 
smears/nMeSHAgeFactors 0.00 
478% 0.00 
416-540%) 0.00 
114-135) 0.00 
(603%; 0.00 
569-637%) 0.00 
(128%; 0.00 
150-229%) 0.00 
81-145%) 0.00 
MeSHVaginalSmearsAssociation 0.00 
519% 0.00 
14-58)) 0.00 
00013; 0.00 
17-88)) 0.00 
development/nMeSHAdult 0.00 
MeSHUterineCervicalNeoplasmsWhich 0.00 
(P=0317) 0.00 
(P=0012) 0.00 
(P=0604) 0.00 
(P=0066 0.00 
441%-572%) 0.00 
329%-457%) 0.00 
148% 0.00 
precancer/nMeSHColposcopy 0.00 
MeSHUterineCervicalDysplasiaEvaluation 0.00 
MeSHUterineCervicalNeoplasmsBiopsy 0.00 
MeSHYoungAdultAssessment 0.00 
follow-up/nMeSHAdolescent 0.00 
543% 0.00 
MeSHVaginalSmearsCross 0.00 
cancer/nMeSHCervicalIntraepithelialNeoplasia 0.00 
MeSHVaginalSmearsMolecular 0.00 
(564%) 0.00 
smears/nMeSHBiomarkers 0.00 
MeSHViralLoadClinical 0.00 
MeSHVaginalSmearsResolving 0.00 
recommended/nMeSHFalseNegativeReactions 0.00 
MeSHSpeciesSpecificityThe 0.00 
II/nMeSHAdult 0.00 
143-1999) 0.00 
smears/nMeSHBiopsy 0.00 
MeSHUterineCervicalNeoplasmsRefining 0.00 
611%; 0.00 
(1000% 0.00 
800%; 0.00 
0738) 0.00 
MeSHVaginalSmears[Expression 0.00 
425% 0.00 
(892% 0.00 
(882% 0.00 
HPV/nMeSHAdenocarcinoma 0.00 
MeSHYoungAdultQuantitative 0.00 
(P=052) 0.00 
398-2810; 0.00 
080-603; 0.00 
P=0125) 0.00 
MeSHVaginalSmearsManaging 0.00 
859% 0.00 
304% 0.00 
MeSHVaginalSmearsConservative 0.00 
MeSHVaginalSmearsEfficiency 0.00 
(484% 0.00 
advised/nMeSHAdolescent 0.00 
0858 0.00 
0792-0925] 0.00 
0492-0753) 0.00 
0820 0.00 
CIN/nMeSH?Prospective 0.00 
(867%) 0.00 
(959% 0.00 
cases/nMeSHCarcinoma 0.00 
23103 0.00 
45789 0.00 
502% 0.00 
212% 0.00 
follow-up/nMeSH?The 0.00 
001-17) 0.00 
cells/nMeSHAdult 0.00 
MeSHVaginalSmearsPerformance 0.00 
resources/nMeSHAdolescent 0.00 
(674%) 0.00 
(651%) 0.00 
(475%) 0.00 
(651% 0.00 
475%) 0.00 
(84%)/nMeSHAdult 0.00 
limited/nMeSHAdult 0.00 
373% 0.00 
results/nMeSHBiomarkers 0.00 
MeSHUterineCervicalNeoplasmsPerformance 0.00 
(659%) 0.00 
0070-0459) 0.00 
004-0384) 0.00 
(965%) 0.00 
0731) 0.00 
(995%) 0.00 
(961%) 0.00 
0839) 0.00 
tool/nMeSHAdolescent 0.00 
(604%) 0.00 
895%) 0.00 
vaccines/nMeSHDNA 0.00 
MeSHSpeciesSpecificityDetection 0.00 
II/nMeSHAdolescent 0.00 
MeSHUterineCervicalNeoplasms[Progression 0.00 
723% 0.00 
00094) 0.00 
MeSHVaginalSmearsAn 0.00 
diagnosis/nMeSHBiopsy 0.00 
(831-38930)] 0.00 
dysplasia/nMeSHAdult 0.00 
65%-15%) 0.00 
reported/nMeSHAdult 0.00 
MeSHUterineCervicalNeoplasmsASC-US 0.00 
487% 0.00 
assays/nMeSHAdolescent 0.00 
(239%) 0.00 
defined/nMeSHCervicalIntraepithelialNeoplasia 0.00 
"AGUS" 0.00 
"AGC" 0.00 
2389206 0.00 
6829 0.00 
(029%) 0.00 
(576%) 0.00 
290% 0.00 
examination/nMeSHAdenocarcinoma 0.00 
4409 0.00 
3626 0.00 
00312) 0.00 
evaluated/nMeSHAdult 0.00 
60390 0.00 
404% 0.00 
System/nMeSHCervicalIntraepithelialNeoplasia 0.00 
326% 0.00 
468% 0.00 
419% 0.00 
787% 0.00 
721% 0.00 
472% 0.00 
643% 0.00 
II/III/nMeSHAdolescent 0.00 
522% 0.00 
(p=000812) 0.00 
(p=000003); 0.00 
(p=000239) 0.00 
(p=000622) 0.00 
ASC-US/nMeSHCervicalIntraepithelialNeoplasia 0.00 
MeSHVaginalSmearsOutcomes 0.00 
(608%) 0.00 
(339%) 0.00 
period/nMeSHAdolescent 0.00 
MeSHUterineCervicalNeoplasms[Importance 0.00 
(462) 0.00 
(HTA)/nMeSHAdult 0.00 
(811%) 0.00 
(189%) 0.00 
(394%); 0.00 
(362%); 0.00 
(220%); 0.00 
ASC-H/nMeSHAged 0.00 
MeSHVaginalSmearsPrognostic 0.00 
491% 0.00 
259% 0.00 
407%; 0.00 
3391) 0.00 
00-43 0.00 
602% 0.00 
(896%) 0.00 
0901) 0.00 
(p=00028) 0.00 
recurrence/nMeSHCervixUteri 0.00 
MeSHUterineCervicalNeoplasmsCervical 0.00 
(p<0005) 0.00 
(p<00001); 0.00 
warranted/nMeSHApoptosisRegulatoryProteins 0.00 
MeSHUterineCervicalNeoplasmsp16INK4A 0.00 
(556% 0.00 
821%) 0.00 
P=0004) 0.00 
MeSHUterineCervicalNeoplasmsEffects 0.00 
10-pg/mL 0.00 
995%) 0.00 
978%) 0.00 
343%) 0.00 
501% 0.00 
535%) 0.00 
100-pg/mL 0.00 
LSIL/nMeSHAdult 0.00 
MeSHViralLoadRole 0.00 
HPV/nMeSHAdolescent 0.00 
lesions/nMeSHCervicalIntraepithelialNeoplasia 0.00 
MeSHVaginalSmearsAnalyses 0.00 
49882 0.00 
349% 0.00 
0743) 0.00 
ASC-US/nMeSHAdult 0.00 
MeSHVaginalSmears[Comparison 0.00 
MeSHUterineCervicalNeoplasmsWhen 0.00 
MeSHUterineCervicalNeoplasmsDetection 0.00 
screening/nMeSHCervicalIntraepithelialNeoplasia 0.00 
841-969) 0.00 
981-996) 0.00 
851-100) 0.00 
994-100) 0.00 
415-469) 0.00 
403-457) 0.00 
MeSHYoungAdultInterobserver 0.00 
044-048) 0.00 
043-049) 0.00 
044-055) 0.00 
interpretations/nMeSHBiopsy 0.00 
MeSHVaginalSmearsImage-guided 0.00 
MeSHVaginalSmears[ASCUS: 0.00 
diagnoses/nMeSHCytodiagnosis 0.00 
neoplasia/nMeSHAdenocarcinoma 0.00 
853%-910%) 0.00 
062-077) 0.00 
07-085) 0.00 
CIN3+/nMeSHAdolescent 0.00 
382%-723%) 0.00 
746%-100%) 0.00 
938%-963%) 0.00 
MeSHVaginalSmearsCan 0.00 
<331 0.00 
-013) 0.00 
problem/nMeSHAged 0.00 
form/nMeSHAged 0.00 
MeSHSurveysandQuestionnaires[Combined 0.00 
(867% 0.00 
Brazilian/nMeSHAged 0.00 
MeSHSocioeconomicFactors[Validation 0.00 
MeSHSurveysandQuestionnairesValidation 0.00 
educated/nMeSHAged 0.00 
accuracy/nMeSHAged 0.00 
MeSHSurveysandQuestionnairesDiscriminant 0.00 
MeSHTurkeyA 0.00 
discussed/nMeSHAged 0.00 
calculation/nMeSHAged 0.00 
MeSHSurveysandQuestionnairesPoststroke 0.00 
PSD/nMeSHAdult 0.00 
MeSHStrokeImproving 0.00 
situations/nMeSHAged 0.00 
education/nMeSHAgeFactors 0.00 
MMSE/nMeSHActivitiesofDailyLiving 0.00 
MeSHReproducibilityofResultsComparison 0.00 
CDR/nMeSH?Characteristics 0.00 
sample/nMeSHAged 0.00 
1063; 0.00 
00011) 0.00 
Mulligan/nMeSHAged 0.00 
backgrounds/nMeSHAgeFactors 0.00 
MeSHSurveysandQuestionnairesCognitive 0.00 
screened/nMeSHAged 0.00 
MeSHReproducibilityofResultsHow 0.00 
SMC/nMeSHAged 0.00 
MeSHSurveysandQuestionnairesCan 0.00 
MeSHSurveysandQuestionnairesInformant 0.00 
time/nMeSHAgeFactors 0.00 
MeSHSurveysandQuestionnairesAssessment 0.00 
instruments/nMeSHAged 0.00 
MeSHTimeFactorsDiagnostic 0.00 
(086) 0.00 
(039) 0.00 
more/nMeSHAged 0.00 
MeSHROCCurveImproving 0.00 
samples/nMeSHAged 0.00 
MeSHSurveysandQuestionnairesSensitivity 0.00 
forms/nMeSHAged 0.00 
impairment/nMeSHAged 0.00 
(-051) 0.00 
(062) 0.00 
(-040) 0.00 
(075) 0.00 
MeSHSurveysandQuestionnairesDifferentiating 0.00 
MeSHSeverityofIllnessIndexInformant 0.00 
MeSHSerialLearning[Awareness 0.00 
awareness/nMeSHActivitiesofDailyLiving 0.00 
performance/nMeSHAged 0.00 
MeSHSwitzerlandDelirium 0.00 
16-703) 0.00 
IQCODE-SF/nMeSHAged 0.00 
MeSHWechslerScalesScreening 0.00 
format/nMeSHCognitionDisorders 0.00 
MeSHSurveysandQuestionnairesCase 0.00 
7690 0.00 
MeSHROCCurveScreening 0.00 
(497% 0.00 
(419% 0.00 
(591% 0.00 
853%; 0.00 
screening/nMeSHAged 0.00 
MeSHNeuropsychologicalTestsCan 0.00 
MeSHSurveysandQuestionnairesMethods 0.00 
139-209] 0.00 
123-173) 0.00 
extensively/nMeSHAged 0.00 
MMSE/nMeSHAged 0.00 
MeSHTranslationsPerformance 0.00 
0943-0968) 0.00 
0945 0.00 
(0931-0960) 0.00 
respectively/nMeSHAgeFactors 0.00 
r=-0679 0.00 
(0928 0.00 
0814) 0.00 
8490 0.00 
MeSHSurveysandQuestionnairesModified 0.00 
MeSHThailandDiogenes 0.00 
MeSHSyndromeThe 0.00 
(050 0.00 
016-084) 0.00 
051-075) 0.00 
tests/nMeSHAged 0.00 
MeSHStrokeThe 0.00 
MeSHPredictiveValueofTestsEveryday 0.00 
groups/nMeSHActivitiesofDailyLiving 0.00 
MeSHVerbalLearningUtility 0.00 
population/nMeSHAged 0.00 
MeSHSurveysandQuestionnairesDouble-contrast 0.00 
MeSHRadiography[MR 0.00 
septum/nMeSHAdult 0.00 
excluded/nMeSHAdnexalDiseases 0.00 
MeSHDopplerHerpes 0.00 
atypically/nMeSHAcyclovir 0.00 
MeSHPolymeraseChainReactionThe 0.00 
734% 0.00 
demonstrated/nMeSHContrastMedia 0.00 
MeSHYoungAdult"Kissing 0.00 
(185% 0.00 
(926% 0.00 
disease/nMeSHEndometriosis 0.00 
MeSHUltrasonographyNodular 0.00 
MeSHNonparametricThe 0.00 
12-31) 0.00 
(009-034) 0.00 
CPP/nMeSHAdult 0.00 
MeSHUltrasonographyMultidetector 0.00 
(985%) 0.00 
(969%) 0.00 
(p=0248) 0.00 
8159 0.00 
MeSHSigmoidDiseasesDeep 0.00 
(630%) 0.00 
(900%) 0.00 
569% 0.00 
067-096) 0.00 
MeSHX-RayComputedEvaluation 0.00 
MeSHNonparametricEndorectal 0.00 
approach/nMeSHAdnexalDiseases 0.00 
MeSHRetrospectiveStudiesUltrasound 0.00 
MeSHUltrasonography[Studies 0.00 
implants/nMeSHAdult 0.00 
MeSHOvarianNeoplasmsPelvic 0.00 
choice/nMeSHAdult 0.00 
MeSHUterineNeoplasmsAdnexal 0.00 
masses/nMeSHAdnexalDiseases 0.00 
MeSHUltrasonographyPelvic 0.00 
endometriosis/nMeSHAdiposeTissue 0.00 
MeSHUterineNeoplasmsTransvaginal 0.00 
methods/nMeSHAdult 0.00 
(894% 0.00 
902%); 0.00 
(860% 0.00 
(500% 0.00 
957%); 0.00 
967%) 0.00 
vagina/nMeSHAbdominalCavity 0.00 
MeSHYoungAdultMagnetic 0.00 
distension/nMeSHAdult 0.00 
MeSHMagneticResonanceImagingDiagnostic 0.00 
MeSHColor[Double-contrast 0.00 
358+/-44 0.00 
856% 0.00 
(351%) 0.00 
MeSHSigmoidDiseasesTransrectal 0.00 
MeSHVaginalDiseases[Comparison 0.00 
MeSHTreatmentOutcomePreoperative 0.00 
MeSHVaginaEfficiency 0.00 
MeSHSensitivityandSpecificityTransrectal 0.00 
162-7315) 0.00 
01-057) 0.00 
resection/nMeSHEndometriosis 0.00 
MeSHVaginalDiseasesThe 0.00 
MeSHVaginaLearning 0.00 
(p=00215) 0.00 
MeSHNonparametricCombination 0.00 
-;004/870;- 0.00 
1956;035/597;019 0.00 
4911;014 0.00 
14564;018 0.00 
840;013 0.00 
490;025 0.00 
4856;004 0.00 
(800%) 0.00 
patients/nMeSHContrastMedia 0.00 
MeSHWaterBowel 0.00 
article/nMeSHAdult 0.00 
MeSHProspectiveStudiesLearning 0.00 
interests/nMeSHAdult 0.00 
MeSHSensitivityandSpecificityThree-dimensional 0.00 
001-020 0.00 
021-040 0.00 
041-060 0.00 
061-080 0.00 
081-099 0.00 
0630-0927 0.00 
0732 0.00 
060-095 0.00 
046-10 0.00 
071-095 0.00 
067-10 0.00 
931-100 0.00 
929-100 0.00 
909-100 0.00 
778-100 0.00 
977-100% 0.00 
interests/nMeSH"DouglasPouch 0.00 
MeSHVideoRecordingDiagnostic 0.00 
0893 0.00 
0804 0.00 
0842; 0.00 
0819 0.00 
0733 0.00 
0873; 0.00 
0856 0.00 
difficulty/nMeSHAdult 0.00 
MeSHYoungAdultTransvaginal 0.00 
rectum/nMeSHAdult 0.00 
endometriomas/nMeSHAdiposeTissue 0.00 
MeSHProspectiveStudiesAgreement 0.00 
(3375% 0.00 
9277% 0.00 
0695-091) 0.00 
9639% 0.00 
0553 0.00 
0056-1) 0.00 
9096% 0.00 
0583 0.00 
0381-0784) 0.00 
0572-0905) 0.00 
8855% 0.00 
0608 0.00 
0443-0774) 0.00 
0726 0.00 
0552-0901) 0.00 
8976% 0.00 
0589 0.00 
0389-0768) 0.00 
USLs/nMeSHAdult 0.00 
MeSHReproducibilityofResultsStandard 0.00 
MeSHReproducibilityofResultsDiagnostic 0.00 
MeSHProspectiveStudiesDiagnosis 0.00 
564% 0.00 
CCDSO/nMeSHAdult 0.00 
MeSHVaginaMultislice 0.00 
dose/nMeSHAdult 0.00 
MeSHWater[Value 0.00 
MeSHUterineDiseasesTumor 0.00 
024-080) 0.00 
(145%) 0.00 
interest/nMeSHAdult 0.00 
implemented/nMeSHAdult 0.00 
MeSHUltrasonographyOffice 0.00 
398E-25); 0.00 
laparoscopy/nMeSHAdult 0.00 
MeSHVaginaEfficacy 0.00 
MeSHLaparoscopy[Diagnostic 0.00 
783% 0.00 
482% 0.00 
(772%) 0.00 
8421 0.00 
respectivelyThe 0.00 
lesions/nMeSHAdnexaUteri 0.00 
MeSHYoungAdultEndometriosis: 0.00 
>093) 0.00 
MeSHNonparametricAdding 0.00 
(550; 0.00 
275-1099) 0.00 
(192; 0.00 
136-271) 0.00 
lesion/nMeSHAdnexalDiseases 0.00 
MeSHVaginaRectal 0.00 
MeSHVaginalDiseasesComparison 0.00 
adequately/nMeSHAdolescent 0.00 
071-1) 0.00 
066-078) 0.00 
082-1) 0.00 
051-072) 0.00 
033-036) 0.00 
070-083) 0.00 
076-082) 0.00 
similar/nMeSHEndometriosis 0.00 
800and 0.00 
locations/nMeSHAdolescent 0.00 
MeSHYoungAdultRectosigmoid 0.00 
indicated/nMeSHAdult 0.00 
MeSHSigmoidDiseasesAssessment 0.00 
adhesions/nMeSHAdnexalDiseases 0.00 
MeSHVaginalDiseasesDiagnosis 0.00 
947%; 0.00 
943%; 0.00 
888%; 0.00 
MeSHVaginaThree-dimensional 0.00 
(0891 0.00 
0839-0943 0.00 
0720-0858 0.00 
00193) 0.00 
08754 0.00 
CPR-24750)/nMeSHAdolescent 0.00 
MeSHYoungAdultCharacterization 0.00 
MeSHROCCurveDeep 0.00 
pain/nMeSHEndometriosis 0.00 
(987%) 0.00 
432% 0.00 
466% 0.00 
setting/nMeSHAdult 0.00 
MeSHVaginaSonovaginography 0.00 
MeSHVaginalDiseasesAccuracy 0.00 
456% 0.00 
MeSHSensitivityandSpecificityEndorectal 0.00 
(0-034) 0.00 
(004-04) 0.00 
15-liter 0.00 
MeSHSensitivityandSpecificityMultidetector 0.00 
MDCT-e/nMeSHAdministration 0.00 
MeSHWater"Tenderness-guided" 0.00 
056-091) 0.00 
MeSHVaginaEvaluation 0.00 
(711%) 0.00 
866% 0.00 
746% 0.00 
MeSHYoungAdultRole 0.00 
improved/nMeSHAdolescent 0.00 
MeSHSigmoidDiseasesEvaluation 0.00 
MeSHUterusStaging 0.00 
MeSHMagneticResonanceImaging[Magnetic 0.00 
(686%) 0.00 
(314%) 0.00 
(657%) 0.00 
(343%)--in 0.00 
(374%) 0.00 
(257%) 0.00 
implants/nMeSHAbdominalWall 0.00 
tissue/nMeSHAdult 0.00 
(436%) 0.00 
suspected/nMeSHAdnexalDiseases 0.00 
MeSHUltrasonographyMultislice 0.00 
(948%) 0.00 
MeSHWaterThe 0.00 
(538%) 0.00 
suspected/nMeSHAdult 0.00 
MeSHUterineNeoplasmsSonographic 0.00 
056-065) 0.00 
helpful/nMeSHAdolescent 0.00 
304-26) 0.00 
006-023) 0.00 
MeSHYoungAdultBarium 0.00 
(718%) 0.00 
(238%) 0.00 
(743%) 0.00 
(310%) 0.00 
7560 0.00 
rectosigmoid/nMeSHAdult 0.00 
MeSHVaginaDeep 0.00 
(308%; 0.00 
248-375) 0.00 
(164%; 0.00 
119-222) 0.00 
(154%; 0.00 
111-211) 0.00 
(134%; 0.00 
94-188) 0.00 
(239%; 0.00 
185-302) 0.00 
0716-0934) 0.00 
0939-0994) 0.00 
141-134) 0.00 
0075-0295) 0.00 
0786) 0.00 
-2398 0.00 
-4685 0.00 
-01112) 0.00 
-3462 0.00 
-3854 0.00 
-30709) 0.00 
2591-3374) 0.00 
vascular/nMeSHAdult 0.00 
MeSHVaginaTransvaginal 0.00 
excellence/nMeSHAdult 0.00 
MeSHYoungAdultBeyond 0.00 
resolution/nMeSHAdult 0.00 
MeSHSensitivityandSpecificityDiagnosis 0.00 
is/nMeSHAdult 0.00 
MeSHUterineDiseasesA 0.00 
(91%)/nMeSHAdolescent 0.00 
MeSHVaginaEndometriosis: 0.00 
MeSHUterineHemorrhageResults 0.00 
(237%) 0.00 
(316%) 0.00 
(447%) 0.00 
MeSHRetrospectiveStudies[Preoperative 0.00 
MeSHVaginaFeasibility 0.00 
(9697%) 0.00 
(9286%) 0.00 
ligaments/nMeSHAdult 0.00 
MeSHSigmoidDiseasesCan 0.00 
99%15024 0.00 
involvement/nMeSHEndometriosis 0.00 
8650% 0.00 
9911% 0.00 
9145% 0.00 
9814% 0.00 
(7085%) 0.00 
conditions/nMeSHAdnexalDiseases 0.00 
MeSHVaginaComparison 0.00 
morbidity/nMeSHAdolescent 0.00 
MeSHYoungAdultSusceptibility-weighted 0.00 
MRI/nMeSHAdult 0.00 
ovaries/nMeSHAdult 0.00 
MeSHVaginalDiseasesThree-dimensional 0.00 
069-093) 0.00 
741%; 0.00 
857%; 0.00 
714%; 0.00 
MeSHYoungAdultAnatomic 0.00 
MeSHUltrasonography[Prospective 0.00 
Dopplermeasurement 0.00 
7141% 0.00 
3571% 0.00 
9655% 0.00 
8571% 0.00 
8593% 0.00 
(4285%) 0.00 
cysts/nMeSHAdolescent 0.00 
MeSHYoungAdultExtended 0.00 
MeSHUrologicDiseasesEndoscopic 0.00 
(619%); 0.00 
wall/nMeSHAdult 0.00 
MeSHUterineDiseasesTransvaginal 0.00 
(266%) 0.00 
(005) 0.00 
combination/nMeSHAdult 0.00 
MeSHSensitivityandSpecificityTransvaginal 0.00 
MeSHVaginaA 0.00 
MeSHYoungAdultScoring 0.00 
9902% 0.00 
9964% 0.00 
8391% 0.00 
9712% 0.00 
MeSHUltrasonographyAcoustic 0.00 
endometrioma/nMeSHAdnexalDiseases 0.00 
MeSHYoungAdultEndometriomas: 0.00 
imaging/nMeSHAdnexalDiseases 0.00 
MeSHUltrasonographyDeeply 0.00 
678% 0.00 
937%; 0.00 
974%; 0.00 
273% 0.00 
fornix/nMeSHAdult 0.00 
MeSHandJelliesDiagnosis 0.00 
786%-997%) 0.00 
733%-945%) 0.00 
251-115) 0.00 
003-041) 0.00 
MeSHVaginalDiseasesTransvaginal 0.00 
(836%) 0.00 
(681%) 0.00 
(509%) 0.00 
(632%) 0.00 
805% 0.00 
IU/ml)/nMeSHAdolescent 0.00 
MeSHColorEndoluminal 0.00 
MeSHRectalDiseasesThe 0.00 
413%; 0.00 
928%; 0.00 
931%; 0.00 
302% 0.00 
516%; 0.00 
861%; 0.00 
480% 0.00 
840% 0.00 
0786 0.00 
0691; 0.00 
0686; 0.00 
MeSHVaginaValidation 0.00 
MeSHUltrasonographyEndometriosis: 0.00 
03)/nMeSHAdiposeTissue 0.00 
MeSHVaginaDiagnostic 0.00 
(585%) 0.00 
(556%) 0.00 
MeSHUrinaryBladderDiseasesA 0.00 
(6956% 0.00 
(3044% 0.00 
5769 0.00 
7652 0.00 
infertility(ABSTRACT 0.00 
hilius" 0.00 
(329%) 0.00 
MeSHVaginaDouble-contrast 0.00 
MeSHSigmoidNeoplasmsValue 0.00 
endometriosis/nMeSHAdnexaUteri 0.00 
MeSHUterusComparison 0.00 
(942%) 0.00 
strategies/nMeSHCross-SectionalStudies 0.00 
MeSHVaginaDoes 0.00 
infiltration/nMeSHAdolescent 0.00 
MeSHWaterIschaemia 0.00 
candidates/nMeSHAdrenergicbeta-Agonists 0.00 
MeSHReproducibilityofResultsPrognostic 0.00 
clear/nMeSHAdult 0.00 
MeSHWaitingListsClinical 0.00 
(HR=478) 0.00 
(HR=114) 0.00 
(HR=102) 0.00 
MeSHTreatmentOutcome[Prognostic 0.00 
disease/nMeSHCoronaryDisease 0.00 
MeSHChronicEvaluation 0.00 
MeSHThalliumValue 0.00 
circulation/nMeSHAdult 0.00 
MeSHLeftSignificance 0.00 
dialysis/nMeSHCalcinosis 0.00 
MeSHSensitivityandSpecificityPretransplant 0.00 
P<0001] 0.00 
P=0033) 0.00 
P=0030) 0.00 
recipients/nMeSHAdolescent 0.00 
MeSHRetrospectiveStudiesElectron-beam 0.00 
[24079 0.00 
31653 0.00 
4434; 0.00 
(1052 0.00 
3159 0.00 
MeSHX-RayComputedPrognostic 0.00 
population/nMeSHAcuteDisease 0.00 
MeSHSingle-PhotonNoninvasive 0.00 
MeSHThalliumRadioisotopesPredictive 0.00 
)303 0.00 
0008)/nMeSHAdult 0.00 
MeSHTimeFactorsEvaluation 0.00 
(005<P<010) 0.00 
scintigrams/nMeSHAdult 0.00 
MeSHTreatmentOutcomeUse 0.00 
setting/nMeSHCalcinosis 0.00 
MeSHSubtractionTechniquePreoperative 0.00 
test/nMeSHAdrenergicbeta-Agonists 0.00 
MeSHRiskFactorsCardiac 0.00 
MeSHTimeFactorsPrevalence 0.00 
factors/nMeSHAdult 0.00 
MeSHSpiralComputedValidation 0.00 
114-246) 0.00 
evaluation/nMeSHAgeofOnset 0.00 
MeSHSmokingAssessment 0.00 
(541%) 0.00 
(662%) 0.00 
(346%) 0.00 
recommended/nMeSHAdult 0.00 
MeSHWaitingListsCoronary 0.00 
(P=0007) 0.00 
(P=00002) 0.00 
(P=0003) 0.00 
revised/nMeSHAdult 0.00 
MeSHSingle-PhotonHigh 0.00 
ABI/nMeSHAdult 0.00 
MeSHUltrasonographyNoninvasive 0.00 
MeSHVasodilatorAgentsUtility 0.00 
[080+/- 0.00 
vs070+/-006 0.00 
P=0001) 0.00 
>075 0.00 
9047%and 0.00 
factorspatients 0.00 
CAG/nMeSHAdult 0.00 
MeSHUltrasonographyPrognostic 0.00 
MeSHSingle-PhotonNon-invasive 0.00 
transplantation/nMeSHEchocardiography 0.00 
MeSHLeftProspective 0.00 
candidates(ABSTRACT 0.00 
MeSHWaitingListsEvaluation 0.00 
MeSHRiskRisk 0.00 
MeSHLeftInformational 0.00 
therapy/nMeSHAged 0.00 
MeSHSexDistributionCoronary 0.00 
MeSHTimeFactorsIncidence 0.00 
(1243%) 0.00 
(4405%) 0.00 
(1310%) 0.00 
PCE/nMeSHCoronaryArteryBypass 0.00 
MeSHSurvivalAnalysisAtherosclerotic 0.00 
MeSHRiskFactorsRelationship 0.00 
(0117 0.00 
(0235 0.00 
MeSHTroponinDobutamine 0.00 
MeSHProspectiveStudiesDobutamine 0.00 
MeSHSensitivityandSpecificityPre-transplant 0.00 
transplantation/nMeSHCoronaryAngiography 0.00 
MeSHTreatmentFailureCoronary 0.00 
disease/nMeSHCalcinosis 0.00 
MeSHUremiaThallium 0.00 
($1000 0.00 
$5000) 0.00 
MeSHThalliumRadioisotopesPrognostic 0.00 
MeSHVasodilatorAgentsPretransplant 0.00 
MeSHUnitedStatesAsymptomatic 0.00 
cardiomyopathy/nMeSHAdult 0.00 
MeSHHomologous[Diagnostic 0.00 
MeSHVasodilatorAgentsThe 0.00 
MeSHLeftNoninvasive 0.00 
MeSHUremiaIneffectiveness 0.00 
MeSHEmission-ComputedDiagnostic 0.00 
MeSHVasodilatorAgentsMyocardial 0.00 
715% 0.00 
980% 0.00 
0727 0.00 
MeSHLeftNatural 0.00 
MeSHHomologousPreoperative 0.00 
MeSHLeftDobutamine 0.00 
132+/-048 0.00 
MeSHLeftPrognostic 0.00 
MeSHThalliumRadioisotopesMyocardial 0.00 
102-182) 0.00 
HR=385; 0.00 
146-1322) 0.00 
HR=325; 0.00 
131-1082) 0.00 
MeSHSingle-PhotonUsefulness 0.00 
patients/nMeSHCoronaryAngiography 0.00 
MeSHSensitivityandSpecificityTechnetium 0.00 
angiography/nMeSHCoronaryAngiography 0.00 
MeSHUnitedKingdomCombined 0.00 
imaging/nMeSHAdult 0.00 
MeSHVasodilatorAgents[Prevalence 0.00 
MeSHSeverityofIllnessIndexAssessment 0.00 
MeSHUremiaComparison 0.00 
dobutamine/nMeSHAdult 0.00 
MeSHYoungAdultRoutine 0.00 
MeSHRiskFactorsRenal 0.00 
(105%) 0.00 
(828% 0.00 
(748% 0.00 
841% 0.00 
MeSHTreatmentOutcomeUsefulness 0.00 
electrocardiogram/nMeSHAdult 0.00 
MeSHUremiaRole 0.00 
angiography/nMeSHConfidenceIntervals 0.00 
MeSHLeftA 0.00 
MACE/nMeSHComorbidity 0.00 
MeSHRiskFactorsValidation 0.00 
MeSHSingle-PhotonEchocardiography-based 0.00 
MeSHTreatmentOutcomeAssessment 0.00 
(083+/- 0.00 
MeSHRenalDialysisStress 0.00 
transplant/nMeSHDobutamine 0.00 
MeSHVasodilatorAgentsStress 0.00 
MeSHLeftCardiac 0.00 
MeSHMiddleAgedPredicting 0.00 
25-81) 0.00 
prognosis/nMeSHAged 0.00 
MeSHSingle-PhotonPerfusion 0.00 
(83%)/nMeSHAdministration 0.00 
MeSHThalliumRadioisotopesCoronary 0.00 
stenosis)/nMeSHAged 0.00 
MeSHX-RayComputedInclusion 0.00 
(245% 0.00 
patients/nMeSH?Combining 0.00 
measures/nMeSHAged 0.00 
MeSHtauProteinsEvaluation 0.00 
substantially/nMeSHAged 0.00 
MeSHReproducibilityofResultsPrincipal 0.00 
MeSHSensitivityandSpecificityVascular 0.00 
pathway/nMeSHAged 0.00 
MeSHPositron-EmissionTomographyMCI 0.00 
genotype/nMeSHAged 0.00 
MeSHSingle-BlindMethodFDG-PET 0.00 
MeSHtauProteinsCerebral 0.00 
698+/-58 0.00 
MeSHEmission-ComputedReduced 0.00 
precuneus/nMeSHAged 0.00 
MeSHTissueDistributionValue 0.00 
biomarkers/nMeSHAgeFactors 0.00 
MeSHtauProteinsComparing 0.00 
172% 0.00 
MeSHtauProteinsEducation 0.00 
MeSHPositron-EmissionTomographyMild 0.00 
converters/nMeSHAlzheimerDisease 0.00 
MeSHEmission-ComputedA 0.00 
foot/nMeSHAdult 0.00 
MeSHTarsalJointsLongitudinal 0.00 
dependent/nMeSHAged 0.00 
MeSHRetrospectiveStudiesMulti-region 0.00 
trials/nMeSHAged 0.00 
MeSHRadiopharmaceuticalsPrediction 0.00 
studies/nMeSHAged 0.00 
MeSHSensitivityandSpecificityMCI 0.00 
follow-up/nMeSHAged 0.00 
MeSHPrognosisDecreased 0.00 
MeSHTemporalLobeNeuropsychological 0.00 
development/nMeSHAged 0.00 
MeSHEmission-ComputedWhat 0.00 
modest/nMeSHAged 0.00 
MeSHSensitivityandSpecificityImpaired 0.00 
MCI/nMeSHAged 0.00 
MeSHEmission-ComputedMapping 0.00 
MeSHSubtractionTechniqueAssociations 0.00 
MeSHSeverityofIllnessIndexPredicting 0.00 
methods/nMeSHAged 0.00 
MeSHSeverityofIllnessIndexPredictors 0.00 
decline/nMeSHAdult 0.00 
MeSHProbabilityResting 0.00 
degeneration)/nMeSHAged 0.00 
MeSHRestLongitudinal 0.00 
progression/nMeSHAged 0.00 
070-095) 0.00 
MeSHRadionuclideImagingAmyloid 0.00 
MeSHPositron-EmissionTomographyHeterogeneity 0.00 
MeSHROCCurveDifferences 0.00 
MeSHTemporalLobeValue 0.00 
1032; 0.00 
quantification/nMeSHAspergillosis 0.00 
>05 0.00 
(287%) 0.00 
109-800; 0.00 
P=004) 0.00 
death/nMeSH?[Evaluation 0.00 
686% 0.00 
disease/nMeSHAntigens 0.00 
MeSHSensitivityandSpecificityGerms 0.00 
parasites/nMeSHAllergyandImmunology 0.00 
MeSHSymbiosisComparison 0.00 
warranted/nMeSHAdolescent 0.00 
MeSHbeta-GlucansDiagnostic 0.00 
MeSHbeta-GlucansComparison 0.00 
infections/nMeSHAspergillosis 0.00 
MeSHPolymeraseChainReactionProspective 0.00 
(097; 0.00 
100/093/055/100 0.00 
ODI/nMeSHAdolescent 0.00 
MeSHbeta-GlucansApplication 0.00 
>05) 0.00 
>or=05 0.00 
>or=50) 0.00 
MeSHSensitivityandSpecificityCombined 0.00 
aspergillosis/nMeSHAspergillosis 0.00 
ascertained/nMeSHAnimals 0.00 
MeSHSensitivityandSpecificityAssessment 0.00 
550% 0.00 
MeSHTimeFactorsPrevention 0.00 
(122%) 0.00 
MeSHHomologousComparison 0.00 
(0873 0.00 
075-099]) 0.00 
(0856 0.00 
071-099]) 0.00 
0871) 0.00 
039-082) 0.00 
0768 0.00 
063-090) 0.00 
IFD/nMeSHAdult 0.00 
MeSHbeta-GlucansValue 0.00 
579%/647%/706%/471%; 0.00 
873%/846%/808%/942%; 0.00 
550%/579%/545%/727%; 0.00 
886%/880%/894%/845% 0.00 
mortality/nMeSHAspergillus 0.00 
MeSHSputumUse 0.00 
?/nMeSH?[Serum 0.00 
neutropenia/nMeSHAdult 0.00 
MeSHbeta-Glucans[The 0.00 
(330%) 0.00 
(636% 0.00 
response/nMeSHAdolescent 0.00 
MeSHMiddleAgedGalactomannan 0.00 
(107%) 0.00 
tests/nMeSHAspergillosis 0.00 
GM/nMeSHAdolescent 0.00 
622% 0.00 
00-10) 0.00 
MeSHYoungAdultDetection 0.00 
test/nMeSHAged 0.00 
MeSHSensitivityandSpecificityPositive 0.00 
(661% 0.00 
MeSHHomologousAspergillus 0.00 
255% 0.00 
=0002) 0.00 
443% 0.00 
447% 0.00 
adults/nMeSHAdolescent 0.00 
MeSHSensitivityandSpecificityUsing 0.00 
(802%) 0.00 
0993 0.00 
MeSHYoungAdultEarly 0.00 
negative/nMeSH?Prevention 0.00 
(996%) 0.00 
MeSHStemCellTransplantationContribution 0.00 
MeSHbeta-GlucansFalse-positive 0.00 
322% 0.00 
588%) 0.00 
GVHD/nMeSHAdolescent 0.00 
MeSHRetrospectiveStudiesGalactomannan 0.00 
institute/nMeSHAdolescent 0.00 
MeSHSensitivityandSpecificityOptimization 0.00 
974%) 0.00 
05--identical 0.00 
16-66) 0.00 
MeSHSerologicTestsGalactomannan 0.00 
MeSHX-RayComputedAdvances 0.00 
MeSHbeta-GlucansUtility 0.00 
MeSHMiddleAgedComparison 0.00 
7718% 0.00 
option/nMeSHAdult 0.00 
MeSHVoriconazoleUsefulness 0.00 
index>or=10 0.00 
initiated/nMeSHAdult 0.00 
MeSHTreatmentOutcome[Early 0.00 
657% 0.00 
676% 0.00 
efficacy/nMeSHAdolescent 0.00 
MeSHSensitivityandSpecificityInvasive 0.00 
IA/nMeSHAirMicrobiology 0.00 
MeSHPatientIsolationPoor 0.00 
MeSHSingle-BlindMethod[Usefulness 0.00 
MeSHTimeFactorsComparison 0.00 
=05)-still 0.00 
154% 0.00 
antibody/nMeSHAged 0.00 
MeSHSerologicTestsDetection 0.00 
MeSHTimeFactorsTreatment 0.00 
MeSHSensitivityandSpecificityContribution 0.00 
408%-728%) 0.00 
878%-985%) 0.00 
studied/nMeSHAdult 0.00 
MeSHSeverityofIllnessIndexPerformance 0.00 
MeSHYoungAdult[Utility 0.00 
(545% 0.00 
636%) 0.00 
(779% 0.00 
692%) 0.00 
MeSHbeta-Glucans[A 0.00 
surveillance/nMeSHAdolescent 0.00 
MeSHSpecimenHandlingRetrospective 0.00 
MeSHbeta-GlucansThe 0.00 
specimens/nMeSHBiomarkers 0.00 
MeSHNonparametricProspective 0.00 
MeSHYoungAdultAspergillus 0.00 
MeSHProspectiveStudies[Analysis 0.00 
MeSHMannansVariables 0.00 
MeSHYoungAdult[Value 0.00 
(955%) 0.00 
MeSHSinusitis[GJB2 0.00 
304%(85/280) 0.00 
c139G>T; 0.00 
c176-191del16; 0.00 
c550C>T 0.00 
c571T>C 0.00 
(193% 0.00 
(179% 0.00 
c344T>G/nMeSHBaseSequence 0.00 
MeSHPointMutation[Combination 0.00 
accurately/nMeSHAdolescent 0.00 
MeSHYoungAdultUse 0.00 
criteria/nMeSHAdolescent 0.00 
(133%) 0.00 
=05 0.00 
8923%/100% 0.00 
4615%/100% 0.00 
9355%/9286% 0.00 
(p=0001 0.00 
MeSHProspectiveStudiesAspergillus 0.00 
infiltrates/nMeSHAdult 0.00 
MeSHSensitivityandSpecificityDiagnostic 0.00 
61-540%) 0.00 
761% 0.00 
729-790%) 0.00 
04-50%) 0.00 
968-991%) 0.00 
035-262) 0.00 
075-136) 0.00 
MeSHSensitivityandSpecificitySurveillance 0.00 
(Index>15) 0.00 
MeSHNeutropeniaA 0.00 
094-100) 0.00 
074-096) 0.00 
066-096) 0.00 
MeSHbeta-GlucansDiagnosis 0.00 
>/=05 0.00 
MeSHRetrospectiveStudiesUse 0.00 
MeSHOpportunisticInfectionsThe 0.00 
16(327%) 0.00 
18(367%) 0.00 
15(306%) 0.00 
17(347%) 0.00 
patients/nMeSHAspergillus 0.00 
mucormycosis/nMeSHAdolescent 0.00 
MeSHSerumLimited 0.00 
MeSHHomologousDevelopment 0.00 
MeSHReproducibilityofResultsGalactomannan 0.00 
ICU/nMeSHAdult 0.00 
11360 0.00 
(657% 0.00 
383-857) 0.00 
(128% 0.00 
43-274) 0.00 
aspergillosis/nMeSHAdolescent 0.00 
MeSHTimeFactorsAssessment 0.00 
needed/nMeSHAdolescent 0.00 
975%; 0.00 
962-984%) 0.00 
873%; 0.00 
769-934%) 0.00 
972-991%) 0.00 
816-963%) 0.00 
format/nMeSHAntigens 0.00 
(533 0.00 
655% 0.00 
(0582 0.00 
6736) 0.00 
(0623 0.00 
6868) 0.00 
0554 0.00 
(0522 0.00 
0823) 0.00 
(016 0.00 
373)] 0.00 
[030 0.00 
(004 0.00 
128)] 0.00 
[024 0.00 
069)] 0.00 
642% 0.00 
MeSHSerologicTestsComparison 0.00 
(854%) 0.00 
diagnosed/nMeSHAntigens 0.00 
MeSHSerumGalactomannan 0.00 
conditions/nMeSHAdolescent 0.00 
308-89%) 0.00 
635% 0.00 
534-727%) 0.00 
75-701% 0.00 
942-999%) 0.00 
MeSHProspectiveStudiesDetection 0.00 
allo-HSCT/nMeSHAspergillosis 0.00 
(646%) 0.00 
(396%) 0.00 
important/nMeSHAdolescent 0.00 
risk/nMeSHAntigens 0.00 
MeSHSensitivityandSpecificitySulfated 0.00 
interaction/nMeSHCalcium 0.00 
